Professional Documents
Culture Documents
Textbook of Pleural Diseases (2008)
Textbook of Pleural Diseases (2008)
Textbook of Pleural Diseases (2008)
Textbook of Pleural
Diseases
Second edition
2 3 4 5 6 7 8 9 10
Commissioning Editor:
Project Editor:
Production Controller:
Cover Designer:
Philip Shaw
Amy Mulick
Karen Tate
Andrew Campling
What do you think about this book? Or any other Hodder Arnold
title? Please send your comments to www.hoddereducation.com
Contents
Contributors
Preface
Acknowledgements
Glossary
Reference annotations
ix
xiii
xv
xvii
xxi
The color plate section appears between pages 298 and 299
1
13
27
39
43
49
59
71
101
113
125
135
151
169
187
vi Contents
201
209
227
233
259
271
285
293
EFFUSIONS
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
315
323
341
367
379
389
397
409
421
431
445
455
465
473
483
491
ASBESTOS-RELATED DISEASES
40
499
Contents vii
41
Malignant mesothelioma
Bruce WS Robinson
507
PNEUMOTHORAX
42
43
Spontaneous pneumothorax
Andrew C Miller
Non-spontaneous pneumothorax
Michael H Baumann
515
533
PEDIATRIC CONSIDERATIONS
44
545
INTERVENTION PROCEDURES
45
46
47
48
49
Drainage techniques
Henri Colt
Pleurodesis
Helen E Davies and YC Gary Lee
Medical thoracoscopy
Robert Loddenkemper
Surgery for pleural diseases
David A Waller and Antonio E Martin-Ucar
Gene therapy in pleural diseases
Steven M Albelda and Daniel H Sterman
551
569
583
599
613
CONCLUSION
50
Index
Future directions
YC Gary Lee and Richard W Light
621
629
Contributors
Bekele Afessa
Division of Pulmonary and Critical Care Medicine, Mayo Clinic
College of Medicine, Rochester, MN, USA
Henri Colt
Pulmonary and Critical Care Division, University of California,
Orange, CA, USA
Steven M Albelda
Pulmonary, Allergy and Critical Care Division, Department of
Medicine, University of Pennsylvania Medical Center,
Philadelphia, PA, USA
Helen E Davies
Oxford Centre for Respiratory Medicine, Oxford, UK
Timothy C Allen
Department of Pathology, The University of Texas Health Center
at Tyler, Tyler, TX, USA
Veena B Antony
Division of Pulmonary, Critical Care and Sleep Medicine,
Department of Medicine, College of Medicine, University of
Florida, Gainesville, FL, USA
Michael H Baumann
Division of Pulmonary and Critical Care Medicine, University of
Mississippi Medical Center, Jackson, MS, USA
Brendan F Bellew
Division of Pulmonary, Critical Care and Sleep Medicine,
Department of Medicine, College of Medicine, University of
Florida, Gainesville, FL, USA
Chris T Bolliger
Division of Pulmonology, Department of Medicine, University of
Stellenbosch, Cape Town, South Africa
Demosthenes Bouros
Department of Pneumonology, University Hospital of
Alexandroupolis, Alexandropoulis, Greece
V Courtney Broaddus
Division of Pulmonary and Critical Care, San Francisco General
Hospital, University of California, San Francisco, CA, USA
Philip T Cagle
Department of Pathology, Baylor College of Medicine, Houston,
TX, USA
Blair Capitano
Department of Pharmacy and Therapeutics, Division of Infectious
Diseases, University of Pittsburgh, Pittsburgh, PA, USA
Jose Castellote
Servicio Aparato Dipestivo, Hospital de Bellvitge, Barcelona,
Spain
Robert JO Davies
Nufeld Department of Clinical Medicine, John Radcliffe
Hospital, Headington, Oxford, UK
Nicholas H de Klerk
Centre for Child Health Research, University of Western Australia,
Australia
Marc de Perrot
Division of Thoracic Surgery, Toronto General Hospital, University
of Toronto, Toronto, ON, Canada
Andreas H Diacon
Division of Pulmonology, Department of Medicine, University of
Stellenbosch, Cape Town, South Africa
Oner Dikensoy
Department of Pulmonary Diseases, Gaziantep University
Hospital, Gaziantep, Turkey
Jeremy J Erasmus
University of Texas MD Anderson Cancer Center, Houston, TX,
USA
Armin Ernst
Beth Israel Deaconess Medical Center, Boston, MA, USA
David Feller-Kopman
Interventional Pulmonology, Johns Hopkins Hospital, Baltimore,
MD, USA
Jaume Ferrer
Respiratory Department, Hospital General Vall dHebron,
Barcelona, Spain
Jocelyne Fleury-Feith
INSERM, Paris, France
Jose Garcia Valero
Departament de Biologia Cellular, Universitat de Barcelona,
Barcelona, Spain
x Contributors
Fergus Gleeson
Nufeld Department of Surgery, John Radcliffe Hospital,
Headington, Oxford, UK
Richard W Light
Vanderbilt University Medical School, Division of Allergy,
Pulmonary and Critical Care Medicine, Nashville, TN, USA
John E Heffner
Providence Portland Medical Center, Oregon Health and Science
University, Portland, OR, USA
Robert Loddenkemper
LungenKlinik Heckeshorn, HELIOS Klinikum Emil von Behring,
Berlin, Germany
Gunnar Hillerdal
Division of Respiratory Medicine, Karolinska University Hospital,
Stockholm, Sweden
Steven Idell
Texas Lung Injury Institute, The University of Texas Health Center
at Tyler, Tyler, TX, USA
Marie-Claude Jaurand
INSERM, Paris, France
Suresh C Jhanwar
Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Joseph John
Department of Medicine, University of Texas Health Center at
Tyler, Tyler, TX, USA
Kellie R Jones
Pulmonary Disease and Critical Care Medicine, Department of
Medicine, Oklahoma Medical Research Foundation, Oklahoma
City, OK, USA
Ioannis Kalomenidis
2nd Department of Pulmonary Medicine, Athens Medical School,
Atticon Hospital, Haidari, Greece
Aryun Kim
Center for Antiinfective Research and Development, Hartford
Hospital, Hartford, CT, USA
Gary T Kinasewitz
Pulmonary and Critical Care Medicine, Department of
Medicin/UHSC, Oklahoma City, OK, USA
Coenraad FN Koegelenberg
Division of Pulmonology, Department of Medicine, University of
Stellenbosch, Cape Town, South Africa
David Feller-Kopman
Johns Hopkins Hospital, Baltimore, MD, USA
Bart N Lambrecht
Department of Pulmonary Medicine, Erasmus Medical Center,
Rotterdam, The Netherlands
YC Gary Lee
Oxford Centre for Respiratory Medicine and University of Oxford,
Oxford, UK; Centre for Respiratory Research, University College
London, London, UK; and University of Western Australia, Perth,
Australia
Edith M Marom
University of Texas MD Anderson Cancer Center, Houston, TX,
USA
Antonio E Martin-Ucar
Department of Thoracic Surgery, Gleneld Hospital, Leicester, UK
Nick A Maskell
North Southmead Hospital, Westbury-on-Trym, Bristol, UK
Andew C Miller
Croydon Chest Clinic, London, UK
Juan F Montes
Departament de Biologia Cellular, Universitat de Barcelona,
Barcelona, Spain
Paul E Moore
Pediatric Pulmonary Medicine, Vanderbilt University, Nashville,
TN, USA
John Mullon
Division of Pulmonary and Critical Care Medicine, Mayo Clinic
College of Medicine, Rochester, MN, USA
A William Musk
Department of Respiratory Medicine, Sir Charles Gairdner
Hospital, Nedlands, Western Australia, Australia
Steven Mutsaers
PathWest and University of Western Australia, Crawley, WA,
Australia
Delia Nelson
School of Biomedical Sciences, Curtin University, Bentley, WA,
Australia
Charles H Nightingale
University of Connecticut School of Pharmacy, Storrs, CT, USA
Marc Noppen
University Hospital UZB, Brussels, Belgium
Edward F Patz Jr
Department of Radiology, Thoracic Imaging Division, Duke
University Medical Center, Durham, NC, USA
Esteban Perez-Rodriguez
Respiratory Department, Ramn y Cajal Hospital and Alcal de
Henares University, Madrid, Spain
Elizabeth Perkett
Pediatric Pulmonary Medicine, Vanderbilt University, Nashville,
TN, USA
Contributors xi
Jos M Porcel
Department of Internal Medicine, Arnau de Vilanova University
Hospital, Lleida, Spain
Xavier Xiol Quingles
Servicio de Aparato Digestivo, Hospital de Bellvitge, Barcelona,
Spain
Najib M Rahman
Oxford Centre for Respiratory Medicine and University of Oxford,
Headington, Oxford, UK
Francisco Rodriguez-Panadero
Unidad Mdico-Quirrgica de Enfermedades Respiratorias,
Hospital Universitario Virgen del Rocio, Sevilla, Spain
Bruce WS Robinson
School of Medicine and Pharmacology, Sir Charles Gairdner
Hospital Unit, Faculty of Medicine and Pharmacology, The
University of Western Australia, Australia
Steven A Sahn
Division of Pulmonary, Critical Care, Allergy and Sleep Medicine,
Medical University of South Carolina, Charleston, SC, USA
Sreerama Shetty
Texas Lung Injury Institute, The University of Texas Health Center
at Tyler, Tyler, TX, USA
Georgios T Stathopoulous
Department of Critical Care and Pulmonary Services, General
Hospital Evangelismos, School of Medicine, National and
Kapodistrian University of Athens, Athens, Greece
Daniel Sterman
Pulmonary, Allergy and Critical Care Division, Department of
Medicine, University of Pennsylvania Medical Center,
Philadelphia, PA, USA
Charlie Strange
Medical University of South Carolina, Charleston, SC, USA
Gian Franco Tassi
Pulmonology Unit, Spedali Civili, Brescia, Italy
Lisete Ribeiro Teixeira
Pulmonary Division Heart Institute, University of So Paulo
Medical School, So Paulo, Brazil
Joseph R Testa
Fox Chase Cancer Center, Philadelphia, PA, USA
Francisco S Vargas
Pulmonary Division Heart Institute, University of So Paulo
Medical School, Brazil
Dimitris A Vassilakis
University of Crete, Crete, Greece
David A Waller
Department of Thoracic Surgery, Gleneld Hospital, Leicester, UK
Mark R Wick
Division of Surgical Pathology and Cytopathology, University of
Virginia Medical Center, Charlottesville, VA, USA
Nicola A Wilson
Centre for Respiratory Research, University College London, UK
Preface
We have been most encouraged and delighted by the very
positive responses received since the publication of the
rst edition of the Textbook of Pleural Diseases in 2003. It
has been our aim to provide a comprehensive, yet easily
readable, reference text that covers both basic and clinical
science on pleural diseases. By doing so, we hope that this
text will serve to stimulate much needed clinical and
research interests in pleural diseases.
Knowledge concerning pleural diseases has grown in
stature and complexity in the past few years. Seven new
chapters have been added to this edition and the remaining chapters substantially updated to reect the expansion
in knowledge in the eld. Ten of the fty chapters in this
edition are written by new expert authors providing fresh
ideas and views. Recent years have seen the incorporation
of new technologies in clinical management of pleural diseases, hence the new chapters on Pleural ultrasound and
Pleural manometry. Likewise, new translational research
techniques are likely to enhance our understanding of
pathophysiology of pleural diseases (see Proteomics in
It is our hope that this book will provide an easy reference for clinicians faced with specic management issues,
yet allow interested readers to gather a comprehensive
picture of the topic including the immuno-pathological
validation behind the disease development. It is our hope
that this book will stimulate interest in pleural disease,
both in its research and clinical practice.
YC Gary Lee
Richard W Light
July 2002
Acknowledgements
Glossary
1AT
-TOS
2D GE
AaPO2
AAV
ACCP
Ad.HSVtk
ADA
ADA2
AFB
AIDS
ALT
ANA
AP
APC
APD
Apo
ARDS
ARNT
AS
ASGP
ATRA
AUC
BAL
BAPE
BCG
bFGF
BLP
BNP
BSA
BTS
CABG
CALGB
CCPTC
CCr5
CEA
CEUS
CGH
CHF
Cl
CLC
cM
CMV
1-antitrypsin
-tocopheryl succinate
two-dimensional gel electrophoresis
alveolar-arterial oxygen gradient
Adeno-associated virus
American College of Chest Physicians
adenovirus to deliver Herpes simplex virus
thymidine kinase
adenosine deaminase
adenosine deaminase isoenzyme 2
acid-fast bacilli
acquired immmunodeciency syndrome
alanine aminotransferase
antinuclear antibodies
apurynic/apyrimidinic
activated protein C
all purpose drainage
apolipoprotein
acute respiratory distress syndrome
aryl hydrocarbon receptor nuclear translocator
ankylosing spondylitis
ascites sialoglycoprotein
All-trans-retinoic acid
area under the curve
bronchoalveolar lavage
benign asbestos pleural effusions
Bacille Calmette-Gurin
basic broblast growth factor
bacteria lipoprotein
B-type natriuretic peptides
bovine serum albumin
British Thoracic Society
coronary artery bypass grafting
Cancer and Leukemia Group B
clear cell papillary thyroid carcinoma
C-C chemokine receptor-5
carcinoembryonic antigen
contrast-enhanced ultrasound
comparative genomic hybridization
congestive heart failure
clearance
cardiotrophin-like cytokine
centiMorgan
Cytomegalovirus
CNF
COPD
CPAP
CPP
CPR
CRP
CSS
CT
CT-1
CTA
CTD
CTP
CTPA
CXR
DC
DCEMRI
DIGE
DPT
DSRCT
EBV
ECG
ECM
EGF
EGFR
ELISA
EM
EMA
EMT
ENA-78
EPIC
EPP
Eps
ERCP
ERK
ERM
ERP
ERS/ATS
ES
ESI
ESR
xviii Glossary
FAK
FCS
FDA
FDG
FDP
FEV1
FGF
FRC
FT-ICR
FVC
GCDFP-15
GCSF
GCV
GM-CSF
GMS
GVHD
H&E
HAART
HB-EGF
HBSS
HCC
hCG
HGF
HHV
HIF
HIV
HPF
HPO
HRCT
HSCT
hsp65
HSV
HSVtk
ICAM
ICAT
ICU
IFN
Ig
IGF
IGFR
IGSF CAM
IL
IMA
IMIG
IMRT
INH
iNOS
INR
IP
IPG
IR
IR-A
ISPP
IT
iTRAQ
IVIG
JAK
KGF
KS
LAK
LAM
LAM
LAP
LAT
LDH
LE
LIF
LM
LMWH
LOH
LPS
LTA
LTBP
LVRS
MALDI
MALDI-TOF
MAP
MAPK
MCP
MDR
MEF
MELD
MetAP2
MHC
MHz
MIC
MIP
MIST
MM
MMP
MMVF
Mn-SOD
MPE
MRI
MRSA
MS
MSCT
MT1
MTAP
MT-MMP
MTUOT
MudPIT
NAP
NB
N-cadherin
NF
NF2
NHL
NK
NO
intravenous immunoglobulin
janus kinase
keratinocyte growth factor
Kaposis sarcoma
lymphokine activated killer
lymphangioleiomyomatosis
lipoarabinomannan
latency associated peptide
limited axillary thoracotomy
lactate dehydrogenase
Lupus erythematosus
leukemia inhibitory factor
light microscopy
low-molecular-weight heparin
loss of heterozygosity
lipopolysaccharide
lipoteichoic acid
latent TGF- binding protein
lung volume reduction surgery
matrix-assisted laser desorption-ionization
matrix-assisted laser desorption-ionizationtime of ight
mitogen-activated protein
mitogen-activated protein kinases
monocyte chemoattractant protein
multidrug resistance
mouse embryonic broblasts
model of end-stage liver disease
methionine aminopeptidase-2
major histocompatibility complex
megahertz
minimum inhibitory concentration
macrophage inammatory protein
Multi-center Intrapleural Streptokinase Trial
malignant mesothelioma
matrix metalloproteinase
man-made vitreous bers
manganese-containing superoxide dismutase
malignant pleural effusions
magnetic resonance imaging
methicillin-resistant Staphylococcus aureus
mass spectrometry
multislice computed tomography
membrane type 1
methylthioadenosine phosphorylase gene
membrane type matrix metalloproteinase
malignant tumors of uncertain origin and type
multidimensional protein identication
technology
neutrophil activating protein
neuroblastoma
neural cadherin
nuclear factor
neurobromatosis type 2
non-Hodgkins lymphoma
natural killer
nitric oxide
Glossary xix
NPM
NPN
NSAID
NSCLC
NSE
OHSS
OHT
OP-CABG
OSM
OVA
PA
PAI
Pak
PAMP
PAR
PARC
PAS
PBL
PCIS
PCP
PCR
PDGF
PET
PET-CT
PFE
PG
PGK
PGN
PI3K
PKC
PLAP
PMF
PNET
PPD
PPE
Ppl
PRR
PSA
PSP
PT
PTLD
PTT
Q
Q-TOF
RA
RA
RalGDS
RANTES
Rb
RCF
RECIST
RH
RHAMM
rhDNase
rhGH
rhIL-11
RIETE
RMS
RNI
RNS
ROC
ROI
ROS
ROSE
RPE
SAHA
SAPS II
SBEM
SBP
SCID
SCNC
scuPA
SDS-PAGE
SELDI-TOF
SEM
SFT
SFTP
sIL-2R
sIL-6R
SLE
SMC
SMRP
SOCS
SRCT
SS
SSAg
SSc
SSP
SV
SV40
SVC
TACE
tag
Tag
TB
TCR
TEM
TF
TFPI
TGF
Th1
TIL
TIM
TIMP
TIPS
TLR
TNF
xx Glossary
TNM
tPA
TPB
TPN
Treg
TS
TSG
TTF1
TTFNA
TTNB
uPA
US
VATS
VCAM-1
Vd
VEGF
VLS
VPF
VV
WBC
WG
WHO
WT-1
XDR
Reference annotation
The reference lists are annotated, where appropriate, to guide readers to key primary papers and major review articles as
follows:
We hope that this feature will render extensive lists of references more useful to the reader and help to encourage selfdirected learning among both trainees and practicing physicians.
1
Pleural disease: historic perspective
GIAN FRANCO TASSI, GIAN PIETRO MARCHETTI
The pleura as an anatomical entity
Pleural diseases
Thoracoscopy
Other diagnostic and therapeutic procedures
1
2
6
7
Conclusions
Key points
References
8
8
9
pus does not drain to the other part. Then there is the costalvertebral pleura, which is a strong membrane with a nervous
structure; it is large and covers all the ribs and is thus in
contact with all the organs of the thoracic cavity. Because of
the sensitivity of the pleural membrane, an infection is followed by a sharp pain in the side of the body. The third membrane is the diaphragm.9
Thus the pleura begins to take on its own identity, being
divided into its principal parts, each with its own characteristics, and with accurate anatomical references.
Three centuries later, Caspar Bauhin, in his Theatrum
Anatomicum (1592), was still more precise when he accurately described visceral pleura. With him, the membrana
costas succigens denitely becomes pleura.10
However, it was only in the monumental work of
Francois Xavier Bichat (17711802) that the function of
the pleura was considered, rather than being simply
regarded as a covering. In his Trait des membranes en
gnral et de diverses membranes en particulier (treatise on
membranes in general and various membranes in particular), he wrote that The serous membranes are characterized
by the lymphatic uid which incessantly lubricates them and
that every serous membrane represents a sack without an
opening spread over the respective organs which it embraces.
Their rst function is doubtless to form about the essential
organs a boundary which separates them from those of their
vicinity. A second function is to facilitate the moving of the
organs. Also, the surface of the pleura has a smooth and
pale aspect because of a serous uid of which the membrane
is the source. This uid is constantly produced and reabsorbed. It is so thin that the color of the underlying parts can
be distinguished.11
PLEURAL DISEASES
It should be emphasized that the discussion of pleural
infections in a historical context, and then making a systematic reconstruction, are extremely difcult owing to
the imprecise nature of the terminology used. For
example, the word empyema was used not only to
describe the disease but also for the operation performed
to drain the empyema. The nature of the material removed
in an intervention was not always specied, meaning that
they could have been transudates, inammatory exudates,
or purulent effusions, since paracentesis thoracis (thoracic paracentesis) was carried out in the presence of any
accumulation of liquid, almost always with the broad denition of bad humor. Also, an initially clear liquid often
became purulent with the use of unsterile instruments.
The rst recognized and described pleural disease was
infectious pleurisy, both because the symptoms were often
clear, such as fever and characteristic thoracic pain, and
because of its frequent evolution into empyema.
The frequency, morbidity and mortality for this disease
were extremely high until the twentieth century. An
approximate attempt at quantication is that between
400BC and 1600AD, death was the result of pleural infection in 80 percent of cases, in 70 percent between 1600
and 1800, in 50 percent until 1900, in 30 percent until
1950, with a gradual reduction to the present-day 35
percent. Each step of this improvement is the result of a
signicant therapeutic advance.
The rst to illustrate pleurisy was Hippocrates of Kos
(460377BC), who frequently discussed it in his aphorisms
and treatise on diseases. The symptoms described were: a
constant fever, sweat, a cough and pain. He said When
pleuritis arises, a person suffers the following: he has pain in
his side, fever and shivering; he breathes rapidly and he has
orthopnea 12
Many of his aphorisms short sentences which were for
many years the only source of information for practicing
doctors deal with pleurisy: Pleuritis that does not clear up
in fourteen days results in empyema. Pneumonia coming on
pleurisy is bad. Pains and fevers occur rather at the formation of pus than when it is already formed. Others refer to
the prognosis: Persons who become affected with empyema
after pleurisy, if they get clear of it in forty days from the
breaking of it, escape the disease; but if not, it passes into
phthisis. And therapy: When empyema is treated by the
cautery or incision, if pure and white pus ow from the
wound, the patients recover; but if mixed with blood, slimy
and fetid, they die.13
Hippocrates recommended treating empyema by
draining through the mouth, or with purgatives, or inducing vomiting, but also attempted a more modern
approach, advising an oblique cut in the lowest intercostals
space, perforation or removal of a piece of rib, thereby creating the rst open drainage system, and lling the incision
with linen gauze. He suggested washing the cavity with oil
and warm wine; an empyema can drain rst from the
lungs rather than from the thoracic wall; he describes
(digital) clubbing in chronic suppuration. He also identied the most appropriate location for the incision in the
thoracic wall with the sign of damp earth, which was
achieved by covering the patients thorax in mud and
making the incision in the part which dried rst. He was
also responsible for hippocratic succussion, which
involves shaking the patient by the shoulders in order to
identify the sound of liquid inside the thorax. This maneuver only had positive results in the presence of a certain
level of air and liquid, and was therefore only possible in
the nal stages of the disease.14
From the ancient Roman period there is not only documentary evidence regarding the history of pleural disease,
but also archaeological discoveries from excavations at
Pompei which have produced surgical instruments that
were apparently used to drain purulent accumulations.
Aulus Cornelius Celsus (25BC to 50AD) identied the
characteristics of inammation (rubor, tumor, calor,
dolor), applicable also to thoracic suppuration, and he
describes pleurisy in his De Medicina (book IV): The
stomach is girt about by the ribs, and in these also severe
pains occur. And the commencement either is from a chill, or
Pleural diseases 3
Pleural diseases 5
THORACOSCOPY
The rst in vivo observation of the pleura was undoubtedly
carried out by an Irish doctor, Samuel Gordon, who in the
February edition of the 1866 Dublin Quarterly Journal
refers to a clinical case: Most extensive pleuritic effusion
rapidly becoming purulent; paracentesis; introduction of a
drainage tube; examination of interior of pleura by the endoscope (Figure 1.4). With the aid of an expert endoscopist,
Cruise, and a binocular instrument, he observed a granular surface and understood that: This case is also very
remarkable as being the rst in which an examination of the
interior of the chest has been made by the endoscope.34
His initiative remained isolated, as it would be more
than 40 years before pleural endoscopy was mentioned
again, when Hans Christian Jacobaeus (Figure 1.5), a
Swedish internist, published On the possibility of using a
cistoscope to examine the serous cavity, dedicated to
laparoscopy and thoracoscopy. He used a rigid cistoscope
of Nitze n. 14 (14 Charrires = 4.6 mm), provided with a
direct passage was made between the pleural cavity and the
skin to allow open drainage of pus. The skin was folded
back around the edges. This method is still used in a
minority of cases which cannot be treated with less invasive methods.46
CONCLUSIONS
The famous French surgeon Guillaume Dupuytren
(17771835) consulted ve doctors when he felt ill with
empyema. Having listened to their conicting diagnoses,
he said, I prefer to die by the hand of God than with the
help of a surgeon.
This chapter outlined the slow and difcult journey
traveled in the development of better management strategies for patients with pleural diseases, especially in establishing interventions which were both simple and effective.
Removing pathological material from an easily accessible
(pleural) cavity would appear a simple task in theory. In
reality, it has taken centuries of research to arrive at our
current practices.47
KEY POINTS
References 9
REFERENCES
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
PART
BASIC SCIENCE
13
27
39
43
49
59
71
101
113
125
135
151
169
187
2
Anatomy of the pleura
NAJIB M RAHMAN, NAI-SAN WANG
Introduction
Embryology
Gross anatomy
The pleural cavity
Microscopic anatomy
Mesothelial cells
The microvillus and lubricating membrane
The blood supply of the pleura
Innervation
Contents of the pleural space
13
13
14
14
15
15
16
17
18
18
INTRODUCTION
The precise structure and function of the pleural space is
not fully understood. There is marked inter-species variation in the ultrastructure of the pleura; in humans the
pleural cavities are separated by the mediastinum, whereas
other mammals (e.g. mice, American buffalo) lack complete separation between the left and right pleurae, allowing free movement of air and uid. The adult elephant is
the only mammal that does not possess a pleural cavity a
normal pleural space is present in utero, but in late gestation the parietal pleural is replaced with a dense sheet of
connective tissue.1 The pleural space is then obliterated
with loose connective tissue, permitting movement of the
lung against the chest wall. Theories have been advanced as
to why the elephant lacks a pleural space,2 but the variations seen between mammals in the structure of the pleural
cavity is as yet to be explained.
In humans, each hemithorax is constructed like a vertical, cone-shaped bellow with the diaphragm as the moving
part at the caudal and widest end, and the trachea and
nasal structures superiorly creating a narrow outlet/inlet
and providing protection and functional adaptation for
the lung. Within the thoracic cage, the lung must be able
to both move and change volume with the respiratory
cycle.
The lung expands during inhalation and deates during
exhalation, creating movement between the lung surface
and the inner chest wall. In order to decrease friction gen-
18
19
19
22
22
23
23
23
24
EMBRYOLOGY
All body cavities, including the pleural peritoneal and pericardial cavities, are derived from the coelom, the primitive
body cavity. The coelom derives from the primitive mesoderm of the embryo and forms a cavity lined by serous
membrane before all internal organs develop.
In the human embryo, the primitive mesoderm on both
sides of the notochord divides rst into the medial segmented and natural non-segmented plates. The left and
right medial segmented plates later develop into the skull,
vertebra, ribs and the thick muscles of the dorsal (rear)
parts of the body wall.
In contrast, the lateral non-segmented plates split into
the internal splanchnopleure (the precursor of the internal
organs) and the lateral or external somatopleure (the precursor of the anterior and lateral body wall), between
GROSS ANATOMY
To the naked eye, the normal pleural surfaces are smooth,
wet and semi-transparent. In humans, the left and right
pleural cavities are entirely separated from one another (by
the mediastinum) and from the pericardial space.
Although the visceral and parietal pleura originate from
the same serous membrane of the coelom, they appear
macroscopically different because of different underlying
structures and topography (see section The regional difference).
The visceral pleura covers the entire surface of the lung,
including the interlobular ssures. The parietal pleura
covers the inner surface of the entire thoracic cage, including the mediastinal surfaces and diaphragm. The visceral
and parietal pleura coalesce at the lung hilae, where the
major airways and pulmonary vessels penetrate. The area
of the entire pleural surface has been estimated to be 2000
cm2 in an average adult male.
The visceral pleura adheres tightly to the lung surface
throughout the thorax. The parietal pleura is further subdivided in to different anatomical regions as follows:
the costal pleura, lining the inner surface of the ribs and
intercostal muscles;
the diaphragmatic pleura, covering the convex surface
of the diaphragm;
Mesothelial cells 15
MICROSCOPIC ANATOMY
Layers of the pleural membrane
The visceral and parietal pleura in humans are approximately 40 mm across. By light microscopy, the pleura is
generally divided into ve layers (see Figure 2.1), consisting of a single cellular layer and four subcellular layers.
Proceeding from the pleural surface, the layers are as
follows:
MESOTHELIAL CELLS
1 a single layer of mesothelial cells;
2 a thin subendothelial connective tissue layer, including
a basal lamina;
3 a thin supercial and elastic layer (often merged with
the second in layer);
Fat cell
Capillaries
Nerve
Lymphatic valves
5. Deep fibroelastic layer
Figure 2.1 A schematic drawing of the pleura. On light microscopy, the pleura is divided into ve layers. From the pleural surface, the
layers are: rst, a single layer of mesothelial cells; second, a thin submesothelial connective tissue lair, including a basal lamina; third, a
thin supercial elastic layer; fourth, a loose connective tissue layer; and fth, a deep broelastic layer. The thickness of each layer is
markedly varied between species and between regions within the same individual.
The venous drainage of the parietal pleura follows its arterial supply, with the majority eventually draining into the
azygos vein and subsequently into the superior vena cava.
Venous blood derived from the diaphragm drains either
caudally into the inferior vena cava through the inferior
phrenic veins or cranially into the superior vena cava
through the superior phrenic veins, which run parallel
with the internal mammary artery and thence into the
brachiochepalic trunk.
INNERVATION
The costal parietal pleura and the peripheral part of the
diaphragm are innervated by somatic intercostals
nerves,15,25 thus pain felt in these areas is referred to the
adjacent chest wall. The central portion of the diaphragm
is innervated by the phrenic nerve, resulting in referred
pain to the ipsilateral shoulder tip during central
diaphragm irritation.
The visceral pleura is extensively innervated by pulmonary branches of the vagus nerve and sympathetic
trunk. However, the visceral pleural contains no pain
bers in contrast to the parietal pleura, and this is of clinical relevance. The presence of pleuritic chest pain therefore usually indicates involvement of the parietal pleural in
the disease process.
contact between the visceral and parietal pleura,34 suggesting that the pleural space is a real rather than a potential
space.
Normal pleural uid contains 12 g of protein per
100 mL, a gure similar to the concentration detected in
the interstitial uid of both animals and humans.29,35
However, the concentration of large molecular weight proteins (e.g. lactate dehydrogenase, molecular weight
134 000) in pleural uid is less than half that of serum,
implying some regulation of molecular passage into the
pleural cavity. There are 1400 to 4500 cells per microliter
of pleural uid in animals or humans,29,30,35 largely made
up of macrophages with a few leukocytes and red blood
cells, again implying a restriction to cellular passage into
the pleural cavity. (For further description of normal
pleural uid composition, see Chapter 4, Normal physiological uid and cellular contents by M Noppen.)
LYMPHATICS
The lymphatics within the lung are divided into two
systems: the supercial or pleural plexus, localized in the
subpleural connective tissue layer of the visceral pleura, and
the deep plexus located in the bronchovascular bundles.
The deep plexus includes peribronchial, peripulmonary
vascular and interlobular septum or connectivity tissue.
Communications between the two plexuses exist only at the
junction of the pleura and the interlobular septum.5,15
Stomata
Ovoid or round openings of 26 mm or greater in diameter, known as stomata, have been demonstrated on the
parietal pleural surface of the anterior lower chest wall,
mediastinum, and diaphragm in rabbits, mice and sheep
(Figures 2.42.6).13,20,4547,49 The stomata connect the
pleural cavity with the lacunae (see section Lacuna and
lymphatic channels), which are dilated lymphatic spaces
in the parietal pleural wall that in turn drain into larger
collecting lymphatic ducts.20 Stomata appear to be unique
to the parietal (and peritoneal) pleura.
Beneath the stomal openings, the substructure of the parietal pleura is made of up a loosely knit layer of interweaving connective tissue bundles (Figures 2.7 and 2.8).53,54
The membrana cribriformis forms the roof of a dilated
lymphatic space the lacuna (see section Lacuna and lymphatic channels). The pleural surface of this connective
tissue bundle network is covered with a layer of mesothelial cells, with the opposite surface covered with a layer of
lymphatic endothelial cells (Figures 2.7 and 2.8).47 The
membrana cribriformis is therefore made up of lining cells
bridging a connective tissue bundle mesh, and it is postulated that stomas are formed when the lining cells on both
Kampmeiers foci
In 1928, Kampmeier described small milky spots in the
dorsal and caudal portion of the human mediastinum.57 At
light microscopy, these foci are made up of modied
cuboidal mesothelial cells with stomas and are associated
with an aggregate of lymphocytes, histiocytes, plasma cells
and other mononuclear cells, located around a central
lymphatic or vascular vessel. The mesothelial cells have
increased cytoplasmic mass and granules, suggesting cellular activity (see section The resting and reactive mesothelial cell). Under scanning electron microscopy, the foci
appear as irregular, elevated mound-like structures.20
Similar foci have been identied in the thoracic cavity of
dogs and in the mesentery of many species.58,59 It is postulated that these structures act as local host defence mechanisms, similar to the tonsils in the oropharynx or Peyers
patches in the gut. Infectious organisms and noxious particles may bypass these foci, and appear via the draining
lymphatic channels in the parasternal lymph nodes.60
Visceral pleura
In the apical portion of the hemithorax, the visceral pleura
is relatively thin with attened mesothelial cells and sparse
microvilli, reecting paucity of movement in the statically
expanded upper lung. Beneath the mesothelial cell layer,
the basal lamina and deeper three layers are often difcult
to distinguish, especially in the apex where the systemic
arterial supply is replaced by a pulmonary supply (see
section The blood supply of the visceral pleura). This
thin pleura is the site of bleb formation seen in some
patients with spontaneous pneumothorax and is often the
site of bullae formation in chronic obstructive pulmonary
disease. Rupture of these structures results in
pneumothorax.
In more basal areas where the lung moves and stretches
more, the visceral pleura is thicker with cuboidal mesothelial cells showing increased microvilli.11,13,14 The amount of
collagen and elastic bers increases within the deeper
layers toward the lower part of the lung.
Parietal pleura
Pleura overlying the inner rib surfaces is thin with attened mesothelial cells, sparse microvilli and thin subcellular layers. The dense fth layer of broelastic tissue fuses
with the perichondrium or periosteum of the rib.
Key points 23
KEY POINTS
REFERENCES
1. West JB, Fu Z, Gaeth AP, Short RV. Fetal lung development in the
elephant reects the adaptations required for snorkeling in adult
life. Respir Physiol Neurobiol 2003; 138: 32533.
2. West JB. Snorkel breathing in the elephant explains the unique
anatomy of its pleura. Respir Physiol 2001; 126: 18.
3. Patten BM, Carlson BW. Foundations of embryology, 3rd edn. New
York: McGraw-Hill; 1974.
4. Hesseldahl H, Larsen JF. Ultrastructure of human yolk sac:
endoderm, mesenchyme, tubules and mesothelium. Am J Anat
1969; 126: 31535.
5. von Hayek H. The parietal pleura and visceral pleura. New York:
Hafner; 1960.
6. Pistolesi M, Miniati M, Giuntini C. Pleural liquid and solute
exchange. Am Rev Respir Dis 1989; 140: 82547.
7. Rabinowitz JG, Cohen BA, Mendleson DS. Symposium on
nonpulmonary aspects in chest radiology. The pulmonary ligament.
Radiol Clin North Am 1984; 22: 65972.
8. Morrissey BM, Bisset RA. The right inferior lung margin: anatomy
and clinical implication. Br J Radiol 1993; 66: 5035.
9. Satoh K, Sato A, Kobayashi T, et al. Septal structure of incomplete
interlobar ssures of the lung. Acad Radiol 1996; 3: 4758.
10. Webb WR, LaBerge JM. Radiographic recognition of chest tube
malposition in the major ssure. Chest 1984; 85: 813.
11. Wang NS. The regional difference of pleural mesothelial cells in
rabbits. Am Rev Respir Dis 1974; 110: 62333.
12. Michailova KN. The serous membranes in the cat. Electron
microscopic observations. Ann Anat 1996; 178: 41324.
13. Mariassy AT, Wheeldon EB. The pleura: a combined light
microscopic, scanning, and transmission electron microscopic
study in the sheep. I. Normal pleura. Exp Lung Res 1983; 4:
293314.
14. Albertine KH, Wiener-Kronish JP, Roos PJ, Staub NC. Structure,
blood supply, and lymphatic vessels of the sheeps visceral pleura.
Am J Anat 1982; 165: 27794.
15. Nagaishi C. Functional anatomy and histology of the lung. Tokyo:
Igaku Shoin; 1972.
16. Michailova K, Wassilev W, Wedel T. Scanning and transmission
electron microscopic study of visceral and parietal peritoneal
regions in the rat. Ann Anat 1999; 181: 25360.
17. Odor DL. Observations of the rat mesothelium with the electron
and phase microscopes. Am J Anat 1954; 95: 43365.
18. Legrand M, Pariente R, Andre J, Chretien J, Brouet G.
[Ultrastructure of the human parietal pleura]. Presse Med 1971;
79: 251520.
19. Andrews PM, Porter KR. The ultrastructural morphology and
possible functional signicance of mesothelial microvilli. Anat Rec
1973; 177: 40926.
20. Wang NS. Mesothlelial cells in situ. In: Chretien J, Bignon J, Hirsch
A (eds). The pleura in health and disease. New York: Marcel Dekker,
1985: 2342.
21. Inoue T, Osatake H. Three-dimensional demonstration of the
intracellular structures of mouse mesothelial cells by scanning
electron microscopy. J Submicrosc Cytol Pathol 1989; 21: 21527.
22. Simionescu M, Simionescu N. Organization of cell junctions in the
peritoneal mesothelium. J Cell Biol 1977; 74: 98110.
23. Nomura K, Kida K, Kudoh S. [A morphological study to elucidate
the differences in visceral pleura in young and old mice]. Nippon
Ika Daigaku Zasshi 1998; 65: 22735.
24. Madison LD, Bergstrom-Porter B, Torres AR, Shelton E. Regulation
of surface topography of mouse peritoneal cells. Formation of
microvilli and vesiculated pits on omental mesothelial cells by
serum and other proteins. J Cell Biol 1979; 82: 78397.
25. Clemente CD. Anatomy of the human body, 30th edn. Philadelphia:
Lea & Febiger, 1985.
26. Davila RM, Crouch EC. Anatomic organisation and function of the
human pleura. Semin Respir Crit Care Med 1979; 82: 78397.
27. Bernaudin JF, Fleury JY. Anatomy of the blood and lymphatic
circulation of the pleural serosa. In: Chretien J, Bignon J, Hirsch A
(eds). The pleural in health and disease. New York: Marcel Dekker;
1985: 10124.
28. Milne ENC, Pistolesi M. Reading the chest radiograph: a physiologic
approach. St Louis: Mosby; 1993.
29. Yamada S. Uber die serose Flussigkeit in der Pleurahohle der
gesunde Menschen. Z Ges Exp Med 1933; 90: 3428.
30. Miserocchi G, Agostoni E. Contents of the pleural space. J Appl
Physiol 1971; 30: 20813.
31. Noppen M, De Waele M, Li R, et al. Volume and cellular content of
normal pleural uid in humans examined by pleural lavage. Am J
Respir Crit Care Med 2000; 162: 10236.
32. Butler JP, Huang J, Loring SH, et al. Model for a pump that drives
circulation of pleural uid. J Appl Physiol 1995; 78: 239.
33. Agostoni E, Miserocchi G, Bonanni MV. Thickness and pressure of
the pleural liquid in some mammals. Respir Physiol 1969; 6:
24556.
34. Albertine KH, Wiener-Kronish JP, Bastacky J, Staub NC. No
evidence for mesothelial cell contact across the costal pleural
space of sheep. J Appl Physiol 1991; 70: 12334.
35. Sahn SA, Willcox ML, Good JT Jr, Potts DE, Filley GF.
Characteristics of normal rabbit pleural uid: physiologic and
biochemical implications. Lung 1979; 156: 639.
36. Miserocchi G. Physiology and pathophysiology of pleural uid
turnover. Eur Respir J 1997; 10: 21925.
37. Staub NC. New concepts about the pathophysiology of pulmonary
edema. J Thorac Imaging 1988; 3: 814.
38. Miserocchi G, Venturoli D, Negrini D, Del Fabbro M. Model of
pleural uid turnover. J Appl Physiol 1993; 75: 1798806.
39. Shumko JZ, Feinberg RN, Shalvoy RM, DeFouw DO. Responses of
rat pleural mesothelia to increased intrathoracic pressure. Exp
Lung Res 1993; 19: 28397.
40. Wang NS. Morphological data of pleura normal conditions. In:
Chretien J, Hirsch A (eds). The pleural in health and disease. New
York: Masson Publishing USA Inc; 1983: 1024.
41. Courtice FC, Simmonds WJ. Physiological signicance of lymph
drainage of the serous cavities and lungs. Physiol Rev 1954; 34:
41948.
42. Wilson JL, Herrod CM, Searle GL, et al. The absorption of blood
from the pleural space. Surgery 1960; 48: 76674.
43. von Recklinghausen FV. Zur Fettresorption. Virchow Arch (Pathol
Anat) 1863; 26: 172278.
44. Dybkowsky. Ueber Aufsaugang und Absonderung der Pleurawand.
Ber d Kgl Sachs Gesellsch d Wissensch Math-physik Kl 1866; 18:
191218.
45. Wheeldon EB, Mariassy AT, McSporran KD. The pleura: a combined
light microscopic and scanning and transmission electron
microscopic study in the sheep. II. Response to injury. Exp Lung
Res 1983; 5: 12540.
46. Tsilibary EC, Wissig SL. Absorption from the peritoneal cavity: SEM
study of the mesothelium covering the peritoneal surface of the
muscular portion of the diaphragm. Am J Anat 1977; 149:
12733.
47. Wang NS. The preformed stomas connecting the pleural cavity and
the lymphatics in the parietal pleura. Am Rev Respir Dis 1975;
111: 1220.
48. Miura T, Shimada T, Tanaka K, Chujo M, Uchida Y. Lymphatic
drainage of carbon particles injected into the pleural cavity of
the monkey, as studied by video-assisted thoracoscopy and
electron microscopy. J Thorac Cardiovasc Surg 2000; 120:
43747.
49. Li J. Ultrastructural study on the pleural stomata in human. Funct
Dev Morphol 1993; 3: 27780.
References 25
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
3
Mesothelial cells
MARIE-CLAUDE JAURAND, JOCELYNE FLEURY-FEITH
Introduction
Mesothelial cell morphology
Regulation of mesothelial cell proliferation
Physiopathology of mesothelial cells
27
27
30
32
INTRODUCTION
Mesothelial cells form the monolayer mesothelium covering connective tissue over the basal lamina of the pleura.
Morphological studies have shown that mesothelial cells
may present different phenotypes, likely dependent on the
various functions of the serosa that may differ between
parietal, visceral and mediastinal pleura. Mesothelial cells
also play a role in the maintenance of pleural homeostasis
in response to stimuli (mechanical injury, inammation).
Mesothelial cells have secretary functions and can synthesize glycosaminoglycans and surfactant, providing lubrication between parietal and visceral pleura.1 The main
pleural pathologies are inammatory processes (tuberculosis, other bacterial and viral infections) and cancers (e.g.
mesothelioma). The aim of the chapter is to summarize
our present knowledge on the morphology and biology of
pleural mesothelial cells, focusing on functions and pathophysiological pathways involved in pleural diseases.
Conclusions
Key points
References
34
34
35
28 Mesothelial cells
(a)
(b)
Figure 3.1 Mesothelial cells in situ. (a) Light micrograph of
mesothelium: , mesothelial cells (CT = submesothelial
connective tissue, 312). (b) Transmission electron microscopy:
, microvilli; , junctions; , basal lamina (3120).
and longer than those on the at cells, which have few and
short microvilli.1 Cubic cells are located at the visceral
mesothelial layer of the lung and the heart. Flat mesothelial cells are more numerous than cubic cells, and form the
parietal sheet of the pleura and pericardium.
By TEM, cubic mesothelial cells have a large, rounded
or ovoid nucleus with multiple and deep indentations,
generally in the centre of the cell.1 Organelles are well
developed and form clusters or are perinuclearly and
homogeneously distributed.1 Cytoplasm of cubic mesothelial cells may be electron-dense or electron-lucent.
Golgi apparatus is well developed. Flat mesothelial cells
30 Mesothelial cells
(a)
(b)
Figure 3.3 Immunocytochemistry of a human malignant
mesothelioma cell line performed with cytokeratin (a) and
vimentin (b) antibodies, showing positive cells with both
antibodies (268).
TNF-
Fn
Lam
Elast
Tn
Coll
ECM
IL-6
HGF/SF
TGF-
IGF-I
IG F-BP3
IGF-II
PAI-1
PAI-2
TF
HA
Normal cell
Met
IGF-R
EGF-R
PDGF
-R
EGF
IL6-R
IGF-R II
IGF-I
HA
PDGF
PDGF-R
VEGF-R
IGF-BP3
CD44
HGF/SF
Tumor cell
Met
IL-6
IL-8
TGF-
GM-CSF
G-CSF
M-CSF
Figure 3.4 Schematic representation of the factors produce by mesothelial cells and receptors (human, ; rat, ; both species, ) present
in normal and malignant mesothelial cells. See text for details. Thin arrows indicate modulation of the expression of one factor () by
another one (). Coll, collagen; ECM, extracellular matrix; EGF, epidermal growth factor; EGF-R, epidermal growth factor receptor; Elast,
elastin; Fn, bronectin; G-, M- and GM-CSF, granulocyte-, macrophage- and granulocyte/macrophage colony stimulating factors,
respectively; HA, hyaluronan; HGF/SF, hepatocyte growth factor/scattering factor; IGF-I, insulin-like growth factor receptor; IL-6,
interleukin 6; IL-8, interleukin 8; Lam, laminine; PAI, plasminogen activator inhibitor; PDGF, platelet-derived growth factor; PDGF-R,
platelet-derived growth factor receptor; TF, tissue factor; TGF-b, transforming growth factor b; Tn, tenascin; TNF-a, tumor necrosis factor
a; VEGF-R, vascular endothelial growth factor receptor.
32 Mesothelial cells
Human MM cells produce mRNA transcripts for IGFI, IGF-binding protein 3 and of IGF-I receptor; the expressions of IGF-I and IGF-binding protein 3 at a protein level
have also been conrmed.45 IGF-I appears to be an important regulator of MM cell growth (Figure 3.4).
The HGF/SF and c-Met pathway could be involved in
an autocrine fashion in the control of MM cell proliferation. Several studies have demonstrated the expression of
HGF/SF and c-Met in MM cell lines, and in parafn sections.52,6267 Nevertheless, expression of HGF/SF could be
limited to spindle-shaped cells.63 In addition to the cell
growth regulation, HGF/SF exerts stimulatory effect on the
motility, spreading and proliferation of MM cells and
stimulated the expression of matrix metalloproteinases.52,63,65
Vascular endothelial growth factor plays a role in the
growth of mesothelioma. MM cells express both VEGF
and VEGF receptors [fms-like tyrosine kinase (Flt-1) or
fetal liver kinase (Flk-1)], and their expression appears to
be enhanced in MM cells when compared with benign
cells.51 An autocrine role of VEGF has been suggested,
using neutralizing antibodies against VEGF or the VEGF
receptors Flt-1 and Flk-1.50
Malignant mesothelioma cells are resistant to apoptosis, but the mechanism remains to be elucidated. The antiapoptotic factor, Bcl-x, seems to play a role in this
resistance.6870 In MM cells, survival could be promoted by
an activation of the AKT/PKB pathway.71
Phagocytosis
Mesothelial cells have been shown to phagocytose mineral
particles such as asbestos bers, talc and quartz, as well as
glass microbeads.72 It has been demonstrated that asbestos
bres can be translocated from the lung to the pleura; hence
mesothelial cells can interact directly with bers and
respond to circulating mediators.7981 (See also Chapter 10,
Pleural reaction to mineral dusts.) The response of mesothelial cells has been largely studied in the context of brogenic
and carcinogenic potency of the bers. Internalization of
asbestos bers by rat mesothelial cells results in a lysosomal
degranulation in the phagocytic vacuole.21 Human
34 Mesothelial cells
CONCLUSIONS
A better knowledge of the biology of mesothelial cells is
needed to improve our ability to treat pleural diseases.
Further research should focus on the multipotent properties of mesothelial cells and better dene the pathways
KEY POINTS
The pleural mesothelium consists of a singlelayer epithelial sheet over a basal lamina, supported by the submesothelial connective tissue.
The apical surface of mesothelial cells shows heterogeneity from numerous randomly-oriented
long microvilli to relatively few microvilli. The
cytoplasm of mesothelial cells contains scattered
microtubules, dispersed microlaments and
bundled intermediate laments. Numerous plasmalemmal vesicles suggest intense pinocytic and
intracellular trafcking activity of mesothelial
cells.
The mesothelium acts as a barrier for exchange of
ions and small molecules. Mesothelial cells can
secrete immunomodulatory molecules, procoagulants and brinolytic mediators. Mesothelial
cells can phagocytose foreign particles. These
multiple functions make the mesothelial cell
crucial in maintaining pleural integrity.
The cellular source involved in the regeneration
of normal or damaged mesothelium is controversial. Mechanisms of mesothelium regeneration include centripetal migration of mesothelial
cells at the border of the damaged area, and/or
attachment of exfoliated mesothelial cells or precursor cells. It has been suggested that mesothelial cells could be multipotent cells.
Multiple cytogenetic alterations, loss of heterozygozity and frequent deletions are common features in malignant mesothelioma cells. Exposure
of mesothelial cells to asbestos bers results in
cell injury that may be responsible for the carcinogenicity of the bers.
Development of animal models of mesothelioma
help identify key genes related to the underlying
oncogenic processes. Somatic genetic alterations
in malignant mesotheliomas obtained by
intraperitoneal inoculation of asbestos or
ceramic bers in hemizygous NF2+/- mice were
similar to those observed in human malignant
mesothelioma.
References 35
REFERENCES
= Key primary paper
= Major review article
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
36 Mesothelial cells
43. Mutsaers SE, McAnulty RJ, Laurent GJ, et al. Cytokine regulation
of mesothelial cell proliferation in vitro and in vivo. Eur J Cell Biol
1997; 72: 249.
44. Zhong J, Gencay MM, Bubendorf L, et al. ERK1/2 and p38 MAP
kinase control MMP-2, MT1-MMP, and TIMP action and affect cell
migration: a comparison between mesothelioma and mesothelial
cells. J Cell Physiol 2006; 207: 54052.
45. Lee TC, Zhang YH, Aston C, et al. Normal human mesothelial cells
and mesothelioma cell lines express insulin-like growth factor-I
and associated molecules. Cancer Res 1993; 53: 285864.
46. Fujino S, Yokoyama A, Kohno N, Hiwada K. Interleukin 6 is an
autocrine growth factor for normal human pleural mesothelial
cells. Am J Respir Cell Mol Biol 1996; 14: 50815.
47. Heldin P, Asplund T, Ytterberg D, et al. Characterization of the
molecular mechanisms involved in the activation of hyaluronan
synthetase by platelet-derived growth factor in human
mesothelial cells. Biochem J 1992; 283: 16570.
48. Jacobson A, Brinck J, Briskin MJ, et al. Expression of human
hyaluronan synthases in response to external stimuli. Biochem J
2000; 348: 2935.
49. Asplund T, Heldin P. Hyaluronan receptors are expressed on human
malignant mesothelioma cells but not on normal mesothelial cells.
Cancer Res 1994; 54: 451623.
50. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth
factor is an autocrine growth factor in human malignant
mesothelioma. J Pathol 2001; 193: 46875.
51. Lee YCG, Melkerneker D, Thompson PJ, et al. Transforming growth
factor b induces vascular endothelial growth factor elaboration
from pleural mesothelial cells in vivo and in vitro. Am J Respir Crit
Care Med 2002; 165: 8894.
52. Klominek J, Baskin B, Liu Z, Hauzenberger D. Hepatocyte growth
factor/scatter factor stimulates chemotaxis and growth of
malignant mesothelioma cells through c-met receptor. Int J
Cancer 1998; 76: 2409.
53. Rutten AA, Bermudez E, Stewart W, et al. Expression of insulin-like
growth factor II in spontaneously immortalized rat mesothelial
and spontaneous mesothelioma cells : a potential autocrine role of
insulin-like growth factor II. Cancer Res 1995; 55: 36349.
54. Owens MW, Milligan SA. Growth factor modulation of rat pleural
mesothelial cell mitogenesis and collagen synthesis effects of
epidermal growth factor and platelet-derived growth factor.
Inammation 1994; 18: 7787.
55. Adamson IYR, Bakowska J, Prieditis H. Proliferation of rat pleural
mesothelial cells in response to hepatocyte and keratinocyte
growth factors. Am J Respir Cell Mol Biol 2000; 23: 3459.
56. Gordon GJ, Mani M, Mukhopadhyay L, et al. Expression patterns of
inhibitor of apoptosis proteins in malignant pleural mesothelioma.
J Pathol 2007; 211: 44754.
57. Versnel MA, Claessonwelsh L, Hammacher A, et al. Human
malignant mesothelioma cell lines express PDGF beta-receptors
whereas cultured normal mesothelial cells express predominantly
PDGF alpha-receptors. Oncogene 1991; 6: 200511.
58. Ramael M, Buysse C, Vandenbossche J, et al. Immunoreactivity for
the beta-chain of the platelet-derived growth factor receptor in
malignant mesothelioma and non-neoplastic mesothelium. J
Pathol 1992; 167: 14.
59. Fredriksson L, Li H, Eriksson U. The PDGF family: four gene
products form ve dimeric isoforms. Cytokine Growth Factor Rev
2004; 15: 197204.
60. Metheny-Barlow LJ, Flynn B, van Gijssel HE, et al. Paradoxical
effects of platelet-derived growth factor-A overexpression in
malignant mesothelioma. Antiproliferative effects in vitro and
tumorigenic stimulation in vivo. Am J Respir Cell Mol Biol 2001;
24: 694702.
61. Walker C, Bermudez E, Stewart W, et al. Characterization of
patelet-derived growth factor and platelet-derived growth factor
receptor expression in asbestos-induced rat mesothelioma. Cancer
Res 1992; 52: 3016.
References 37
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
4
Normal physiological uid and cellular contents
MARC NOPPEN
Animal studies
Human studies
39
40
Key points
References
41
41
ANIMAL STUDIES
Data derived from animal studies are summarized in Table
4.1. Although there is a certain degree of concordance as to
the total volume and total white blood cell count of
normal rabbit and dog pleural uid, there is a large disparity between the various differential cell counts between the
various animal models. The reasons for this disparity
include differences in identication of and distinction
between macrophages, monocytes and mesothelial cells,
and methodological differences in xation, staining and
uid retrieval techniques (aspiration or lavage), and possible genuine interspecies differences.6
Miserocchi and Agostoni7 collected pleural uid from
the costodiaphragmatic sinuses of rabbits and dogs. In
rabbits, 0.46 mL of free uid could be retrieved from both
pleural spaces (0.2 mL/kg). In dogs, 0.55 mL or 0.15 mL/kg
could be collected. When the volume of uid adherent to
the lung surfaces was assessed and included, volumes of
pleural uid rose to 0.4 mL/kg and 0.26 mL/kg, respectively. Total and differential white blood cell counts were
performed using a cell counting chamber and May
GrnwaldGiemsa stained cell smears. In rabbits, 2442
595 cells/mL were present, including 31.8 percent mesothelial cells, 60.8 percent monocytes and 7.4 percent lymphocytes. In dogs, 2208 734 cells/mL were present, including
69.6 percent mesothelial cells, 28.2 percent monocytes and
2.2 percent lymphocytes. Stauffer et al.8 compared different cytopreparations and different methods of uid collection in rabbits: aspiration of the free uid versus irrigation
with 10 mL Hanks solution. The total volume of aspirated
pleural uid volume for both pleural spaces was 0.45
0.12 mL (0.13 mL/kg). Total white blood cell count for the
original aspirated uid was 1503 281 cells/mL.
7
7
8
9
10
10
11
12
13
14
15
16
17
17
17
17
aNot
Species
Mean volume
(right and left
pleural space)
(mL/kg)
Total white
blood cell
count
(cells/mL)
Macrophages
(%)
Monocytes
(%)
Mesothelial
cells (%)
Lymphocytes
(%)
Rabbits
Dogs
Rabbits
Rabbits
Rabbitsb
Rabbitsc
Rabbits
Rabbits
Rabbits
Dogs
Sheep
Sheep
Rats
Puppies
Cats
Pigs
0.2a
0.15a
0.13
0.13
NR
NR
0.1
0.09
0.22
0.1
0.12
0.04
0.6
1.33
0.28
O.22
2442 595
2208 734
1503 281
1503 414
NR
NR
1216 800
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
7.616
7.5 1.5
9.25
5
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
60.8
28.2
38.670.1
70.1 3.6
66.5
60.17
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
31.8
69.8
3.725.4
8.9 1.6
8
10
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
7.4
8.2
1010.6
10.6 1.8
9.75
11
NR
NR
NR
NR
NR
NR
NR
NR
NR
NR
including uid adherent to lung surfaces; buid retrieved by aspiration; cuid retrieved by lavage; NR = not reported.
HUMAN STUDIES
Reliable data on the volume and cellular content of pleural
uid in normal humans are scarce because of the obvious
difculties in retrieving this small amount of uid without
disturbing the pleural environment. The rst study
addressing this issue was that of Yamada,18 published in
1933, who punctured the ninth or tenth intercostals space
on the dorsal axillary line in a group of healthy Japanese
soldiers. In approximately 30 percent of cases, some uid
was aspirated after a period of rest, whereas in approximately 70 percent of cases some uid was retrieved after
exercise. Usually only a few drops of foam was aspirated
but, in a few cases, up to 20 mL could be retrieved. Total
white blood cell count was 4500 cells/mL (range
17006200). Differential cell count showed 53.7 percent
cells similar to monocytes, 10.2 percent lymphocytes, 3
percent mesothelial cells, 3.6 percent granulocytes and
29.5 percent deteriorated cells of difcult classication.
More recently, a pleural lavage technique was used to
retrieve the few milliliters of pleural uid present in the
pleural space of otherwise healthy participants undergoing
thoracoscopic sympathectomy for the treatment of essential hyperhidrosis.19 In analogy with bronchoalveolar
References 41
KEY POINTS
REFERENCES
5. Mills PC, Chen Y, Hills YC, Hills BA. Comparison of surfactant lipids
between pleural and pulmonary lining uids. Pulm Pharmacol Ther
2006; 19: 2926.
6. Noppen M. Normal volume and cellular contents of pleural uid.
Curr Opin Pulm Med 2001; 7: 18082.
7. Miserocchi G, Agostoni E. Contents of pleural space. J Appl Physiol
1971; 30: 20813.
8. Stauffer JL, Potts DE, Sahn SA. Cellular contents of the normal
rabbit pleural space. Acta Cytol 1978; 22: 57074.
9. Sahn SA, Willcox ML, Good JT , Potts DE, Filley DF. Characteristics
of normal rabbit pleural uid: physiologic and biochemical
implications. Lung 1979; 156: 639.
10. Novakov IP, Peshev ZP. Cell types in the normal pleural uid from
rabbits. Trakia J Sci 2005; 3: 225.
11. Broaddus VC, Araya M. Liquid and protein dynamics using a new
minimally invasive pleural catheter in rabbits. J Appl Physiol 1992;
72: 8517.
12. Wang PM, Lai-Fook SJ. Pleural tissue hyaluran produced by postmortem ventilation in rabbits. Lung 2000; 178: 112.
13. Agostoni E, Zocchi L. Starling forces and lymphatic drainage in
pleural liquid and protein exchanges. Respir Physiol 1991; 86:
27181.
14. Mellins RB, Levine OR, Fishman AP. Effects of systemic and
pulmonary venous hypertension on pleural and pericardial uid
accumulation. J Appl Physiol 1970; 29: 5469.
15. Wiener-Kronish JP, Albertine KH, Licko V, Staub NC. Protein egress
16.
17.
18.
19.
20.
21.
22.
23.
and entry rates in pleural uid and plasma in sheep. J Appl Physiol
1984; 56: 45963.
Broaddus VC, Araya M, Carlton DP, Bland RD. Developmental
changes in pleural liquid protein concentration in sheep. Am Rev
Respir Dis 1991; 143: 3841.
Miserocchi G, Negrini D, Mortola J. Comparative features of
Starling-lymphatic interaction at the pleural level in mammals. J
Appl Physiol 1984; 56: 11516.
Yamada S. Uber die serse Flssigkeit in der Pleurahhle der
gesunden Menschen. Z Ges Exp Med 1933; 90: 3428.
Noppen M, De Waele M, Li R, et al. Volume and cellular content of
normal pleural uid in humans examined by pleural lavage. Am J
Respir Crit Care Med 2001; 7: 18082.
Noppen M, Herregodts P, Dhaese J, Vincken W, Dhaens J. A
simplied thoracoscopic sympathicolysis technique for essential
hyperhidrosis: results in 100 consecutive patients. J Laparoendosc
Surg 1996; 6: 1519.
Scherpereel A, Madsen P, Chahine B, et al. T cell subsets in pleural
uid of healthy subjects. Am J Respir Crit Care Med 2007; 175:
A452.
De Smedt A, Vanderlinden E, Demanet C, et al. Characterisation of
pleural inammation occurring after primary spontaneous
pneumothorax. Eur Respir J 2004; 23: 896900.
Noppen M, Vanderlinden E, Demanet C, De Waele M. Pleural
lavage in non-exudative benign asbestos-related pleural disease.
Am J Respir Crit Care Med 2002; 165: A33.
5
Physiology: uid and solute exchange in normal
physiological states
V COURTNEY BROADDUS
Introduction
Pleural uid production
Pleural uid absorption
43
43
46
INTRODUCTION
The major function of the pleura and the pleural space
may be to permit the lungs to expand and deate easily
within the chest. The pleural coverings allow the lungs to
move with minimal friction and adjust their shape during
changes in size. Because the space is under subatmospheric
pressure with no internal barriers to liquid movement, the
pleural space can also accommodate large volumes of
liquid. These collections, pleural effusions, are a common
clinical issue. In this chapter, we will discuss what is known
about normal movement of liquid and solutes into and out
of the pleural space.
The division of the pleura into visceral and parietal
membranes is based primarily upon the structures each
envelops, though structural histological differences
between the two exist. The visceral pleura encloses the
lungs and interlobar ssures before turning back on itself
to form the parietal pleura covering the inner wall of the
chest, the diaphragm and the mediastinum. In the normal
state, a subatmospheric intrapleural pressure keeps the visceral pleura, which is rmly attached to the lung
parenchyma, mechanically coupled to the parietal pleura,
which is attached to the chest wall. Indeed, it is the subatmospheric pressure that allows the pleural space to act as a
sump for the collection of excess liquid produced elsewhere in the body. The balance of pleural pressures keeps
the mediastinum midline and, if the mediastinum is not
xed in position, a rise in intrapleural pressure due to the
presence of intrapleural liquid or air will cause a shift of
the mediastinum to the contralateral side.
Under normal conditions, the pleural space is home to
a small amount of uid, recently quantied in humans by
Key points
References
47
47
20 mm
Figure 5.1 Parietal pleura. The parietal pleura is lined by
mesothelial cells (M) adjacent to the pleural space (PS). The blood
supply is via the intercostal arteries (B). The parietal pleura, but
not the visceral pleura, contains the lymphatics (L) that drain
pleural liquid via stomata that open into the pleural space.
Figure 5.2 Visceral pleura. The visceral pleura (VP) lies between
the pleural space (PS) and the alveoli of the lung parenchyma,
and is lined by mesothelial cells (M). The blood supply to the
visceral pleura is via the bronchial arteries (A). (Reproduced from
Reference 3 by courtesy of Marcel Dekker, Inc.)
Parietal pleura
Visceral pleura
Pleural
space
Pulmonary
capillaries
Lymphatic
stomata
Alveoli
15 m
Intercostal
microvessels
40 m
Bronchial
microvessels
serum in patients.19 Thus, passive forces alone may be sufcient to explain the small difference in ionic concentrations between pleural liquid and serum and are more
consistent with the leaky nature of the mesothelium.8,20
Once it enters the pleural space, pleural liquid very
slowly ows toward the dependent regions of the pleural
space.21 Such ow has been proposed based on ndings of
pleural pressure gradients. Pleural pressure has been
exceedingly difcult to measure: even by placing a small
catheter into the pleural space, the space is greatly widened
and pressures are measured consistent with a static
column of liquid. However, when pleural pressures are
measured with micropipettes that do not distort the space,
pleural pressure gradients are consistent with a gradual
ow of liquid from the top to bottom.22,23
Based on noninvasive studies in different species, the
production of pleural liquid is normally slow. In earlier
studies, measured ows were probably overestimated due
to inammation and distortion caused by invasive techniques used to measure the uid turnover. Based upon
radiolabel studies or minimally invasive techniques that
leave the pleural space intact, pleural liquid production has
been measured at approximately 0.01 mL/(kg h) in
awake sheep9 and 0.02 in rabbits.14 The half-time of pleural
liquid turnover in sheep and rabbits is 68 hours.14 At
these rates, there would be an entry (and exit) of 15 mL per
day in a 60 kg human.
References 47
5.
6.
7.
8.
9.
10.
KEY POINTS
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
REFERENCES
23.
24.
1. Noppen M, De Waele M, Li R, et al. Volume and cellular content of
normal pleural uid in humans examined by pleural lavage. Am J
Respir Crit Care Med 2000; 162: 10236.
2. Albertine KH, Wiener-Kronish JP, Bastacky J, Staub NC. No
evidence for mesothelial cell contact across the costal pleural
space of sheep. J Appl Physiol 1991; 70: 1234.
3. Staub NC, Wiener-Kronish JP, Albertine KH. Transport through the
pleura: physiology of normal liquid and solute exchange in the
pleural space. In: Chretien J, Bignon J, Hirsch A (eds). The pleura in
health and disease. New York: Marcel Dekker, Inc., 1985: 1745.
4. Broaddus VC, Light RW. Pleural effusion. In: Mason RJ, Murray JF,
Broaddus VC, Nadel JA (eds). Murray Nadels Textbook of
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
6
Physiology: changes with pleural effusion and
pneumothorax
RICHARD W LIGHT
Effects of effusion on the pleural pressure
Effects of effusion on pulmonary function
Effects of effusion on blood gases
Effects of effusion on exercise tolerance
Effects of effusion on the diaphragm
Effects of effusion on the heart
Effects of pneumothorax on pleural pressure
49
51
52
54
54
55
55
56
56
57
57
57
57
57
10
5
0
5
10
15
20
Transudates Malignancies Miscellaneous Trapped lung
exudates
0
210
220
230
240
250
400
800
1200
1600
2000
2400
2800
3200
3600
Table 6.1 Mean pulmonary functions baseline and 24 hours after therapeutic thoracentesis
Test
FVC (mL) , n = 26
FEV1 (mL), n = 26
TLC (mL), n = 12
Sgaw, n = 12
DLCO, n = 9
Before
After
Change SEM
2060
1360
4580
0.18
13.4
2470
1640
5280
0.14
14.1
410 76a
380 55a
700 196a
-0.04 0.02
0.7 0.70
FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; TLC, total lung capacity; Sgaw,
specic airway conductance; DLCO, diffusion capacity of the lung.
ap < 0.001.
1000
500
1000
2000
3000
4000
100
80
48
70
46
60
44
50
40
42
40
30
38
20
36
10
34
10
20
PaCO2
50
(torr)
(mmHg)
52
MAP
90
30
40
50
60
32
70
10
Volpl (mL/kg)
20
30
40
50
60
70
50
60
70
Volpl (mL/kg)
600
50
PaO2
500
Qs/Qt
45
40
35
(%)
(torr)
400
300
30
25
200
20
100
0
15
0
10
20
30
40
50
60
70
10
Volpl (mL/kg)
10
20
30
40
Volpl (mL/kg)
Figure 6.4 Mean arterial pressure (MAP), arterial partial pressure of O2 and CO2 (PaO2, PaCO2) and intrapulmonary shunt (Qs/Qt) in pigs.
Solid circles indicate increasing intrapleural volume (Volpl) and open triangles indicate decreasing Volpl. Reprinted with permission from
Reference 12.
Table 6.2 Effects of position on oxygenation status of patients with pleural effusion
Study
Sonnenblick et al.17
Chang et al.19
Romero et al.20
Neagley et al.18
Effusion side up
8
21
33
10
Table 6.3 Results of maximal exercise tests before and after a therapeutic thoracentesis in 15 patients from whom a mean of 1612 mL
pleural uid was removed
FEV1, L (%pred)
FVC, L (%pred)
Max Work, watts (%pred)
Pre
Post
Change
0.18 0.23
0.31 0.43
1.3 19.4
46 226
3.1 11.8
1.2 5.2
-0.9 4.7
0.2 12.9
-6.1 10.6
0.11 0.67
0.58 1.14
0.83 1.57
0.007
0.013
0.794
0.449
0.321
0.394
0.454
0.953
0.049
0.547
0.083
0.070
FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; V O2, oxygen consumption per minute; V E max, minute ventilation at maximum
ray).26 It was unusual to have chamber collapse with isolated right pleural effusion. Hemodynamics were studied in
22 mechanically ventilated patients with moderate to large
pleural effusions before and after they underwent drainage
of the effusions with a pigtail catheter by Ahmed et al.27
They reported that the mean cardiac output increased from
7.7 to 8.4 L/minute, but that this change was not statistically
signicant. However, the pulmonary capillary wedge pressure and the central venous pressure both decreased
signicantly after the pleural uid was drained.
There have been three reports of patients with compromised cardiac output attributed to large pleural effusions.2830 Negus et al.28 reported a 60-year-old woman
who presented with a large left sided pleural effusion with
marked mediastinal shift to the right. Shortly after presentation, her blood pressure became unobtainable and her
carotid and femoral pulses were very weak. When a chest
tube was placed and 1125 mL of pleural uid was withdrawn, the blood pressure rose to 140/86 and the pulses
became bounding.28. Kisanuki et al.29 reported a 68-yearold man who presented with a blood pressure of 90/60 and
a large left encapsulated pleural effusion. A two-dimensional echocardiogram revealed that the pleural effusion
compressed the lateral wall of the left ventricle. With Mmode echocardiogram, the left ventricular collapse was
observed throughout diastole. After drainage of 500 mL of
pleural uid, the blood pressure rose from 90/60 to 120/80
and the left ventricular collapse during diastole resolved.29
Kopterides et al.30 reported two patients who had hemodynamic compromise with large left-sided effusions in whom
left ventricular diastolic collapse was demonstrated by
transthoracic echocardiograph. It is interesting that all
four of the patients in the above three reports had left sided
effusions. It is probable that the increased pleural pressure
resulting from the pleural uid is responsible for the
decreased cardiac output.
EFFECTS OF PNEUMOTHORAX ON
PULMONARY FUNCTION
When there is a communication between the alveoli and
the pleural space or between the ambient air and the
pleural space, air will enter the pleural space because the
pleural pressure is normally negative.10 As air enters the
pleural space, the pleural pressure gradually increases. Air
will continue to enter the pleural space until the pleural
pressure becomes zero or the communication is closed.
Since both the hemithorax and the lung are distensible
objects whose volume depends upon their distending pressure, the hemithorax will enlarge while the lung will
become smaller as the pleural pressure increases due to air
entering the pleural space.
Since patients with signicant pneumothoraces are
usually symptomatic, there is a dearth of information
available concerning their pulmonary function. In general,
when a pneumothorax is present, the increase in the
volume of the hemithorax is less than the decrease in the
volume of the lung. For example, if a volume of air equal
to 33 percent of the vital capacity is introduced into the
pleural space, the volume of the lung will decrease by 25
percent of the vital capacity while the volume of the
hemithorax will increase by 8 percent of the vital capacity
(Figure 6.5).10
60
50
40
Thoracic cavity
volume (8% VC)
30
Lung volume (25% VC)
20
10
20
15
10
5
10
15
20
References 57
EFFECTS OF PNEUMOTHORAX ON
DIAPHRAGMATIC FUNCTION
KEY POINTS
There have been no studies on the effects of a pneumothorax on the exercise tolerance of either animals or man.
However, it would be anticipated that the exercise tolerance would be markedly impaired since many patients are
dyspneic at rest.
REFERENCES
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
7
Pleural inammation and infection
VEENA B ANTONY, BRENDAN F BELLEW
Introduction
Microbial virulence factors
Defense mechanisms of the pleura
Pleural inammatory cells
Initiation of inammation
59
60
61
63
64
INTRODUCTION
The pleural mesothelium is a monolayer of cells that may
vary in shape from attened ovoid to columnar or
cuboidal. The mesothelium adheres to a basement membrane that comprises a matrix of connective tissue.1 The
basement membrane of the pleura is a complex structure
that plays an important role in inammation of the pleural
space.2 The visceral pleura is nourished by a large network
of capillaries that originate from the bronchial arteries.
The parietal and diaphragmatic surfaces of the pleura are
supplied by the blood vessels local to those areas. Together,
the visceral, parietal and diaphragmatic surfaces of the
pleura form a closed boundary around the pleural space.
Under normal conditions the volume of uid in the
pleural space is very small, in the range of 0.20.5 mL. The
pleural space may expand to accommodate much larger
volumes under certain conditions, such as pleural effusion.
Although the pleural space is drained by lymphatic vessels,
they are not present in large numbers. Indeed, the lymphatic vessels draining the pleural space may grow in size
and number according to need.3 Among the lymph nodes
that drain pleural structures are the mediastinal, intercostal and sternal lymph nodes. Normally, pleural uid is
characterized by low protein concentration and low cellularity with an absence of inammatory cells.4
The development of pleural infections depends on the
balance between immune pleural responses and the virulence of the organism. Pleural infections were recognized
over 300 years ago and pleural empyema was described in
great detail in 1685 by Thomas Willis.5 Sources of pleural
infection may be several. A classic mechanism whereby
organisms enter the pleural space is pneumonia, where
Perpetuation of inammation
Resolution and repair
Inhibition of pleural inammatory responses
Key points
References
65
66
66
67
67
the invasion of the alveolar air space by organisms is followed by a breach of the pleural barrier with the development of parapneumonic effusions. Other mechanisms
where the pleura may be contaminated by infecting
organisms are the rupture of subpleural tuberculous foci
or granuloma, or dissemination of infectious particles and
toxins via the bloodstream. Intra-abdominal infections
may enter the pleural space through the diaphragm and
penetrating injury to the chest wall may also result in
introduction of organisms into the pleura. A devastating
and dangerous form of pleural infection is seen in
Boerhaaves syndrome where there is rupture of the
esophagus and contamination of the pleural space with
mouth and stomach ora.
Upon infection, the microorganism is recognized by
the pleural mesothelial cell which remains the rst line of
defense. Pleural responses to infection include those of
innate immunity as well as adaptive or acquired immunity. Innate immunity was formerly thought to be a nonspecic immune response characterized by engulfment
and digestion of microorganisms by mucosal cells,
mesothelial cells, macrophages and other leukocytes. It is
now recognized that innate immunity possesses specicity. Also, mesothelial cells and other phagocytic cells are
capable of discriminating between pathogens and self.
Importantly, innate immune responses and acquired
immune responses are closely linked and innate immune
responses can be a prerequisite for the presence of adaptive immunity.6 In this review, we consider both innate
immune responses and acquired immune responses
against invading organisms in the pleural space as well as
the virulence factors that contribute to the establishment
of an infection.
Mononuclear cells
Mesothelial cells recruit signicant numbers of mononuclear cells to the pleural space during a variety of infections. This inux may be strong and persistent in response
to infections such as tuberculosis.81 Mesothelial cells
release several C-C chemokines, which recruit mononuclear cells to the pleural space. Among the C-C
chemokines are regulated upon activation, normally T-cell
expressed and secreted (RANTES) and MCP-1, -2 and -3.
The expression of C-C receptors, specically CCR2 on
mononuclear cells, is regulated in part by factors produced
at local sites of inammation such as the pleural space.
Thus, CCR2 expression is high while the mononuclear
cells are in the peripheral blood circulation, but is signicantly reduced when the mononuclear cells reach the
pleural space. This mechanism serves to localize and
immobilize the monocytes once they reach the pleural
cavity.82 Also, the C-X3-C chemokine fractalkine in its
soluble form is chemotactic for monocytes and in its membrane-bound form promotes strong adhesion by monocytes.83
Eosinophils
Eosinophils are identied as playing an important role in
the pathogenesis of idiopathic or allergic responses to
pleural injury, parasitic diseases, the presence of air or
blood in the pleural space and in hypersensitivity
responses to certain drugs.84 The mechanisms and control
of the accumulation of these cells in the pleural space is
unclear.
Lymphocytes
The pleural space has a small population of lymphocytes,
both B-lymphocytes and T-lymphocytes.85 The T-lymphocytes include gd-T cells and CD4-/CD8-ab-T cells. During
granulomatous inammation, the number of lymphocytes
can increase dramatically reecting either a Th-1, CD4 Tcell predominant response in diseases such as tuberculosis,
or a CD8+ response in some diseases as in certain lymphomas, etc. The production of antibodies by B cells and
associated lymphoid tissue is important for resistance to
infectious processes; however, little is known about this
immune processing pathway in the pleural space.
INITIATION OF INFLAMMATION
The mesothelial cell plays a critical role in the initiation of
inammatory responses in the pleural space because it is
the rst cell to recognize the invasion of the pleural space.
Pleural inammation is not only associated with an inux
of a large number of inammatory cells, but also with a
transfer of proteins and a change in the permeability of the
pleura. Pleural mesothelial cells release chemokines in a
polar fashion, with a higher concentration being released
on the apical surface, which leads to directed migration of
phagocytic cells into the pleural space. However, the
mechanisms whereby pleural integrity to proteins and
uid is breached with the development of an exudative
high-protein-containing effusion are beginning to be elucidated. An infectious agent can initiate a cascade of events
which include release of nitric oxide and production of
vascular permeability factor (VPF)/vascular endothelial
growth factor (VEGF) through the accumulation of
HIF-1a. VEGF downregulates both cadherins and
Perpetuation of inammation 65
PERPETUATION OF INFLAMMATION
Following initiation of the inammatory process, several
mediators cells and extracellular matrix components
play a critical role in perpetuating the process of inammation. An example of an extracellular matrix component
that plays a role in perpetuation of inammation is
hyaluronan. Hyaluronan is a high molecular weight nonsulfated glycosaminoglycan produced by mesothelial cells,
under both normal and inammatory conditions.
Hyaluronan is present in the pericellular and extracellular
matrix of mesothelial cells. Hyaluronan is a linear polysaccharide composed of repeating alternation of N-acetyl glucosamine and glucuronide with each N-acetyl glucosamine
joined to gluconuride by a b-1,4 glycosidic linkage and
each glucuronide joined to the next N-acetyl glucosamine
by a b-1,3 glycosidic linkage.102 Each molecule of hyaluronan may contain 10 000 or more disaccharide repeats and
have a molecular mass of several million Daltons. This
high molecular weight hyaluron is a relatively inactive
component but when it undergoes hydrolysis it produces
fragments of low molecular weight, which may mediate
multiple processes. Low molecular weight fragments of
hyaluronan induce mesothelial cells to express the
chemokines MCP-1 and IL-8.103 Hyaluronan interacts
with specic malignant cell receptors, such as CD44 and
the receptor for hyaluronic acid mediated motility
(RHAMM).104 We have demonstrated that the standard
isoform, CD44s, which does not contain variant exon
product and is highly expressed in malignant breast cancer
cells, is a specic mechanism whereby breast cancer cells
adhere to pleural mesothelial cells.105 Addition of CD44s
antibody to the media blocks adherence of malignant
breast cancer MCF7 cells to mesothelial monolayers.106
Regulation of the degree of adherence can be regulated by
the presence or absence of the variant exon products. The
References 67
4.
5.
6.
7.
KEY POINTS
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
REFERENCES
= Key primary paper
= Major review article
22.
23.
24.
25.
References 69
92. Mazure NM, Chen EY, Laderoute KR, Giaccia AJ. Induction of
vascular endothelial growth factor by hypoxia is modulated by a
phosphatidylinositol 3-kinase/Akt signaling pathway in Ha-rastransformed cells through a hypoxia inducible factor-1
transcriptional element. Blood 1997; 90: 332231.
93. Becker PM, Alcasabas A, Yu AY, Semenza GL, Bunton TE. Oxygenindependent upregulation of vascular endothelial growth factor
and vascular barrier dysfunction during ventilated pulmonary
ischemia in isolated ferret lungs. Am J Respir Cell Mol Biol 2000;
22: 2729.
94. Thickett DR, Armstrong L, Millar AB. Vascular endothelial growth
factor (VEGF) in inammatory and malignant pleural effusions.
Thorax 1999; 54: 70710.
95. DArcangelo D, Facchiano F, Barlucchi LM, et al. Acidosis inhibits
endothelial cell apoptosis and function and induces basic
broblast growth factor and vascular endothelial growth factor
expression. Circ Res 2000; 86: 31218.
96. Mohammed KA, Nasreen N, Ward MJ, Antony VB. Induction of
acute pleural inammation by Staphylococcus aureus. I. CD4+ T
cells play a critical role in experimental empyema. J Infect Dis
2000; 181: 16939.
97. Zhang XY, Pettengell R, Nasiri N, et al. Characteristics and growth
patterns of human peritoneal mesothelial cells: comparison
between advanced epithelial ovarian cancer and non-ovarian
cancer sources. J Soc Gynecol Invest 1999; 6: 33340.
98. Nasreen N, Mohammed KA, Hardwick J, et al. Polar production of
interleukin-8 by mesothelial cells promotes the transmesothelial
migration of neutrophils: role of intercellular adhesion molecule1. J Infect Dis 2001; 183: 163845.
99. Corada M, Liao F, Lindgren M, et al. Monoclonal antibodies
directed to different regions of vascular endothelial cadherin
extracellular domain affect adhesion and clustering of the protein
and modulate endothelial permeability. Blood 2001; 97:
167984.
100. Blankesteijn WM, van Gijn ME, Essers-Janssen YP, Daemen MJ,
Smits JF. Beta-catenin, an inducer of uncontrolled cell
proliferation and migration in malignancies, is localized in the
cytoplasm of vascular endothelium during neovascularization after
myocardial infarction. Am J Pathol 2000; 157: 87783.
101. Dejana E. Endothelial adherens junctions: implications in the
control of vascular permeability and angiogenesis. J Clin Invest
1996; 98: 194953.
102. Bourguignon LY, Lokeshwar VB, Chen X, Kerrick WG. Hyaluronic
acid-induced lymphocyte signal transduction and HA receptor
(GP85/CD44)-cytoskeleton interaction. J Immunol 1993; 151:
663444.
103. Haslinger B, Mandl-Weber S, Sellmayer A, Sitter T. Hyaluronan
fragments induce the synthesis of MCP-1 and IL-8 in cultured
human peritoneal mesothelial cells Cell Tissue Res 2001; 305:7986.
104. Ponta H. The CD44 protein family. Int J Biochem Cell Biol 1998;
30: 299305.
105. Hott J, Godbey S, Antony V. The role of the mesothelial cell in
pleural metastasis: inhibition of breast carcinoma cell adherence
to pleural cells by hyaluronidase. FASEB J 1992; 6: 1919.
106. Hott J, Godbey S, Antony VB. The role of the mesothelial cell in
pleural metastasis: breast carcinoma cell adherence to pleural
mesothelial cells by a mechanism involving hyaluronate and CD44.
Am Rev Respir Dis 1993; 147: A794.
107. Johnson JP. Cell adhesion molecules of the immunoglobulin
supergene family and their role in malignant transformation and
progression to metastatic disease. Cancer Metastasis Rev 1991;
10: 1122.
108. Underhill C. CD44: the hyaluronan receptor. J Cell Sci 1992; 103
(Pt 2): 2938.
109. Lee YCG, Lane, KB, Zoia O, et al. Transforming growth factor-b
induces collagen synthesis without inducing IL-8 production in
mesothelial cells. Eur Respir J 2003; 22:197202.
8
Immunology
NICOLA A WILSON, STEVEN E MUTSAERS, YC GARY LEE
Introduction
Cytokine growth factors in pleural brosis
Cytokines in pleural uid formation
Immunomodulatory cytokines
71
71
79
81
INTRODUCTION
The term cytokine was rst used in 1974 to describe the
group of low molecular weight molecules that are secreted
by one cell to mediate cellcell interaction and regulate the
behavior of the same or other nearby cells. The last decade
has seen an explosion of literature on cytokine research.
The majority of cytokines are multifunctional, share overlapping functions, and their actions are often cell- and
environment-specic. Disruption of the balances of the
cytokine network underlies the pathogenesis of disease
states. Therapeutic manipulation of cytokine proles are
increasingly used in clinical trials.
The presence of many cytokines has been demonstrated
in pleural uids or in the pleura. Resident mesothelial cells,
as well as inltrating inammatory and cancer cells, are
known to produce a vast variety of cytokines. Cytokines can
also reach the pleural space from the systemic circulation.
Actual evidence of cytokine actions in the pleura is limited
and their functions in the pleura are often extrapolated
from results in other systems. Several cytokines of interest
are described below and are arbitrarily divided into groups
according to their reported functions in the pleura.
Summary
Key points
References
89
89
89
72
Immunology
sions19 have been achieved in animal models by neutralizing TGF-b functions, or by increasing the levels of
inhibitory Smad proteins.20
The use of pan-specic neutralizing anti-TGF-b antibodies have been shown to decrease the volume of pus and
the adhesions formed during Pasteurella multocidainduced empyema in rabbits.21 Importantly, the microscopic pleural thickness and broblast scores were also
decreased. Similarly, the volume of pleural effusion and
recruitment of inammatory cells to the pleural cavity
were decreased by neutralizing pan anti-TGF-b antibodies
during Mycobacterium tuberculosis antigen-specic pleural
effusion formation.22
PLEURODESIS
Stimulating factors
(e.g. tissue injury; irradiation; TGF-;
angiotensin II; thromboxane; glucose and
glycosylation products, etc.)
Mesothelial cells
Inflammatory cells
Cancer cells (in pleural malignancies)
TGF -b
Activators
To convert latent TGF-b
into its active form
(e.g. plasmin, ROS,
thrombospondin)
TGF-
Matrix
synthesis
Matrix
degradation
Pleural fibrosis
(a)
(b)
Figure 8.3 The pleura (indicated by the arrows) following treatment with transforming growth factor (TGF)-b2 injection (a) is signicantly
thickened with a large amount of collagen and brous tissue deposition compared with pleura from the control side (b). Reprinted from Lee
YCG, Lane KB, Parker RE, et al. Thorax 2000; 55: 105862 with permission from the publisher, the BMJ Publishing Group.
74
Immunology
liferation. TGF-b acts as a tumor suppressor by also promoting cellular differentiation or apoptosis48 in normal
human cells, including mesothelial cells,49 and during the
early stage of carcinogenesis. However, advanced tumors
are often resistant to such TGF-b-mediated growth arrest,
probably as a result of reduced TGF-b signaling secondary
to mutations in genes encoding TGF-b signaling mediators.48 Once resistance develops, the more aggressive forms
of cancer cells can make use of TGF-b to enhance their
growth and metastasis in several ways. TGF-b signaling in
the tumor microenvironment signicantly affects carcinoma initiation, progression and metastasis via epithelial
cell autonomous and interdependent stromalepithelial
interactions (see review50). TGF-b can promote angiogenesis essential for tumor growth, and increases extracellular
matrix synthesis by cancer cells, allowing their binding to
cell-adhesion molecules, thereby facilitating distant metastasis. The immunosuppressive functions of TGF-b may
enable cancer cells to escape immune surveillance.48
The effect of TGF-b on pleural malignancies is largely
unknown. In mesothelioma cells, TGF-b increases the synthesis of matrix protein10 and urokinase-type plasminogen
activator. Antagonizing TGF-b activity can inhibit
mesothelioma cell proliferation and tumor growth in
vivo.51 Small molecule inhibitor of ALK5 kinase (TBR-I)
can prevent tumor recurrence in a malignant mesothelioma model which overexpresses TGF-b.52
Given the complex relationship between TGF-b and
cancer, the potential application of TGF-b or its antagonists
as cancer therapy require careful clinical assessments.1
TGF-b ACTIVATION
MESOTHELIOMA
76
Immunology
Epidermal growth factor participates in eliciting inammatory responses in the pleura. Pretreatment of mesothelial cells with EGF greatly enhanced mononuclear
leukocyte adhesion.108 Prolonged co-culture for 3 weeks
stimulated proliferation and differentiation of monocytes/macrophages on the mesothelial surface. Adhesion
was not related to EGF-induced upregulation of ICAM-1
or CD44 expression on mesothelial cells.108 Proliferation
of the mononuclear leukocytes was most likely due to
EGF-stimulated mesothelial cell production of
macrophage colony-stimulating activity, shown to be due
predominantly to macrophage colony-stimulating
factor.108
Epidermal growth factor alone does not induce nitric
oxide (NO) production by mesothelial cells but does
augment NO synthesis induced by endotoxin.109 In addition, EGFR ligands can act as chemoattractants on normal
mesothelial cells.99
Epidermal growth factor also promotes adhesion of
malignant cells to the mesothelium in vitro and may therefore be important in tumor deposition in the
pleura/peritoneum in vivo.104 It may also have a role in
effusion formation. Peritoneal infusion of EGF via osmotic
minipumps resulted in dose-dependent formation of
bloody ascites. The EGF-induced ascites were signicantly
inhibited using indomethacin or dexamethasone.110 EGF
also activates the NA+H+ exchanger in human pleural
mesothelial cells, a mechanism requiring protein kinase C
(PKC) activation.111
MESOTHELIOMA
The EGF receptor has been associated with the pathogenesis of asbestos-related pleural disease. Crocidolite and erionite bers stimulate increases in EGFR synthesis112,113 and
elevated serum levels of secreted EGFR are found in retired
asbestos workers when compared with non-exposed individuals.114 Intense patterns of EGFR protein expression are
linked to mesothelial cells phagocytosing long bers112 and
previous studies have shown a correlation between
asbestos ber length and carcinogenicity.115 The asbestos
bers induce autophosphorylation of EGFR in pleural
mesothelial cells which activates the MAPK signaling
pathway and induction of the AP-1 family members c-fos
and c-jun,112,116118 leading to cell proliferation and carcinogenesis.
Overexpression of EGFR plays an important role in the
pathogenesis and progression of a variety of malignancies.
EGFR are expressed on normal mesothelial cells99 and is
overexpressed in many malignant mesotheliomas, with
reports varying from 44 to 97.6 percent.119123 EGFR positivity has been associated with improved survival121,122 but
this was not supported by other studies.119,120,123 The discrepancies in the ndings may be partly explained by the
greater expression of EGFR in the epithelioid mesothelioma, which has a better prognosis than the sarcomatoid
tumors.121,122 EGF also upregulates MMP-3 and -9 production by mesothelioma cells which may participate in
the local invasion and spread of the tumor.124
The therapeutic potential of EGFR inhibitors in the
treatment of mesothelioma is unclear. Several in vitro
studies using small molecule tyrosine kinase inhibitors
(e.g. PD153035 and getinib) have shown signicant inhibition of EGFR-dependent cell signaling, including Akt
phosphorylation and extracellular signal-regulated kinases
1 and 2 in mesothelioma cell lines examined. This has led
to the suppression of mesothelioma cell motility, invasion
and proliferation.125,126 Getinib also increased tumor
responsiveness to radiation therapy in an animal model of
mesothelioma.127 Another tyrosine kinase inhibitor, tyrphostin AG-1478, signicantly ameliorated asbestosinduced increases in the mRNA of the protooncogene
c-fos. Pretreatment of mesothelial cells with AG-1478 also
reduced apoptosis in cells exposed to asbestos.113
However, a recent phase II study by the Cancer and
Leukemia Group B (CALGB) using getinib failed to
provide benets in 43 patients with previously untreated
mesothelioma.122 This may be explained by the absence of
common EGFR tyrosine kinase domain mutations in
mesotheliomas which recently has been shown to confer
sensitivity to getinib in lung cancers.128 A similar study by
the Southwest Oncology Group examined the effect of the
tyrosine kinase inhibitor erlotinib in 63 previously
untreated mesothelioma patients, with the same outcome
as the CALGB study.129 Activation of the extracellular
signal-regulated kinase (ERK) and phosphatidylinositol 3kinase/Akt downstream pathways were suggested as possi-
In vitro talc-stimulated mesothelial cells increased their bFGF transcription and secretion.135 Pleural broblasts proliferate when incubated with conditioned medium from
talc stimulated mesothelial cells this response is diminished by neutralizing antibodies against b-FGF.135 A higher
pleural level of b-FGF was seen in patients who had a successful talc-induced pleurodesis, compared with those in
whom talc pleurodesis failed.135
MALIGNANT PLEURAL DISEASES
effusions (including mesotheliomas) compared with nonmalignant ones. Signicantly, an inverse correlation is
observed between b-FGF levels found in mesothelioma
effusions and patient survival. High serum b-FGF levels are
also associated with reduced survival.133 However, another
study reported a negative correlation between b-FGF and
tumor size observed during thoracoscopy.135
Interleukin-1 induced mesothelial cell production of bFGF in one study134 but not in another.106 In both studies,
TNFa did not stimulate b-FGF release. IL-2, however, can
produce a marked suppression of b-FGF expression.106 In
mesothelioma cells, b-FGF increases glycosaminoglycans
production but has no signicant effect on heparan sulfate
synthesis.138
78
Immunology
novel IGF-R1 inhibitor, NVP-AEW541, has shown concentration-dependent inhibitory effects on cultured
mesothelioma cells.174 Further evaluation of NVPAEW541 is required for its possible therapeutic potential in
vivo. The IGFR adaptor proteins, insulin receptor substrate
(IRS)-1 and -2, also appear to play roles in the phenotype
of mesothelioma. Mesotheliomas that signal through
IRS-1 have increased cellular growth whereas those that
signal through IRS-2 have increased motility.170 This may
affect tumor pathology as preferential signaling through
IRS-1 may lead to increased local spread of the tumor
whereas utilization of IRS-2 may promote metastases.175
Mesotheliomas express IGFBP 2, 4 and 5 but not 1, 3 or
6. The absence of the benecial IGFBP-3 together with the
presence of the deleterious IGFBP-4 would allow for a
more aggressive phenotype.176 However, in another study,
IGFBP1-4 were overexpressed whereas IGFBP-5 was
underexpressed.177 In this case, IGFBP-5 may be an
inhibitor of IGF-1 activation and its decrease could lead to
over stimulation of the receptor and autocrine stimulation
or growth.170 More studies need to conrm these observations.
SOLITARY FIBROUS TUMOR OF THE PLEURA
80
Immunology
VEGF levels are higher in malignant than in benign effusions,194 the VEGF level is of limited use as a diagnostic
tool191,192 for malignant effusions, or to predict cancer
staging193 and histological cancer cell types.193
Different isoforms of VEGF have been shown to be
involved in the evolution of malignant pleural effusions
with different characteristics by the implantation of lung
cancer cells transfected with these isoforms.195 VEGF-A
promotes tumor cells dissemination, capillary neogenesis
and bloody effusions, while VEGF-D promotes both
pleural and lymph node tumor dissemination.195
The majority of VEGF in the effusions is believed to
originate from local pleural or peritoneal production.196,197
Quiescent mesothelial cells produce large amounts of
VEGF, which can be increased at mRNA and protein level
by FGF-2.198 Mesothelial cells are likely to represent the
principal source of pleural uid VEGF,29,190 but inltrating
inammatory cells and malignant cells (in malignant pleuritis) also contribute to VEGF production.189
Most malignant cell types overexpress VEGF.199,200 This
includes lung201 and breast202 carcinomas and mesothelioma.203 Immunohistochemistry has conrmed the presence of VEGF in malignant cells in human pleural
tissue,194 suggesting that they may be a source of the consistently high VEGF in malignant pleural effusions. VEGF
is likely to be an autocrine growth factor in mesothelioma.197 Functional coexpression of VEGF-C (a protein
closely related to VEGF), as well as its receptor VEGFR-3,
has been demonstrated in malignant mesothelioma.204
Empyema uids contain high levels of VEGF,191,205 signicantly above those in uncomplicated parapneumonic
effusions.190 Staphylococcus aureus, a common causative
organism in empyema, can stimulate a dose- and timedependent VEGF release from mesothelial cells.190
Acidosis206 and hypoglycemia,207 common biochemical
characteristics of empyema uids, are also known to
induce VEGF. VEGF is also elevated and correlated with
other cytokines such as IL-1b and TNFa in tuberculous
pleural effusions.208
In post-coronary artery bypass grafting (CABG) pleural
effusions, VEGF levels correlate with inammatory cells
and lactate dehydrogenase (LDH) levels, as well as with
protein levels which reect the degree of vascular hyperpermeability.209 VEGF is likely to contribute to the generalized hyperpermeability and the resultant formation of
large effusions in ovarian hyperstimulation syndrome210
and in Meigs syndrome.211
Hypoxia and ischemia are amongst the most established stimulators of VEGF212215 and may contribute to
the pathogenesis of pleural effusion from pulmonary
emboli.191
TARGETING VEGF TO CONTROL PLEURAL OR PERITONEAL
EFFUSIONS
Vascular endothelial growth factor is essential in malignant effusion formation.216 When cancer cells are injected
Immunomodulatory cytokines 81
IMMUNOMODULATORY CYTOKINES
Many cytokines participate in the inammatory process,
and the majority is likely to have a role in pleural inammation. A comprehensive review of all these cytokines is
outside the scope of this chapter. The key inammatory
cytokines and their effects in the setting of pleural pathology have been included in Chapter 7, Pleural inammation and infection. Several important pro-inammatory
cytokines and their pertinent actions in the pleura are
highlighted below.
82
Immunology
Amongst its pleiotropic nature, TNF-a is known to stimulate broblast proliferation and regulate collagen production.260 TNF-a induce epithelialmesenchymal
transformation of mesothelial cells, altering expression of
cytokeratins 8 and 18, MMP-9 and collagen, but not that
of vimentin.261 It is likely that TNF-a has a role in the
brotic processes in the pleura. In vitro, TNF-a has been
shown to stimulate and reduce mesothelial cell production
of plasminogen activator inhibitor (PAI)-1 and tissue-type
plasminogen activator (tPA).262 Experimentally, antiTNF-a antibodies inhibit talc pleurodesis.263 In clinical
studies, pleural brosis from tuberculous pleuritis occurs
more commonly in patients with higher pleural uid
TNF-a and IL-1 levels.257
Polymorphisms of TNF-a have recently been associated
with silicosis264 and asbestosis265 and genetic predisposition may have a role in pleural brosis.
PLEURAL MALIGNANCY
The role of TNF-a in the biology of mesothelioma is complicated. Recent evidence suggests a critical role of TNF-a
in asbestos-induced malignant transformation of
mesothelial cells. Although asbestos is usually cytotoxic to
mesothelial cells, treatment with TNF-a signicantly
reduced asbestos cytotoxicity via activation of nuclear
factor (NF)-kB. This protective mechanism allows more
asbestos-damaged mesothelial cells to survive and undergo
malignant transformation.266 TNF-a and IL-1b are
involved in malignant transformation of human benign
mesothelial cells induced by erionite.267
Tumor necrosis factor-a has also been shown to
enhance SN38-mediated apoptosis in malignant mesothe-
Anti-TNF-a agents are now available and their antiinammatory effect in the pleura has been conrmed in
animal models. TNF-a-converting enzyme (TACE)
cleaves the precursor form of TNF, allowing the mature
form to be secreted into the extracellular space. In the
pleural space, a TACE inhibitor signicantly reduces the
pleural uid TNF-a accumulation in zymosan-induced
pleural inammation.273 Similarly, GW3333, a dual
inhibitor of TACE and MMPs, effectively inhibits the
increase in TNF-a and the associated inux of inammatory cells in zymosan-induced pleuritis.274
Steroids can also inhibit TNF-a and IL-1 production in
the pleura. FR167653, a cytokine synthesis inhibitor, also
suppresses TNF-a and IL-1b accumulation in the pleura in
rat carrageenin-induced pleurisy. As a result, it inhibits
plasma exudation and leukocyte inltration and signicantly lowered the prostanoid levels in the exudates.275
These agents thus may have a role in treating pleural
inammation and may also prevent the development of
subsequent brothorax. Anti-IL-1 strategies are available
but little is known about their clinical effectiveness in the
pleural setting.
IL-2
Interleukin 2 is a pleiotropic cytokine with a variety of
effects on the immune system. Its effects are often environment-specic; hence conicting accounts have been
reported.
The interaction of IL-2 with the IL-2 receptor induces
proliferation and differentiation of various T lymphocyte
subsets, and stimulates a cytokine cascade that includes
various interleukins, interferons and TNF-a. IL-2 induces
mesothelial cell expression of CCR2 and cell proliferation.
Intrapleural IL-2 administration induces nitric oxide
accumulation in the pleural uid.276 Haptotactic
migration is upregulated when mesothelial cells are
cultured with IL-2 (see Chapter 7, Pleural inammation
and infection).
IL-2 LEVELS IN PLEURAL EFFUSIONS
Immunomodulatory cytokines 83
Recombinant IL-2s (e.g. aldesleukin, teceleukin) are nonglycosylated, modied forms of the endogenous compound. High-dose IL-2 results in objective regression of
metastatic melanoma and renal cell carcinoma in
approximately 15 percent of patients,281 though response
rates are lower in other malignancies.282 The growth
inhibitory effect of IL-2 on cancer cells varies with the
proliferative status of these cells. In highly proliferating
mesothelioma cells, a reduction of malignant cells in the
S-phase, with an accumulation in G0/G1 of the cell cycle
followed by apoptosis, is observed. In cells proliferating
at a lower rate, IL-2 produces late cytotoxic effects with
resultant apoptosis, without obvious inuence on the cell
cycle.276
Interleukin-2 has anti-proliferative effects on human
malignant mesothelioma cells and thus has been used for
the management of malignant pleural effusions283 and
mesothelioma. IL-2 also augmented the in vitro cytolytic
activity of mesothelial cells and cytolytic T-cells, isolated
from malignant pleural effusions, against autologous
tumors. Lymphocytes recovered from malignant pleural
effusions show depressed proliferation, IFN-g production
and cytolytic activity, as compared with lymphocytes from
tuberculous effusions. Both IL-7 and IL-12, as well as
TCR-CD3 (T-cell receptor-CD3), in the presence of IL-2,
can restore the immunosuppressed cytolytic activity of the
lymphocytes of malignant effusions against autologous
tumors.284,285
In a murine model of mesothelioma, intratumoral
injection of IL-2 induced tumor regression in part via
CD8+ T-cells. Complete regression was seen with small
tumors, but less so with bulky lesions.286,287
In humans, IL-2 as a palliative therapy for malignant
effusions has been reported in case series. Intracavitary
administration of low-dose IL-2, as an initial treatment,
resulted in an objective clinical response in 72 percent for
a median duration of 5 months in 100 patients with malignant (68 percent pleural) effusions. The response is better
in pleural than in peritoneal effusion control.288 Similar
results were achieved in another study of 21 patients with
malignant pleural effusions from non-small cell lung carcinomas. Complete response was achieved in 33 percent,
and partial response in 29 percent, with a median duration
of 8 months (range 410 months).289 Treatment was well
tolerated in both studies. The effectiveness of IL-2 has yet
to be compared with conventional therapies for malignant
pleural effusions.
When high dose intravenous IL-2 is used to treat metastatic diseases, vascular leak syndrome (VLS) can occur which
often limits the dosage that can be administered. VLS is
characterized by an increase in vascular permeability
accompanied by signicant extravazation of uids and
proteins resulting in interstitial edema, anasarca and, at
times, cardiovascular or respiratory failure. Pleural, pericardial and peritoneal effusions occur as part of the generalized vascular hyperpermeability.295 VLS is generally
believed to involve endothelial cell damage and is mediated by nitric oxide. CD4+/CD25+ T-regulatory cells have
an important regulatory role, as their depletion in murine
models demonstrates a signicant increase in IL-2 induced
VLS.296 Natural killer (NK) and polymorphonuclear cells
are important in late events, including edema, of VLS.297
The potential role of IL-2 in vascular leakage and pleural
uid formation in other conditions has not been explored.
IL-6
Interleukin-6 is a member of a family of closely related
pleiotropic cytokines which also include IL-11,
IL-27, IL-31, leukemia inhibitory factor (LIF), oncostatin
M (OSM), ciliary neurotrophic factor (CNF) and cardiotrophin 1 (CT-1), cardiotrophin-like cytokine (CLC)
and neuropoietin (NPN).298 Individual family members
play important roles in the immune, nervous, cardiovas-
84
Immunology
cular and hemopoietic systems, as well as bone metabolism, inammation, wound repair, the acute phase
response and development of the embryo.299 Their actions
are mediated through specic cell surface receptors, consisting of a unique a or b chain and the shared signal transducing subunit, glycoprotein b-subunit (gp)130 as part of
a multimeric (a, b) receptor complex.300,301 By itself, gp130
does not provide high-afnity binding to any of the IL6family cytokines, but rather converts low-afnity binding
to specic a-subunit receptors into a high-afnity receptor complex.302
Soluble forms of the a-subunits lacking the transmembrane and cytoplasmic domains have been identied for
IL-6, IL-11 and LIF, as well as gp130.302 The soluble IL-6
receptor (sIL-6R) is generated either by limited proteolysis
of the IL-6R303 or translation from alternatively spliced
mRNA.304 sIL-6R can only bind its ligand, IL-6, however
the complex of IL-6 and sIL-6R can bind to and activate
gp130 on cells which do not express the membrane-bound
IL-6R, thereby initiating signaling.305
Gp130 has no intrinsic tyrosine kinase activity and thus
requires recruitment and activation of specic kinases and
docking proteins. Following binding of the cytokine to its
a or b subunit and subsequent dimerization with gp130,
cytoplasmic janus kinases (JAKs) are recruited and phosphorylate gp130.306 The subsequent activation of intracellular signaling is dependent on specic phosphotyrosine
residues on gp130, which act as docking sites for SH2
domain-containing intermediate signaling molecules. For
example, the Src homology protein tyrosine phosphatase 2
(SHP2) binds to membrane proximal tyrosine residues
(Y759 in humans, Y757 in mice) and is necessary and sufcient for activation of the MAPK/ERK pathway. In contrast, members of the STAT transcription factors dock to
several membrane distal phosphotyrosine residues. Once
phosphorylated, STAT proteins form a homodimer,
translocate to the nucleus and activate target genes.307 This
system is negatively regulated by a number of inhibitory
molecules, most notably the family of suppressor of
cytokine signaling (SOCS) proteins.
ROLE OF IL-6 IN INFLAMMATION
nitric oxide synthase and cylco-oxygenase-2, are signicantly reduced in IL-6 knockout mice compared with
wild-type controls.309 Pretreatment of the wild-type mice
with IL-6 neutralizing antibodies before carrageenan treatment results in the same responses as for the knockout
animals.309
Interleukin-6 dictates the transition from acute to
chronic inammation by changing the nature of the leukocyte inltrate (from polymorphonuclear neutrophils to
monocytes/macrophages).310312 IL-6 is also involved in
the development of specic cellular and humoral immune
responses, including B cell proliferation and differentiation, immunoglobulin secretion and T-cell activation, thus
favoring chronic inammatory responses.313
IL-6 LEVELS IN PLEURAL EFFUSIONS
Immunomodulatory cytokines 85
associated with thrombocytosis.330 It has been hypothesized that large amounts of IL-6 from the pleural uid of
patients with mesothelioma leak into the systemic circulation and induce the systemic inammatory reactions
related to mesothelioma,330 including thrombocytosis,
fever and cachexia.338
Production of IL-6 by mesotheliomas has also been
measured as a way to predict tumor response to
chemotherapy. Gemcitabine, and to a lesser extant irinotecan, but not most other agents, inhibit IL-6 secretion at
low doses but stimulate a surge in IL-6 at higher doses.315
These results suggest a palliative role for low doses of these
chemotherapeutic agents in non-responders by decreasing
the secretion of IL-6.
OTHER PLEURAL DISEASES
IL-8
Interleukin-8 is one of the most studied chemokines, and
its role in pleural inammation is well established.
Mesothelial cells express IL-8 basally.342,343 Inammatory
stimuli,344 asbestos bers345 and infective agents,346,347
among others, are known to stimulate signicant increases
in mesothelial cell production of IL-8.
Interleukin-8 is a downstream cytokine from TNF-a
and IL-1. In humans, signicant elevation of pleural levels
of IL-8 is seen after intrapleural administration of TNF-a
in mesothelioma patients.348 In vitro, exposure of mesothelial cells to TNF-a or IL-1b stimulates IL-8 release in a
time- and dose-dependent fashion,248,252,342,343,345,349352
which is diminished by IFN-g.353 The stimulatory effects of
TNF-a and IL-1 can be synergistic.342 IL-8 secretion from
pleural broblast is also induced by IL-1, TNF-a and
86
Immunology
IL-10
Interleukin-10 is an antiinammatory cytokine with
potent immunosuppressive properties. In humans, the
main sources of IL-10 are lymphocytes and monocytes,
but macrophages, mast cells and eosinophils also synthesize IL-10.371,372 Circulating levels of IL-10 are elevated in
patients with sepsis and have been associated with an
adverse clinical outcome. Experimental studies show that
exogenous IL-10, as an anti-inammatory agent, can
improve outcome in sepsis372 and inhibit airway inammation in asthma.371 IL-10 also carries strong immunosuppressive actions mediated through the downregulation
of pro-inammatory cytokines, the major histocompatibility complex (MHC) class II molecules and T-cell mediated inammatory responses, including delayed
hypersensitivity and Th2-driven allergic responses.372
It is likely IL-10 plays a role during the early phases of
pleural inammation, in mediating cell trafcking to the
pleura and vascular leak.373,374 Intrapleural IL-10 inhibits
the early phase of carrageenan-induced pleural inammation in a murine model.373 IL-10 null mice had enhanced
rates of pleural exudation and polymorphonuclear cell
trafcking; while mice injected with anti-IL-10 neutralizing antibodies had increased leukocyte inux and vascular
leakage in the early phase of carrageenan-induced pleural
inammation.373
Interleukin-10 is present in tuberculous and malignant
pleural effusions. Its pleural uid concentrations are signi-
Immunomodulatory cytokines 87
cantly higher than the corresponding serum levels, suggesting that local production is its principal source.375 Resident
pleural macrophages may be a source of pleural IL-10, as
macrophage ablation in a murine model of carrageenan
pleurisy has demonstrated a reduced level of IL-10 as well
as other inammatory cytokines.376 Alveolar macrophages
isolated from older rats produce less IL-10 than those isolated from young rats.377 These rats also exhibit signicantly
reduced pleural uid IL-10 levels during carrageenaninduced pleurisy than younger rats. However, the effusion
IL-10 level does not correlate with lymphocyte subpopulations in the pleural uids or in blood378 and does not predict
survival in malignant effusions.375
Tumor cells can produce IL-10, which is known to suppress the production of anti-tumor cytokines (such as
TNF-a and IL-1b) by pleural macrophages.379 IL-10 is
reported to promote the growth of activated or neoplastic
B lymphocytes380 and its expression has been shown in
high levels in cell lines of primary effusion lymphoma381
and in pyothorax-associated lymphoma.382
In tuberculous effusions, IL-10 levels decrease over the
course of the disease.383 IL-10 may be induced in the early
stages of chronic disease by Th1 type cytokine proles, but
its host-protective downregulatory effects on immune
response may allow the mycobacterium to persist.383 An
inverse correlation also exists between IL-10 and mononuclear cell proliferation in tuberculous pleuritis384 and high
IL-10 levels have been associated with pleural necrosis.
In murine models of Staphylococcus aureus empyema,
IFN-g levels rise in the controls, whereas the interleukin10 level increases signicantly in the CD4 knockout mice.
Therapeutic use of IL-10, especially in sepsis, has been
explored in phase I and II trials.385 Further investigations on
its potential use in pleural diseases would be worthwhile.
IL-12
Interleukin-12 is a heterodimeric cytokine that enhances
cell-mediated and cytotoxic immune responses to intracellular pathogens and tumors.210 IL-12 is produced primarily by antigen presenting cells. It is considered crucial in
promoting Th1 responses and subsequent cell mediated
immunity. These functions are facilitated by the ability of
IL-12 to stimulate T lymphocyte and NK cell proliferation,
their cytotoxicity and IFN-g production. IL-12 receptors
comprise of two subunits IL-12R-b1 and -b2, which are
expressed mainly on activated T and NK cells.386,387
TUBERCULOUS PLEURITIS
mediated immunity, fail to develop granulomatous reactions and are prone to develop TB.387 In TB patients, the
percentage of T cells expressing IL-12 receptors is signicantly decreased, and IFN-g production by peripheral
monocytes is also reduced.388 In TB pleuritis, the mean
IL-12 concentrations are tenfold higher in pleural uid
than in serum.389 In vitro, pleural uid cells have been
shown to proliferate and produce bioactive IL-12 when
stimulated with M. tuberculosis.389 IL-12 in turn induces
mononuclear cells in pleural effusions to increase their
killing activity dose-dependently and enhances their production of IFN-g.390
Pleural malignancy
Interleukin-12 is considered to have potent anti-tumor
effects. Systemic administration of recombinant IL-12
induces a signicant and persistent anti-tumor immune
response, mediated by CD4 and CD8 T lymphocytes, and
results in growth inhibition or even regression in a murine
model of mesothelioma.391 IL-12 may also be useful as a
candidate for gene therapy in malignant pleural diseases.
Paracrine secretion of IL-12, generated by gene transfer,
can induce immunity against mesothelioma locally and at
a distant site, without causing signicant systemic complications.392
A Th2 to Th1 shift is observed when lymphocytes from
malignant effusions are treated with IL-12. The use of lymphocytes treated in this fashion as a novel adoptive
immunotherapy for cancer has been suggested.393 Other
studies have reported that, upon IL-12/IL-2 co-stimulation,
monocytes isolated from malignant pleural effusions are
able to produce cytokines of both the Th1 and Th2 types.394
Interleukin-12 also serves to augment the anti-cancer
effects of other cytokines. In vitro, IL-12, in the presence of
IL-2, can restore the cytolytic activity of the lymphocytes
in malignant pleural effusion against autologous tumor.284
In vivo, co-administration of IL-15 with IL-12 activates the
CD8+ T lymphocytes and NK cells, providing strong antitumor activity against malignant pleuritis in mice. The
therapeutic effect is probably mainly due to enhanced
IFN-g production as the administration of anti-IFN-g
antibodies inhibits the benecial effect of IL-15 and IL12.395 IL-12 has also been shown to promote pleural and
blood monocyte cytotoxic activity against a small cell lung
cancer cell line.394
Interleukin-12 has now been used in small clinical trials
against a variety of malignancies. Whether it has a therapeutic value against pleural mesothelioma awaits investigation.
Interferons
There are two types of interferon: type I and type II. The
type I IFNs consist of seven classes, of which the
88
Immunology
IFN-a and IFN-b are the most studied. There is only one
human IFN-b but there are multiple IFN-a species. Type
II interferon consists of IFN-g only. In addition, four IFNlike cytokines have been reported.396 Type I IFNs are
secreted by virus infected cells while the type II IFN is
secreted mainly by T cells, NK cells and macrophages.396
Toll-like receptors play an important role in the expression
of IFNs397 as well as monocyte-derived pro-inammatory
cytokines such as IL-12, IL-15 and IL-18, especially in
combination.394,398,399
The interferons and IFN-like molecules signal through
the Jak-Stat pathway. The type I interferons all share the
same receptor complex, whereas type II IFN-g binds to a
distinct receptor. The type I IFNs predominantly signal
through Stat1 and Stat2 but IFN-a and IFN-b pathways
can involve Stat3, Stat4, Stat5 and IFN regulatory factors in
various cells under different conditions. IFN-g activates
Jak1, Jak2 and Stat1 that in turn induce genes containing
the g-activation sequence in the promoter. IFN-g can also
activate Stat3 and Stat5. The IFNs can also activate other
pathways including PI3K, Akt, NF-kB, MAPK and
others.396
The type I interferons exhibit a wide array of biological
activities including antiviral, antiproliferative and cytotoxicity, on a wide variety of immune cells to increase the
expression of tumor-associated antigens and other surface
molecules such as MHC class I antigens, activation of proapoptotic proteins, modulation of differentiation and
antiangiogenic activity.396
TUBERCULOUS PLEURITIS
References 89
SUMMARY
A comprehensive understanding of the cytokine network
is crucial to the understanding of the pathophysiology of
pleural diseases. However, the complex range of overlapping functions of the ever-expanding number of cytokines
and their diverse inter-relations make the study of
cytokine behavior in pleural disease an extremely challenging task. It is anticipated that in the rapid expansion of our
knowledge in cytokines and their intracellular pathways,
breakthroughs in the diagnosis and management of
pleural diseases will be made.
REFERENCES
2.
3.
KEY POINTS
4.
5.
6.
7.
8.
9.
10.
Lee YCG, Lane KB. The many faces of transforming growth factor
beta in pleural diseases. Curr Opin Pulm Med 2001; 7: 1739.
Jagirdar J, Lee TC, Reibman J, et al. Immunohistochemical
localization of transforming growth factor beta isoforms in
asbestos-related diseases. Environ Health Perspect 1997; 105
(Suppl 5): 1197203.
Maeda J, Ueki N, Ohkawa T, et al. Local production and
localization of transforming growth factor-beta in tuberculous
pleurisy. Clin Exp Immunol 1993; 92: 328.
Cheng D-S, Lee YC, Roger JT, et al. Vascular endothelial growth
factor level correlates with transforming growth factor-beta
isoform levels in pleural effusions. Chest 2000; 118: 174753.
Martin M, Lefaix J, Delaniau S. TGF-beta 1 and radiation brosis: a
master switch and a specic therapeutic target? Int J Radiat Oncol
Biol Phys 2000; 47: 27790.
Branton MH, Kopp JB. TGF-b and brosis. Microbes Infect 1999; 1:
134965.
Yang L, Qiu CX, Ludlow A, Ferguson MW, Brunner G. Active
transforming growth factor-beta in wound repair: determination
using a new assay. Am J Pathol 1999; 154: 10511.
Sheppard D. Transforming growth factor beta. A central modulator
of pulmonary and airway inammation and brosis. Proc Am
Thorac Soc 2006; 3: 4137.
Sasse SA, Jadus MR, Kukes GD. Pleural uid transforming growth
factor b-1 correlates with pleural brosis in experimental
empyema. Am J Respir Crit Care Med 2003; 168: 7005.
Kinnula V, Linnala A, Viitala E, Linniainmaa K, Virtanen I. Tenascin
and bronectin expression in human mesothelial cells and pleural
90
Immunology
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
References 91
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92
Immunology
92. Harvey P, Clark IM, Jaurand MC, Warn RM, Edwards DR.
Hepatocyte growth factor/scatter factor enhances the invasion of
mesothelioma cell lines and the expression of matrix
metalloproteinases. Br J Cancer 2000; 83: 114753.
93. Uchiyama A, Morisaki T, Beppu K, et al. Hepatocyte growth factor
and invasion-stimulatory activity are induced in pleural uid by
surgery in lung cancer patients. Br J Cancer 1999; 81: 7216.
94. Yashiro M, Chung YS, Inoue T, et al. Hepatocyte growth factor
(HGF) produced by peritoneal broblasts may affect mesothelial
cell morphology and promote peritoneal dissemination. Int J
Cancer 1996; 67: 28993.
95. Saimura M, Nagai E, Mizumoto K, et al. Intraperitoneal injection of
adenovirus-mediated NK4 gene suppresses peritoneal
dissemination of pancreatic cancer cell line AsPC-1 in nude mice.
Cancer Gene Ther 2002; 9: 799806.
96. Tanaka T, Shimura H, Sasaki T, et al. Gallbladder cancer treatment
using adenovirus expressing the HGF/NK4 gene in a peritoneal
implantation model. Cancer Gene Ther 2004; 11: 43140.
97. Xian CJ. Roles of epidermal growth factor family in the regulation
of postnatal somatic growth. Endocr Rev 2007; 28: 28496.
98. Carpenter G. The EGF receptor: a nexus for trafcking and
signaling. Bioessays 2000; 22: 697707.
99. Palmer U, Liu Z, Broome U, Klominek J. Epidermal growth factor
receptor ligands are chemoattractants for normal human
mesothelial cells. Eur Respir J 1999; 14: 40511.
100. Gabrielson EW, Gerwin BI, Harris CC, et al. Stimulation of DNA
synthesis in cultured primary human mesothelial cells by specic
growth factors. FASEB J 1988; 2: 271721.
101. Goodglick LA, Vaslet CA, Messier NJ, Kane AB. Growth factor
responses and protooncogene expression of murine mesothelial
cell lines derived from asbestos-induced mesotheliomas. Toxicol
Pathol 1997; 25: 56573.
102. Owens MW, Milligan SA. Growth factor modulation of rat pleural
mesothelial cell mitogenesis and collagen synthesis. Effects of
epidermal growth factor and platelet-derived factor. Inammation
1994; 18: 7787.
103. Pache JC, Janssen YM, Walsh ES, et al. Increased epidermal growth
factor-receptor protein in a human mesothelial cell line in
response to long asbestos bers. Am J Pathol 1998; 152: 33340.
104. van Rossen ME, Hoand LJ, van den Tol MP, et al. Effect of
inammatory cytokines and growth factors on tumour cell
adhesion to the peritoneum. J Pathol 2001; 193: 5307.
105. Mutsaers SE, McAnulty RJ, Laurent GJ, et al. Cytokine regulation
of mesothelial cell proliferation in vitro and in vivo. Eur J Cell Biol
1997; 72: 249.
106. Jayne DG, Perry SL, Morrison E, Farmery SM, Guillou PJ. Activated
mesothelial cells produce heparin-binding growth factors:
implications for tumour metastases. Br J Cancer 2000; 82: 12338.
107. Faull RJ, Stanley JM, Fraser S, Power DA, Leavesley DI. HB-EGF is
produced in the peritoneal cavity and enhances mesothelial cell
adhesion and migration. Kidney Int 2001; 59: 61424.
108. Muller J, Yoshida T. Interaction of murine peritoneal leukocytes
and mesothelial cells: in vitro model system to survey cellular
events on serosal membranes during inammation. Clin Immunol
Immunopathol 1995; 75: 2318.
109. Owens MW, Milligan SA, Grisham MB. Nitric oxide synthesis by rat
pleural mesothelial cells: Induction by growth factors and
lipopolysaccharide. Exp Lung Res 1995; 21: 73142.
110. Ohmura E, Tsushima T, Kamiya Y, et al. Epidermal growth factor
and transforming growth factor alpha induce ascitic uid in mice.
Cancer Res 1990; 15: 49157.
111. Liaw YS, Yang PC, Yu CJ, et al. PKC activation is required by EGFstimulated Na(+)-H+ exchanger in human pleural mesothelial
cells. Am J Physiol 1998; 274(5 Pt 1): L665L72.
112. Faux SP, Houghton CE, Hubbard A, Patrick G. Increased expression
of epidermal growth factor receptor in rat pleural mesothelial cells
correlates with carcinogenicity of mineral bres. Carcinogenesis
2000; 21: 227580.
References 93
131.
132.
133.
134.
135.
136.
137.
138.
139.
140.
141.
142.
143.
144.
145.
146.
147.
148.
149.
150.
94
Immunology
170. Hoang CD, Zhang X, Scott PD, et al. Selective activation of insulin
receptor substrate-1 and -2 in pleural mesothelioma cells:
association with distinct malignant phenotypes. Cancer Res 2004;
64: 747985.
171. Lee TC, Zhang Y, Aston C, et al. Normal human mesothelial cells
and mesothelioma cell lines express insulin-like growth factor I
and associated molecules. Cancer Res 1993; 53: 285864.
172. Porcu P, Ferber A, Pietrzkowski Z, et al. The growth-stimulatory
effect of simian virus 40 T antigen requires the interaction of
insulinlike growth factor 1 with its receptor. Mol Cell Biol 1992;
12: 506977.
173. Pass HI, Mew DJ, Carbone M, et al. The effect of an antisense
expression plasmid to the IGF-1 receptor on hamster
mesothelioma proliferation. Dev Biol Stand 1998; 94: 3218.
174. Whitson BA, Jacobson BA, Frizelle S, et al. Effects of insulin-like
growth factor-1 receptor inhibition in mesothelioma. Ann Thorac
Surg 2006; 82: 9961001.
175. Whitson BA, Kratzke RA. Molecular pathways in malignant pleural
mesothelioma. Cancer Lett 2006; 239: 1839.
176. Hodzic D, Delacroix L, Willemsen P, et al. Characterization of the
IGF system and analysis of the possible molecular mechanisms
leading to IGF-II overexpression in a mesothelioma. Horm Metab
Res 1997; 29: 54955.
177. Hoang CD, DCunha J, Kratzke MG, et al. Gene expression proling
identies matriptase overexpression in malignant mesothelioma.
Chest 2004; 125: 184352.
178. Briselli M, Mark EJ, Dickersin GR. Solitary brous tumours of the
pleura: eight new cases and review of 360 cases in the literature.
Cancer 1981; 47: 267889.
179. Cole FH Jr, Ellis RA, Goodman RC, Weber BC, Courington DP.
Benign brous pleural tumor with elevation of insulin-like growth
factor and hypoglycemia. South Med J 1990; 83: 6904.
180. Fukasawa Y, Takada A, Tateno M, et al. Solitary brous tumor of
the pleura causing recurrent hypoglycemia by secretion of insulinlike growth factor II. Pathol Int 1998; 48: 4752.
181. Masson EA, MacFarlane IA, Graham D, Foy P. Spontaneous
hypoglycaemia due to a pleural broma: role of insulin like growth
factors. Thorax 1991; 46: 9301.
182. Kishi K, Homma S, Tanimura S, Matsushita H, Nakata K.
Hypoglycemia induced by secretion of high molecular weight
insulin-like growth factor-II from a malignant solitary brous
tumor of the pleura. Intern Med 2001; 40: 3414.
183. Rena O, Filosso PL, Papalia E, et al. Solitary brous tumour of the
pleura: surgical treatment. Eur J Cardiothorac Surg 2001; 19: 1859.
184. Chang ED, Lee EH, Won YS, et al. Malignant solitary brous tumor
of the pleura causing recurrent hypoglycemia;
immunohistochemical stain of insulin-like growth factor i receptor
in three cases. J Korean Med Sci 2001; 16: 2204.
185. Li Y, Chang Q, Rubin BP, et al. Insulin receptor activation in
solitary brous tumours. J Pathol 2007; 211: 5504.
186. Bourcigaux N, Arnault-Ouary G, Christol R, et al. Treatment of
hypoglycemia using combined glucocorticoid and recombinant
human growth hormone in a patient with a metastatic non-islet
cell tumor hypoglycemia. Clin Ther 2005; 27: 24651.
187. Drake WM, Miraki F, Siddiqi A, et al. Dose-related effects of growth
hormone on IGF-I and IGF-binding protein-3 levels in non-islet cell
tumour hypoglycaemia. Eur J Endocrinol 1998; 139: 5326.
188. Olchovsky D, Shimon I, Goldberg I, et al. Elevated insulin-like
growth factor-1 and insulin-like growth factor binding protein-2
in malignant pleural effusion. Acta Oncol 2002; 41: 1827.
189. Grove CS, Lee YCG. Vascular endothelial growth factor: the key
mediator in pleural effusion formation. Curr Opin Pulm Med 2002;
8: 294301.
190. Mohammed KA, Nasreen N, Hardwick J, et al. Bacterial induction
of pleural mesothelial monolayer barrier dysfunction. Am J Physiol
Lung Cell Mol Physiol 2001; 281: L119L25.
191. Cheng D, Rodriguez RM, Perkett EA, et al. Vascular endothelial
growth factor in pleural uid. Chest 1999; 116: 7605.
192. Cheng DS, Lee YC, Rogers JT, et al. Vascular endothelial growth
factor level correlates with transforming growth factor beta
isoform levels in pleural effusions. Chest 2000; 118: 174753.
193. Yanagawa H, Takeuchi E, Suzuki Y, et al. Vascular endothelial
growth factor in malignant pleural effusion associated with lung
cancer. Cancer Immunol Immunother 1999; 48: 396400.
194. Ishimoto O, Saijo Y, Narumi K, et al. High level of vascular
endothelial growth factor in hemorrhagic pleural effusion of
cancer. Oncology 2002; 63: 705.
195. Ishii H, Yazawa T, Sato H, et al. Enhancement of pleural
dissemination and lymph node metastasis of intrathoracic lung
cancer cells by vascular endothelial growth factors (VEGFs). Lung
Cancer 2004; 45: 32537.
196. Kraft A, Weindel K, Ochs A, et al. Vascular endothelial growth
factor in the sera and effusions of patients with malignant and
nonmalignant disease. Cancer 1999; 85: 17887.
197. Strizzi L, Catalano A, Vianale G, et al. Vascular endothelial growth
factor is an autocrine growth factor in human malignant
mesothelioma. J Pathol 2001; 193: 46875.
198. Sako A, Kitayama J, Yamaguchi H, et al. Vascular endothelial
growth factor synthesis by human omental mesothelial cells is
augmented by broblast growth factor-2: possible role of
mesothelial cell on the development of peritoneal metastasis. J
Surg Res 2003; 115: 11320.
199. Brown LF, Detmar M, Claffey K, Nagy JA. Vascular permeability
factor/vascular endothelial growth factors: A multifunctional
angiogenic cytokine. EXS 1997; 79: 23369.
200. Ferrara N, Keyt B. Vascular endothelial growth factor: Basic
biology and clinical implications. EXS 1997; 79: 20932.
201. Takahama M, Tsutsumi M, Tsujiuchi T, et al. Enhanced expression
of Tie2, its ligand angiopoietin-1, vascular endothelial growth
factor, and CD31 in human non-small cell lung carcinomas. Clin
Cancer Res 1999; 5: 250610.
202. Yoshiji H, Gomez DE, Shibuya M, Thorgeirsson UP. Expression of
vascular endothelial growth factor, its receptor, and other
angiogenic factors in human breast cancer. Cancer Res 1996; 56:
20136.
203. Cacciotti P, Strizzi L, Vianale G, et al. The presence of simian-virus
40 sequences in mesothelioma and mesothelial cells is associated
with high levels of vascular endothelial growth factor. Am J Respir
Cell Mol Biol 2002; 26: 18993.
204. Masood R, Kundra A, Zhu S, et al. Malignant mesothelioma growth
inhibition by agents that target the VEGF and VEGF-C autocrine
loops. Int J Cancer 2003; 104: 60310.
205. Thickett DR, Armstrong L, Millar AB. Vascular endothelial growth
factor (VEGF) in inammatory and malignant pleural effusions.
Thorax 1999; 54: 70710.
206. DArcangelo D, Facchiano F, Barlucchi LM, et al. Acidosis inhibits
endothelial cell apoptosis and function and induces basic
broblast growth factor and vascular endothelial growth factor
expression. Circ Res 2000; 86: 3128.
207. Clauss M, Schaper W. Vascular endothelial growth factor: a jack
of all trades or a nonspecic stress gene? Circ Res 2000; 86:
2512.
208. Momi H, Matsuyama W, Inoue K, et al. Vascular endothelial
growth factor and proinammatory cytokines in pleural effusions.
Respir Med 2002; 96: 81722.
209. Kalomenidis I, Stathopoulos GT, Barnette R, et al. Vascular
endothelial growth factor levels in post-CABG pleural effusions
are associated with pleural inammation and permeability. Respir
Med 2007; 101: 2239.
210. Light RW. Pleural diseases, 4th edn. Baltimore: Lippincott,
Williams & Wilkins, 2001.
211. Ishiko O, Yoshida H, Sumi T, Hirai K, Ogita S. Vascular endothelial
growth factor levels in pleural and peritoneal uid in Meigs
syndrome. Eur J Obstet Gynecol Reprod Biol 2001; 98: 12930.
212. Ferrara N. Molecular and biological properties of vascular
endothelial growth factor. J Mol Med 1999; 77: 52743.
References 95
96
Immunology
References 97
291.
292.
293.
294.
295.
296.
297.
298.
299.
300.
301.
302.
303.
304.
305.
306.
307.
308.
309.
310.
311.
312. McLoughlin RM, Jenkins BJ, Grail D, et al. IL-6 trans-signaling via
STAT3 directs T cell inltration in acute inammation. Proc Natl
Acad Sci USA 2005; 102: 958994.
313. Gabay C. Interleukin-6 and chronic inammation. Arthritis Res
Ther 2006; 8 (Suppl 2): S3.
314. Fujino S, Yokoyama A, Kohno N, Hiwada K. Interleukin 6 is an
autocrine growth factor for normal human pleural mesothelial
cells. Am J Respir Cell Mol Biol 1996; 14: 50815.
315. McLaren BR, Robinson BW, Lake RA. New chemotherapeutics in
malignant mesothelioma: effects on cell growth and IL-6
production. Cancer Chemother Pharmacol 2000; 45: 5028.
316. Menet E, Corbi P, Ancey C, et al. Interleukine-6 (IL-6) synthesis
and gp130 expression by human pericardium. Eur Cytokine Netw
2001; 12: 63946.
317. Schmitter D, Lauber B, Fagg B, Stahel RA. Hematopoietic growth
factors secreted by seven human pleural mesothelioma cell lines:
interleukin-6 production as a common feature. Int J Cancer 1992;
51: 296301.
318. Yao V, Platell C, Hall JC. Peritoneal mesothelial cells produce
inammatory related cytokines. ANZ J Surg 2004; 74: 9971002.
319. Wong CF, Yew WW, Leung SK, et al. Assay of pleural uid
interleukin-6, tumour necrosis factor-alpha and interferon-gamma
in the diagnosis and outcome correlation of tuberculous effusion.
Respir Med 2003; 97: 128995.
320. De Smedt A, Vanderlinden E, Demanet C, et al. Characterisation of
pleural inammation occurring after primary spontaneous
pneumothorax. Eur Respir J 2004; 23: 896900.
321. Torres SR, Frode TS, Nardi GM, et al. Anti-inammatory effects of
peripheral benzodiazepine receptor ligands in two mouse models
of inammation. Eur J Pharmacol 2000; 408: 199211.
322. Utsunomiya I, Ito M, Oh-ishi S. Generation of inammatory
cytokines in zymosan-induced pleurisy in rats: TNF induces IL-6
and cytokine-induced neutrophil chemoattractant (CINC) in vivo.
Cytokine 1998; 10: 95663.
323. Lin CC, Liu CC, Lin CY. Changes in cell population and tumor
necrosis factor, interleukin-6, and interleukin-8 in malignant
pleural effusions after treatment with intrapleural tetracycline.
Am Rev Respir Dis 1993; 147: 15036.
324. Yahara N, Abe T, Morita K, Tangoku A, Oka M. Comparison of
interleukin-6, interleukin-8, and granulocyte colony-stimulating
factor production by the peritoneum in laparoscopic and open
surgery. Surg Endosc 2002; 16: 16159.
325. Yom SS, Busch TM, Friedberg JS, et al. Elevated serum cytokine
levels in mesothelioma patients who have undergone pleurectomy
or extrapleural pneumonectomy and adjuvant intraoperative
photodynamic therapy. Photochem Photobiol 2003; 78: 7581.
326. Alexandrakis MG, Kyriakou DS, Bouros D, et al. Interleukin-6 and
its relationships to acute phase proteins in serous effusion
differentiation. Oncol Rep 2001; 8: 41520.
327. Marie C, Losser MR, Fitting C, et al. Cytokines and soluble cytokine
receptors in pleural effusions from septic and nonseptic patients.
Am J Respir Crit Care Med 1997; 156: 151522.
328. Xirouchaki N, Tzanakis N, Bouros D, et al. Diagnostic value of
interleukin-1alpha, interleukin-6, and tumor necrosis factor in
pleural effusions. Chest 2002; 121: 81520.
329. Alexandrakis MG, Coulocheri SA, Bouros D, Eliopoulos GD.
Evaluation of ferritin, interleukin-6, interleukin-8 and tumor
necrosis factor alpha in the differentiation of exudates and
transudates in pleural effusions. Anticancer Res 1999; 19: 360712.
330. Nakano T, Chahinian AP, Shinjo M, et al. Interleukin 6 and its
relationship to clinical parameters in patients with malignant
pleural mesothelioma. Br J Cancer 1998; 77: 90712.
331. Hoheisel G, Izbicki G, Roth M, et al. Compartmentalization of proinammatory cytokines in tuberculous pleurisy. Respir Med 1998;
92: 147.
332. Yamaguchi T, Kimura H, Yokota S, et al. Effect of IL-6 elevation in
malignant pleural effusion on hyperbrinogenemia in lung cancer
patients. Jpn J Clin Oncol 2000; 30: 538.
98
Immunology
352. Betjes MG, Tuk CW, Struijk DG, et al. Interleukin-8 production by
human peritoneal mesothelial cells in response to tumor necrosis
factor-alpha, interleukin-1, and medium conditioned by
macrophages cocultured with Staphylococcus epidermidis. J Infect
Dis 1993; 168: 120210.
353. Man L, Lewis E, Einbinder T, et al. Major involvement of CD40 in
the regulation of chemokine secretion from human peritoneal
mesothelial cells. Kidney Int 2003; 64: 206471.
354. Loghmani F, Mohammed K, Nasreen N, et al. Inammatory
cytokines mediate CC (monocyte chemotactic protein 1) and
CXC (interleukin 8) chemokine expression in human pleural
broblasts. Inammation 2002; 26: 7382.
355. Fukumoto T, Matsukawa A, Yoshimura T, et al. IL-8 is an essential
mediator of the increased delayed-phase vascular permeability in
LPS-induced rabbit pleurisy. J Leukoc Biol 1998; 63: 58490.
356. Antony VB, Godbey SW, Kunkel SL, et al. Recruitment of
inammatory cells to the pleural space. Chemotactic cytokines, IL8, and monocyte chemotactic peptide-1 in human pleural uids. J
Immunol 1993; 151: 721623.
357. Pace E, Gjomarkaj M, Melis M, et al. Interleukin-8 induces
lymphocyte chemotaxis into the pleural space. Role of pleural
macrophages. Am J Respir Crit Care Med 1999; 159: 15929.
358. Nasreen N, Mohammed KA, Hardwick J, et al. Polar production of
interleukin-8 by mesothelial cells promotes the transmesothelial
migration of neutrophils: role of intercellular adhesion molecule1. J Infect Dis 2001; 183: 163845.
359. Ceyhan BB, Ozgun S, Celikel T, Yalcin M, Koc M. IL-8 in pleural
effusion. Respir Med 1996; 90: 21521.
360. Segura RM, Alegre J, Varela E, et al. Interleukin-8 and markers of
neutrophil degranulation in pleural effusions. Am J Respir Crit
Care Med 1998; 157: 156572.
361. Broaddus VC, Hebert CA, Vitangcol RV, et al. Interleukin-8 is a
major neutrophil chemotactic factor in pleural liquid of patients
with empyema. Am Rev Respir Dis 1992; 146: 82530.
362. Park JS, Kim YS, Jee YK, Myong NH, Lee KY. Interleukin-8
production in tuberculous pleurisy: Role of mesothelial cells
stimulated by cytokine network involving tumour necrosis factora; and interleukin-1b. Scand J Immunol 2003; 57: 4639.
363. Galffy G, Mohammed KA, Nasreen N, Ward MJ, Antony VB.
Inhibition of interleukin-8 reduces human malignant pleural
mesothelioma propagation in nude mouse model. Oncol Res 1999;
11: 18794.
364. Galffy G, Mohammed KA, Dowling PA, et al. Interleukin 8: an
autocrine growth factor for malignant mesothelioma. Cancer Res
1999; 59: 36771.
365. Catania A, Colombo G, Carlin A, et al. Autocrine inhibitory
inuences of a-melanocyte-stimulating hormone in malignant
pleural mesothelioma. J Leukoc Biol 2004; 75: 2539.
366. Nasreen N, Hartman DL, Mohammed KA, Antony VB. Talc-induced
expression of C-C and C-X-C chemokines and intercellular
adhesion molecule-1 in mesothelial cells. Am J Respir Crit Care
Med 1998; 158: 9718.
367. van den Heuvel MM, Smit HJ, Barbierato SB, et al. Talc-induced
inammation in the pleural cavity. Eur Respir J 1998; 12: 141923.
368. Miller EJ, Kajikawa O, Pueblitz S, et al. Chemokine involvement in
tetracycline-induced pleuritis. Eur Respir J 1999; 14: 138793.
369. Tsuchiya I, Kasahara T, Yamashita K, et al. Induction of
inammatory cytokines in the pleural effusion of cancer patients
after the administration of an immunomodulator, OK-432: role of
IL-8 for neutrophil inltration. Cytokine 1993; 5: 595603.
370. Kataoka M, Morishita R, Hiramatsu J, et al. OK-432 induces
production of neutrophil chemotactic factors in malignant pleural
effusion. Intern Med 1995; 34: 3526.
371. Bellinghausen I, Knop J, Saloga J. The role of interleukin 10 in the
regulation of allergic immune responses. Int Arch Allergy Immunol
2001; 126: 97101.
372. Oberholzer A, Oberholzer C, Moldawer LL. Interleukin-10: a
complex role in the pathogenesis of sepsis syndromes and its
References 99
373.
374.
375.
376.
377.
378.
379.
380.
381.
382.
383.
384.
385.
386.
387.
388.
389.
390.
391.
100
Immunology
423.
424.
425.
426.
427.
428.
429.
430.
431.
432.
9
Pleural brosis
SREERAMA SHETTY, JOSEPH JOHN, STEVEN IDELL
Overview: The pathogenesis of pleural brosis and
disordered brin turnover
Linkage between disordered brin turnover and brosis
Coagulation and pleural injury
Fibrinolysis and pleural injury
101
102
103
103
104
106
108
108
102
Pleural brosis
plasminogen activator inhibitors (PAI) as well as plasminogen activators (PA), including both tissue-type PA
(tPA) and urokinase-type PA (uPA).2
The major PA implicated in clearance of extravascular
brin in the lung is uPA (Figure 9.1).8 The relative expression of uPA versus that of PAIs and antiplasmins is a key
determinant of local brinolytic capacity. With ongoing
remodeling of transitional brin, collagen deposition
eventually leads to progressive scarring and brotic repair.
The desmoplastic response associated with solid neoplasms is predicated on a similar sequence of events,1,19 as
is accelerated pulmonary brosis following ARDS2,8,20 and
in various interstitial lung diseases.18,21,22
There is good evidence to support the hypothesis that
extravascular brin in pleural (or other) diseases is pathophysiologic rather than incidental.1,2,8,2326 Perturbations
of either coagulation or brinolytic pathways can inuence inammation and tissue repair in several different
ways. For example, components of coagulation and brinolytic pathways are interactive with other proinammatory pathways, and interactions with the complement and
kinin systems can amplify the local inammatory
response.2 The expression of tissue factor can also be stimulated by a variety of cytokines now known to be elaborated in pleural diseases.6,27 Thrombin can inuence
cytokine expression and increase vascular permeability via
cellular signaling.28,29 In addition, brin and its derivatives
can independently inuence the inammatory response.
For example, brin and its products can disrupt endothelial cell organization,30 suppress lymphocyte proliferation,31 and promote directed migration of macrophages
and broblasts.32 In addition, proteolytic fragments of
brin(ogen) can effect increased vascular permeability.30,33,34 Plasmin, which is generated from plasminogen
through the action of PAs, including uPA, can also activate
transforming growth factor (TGF)-b and thereby promote
brotic repair.26 The induction of PAI-1 by TGF-b is likely
to be involved in this process. These observations strongly
support the concept that disordered brin turnover is
central to the pathogenesis of pleural inammation and
repair.
uPAR
Mesothelial
cell
uPA
Pgn
Particulates:
Asbestos
Pleural
injury
() PAI-1
Plasmin
Fibrin
()
Coagulation
TF
VIIA
Mesothelial
cell
104
Pleural brosis
mRNA binding
protein
Cell
cytoplasm
Phosphorylation
Newly dened post-transcriptional pathways by which uPA, uPAR and PAI-1 are regulated 105
106
Pleural brosis
loculation, malignant effusions with loculation and hemothorax with pleural organization.111121 The clinical endpoints of efcacy in these studies included improvement in
radiographic evidence of pleural injury, pleural drainage
and the need for further surgical procedures. The
intrapleural administration of brinolysins appears to be
well tolerated, generally does not cause clinically important systemic brinolysins and reduces the need for
surgery.110114,122,123 Other reports have shown that the
increased volume of pleural drainage associated with use
of thrombolytic therapy does not uniformly alter the morbidity or mortality of underlying empyema.115 In 2000, an
evidence-based guideline on the management of parapneumonic effusions from the American College of Chest
Physicians (ACCP) supported the optional use of brinolytic interventions if the effusion was large, loculated or
was associated with thickened pleura, positive culture, pus,
or pH was < 7.2. Fibrinolytic therapy was associated with
lower mortality and a decreased need for second intervention in patients with empyema and extensive disease and at
risk for poor outcome.4 A Cochrane review assessed the
evidence for efcacy of brinolytic therapy from available
randomized controlled trials in 2004. The review concluded that intrapleural brinolytic interventions is an
adjunctive therapy for patients with empyema or complicated parapneumonic effusions as it confers signicant
benets in terms of hospital stay, duration of fever, radiographic improvement and the need for surgical treatment. However, the routine use of brinolysins was not
recommended because the numbers of patients in these
randomized trials were small and study designs heterogeneous.124,125
More recently, a randomized controlled trial in 53 subjects showed improved outcomes and decreased need for
surgery when brinolysins with streptokinase was used in
adjunction to drainage.126 However, a large randomized
controlled clinical trial (MIST1) including 454 subjects
with pleural infection treated with intrapleural streptokinase or placebo127 recently challenged the prevailing favorable view of the efcacy of intrapleural brinolytic therapy.
In this trial, streptokinase did not alter mortality, the need
for surgery at 3 and 12 months, radiological appearance, or
length of stay. A meta-analysis of all trials using brinolysins for pleural infection arrived at results similar to
MIST1, in large part because the MIST1 trial contributed
75 percent of the subjects in the analysis.128 These new
results have sparked discussions to explain the differences
between these results and those of multiple trials supporting the use of intrapleural brinolysins.129133 While the
basis for the disparity is unclear, differences in outcomes
may relate to enrolment of subjects with early effusions
versus those with relatively protracted illness and wellestablished pleural reaction where brinolysins may be less
likely to be efcacious. The advanced age of subjects and
commitment to intrapleural brinolysis because of limited
availability of surgery may have contributed to masking of
potential benets of brinolysins in patients with pleural
108
Pleural brosis
REFERENCES
= Key primary paper
= Major review article
* = Paper that represents the rst formal publication of a
management guideline
1.
2.
3.
*4.
5.
6.
KEY POINTS
Pleural injury and repair is characterized by disordered brin turnover, which contributes to the
pathogenesis of pleural brosis.
Intrapleural coagulation is initiated by increased
local expression of tissue factor and brinolysis is
concurrently downregulated, owing mainly to
increased expression of PAI-1 and downstream
anti-plasmins.
Formation of adhesions between the visceral and
parietal pleural surfaces occurs in association
with intrapleural coagulation and downregulation of brinolysis.
7.
8.
9.
10.
11.
12.
References 109
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
110
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
Pleural brosis
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
procoagulant and brinolytic gene expression during bleomycininduced lung injury in the mouse. J Clin Invest 1995; 96: 162130.
Eitzman DT, McCoy RD, Zheng X, et al. Bleomycin-induced
pulmonary brosis in transgenic mice that either lack or
overexpress the murine plasminogen activator inhibitor-1 gene. J
Clin Invest 1996; 97: 2327.
Idell S, Kumar A, Zwieb C, et al. Effects of TGF-beta and TNF-alpha
on procoagulant and brinolytic pathways of human tracheal
epithelial cells. Am J Physiol 1994; 267: L693703.
Li XY, Brown GM, Lamb D, Donaldson K. Increased production of
plasminogen activator inhibitor in vitro by pleural leukocytes from
rats intratracheally instilled with crocidolite asbestos. Environ Res
1991; 55: 13544.
Donaldson K, Brown GM, Bolton RE, Davis JM. Fibrinolysis by rat
mesothelial cells in vitro: the effect of mineral dusts at non-toxic
doses. Br J Exp Pathol 1988; 69: 48794.
Bosma PJ, Kooistra T. Different induction of two plasminogen
activator inhibitor 1 mRNA species by phorbol ester in human
hepatoma cells. J Biol Chem 1991; 266: 178459.
Fattal PG, Schneider DJ, Sobel BE, Billadello JJ. Posttranscriptional regulation of expression of plasminogen activator
inhibitor type 1 mRNA by insulin and insulin-like growth factor 1.
J Biol Chem 1992; 267: 1241215.
Tillmann-Bogush M, Heaton JH, Gelehrter TD. Cyclic nucleotide
regulation of PAI-1 mRNAStability. Identication of cytosolic
proteins that interact with an a-rich sequence. J Biol Chem 1999;
274: 11729.
Shetty S, Idell S. Post-transcriptional regulation of plasminogen
activator inhibitor-1 in human lung carcinoma cells in vitro. Am J
Physiol Lung Cell Mol Physiol 2000; 278: L14856.
Shetty S, Bdeir K, Cines DB, Idell S. Induction of plasminogen
activator inhibitor-1 by urokinase in lung epithelial cells. J Biol
Chem 2003; 278: 1812431.
Pedersen H, Brunner N, Francis D, et al. Prognostic impact of
urokinase, urokinase receptor, and type 1 plasminogen activator
inhibitor in squamous and large cell lung cancer tissue. Cancer Res
1994; 54: 46715.
Pedersen H, Grondahl-Hansen J, Francis D, et al. Urokinase and
plasminogen activator inhibitor type 1 in pulmonary
adenocarcinoma. Cancer Res 1994; 54: 1203.
Heaton JH, Dlakic WM, Dlakic M, Gelehrter TD. Identication and
cDNA cloning of a novel RNA-binding protein that interacts with
the cyclic nucleotide-responsive sequence in the Type-1
plasminogen activator inhibitor mRNA. J Biol Chem 2001; 276:
33417.
Saksela O, Rifkin DB. Cell-associated plasminogen activation:
regulation and physiological functions. Annu Rev Cell Biol 1988;
4: 93126.
Duggan C, Maguire T, McDermott E, et al. Urokinase plasminogen
activator and urokinase plasminogen activator receptor in breast
cancer. Int J Cancer 1995; 61: 597600.
Blasi F, Vassalli JD, Dano K. Urokinase-type plasminogen activator:
proenzyme, receptor, and inhibitors. J Cell Biol 1987; 104: 8014.
Shetty S, Kumar A, Idell S. Post-transcriptional regulation of
urokinase receptor mRNA: identication of a novel urokinase
receptor mRNA binding protein in human mesothelioma cells. Mol
Cell Biol 1997; 17: 107583.
Shetty S, Muniyappa H, Halady PK, Idell S. Regulation of urokinase
receptor expression by phosphoglycerate kinase. Am J Respir Cell
Mol Biol 2004; 31: 1006.
Shetty S. Regulation of urokinase receptor mRNA stability by
hnRNP C in lung epithelial cells. Mol Cell Biochem 2005; 272:
10718.
Tran H, Maurer F, Nagamine Y. Stabilization of urokinase and
urokinase receptor mRNAs by HuR is linked to its cytoplasmic
accumulation induced by activated mitogen-activated protein
kinase-activated protein kinase 2. Mol Cell Biol 2003; 23:
717788.
References 111
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
139.
112
Pleural brosis
140. Chen JP, Lue KH, Liu SC, et al. Intrapleural urokinase treatment in
children with complicated parapneumonic effusion. Acta Paediatr
Taiwan 2006; 47: 616.
141. Thomson AH, Hull J, Kumar MR, et al. Randomised trial of
intrapleural urokinase in the treatment of childhood empyema.
Thorax 2002; 57: 3437.
142. Singh M, Mathew JL, Chandra S, et al. Randomized controlled trial
of intrapleural streptokinase in empyema thoracis in children. Acta
Paediatr 2004; 93: 14435.
143. Kurt BA, Winterhalter KM, Connors RH, et al. Therapy of
parapneumonic effusions in children: video-assisted thoracoscopic
surgery versus conventional thoracostomy drainage. Pediatrics
2006; 118: e54753.
144. Sonnappa S, Cohen G, Owens CM, et al. Comparison of urokinase
and video-assisted thoracoscopic surgery for treatment of
childhood empyema. Am J Respir Crit Care Med 2006; 174: 2217.
145. Higazi AA, Mazar A, Wang J, et al. Single-chain urokinase-type
plasminogen activator bound to its receptor is relatively resistant
to plasminogen activator inhibitor type 1. Blood 1996; 87:
35459.
146. Vermeer F, Bosl I, Meyer J, et al. Saruplase Is a safe and effective
thrombolytic agent; observations in 1,698 patients: results of the
PASS Study. J Thromb Thrombolysis 1999; 8: 14350.
147. Idell S, Mazar A, Cines D, et al. Single-chain urokinase alone or
complexed to its receptor in tetracycline-induced pleuritis in
rabbits. Am J Respir Crit Care Med 2002; 166: 9206.
148. Idell S, Allen T, Chen S, et al. Intrapleural activation, processing,
efcacy and duration of protection of single-chain urokinase in
evolving tetracycline-induced pleural injury in rabbits. Am J
Physiol Lung Cell Mol Physiol 2007; 292: L2532.
149. Strange C, Baumann MH, Sahn SA, Idell S. Effects of intrapleural
heparin or urokinase on the extent of tetracycline-induced pleural
disease. Am J Respir Crit Care Med 1995; 151: 50815.
150. Bruckner A, Filderman AE, Kirchheimer JC, et al. Endogenous
151.
152.
153.
154.
155.
156.
157.
158.
159.
160.
10
Pleural reaction to mineral dusts
JAUME FERRER, JOS GARCA-VALERO, JUAN F MONTES
Introduction
Pleural involvement by silica and non-brous silicates
Dynamics of bers and particles in lung and pleura
Mechanisms of mesothelial damage
113
113
114
114
INTRODUCTION
Inhalation of mineral dusts can cause pleural disease.
Pleural abnormalities can occur in patients with pneumoconioses, and on occasions the pleura may be affected
without lung involvement. Inorganic pleural disease
includes several pathological disorders, ranging from
pleural brosis and calcication to malignant transformation.
Mesothelial cell damage has been studied in vitro and in
vivo, particularly after exposure to asbestos and man-made
mineral bers. However, despite considerable research
efforts, the mechanisms by which the pleura are affected by
mineral dusts remain poorly understood. In addition to
secondary involvement as a result of mineral dust inhalation, the pleura can also be directly exposed from therapeutic intrapleural administration of talc. Talc is currently
the most commonly used agent for human pleurodesis
(see also Chapter 25, Effusions from malignance and
Chapter 46, Pleurodesis). Consequently, the effects of talc
on mesothelial cells will also be discussed.
In this chapter we focus on current knowledge of
pleural involvement by inhaled and intrapleurally introduced mineral dusts.
116
120
120
material, dust would be carried towards the bronchomediastinal lymphatic trunk, and backwards to the intercostal vessels, leading to lymphangitis and reactive brosis.
The nding of coal dust in intercostal vessels in cases of
coal pneumoconiosis supports this theory.24
lial cells.47 Moreover, increased DNA synthesis and apoptosis are in dynamic balance in asbestos-exposed mesothelial cells.37 Apoptosis is the key mechanism for eliminating
mesothelial cells damaged by asbestos, ensuring the
removal of cells carrying genetic abnormalities with potential harmful biological effects.
Attention has recently been paid to the role of ROS in
cell toxicity caused by asbestos. Iron present in the surface
of asbestos bers and other silicates drive local generation
of ROS via redox reactions.48 Oxidation also occurs after
the respiratory burst of phagocytosis of large asbestos
bers.44 The participation of ROS in asbestos mesothelial
damage has been suggested by recent in vitro studies.
Culture medium from asbestos-exposed mesothelial cells
contains dose-dependent increases of oxidant-induced
base modications such as 8-oxo-2-deoxyguanosine and
8-hydroxydeoxyguanosine, thereby indicating DNA
damage.49,50 However, overexpression of the antioxidant
enzymes heme oxygenase and manganese-containing
superoxide dismutase (Mn-SOD) in asbestos-exposed
human mesothelial cells suggests a reaction against oxidative damage.51
Recent in vitro data have contributed to the elucidation of the signal transduction cascade, through which
asbestos bers regulate gene expression in mesothelial
cells. Phosphorylation of the epidermal growth factor
receptor (EGF-R) on mesothelial cells by asbestos, especially the longest bers,52 appears to be the initial step,
since it is known to induce cell proliferation.53
Phosphorylation of the mitogen-activated protein (MAP)
kinases and extracellular signal-regulated kinases (ERK) 1
and 2 would then occur, and these activated kinases
would translocate to the nucleus to induce c-fos transactivation.54 In a recent study, crocidolite was shown to be
able to induce activation of the p38 arm of the MAP
pathway in rat mesothelial cells.55
After activation by MAPK signaling cascades, the proliferative effect of asbestos on mesothelial cells can be
mediated by upregulation of the early response protooncogenes c-fos and c-jun.56 The c-fos and c-jun proteins
form the AP-1 transcription factor, which binds to AP-1
DNA sites and regulates transition of the G1 to S phase of
the cell cycle.57
It is probable that biopersistence of asbestos, mainly
amphiboles, in lung and pleura cause a low-grade but sustained inammation and cell proliferation via c-fos and
c-jun and protein kinase C (PKC) pathways. Regulatory
mechanisms such as DNA repair and apoptosis would be
bypassed, favoring uncontrolled cell growth in certain
cases and after a long latency period.
Alternative mechanisms of DNA modication have
been proposed. Mechanical interference of asbestos bers
with chromosomes, including severing, piercing or disruption of the mitotic spindle, are known to occur.30,40
Another possibility is transfection of exogenous DNA into
mesothelial cells. Transfection of plasmid DNA into
mesothelial cells by asbestos bers has been carried out in
contact with particles translocated to the pleura21 or indirectly through pulmonary mediators and inux of inammatory cells. Oxidant mechanisms are probably involved
in direct mesothelial damage by silica and non-brous silicates.72
To our knowledge, non-brous particles are not toxic
to mesothelial cells73 and do not produce genetic changes.
Mesothelioma has not been associated with silica or nonasbestos silicate human inhalation, and this tumor has not
developed in animals after intrapleural administration of
quartz.74
PLEURAL INFLAMMATION
(a)
(b)
Figure 10.2 Extrapleural dissemination of talc to pulmonary parenchyma (a, 40) and mediastinum (b, 200). Talc particles are seen as
bright structures when observed by means of 45 polarized light microscopy.
KEY POINTS
REFERENCES
References 121
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
References 123
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
11
Genetic alterations in mesothelioma pathogenesis
JOSEPH R TESTA, SURESH C JHANWAR
Mechanisms of asbestos carcinogenicity
Recurrent cytogenetic abnormalities
Deletion mapping of recurrent chromosomal losses
Involvement of tumor suppressor genes
An Nf2 mouse model recapitulating molecular features of
human malignant mesothelioma
AKT/Akt kinase activation in malignant mesothelioma
125
126
126
128
130
131
131
131
132
132
133
133
MECHANISMS OF ASBESTOS
CARCINOGENICITY
Whether asbestos bers act directly on mesothelial cells or
indirectly via induction of reactive oxygen species (ROS)
and growth factors5,6 is not fully understood. In vitro
studies have demonstrated that asbestos can physically
interact with the mitotic spindle apparatus, which could
result in aneuploidy and other forms of chromosome
damage.7 In vivo, however, iron-rich crocidolite asbestos
bers may lead to the release of ROS when hydrogen peroxide and superoxide react to form hydroxyl radicals.
Asbestos bers induce expression and enzymatic activation of the mammalian DNA repair enzyme, apurinic/
apyrimidinic endonuclease, suggesting that ROS generated
by asbestos may produce DNA damage such as G to T
transversions.8 Recent evidence indicates that G to T transversions, often induced by the premutagenic DNA adduct
8-hydroxydeoxyguanosine, are among the most prevalent
mutations detected following crocidolite treatment of
omenta from lacI transgenic rats.9 Moreover, the inammatory response to asbestos leads to the generation of
various cytokines responsible for the local and systemic
immunosuppressive activity of asbestos.10 In addition,
asbestos can induce autophosphorylation of the epidermal
growth factor (EGF) receptor, which results in increased
expression of c-fos and c-jun, which encode transcription
Chromosome 1p22
In order to map the critically deleted segment of 1p, LOH
analyses were performed on 50 MMs using a large panel of
DNA markers distributed along the short arm of chromosome 1.17 Allelic losses at 1p2122 were observed in 36
cases (72 percent), and we were able to localize the SRO of
deletions to a 4-centiMorgan (cM) region in 1p22. We
ruled out the involvement of BCL10,18,19 a gene located at
1p22 that encodes a protein containing an N-terminus
caspase recruitment domain homologous to the motif
found in several regulatory and effector apoptotic molecules. DNA analysis of other candidate TSGs in 1p22 have
not revealed any mutations, although expression of several
genes in this region are often downregulated in MM cells
compared with that observed in normal mesothelial cells
(JR Testa, unpublished data).
Chromosome 3p21
Two independent research groups demonstrated that 3p is
a common site of allelic loss in MM.20,21 For example, we
detected LOH from 3p in 15 of 24 (63 percent) MMs, with
the highest frequency of allelic loss being at 3p21.3. Losses
from this region have also been reported in other forms of
cancer, particularly lung tumors, suggesting that perturbation of a TSG(s) located at this site may play a role in the
development of multiple tumor types. The nature of the
TSG(s) located in this region is not known, although a
homozygous deletion of the beta-catenin gene (CTNNB1),
located at 3p21.3, has been reported in one MM cell line.22
None of the remaining nine MM cell lines and tumor specimens examined showed deletions or aberrant expression
of CTNNB1.
Chromosome 6q1425
A LOH analysis of 6q in MMs has revealed a complex
pattern of allelic loss.23 LOH at 6q occurs in c. 60 percent
of MMs, and deletions fall into several discrete regions
including 6q1421, 6q16.321, 6q2123.2 and 6q25.
Multiple non-overlapping regions of 6q loss have also been
described in other types of cancer, such as non-Hodgkins
lymphoma.
Chromosome 9p21
We performed gene dosage studies on a series of MM cell
lines, 83 percent of which showed homozygous or hemizygous deletions involving an approximately 1-megabase
Chromosome 13q13.314.2
Some cytogenetic investigations of MM have revealed frequent losses in chromosomes 13 and 14. To dene the
SRO of deletions from these chromosomes, we performed
LOH analyses on 30 MMs using 25 microsatellite markers
in 13q and 21 markers in 14q.25 Twenty of the 30 MMs (67
percent) showed allelic loss of at least one marker in 13q.
The SRO of deletions was delineated as an approximately
7-cM region located at 13q13.314.2. Thirteen of the 30
MMs (43 percent) displayed allelic losses from 14q, with at
least three distinct regions of LOH located at segments
q11.213.2, q22.324.3 and q32.12. These data highlight a
single region of chromosomal loss in 13q in many MMs,
implicating the involvement of a TSG that is critical to the
pathogenesis of this malignancy. In contrast, the lower
incidence and diffuse pattern of allelic losses in 14q suggest
that several TSGs in this chromosome arm may contribute
to tumorigenic progression in some MMs.
Chromosome 15q15
Our CGH analyses demonstrated losses from 15q in 13 of
24 (54 percent) MM cell lines examined, and LOH analyses showed allelic losses from one or more 15q loci in 10 of
these 13.15 The SRO was located at 15q11.115. Losses
overlapping this region have also been observed in other
types of cancer, such as metastatic tumors of the breast,
lung and colon, suggesting that this region harbors a TSG
that may contribute to the progression of a variety of
epithelial cancer types. In subsequent studies, we performed a high density LOH analysis of 15q in 46 MMs.
These studies have dened a minimally deleted region of
approximately 3cM, which was conrmed to reside at
15q15 by uorescence in situ hybridization analysis with
DNA probes known to map to this region.25
p16INK4a
One product of the CDKN2A/ARF locus, p16INK4a, is
capable of binding to and inhibiting the cyclin-dependent
kinase CDK4. Shortly after being cloned, the p16INK4a gene
was identied as the 9p21 TSG, and homozygous deletions
of p16INK4a were detected at high frequencies in cell lines
derived from various types of cancer.26 To assess the possible involvement of p16INK4a in MM, we performed deletion
mapping studies of 40 MM cell lines;27 34 (85 percent) of
the lines had homozygous deletions of one or more
Table 11.1 Summary of allelic losses and tumor suppressor genes associated with multistep tumorigenesis
in human malignant mesothelioma
Chromosome region
1p22
3p21.3
6q14-25
9p21
13q13.214.2
15q15
17p13
17q2125
22q12
72
63
60
83b
67
48
40
70
72
TP53
NF2
aPercentages shown reect incidence of allelic loss observed in mesothelioma cell lines examined by the authors. Note:
each of these common sites of allelic loss was conrmed in a subset of cases for which corresponding tumor tissue was
available.
bAt the p16INK4a/p14ARF locus, 85 percent of cell lines exhibited homozygous losses, nearly all of which affected both
p16INK4a and p14ARF; 78 percent of these cell lines also showed homozygous loss of p15INK4b.
p21.3
p22
MTAP
p16
p14ARF
p21
p53
q11.213.2
q13.314.2
q1421
p13
q21.325
NM 23
q16.321
q12
NF2
q15
q22.324.3
q2123.2
q32.12
q25
13
14
15
17
22
Figure 11.1 Idiograms of chromosomes frequently altered in malignant mesothelioma (MM), indicative of multistep tumorigenesis in
this disease. Brackets demarcate minimally deleted regions (SROs) in each chromosome. Locations of TSGs (p14ARF, p16INK4a, TP53 and NF2)
known to be either mutated or homozygously deleted in MM are shown; other candidate genes (MTAP, NM23) are also indicated. (See also
Color Plate 4.)
p14ARF
In most cases, homozygous deletion of the CDKN2A/ARF
locus also leads to inactivation of another putative TSG,
p14ARF, because p16INK4a and p14ARF share exons two and
three, although their reading frames differ. p14ARF is essential for the activation of p53 in response to the action of
certain oncogene products such as Ras or Myc.30 The
p16INK4a product, on the other hand, induces cell cycle
arrest at the G1 phase by inhibiting the phosphorylation of
the retinoblastoma protein, pRb. Therefore, homozygous
loss of p14ARF and p16INK4a would collectively affect both
p53- and pRb-dependent growth regulatory pathways,
respectively. CDKN2B (p15INK4b), another gene located
near the CDKN2A/ARF locus, is also frequently deleted in
human MMs,31 although to date a critical role for p15INK4b
in MM has not been clearly dened.
The methylthioadenosine phosphorylase gene (MTAP)
is also frequently co-deleted with the CDKN2A/ARF locus
in MM. For example, in one study of 95 MM cases, 70
tumors showed homozygous deletions of p16INK4a, 64 (91
percent) of which exhibited co-deletion of MTAP.32
Whether loss of MTAP expression plays a fundamental
role in MM pathogenesis is unknown at this time, but this
enzyme may represent an interesting therapeutic target
(see below).
TP53
While loss of p14ARF is frequently observed in MM, mutations of the p53 gene (TP53) are less commonly reported
in this malignancy.3335 TP53 is located at chromosome
17p13, and loss or relative deciency of the short arm of
chromosome 17 is a recurrent change in MM. Immunohistochemical staining of p53 protein in MM cell lines was
performed by one of us (SCJ). Mutant p53 protein was
detected in a signicant percentage (>50 percent) of cells
NF2
As noted earlier, numerical loss of a copy of chromosome
22 is a frequent occurrence in MM. Although germline
mutations of the neurobromatosis type 2 TSG, NF2, predispose affected individuals to tumors of neuroectodermal
origin, somatic mutations of NF2 have occasionally been
identied in seemingly unrelated malignancies.36 Therefore, two groups independently embarked on mutational
studies of NF2 in MM. We identied nucleotide mutations
in 8 of 15 (53 percent) MM cell lines.37 The mutations,
which included deletions and insertions and one nonsense
mutation, predicted truncated forms of the NF2 protein,
known as merlin or schwannomin. Similarly, Sekido and
colleagues38 detected somatic mutations in one MM specimen and in 7 of 17 (41 percent) MM cell lines. In our
study, the mutations observed in cDNAs from MM cell
lines were conrmed in genomic DNA from six matched
primary tumor specimens.37 The two cDNA alterations
that could not be conrmed by genomic analysis were
both splicing related: i.e., deletion of exon 10 in one cell
line, and a 43-bp insertion between exons 13 and 14 in the
other.
In a follow-up investigation, mutations in the NF2
coding region were detected in 12 of 23 (52 percent) additional MM cell lines.39 Western blot analyses revealed loss
of merlin expression in each of the 12 cell lines having
alterations of the NF2 gene. In addition, two cell lines with
NF2 mutations reported in an earlier study were also
examined, both of which lacked NF2 expression. LOH
analyses were performed on the entire 25 MM cell lines
using two polymorphic DNA markers residing at or near
the NF2 locus in chromosome 22q12. Eighteen of the 25
cell lines showed losses at one or both of these loci. All
cases exhibiting mutation and aberrant expression of NF2
displayed LOH, consistent with bi-allelic inactivation of
NF2 in MM.
Merlin exhibits signicant homology to the ezrin
radixinmoesin (ERM) family of proteins known to play a
role in cell surface dynamics by linking the cytoskeleton to
components of the cell membrane. However, the mechanisms by which merlin exerts its tumor suppressor activity
are incompletely understood. One mechanism involves
susceptibility gene could lead to the development of therapeutic approaches for members of these families.
Moreover, it is possible that the same gene may be a target
in sporadic MMs associated with exposure to asbestos and,
thus, the eventual isolation of this gene might enhance our
understanding of molecular mechanisms involved in the
pathogenesis of MM generally.
CONCLUSIONS
Multiple genetic changes are involved in the development
of most cancers. Asbestos is known to cause genetic
damage. In a normal cell, mitosis is controlled through a
delicate balance of phosphorylation and dephosphorylation events. Autophosphorylation of the EGF receptor
results in phosphorylation of MEK1 kinase, which in turn
phosphorylates ERK (MAP kinases). The activation of
these kinases causes activation of other intermediaries, and
this in turn stimulates c-fos and c-jun and other members
of the AP-1 family and induces cell division.5
Downregulation of AP-1 activity is achieved through the
phosphatase PP2A, which dephosphorylates MAP kinases.
Asbestos, working through this mechanism, may induce
tumor formation. Asbestos can induce both DNA damage
and autophosphorylation of the EGF receptor, which
eventually leads to AP-1 expression and cell division.58 As
a result of inactivation of p53, mutations caused by
asbestos would not undergo repair at the G1/S checkpoint
mediated by p53 through p21. While most DNA alterations will either be of no signicance or lead to cell death,
a few cells could potentially develop perturbations of key
cell cycle regulatory genes,12 become immortalized
and tumorigenic. Evidence in support of this notion
comes from experiments with p53 knockout mice, in
which p53-decient animals were shown to be more susceptible to asbestos-induced MMs than wild-type mice.59
In summary, there is now a large body of experimental
and epidemiological data in support of the assertion that
asbestos, or at least amphibole asbestos, causes MM. These
data also suggest that exposure to asbestos is usually not
sufcient for MM development and that other factors,
such as genetic predisposition, may render some individuals more susceptible to asbestos carcinogenicity. Cytogenetic and molecular genetic studies indicate that MM
results from the accumulation of numerous somatic
genetic events, mainly deletions, suggesting a multistep
cascade involving the inactivation of multiple TSGs. To
date, several TSGs have been shown to be frequently
altered in MMs, and their disruption would be expected to
have profound consequences on the growth and behavior
of a mesothelial cell. The identication of all of the critical
somatic genetic alterations in MM and understanding how
each of them contributes to the pathogenesis of this malignancy may ultimately lead to the design of more effective
therapeutic strategies.
KEY POINTS
References 133
Biallelic inactivation of the NF2 tumor suppressor gene, located in chromosome 22q, occurs in
approximately 50 percent of mesotheliomas.
Inactivation of NF2 results in increased cell proliferation by promoting Pak-induced cyclin D1.
NF2 inactivation also enhances tumor cell
spreading and invasion by augmenting focal
adhesion kinase (FAK) activity, suggesting that
loss of merlin function is a critical step in the
pathogenesis of mesothelioma.
Nf2(+/-) knockout mice treated with asbestos
show accelerated formation of mesotheliomas
compared with wild-type mice, and the tumors
in Nf2 knockout mice faithfully recapitulate
many of the same molecular genetic and signaling perturbations observed in human mesothelioma. Thus, this murine model has signicant
implications for preclinical testing of novel therapeutic drugs.
Genetic predisposition may render some individuals more susceptible to mineral ber carcinogenicity.
ACKNOWLEDGMENTS
This work was supported by NIH grants CA 45745, PO1
CA114047 and CA 06927, and by a gift from the Local 14
Mesothelioma Fund of the International Association of
Heat and Frost Insulators and Asbestos Workers, in
memory of Hank Vaughan and Alice Haas (to JRT).
REFERENCES
2.
3.
4.
5.
6.
7.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
12
Proteomics in pleural disease
JOOST HEGMANS, BART LAMBRECHT
Proteomics and its complexity
Biomarkers
Traditional biomarkers for pleural diseases
Novel biomarkers for pleural diseases
Current techniques for proteomic analysis to discover
novel biomarkers
135
136
136
138
138
degradomics
glycomics
serum peptidome
lipidome
clinical proteomics
Genome: The entire collection of genes in the complete DNA sequence of an organism
Transcriptome: The complete set of mRNAs that are transcribed from the genome
Proteome: The expressed set of proteins that are encoded by the genome
Genomics: Investigations and techniques for identifying the genome
Proteomics: Investigations and techniques for identifying the proteome
metabolome
toponomics
subproteomics
functional proteomics
phosphoproteomics
Figure 12.1 The omes and omics era. Because of the success
of genomics and proteomics, the sufx -ome and omics has
now widely migrated to a host of other contexts.
146
147
147
147
quantication of proteins but also involves the comprehensive study of their structure, localization, modication,
interactions, activities and function of all proteins in body
uids, tissues or cell types under given conditions.1
Proteomics is relatively more challenging than genomics
because a single gene can give rise to multiple protein
products through alternative splicing, proteolysis of proteins and post-translational modications (20 000
25 000 different genes versus approximately 1 000 000
different proteins).2,3 Currently there are more than 300
different types of post-translational modications known,
and new ones are regularly discovered.4,5 They are often
transient and occur in vivo only in a small fraction of proteins (<1 percent) and include glycosylation, phosphorylation, acetylation, nitration, ubiquitation and disulde
bond formation.47 Post-translational modications regulate protein function, determining their activity state, cellular location and dynamic interactions with other
proteins or nucleic acids.6
Exploring the structure and activity of proteins is
increasingly used to address biomedical questions that
may help to elucidate the molecular basis of health and
disease and, for example, to address fundamental questions in the progression of a disease from a normal to a
pathophysiologic state (clinical proteomics). We will
discuss different aspects of proteomics, including new
proteomic platforms as well as their limitations. It is of no
surprise that none of these proteomic approaches currently come close to detecting all proteins present in
complex biological systems. When the obstacles can be
overcome, it will enable abundant harvesting of diagnostic
biomarkers leading to a new era of personalized clinical
medicine.
BIOMARKERS
The levels of particular proteins in tissues, serum and
other body uids have been used extensively to diagnose,
monitor or predict disease prognosis using conventional
protein quantication techniques, such as immunohistochemistry and enzyme-linked immunosorbent assay
(ELISA). These proteins are then called biomarkers and
are differentially present in a sample taken from a subject
of one phenotypic status (e.g. having a disease) compared
with another phenotypic status (e.g. healthy). They can be
found (either newly formed, or at increased or decreased
amounts) in blood, body uids or in tissues, and indicate
a particular disease state. They are produced and sometimes secreted by transformed cells or they can be the
result of the bodys response to the development of this
disease. Proteinases derived from the diseased tissue
microenvironment give rise to peptides within the circulatory system (termed the blood or serum peptidome) and
can be a rich source of disease-specic information.810
Examples of characteristic biomarkers that physicians use
for diagnosis, prognosis and/or surveillance include: CA
125 (ovarian cancer), estrogen receptor/progesterone
receptor, Her2/neu, CA 15-3 and CA 27-29 (breast
cancer), PSA (prostate cancer), beta-amyloid and Tau
protein (Alzheimer) and CEA (ovarian, lung, breast, pancreas and gastrointestinal tract cancers). These biomarkers
can objectively be measured and evaluated as an indicator
of normal biological or pathogenic processes or to determine pharmacological responses to a therapeutic intervention. They may support early detection (diagnostic or
screening marker), molecular classication, predictor of
metastasis in cancer, treatment response, to determine the
prognosis, and so forth. The characteristics of an ideal biomarker are specic, sensitive, predictive, robust and
preferably easily accessible in a non-invasive way. In the
clinical setting, there is a constant need for new biomarkers with improved sensitivity and specicity. The source
material for the identication of these new biomarkers is
shifting away from tissue-cultured cells to the discovery of
proteins that change in actual diseased tissues or body
uids. However, tissues are heterogeneous; they are composed of interacting cell populations. New technology has
made it possible to analyze diseased cells in the tissue
itself,11 or to physically separate the desired cells directly
from the surrounding cells under microscopic visualization by laser-capture microdissection (Figure 12.2).12 This
technology has been applied to discover dozens of new
protein targets that are either a cause or a consequence of
the disease process in the actual tissue.1219
Pleural diseases are often accompanied by the presence
of pleural uid in the thoracic cage. Discovering the
changes in expression of pleural proteins being overexpressed and/or abnormally shed into the effusion
proteome may elucidate the basic molecular mechanisms
that either cause, or result from, the diseased state of the
patient. For example, cancer cells may release proteins (e.g.
Cap
Transfer
film
Cells
of interest
Microscope
slide
(b)
Infrared laser
pulse
Transfer of
selected cells
(c)
(a)
(a)
Figure 12.2 Laser capture microdissection allows researchers to compare normal with
diseased cells by isolating distinct subpopulations from (stained) tissue sections under
direct microscopic visualization. (a) After locating the cellular population of interest (top
picture), a cap with lm backing is placed over the target area (middle picture). Pulsing
the infrared laser locally expands the thermosensitive polymer lm to reach down and
adhere the target cell(s) beneath the laser pulse. Lifting the cap from the tissue section
removes the target cells now attached to the cap (lower picture). The cap holding the
captured cells is then transferred to a tube, where an extraction buffer is used to
remove the cells for further analysis. An example shows the laser outline of the cells to
be collected (b), the remaining cells after laser capture (c), and the cells collected from
the outlined area (d). (See also Color Plates 57.)
(d)
Protein digestion
Trypsin
Lys-C
Asp-N
Glu-C
High-resolution one- and two-dimensional gel electrophoresis (1D and 2D GE, respectively) has traditionally
been the gold-standard discovery-based tool for proteomics38,39 and was used for analyzing the proteome of
body uids, for instance for plasma,40 urine,41 cerebrospinal
uid42,43 and pleural uid.4447 Unfortunately, pleural
uids, like most of the body uids, contain an enormous
amount of different proteins and salt ions. Albumin and
immunoglobulin fragments are the major protein components, representing 5070 percent and 1020 percent of the
total pleural proteins, respectively (mg/mL range).
Together with transferrin, brinogen, haptoglobin, antitrypsin, complement components and a few other proteins,
the top 20 proteins are responsible for approximately 99
percent of the protein mass. Pleural effusions contain a
tremendous array of very-low-abundance molecules such
as signaling and regulatory proteins. For example, comparatively small quantities of cytokines are detected by cytokine
arrays and ELISA, such as transforming growth factor-beta
(TGF-b), interleukin (IL) (IL-1, IL-6, IL-8, and IL-10) or
vascular endothelial growth factor (VEGF), but these are in
Peptide separation
High-performance liquid chromatography (HPLC)
Ion exchange
Sample ionization
Electrospray ionization
Matrix-assisted laser desorptionionization (MALDI)
Mass spectrometry
Quadrupole (Q)
Time of flight (TOF)
Quadrupole ion traps (IT)
Fourier-transform ion cyclotron resonance (FT-ICR)
Data analysis
Peptide search
Sequest
Mascot
Molecular mass
3
200
kDa
Isoelectric point
pH
10
Protein spot
10
(a)
Figure 12.4 Two-dimensional (2D) electrophoresis is used to
separate protein mixtures according to their isoelectric point (rst
dimension) and to their molecular mass (second dimension) (a).
Human pleural effusion was depleted of albumin and
immunoglobulin G (IgG) and resolved by 2D gel electrophoresis
(b).
(b)
originate from diseased cells and may contain disease-specic information and with it represent potential candidates for useful biomarkers concentrated in or only
measurable in pleural effusions. To discover these proteins, the development of quantitative proteomics such as
differential gel electrophoresis and isotope-coded afnity
tags has widened the applicability to detect proteins of
interest.
Patient
Serum
Albumin and
Ig removal
Pleural
effusion
Labeling
with Cy3
Labeling
with Cy2
Labeling
with Cy5
First dimension:
isoelectric focusing
Second dimension:
relative molecular
masses
pl
MW
SDS-PAGE
Imagin on typhoon
Cy3
Cy2
Cy5
MALDI-TOF MS
Once proteins are separated by SDS-PAGE and stained,
they have to be characterized. MS, and in particular
MALDI-TOF MS, is indispensable technology for protein
mixture proling and for the identication of proteins. It
was invented in the late 1980s86,87 and the importance has
been recognized by the share of the 2002 Nobel Prize for
Chemistry to Koichi Tanaka for its invention.88
Spots of interest are excised from the gel, destained and
subsequently digested with proteolytic enzymes and/or
chemicals. Trypsin is most commonly used in identication studies. Trypsin is a very stable and efcient protease
that specically cleaves at the C-terminal side of lysine and
Table 12.1 Advantages and disadvantages of selected proteomic technologies for protein proling
Technique
Advantages
Disadvantages/limitations
2D GE
DIGE
ICAT
MALDI
SELDI
Protein array
Abbreviations: 2D GE, two-dimensional gel electrophoresis; DIGE, differential gel electrophoresis; ICAT, isotope-coded afnity tag; MALDI, matrix-assisted
laser desorption/ionization; MS, mass spectrometry; SELDI, surface-enhanced laser desorption/ionization.
Sample 1
Sample 2
Label cysteines
with light (12C) tag
Label cysteines
with heavy (13C) tag
Enzymatic digestion
Intensity
Abundance
ratio (light/heavy)
m/z
Wash to
reduce
non-specific
binding
Add matrix
ions
Detector
TOF-MS
Mass analyser
(a)
PU
LS
ED
Matrix ions
Analyte ions
LA
SE
R
Analyte molecules
Matrix molecules
(b)
Droplets releasing
analyte ions
SPRAY NEEDLE
Analyte mixture
M
a
s
s
a
n
a
l
y
s
e
r
tion on the basis of hydrophobicity. Ionized and fragmented protein samples are introduced into a mass analyzer, which separates and detect the ions according to
their m/z ratios. Besides the already described time-ofight device (TOF as in MALDI-TOF and SELDI-TOF),
other basic types of mass analyzers are the quadrupole
(Q), quadrupole ion trap (IT), and Fourier transform
ion cyclotron (FT-ICR-MS or FTMS), each with its own
strengths and weaknesses. Each of these instruments
generates a mass spectrum, hence the term mass spectrometry.
A Q mass lter consists of four parallel rods through
which direct current and radio frequency alternate electric
elds are applied to sort the introduced ions. For each
combination of voltages and frequencies, only ions with a
specic m/z ratio pass undeected through the Q mass
lter. Ions of the desired mass are fragmented in a gas collision cell, the masses of these daughter fragments then
being measured by a TOF mass analyzer. Precise stepping
of the settings allows the quadrupole to be used as a mass
analyzer to scan for ions over a large m/z range. In IT mass
spectrometry, the ions of a selected mass are rst caught
(trapped) in a dynamic electric eld and are then sequentially according to their m/z value ejected onto the
detector with the help of another electric eld. Trapped
ions can also be fragmented by increasing the energy of the
trap, with the mass detector measuring the masses of these
fragments for peptide identication. In contrast to IT,
FTMS keep the ions conned in the high magnetic eld of
a super-conducting magnet. The ions circle with frequencies that are inversely proportional to their m/z value. This
circling induces an alternating current in the metal plates
that make up the trap. This time-varying current constitutes a frequency spectrum of the ion motion and is
converted by the mathematical operation Fourier transformation which explains the name into a mass spectrum
with high resolution and mass accuracy.
The number of possible instrumental congurations is
large because different analyzers can be coupled with
various sources, such as the popular quadrupole-time of
ight hybrid (Q-TOF) mass spectrometer. When more
accuracy and sensitivity than MALDI or SELDI is needed,
for instance for the analysis of post-translational modications of proteins, high pressure LC is coupled to an ESI
source and an FTMS instrument with electron capture dissociation can be used. The LC-ESI-triple quadrupole with
multiple ionization sources is the instrument of choice for
looking at biomarkers or drug efcacy. However, as there
is no single instrument that can do it all, state of the art
proteomics facilities need to be equipped with several different types of MS instruments.
Highly complex protein mixtures (e.g. unfractionated
cellular lysates) that cannot be efciently resolved on gel
can be reduced, alkylated, digested and fractionated
through a strong cationic exchange column, and further
separated on a reverse-phase column in a technique known
as multidimensional protein identication technology
(MudPIT).105 This approach, whereby 2D liquid chromatography (cation exchange followed by reverse-phase
chromatography) is coupled to tandem MS, was applied to
yeast proteomic analysis and a total of 1484 proteins were
detected and identied, including the identication of 131
proteins that are membrane localized a highly problematic class of proteins due to their intrinsic hydrophobic
nature. This technique reduces the bias against the detection of basic and hydrophobic proteins and is very sensitive
and reproducible.
References 147
FUTURE PERSPECTIVES
Due to the aforementioned current limitations, at present,
clinical proteomics cannot replace invasive standardized
diagnostic procedures such as open pleural biopsy, but
holds great promise and potential for future highly
improved diagnosis and care of the patient. Many complementary technologies have been developed and are continuously improved, such as DIGE, ICAT, protein arrays and
various developments in the eld of mass spectrometry.
Ongoing rapid developments in separation techniques,
automation, sample throughput and bioinformatics will
further stimulate the investigation of pleural effusions and
will ultimately lead to new insights into the mechanisms of
the causative diseases. The identication of pleural biomarkers (single or as a panel) for an earlier diagnosis,
prognosis or prediction of therapeutic responses in pleural
diseases is still in its infancy. However, recent studies on
SMRP in pleural uid and serum of mesothelioma patients
has shown that highly specic biomarkers can be discovered with potential use in a clinical setting, even before the
tumor is clinically apparent.
There is still a large gap between the discovery of new
pleural disease biomarkers by proteomics and their clinical
utility. It can only be overcome by intensive collaboration
of teams of research scientists, clinicians and statisticians
to conduct large prospective, multicenter clinical trials to
validate and standardize these technologies. Recently, a
team of 26 authors has attempted to initiate a constructive
discussion about the denition of clinical proteomics,
study requirements, pitfalls, and (potential) use for clinical
proteome analysis.121 These kinds of initiatives are important for the evaluation and validation of the proteomic
technologies. As the different proteomic technologies continues to improve, it will add new dimensions to the analyses of clinically relevant samples and promises to
revolutionize the way pleural diseases will be diagnosed,
treated and managed in the near future.
KEY POINTS
The proteome differs from cell to cell and is constantly changing through its biochemical interactions with the genome and the environment.
Biomarkers are proteins that are differentially
present in a sample taken from a subject of one
phenotypic status (e.g. having a disease) compared with another phenotypic status (e.g.
healthy) and can therefore be used to diagnose,
monitor or prognose a particular disease state.
Potential biomarkers can be identied by the
separation of a complex mixture of proteins by
electrophoresis, mass measurement of peptides
generated after spot proteolysis by mass spectrometry and searching in databases, but various
other approaches are now evolving.
The choice of an appropriate methodology to
study novel biomarkers will depend on the goals
of the specic study, amount and number of
samples, availability of resources and other
factors.
Although technical advances have been signicant in previous decades, we are still confronted
with the challenges of evaluation and validation
of the proteomic technologies, understanding the
massive volume of data, translating the information to t clinical contents and incorporating it
into clinical studies.
REFERENCES
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
References 149
55. Sloane AJ, Duff JL, Wilson NL, et al. High throughput peptide mass
ngerprinting and protein macroarray analysis using chemical
printing strategies. Mol Cell Proteomics 2002; 1: 4909.
56. Wu SL, Amato H, Biringer R, et al. Targeted proteomics of lowlevel proteins in human plasma by LC/MSn: using human growth
hormone as a model system. J Proteome Res 2002; 1: 45965.
57. Choudhary G, Wu SL, Shieh P, Hancock WS. Multiple enzymatic
digestion for enhanced sequence coverage of proteins in complex
proteomic mixtures using capillary LC with ion trap MS/MS. J
Proteome Res 2003; 2: 5967.
58. Sanchez JC, Appel RD, Golaz O, et al. Inside SWISS-2DPAGE
database. Electrophoresis 1995; 16: 113151.
59. Adkins JN, Varnum SM, Auberry KJ, et al. Toward a human blood
serum proteome: analysis by multidimensional separation coupled
with mass spectrometry. Mol Cell Proteomics 2002; 1: 94755.
60. Tonge R, Shaw J, Middleton B, et al. Validation and development
of uorescence two-dimensional differential gel electrophoresis
proteomics technology. Proteomics 2001; 1: 37796.
61. Von Eggeling F, Gawriljuk A, Fiedler W, et al. Fluorescent dual
colour 2D-protein gel electrophoresis for rapid detection of
differences in protein pattern with standard image analysis
software. Int J Mol Med 2001; 8: 3737.
62. Yan JX, Devenish AT, Wait R, et al. Fluorescence two-dimensional
difference gel electrophoresis and mass spectrometry based
proteomic analysis of Escherichia coli. Proteomics 2002; 2:
168298.
63. Nordvarg H, Flensburg J, Ronn O, et al. A proteomics approach to
the study of absorption, distribution, metabolism, excretion, and
toxicity. J Biomol Tech 2004; 15: 26575.
64. Alban A, David SO, Bjorkesten L, et al. A novel experimental design
for comparative two-dimensional gel analysis: two-dimensional
difference gel electrophoresis incorporating a pooled internal
standard. Proteomics 2003; 3: 3644.
65. Unlu M, Morgan ME, Minden JS. Difference gel electrophoresis: a
single gel method for detecting changes in protein extracts.
Electrophoresis 1997; 18: 20717.
66. Patton WF. Detection technologies in proteome analysis. J
Chromatogr B Analyt Technol Biomed Life Sci 2002; 771: 331.
67. Lilley KS, Friedman DB. All about DIGE: quantication technology
for differential-display 2D-gel proteomics. Expert Rev Proteomics
2004; 1: 4019.
68. Morita A, Miyagi E, Yasumitsu H, et al. Proteomic search for
potential diagnostic markers and therapeutic targets for ovarian
clear cell adenocarcinoma. Proteomics 2006; 6: 588090.
69. Zhou G, Li H, DeCamp D, et al. 2D differential in-gel
electrophoresis for the identication of esophageal scans cell
cancer-specic protein markers. Mol Cell Proteomics 2002; 1:
11724.
70. Alfonso P, Nunez A, Madoz-Gurpide J, et al. Proteomic expression
analysis of colorectal cancer by two-dimensional differential gel
electrophoresis. Proteomics 2005; 5: 260211.
71. Lee IN, Chen CH, Sheu JC, et al. Identication of human
hepatocellular carcinoma-related biomarkers by two-dimensional
difference gel electrophoresis and mass spectrometry. J Proteome
Res 2005; 4: 20629.
72. Yu KH, Rustgi AK, Blair IA. Characterization of proteins in human
pancreatic cancer serum using differential gel electrophoresis and
tandem mass spectrometry. J Proteome Res 2005; 4: 174251.
73. Nayak SS, Kamath SS, Kundaje GN, Aroor AR. Diagnostic
signicance of estimation of serum apolipoprotein A along with
alpha-fetoprotein in alcoholic cirrhosis and hepatocellular
carcinoma patients. Clin Chim Acta 1988; 173: 15764.
74. Matsuura T, Koga S, Ibayashi H. Increased proportion of
proapolipoprotein A-I in HDL from patients with liver cirrhosis and
hepatitis. Gastroenterol Jpn 1988; 23: 394400.
75. Fujii S, Koga S, Shono T, Yamamoto K, Ibayashi H. Serum
apoprotein A-I and A-II levels in liver diseases and cholestasis. Clin
Chim Acta 1981; 115: 32131.
13
Pleural pharmacokinetics
ARYUN KIM, BLAIR CAPITANO, CHARLES H NIGHTINGALE
Introduction
Basic pharmacokinetic principles
Pharmacokinetics specic to the pleural uid
151
151
155
Key points
References
167
167
INTRODUCTION
Introduction to pharmacokinetics
Pharmacokinetics is the study of the movement of the
drug throughout the body, which consists of four phases:
absorption, distribution, metabolism and elimination
(Figure 13.1). A multitude of factors specic to the pharmaceutical agents as well as the patient have the propensity
to affect the pharmacokinetics of a particular agent. These
factors include, but are not limited to, the chemical structure of the drug, the dosage form, the degree of protein
binding, drug interactions, body composition, hepatic and
renal functions, as well as the specic disease being treated
and any underlying diseases.
While an understanding of basic pharmacokinetic
principles is essential for the purposes of this chapter, a
Drug
Absorption
Body
Distribution
Metabolism
Elimination
Plasma concentration
AUC
Time
Distribution
Distribution refers to the dispersion of the drug from the
blood to the extravascular spaces, including organs, tissue
and uids. This process is reversible and may occur rapidly
or slowly until distribution equilibrium is reached. The
amount of drug that remains in the plasma and that which
reaches specic sites in the body, such as the pleural space,
at distribution equilibrium depends on a variety of factors.
These factors include the physiochemical properties of the
agent that affect its ability to permeate membranes,
protein- and tissue-binding characteristics of the agent,
blood perfusion of the site and the physical condition of
the patient. Once distribution equilibrium is reached, the
amount of drug at various sites in the body is rarely equal.
Depending on the agent and its ability to permeate membranes, the drug concentration in a specic space, tissue or
uid may exceed that of the plasma or may be much lower
than plasma.
The apparent volume of distribution (Vd) is a derived
pharmacokinetic parameter that allows one to estimate the
extent of distribution or the afnity for plasma transfer to
tissues of an agent. The Vd is not an actual body volume,
but is simply a proportionality constant that relates the
amount of drug administered to the resultant plasma concentration. It may be thought of as simply the volume of
space needed to account for a total dose given when examining the resultant plasma concentration. The observed
decline of plasma concentration over time is due to the fact
that drug distribution and elimination commence immediately and simultaneously following administration. The
shape and slope of the plasma concentrationtime curve
reect the rate of both of these processes. Shortly after
intravenous administration, however, the rate of distribution is thought to exceed that of elimination. Immediately
following intravenous administration, when the plasma
concentration is at its maximum (Cpmax), the equation
given below may be applied to estimate the dose needed to
achieve a specic plasma concentration and characterize
the distribution of a particular agent:
Vd = Dose/Cpmax
The Vd is a property that is inherent to each drug.
However, it may be affected by disease states that alter total
body volume and protein stores that change distribution
characteristics of the drug. The Vd may range from one to
several liters, depending on the degree of tissue penetration and binding of an individual agent. For example, it
may be concluded that the distribution of a drug with a Vd
similar to the amount of total body extracellular uid
(1518 L in a 70 kg person) is limited mainly to the
extravascular space. A drug with a Vd that exceeds the total
amount of body water is thought to have a large afnity for
the tissues and other extravascular spaces.
It follows, therefore, that a drug with a large Vd at distribution equilibrium would be expected to have a small
plasma concentration and the reverse is also true. Factors
associated with decreased plasma drug concentrations,
such as decreased plasma protein binding, would consequently result in a larger Vd. Generally speaking, a drug
with a large Vd is thought to have a high degree of distribution to extravascular tissues, spaces and uids and a
smaller plasma concentration. It must be kept in mind,
however, that the Vd does not provide insight into the
exact distribution sites, it simply estimates the afnity of
the drug for extravascular areas of the body.
Compartmental models
The human body is undoubtedly a very complex system
composed of a multitude of different tissues, spaces and
uids. Compartment models are used in the area of pharmacokinetics to simplify the complexity of drug distribution and elimination in order to allow the application of
mathematical principles to depict and quantify the timecourse of drug concentrations in the body. Spaces, tissues
and uids with similar types of drug distribution characteristics are grouped into the same compartment.
The one-compartment model is the most straightforward and holds the underlying assumption that the body
behaves as one large container (Figure 13.3). The central
compartment or rst compartment is thought to be congruent with the systemic circulation and consists of the
most highly perfused tissues and organs such as the heart,
kidneys and lungs. Since most drugs are metabolized and
eliminated via the liver and kidneys, elimination is
accepted to occur strictly from the rst compartment.
Drugs that display one-compartment model behavior are
assumed to be distributed and equilibrate very rapidly
throughout the body following administration. From
another perspective, areas in the body that may be considered as parts of the central compartment contain drug
concentrations that equilibrate at a rate that is proportionate to drug concentrations in the plasma. This is not
to say that drug concentrations within spaces of a single
compartment are identical, simply that the rate at which
Central
compartment
Drug
A0
A1
Drug
A0
Central
compartment
A1
k12
Peripheral
compartment
A2
k21
k10
100
distribution elimination
10
elimination distribution
10
Plasma concentration
(mg/mL)
100
80
60
40
20
0
12
Elimination
Elimination refers to the biochemical conversion of the
drug to metabolic products, where appropriate, and the
movement of drug and metabolites from the blood to the
urine, bile and feces out of the body. Although distribution
and elimination immediately and simultaneously occur
shortly following intravenous administration, the distribution rate at this point is generally much higher than the
rate of elimination. Once distribution is complete,
however, elimination predominates and the drug is
removed from the body. The initial component of the
plasma drug concentrationtime curve, for the most part,
depicts drug movement within the body and the latter part
of the declining curve represents drug movement or elimination from the body.
FIRST-ORDER AND ZERO-ORDER ELIMINATION
The elimination of drugs is classied in the study of pharmacokinetics as a rst-order or zero-order process. Firstorder elimination is characterized by drugs for which the
amount of drug eliminated over a certain period is
dependent on the amount of drug remaining in the body.
Conversely, in a zero-order process, the amount of drug
eliminated over time is constant and independent of the
amount of drug remaining in the body. When administered in conventional doses, most drugs display rst-order
Time (h)
Time (h)
100
10
3
Time (h)
Figure 13.6
elimination.
Pharmacokinetic mathematical models have been developed to assist clinicians in determining proper doses to
target specic plasma concentrations based on the fact that
a plot of the natural log of the plasma concentrationtime
prole for a rst-order elimination process produces a
straight line. The slope of this line yields the elimination
rate constant (k) or the percentage of drug eliminated over
an interval of time. The formula to nd the slope of a
straight line is:
Slope = DY/DX
where DY = Y2 - Y1 and DX = X2 - X1. Application of this
formula to the straight line of a plot of the natural log of
the plasma concentration versus time yields the formula
for the elimination rate constant (k) that corresponds to
units of inverse time (per hour, per minute). This formula
allows for the calculation of k when two plasma concentration timepoints are known for a drug following rst-order
elimination:
Introduction
k = ln Cp2 - ln Cp1/t2 - t1
where D ln Cp = the natural log of plasma concentration,
Dt = the corresponding values for time, and k = the elimination rate constant.
The half-life (t1/2) is the time it takes for the plasma
concentration to be reduced by 50 percent (Figure 13.7).
Practically speaking, it takes ve half-lives for the drug to
be 97 percent removed from the body. The plasma t1/2 may
be calculated by the formula:
t1/2 = 0.693/k
Clearance (Cl) refers to the inherent ability of the eliminating organs of the body to remove drug and metabolites
from the blood per unit time. It is a function of capacity of
organs such as the kidney and liver to process drugs and
the degree of blood ow that presents these organs with
drugs to eliminate. Clearance does not represent the
amount of drug removed but the volume of blood that is
cleared of drug over a certain interval of time. The amount
of drug cleared depends on the concentration of drug in
the plasma as well as the rate of blood ow to eliminating
organs. The extraction ratio is the fraction of drug presented to an eliminating organ that is cleared after one pass
through that organ. Many factors may affect clearance,
such as the extraction ratio, the body surface area of the
patient, plasma protein binding, renal and hepatic function and the cardiac output of the patient, which controls
blood ow to the eliminating organs. When the rate of
administration is equal to the clearance, such as may be the
case in continuous infusion, the concentration in the
plasma may remain constant or achieve steady-state (Cpss).
The AUC, which accounts for total drug exposure, may be
calculated if the clearance is known.14
AUC = Dose/Cl
Cpmax
100
t1/2
10
AUC
1
Time (h)
PROTEIN BINDING
Plasma
Tissue
Db
Db
Df
Df
Molecular weight
% Protein binding
NA
781.75
1425.45
030
411
030
372.48
371.39/255.22
539.6/322.3
65
28/38
2633/26
437.52
317.37/380.43
2
20/40
476.48
449.44
477.4
446.37
661.59
636.6
571.5
7486
6579
3150
3350
8590
17
1619
733.94
785
747.96
7590
750 (concentration dependent)
4250
331.4
361.4
370.38
437.9
402.42
1643
20
50
50
20
1485.75
337.35
585.65
504.96
171.16
822.95
137.14
1050
31
7189
94
<20
80
1015
279.1
300.1
371.25
579.99
588.58
517.41
597.49
60a
Platinum 90b
0 (platinum 30 irreversible)c
7476
97
78
7381
Antimicrobial agents
Since the late 1970s, several studies have examined antimicrobial concentrations obtained in the pleural uid.
Although several studies have been conducted and many
reference books and drug package inserts list the degree of
pleural penetration of various agents; the data is severely
lacking and unsound and reference data should be considered with caution.
The rationale behind this conclusion is that the many
studies conducted examined penetration in relatively
small, heterogeneous patient groups. The study patients
consisted of those that had transudative effusions together
with those that had exudative effusions. Many studies
included patients that were not infected or combined
those that were infected with those that had malignancy.2022
Most studies involved the administration of a single
dose of drug as opposed to multiple doses. This is not an
ideal condition under which to observe drug pharmacokinetics since the patients plasma drug levels would not be
considered to be at a steady-state distribution equilibrium. Consequently, the pleural uid levels would not
reect the distribution equilibrium with the plasma and
may underestimate drug concentrations. These conditions
do not represent those observed in a clinical situation with
multiple dosing and possible drug accumulation.
Another limitation to the available literature is that
many studies did not follow pleural uid or plasma drug
concentrationtime proles. In many instances, nonsimultaneous plasma and pleural uid levels were taken
for each patient. Therefore, it is not known whether the
drug levels found in the pleural uid actually reect the
maximum concentrations attainable. It is clear that antibiotic pharmacokinetics in the pleural space is an area that
requires further study.
Despite the limitations of the available data, several
conclusions may be made regarding general principles of
antibiotic pharmacokinetics in the pleural uid relative to
that of the plasma.
Selected studies will be reviewed to illustrate some key
points. Table 13.2 provides a summary of drug penetration
and peak pleural uid to serum ratios.20,2334
LACK OF CORRELATION BETWEEN PLEURAL FLUID AND
ASCITIC FLUID PHARMACOKINETICS
Because there are similarities between the pleural and peritoneal cavity with regard to the mesothelium and lymphatic system, an assumption is made by some clinicians
that antibiotic characteristics of penetration and elimination from ascitic uid may be extrapolated to those of the
pleural uid. Although this may be true to a certain extent
when considering the permeation of the mesothelium, discriminating conclusions must be made.
Lechi and colleagues23 examined the pharmacokinetics
of cefuroxime, 1 g, administered intravenously to ve
patients with ascites and six patients with pleural effusion
(three transudates, three exudates). Simultaneous serum
and ascitic uid levels were followed over 12 hours and
serum and pleural uid levels were followed at 3-hour
intervals for each patient over 6 hours. In other words,
continuous data did not exist for all patients in the pleural
uid group.
The average maximum pleural uid concentration
(Cmax, approximately 8 mg/mL) was reached more quickly
in most patients (approximately 1.52 hours) compared
with that of the ascitic uid (45 hours; approximately
45 mg/mL). The antibiotic penetrated to the ascitic uid
more readily with a mean Cmax serumascitic uid ratio of
26 percent compared with the mean Cmax serumpleural
uid ratio of 810 percent (n = 5). The pleural uid concentration never exceeded that of the serum concentration, displaying a maximum average pleural uidserum
ratio of approximately 50 percent at the end of 6 hours
when serum concentrations were at a minimum.
Conversely, the cefuroxime ascitic uid concentration
greatly exceeded that of the serum as serum levels declined
and at the end of 12 hours, the ascitic uidserum ratio
was approximately 1.80. The mean elimination t1/2 from
the pleural uid was approximately 5.1 hours, two times
longer than that of the serum (n = 4).
There are many limitations to this study in that continuous data was not supplied for the pleural patients and
numerical concentration data was not provided for the
ascitic patients. However, two observations may be made.
First, it is clear that the pharmacokinetic drug prole in the
ascitic uid contrasted with that of the pleural uid. The
time to Cmax (Tmax) and degree of penetration were quite
different. Second, it is evident that elimination from the
AMB
AMK
AMK
AMK
AMP
AMP
AMP
CAZ
CFP
CIP
CIP
CIP
CIP
CIP
CIP
CLI
CXM
GEN
OFX
OXA
OXA
PEN
PEN
PEN
PEN
PEN
TOB
VAN
VAN
Pleural disease
Levels
(n)
Dose
Route
Cmaxa
PF/Serum
AUCa
PF/Serum
t1/2 (h)
PF
t1/2 (h)
Serum
Reference
1
1
10
10
1
1
6
5
6
7
3
2
3
5
15
1
4
M
M
S
S
S
M
S
S
S
S
S
S
M
S
M
M
S
IV
IM
IV
IP
PO
PO
IV
IV
IV
IV
PO
PO
PO
PO
PO
IV
IV
0.38
1.00
0.43
2.39
0.60
0.80
0.49
NA
0.07
0.24
0.50
0.45
2.00
0.70
0.63
0.80
NA
NA
NA
0.80
NA
NA
NA
NA
0.38
NA
NA
NA
NA
NA
2.09
NA
NA
NA
NA
NA
4.3
NA
NA
NA
NA
NA
6.96
NA
NA
NA
NA
NA
NA
NA
~5.10
NA
NA
2.62
~2.88
NA
NA
NA
NA
2.9
NA
NA
NA
NA
NA
NA
NA
~2.39
34
24
27
27
24
24
20
28
29
33
33
33
33
31
32
24
23
1
21
1
2
3
2
5
2
3
1
9
4
S
M
S
M
S
S
M
S
M
M
M
M
IM
PO
IV
IV
PO
IV
IV
IV
IV
IM
IVintermittent
IVcontinuous
0.20
0.820.92
5.10
7.95
0.13
0.75
1.20
0.20
1.10
1.20
0.39
NA
NA
2.09
NA
NA
NA
NA
NA
NA
NA
NA
0.88 0.07
0.86 0.14
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
6.4 1.5
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
6.3 1.9
NA
24
30
24
24
24
24
24
24
24
24
25
25
AMB, amphotericin B; AMK, amikacin; AMP, ampicillin; AUC, area under the drug concentration-time curve; Cmax, maximum drug concentration; CAP, community-acquired pneumonia; CAZ, ceftazidime; CFP,
cefoperazone; CIP, ciprooxacin; CLI, clindamycin; CXM, cefuroxime; GEN, gentamicin; IM, intramuscular; IP, intrapleural; IV, intravenous; IVcontinuous, continuous intravenous infusion; IVintermittent, intermittent
intravenous infusion; M, multi-dose; NA, not available; OFX, ooxacin; OXA, oxacillin; PEN, penicillin; PF, pleural uid; PO, oral; S, single-dose; t1/2, elimination half-life; TOB, tobramycin; VAN, vancomycin.
a
PF/Serum ratios were determined using mean results.
The penetration of a variety of antibiotics, including penicillins, cephalosporins, clindamycin and the aminoglycosides was evaluated in 16 patients with pleural empyema,
uncomplicated parapneumonic effusion or carcinomatous
effusions, respectively.24 The mean pleural uid to serum
concentration ratios is displayed in Table 13.2. The penetration for all antibiotics in the case of multiple doses in an
infected effusion was very high with a pleural uid to
serum ratio of 0.80 in all cases. Although a small number
of patients were studied, the penetration of penicillin,
cephalothin and oxacillin appeared to be higher with multiple versus single dosing. Penetration of penicillin in the
patients with carcinomatous effusions was found to be
lower than that of infected patients. The limitation of the
study is that it did not follow simultaneous pleural uid
and plasma drug concentrations over time. However, it
illustrates that the penetration of antibiotics into infected
pleural effusions was excellent and that penetration into
the carcinomatous effusions was less favorable. Further, it
hints that greater penetration or accumulation may occur
with multiple dosing once steady-state distribution equilibrium is reached.
Drug concentration
(mg/L)
Drug concentration
(mg/L)
2
1
0
4
3
2
1
0
Average plasma
concentration
Average plasma
concentration
Drug concentration
(mg/L)
Drug concentration
(mg/L)
6
4
2
0
Figure 13.9
4
2
0
2
Time (h)
Time (h)
Average plasma
concentration
3
Time (h)
Time (h)
Average plasma
concentration
Penetration of ciprooxacin into sterile (Groups 13) and empyemic (Group 4) human pleural uid.33
infected patients. Finally, in all patient groups, elimination of drug from the pleural uid was much slower than
that of the plasma.
Vancomycin was found to readily penetrate to the
pleural uid of 16 uninfected patients who underwent thoracotomy for the treatment of bronchial cancer. The
patients received vancomycin as either a 15 mg/kg intermittent infusion twice daily (n = 8) or a 500 mg loading
dose followed by a 30 mg/kg continuous infusion presumably over 24 hours (n = 8).25 The vancomycin AUC012
pleural uidserum ratio exceeded 0.80 in all patients,
with an average ratio value of 0.88 0.07 and 0.86 0.14
in the intermittent and continuous infusion groups,
respectively. The average vancomycin Cmax was observed at
1 hour (48.3 14.9 mg/mL) in the serum and at 2 hours
(19 4.8 mg/mL) in the pleural uid, following receipt of
intermittent infusion. This indicates a 1-hour lag time for
vancomycin penetration from the blood to pleural uid in
these patients. The pleural uid concentrations ranged
from 11.8 2.7 mg/mL at 0 hours to 13.7 3.5 mg/mL at 12
hours, following the start of dose administration in the
continuous infusion patient group. An average vancomycin concentration of approximately 14 and 12 mg/mL
was maintained in the serum and pleural uid over 12
hours, respectively, in those patients who received a bolus
followed by continuous infusion. The average vancomycin
concentration at 12 hours in the intermittent infusion
group was 6.6 2.3 mg/mL. It should be noted that blood
samples were not obtained beyond the 12-hour timepoint
or at steady-state distribution equilibrium. Thus, it would
be of interest to know the true lag time for pleural uid to
reach its Cmax in relation to serum had more samples been
obtained once a steady state was achieved.
While the average vancomycin AUC012 was similar
between groups, higher concentrations were achieved
more quickly in patients who received the loading dose
followed by continuous infusion. As may be expected,
higher concentrations were longer sustained in the pleural
uid with administration via continuous infusion. Despite
its large molecular size and poor lipid solubility, vancomycin readily reached the pleural uid in these patients
with administration by both intermittent and continuous
infusion. A possible explanation of the large degree of
pleural uid penetration may be lung inammation that
may be associated with malignancy.
Pharmacokinetic studies in the pediatric population are
infrequent, and even more so when exploring pleural uid
penetration. Giachetto and colleagues26 reported the
pleural uid and serum concentrations of hospitalized
children with community-acquired pneumonia and
empyema who received either ampicillin (ages 10 months
to 5 years) or penicillin (ages 512 years). Blood and
pleural uid samples were collected from the patients after
receipt of ampicillin (n = 9) 400 mg/kg/day as an intravenous bolus in six divided doses or penicillin (n = 4)
200 000 IU/kg.day intravenous infusion over 20 minutes in
six divided doses. Drug concentrations were determined in
ANIMAL DATA
CONCLUSIONS REGARDING ANTIBIOTICS
The main reason why data is lacking regarding the penetration of antimicrobial agents in the setting of infected
effusion is the difculty in performing studies with multiple doses of medication in acutely ill patients over an
extended period of time. The pleural empyema rabbit
In general, it seems that most antibiotics do attain therapeutic concentrations in the pleural space (Table 13.2) to
varying degrees; however, these concentrations lag behind
those of the serum. Delayed peak concentration is unlikely
Cmax PF/Serum
AUC PF/Serum
Tmax PF (hours)
Reference
CLI
CLR
CRO
GEN
GEN
IPM
IPM/CIL
LVX
MEM
MEM/CILa
MTZ
MXF
MXF
MXF
PEN
VAN
2
3
2
2
10
3
3
3
3
3
2
15
22
3
2
2
0.40
0.82
0.20
0.10
0.30
0.08 0.05
0.06 0.02
0.74
0.06 0.02
0.07 0.01
0.70
0.71
0.63
0.58
0.30
0.20
0.74
1.57
0.82
0.50
NA
0.58 0.17
0.51 0.11
1.13
0.89 0.13
0.79 0.04
0.98
2.01
1.17
1.37
2.31
0.61
6
1
4
1
3
0.5
0.51
6
0.5
0.5
0.25
1.52.5
1.52.5
6
2
1
36
39
36
36
35
40
40
38
40
40
36
37
37
38
36
36
AUC, area under the drug concentration-time curve; Cmax, maximum drug concentration; CLI, clindamycin; CLR, clarithromycin; CRO, ceftriaxone; GEN,
gentamicin; IPM, imipenem; IPM/CIL, imipenem/cilastatin; LVX, levooxacin; MEM, meropenem; MEM/CIL, meropenem/cilastatin; MTZ, metronidazole; MXF,
moxioxacin; NA, not available; PEN, penicillin; PF, pleural uid; Tmax, time to maximum drug concentration; VAN, vancomycin.
aMeropenem was also studied with cilastatin because although stable in humans, meropenem is easily hydrolyzed by dehydropeptidase in rabbits.
to be an issue with multiple dosing. The quinolones, penicillins and aminoglycosides seem to penetrate the pleural
uid especially well, although the aminoglycosides cannot
be recommended. Antibiotic elimination from the pleural
space lags behind that of the serum. This may be benecial
to treat infection but accumulation may occur with multiple dosing and caution is advised when administering
toxic agents. The lag in clearance of the pleural uid indicates that AUC pleural uid to serum ratios will exceed
peak pleural uid to serum ratios for many agents.
Therefore, while the pleural uid peak is lower, total drug
exposure may be closer in range. Although unnecessary in
the majority of cases, intrapleural administration of antibiotics offers the advantage of achieving higher peak pleural
uid levels and may be considered in special cases. Further,
the effects of the extraordinary peaks and the possibility
and degree of drug accumulation are not known.
Antineoplastic agents
Since the pharmacological intent of anti-cancer agents is to
destroy cells, and these agents effectively do so without discrimination between healthy and malignant cells, antineoplastic agents are undoubtedly the most toxic drugs
administered to humans. The greatest challenge in the
drug therapy of malignancy lies in the creation of a balance
between efcacy and safety. Dosage administration design
presents an opportunity to artfully manipulate the balance
between efcacy and safety through not only dosage
adjustment, but also by route of administration. Intrapleural chemotherapy for treatment of pleural malignancies, especially mesothelioma, has attracted considerable
attention. The nal focus of this chapter is the pharmacokinetics associated with the intrapleural administration of
anti-cancer chemotherapy agents.
Dose
(mg/m2)
Route
Concentrationa
PF/Serum
Cmax Serum
(mg/L)
AUCa
PF/Serum
AUCa
Type
Cl (L/h)b
PF
CBDCA
CDDPfree
3
3
270
60
IP
IP
166 66
140 19
3.3 1.1
1.1 0.1
48
82
46
46
10
10
80
80
IP
IP
59.6
8.38
1.8
0.4
10.9
104
24 h
24 h
116.9c
10.5c
NA
NA
47
47
3
3
7
90
90
90
IP
IP
IV
NA
NA
NA
1
2.3
2.3
47.5
NA
NA
4h
NA
NA
5.68
NA
NA
122
NA
132
44
44
44
11
11
14
100
100
153203
IP
IP
IP
NA
NA
129.25
NA
NA
1.5
28.6
47.6
NA
4h
4h
NA
28 14.3
NA
NA
NA
NA
8.7 6.5
45
45
48
10
10
200
200
IP
IP
NA
NA
2.1
0.8
27 4.6
23 9.2
48 h
48 h
NA
NA
NA
NA
49
49
7
7
11
200
200
8
IP
IP
IP
NA
NA
NA
2.0
0.8
NA
25 6.2
37 7.7
195.7
48 h
48 h
NA
NA
2.3 1.0
NA
NA
5.5 4
49
49
45
12
10
1
4
2
2
30
80
100
100
150
225
IP
IP
IP
IP
IP
IP
157
58
68
NA
NA
NA
NA
3
2.5
NA
NA
NA
NA
36.9
210
31
16
23
NA
24 h
2.6
62.5c
NA
2
1.5
2
3.9
NA
NA
NA
NA
NA
41
47
42
43
43
43
CDDP
total
free
CDDP
total
free
CDDP
CDDP
total
free
CDDPtotal
CDDP
total
free
CDDP
total
free
MTC
MTX
VP-16
VP-16
VP-16
VP-16
VP-16
Cl (L/h)b
Serum
Reference
AUC, area under the drug concentration-time curve; Cmax, maximum drug concentration; CBDCA, carboplatin; CDDP, cisplatin; CDDPfree, unbound cisplatin;
CDDPtotal, unbound and bound cisplatin; Cl, clearance; IP, intrapleural; IV, intravenous; MTC, mitomycin; MTX, methotrexate; NA, not available; PF, pleural
uid; VP-16, etoposide.
aPF/Serum ratios were determined using mean results.
bUnless otherwise indicated.
cReported as the elimination half-life instead.
As mentioned previously, in order for the drug to be eliminated from the body, it must rst be transferred from the
pleural cavity to the systemic circulation through which it
may reach the organs of metabolism and elimination,
mainly the liver and kidneys. Bogliolo and colleagues44
administered cisplatin 90 mg/m2 intrapleurally to four
patients and intravenously to seven patients. The drug
elimination t1/2 from the pleural uid, representing either
transfer to the systemic circulation or tissue binding, was
2.08 0.65 hours for intrapleurally administered drug.
The mean platinum AUC of the plasma after 4 hours was
0.27 0.03 mg/minute.mL compared with 12.83
4.06 mg/minute.mL in the pleural uid. The average total
platinum Cmax drug concentration of those patients that
received intravenous cisplatin was two times greater than
References 167
The intrapleural administration of an anti-cancer chemotherapeutic agent results in much higher intrapleural
exposure compared with systemic exposure, as shown by
the differences in drug AUC. Drug distributes to the systemic circulation at a very slow rate, prolonging total body
elimination and intrapleural exposure. The systemic distribution and prolonged elimination of drug may result in
systemic toxicity. Potential toxicity may be combated
through the systemic administration of neutralizing agents
where appropriate, or facilitated by pleural uid drug
elimination. The lower systemic drug concentration may
lead to higher neutralizing agenttoxic agent systemic concentration ratio, resulting in better control of toxicity.41
REFERENCES
2.
3.
4.
5.
6.
KEY POINTS
7.
8.
9.
10.
11.
14
Experimental models: pleural diseases other than
mesothelioma
GEORGIOS T STATHOPOULOS, YC GARY LEE
Animal models for pleural diseases
In vitro studies of mesothelial cells and in situ studies of
mesothelial monolayers
Conclusions
Key points
169
179
180
180
References
Appendix 14.1
Appendix 14.2
Appendix 14.3
181
185
185
186
The rabbit model is most commonly used in pleurodesis studies,22,26 though mice,27 sheep28 (see Appendix 14.2),
rats,29 dogs21 and pigs30 have been employed. The results of
common pleurodesing agents applied to different species
appear similar; hence the choice of species depends mainly
on experience and cost.
With New Zealand white rabbits, the pleurodesing agent
is injected either directly or via a chest tube, the method of
delivery having little effect on the outcome.31 Likewise, the
pH of the pleurodesing agent does not affect its effectiveness.32,33 Conventional agents, e.g. talc, doxycycline and
bleomycin, induce acute pleural inammation and
denudement of mesothelial cells.23,34,35 Inammation may
resolve (failed pleurodesis) or, if sufciently intense, will
persist and lead to collagen deposition, brosis and symphysis.36 Pleurodesis is usually evident 14 to 28 days after
administration of the pleurodesing agent. However, with
pro-brotic transforming growth factor beta (TGF-b), signicant adhesions can be seen as soon as after 24 hours.22
Pleural brosis can be graded macroscopically at
autopsy (Table 14.1). In addition, pleural thickening and
collagen deposition can be measured microscopically
using multiple samples from different lung regions to
avoid sampling bias, and the contralateral pleural space as
the control.22,37 In our experience, chest tube insertion and
saline or albumin injections do not result in signicant
adhesions. Hemothoraces, however, either from trauma or
the experimental agent, can induce adhesions. Recently, a
pleurodesis grading system based on transthoracic ultrasound ndings, specically the disappearance of the
normal pleural gliding sign, was developed in rabbits and
was validated against pleurodesis grading at autopsy23,24
(Table 14.2). Whether this system is applicable to other
species, including humans, remains to be tested.
One concern of the published pleurodesis studies is that
they were performed in animals with normal pleura,
whereas human pleurodesis is usually applied to patients
with abnormal pleurae (especially malignant pleural
metastases). However, pleurodesis results from animal
models are similar to those from clinical investigations.
For example, talc was effective in producing pleurodesis,
Grade
0
1
2
Gliding sign
Denitely present
Questionable
Denitely absent
(a)
(b)
qualitative rather than quantitative data. Also, if inammatory mediators are to be investigated, they have to be
extracted from histology tissues. In vitro studies of inammatory cells fail to provide knowledge on the complex
interactions between various cells and mediators.
Therefore, investigators often employ animal models of
pleural inammation that allow the study of cells and
uids accumulated during inammation.55
Pleural models of inammation offer several advantages. The pleural cavity provides a conned compartment
lined by mesothelial cells in close contact with the systemic
circulation where inammatory cells and mediators
collect. These can be monitored in a dynamic fashion by
assaying the pleural uid. The histological changes of
inammation can be assessed in pleural tissues and effects
of pro- or anti-inammatory agents can be investigated
following their intrapleural administration.
Various methods have been used to induce pleural
inammation (Table 14.3), and each yields an inammatory reaction characterized by a distinct prole of cell and
mediator accumulation. Depending on the predominant
(c)
Figure 14.1 (a) Histological section through a Lewis lung
adenocarcinoma (LLC)-induced pleural tumor in a C57BL/6 mouse,
stained with hematoxylin and eosin ( 40). Note that the tumor
bridges the parietal and visceral pleurae. cw, chest wall; l, lung; r,
rib; pt, pleural tumor; pc, pleural cavity. (b) Cytocentrifugal
preparation of malignant pleural effusion cells from the LLCC57BL/6 model, stained with May-Grnwald-Giemsa ( 400).
Alien adenocarcinoma cells are mixed with host inammatory
cells. cc, cancer cell; m, mononuclear cell; l, lymphocyte; n,
neutrophil polymorphonuclear cell. (c) Vascular hyperpermeability
induced in the skin of a C57BL/6 mouse by malignant pleural
uids from the LLC-C57BL/6 model, compared with PBS (negative
control). After intradermal injection of 50 mL pleural uid or PBS,
the mouse received 0.8 mg Evans blue in 200 mL normal saline.
The mouse was killed and the skin inverted and photographed
after 30 minutes. Circles represent areas of dye extravasation, and
numbers relative surface area in respect to PBS (control). Evans
blue avidly binds to albumin; hence its extravasation indicates
vascular hyperpermeability. (See also Color Plates 810.)
Table 14.3 A large variety of agents have been used to induce pleural inammation. This
table outlines the common and some of the uncommon agents used. Interested readers can
refer to the references for individual agents for details
Agent to induce pleural inammation
Most common
Carrageenan
Common
Endotoxin or lipopolysaccharide
Representative reference
Bliven et al.55
Vinegar et al.59
Zymosan
Broaddus et al.65
Fukumoto et al.66
Yamamoto et al.54
Berkenkopf et al.167
Utsunomiya et al.168
Uncommon
Azoles
Bradykinin
Calcium pyrophosphate crystals
Ionophore A23187
Kaolin
Phorbol myristate acetate
Platelet activating factor
Substance P
Hanada et al.169
Saleh et al.170
Perianin et al.171
Wang et al.172
Kawamura et al.173
Oh-ishi et al.174
Tarayre et al.175
Frode-Saleh et al.176
of air.74 Using IL-5- and IL-13-gene-decient mice, investigators revealed that pleural recruitment of eosinophils is
dependent on IL-5 but not IL-13.
As described above, intrapleural injection of LPS in rats
and mice results in recruitment of eosinophils, along with
other cell types.5658,64,65 Eosinophil levels rise signicantly
after 24 hours and their recruitment appears to be mediated by T lymphocytes.58 LPS-induced pleural eosinophilia
is mediated by P-selectin and IL-8 and is inhibited by corticosteroids.56,64,65 The clinical value of this model remains
unclear.
MODELS FOR PLEURAL INFECTION BY COMMON PATHOGENS
(EMPYEMA)
Thoracic empyema remains a common disease with significant morbidity and mortality.75,76 Animal experiments on
empyema are most commonly performed using New
Zealand white rabbits, though mice and sheep have been
used.
Developing an adequate empyema model is difcult.
Direct introduction of bacteria (such as Streptococcus or
Peptostreptococcus species) into the pleural space usually
results in their complete clearance.77 To successfully initiate pleural infection, prior injury to the pleura may be
required. However, under such situations, overwhelming
sepsis and death can occur if too large a pathogen load is
administered.
Sahn et al.78 used an intrapleural injection of turpentine
in rabbits, resulting in inammation and an exudative
neutrophilic pleural effusion by 72 hours.79 At that point,
bacteria (e.g. Streptococcus pneumonia,78 Escherichia coli,
Peptostreptococcus anaerobius, Bacillus fragilis79 or their
combinations) were introduced by thoracentesis into the
effusion to create an empyema. Turpentine, however, may
impose artifacts, and the authors reported that a high percentage of animals did not develop an exudative effusion
to allow bacterial inoculation.79
Alternatively, Sasse et al.77 showed that intrapleural
injection of a potent rabbit pathogen, Pasteurella multocida, in brainheart infusion agar could produce empyema
without prior administration of turpentine. In this model,
rabbits required daily intramuscular penicillin injections,
to prevent death from sepsis. One drawback of this model
is that P. multocida is a rabbit pathogen but rarely infects
humans.80 Hence, this model is not suitable for certain
investigations, such as studies of antimicrobial treatment
of empyema.
These models are well validated and exhibit pleural
changes similar to that of human empyemas. In the
models of Sahn et al.78 and Sasse et al.77 the induced pleural
uids showed signicant increases in leukocytes and
inammatory indices, as well as markedly reduced pH and
glucose. Pleural adhesions and macroscopic suppurative
changes were evident at necropsy.
Another interesting model of pleural infection by
Staphylococcus aureus was developed using a common
mouse strain, C57BL/6.13 Although intrapleural inoculation of the microorganism did not result in frank
empyema, inammatory cell inux and local cytokine and
chemokine production was observed. This model is interesting for two reasons. First, it can be applied to genetically
engineered animals. In the aforementioned study, CD4
knockout mice showed reduced inammatory response
and retarded pathogen clearance compared with wild-type
mice.13 Second, S. aureus is also pathogenic to humans,
making these data more readily applicable to humans.
Other methods to introduce empyema in guinea pigs and
sheep have been published, but did not gain popularity.8183
There is one important limitation of all these models. In
humans, empyema occurs usually as a complication of
pneumonia, while isolated pleural infection is uncommon.
The animal models used in the literature all involve direct
introduction of microbes into the pleural cavity and development of isolated pleural infection without pneumonia.
Hence, the results of these experiments may not be directly
extrapolated to humans.
Animal models of empyema have facilitated the study
of the pathogenesis of the disease. Studies on rabbits and
mice have revealed the important role of CD4+ lymphocytes in empyema-associated inammation and bacterial
clearance13 and of TGF-b1 in empyema-associated pleural
brosis.84 Other studies have provided valuable information on the optimal treatment of empyema. Animal studies
have lent support to repeated early thoracentesis,85 early
chest tube insertion86 and intrapleural (single or combined) brinolytics for empyema.79,87 Finally, the penetration of antibiotics into the pleural space has been studied
using rabbit models of empyema.8890
MODELS FOR PLEURAL INFECTION BY MYCOBACTERIA
(TUBERCULOUS PLEURITIS)
Choice of species
Rats, mice and hamsters are most commonly used. Larger
animals, such as rabbits, guinea pigs and dogs, have also
been used, especially if direct intrapleural injection is
employed. It is important to note that intra- and interspecies differences in susceptibility to asbestos-induced
damage exist.118 The propensity of mice to develop pulmonary brosis in response to asbestos varies signicantly
among strains, in accord with brotic susceptibility to
radiation or bleomycin. Mice of the 129 strain respond to
asbestos with lower TNF-a and TGF-b expression and
minimal broproliferative lung lesions, compared with
C57BL/6 mice.119 Balb/c mice, another commonly used
strain, have also been found to develop lung changes
similar to human asbestosis after exposure to aerosolized
chrysotile.114 Although no studies have compared murine
strain susceptibility with asbestos-induced pleural brosis,
investigators should be aware that variation is likely to
exist. Interspecies comparison is an important issue, particularly regarding extrapolation of animal study results to
humans. Several reviews concurred that the rat model is
most appropriate for extrapolation of toxicological data to
humans.118,120,121 Maxim and McConnell118 found a significant difference in relative incidence of mesothelioma and
lung cancer between rats and hamsters and concluded that
the rat is a better model than hamsters for human risk
evaluation. They also reported that cells of humans and
rodents have comparable sensitivity to asbestos exposure,
in terms of cytotoxicity and production of mediators. The
deposition rate of respirable bers is lower in humans than
in rats, but so is the clearance rate. Hence, humans and rats
develop brosis at comparable normalized ber
burdens.118
Fiber types
The potency of different types of asbestos bers to induce
brosis and malignancies differs and appears to be related
to their physical properties, especially ber length and
biopersistence.118 Long, but not short, crocidolite bers
were able to induce brotic reactions in the lung and
pleura.106,122,123 However, no ber type should be considered harmless.107 Also, contamination of the asbestos ber
preparation with other mineral dusts is common and can
make the results of studies difcult to interpret. It is therefore crucial that investigators analyze and document the
physical characteristics of the asbestos preparation used in
their experiments. Chrysotile, crocidolite and amosite are
the commonly used bers in experimental models. In most
studies, administration of the vehicle in which the bers
were suspended served as the control. Alternatively,
woolastonite, a relatively non-pathogenic calcium silicate
ber, has been used as control and is known to induce signicantly less mesothelial cell damage than crocidolite.104
Recently, models for asbestos-induced pleural disease have
been extended to investigate the effects of man-made
bers, especially breglass.112,124
Endpoints
Ideally, development of the asbestos-induced pleural diseases, such as pleural brosis, BAPE or mesothelioma,
should be the experimental endpoint. However, since the
lag time for development of such disease is long, many
studies focused on the more immediate/early effects of
bers upon the lung and pleura. Pleural lavage can be analyzed for mediators induced after ber exposure of the
pleura. Mesothelial cells can be harvested for assessment of
proliferative responses, apoptosis or other immunohistochemical analyses.
Animal studies of asbestos exposure have been invaluable in revealing the mechanisms of asbestos-induced lung
and pleural injury. After asbestos inhalation, the pleura
can be assaulted via direct or indirect mechanisms. Using
scanning electron microscopy, inhaled asbestos has been
shown to produce cystic degradation of the pleural surface,
allowing penetration of single bers through the visceral
pleura.125 Inhaled chrysotile bers have been detected in
pleural cells of rats by electron microscopy within varying
time intervals, ranging from 1 week to 3 years after exposure.110,115,126
Rodent studies have shown morphological changes in
mesothelial cells within 2 hours of intratracheal amosite
instillation, followed by early mesothelial proliferation and
macrophage inux within 24 hours.108,127 In addition,
asbestos has been shown to stimulate intracellular signalling cascades such as mitogen-activated protein kinases
(MAPK) and extracellular signal-regulated kinases (ERK)
in mesothelial cells.128,129 These acute changes occur in the
absence of direct penetration of amosite bers into the
pleural space, supporting the view that pleural reactions
result from pleural migration of mediators induced by
asbestos in the airways and lung parenchyma.106 In fact,
antibodies to keratinocyte growth factor (but not to
platelet-derived growth factor) reduce crocidolite-induced
mesothelial proliferation.130
The pleural inammatory reaction to asbestos is multifactorial. Pleural macrophages produce large quantities of
proinammatory nitric oxide and TNF-a after inhaled
chrysotile.126 Reactive nitrogen species and nitrotyrosine
were also found in both visceral and parietal pleurae and
are likely to play a role in pleural injury.113 Intrapleural
crocidolite in rabbits also resulted in signicant elevation
of IL-8 synthesis and neutrophil inux.105 These inammatory changes are usually accompanied by mesothelial
cell proliferation.111 Knockout mice decient in both the
55 and 75 kDa TNF-a receptors are protected from the
pulmonary broproliferative changes induced by
chrysotile,131 further conrmation of the essential role of
TNF-a.
Although BAPE is a common asbestos-induced pleural
condition that precedes diffuse pleural thickening (brosis), it has only occasionally been studied in experimental
settings. Shore et al.132 injected crocidolite intrapleurally
into rabbits and showed the development of a neutrophilic
exudative effusion within 4 hours of injection. When the
uid was reinjected into another rabbit, a polymorphonuclear neutrophil (PMN) response was also elicited.132
Asbestos-related lung and pleural diseases are likely to
continue to increase. While legislation has been implemented in most developed countries to minimize occupational and environmental asbestos exposure since the early
1970s, the long lag time between exposure and clinical
presentation means there is still a large population at risk
of developing disease. Also, chrysotile now constitutes 99
percent of current global asbestos production and sales
remain strong in developing nations despite the recent
conclusion of the International Program on Chemical
Safety of the World Health Organization that exposure to
chrysotile poses increased risks for asbestosis, lung cancer
and mesothelioma in a dose-dependent manner.101
Hence, it is anticipated that animal studies will remain
important in the ongoing effort to understand the pathogenesis of asbestos pleural damage and to design new treatment strategies.
MODELS FOR CHYLOTHORAX
In vitro studies of mesothelial cells and in situ studies of mesothelial monolayers 179
No animal model is ideal. Investigators should understand the advantages and limitations of the use of different
animal species and models. Only through doing so would
they be able to choose or design the most suitable in vivo
model or in vitro experiment that provides the best chance
of answering the scientic question(s) raised. Animal
studies should be planned, conducted and supervised with
a similar degree of scrutiny as that applied to clinical trials.
The ultimate aim should always be to provide better care
to patients with pleural diseases.
Advances in other areas of biomedical sciences, especially animal imaging techniques, should allow the design
of more sophisticated animal models that will improve our
understanding and clinical management of pleural diseases.
KEY POINTS
CONCLUSIONS
If we look carefully enough we will eventually nd an
animal model for every disease.
Leader (1969) at the Federation of American Societies for
Experimental Biology.
Animal experimentation represents one of the fundamental approaches in the long arduous path towards the
understanding of the pathogenesis of various pleural diseases. In vivo studies are essential in the evaluation of novel
therapeutic approaches in pleural diseases, in the study of
pharmacokinetics of drug delivery in the pleural space and
in the investigation of pleural physiological changes in
both normal and disease states.
References 181
REFERENCES
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
Lee YCG, Teixeira LR, Devin CJ, et al. Transforming growth factorb2 induces pleurodesis signicantly faster than talc. Am J Respir
Crit Care Med 2001; 163: 6404.
Dikensoy O, Zhu Z, Donnelly E, et al. Combination therapy with
intrapleural doxycycline and talc in reduced doses is effective in
producing pleurodesis in rabbits. Chest 2005; 128: 373542.
Zhu Z, Donnelly E, Dikensoy O, et al. Efcacy of ultrasound in the
diagnosis of pleurodesis in rabbits. Chest 2005; 128: 9349.
Lee YCG, Light RW. Management of malignant pleural effusions.
Respirology 2004; 9: 14856.
Light RW, Cheng DS, Lee YCG, et al. A single intrapleural injection
of transforming growth factor beta-2 produces an excellent
pleurodesis in rabbits. Am J Respir Crit Care Med 2000; 162:
98104.
Marchi E, Vargas FS, Acencio MMP, et al. Pleurodesis: a novel
experimental model. Respirology 2007; 12: 5004.
Lee YCG, Lane KB, Parker RE, et al. Transforming growth factor
beta-2 (TGFb2) produces effective pleurodesis in sheep with no
systemic complications. Thorax 2000; 55: 105862.
Werebe EC, Pazetti R, Milanez de Campos JR, et al. Systemic
distribution of talc after intrapleural administration in rats. Chest
1999; 115: 1903.
Cohen RG, Shely WW, Thompson SE, et al. Talc pleurodesis: Talc
slurry versus thoracoscopic talc insufation in porcine model. Ann
Thorac Surg 1996; 62: 10002.
Wu W, Teixeira LR, Light RW. Doxycycline pleurodesis in rabbits:
comparison of results with and without chest tube. Chest 1998;
114: 5638.
Sahn SA, Good JT, Jr. The effect of common sclerosing agents on
the rabbit pleural space. Am Rev Respir Dis 1981; 124: 657.
Hurewitz AN, Lidonicci K, Wu CL, Reim D, Zucker S. Histologic
changes of doxycycline pleurodesis in rabbits. Effect of
concentration and pH. Chest 1994; 106: 12415.
Kennedy L, Harley RA, Sahn SA, Strange C. Talc slurry pleurodesis.
Pleural uid and histologic analysis. Chest 1995; 107: 170712.
Bilaceroglu S, Guo Y, Hawthorne ML, et al. Oral forms of
tetracycline and doxycycline are effective in producing
pleurodesis. Chest 2005; 128: 37506.
Mutsaers SE, Kalomenidis I, Wilson NA, Lee YCG. Growth factors in
pleural brosis. Curr Opin Pulm Med 2006; 12: 2518.
Lee YCG, Devin CJ, Teixiera LR, et al. Transforming growth factor
beta-2 induced pleurodesis is not inhibited by corticosteroids.
Thorax 2001; 56: 6438.
Xie C, Teixeira LR, McGovern JP, Light RW. Effect of pneumothorax
on pleurodesis induced with talc in rabbits. Chest 1998; 114:
11436.
Lee YCG, Yasay JR, Johnson JE, et al. Comparing transforming
growth factor (TGF)-b2, talc and bleomycin as pleurodesing agents
in sheep. Respirology 2002; 7: 20916.
Diacon AH, Wyser C, Bollinger CT, et al. Prospective randomized
comparison of thoracoscopic talc poudrage under local anaethesia
versus bleomycin instillation for pleurodesis in malignant pleural
effusions. Am J Respir Crit Care Med 2000; 162: 14459.
Macoviak JA, Stephenson LW, Ochs R, Edmunds LHJ. Tetracycline
pleurodesis during active pulmonary-pleural air leak for prevention
of recurrent pneumothorax. Chest 1982; 81: 7881.
Antony VB, Loddenkemper R, Astoul P, et al. Management of
malignant pleural effusions. Eur Respir J 2001;18: 40219.
Antunes G, Neville E, Duffy J, Ali N. Pleural Diseases Group,
Standards of Care Committee, British Thoracic Society. BTS
guidelines for the management of malignant pleural effusions.
Thorax 2003; 58: ii2938.
Sugiura S, Ando Y, Minami H, et al. Prognostic value of pleural
effusion in patients with non-small cell lung cancer. Clin Cancer
Res 1997; 3: 4750.
Naito T, Satoh H, Ishikawa H, et al. Pleural effusion as a signicant
prognostic factor in non-small cell lung cancer. Anticancer Res
1997; 17: 47436.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65. Broaddus VC, Boylan AM, Hoeffel JM, et al. Neutralization of IL-8
inhibits neutrophil inux in a rabbit model of endotoxin-induced
pleurisy. J Immunol 1994; 152: 29607.
66. Fukumoto T, Matsukawa A, Yoshimura T, et al. IL-8 is an essential
mediator of the increased delayed-phase vascular permeability in
LPS-induced rabbit pleurisy. J Leukoc Biol 1998; 63: 58490.
67. Klein A, Talvani A, Cara DC, et al. Stem cell factor plays a major
role in the recruitment of eosinophils in allergic pleurisy in mice
via the production of leukotriene B4. J Immunol 2000; 164:
42716.
68. Pasquale CP, e Silva PM, Lima MC, et al. Suppression by cetirizine
of pleurisy triggered by antigen in actively sensitized rats. Eur J
Pharmacol 1992; 223: 914.
69. Martins MA, Castro-Faria-Neto HC, Bozza PT, et al. Role of PAF in
the allergic pleurisy caused by ovalbumin in actively sensitized
rats. J Leukoc Biol 1993; 53: 10411.
70. Martins MA, Pasquale CP, e Silva PM, Cordeiro RS, Vargaftig BB.
Eosinophil accumulation in the rat pleural cavity after mast cell
stimulation with compound 48/80 involves protein synthesis and
is selectively suppressed by dexamethasone. Int Arch Allergy Appl
Immunol 1990; 92: 41624.
71. Viola JPB, Kiani A, Bozza PT, Rao A. Regulation of allergic
inammation and eosinophil recruitment in mice lacking the
transcription factor NFAT1: Role of interleukin-4 (IL-4) and IL-5.
Blood 1998; 91: 222330.
72. Pinho V, Oliveira SH, Souza DG, et al. The role of CCL22 (MDC) for
the recruitment of eosinophils during allergic pleurisy in mice. J
Leukoc Biol 2003;73: 35662.
73. Klein A, Talvani A, Silva PMR, et al. Stem cell factor-induced
leukotriene B4 production cooperates with eotaxin to mediate the
recruitment of eosinophils during allergic pleurisy in mice1. J
Immunol 2001; 167: 52431.
74. Kalomenidis I, Guo Y, Peebles RS, et al. Pneumothorax-associated
pleural eosinophilia in mice is interleukin-5 but not interleukin-13
dependent. Chest 2005; 128: 297883.
75. Light RW, Girard WM, Jenkinson SG. The incidence and
signicance of parapneumonic effusions. Am J Med 1980; 69:
50712.
76. Strange C, Sahn SA. Management of paraneumonic pleural
effusions and empyema. Infect Dis Clin North Am 1991; 5: 53959.
77. Sasse SA, Causing LA, Mulligan ME, Light RW. Serial pleural uid
analysis in a new experimental model of empyema. Chest 1996;
109: 104348.
78. Sahn SA, Reller LB, Taryle DA, Antony VB, Good JT Jr. The
contribution of leukocytes and bacteria to the low pH of empyema
uid. Am Rev Respir Dis 1983; 128: 81115.
79. Strange C, Allen ML, Harley R, Lazarchick J, Sahn SA. Intrapleural
streptokinase in experimental empyema. Am Rev Respir Dis 1993;
147: 9626.
80. Boyce JM. Pasteurella multocida. In: Mandell GL (ed.). Principles
and practice of infectious diseases. New York: Churchill
Livingstone, 1990: 17468.
81. Mavroudis C, Gamzel BL, Katzmark S, et al. Effect of hemothorax
on experimental empyema in the guinea pig. J Thorac Cardiovasc
Surg 1985; 89: 4249.
82. Mavroudis C, Gamzel BL, Cox SK, et al. Experimental aerobicanaerobic thoracic empyema in the guinea pig. Ann Thorac Surg
1987; 43: 298302.
83. Pfeffer A, Rogers KM, OKeeffe L, Osborn PJ. Acute phase protein
response, food intake, live weight change and lesions following
intrathoracic injection of yeast in sheep. Res Vet Sci 1993; 55:
3606.
84. Sasse SA, Jadus MR, Kukes GD. Pleural uid transforming growth
factor-beta1 correlates with pleural brosis in experimental
empyema. Am J Respir Crit Care Med 2003; 168: 7005.
85. Sasse S, Nguyen T, Texeira LR, Light RW. The utility of daily
therapeutic thoracentecis for the treatment of early empyema.
Chest 1999; 116: 17038.
References 183
86. Sasse S, Nguyen TK, Mulligan M, et al. The effects of early chest
tube placement on empyema resolution. Chest 1997; 111: 167983.
87. Zhu Z, Hawthorne ML, Guo Y, et al. Tissue plasminogen activator
combined with human recombinant deoxyribonuclease is effective
therapy for empyema in a rabbit model. Chest 2006; 129:
157783.
88. Strahilevitz J, Lev A, Levi I, Fridman E, Rubinstein E. Experimental
pneumococcal pleural empyema model: the effect of moxioxacin.
J Antimicrob Chemother 2003; 51: 6659.
89. Teixeira LR, Sasse SA, Villarino MA, et al. Antibiotic levels in
empyemic pleural uid. Chest 2000; 117: 17349.
90. Liapakis IE, Light RW, Pitiakoudis MS, et al. Penetration of
clarithromycin in experimental pleural empyema model uid.
Respiration 2005; 72: 296300.
91. Patterson RC. The pleural reaction to innoculation with tubercle
bacilli in vaccinated and normal guinea pigs. Am Rev Tuberc 1917;
1: 35371.
92. Widstrom O, Nillsson BS. Pleurisy induced by intrapleural BCG in
immunized guinea pigs. Eur Respir J 1982; 63: 42534.
93. Widstrom O, Egberg N, Chmielewska J, Blomback M. Fibrinolytic
and coagulation mechanisms in stages of inammation: a study of
BCG-induced pleural exudate in guinea pig. Thromb Res 1983; 29:
51119.
94. Phalen SW, McMurray DN. T-lymphocyte response in a guinea pig
model of tuberculous pleuritis. Infect Immun 1993; 61: 1425.
95. Antony VB, Repine JE, Harada RN, Good JT Jr, Sahn SA.
Inammatory responses in experimental tuberculosis pleurisy. Acta
Cytol 1983; 27: 35561.
96. Antony VB, Sahn SA, Antony AC, Repine JE. Bacillus CalmetteGuerin-stimulated neutrophils release chemotaxins for monocytes
in rabbit pleural spaces and in vitro. J Clin Invest 1985; 76:
151421.
97. Moura AC, Leonardo PS, Henriques MG, Cordeiro RS. Opposite
effects of M. leprae or M. bovis BCG delipidation on cellular
accumulation into mouse pleural cavity. Distinct accomplishment
of mycobacterial lipids in vivo. Inamm Res 1999; 48: 30813.
98. Menezes-de-Lima-Junior O, Werneck-Barroso E, Cordeiro RS,
Henriques MG. Effects of inhibitors of inammatory mediators and
cytokines on eosinophil and neutrophil accumulation induced by
Mycobacterium bovis bacillus CalmetteGuerin in mouse pleurisy.
J Leukoc Biol 1997; 62: 77885.
99. Allen SS, McMurray DN. Coordinate cytokine gene expression in
vivo following induction of tuberculous pleurisy in guinea pigs.
Infect Immun 2003; 71: 42717.
100. Allen SS, Cassone L, Lasco TM, McMurray DN. Effect of
neutralizing transforming growth factor b1 on the immune
response against Mycobacterium tuberculosis in guinea pigs.
Infect Immun 2004; 72: 135863.
101. Lee YCG, De Klerk NH, Henderson DW, Musk AW. Malignant
mesothelioma. In: Hendrick DJ, Burge PS, Beckett WS, Churg A
(eds). Occupational disorders of the lung. Recognition,
management and prevention. London, UK: W B Saunders & Co.,
2002: 359379.
102. Chapman SJ, Cookson WO, Musk AW, Lee YC. Benign asbestos
pleural diseases. Curr Opin Pulm Med 2003; 9: 26671.
103. Stathopoulos GT, Karamessini M, Sotiriadi AE, Pastromas VG.
Rounded atelectasis of the lung. Respir Med 2005; 99: 61523.
104. Marchi E, Liu W, Broaddus VC. Mesothelial cell apoptosis is
conrmed in vivo by morphological change in cytokeratin
distribution. Am J Physiol Lung Cell Mol Physiol 2000; 278:
L52835.
105. Boylan AM, Ruegg C, Kim KJ, et al. Evidence of a role for
mesothelial cell-derived interleukin-8 in the pathogenesis of
asbestos-induced pleurisy in rabbits. J Clin Invest 1992; 89:
125767.
106. Adamson IYR, Bakowska J, Bowden DH. Mesothelial cell
proliferation after instillation of long or short asbestos bers into
mouse lung. Am J Pathol 1993; 142: 120916.
107. Dodson RF, Atkinson MAL, Levin JL. Asbestos ber length as
related to potential pathogenicity: a critical review. Am J Ind Med
2003; 44: 2917.
108. Dodson RF, Ford JO. Early response of the visceral pleura following
asbestos exposure: an ultrastructural study. J Toxicol Environ
Health 1985; 15: 67386.
109. Viallat JR, Raybuad F, Passarel M, Boutin C. Pleural migration of
chrysotile bers after intratracheal injection in rats. Arch Environ
Health 1986; 41: 2826.
110. Fasske E. Pathogenesis of pulmonary brosis induced by chrysotile
asbestos. Longitudinal light and electron microscopic studies on
the rat model. Virchows Arch A Pathol Anat Histopathol 1986;
408: 32946.
111. Coin PG, Osornio-Vargas AR, Roggli VL, Brody AR. Pulmonary
brogenesis after three consecutive inhalation exposures to
chrysotile asbestos. Am J Respir Crit Care Med 1996; 154:
151119.
112. McConnell EE, Axten C, Hesterberg TW, et al. Studies on the
inhalation toxicology of two berglasses and amosite asbestos in
the Syrian golden hamster. Part II. Results of chronic exposure.
Inhal Toxicol 1999; 11: 785835.
113. Tanaka S, Choe N, Hemenway DR, et al. Asbestos inhalation
induces reactive nitrogen species and nitrotyrosine formation in
the lungs and pleura of the rat. J Clin Invest 1998; 102: 44554.
114. Bozelka BE, Sestini P, Gaumer HR, et al. A murine model of
asbestosis. Am J Pathol 1983; 112: 32637.
115. Fasske E. Experimental lung tumors following specic
intrabronchial application of chrysotile asbestos. Longitudinal
light and electron microscopic investigations in rats. Respiration
1988; 53: 11127.
116. Humphrey EW, Ewing SL, Wrigley JV, et al. The production of
malignant tumors of the lung and pleura in dogs from
intratracheal asbestos instillation and cigarette smoking. Cancer
1981; 47: 19949.
117. Wagner JC, Berry G, Skidmore JW, Pooley FD. The comparative
effects of three chrysotiles by injection and inhalation in rats.
IARC Sci Publ 1980; 30: 36272.
118. Maxim LD, McConnell EE. Interspecies comparisons of the toxicity
of asbestos and synthetic vitreous bers: A weight-of-theevidence approach. Regul Toxicol Pharmacol 2001; 33: 31942.
119. Brass DM, Hoyle GW, Poovey HG, Liu J-Y, Brody AR. Reduced
tumor necrosis factor-a and transforming growth factor-b1
expression in the lungs of inbred mice that fail to develop
broproliferative lesions consequent to asbestos exposure. Am J
Pathol 1999; 154: 85362.
120. National Research Council. In: Council NR (ed.). Review of the US
Navys exposure standard for manufactured vitreous bers.
Washington DC: National Academies Press, 2000: 163.
121. Warheit D, Hartsky MA. Inuence of gender, species and strain
differences in pulmonary toxicological assessments of inhaled
particles and/or bers. In: Mohr U, Dungworth DL, Mauderly JL,
Oberdorster G (eds). Toxic and carcinogenic effects of solid
particles in the respiratory tract. Washington DC: ILSI Press, 1994.
122. Adamson IYR, Bowden DH. Response of mouse lung to crocidolite
asbestos. 1. Minimal brotic reaction to short bres. J Pathol
1987; 152: 99107.
123. Adamson IYR, Bowden DH. Response of mouse lung to crocidolite
asbestos. 2. Pulmonary brosis after long bres. J Pathol 1987;
152: 10917.
124. Hesterberg TW, Axten C, McConnell EE, et al. Studies on the
inhalation toxicology of two berglasses and amosite asbestos in
the syrian golden hamster. Part I. Results of a subchronic study
and dose selection for a chronic study. Inhal Toxicol 1999; 11:
74784.
125. Voss B, Kerenyi T, Muller KM, Wilhelm M. Scanning electron
microscopical investigations of broncho-alveolar casts after
intratracheal asbestos bre instillation. Int J Hyg Environ Health
2000; 203: 12734.
148.
149.
150.
151.
152.
153.
154.
155.
156.
157.
158.
159.
160.
161.
162.
163.
164.
165.
166.
167.
168.
169.
15
Experimental models: mesothelioma
DELIA NELSON, BRUCE WS ROBINSON
Reasons for establishing models of malignant mesothelioma
Human malignant mesothelioma as experimental models
Animal malignant mesothelioma models
SV40 models
Uses of experimental models of malignant mesothelioma
187
187
189
190
191
193
195
195
SV40 MODELS
The role of SV40 in the development of mesotheliomas has
been explored in animal models in a variety of ways and
SV40 alone induces mesotheliomas in hamsters. However,
we recently used the mesothelin promoter to construct
four mouse lines that express SV40 TAg in mesothelial
cells at different levels.37 All of these mice show a relatively
Asbestos induced
Variable latency
Effusion
Histology:
Epithelial
Sarcomatous
Mixed
Ultrastructure:
Microvilli
Glycogen granules
Tight junctions
Growth in culture
Variable morphology in culture
MHC surface expression:
Class I
Class II
Tumorigenicity
Tumor suppressor expression:
p53
Soluble factor secretion:
TGF-b
VEGF
PDGF-A chain
IL-6
Human MM
Murine MM
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
(approx. 12%)
+
+
+
+
+ (86%)
+
+
(nude mice)
+ (syngeneic mice)
+
+
+
+
+
+
+
+
MHC, major histocompatibility complex; TGF-b, transforming growth factor beta; VEGF, vascular
endothelial growth factor; PDGF, platelet-derived growth factor; IL-6, interleukin 6.
Experimental models designed to characterize the role of the immune system in malignant mesothelioma 193
Pleural models of MM demonstrated a widespread distribution of infectious virus particles throughout the
thorax after intrapleural treatment with adenovirus
vectors that resulted in tumor growth inhibition.32,72 The
use of these models led to a number of clinical trials.
References 195
and permanent tumor regression. This response was associated with tumor inltrating CD8+ T cells and reduced
tumor-associated vascularity. Tumor progression
inevitably occurred in mice with large tumors when treatment was commenced. It was evident that there was only a
small time-frame in which IL-2 treatment could be effective.
re-emerge. However, when debulking surgery was performed in conjunction with vaccination using syngeneic
MM tumor cells transfected with genes encoding for B7-1
or high levels of GM-CSF, there was a statistically signicant delay of tumor growth.96 Debulking surgery appeared
to play a pivotal role in promoting an anti-tumor immune
response induced by immunological gene therapy.
More recently, we have shown that partial and complete debulking surgery was highly effective in eradicating
MM tumors when combined with chemotherapy and a
CD40-based immunotherapy.102 However, only those
mice with partially debulked tumors plus the combination
regimen generated long-term, tumor-specic, protective
memory. We postulate that chemotherapy induced apoptosis of residual tumor cells following incomplete resection
is absolutely required for the induction of long-term
immunological memory. These data are the basis of a
current clinical trial.
In conclusion, experimental models of MM continue to
offer meaningful information for direct clinical translation.
KEY POINTS
REFERENCES
References 197
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
PART
CLINICAL SCIENCE
201
209
227
233
259
271
285
293
315
323
341
367
379
389
397
409
421
431
445
455
465
473
483
491
499
507
515
533
545
551
569
583
599
613
621
16
Approach to patients with pleural diseases
STEVEN A SAHN
History
Physical examination
Diagnostic tests
Time to resolution
201
202
203
204
Patients with pleural effusions may present with symptoms, such as pleuritic chest pain, dyspnea or cough, or the
effusion may be suspected on physical examination or
observed on chest radiograph. The diagnosis of a pleural
effusion signies that the physiologic balance between
normal pleural uid formation and removal has been disturbed, resulting in pleural uid accumulation. Since a
pleural effusion can be a manifestation of disease in virtually any organ in the body, its presence provides the clinician with the opportunity to support or conrm their
clinical diagnosis. Awareness that not only disease in the
thorax can cause a pleural effusion, but abnormalities of
organs juxtaposed to the diaphragm, such as the liver or
spleen, can lead to earlier diagnosis.1 In addition, systemic
diseases, such as systemic lupus erythematosus and
rheumatoid arthritis, and diseases of the lymphatic system,
such as yellow nail syndrome, may also cause pleural effusions. Therefore, the evaluation of a patient with a pleural
effusion starts with, and requires, a thorough history and
physical examination in conjunction with pertinent laboratory tests to allow the clinician to formulate a prethoracentesis diagnosis. Pleural uid analysis can provide
a condent diagnosis when the likelihood of a clinical
diagnosis is high.
HISTORY
Patients presenting with a pleural effusion may be asymptomatic, such as with benign asbestos pleural effusions
(BAPE)2 or rheumatoid pleurisy3 (Table 16.1) or have
symptoms as with lupus pleuritis4 or bacterial pneumonia
(Table 16.2). Patients with small pleural effusions and
without underlying cardiopulmonary disease may be
asymptomatic at presentation and the effusion discovered
Undiagnosed effusions
Future directions
Key points
References
205
206
206
206
Bacterial pneumonia
Carcinomatous pleural effusion
Congestive heart failure
Lupus pleuritis
Malignant mesothelioma
Postcardiac injury syndrome (PCIS)
Pulmonary embolism
Tuberculous pleural effusion
Viral pleurisy
PHYSICAL EXAMINATION
Pleural uid interferes with sound transmission from the
lung to the stethoscope because it separates the lung from
the chest wall. The physical signs of a pleural effusion
depend upon the volume of pleural uid and the degree of
lung compression. The status of the underlying lung and
the patency of the bronchial tree will modulate the physical ndings.
When only 250300 cm3 of pleural uid is present,
detection by physical examination will be problematic.12
At a pleural uid volume of approximately 500 cm3, the
typical physical ndings are: (1) dullness to percussion; (2)
decreased fremitus; and (3) normal vesicular breath
sounds of decreased intensity compared with the contralateral side.12 At a pleural uid volume exceeding
1000 cm3, there usually is: (1) absence of inspiratory
retraction and mild bulging of the intercostal spaces; (2)
decreased expansion of the ipsilateral chest wall; (3) dullness to percussion up to the level of the scapula and axilla;
(4) decreased or absent fremitus posteriorly and laterally;
(5) bronchovesicular breath sounds, which may be of
DIAGNOSTIC TESTS
exudative effusions with a normal heart size are most commonly malignant but can also be seen with lupus pleuritis
and rheumatoid pleurisy.37
When a chest radiograph shows a pleural effusion(s)
with interstitial inltrates, the differential diagnosis
includes congestive heart failure, rheumatoid disease,15
asbestos pleuropulmonary disease,2 lymphangitic carcinomatosis,38 lymphangioleiomyomatosis (LAM),39 viral and
mycoplasma pneumonia,40 sarcoidosis41 and Pneumocystis
jiroveci pneumonia.42
Pleural effusions associated with multiple nodules
suggest cancer (most common), Wegeners granulomatosis,43 rheumatoid disease,2 septic pulmonary emboli,44 sarcoidosis41 and tularemia.45
Radiology
The chest radiograph can provide further diagnostic
insight. Specic diseases should be considered if the only
abnormal radiographic nding is a pleural effusion or if the
effusion is associated with other abnormalities. For
example, when the only abnormality on the chest radiograph is a pleural effusion, infectious causes such as a
tuberculous pleural effusion,13 viral pleurisy14 or a small
bacterial pneumonia are possibilities. An isolated pleural
effusion is more commonly observed with lupus pleuritis4
and rheumatoid pleurisy15 than with another thoracic
manifestation of these diseases. Metastatic cancer, nonHodgkin lymphoma, and leukemia can also present as a
solitary pleural effusion. Other diseases where a pleural
effusion is typically the only radiographic abnormality
include BAPE,2 pulmonary embolism,16 drug-induced
pleural disease,11 yellow nail syndrome,17 hypothyroidism,18 uremic pleuritis,19 chylothorax20 and
constrictive pericarditis.21 When a massive effusion is
present that causes contralateral mediastinal shift, the most
likely diagnosis is carcinoma, usually a non-lung primary.22
With a large or massive pleural effusion without contralateral shift, lung cancer23 and malignant pleural
mesothelioma24 are most likely.
Solitary pleural effusions may also be associated with
disease below the diaphragm.1 Transudates from hepatic
hydrothorax,25 nephrotic syndrome,26 urinothorax27 and
peritoneal dialysis28 can cause this radiographic pattern.
Exudates from acute29 and chronic pancreatitis,30 Meigs
syndrome,31 chylous ascites32 and subphrenic,33 hepatic34
and splenic abscesses35 or splenic hematomas36 can also be
causative.
Bilateral pleural effusions are most commonly transudates, as seen with congestive heart failure, nephrotic syndrome, hypoalbuminemia, peritoneal dialysis and
constrictive pericarditis. The cardiac silhouette is virtually
always enlarged in congestive heart failure but may be of
normal size with nephrotic syndrome, other causes of
hypoalbuminemia and constrictive pericarditis.37 Bilateral
Table 16.3 Diagnoses that can be established denitively by pleural uid analysis
Diseases
Empyema
Malignancy
Lupus pleuritis
Tuberculous pleural effusion
Esophageal rupture
Fungal pleurisy
Cholesterol effusion
Chylothorax
Hemothorax
Urinothorax
Peritoneal dialysis
Extravascular migration of a central venous catheter
Rheumatoid pleurisy
Duro-pleural stula
LE, lupus erythematosus; AFB, acid-fast bacilli; ADA, adenosine deaminase; LDH, lactate dehydrogenase.
From Sahn SA.47
TIME TO RESOLUTION
Knowledge of the time of resolution, either spontaneous
or with therapy, of pleural effusions can be helpful diag-
Undiagnosed effusions
UNDIAGNOSED EFFUSIONS
In the patient with an undiagnosed exudative pleural effusion following the initial pleural uid analysis including
cytology and cultures, the options include observation,
repeat thoracentesis with or without percutaneous pleural
biopsy and medical or video-assisted thoracic surgery
(VATS). The most likely causes of an undiagnosed effusion
are early-stage malignancy (cancer and lymphoma
(usually Hodgkins lymphoma) and mesothelioma), less
commonly tuberculosis, and benign persistent effusions
from yellow nail syndrome, trapped lung, constrictive
pericarditis or drug-induced pleural effusions.
Whether or not the patient with a tuberculous pleural
effusion is treated with anti-tuberculosis medications, the
effusion will resolve in 416 weeks, unless lung entrapment develops; however, the untreated patient has a 65
percent chance of developing active pulmonary or extrapulmonary tuberculosis within the next 5 years.61 Culture
of pleural uid and tissue from pleural biopsy and pleural
tissue histology should establish the diagnosis of tuberculosis in 7580 percent of cases.64 If the aforementioned
studies are negative and the pleural uid is a lymphocytic
(usually >80 percent) exudate and the patient is PPD
(puried protein derivative) positive, the patient should be
treated for tuberculosis. If the patient has a negative PPD
skin test, it should be repeated in 68 weeks; if positive,
205
26 months
6 months to 1 year
Benign persistent
BAPE
CABG surgery
Chronic pancreatic effusion
PCIS
Rheumatoid pleurisy
Sarcoidosis
Tuberculous effusion
BAPE
Rheumatoid pleurisy
BAPE, benign asbestos pleural effusion; CABG, coronary artery bypass graft; LAM, lymphangioleiomyomatosis; CHF, congestive heart failure; PCIS,
postcardiac injury syndrome; YNS, yellow nail syndrome.
From Cohen M, Sahn SA.57
FUTURE DIRECTIONS
With a more comprehensive knowledge of pleural uid
analysis in conjunction with all available clinical information to formulate a pre-test diagnosis, the number of
patients with an undiagnosed effusion should continue to
diminish. As new biochemical, cytological and molecular
biological tests are developed and incorporated into analysis of pleural effusions, the frequency of undiagnosed
pleural effusions should decrease further. Large, prospective studies of pleural uid analysis in patients with clearly
established diagnoses should enhance the presumptive
diagnostic value of pleural uid analysis and thereby avoid
the necessity of repeat thoracentesis or thoracoscopy. As
more pulmonologists develop expertise in thoracoscopy,
enhanced by improved instrumentation, it should be a
rare occurrence to encounter a patient with an unexplained pleural effusion.
KEY POINTS
The differential diagnosis of the exudative effusion can be narrowed by nding a pleural uid
pH <7.30 or a pleural uid/serum glucose ratio
<0.5, a pleural uid lymphocytosis >80 percent
or pleural uid eosinophilia.
Non-malignant pleural effusions that persist for
more than 1 year are found with trapped lung,
yellow nail syndrome, lymphangiectasia and cholesterol effusion (a form of lung entrapment).
The most likely causes of undiagnosed pleural
effusions are early-stage malignancy and chronic
benign persistent effusions, particularly yellow
nail syndrome, trapped lung and drug-induced
pleural effusion.
REFERENCES
= Key primary paper
= Major review article
1. Lorch DG, Sahn SA. Pleural effusions due to diseases below the
diaphragm. Sem Respir Med 1987; 9: 7585.
2. Epler GR, McLoud TC, Gaensler EA. Prevalence and incidence of
benign asbestos pleural effusion in a working population. J Am
Med Assoc 1982; 247: 61722.
3. Carr DT, Mayne JG. Pleurisy with effusion in rheumatoid arthritis,
with reference to the low concentration of glucose in pleural uid.
Am Rev Respir Dis 1962; 85: 34550.
4. Good JT Jr, King TE, Antony VB, Sahn SA. Lupus pleuritis: clinical
features and pleural uid characteristics with special reference to
pleural uid antinuclear antibody titers. Chest 1983; 84: 71418.
5. Estenne M, Yernault JC, Detroyer A. Mechanism of relief of
dyspnea after thoracentesis in patients with large pleural
effusions. Am J Med 1983; 74: 81319.
6. Anthonisen NR, Martin RR. Regional lung function in pleural
effusion. Am Rev Respir Dis 1977; 116: 2017.
7. Sahn SA, Heffner JE. Approach to the patient with pleurisy. In:
Kelley WN (ed). Textbook of internal medicine. Philadelphia: JB
Lippincott Co, 1991: 188790.
8. Stelzner TJ, King TE, Antony VB, Sahn SA. The pleuropulmonary
manifestations of the postcardiac injury syndrome. Chest 1983;
84: 3837.
9. Triggiani E, Belsey R. Oesophageal trauma: incidence, diagnosis,
and management. Thorax 1977; 32: 2419.
10. Henningsen NC, Cederberg A, Hanson A, et al. Effects of long-term
treatment with procainamide: a prospective study with special
regard to ANF and SLE in fast and slow acetylators. Acta Med
Scand 1975; 198: 47582.
11. Sahn SA. Drug-induced pleural disease. In: Camus P, Rosenau E
(eds). Drug-induced and iatrogenic lung disease. London: Hodder
Arnold; 2009, in press.
12. Hopkins HU. Principles and methods of physical diagnosis, 3rd ed.
Philadelphia: W.B. Saunders, 1965.
13. Gopi A, Madhavan SM, Sharma SK, Sahn SA. Diagnosis and treatment
of tuberculous pleural effusion in 2006. Chest 2007; 131: 8749.
14. Alptekin F. An epidemic of pleurisy with effusion in Bitlis, Turkey: a
study of 559 cases. US Arm Forces Med J 1958; 9: 111.
15. Walker WC, Wright V. Pulmonary lesions in rheumatoid arthritis.
Medicine 1968; 47: 50119.
16. Bynum LJ, Wilson JE III. Radiographic features of pleural effusions
in pulmonary embolism. Am Rev Respir Dis 1978; 117: 82934.
References 207
17
Pleural uid analysis
STEVEN A SAHN, JOHN E HEFFNER
Appearance
Exudative versus transudative
Protein and lactate dehydrogenase
Nucleated cells
pH
Glucose
Amylase
Triglycerides and cholesterol
209
210
215
215
217
219
220
221
Immunological studies
Cytological examination
Flow cytometry
Adenosine deaminase
Future directions
Key points
References
221
222
222
222
223
223
223
APPEARANCE
A diagnosis can be established at the bedside by visual
examination of the pleural uid as it is aspirated from the
pleural space. The color, character and odor of the uid
may be either diagnostic or helpful in diagnosis (Table
17.1) A clear, straw-colored uid suggests a transudate but
also may be seen in pauci-cellular exudates. A serosanguinous appearance typically signies a pleural uid
hematocrit <1 percent and is diagnostically unhelpful.
However, a grossly bloody effusion narrows the differential diagnosis to malignancy, benign asbestos pleural effusion (BAPE), post-cardiac injury syndrome (PCIS),
pulmonary infarction and trauma. A hemothorax, which is
most commonly due to trauma,4 may also occur with invasive procedures,5 metastatic disease to the pleura, anticoagulation in the setting of a pulmonary infarction6 and
catamenial hemothorax.7 To diagnose a hemothorax, the
pleural uid hematocrit should be compared with the
blood hematocrit; if the pleural uid hematocrit is at least
50 percent of the peripheral blood hematocrit, a
210
BAPE, benign asbestos pleural effusion; PCIS, post-cardiac injury syndrome; PF, pleural uid; S, serum.
Vasculitis
Wegener granulomatosis
ChurgStrauss syndrome
Familial Mediterranean fever
Malignancy
Carcinoma
Lymphoma
Mesothelioma
Leukemia
Chylothorax
Other inammatory
Pancreatitis
BAPE
Pulmonary infarction
Radiation therapy
Sarcoidosis
PCIS
Hemothorax
ARDS
Cholesterol effusion
Endocrine dysfunction
Hypothyroidism
Ovarian hyperstimulation syndrome
Lymphatic abnormalities
Malignancy
Chylothorax
Yellow nail syndrome
Lymphangiomyomatosis (chylothorax)
Lymphangiectasis
ARDS, acute respiratory distress syndrome; BAPE, benign asbestos pleural effusion; PCIS, post-cardiac injury syndrome.
Comment
Acute diuresis can increase pleural uid protein and LDH concentrations
Uncommon without clinical ascites
Typically small and bilateral; unilateral, larger effusion may be due to pulmonary embolism
Large right effusion may develop within 48 hours of initiating dialysis
Edema uid rarely isolated to pleural space; small bilateral effusions
Unilateral effusion caused by ipsilateral obstructive uropathy
Small effusion caused by increased intrapleural negative pressure; common in ICU patients
Bilateral effusions with normal heart size
Unilateral effusion from imbalance in hydrostatic pressures from a remote inammatory process
Due to acute systemic venous hypertension or acute obstruction of lymphatics
Cerebrospinal uid in pleural space; 2-transferrin diagnostic
Pleural uid tests that discriminate exudates from transudates measure the concentration of large molecular
weight constituents in pleural uid (Table 17.3). Because
exudative effusions typically result from increased permeability and passage between mesothelial cells, these large
molecules can enter the pleural space or undergo release
from intrapleural inammatory or neoplastic cells. In con-
212
trast, transudative effusions result from hydrostatic mechanisms and have lower concentrations of large molecular
weight constituents because intact pleural membranes act
as a diffusion barrier to these compounds.
Various pleural uid testing strategies reported in the
literature recommend either a single pleural uid test
result or multiple tests combined in diagnostic rules to
establish the presence of an exudate. The multi-test strategies combine test results in or rules, which means that
any one of multiple test results can diagnose an exudative
effusion if the single result exceeds a certain limit. As with
any diagnostic test, combining multiple tests in an orrule, increases sensitivity with the inevitable consequence
of decreasing specicity.16,17 Single test results, therefore,
should be used when the goal is to increase specicity and
thereby rule in an exudative effusion. Multiple tests combined with in or-rules increase sensitivity and help clinicians to rule out an exudative effusion if the test result is
negative for an exudate. A positive result of a multiple test
strategy, however, has a decreased positive predictive value
for identifying exudative effusions. In most circumstances,
clinicians would favor an initial multi-test screening strategy with a high sensitivity for evaluating patients with new
onset pleural effusions because of the importance of not
missing an exudative effusion, which carries important
prognostic considerations.
Lights criteria comprise a three-test strategy that
screens patients for exudates by measuring pleural uid
and concurrent serum concentrations of protein and
lactate dehydrogenase (LDH). Test results are combined
into three criteria: (1) pleural uid to serum protein ratio;
(2) pleural uid to serum LDH ratio; and (3) pleural uid
LDH concentration relative to the laboratorys upper limit
of normal for serum LDH.18 An exudative effusion is
dened by the presence of any one of the following criteria: a pleural uid to serum protein ratio >0.5, pleural uid
to serum LDH ratio >0.6 or a pleural uid LDH con-
Table 17.4 Cut-off points derived from a meta-analysis of pooled data and cut-off points commonly recommended by individual studies
Meta-analysis ROC cutoff point5
P-PF
P-R
LDH-PF
>2.9 g/dL
>0.5
>0.45% of upper limits of serum normal
LDH-R
C-PF
>0.6
>45 mg/dL
C-R
A-G
P-G
>0.3
1.2 g/dL
Not assessed
>3 g/dL42
>0.518
>2/3 of upper limits of serum normal41
>81% upper limits of serum normal 30
>0.6 18
>45 mg/dL20
>54 mg/dL23
>55 mg dL43
>60 mg/dL21,22
>0.3 2124
1.2 g/dL44, 45
3.1 g/dL27,28
P-PF, pleural uid protein; P-R, pleural uid to serum protein ratio; LDH-PF, pleural uid LDH; LDH-R, pleural uid to serum LDH ratio; C-PF, pleural uid
cholesterol; C-R, pleural uid to serum cholesterol ratio; A-G, serum to pleural uid albumin gradient;19 P-G, serum to pleural protein gradient.27,28
91.5
(89.3 to 93.7)
89.5
(87.4 to 91.6)
88.0
(85.8 to 90.3)
91.4
(89.4 to 93.3)
89.0
(86.8 to 91.2)
92.0
(90.1 to 93.9)
86.8
(82.2 to 91.4)
83.8
(77.5 to 88.6)
83.0
(77.6 to 88.4)
90.9
(87.4 to 94.5)
81.8
(77.1 to 86.6)
85.0
(80.6 to 89.4)
81.4
(76.6 to 86.2)
81.4
(76.6 to 86.2)
91.8
(86.4 to 97.3)
90.6
(80.1 to 96.1)
94.2
(92.6 to 95.9)
95.4
(94.3 to 96.7)
93.3
(91.8 to 94.8)
94.7
(93.4 to 96.0)
93.3
(91.7 to 94.8)
94.1
(92.5 to 95.7)
94.0
(91.3 to 96.6)
Not available
AUC, area under the receiver operating characteristic curve; CI, condence interval; P-PF, pleural uid protein; P-R, pleural uid to serum protein ratio;
LDH-PF, pleural uid LDH; LDH-R, pleural uid to serum LDH ratio; C-PF, pleural uid cholesterol; C-R, pleural uid to serum cholesterol ratio; A-G, serum
to pleural uid albumin gradient; P-G, pleural uid to serum protein gradient. Data extracted from references 19 and 28.
214
100
90
80
70
60
50
40
30
20
10
0
0.3
0.4
0.5
0.6
0.7
0.8
LDH ratio
0.9
1.0
patient with CHF who is undergoing diuresis, the physician would have a low pretest clinical suspicion of an
exudative effusion in the absence of clinical signs of a coexisting clinical condition. Findings of Lights criteria being
slightly in the exudative range would not sufciently
increase the clinicians initial low pretest suspicion of an
exudative effusion to justify a post-test diagnosis of an
exudative effusion. The clinician should conclude that the
patient has a transudative effusion with exudative characteristics by Lights criteria as a result of diuresis (i.e. false
positive test result).
This approach to pleural uid analysis relies on knowledge of the likelihood ratio associated with an individual
pleural uid test result.17, 40 A likelihood ratio is the likelihood that a given test result would be expected in a patient
with the target disorder compared with the likelihood that
the same result would be expected in a patient without that
disorder, in this case, an exudative pleural effusion. The
clinician then estimates the pretest that an exudate
probably exists based on their clinical experience and other
relevant laboratory results, converts the probability to
pretest odds and multiplies the odds by the likelihood ratio
to calculate the post-test odds, which is then re-converted
to a post-test probability.
Binary likelihood ratios that provide single likelihood
ratio values for test results above and below the cut-off
point overestimate the probability of an exudative effusion
if test results return slightly above the cut-off point and
severely underestimate the probability of an exudate when
results return extremely high values (Figure 17.2). Multilevel and continuous likelihood ratios provide more
precise likelihood values for specic pleural uid test
results. Both multilevel and continuous likelihood ratios
have been reported for pleural uid tests that discriminate
between exudates and transudates for pooled34, 41 and
single-center patient series data.30 Their application has
been reviewed recently elsewhere.15 Although seemingly
cumbersome, these calculations are quickly performed by
pre-programmed computer systems integrated with laboratory reporting software. Whether used in regular clinical
practice or not, the application of likelihood ratios to
selected patients demonstrates that tests used for discriminating between transudates and exudates have less clinical
value, compared with a physicians clinical impressions,
than what is commonly believed.
In summary, Lights criteria have served well for three
decades in assisting clinicians in discriminating between
exudative and transudative effusions. Because two of the
criteria in Lights criteria (pleural uid LDH and pleural
uid-to-serum LDH) are highly correlated, one or the
other should be excluded from the model (Abbreviated
Lights criteria) to improve the rules diagnostic performance.19,31,32 Because most of the individual pleural uid
tests reported in the literature have similar diagnostic
properties, as compared with each criterion within Lights
criteria,19,30,31 multi-test strategies that avoid venipuncture
may have clinical utility. The two-test diagnostic combina-
malignancy,18 parapneumonic effusions18 and Pneumocystis carinii pneumonia should be considered.49 A pleural
uid LDH concentration greater than three times the
upper limits of normal for serum LDH is typically seen
only in a complicated parapneumonic effusion or
empyema,50,51 rheumatoid pleurisy52 or pleural paragonimiasis53; it is less often observed with malignancy and
rarely with a tuberculous pleural effusion.18
40
35
Likelihood ratio
30
25
20
15
NUCLEATED CELLS
10
5
0
0.0
0.2
0.4
1.8
2.0
216
Comment
most common cause of lymphocyte predominant exudate; usually 9095% lymphocytes
4006800 lymphocytes/L; lymphoma most common cause
Often 100% of nucleated cells are lymphocytes; diagnostic yield on cytology or pleural biopsy
higher with non-Hodgkin lymphoma
A cause of a persistent effusion
Usually associated with lung entrapment
Usually >90% lymphocytes; prevalence <2%
New or increased effusion 26 weeks after transplant
Occurs >2 months following surgery; not associated with unexpandable lung
Renal failure present for 12 years; most effusion resolve with continued dialysis in 46 weeks
the pretest diagnosis is a transudate. Transudative effusions are mononuclear cell predominant, a combination of
lymphocytes, macrophages and mesothelial cells.
When the lymphocyte population is 80 percent or
greater of the total nucleated cells, the differential
diagnosis of the exudative effusion is narrowed to the
following diagnoses (Table 17.6).61 The most common of
these diagnoses is a tuberculous effusion.62 Lymphoma,62
yellow nail syndrome,63 chronic rheumatoid pleurisy,56,64
uremic pleuritis,65 sarcoidosis,66,67 chylothorax,68 acute
lung rejection69 and post-coronary artery by-pass surgery
(CABG surgery)70 are also causes of >80 percent of
lymphocytes in pleural uid. All of the aforementioned
diagnoses can occur with a lymphocyte population of <80
percent; however, a lymphocyte population of <50 percent
is rarely found. In contrast to lymphoma, only about 60
percent of patients with metastatic carcinoma to the pleura
have a majority of lymphocytes (usually 5075 percent of
total nucleated cells).62 An undiagnosed, lymphocytepredominant, exudative effusion is the most appropriate
indication for percutaneous pleural biopsy and the most
sensitive diagnostic procedure in tuberculous pleural
effusion with the exception of thoracoscopy.71,72
Lymphoma, carcinoma, sarcoidosis and occasionally
rheumatoid pleurisy may be diagnosed by percutaneous
pleural biopsy.
Pleural uid eosinophilia (PFE) is dened as a pleural
uid eosinophil count 10 percent of the total nucleated
cell count. It appears that eosinophils, produced in the
bone marrow, are attracted to the pleural space by the
chemotactic factor, IL-5.73 Causes of PFE are shown in
Table 17.7. Pneumothorax and hemothorax are the most
common causes of PFE. It had been thought that the
nding of PFE virtually excluded the diagnosis of malignancy. However, recent studies have shown that the prevalence of malignancy is similar in both eosinophilic and
non-eosinophilic pleural effusions.74,75 Eosinophilic pleuritis is a common early nding in patients who require
thoracotomy or thoracoscopy for spontaneous pneumothorax. In contrast to the rapid movement of eosinophils
into pleural tissue and pleural uid in pneumothorax,76
Hemothorax
Benign asbestos
Pulmonary embolism
Parasitic disease
Fungal disease
Drug-induced
Lymphoma
Carcinoma
ChurgStrauss Syndrome
Tuberculous pleurisy
Sarcoid pleurisy
aPFE,
Comment
Effusion in 1020%; tissue
eosinophilia and PFE occurs early
and is a common nding
PFE occurs 12 weeks following a
hemothorax
30% incidence of PFE; up to 50%
eosinophils/total nucleated cells
Associated with infarction and
pleural space hemorrhage
Paragonimiasis, hydatid disease,
amebiasis, ascariasis
Histoplasmosis, coccidioidomycosis
Dantrolene, bromocriptine,
nitrofurantoin, valproic acid
Hodgkin disease
58% with PFE
High pleural uid eosinophil counts;
associated with blood eosinophilia
Rare
Rare
pH
217
pH
Pathogenesis
A limited number of pleural effusions are associated with a
low pleural uid pH (<7.30) (Table 17.8).86, 87 Pleural uid
pH should only be measured with a blood gas analyzer.
Pleural uid pH decreases as a result of high metabolic
activity of intrapleural cellular constituents or by an
abnormal pleural membrane that blocks the efux of
protons and organic acids from the pleural space into the
circulation.87 Urinothorax is a rare cause of a low pleural
uid pH in patients with acidic urine and is the only transudate associated with pleural uid acidosis.88 The
extravasated urine from the capsule of the kidney moves
retroperitoneally across the diaphragm into the ipsilateral
pleural space.
The presence of a low pleural uid pH provides diagnostic and prognostic information in various clinical settings. A low pH may also confound pleural uid analysis
by suggesting an alternative diagnosis, such as pleural
space infection, when it occurs in the setting of a less
common condition associated with a low pH effusion,
such as rheumatoid pleurisy.
In the only study of acidbase characteristics of normal
human pleural uid, the pH was measured at 7.64, 0.23 pH
Table 17.8 Diagnoses associated with pleural uid acidosis (pH <7.30)
Disease
Estimated incidence
of pH <7.30 (%)
Range of pH
Comments
Parapneumonic effusion
Uncomplicated
05
7.457.20
Complicated or empyema
Esophageal rupture
Rheumatoid pleurisy (chronic)
Malignant effusion
~100
~100
~100
3040
7.295.00
6.805.00
7.156.80
7.506.90
Lupus pleuritis
Tuberculous effusion
1520
1020
7.406.85
7.406.95
Hemothorax
<10
7.507.17
Pancreatic effusion
Pulmonary infarction
Diaphragmatic hernia with
bowel infarction
Rare
Rare
Single report
7.507.28
7.527.29
7.15
218
Parapneumonic effusions
Some experts categorize parapneumonic effusions as
uncomplicated or complicated. Uncomplicated parapneumonic effusions resolve with antibiotic therapy alone.
Complicated effusions require pleural uid drainage to
accelerate patient recovery and avoid progression to an
empyema or lung entrapment. Because these categorizations require knowledge of a patients subsequent clinical
course, various strategies have been investigated to estimate the likely course of a parapneumonic effusion upon
initial presentation. Pleural uid pH has been found to be
lower in patients who follow a complicated rather than an
uncomplicated course.50,51,86,9699
A meta-analysis examined the prognostic performance
of pleural uid pH in patients with parapneumonic effusions.100 This study combined patient-level data from
seven primary investigations that measured pleural uid
pH in samples from patients with non-purulent parapneumonic effusions.50,51,86,9699 Receiver operating characteristics were used to determine the diagnostic accuracy of
pleural uid pH, which was reported as the area under the
receiver operating characteristic curve (AUC).101 The metanalysis found that pleural uid pH was lower in pleural
uid samples from patients who followed a complicated
rather than an uncomplicated course and that the AUC for
pH was 0.89.100 This value for AUC indicated that pleural
uid pH had good discriminative properties for differentiating between complicated and uncomplicated parapneumonic effusions.
Published primary studies recommend various cutpoints below which a complicated effusion can be
Glucose 219
GLUCOSE
In the normal physiological state, blood and uid glucose
concentration should be equivalent because glucose is of
low molecular weight and should be transported from
blood to pleural uid by simple diffusion across the
endothelial and mesothelial membranes. It is unlikely that
a carrier transport system for glucose exists between blood
and pleural uid, as is postulated between blood and cerebrospinal uid,113 because all transudative effusions and
most exudative effusions have a pleural glucose that
mirrors blood glucose. A small group of exudative pleural
effusions, the same as those with a low pleural uid pH,
may present with a low pleural uid glucose concentration.114 A low pleural uid glucose concentration has been
dened as <60 mg/dL or a pleural uid to serum glucose
ratio of <0.5 (Table 17.9). Post-pneumonic empyema and
the anaerobic empyema associated with esophageal
rupture have low pleural uid glucose concentrations that
tend to increase towards normal with treatment. In experimental empyema, the glucose falls rapidly following penetration of bacteria into the pleural space.93 Glucose
concentration correlates inversely with pleural uid lactate
and pCO2, both in vivo and in vitro, suggesting that the
accumulation of these glucose end-products is responsible
for the decrease of pleural uid pH in empyema.93 Glucose
utilization is increased by neutrophil phagocytosis and
bacterial metabolism and exceeds the replacement of
glucose from blood to pleural uid.94 While increased
glucose utilization is the primary mechanism for low
glucose in empyema, an abnormal pleural membrane produced by the rheumatoid state is the cause of low glucose
concentration in rheumatoid pleurisy.115,116 A pleural uid
glucose concentration of zero is found almost exclusively
in patients with empyema and rheumatoid pleurisy.114
Like rheumatoid effusions, the major mechanism of the
low glucose concentration in malignancy is an abnormal
pleura, which is due to tumor inltration that decreases
glucose movement into the pleural space. In some cases,
free cancer cells contribute to increased glucose utilization
and an increase in the end-products of glucose metabolism, CO2 and lactate acid, which accumulate due to
220
Table 17.9 Diagnoses associated with low pleural uid glucose concentration (glucose <60 mg/dL or PF/S <0.5)
Disease
Estimated incidence
of glucose pleural
uid/serum <0.5
Range of glucose
concentration
(mg/dL)
Comments
Rheumatoid pleurisy
8590%
0118
Empyema
8090%
0145
Esophageal rupture
4050%
15120
Malignant effusion
3040%
15167
Lupus pleuritis
2030%
32160
Tuberculous effusion
2030%
10140
AMYLASE
An increased pleural uid amylase, dened as either a
value greater than the upper limits of normal of the serum
or a pleural uid amylase ratio >1.0, is found in pancreatic
disease,118,122124 esophageal rupture110,111,121,125,126 and
malignancy.111,112,123,127,128 Rarely, an amylase-rich pleural
IMMUNOLOGICAL STUDIES
Approximately half of the patients with systemic lupus
erythematosus will develop pleuritic chest pain or a pleural
effusion during the course of their disease and, in 5 percent
of patients, pleuritis may be the presenting manifestation.138 Approximately 5 percent of patients, mostly men
with active rheumatoid disease, will develop pleurisy.139,140
222
CYTOLOGICAL EXAMINATION
Pleural uid cytology has a widely variable diagnostic
yield, ranging from 40 to 90 percent of patients with
pleural malignancy.143,144,147,148 There are several reasons
for this variability. One important consideration is that the
effusion may be paramalignant, which is dened as a
pleural effusion associated with a known malignancy but
the pleura is not involved with tumor.149 These paramalignant effusions result from local effects of the tumor, such
as obstructive atelectasis or pneumonia, systemic effects
such as pulmonary embolism, and complications of
therapy, such as radiation pleuritis or drug-induced
pleurisy. Other explanations for the variable cytological
diagnosis include the type of tumor (high positivity with
adenocarcinoma150 and low in Hodgkin lymphoma),151
FLOW CYTOMETRY
While ow cytometry should not be routinely used to differentiate benign and malignant pleural effusions, it can be
helpful in the diagnosis of lymphoma involving the pleura.
Flow cytometry can specically dene lymphocyte surface
markers.152 Therefore, it can dene clonality of a population of lymphocytes to determine whether the cells are
from T- or B-cell lineage. Therefore, ow cytometry is
most helpful in patients with a lymphocyte predominant
pleural effusion when lymphoma is in the differential diagnosis.
ADENOSINE DEAMINASE
Adenosine deaminase (ADA) is an enzyme found in most
cells and is important in the degradation of purines. It is
required for lymphoid cell differentiation and is also
involved in monocytemacrophage maturation. The assay
for ADA is easily and rapidly performed, is of relatively low
cost and has been used in areas of high tuberculosis prevalence to aid in the diagnosis of tuberculosis.153,154 Pleural
uid/serum ADA ratios of >1 have been observed, not
only in tuberculous effusions, but in rheumatoid disease
and empyema, while other exudates have similar ADA
levels in pleural uid and serum.151,155 Furthermore,
patients with tuberculous effusions, rheumatoid pleurisy,
empyema and malignancy have higher ADA activity in
pleural uid than other exudates and CHF.156 The diagnostic cut-off points for ADA have been reported from 40
to 60 U/L.157161 Selecting a cut-off point of 40 U/L will
increase the sensitivity of ADA but decrease its specicity,
while choosing a cut-off point of 60 U/L will increase
specicity but decrease sensitivity.
Some authors have suggested that determination of
ADA isoenzymes will enhance its diagnostic utility. In a
tuberculous effusion, ADA-2 is the predominant isoform
accounting for over 80 percent of ADA activity, whereas
ADA-1 accounts for approximately 70 percent of the activity of the total ADA activity in empyema.158 ADA-2 probably reects monocyte/macrophage origin, while ADA-1
originates from lymphocyte or neutrophil turnover.
However, measurement of ADA-2 is substantially more
expensive than measurement of total ADA and, currently,
is not available clinically in the USA.153 The decline in the
number of cases of tuberculous pleural effusions in the
USA may have contributed to the relative unavailability of
References 223
FUTURE DIRECTIONS
REFERENCES
2.
KEY POINTS
3.
4.
tial of the exudate to complicated parapneumonic effusion/empyema, malignancy, rheumatoid pleurisy, tuberculosis, esophageal rupture
and lupus pleuritis.
Amylase should be measured on pleural uid
only if there is a pretest suspicion of pancreatic
disease, esophageal rupture or malignancy.
Chylothorax can be diagnosed presumptively if
the triglyceride concentration exceeds 110 mg/dL
and is highly unlikely if the triglyceride concentration is <50 mg/dL. Chylomicron determination should be carried out for triglyceride levels
between 50 and 110 mg/dL; its presence conrms
a chylothorax.
Rheumatoid pleurisy can be diagnosed by characteristic cytological ndings that include a background of granular material, large elongated cells
and giant round or oval multinucleated cells.
5.
6.
7.
8.
9.
10.
11.
12.
13.
224
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
Stark DD, Shanes JG, Baron RL, Roach DD. Biochemical features of
urinothorax. Arch Intern Med 1982; 42: 150511.
Heffner JE. Discriminating between transudates and exudates. Clin
Chest Med 2006; 27: 24152.
Heffner JE, Feinstein D, Barbieri C. Methodologic standards for
diagnostic test research in pulmonary medicine. Chest 1998; 114:
87785.
Heffner JE. Evaluating diagnostic tests in the pleural space.
Differentiating transudates from exudates as a model. Clin Chest
Med 1998; 19: 27793.
Light RW, MacGregor I, Luchsinger PC, Ball WC. Pleural effusion:
the diagnostic separation of transudates and exudates. Ann Intern
Med 1972; 77: 50713.
Heffner JE, Brown LK, Barbieri C. Diagnostic value of tests that
discriminate between exudative and transudative pleural
effusions. Chest 1997; 111: 9709.
Costa M, Quiroga T, Cruz E. Measurement of pleural uid
cholesterol and lactate dehydrogenase. A simple and accurate set
of indicators for separating exudates from transudates. Chest
1995; 108: 12603.
Hamm H, Brohan U, Bohmer R, Missmahl H-P. Cholesterol in
pleural effusions. A diagnostic aid. Chest 1987; 92: 296302.
Romero S, Candela A, Martn C, et al. Evaluation of different
criteria for the separation of pleural transudates from exudates.
Chest 1993; 104: 39904.
Suay VG, Moragn EM, Viedma EC, et al. Pleural cholesterol in
differentiating transudates and exudates. A prospective study of
232 cases. Respiration 1995; 62: 5763.
Valds L, Pose A, Surez J, et al. Cholesterol: a useful parameter
for distinguishing between pleural exudates and transudates.
Chest 1991; 99: 1097102.
Chibante A, Neves D, Miranda S, Dias R. [Cholesterol as a
diferential parameter to separate pleural transudates from
exsudates.]. Rev Port Pneumol 2006; 12 (6 Suppl 1): 25.
Roth BJ, OMeara TF, Cragun WH. The serum-effusion albumin
gradient in the evaluation of pleural effusions. Chest 1990; 98:
5469.
Romero-Candeira S, Fernandez C, Martin C, Sanchez-Paya J,
Hernandez L. Inuence of diuretics on the concentration of
proteins and other components of pleural transudates in patients
with heart failure. Am J Med 2001; 110: 6816.
Romero-Candeira S, Hernandez L, Romero-Brufao S, et al. Is it
meaningful to use biochemical parameters to discriminate
between transudative and exudative pleural effusions? Chest
2002; 122: 15249.
Atalay F, Ernam D, Hasanoglu HC, Karalezli A, Kaplan O. Pleural
adenosine deaminase in the separation of transudative and
exudative pleural effusions. Clin Biochem 2005; 38: 106670.
Porcel JM, Pena JM, Vicente de Vera C, et al. Bayesian analysis
using continuous likelihood ratios for identifying pleural exudates.
Respir Med 2006; 100: 19605.
Gonlugur U, Gonlugur TE. The distinction between transudates and
exudates. J Biomed Sci 2005; 12: 98590.
Joseph J, Badrinath P, Basran GS, Sahn SA. Is the pleural uid
transudate or exudate? A revisit of the diagnostic criteria. Thorax
2001; 56: 86770.
Chakko SC, Caldwell SH, Sforza PP. Treatment of congestive heart
failure. Its effect on pleural uid chemistry. Chest 1989; 95:
798802.
Heffner JE, Highland K, Brown LK. A meta-analysis derivation of
continuous likelihood ratios for diagnosing pleural uid exudates.
Am J Respir Crit Care Med 2003; 167: 15919.
Tomcsanyi J, Nagy E, Somloi M, et al. NT-brain natriuretic peptide
levels in pleural uid distinguish between pleural transudates and
exudates. Eur J Heart Fail 2004; 6: 7536.
Porcel JM. The use of probrain natriuretic peptide in pleural uid
for the diagnosis of pleural effusions resulting from heart failure.
Curr Opin Pulm Med 2005; 11: 32933.
37. Light RW. The undiagnosed pleural effusion. Clin Chest Med 2006;
27: 30919.
38. Kolditz M, Halank M, Schiemanck CS, Schmeisser A, Hoffken G.
High diagnostic accuracy of NT-proBNP for cardiac origin of
pleural effusions. Eur Respir J 2006; 28: 14450.
39. Gegenhuber A, Mueller T, Dieplinger B, et al. Plasma B-type
natriuretic peptide in patients with pleural effusions: preliminary
observations. Chest 2005; 12: 10039.
40. Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB.
Evidence-based medicine. How to practice and teach EBM, 2nd
edn. Edinburgh: Churchill Livingstone, 2000.
41. Heffner JE, Sahn SA, Brown LK. Multilevel likelihood ratios for
identifying exudative pleural effusions. Chest 2002; 121:
191620.
42. Leuallen EC, Carr DT. Pleural effusion, a statistical study of 436
patients. N Engl J Med 1955; 252: 7983.
43. Light RW. Pleural diseases. Baltimore: Williams & Wilkins, 1995:
3674.
44. Meisel S, Shamiss A, Thaler M, et al. Pleural uid to serum
bilirubin concentration for the separation of transudates and
exudates. Chest 1990; 98: 1414.
45. Burgess L, Maritz FJ, Taljaard JJF. Comparative analysis of the
biochemical parameters used to distinguish between pleural
transudates and exudates. Chest 1995; 107: 16049.
46. Sahn SA. State of the art. The pleura. Am Rev Respir Dis 1988;
138: 184234.
47. Winterbauer RH, Riggins RCK, Griesman FA, Bauermeister DE.
Pleuropulmonary manifestions of Waldenstroms
macroglobulinemia. Chest 1974; 66: 36875.
48. Rodriguez JN, Pereira A, Martinez JC, et al. Pleural effusion in
multiple myeloma. Chest 1994; 105: 6224.
49. Horwitz ML, Schiff M, Samuels J, et al. Pneumocystis carinii
pleural effusion. Pathogenesis and pleural uid analysis. Am Rev
Respir Dis 1993; 148: 2324.
50. Light RW, Girard WM, Jenkinson SG, George RB. Parapneumonic
effusions. Am J Med 1980; 69: 50711.
51. Potts DE, Levin DC, Sahn SA. Pleural uid pH in parapneumonic
effusions. Chest 1976; 70: 32831.
52. Pettersson T, Klockars M, Helmstrom PE. Chemical and
immunological features of pleural effusions: comparison between
rheumatoid arthritis and other diseases. Thorax 1982; 37: 35461.
53. Johnson JR, Falk A, Iber C, Davies S. Paragonimiasis in the United
States. A report of 9 cases in Hmong immigrants. Chest 1982; 82:
16871.
54. Light RW, Erozan YS, Ball WC Jr. Cells in pleural uid: their value
and differential diagnosis. Arch Intern Med 1973; 132: 85460.
55. Berger HW, Mejiia E. Tuberculous pleurisy. Chest 1973; 63:
8892.
56. Pettersson T, Riska H. Diagnostic value of total and differential
leukocyte counts in pleural effusions. Acta Med Scand 1981; 210:
12935.
57. Antony VB, Repine JE, Sahn SA. Experimental models of
inammation in the pleural space. In: Chretein J, Bignon J, Hirsch
A (eds). The pleural in health and disease. New York: Marcel
Dekker, 1985: 387400.
58. Antony VB, Godbey SW, Kunkel SL, et al. Recruitment of
inammatory cells to the pleural space. Chemotactic cytokines, IL8, and monocyte chemotactic peptide-1 in human pleural uids. J
Immunol 1993; 151: 721623.
59. Broaddus VA, Hebert CA, Vitangcol RV, et al. Interleukin-8 is a
major neutrophil chemotactic factor in pleural liquid of patients
with empyema. Am Rev Respir Dis 1992; 146: 82530.
60. Antony VB, Sahn SA, Antony AC, Repine JE. Bacillus
CalmetteGuerin-stimulated neutrophils release chemotaxins for
monocytes in rabbit pleural spaces and in vitro. J Clin Invest 1985;
76: 151421.
61. Sahn SA. Diagnostic value of pleural uid analysis. Semin Respir
Crit Care Med 1995; 16: 26978.
References 225
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
226
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
134.
135.
136.
137.
138.
139.
140.
141.
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.
153.
154.
155.
156.
157.
158.
159.
160.
161.
Coe JE, Aikawa JK. Cholesterol pleural effusion. Arch Intern Med
1961; 108: 76374.
Harvey AM, Shulman LE, Tumulty PA, et al. Systemic lupus
erythematosis: review of the literature and clinical analysis of 138
cases. Medicine 1954; 33: 291437.
Walker WC, Wright V. Rheumatoid pleuritis. Ann Rheum Dis 1967;
26: 46774.
Horler AR, Thompson M. The pleural and pulmonary complications
of rheumatoid arthritis. Ann Intern Med 1959; 50: 11791203.
Khare V, Baethge B, Lang S, et al. Antinuclear antibodies in pleural
uid. Chest 1994; 106: 86671.
Halla JT, Schrohenloher RE, Volanakis JE. Immune complexes and
other laboratory features of pleural effusions. Ann Intern Med
1980; 92: 74852.
Levine H, Szanto M, Grieble HG, et al. Rheumatoid factor in nonrheumatoid pleural effusions. Ann Intern Med 1968; 69: 48792.
Hunder GG, McDue FC, Heppern GG. Pleural uid complement in
systemic lupus erythematosus in rheumatoid arthritis. Ann Intern
Med 1972; 76: 35762.
Glovsky MM, Louie JS, Pitts WH Jr, Alenty A. Reduction of pleural
uid complement activity in patients with systemic lupus
erythematosus and rheumatoid arthritis. Clin Immunol
Immunopathol 1976; 6: 3141).
Andrews BS, Arora NS, Shadforth MF, et al. The role of immune
complexes in the pathogenesis of pleural effusions. Am Rev Respir
Dis 1981; 125: 11520.
Grunze H. The comparative diagnostic accuracy, efciency, and
specicity of cytologic techniques used in the diagnosis of
malignant neoplasm and serous effusions of the pleuroperitoneal
cavities. Acta Cytol 1964; 8: 15064.
Jarvi OH, Kunnas RJ, Laitio MT, Tyrkko JES. The accuracy and
signicance of cytologic cancer diagnosis of pleural effusions.
Acta Cytol 1972; 16: 1527.
Sahn SA. Malignant pleural effusions. Sem Respir Med 1987; 9:
4353.
Naylor B, Schmidt RW. The case for exfoliative cytology of serous
effusions. Lancet 1964; i: 7112.
Melamed MR. The cytologic presentation of malignant lymphomas
in related diseases and effusions. Cancer 1963; 16: 41331.
Moriarty AT, Wiersema L, Snyder W, et al. Immunophenotyping of
cytologic specimens by ow cytometry. Diagn Cytopathol 1993; 9:
2528.
Kataria YP, Khurshid I. Adenosine deaminase in the diagnosis of
tuberculous pleural effusion. Chest 2001; 120: 3346.
Roth BJ. Searching for tuberculosis in the pleural space. Chest
1999; 116: 35.
Pettersson T, Kaarina O, Weber TH. Adenosine deaminase in the
diagnosis of pleural effusions. Acta Med Scand 1984; 215:
299304.
Lee YCG, Rogers JT, Rodriguez RM, et al. Adenosine deaminase
levels in nontuberculous lymphocytic pleural effusions. Chest
2001; 120: 35661.
Valdes L, San Jose E, Alvares D, et al. Diagnosis of tuberculous
pleurisy using the biologic parameters adenosine deaminase,
lysozyme, and interferon-gamma. Chest 1993; 103: 45865.
Ungerer JPJ, Oosthuizen HM, Retief JH, Bissbort SH. Signicance
of adenosine deaminase and its isoenzymes in tuberculous
effusions. Chest 1994; 106: 337.
Burgess LJ, Maritz FJ, Roux IL, Taljaard JJ. Use of adenosine
deaminase as a diagnostic tool for tuberculous pleurisy. Thorax
1995; 50: 6724.
Valdes L, Alvarez D, San Jose E, et al. Tuberculous pleurisy: a study
of 254 patients. Arch Intern Med 1998; 158: 201721.
Valdes L, Alvares D, San Jose E, et al. Value of adenosine
deaminase in the diagnosis of tuberculous pleural effusions in
young patients in a region of high prevalence of tuberculosis.
Thorax 1995; 50: 6003.
18
Pleural manometry
DAVID FELLER-KOPMAN, ARMIN ERNST
Introduction
Normal pleural pressure physiology
Denitions: lung entrapment versus trapped lung
Technique
Manometry in the clinical setting
Re-expansion pulmonary edema
227
227
228
229
229
230
INTRODUCTION
The rst measurements of intrapleural pressure (Ppl) during
the removal of pleural uid were made by the German
internist Heinrich Quincke in 1878.1 The clinical use of
pleural manometry gained favor in the early twentieth
century, when physicians would measure pleural pressure to
conrm entry into the pleural space while inducing pneumothorax for the treatment of tuberculosis. It was also noted
at that time that approximately 5 percent of patients would
develop unexpandable lung due to parenchymal or visceral
pleural scarring, with the formation of a pleural effusion ex
vacuo.2 The monitoring of pleural pressure, though interesting from a physiological standpoint in and of itself, can be
used clinically to minimize the pressure-related complications associated with thoracentesis including the
development of symptoms, such as chest discomfort3 and
re-expansion pulmonary edema, as well as to predict the
success of pleurodesis in patients with malignant effusions.4
Though the last three decades have seen a resurgence of
using pleural manometry in the care of patients, it remains
an underutilized technique. This chapter will review the
pressure physiology of the pleural space, and discuss the clinical application of manometry.
Pleurodesis
Symptoms
Conclusion
Key points
References
230
230
231
231
231
prior to the insertion of the device.10 Though there continues to be great debate between the two dominant theories
of normal pleural pressure physiology,10,11 these conceptual differences may only be of practical importance at the
termination of a thoracentesis, when there is only a physiological amount (58 mL) of pleural uid present. In the
presence of even a small effusion (several hundred milliliters), one can measure Ppl with a variety of techniques as
the viscous resistance to ow becomes negligible. The
pressure measured, therefore, is an accurate representation
of the hydrostatic pressure in the effusion at the level of the
catheter/transducer.
There has been some suggestion that when measuring
Ppl, the height of the manometer relative to the effusion is
insignicant.12 The reason for this was assumed to be that
as Pascals law states, in an enclosed system such as the
chest, pressure is transmitted equally in all directions and
will exert the same force equally on the lung, chest wall and
manometer, regardless of where the needle is inserted.
This is in contrast to an open system, where the only force
is that of gravity.12
More realistically, in a hydrothorax, a hydrostatic pressure gradient of 1 cmH2O/cm height is present, and so the
pressure read by the manometer represents the pressure at
a specic level, and not the pressure thoughout the
hydrothorax. With the removal of pleural uid and a
reduction in the height of the uid column above the
catheter, the inuence of the hydrostatic pressure gradient
becomes less. The measured Ppl therefore does depend on
where in the effusion the catheter is placed. Placing the
catheter at the most dependent part of the effusion has the
potential benets of (1) maximizing the amount of uid
that is able to be removed, and (2) minimizing the creation
of deformation forces from the contact of the catheter with
the lung. With this approach, the pressure measured at the
level of the catheter will reect the pressure in the pleural
space, and hence the pressure exerted on the lung and
chest wall, at that level (Figure 18.1).
4cm
6cm
10cm
TECHNIQUE
Pleural pressure can be measured via several techniques.
These include using a U-shaped water manometer,16 an
overdamped water manometer17 or sophisticated electronic transducer systems that allow sampling several
times a second as well as the ability to store data for further
analysis. A benet of the U-shaped manometer is the fact
that it is relatively inexpensive. A disadvantage, however, is
the fact that it may be difcult to accurately record values
due to the inspiratory and expiratory pleural pressure
swings. Electronic transducer systems can be congured to
standard monitors in the intensive care unit (ICU),
however, one needs to calibrate an offset as these monitors are not calibrated to measure negative pressure.
Additionally, ICU hemodynamic transducers report data
in mmHg, instead of the standard cmH2O typically used
for Ppl measurements. This problem is easily resolved by
adding the conversion factor of 1 mmHg = 1.36 cmH2O. A
distinct advantage of using an electronic transducer system
is the ability to examine the Ppl curves after the data has
been collected. This allows one to measure end inspiratory
and end expiratory, as well as mean Ppl. Though it is
unclear at this time which of these pressures is clinically
most important, it is likely that future studies will clarify
this issue. Most authors currently report mean or endexpiratory (i.e. FRC) Ppl. It may be, however, that end
inspiratory pressure is most related to the development of
complications such as re-expansion pulmonary edema
(RPE). Doelken et al.17 have recently described their use of
an overdamped water manometer that uses a 22ga needle
as a resistor, and have shown excellent correlation to the
electronic system (r = 0.97). The benets of this system are
that it is relatively easy to set up and it also provides realtime mean Ppl without the large respirophasic swings that
are encountered with systems that are not damped.
10
Pleural pressure (cmH2O)
0
10
20
30
40
50
400
ments in FVC, consistent with the physiology of unexpandable lung. That is to say, the lack of increase in lung
volume correlates with more negative pleural pressure.
Huggins and colleagues15 have recently described their
use of an air-contrast computed tomography (CT) scan
to visualize visceral pleural thickening and help dene the
cause of unexpandable lung in a group of 247 consecutive
patients undergoing pleural manometry during thoracentesis. They identied 11 patients with a clinical diagnosis of
trapped lung. All of these patients developed a mean Ppl of
less than 25 cmH2O and had prior pleural uid analysis
that was not suggestive of malignancy or pleural inammation. At the termination of the therapeutic thoracentesis, they instilled atmospheric air, a diagnostic
pneumothorax with the goal of raising the Ppl to a more
physiological mean of 5 cmH2O. A subsequent CT scan
conrmed visceral pleural thickening in all 11 patients. As
expected, all of these patients had a high pleural elastance
(Eps >19 cmH2O/L). The authors favor using the air-contrast CT as part of the diagnostic approach to patients with
trapped lung as a way of minimizing additional pleural
interventions that will be of little value, and in fact have
incorporated the diagnostic pneumothorax as part of
their routine protocol should patients develop signicantly
low Ppl and pleural uid is still present.
PLEURODESIS
For pleurodesis to be successful, the pleural surfaces need
to appose each other. If the lung is entrapped and does
not re-expand during thoracentesis, the odds of successful
pleurodesis are reduced. This fact is likely the single
largest confounder in the multiple studies comparing
pleurodesis agents, as documentation of lung re-expansion was used as a criteria prior to randomization in only
two studies.23,24 Lan and colleagues4 used pleural manometry to predict lung re-expansion and found that a pleural
space elastance of 19 cmH2O after the removal of 500
mL of pleural uid predicted pleurodesis failure. This is
clinically important, as patients with lung entrapment can
still achieve pleural palliation with a signicant reduction
in their dyspnea with the placement of a chronic
indwelling (PleurX) catheter,25 and one should not
attempt pleurodesis prior to documenting full lung
expansion by either manometry or imaging after complete
removal of pleural uid.
SYMPTOMS
The development of symptoms such as cough and chest
pain/discomfort is quite common during therapeutic thoracentesis. As most physicians do not currently perform
pleural manometry during thoracentesis, we investigated
the relationship of Ppl to patient symptoms as pleural uid
is removed.3 We measured end expiratory Ppl during therapeutic thoracentesis in 169 consecutive patients undergoing therapeutic thoracentesis. Symptoms developed in 17
percent of patients (cough in 6 percent and chest discomfort in 11 percent). We distinguished between the sensations of a sharp, ipsilateral pain that is typically felt over
the ipsilateral shoulder/scapula and another, more vague
References 231
CONCLUSION
In conclusion, pleural manometry provides a better
understanding of the underlying pleural pathophysiology
and aids the physician in both diagnostic and therapeutic
decisions. Measurement of Ppl can distinguish between
lung entrapment and trapped lung, allows for the safe
removal of large effusions and is a useful tool to select
appropriate patients with malignant pleural effusions for
pleurodesis. If formal manometry is not performed during
thoracentesis, the symptom of a vague chest discomfort
can be used as a surrogate for potentially dangerous drops
in pleural pressure.
KEY POINTS
REFERENCES
19
Radiology: diagnostic
FERGUS V GLEESON
Techniques
Normal anatomy
Pleural uid
Empyema
Tuberculous empyema
Malignant pleural effusions
Chylothorax and pseudochylothorax
233
234
236
240
242
242
243
TECHNIQUES
Chest radiography (CXR), ultrasound (US), computed
tomography (CT), multislice computed tomography
(MSCT), high-resolution computed tomography (HRCT),
magnetic resonance imaging (MRI) and positron emission
tomography combined with computed tomography (PETCT) may all be used to investigate pleural diseases.
Interestingly, except for MRI, all techniques are also able
to demonstrate normal pleural surfaces.
Chest radiography
Whenever possible, both posterioranterior (PA) and
lateral CXRs should be performed to assess the pleura.
Conventional high-kilovoltage and digital CXR may be
used. Additional lms may be of value, for example a lateral
decubitus CXR to demonstrate small volumes of uid,1 a
shoot-through lateral supine CXR to detect a pneumothorax in patients in the intensive care unit (ICU)2 and oblique
lms to conrm pleural thickening. However, oblique
views have mostly been replaced by CT and HRCT for this
purpose,3 and the increasing use of CT and US is replacing
the lateral supine CXR in the ICU. Supine CXRs are commonly performed in critically ill patients but are of less
value than an erect lm in the detection of uid and air.4
Ultrasound
Ultrasound, because of its low cost, ease of use and
portability, is commonly performed to assess pleural
Hemothorax
Focal pleural disease
Diffuse pleural disease
Air
Future directions
Key points
References
244
244
247
252
255
255
255
NORMAL ANATOMY
Chest radiography
Ultrasound
Normal pleura is seen as an echogenic stripe, the pleural
stripe (Figure 19.1), comprising both the opposing visceral and parietal layers, associated with distal reverberation echoes, because the pleura reects most of the
acoustic energy of the ultrasound beam. These distal reverberation artifacts, often described as comet tails, are produced by any small, highly reective object in the scanning
plane27 and manifest as an echogenic band extending from
the object into the deeper portions of the image.28 A
comet tail can be produced by different structures at the
pleural surface, such as small foreign bodies, foci of calcication and discrete air collections.
During respiration, small hypoechoic inhomogeneities
are seen to move at the pleural stripe, producing a shimmering movement described as the lung sliding sign.29
The comet tail and lung sliding signs disappear in the
presence of a pneumothorax.2931
Ultrasound is also able to assess the pleural surface of
the diaphragm in the normal individual.32 It is best
assessed in the right or left intercostal spaces between the
anteroaxillary and midaxillary lines to observe the zone of
apposition of the diaphragm 0.52 cm below the
costophrenic recess. On ultrasound, the diaphragm is seen
to consist of ve layers: two outer bright parallel lines representing the pleural and peritoneal membranes separated
from the bright layer of the diaphragm muscular layer by
hypoechoic layers of connective tissue on either side.32,33
Computed tomography
VISCERAL PLEURA: FISSURES AND JUNCTION LINES
PLEURAL FLUID
Chest radiography
POSTERIORANTERIOR AND LATERAL RADIOGRAPHS
Pleural uid
237
Large amounts of uid can be missed on a supine radiograph as the pleural uid layers posteriorly.40 On a supine
radiograph, approximately 175525 mL of uid is required
to cause blunting of the costophrenic angle and this
amount of uid may also cause a general increased haziness over the lower pulmonary zones or a density over the
apex.44 The presence of an apical cap occurs because the
apex is dependent in the supine position and so uid tends
to pool in this area.21 A normal supine radiograph does not
exclude an effusion. Several radiographic signs suggest the
presence of uid: increased homogeneous density over the
lung, an apical cap, blunting of the costophrenic sulcus,
elevation of the hemidiaphragm, accentuation of the horizontal ssure and reduced lower lobe vasculature.51
SUBPULMONARY EFFUSION
(b)
Figure 19.5 Fluid in the left oblique ssure simulating a mass
on both posterioranterior (a) and lateral chest radiography (b).
of attachment and, if malignant, may involve the underlying rib. If a loculated effusion is suspected, a decubitus lm
may demonstrate uid movement enabling differentiation
between a mass and uid. In addition, loculated effusions
may simulate a mass if they collect in the interlobar ssures or along the mediastinum. These are more frequently
right-sided and in the horizontal rather than the oblique
Pleural uid may also collect in a subpulmonary location.40 These effusions are often transudates associated
with cardiac, renal and hepatic failure. They can be unilateral or bilateral and tend to occur on the right side if unilateral.52 The main ndings include elevation of the
ipsilateral hemidiaphragm, attening of its medial aspect
and displacement of the peak of the diaphragm laterally,
with the contour on either side of the peak being straighter
than usual. The medial slope is gradual and the lateral one
is steep. These appearances are accentuated on expiration.
The costophrenic angle is often ill-dened, while both the
lateral and posterior angles may be well-dened. A further
way of distinguishing a subpulmonic effusion from a
normal effusion is by the apparent absence of vessels below
the hemidiaphragm owing to the absence of parenchymal
tissue passing below the hemidiaphragm on the PA radiograph.53 A subpulmonic effusion is more easily recognized on the left because of separation of the stomach
bubble from the apparent left hemidiaphragm.
Occasionally, a diaphragmatic spur will be seen if uid
enters the inferior accessory ssure. If uid extends into a
Ultrasound
Ultrasound is commonly used to further assess a pleural
effusion detected on a CXR.54,55 In addition to conrming
the presence or absence of suspected pleural uid, it may
be used to guide aspiration or chest-drain insertion.56,57
On ultrasound, uid is most frequently seen as an anechoic or hypoechoic collection, often delineated by the
echogenic line of visceral pleura and/or lung (Figure 19.6).
In addition to conrming an effusion, it may be possible to
distinguish between a transudative and exudative effusion.57,58 The internal echogenicity of pleural effusions can
be anechoic (non-complex), or echoic (complex) and
non-septated or septated, such that pleural uid appearances can range from anechoic to echoic and septated
(complex septated) (Figure 19.7).57 Transudates are always
anechoic, whereas an anechoic effusion can either be a
transudate or an exudate.58 Pleural effusions that are
complex septated, complex non-septated or homogeneously echogenic are always exudates. Thickened
pleura, a pleural nodule or an associated parenchymal
lesion detected in adjacent consolidated or atelectatic lung
are also indicative of an exudate.58 The detection of a
pleural nodule, commonly positioned on the diaphragm,
is strongly suggestive of malignancy (Figure 19.8); homogeneous echogenic effusions are mostly caused by a hemorrhagic effusion or an empyema.58
Other signs that may occur in patients with an effusion
include dynamic ap or swirl signs, often caused by consolidated or collapsed lung, debris attached to the chest
wall, or by movement of a septa within a loculated collection.59 Malignant pleural effusions are more likely to have
an echogenic swirling pattern secondary to respiratory
movement or cardiac pulsation than benign disease, but
Pleural uid
239
Computed tomography
The majority of patients with transudative or parapneumonic effusions can be managed with CXR and US. Noninfective exudative effusions such as those caused by
malignancy frequently require contrast-enhanced CT
either to aid in diagnosis or to help in clinical management
and follow-up.
Identication of pleural uid and its etiology is readily
performed with contrast-enhanced CT.71 When scanned
on MR images by very high signal intensity on both T1and T2-weighted images. In subacute or chronic
hematomas a concentric ring sign may be seen. This is
composed of an outer dark rim due to hemosiderin and a
bright center as a result of the shortening effects of methemoglobin.79
EMPYEMA
Chest radiography
Magnetic resonance imaging
Pleural uid returns low signal intensity on T1-weighted
images and a relatively high signal intensity on T2weighted images (Figure 19.13). Magnetic resonance may
be superior to CT in the differentiation of transudates and
exudates.78 Using a triple-echo pulse sequence and normalized MRI intensities, complex exudates have greater
signal intensity than simple exudates, which in turn are
brighter than transudates.40,78 Magnetic resonance also
allows differentiation of pleural effusion from parenchymal disease and from pleural tumor. Subacute and chronic
hemorrhage into the pleural space can also be recognized
Empyema 241
Computed tomography
Critically ill patients and those who for other reasons are
unsuitable for assessment by US may be imaged by contrast-enhanced CT. As with other exudative effusions,
pleural enhancement is seen.75,76 Parietal pleural
enhancement and thickening is readily visualized,
although visceral pleural enhancement, often adjacent to
consolidated or atelectatic lung, may not be appreciated.71,76,81 There is also an increase in thickening and
attenuation of the adjacent extraparietal pleural fat
(Figure 19.11).76 There is a trend for CT-detected pleural
thickening to increase with the stage of the effusion but
it is unfortunately not possible to predict outcome in this
regard.74 It has also been shown that marked pleural
thickening or pleural peel may completely resolve on
long-term follow-up.85
If a lung abscess is suspected from the CXR, then CT
may be used to conrm the diagnosis (Figure 19.14).43 As
on the CXR, pulmonary abscesses tend to be rounder than
empyemas and often make an acute angle with the chest
wall compared with the obtuse angle commonly seen in an
empyema on CT.81 In addition, the passive atelectasis
seen adjacent to the empyema, as a result of reduction in
hemithorax space, is not seen in patients with a pulmonary
abscess as these replace lung rather than displace it.
Pulmonary abscesses also tend to have signicantly thicker
walls than empyemas.
(a)
(b)
Ultrasound
Figure 19.14 Characteristic pulmonary abscess on computed tomography forming an acute angle with the right chest wall. (a) The
abscess on mediastinal windows. (b) The abscess on lung windows. Note the absence of signicant passive atelectasis.
TUBERCULOUS EMPYEMA
Ultrasound
As with parapneumonic effusions and empyema, malignant pleural effusions may be anechoic, echoic or complex
septated.58 The detection of a pleural or diaphragmatic
nodule appears specic for malignancy93,94 and if US is
used as an aid to thoracentesis, the assessment of the
diaphragmatic pleural surface is of value since the majority of patients with malignant effusions have associated
diaphragmatic pleural thickening that is detectable on US
(Figure 19.15).95 Pleural thickening outside the diaphragmatic surface may be difcult to detect on US.
Computed tomography
In patients with suspected malignant pleural effusion and
negative cytology on aspiration, contrast-enhanced CT is
the next most commonly performed investigation. As
with other causes of exudative effusions, pleural enhancement is commonly seen in patients with malignant effusions.75,92 This is commonly nodular or irregular, or has a
pleural thickness of >1 cm (Figure 19.16).95 Using these
criteria for assessment, contrast-enhanced CT has been
shown to have a sensitivity of >80 per cent and to be
highly specic in the evaluation of patients with suspected
malignant effusions.77,95 In addition, conrmation that
there is no apparent malignant cause for the effusion
appears reliable with CT.77 Further information such as
bone or liver metastases may also be apparent on scanning.77,90 The distribution of malignant pleural thickening
detected with CT appears to correlate with that seen at
thoracoscopy. The majority of patients have thickening,
which is either solely or maximally posteriorly and
basally. A secondary role for CT is the ability to either
directly or indirectly guide biopsy of a detected abnormality (Figure 19.17).96
Chest radiography
The appearance of malignant pleural effusions ranges from
an isolated non-loculated effusion of varying size to an
effusion with an associated pulmonary or mediastinal
mass. The presence of associated abnormalities on the
CXR will direct appropriate further investigation which, in
most instances, is contrast-enhanced CT. In the absence of
an abnormality other than the effusion, further imaging
will be directed by clinical history and examination, and
the results of aspiration cytology.
Computed tomography
Computed tomography may help to dene the cause of the
chylothorax that is not apparent on the CXR, such as
tumor compressing the thoracic duct.101 However, the CT
attenuation of the chyle is often indistinguishable from
other effusions because it is protein rich.
Lymphoscintigraphy
This technique uses 99mTc-sulphur microcolloid, antimony sulde colloid, stannous phytate, rhenium sulfur
colloid, human serum albumin or dextran injected subcutaneously between the toes and scanning 26 hours later.
Its use in investigating chylothorax has been limited to a
few case reports. It is able to demonstrate abnormal lymphatic drainage in the cases of chylothorax.102 It may be
possible to distinguish between lymphatic drainage and
transdiaphragmatic movement of chylous peritoneal uid
through the pleuroperitoneal canal by radioisotope migration speed. Overall, lymphoscintigraphy may be useful in
selecting those patients that would be suitable for surgery
and to assess the effects of surgery.102
HEMOTHORAX
Hemothorax usually results from trauma, although several
other conditions may be causative.103 On a standard radiograph the presence of rib fractures and a known clinical
history of trauma may help to distinguish a hemothorax
from a pleural effusion. A CT scan may also show areas of
active bleeding as foci of high attenuation (Figure
19.19).104 Loculation is frequently seen and brin bodies
may also form. The end stage of a hemothorax may result
in massive pleural thickening.
CHEST RADIOGRAPHY
COMPUTED RADIOGRAPHY
Lymphoma
Lymphomatous pleural masses are rare, with the more
usual manifestation of pleural disease being pleural effusion with pleural thickening or nodules in association with
disease elsewhere.
CHEST RADIOGRAPHY
Figure 19.23 Characteristically heterogeneously enhancing
right pleural broma on contrast enhanced computed
tomography.
(a)
CHEST RADIOGRAPHY
The radiographic appearance is of a smooth, uninterrupted pleural density extending over at least one-fourth
of the chest wall, often as a subtle increase in radiographic
density, with or without costophrenic angle obliteration.131
COMPUTED TOMOGRAPHY
(a)
(b)
Figure 19.26 Diffuse bilateral angular pleural thickening on
chest radiography (a) (arrows). Diffuse extensive pleural
thickening on computed tomography extending up to the
posterior mediastinal surfaces bilaterally but not onto them (b)
(arrows).
Spiral CT should be performed to assess the pleural thickening and also to assess the lungs and mediastinum. In differentiating malignant from benign pleural thickening the
most useful CT signs are: circumferential thickening (100
percent specicity); nodularity (94 percent specicity);
parietal pleural thickening >1 cm (94 percent specicity);
and mediastinal pleural involvement (88 percent specicity) (Figure 19.29).95 Using these CT features and
cutting needle biopsy provided a positive and negative predictive value of 100 percent.140 It has, however, been
shown that the presence of circumferential pleural thickening in the presence of a pleural effusion is less specic
for malignancy.77 Two reports suggest that MRI may be of
value in helping differentiate benign from malignant
disease (Figure 19.30).13,141 The use of contrast-enhanced
fat-saturated T1 sequences appears helpful in differentiating disease etiology in particular, by assessing focal thickening and enhancement of interlobar ssures.
(a)
(a)
Malignant mesothelioma
CHEST RADIOGRAPHY
The most common ndings of diffuse malignant mesothelioma (see Chapter 41, Malignant mesothelioma) are
irregular, nodular opacities around the periphery of the
lung with or without an associated pleural effusion.142,143
The effusion is usually unilateral and is present in 60
percent of patients, with only 5 percent of patients having
bilateral disease.144 The effusion may obscure underlying
pleural masses until thoracentesis is performed. The effusion is characteristically not associated with contralateral
shift of the mediastinum because of lung encasement by
the pleural tumor. The mediastinum is either centrally
located or may be shifted towards the affected side.139
However, large effusions may be associated with contralateral shift of the mediastinum. Volume loss on the affected
side may be demonstrated by narrowing of the intercostal
spaces, elevation of the hemidiaphragm or ipsilateral shift
of the mediastinum. Pleural masses without an associated
effusion are seen in less than 25 per cent of patients on
their initial radiograph.95
Evidence of previous asbestos exposure may also be
apparent on the radiograph, especially the presence of
benign calcied or noncalcied pleural plaques. However,
(b)
Figure 19.30 Coronal magnetic resonance imaging sequences
pre-(T1) (a) and post-gadolinium (fat-saturated T1) (b),
demonstrating the avid enhancement of right-sided pleural
malignancy (arrow).
Several studies have shown that CT is superior to radiography in the assessment of the presence and extent of
mesothelioma. The CT ndings of mesothelioma include
pleural thickening in 90 percent, extending into the interlobular ssures in 90 percent, pleural effusion in 70
percent, loss of volume of the affected hemithorax in 40
percent, pleural calcication in 20 percent and invasion of
the chest wall in up to 20 percent of patients.145
The CT features suggestive of mesothelioma are similar
to other causes of pleural malignancy described earlier.
However, the presence of calcication within the pleural
thickening suggests a benign process, with 10 percent of
patients with mesothelioma having evidence of pleural calcication compared with up to 50 per cent of patients with
benign pleural thickening.95,146
Although volume loss is often seen in mesothelioma it
is a relatively non-specic nding, since it is seen in both
benign and malignant disease.142,145
A benign pleural effusion (see Chapter 40, Asbestosrelated pleural diseases) may also occur in up to 3 percent
of the asbestos exposed population. The effusion is usually
unilateral and other manifestations of asbestos-related
disease may be present. Differentiation of a benign
asbestos effusion and asbestos-related mesothelioma can
be difcult, but benign asbestos-related disease tends to be
a symmetrical process and, on CT, pleural involvement is
bilateral in most patients.95 Also, as previously described,
malignant pleural disease tends to involve the entire
pleural surface whereas benign disease does not involve the
mediastinal pleura.95
Differentiation of mesothelioma from metastatic
disease is limited radiologically. The presence of hilar
adenopathy is more common in metastatic disease.95,147
True hilar involvement with no mediastinal involvement is
rare in metastatic pleural disease except for bronchogenic
carcinoma, lymphoma and renal cell carcinoma.
Unfortunately, the tendency for mesothelioma to involve
the inferior hemithorax appears non-specic.95 Rib
destruction and chest wall invasion are also good indicators of malignancy. Although rarely seen, infections such
as actinomycosis, tuberculosis and nocardiosis may cause
rib destruction but often at a single site rather than the
multiple sites often seen in malignancy.
Computed tomography not only has an important role
in diagnosis and staging but also in follow up.148 The
advent of new effective chemotherapeutic agents means
that the assessment of tumor response is now an important
criteria for both continuing chemotherapy and the evaluation of new therapies. Tumor response is assessed using
contrast enhanced CT and may be evaluated using either
the World Health Organisation (WHO)149 assessment criteria or now more commonly the Response Evaluation
Criteria in Solid Tumors (RECIST) guidelines.150,151
Difculties in accurate measurement of pleural thickening
on CT, and in accurately measuring the same area of thickening on sequential scans, make the measurements less
reliable than in other organs. Interobserver variability is a
further confounding factor and the use of automated or
semi-automated software may produce more consistent
methods for measurement in the future.148
Along with CT, MRI allows clear visualization of the circumferential pleural thickening, ssural thickening,
pleural effusion and diaphragmatic invasion. The full
extent of the tumor may be readily assessed on coronal and
sagittal images. Mesothelioma returns an intermediate
signal on T1-weighted images and an increased signal relative to the chest wall musculature on T2-weighted
images;13 it may also show avid pleural enhancement on
T1-weighted sequences post gadolinium, and this may be
of value in differentiating benign from malignant
disease.13,141 Additional ssural and diaphragmatic invasion detected by MRI appears reliable in differentiating
mesothelioma from other causes of malignant pleural
thickening.141 Although MRI offers no apparent advantages over contrast-enhanced MSCT in staging
disease,91,152 when performed as a dynamic contrast
enhanced examination it may be of value in predicting
response to chemotherapy, although PET-CT may also be
of value in this regard (see below).15
Although PET-CT is not routinely used in the investigation of mesothelioma, it has been shown to be of value in
providing prognostic information and assessing response
to chemotherapy in patients with mesothelioma (Figure
19.31).153 Tumours with a low standardized uptake value
are more likely to be epithelioid and to have a better prognosis. A reduction in metabolic activity post chemotherapy correlates with an increased time to progression and
increased survival. The pattern and measurement of metabolic activity may also correlate with the surgical stage. It
may also be more accurate than the other imaging modalities in detecting distant metastatic disease.154 In a study of
29 patients, PET-CT detected additional metastatic disease
not identied on clinical examination and CT scanning in
7 of 29 patients.154
Staging of mesothelioma
Using the recent international TNM staging system proposed by the International Mesothelioma Interest Group,
the CT and MR criteria for RESECTABILITY are as
follows:
1 Preserved extrapleural fat planes.
2 Normal CT attenuation values and MR signal intensity
characteristic of structures adjacent to the tumor.
3 Absence of extrapleural soft tissue masses.
4 Smooth inferior diaphragmatic surface.
The imaging criteria for UNRESECTABILITY are as
follows:
(a)
(b)
(c)
(d)
Figure 19.31 (a) Positron emission tomography (PET) scan and (b) PET-computed tomography (CT) scan demonstrating high grade FDG
activity (arrowed) in sarcomatoid mesothelioma, with circumferential pleural thickening. (c) PET scan and (d) integrated PET-CT scan
demonstrating epithelioid mesothelioma (arrowed), with low grade uorodeoxyglucose (FDG) activity, associated with pleural effusion.
(For (b) and (d), see also Color Plates 11 and 12.)
1
2
3
4
Computed tomography and MR cannot easily distinguish between stages T1a, T1b and T2 as they cannot easily
distinguish the parietal and visceral pleura or detect
diaphragmatic muscle invasion. They can, however, enable
distinction of stage 3 from stage 4.91,155,156
AIR
Pneumothorax
CHEST RADIOGRAPHY
The majority of pneumothoraces are identied on a standard PA CXR taken on inspiration.157,158 Routinely, only
Air
(a)
(a)
(b)
(b)
Figure 19.32 Left upper lobe bulla on chest radiography
(arrow), (a) readily differentiated from an apical left
pneumothorax with abnormal lung (arrow) by its concave
surface (b).
253
between 25 and 40 percent of patients with a pneumothorax post lung-biopsy not detected by CXR but present
on CT (Figure 19.36).158 Several studies have also shown
that CT is superior to a supine radiograph in the detection of a pneumothorax, with up to 50 percent of pneumothoraces detected only by CT.158,165,174 In those
patients where the pneumothorax is secondary to trauma,
CT scanning may also demonstrate other signs such as
parenchymal contusion, inltrates, pneumatoceles and
pericardial effusion.
Bronchopleural stula
CHEST RADIOGRAPHY
The radiographic features commonly reect the underlying etiology (e.g. post pneumonectomy, empyema, etc.). If
a bronchopleural stula arises as a complication following
a recent pneumonectomy, several signs are demonstrated
on the CXR. These include an increase in the amount of air
in the operated hemithorax, a decreased amount of uid,
loss of the normal mediastinal shift toward the operated
side and, occasionally, an aspiration pneumonitis. The
clinico-radiographic features usually enable a diagnosis. If
clinical doubt persists, then CT175 or ventilation scanning
may be diagnostic (Figure 19.37).176
COMPUTED TOMOGRAPHY
Computed tomography is the optimal way of demonstrating the communication between the lung or airway
and the pleural space. Thin-section CT may be required
to determine the location, size and number of stulas.175
In addition to demonstrating stulas, CT may provide
additional diagnostic information such as tumor recurrence.
References 255
REFERENCES
FUTURE DIRECTIONS
The proven value of US and CT in the assessment of
patients with pleural disease has inevitably led to an
increase in their clinical use. The decreased cost of portable
US machines has led to an explosion in its use and a move
away from its provision by radiologists. The advent of
MSCT has also enabled CT scans to be performed on
patients previously thought unt to scan. The advent of
PET-CT has also opened the door to the use of PET scanning in patients with pleural malignancy. Increasingly
these tests are being used not only in diagnosis and staging,
but also to guide therapeutic decisions and are being investigated as surrogate markers of function and morphology.
It is perhaps their role as surrogate biomarkers of disease
that is the next and most exciting step in their use.
KEY POINTS
27. Goodman TR, Traill ZC, Phillips AJ, Berger J, Gleeson FV. Ultrasound
detection of pneumothorax. Clin Radiol 1999; 54: 7369.
28. Sistrom CL, Reiheld CT, Gay SB, Wallace KK. Detection and
estimation of the volume of pneumothorax using real-time
sonography: efcacy determined by receiver operating
characteristic analysis. Am J Roentgenol 1996; 166: 31721.
29. Lichtenstein DA, Menu Y. A bedside ultrasound sign ruling out
pneumothorax in the critically ill. Lung sliding. Chest 1995; 108:
13458.
30. Wernecke K, Galanski M, Peters PE, et al. Pneumothorax:
evaluation by ultrasound-preliminary results. Thorac Imaging
1987; 2: 768.
31. Targhetta R, Bourgeois JM, Chavagneux R, et al. Ultrasonic signs
of pneumothorax: preliminary work. J Clin Ultrasound 1993; 21:
24550.
32. Ueki J, De Bruin PF, Pride NB. In vivo assessment of diaphragm
contraction by ultrasound in normal subjects. Thorax 1995; 50:
115761.
33. McCool FD, Benditt JO, Conomos P, et al. Variability of diaphragm
structure among healthy individuals. Am J Respir Crit Care Med
1997; 155: 13238.
34. Proto AV, Ball JB. Computed tomography of the major and minor
ssures. Am J Roentgenol 1983; 140: 43948.
35. Marks BW, Kuhns LR. Identication of the pleural ssures with
computed tomography. Radiology 1982; 143: 13941.
36. Webb RW, Muller NL, Naidich DP. High resolution CT of the lung,
2nd edn. Philadelphia: Lippincott, Williams and Williams, 1996.
37. Im J-G, Webb WR, Rosen A, Gamsu G. Costal pleura: appearances
at high-resolution CT. Radiology 1989; 171: 12531.
38. Vix VA. Extrapleural costal fat. Radiology 1974; 112: 5635.
39. Sargent EN, Boswell WD, Ralls PW, Markovitz A. Subpleural fat
pads in patients exposed to asbestos: distinction from noncalcied pleural plaques. Radiology 1984; 152: 2737.
40. Mueller NL. Imaging of the pleura. Radiology 1993; 186: 297309.
41. Collins JD, Burwell D, Furmanski S, Lorber P, Steckel RJ. Minimal
detectable pleural effusions. Radiology 1972; 105: 513.
42. Blackmore CC, Black WC, Dallas RV, Crow HC. Pleural uid volume
estimation: a chest radiograph prediction rule. Acad Radiol 1996;
3: 1039.
43. Davis S, Gardner Q. The shape of a pleural effusion. Br Med J
1963; 26: 4367.
44. Henschke CI, Davis SD, Romano PM, Yankelevitz DF. Pleural
effusions: pathogenesis, radiologic evaluation, and therapy. J
Thorac Imag 1989; 4: 4960.
45. Oestreich AE, Haley C. Pleural effusion: the thorn sign. Chest
1981; 79: 3656.
46. Fleischner FG. Atypical arrangement of free pleural effusion.
Radiol Clin North Am 1963; 1: 34762.
47. Maher GG, Berger HW. Massive pleural effusion: malignant and
non-malignant causes in 46 patients. Am Rev Respir Dis 1972;
105: 45860.
48. Liberson M. Diagnostic signicance of the mediastinal prole in
massive unilateral pleural effusions. Am Rev Respir Dis 1963; 88:
17680.
49. Mulvey RB. The effect of pleural uid on the diaphragm. Am J
Roentgenol 1965; 84: 10805.
50. Yousef MMA. Case of the fall season. Semin Roentgenol 1980; 15:
26971.
51. Ruskin JA, Gurney JW, Thorsen MK, Goodman LR. Detection of
pleural effusions on supine chest radiographs. Am J Roentgenol
1987; 148: 6813.
52. Petersen JA. Recognition of infrapulmonary pleural effusion.
Radiology 1960; 74: 3441.
53. Schwartz MI, Marmorstein BL. A new radiologic sign of
subpulmonic effusion. Chest 1975; 67: 1768.
54. Eibenberger KL, Dock WI, Ammann ME, et al. Quantication of
pleural effusions: sonography versus radiography. Radiology 1994;
191: 6814.
References 257
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
129.
20
Radiology: interventional
EDITH M MAROM, JEREMY J ERASMUS, EDWARD F PATZ JR
Introduction
Pre-procedure preparation
Selection of imaging guidance
Thoracentesis
Tube thoracostomy
259
259
259
260
260
INTRODUCTION
Abnormalities of the pleura and pleural space are caused
by a variety of disorders including infection, trauma,
inammation and neoplasms. Although some patients can
be managed conservatively, interventional procedures
including pleural uid aspiration with or without placement of a drainage catheter, or pleural biopsies are frequently performed for either diagnostic or therapeutic
purposes. The type of intervention depends on a spectrum
of clinical and imaging features including symptoms,
extent of disease and the etiology of the pleural abnormality. This review discusses the more common transthoracic
interventional procedures that are used to diagnose and
treat pleural disease, including thoracentesis, pleural
catheter placement and pleural biopsy.
PRE-PROCEDURE PREPARATION
Before any procedure is performed, the indications, contraindications, management issues including goals and
risks of the procedure should be reviewed. These risks and
benets should be explained in detail to the patient and
informed consent obtained. Although laboratory blood
work including platelet count, prothrombin time and
international normalization ratio (INR) are typically performed, in the absence of a known bleeding diathesis or
blood dyscrasia, the true utility of such tests has not been
clearly determined. Most institutions suggest a relative
contraindication to pleural intervention are patients with a
platelet count <50 000, prothrombin time >3 seconds
above control or an INR of >1.5.
Pleural biopsy
Conclusions and future directions
Key points
References
266
267
267
267
TUBE THORACOSTOMY
Catheter thoracostomy is usually used to manage patients
with malignant pleural effusions, parapneumonic effusions or empyemas, and pneumothoraces.
TECHNIQUE
(a)
(b)
(c)
(a)
(b)
(c)
Figure 20.2 Forty-two-year-old woman presents with cough
and fever. (a) Frontal chest radiograph demonstrates a poorly
dened opacity in the left base. (b) Lateral radiograph suggests
this posterior opacity is in the pleural space. (c) Axial computed
tomography image conrms a posterior uid collection.
(d) Follow-up chest radiograph 2 days after the pig-tail chest
tube shows almost complete resolution of the infected collection.
(d)
(a)
Pneumothorax
Imaging can be used to place a chest catheter in patients
with a symptomatic pneumothorax, or in high-risk
patients with a small, but expanding pneumothorax. It is
very useful in patients with lung or pleural disease and a
loculated pneumothorax that requires a chest tube.
Although pneumothoraces are not uncommon after
transthoracic needle aspiration biopsies of the lung (up to
61 percent),108118 or transbronchial biopsy, chest catheter
placement is typically only performed when patients are
symptomatic or when the pneumothorax is increasing in
size96,112,119,120 (Figure 20.3). Success rates of small-bore
catheters (710 F) is high (8797 percent) with most pneumothoraces resolving within 2472 hours following
catheter insertion.112,121,122 The treatment of a pneumothorax with a small-bore catheter has a similar success rate
to that of large-bore chest tube drainage. Lack of response
is usually due to technical factors (catheter malposition
and occlusion) or a very large air leak.112,121,123,124
TECHNIQUE
Imaging-assisted guidance is chosen according to availability and the clinical scenario: if the pneumothorax
(b)
Figure 20.3 Fifty-seven-year-old man with a right upper lobe nodule presents for percutaneous biopsy. (a) Chest lm immediately
following the biopsy shows the poorly dened right nodule (curved arrow) and a right pneumothorax (straight arrow). (b) Follow-up chest
lm after the pig-tail catheter shows almost complete resolution of the pneumothorax.
PLEURAL BIOPSY
Infections, inammation and neoplasms of the pleura can
manifest as diffuse or focal pleural abnormalities. When
there is an accompanying effusion, thoracentesis may be
diagnostic. However, a pleural biopsy is often required to
establish a diagnosis as the yield from thoracentesis in
some diseases, including tuberculosis or malignancy, is less
than optimal.131 In some cases, cytological evaluation of
specimens obtained from transthoracic needle aspiration
may be ambiguous, such as seen with benign disease, or it
may be difcult to distinguish reactive mesothelial cell
hyperplasia from metastatic adenocarcinoma and
mesothelioma.132135 Thus, depending on the clinical scenario, a core-needle biopsy that can obtain larger tissue
samples may be required.133 These larger core specimens
can be obtained using Cope or Abrams biopsy needles
without imaging-assisted guidance, although imagingassisted biopsy has a higher diagnostic yield. For instance,
by using ultrasound guidance, the conrmation of tuberculous pleural involvement increases from 20 to 86
percent when compared with procedures performed
without imaging-assisted guidance. Similarly, for patients
with either primary or metastatic pleural disease, the use of
ultrasound or CT increases the diagnostic rate.136,137 In
rare cases, additional tissue is needed for special pathology
stains and analysis, and video-assisted thoracoscopic
surgery (VATS) may be necessary.138 In one comparative
study, the diagnostic sensitivity of VATS for mesothelioma
was 94 percent, compared with 86 percent for image
guided core needle biopsy, but the procedure requires that
the visceral and parietal pleurae not be adherent.139 A
further disadvantage is that chest wall seeding occurs in 22
percent of surgical biopsies as compared with only 4
percent in image guided core needle biopsy.139 This
seeding along the needle tract can be eliminated by treating the region of biopsy with radiotherapy.140
Technique
Large pleural masses can usually be biopsied under uoroscopic guidance, but ultrasound and CT are usually used.
The needle insertion site should be selected to avoid traversing lung or vessels. In this regard, it is best to place the
needle parallel to a small pleural abnormality (rather than
perpendicular), to enable adequate needle manipulation at
the time of biopsy without violation of the visceral pleura.
A coaxial biopsy needle may be used so that multiple specimens can be obtained if necessary. The outer sheath is
introduced to the level of the parietal pleural. Multiple
specimens are then obtained with an automated cutting
References 267
KEY POINTS
REFERENCES
1. Mathisen DJ. A surgeons view of interventional radiology in
general thoracic surgery patients. Semin Intervent Radiol 1991; 8:
857.
2. Light RW. Pleural diseses, 3rd ed. Baltimore: Williams and Wilkins,
1995.
3. Raptopoulos V, Davis LM, Lee G, et al. Factors affecting the
development of pneumothorax associated with thoracentesis. AJR
Am J Roentgenol 1991; 156: 91720.
4. Seneff MG, Corwin RW, Gold LH, Irwin RS. Complications
associated with thoracocentesis. Chest 1986; 90: 97100.
5. Grogan DR, Irwin RS, Channick R, et al. Complications associated
with thoracentesis. A prospective, randomized study comparing
three different methods. Arch Intern Med 1990; 150: 8737.
6. Collins TR, Sahn SA. Thoracocentesis. Clinical value, complications,
technical problems, and patient experience. Chest 1987; 91:
81722.
7. Jones PW, Moyers JP, Rogers JT, et al. Ultrasound-guided
thoracentesis: is it a safer method? Chest 2003; 123: 41823.
8. Kohan JM, Poe RH, Israel RH, et al. Value of chest ultrasonography
versus decubitus roentgenography for thoracentesis. Am Rev
Respir Dis 1986; 133: 11246.
9. Ong KC, Indumathi V, Poh WT, Ong YY. The diagnostic yield of
pleural uid cytology in malignant pleural effusions. Singapore
Med J 2000; 41: 1923.
10. Anderson CB, Philpott GW, Ferguson TB. The treatment of
malignant pleural effusions. Cancer 1974; 33: 91622.
11. Bruneau R, Rubin P. The management of pleural effusions and
chylothorax in lymphoma. Radiology 1965; 85: 108592.
12. Fracchia AA, Knapper WH, Carey JT, Farrow JH. Intrapleural
chemotherapy for effusion from metastatic breast carcinoma.
Cancer 1970; 26: 6269.
13. Johnston WW. The malignant pleural effusion. A review of
cytopathologic diagnoses of 584 specimens from 472 consecutive
patients. Cancer 1985; 56: 9059.
14. Sahn SA. Pleural effusion in lung cancer. Clin Chest Med 1993; 14:
189200.
15. Chernow B, Sahn SA. Carcinomatous involvement of the pleura: an
analysis of 96 patients. Am J Med 1977; 63: 695702.
16. Tattersall M. Pleural effusions. Curr Opin Oncol 1992; 4: 6426.
17. Hausheer FH, Yarbro JW. Diagnosis and treatment of malignant
pleural effusion. Semin Oncol 1985; 12: 5475.
18. Seaton KG, Patz EF Jr, Goodman PC. Palliative treatment of
malignant pleural effusions: value of small-bore catheter
thoracostomy and doxycycline sclerotherapy. AJR Am J Roentgenol
1995; 164: 58991.
19. Andrews CO, Gora ML. Pleural effusions: pathophysiology and
management. Ann Pharmacother 1994; 28: 894903.
20. Kennedy L, Sahn SA. Talc pleurodesis for the treatment of
pneumothorax and pleural effusion. Chest 1994; 106:
121522.
21. Clementsen P, Evald T, Grode G, et al. Treatment of malignant
pleural effusion: pleurodesis using a small percutaneous catheter.
A prospective randomized study. Respir Med 1998; 92: 5936.
22. Parulekar W, Di Primio G, Matzinger F, Dennie C, Bociek G. Use of
small-bore vs large-bore chest tubes for treatment of malignant
pleural effusions. Chest 2001; 120: 1925.
23. Goff BA, Mueller PR, Muntz HG, Rice LW. Small chest-tube
drainage followed by bleomycin sclerosis for malignant pleural
effusions. Obstet Gynecol 1993; 81: 9936.
24. Morrison MC, Mueller PR, Lee MJ, et al. Sclerotherapy of
malignant pleural effusion through sonographically placed smallbore catheters. AJR Am J Roentgenol 1992; 158: 413.
25. OMoore PV, Mueller PR, Simeone JF, et al. Sonographic guidance
in diagnostic and therapeutic interventions in the pleural space.
AJR Am J Roentgenol 1987; 149: 15.
26. Marom EM, Patz EF Jr, Erasmus JJ, et al. Malignant pleural
effusions: treatment with small-bore-catheter thoracostomy and
talc pleurodesis. Radiology 1999; 210: 27781.
27. Parker LA, Charnock GC, Delany DJ. Small bore catheter drainage
and sclerotherapy for malignant pleural effusions. Cancer 1989;
64: 121821.
50. McLeod DT, Calverley PM, Millar JW, Horne NW. Further
experience of Corynebacterium parvum in malignant pleural
effusion. Thorax 1985; 40: 51518.
51. Millar JW, Hunter AM, Horne NW. Intrapleural immunotherapy
with Corynebacterium parvum in recurrent malignant pleural
effusions. Thorax 1980; 35: 8568.
52. Moffett MJ, Ruckdeschel JC. Bleomycin and tetracycline in
malignant pleural effusions: a review. Semin Oncol 1992; 19(2
Suppl 5): 5962; discussion 623.
53. Ostrowski MJ, Halsall GM. Intracavitary bleomycin in the
management of malignant effusions: a multicenter study. Cancer
Treat Rep 1982; 66: 19037.
54. Ostrowski MJ. An assessment of the long-term results of
controlling the reaccumulation of malignant effusions using
intracavity bleomycin. Cancer 1986; 57: 7217.
55. Paladine W, Cunningham TJ, Sponzo R, et al. Intracavitary
bleomycin in the management of malignant effusions. Cancer
1976; 38: 19038.
56. Pearson FG, MacGregor DC. Talc poudrage for malignant pleural
effusion. J Thorac Cardiovasc Surg 1966; 51: 7328.
57. Robinson LA, Fleming WH, Galbraith TA. Intrapleural doxycycline
control of malignant pleural effusions. Ann Thorac Surg 1993; 55:
111521; discussion 212.
58. Ruckdeschel JC, Moores D, Lee JY, et al. Intrapleural therapy for
malignant pleural effusions. A randomized comparison of
bleomycin and tetracycline. Chest 1991; 100: 152835.
59. Rusch VW, Figlin R, Godwin D, Piantadosi S. Intrapleural cisplatin
and cytarabine in the management of malignant pleural effusions:
a Lung Cancer Study Group trial. J Clin Oncol 1991; 9: 31319.
60. Sorensen PG, Svendsen TL, Enk B. Treatment of malignant pleural
effusion with drainage, with and without instillation of talc. Eur J
Respir Dis 1984; 65: 1315.
61. Trotter JM, Stuart JFB, McBeth F, et al. The management of
malignant effusions with bleomycin. Br J Cancer 1979; 40: 310.
62. Webb HE, Oaten SW, Pike CP. Treatment of malignant ascitic and
pleural effusion with Corynebacterium parvum. Br Med J 1978; 1:
33840.
63. Yasumoto K, Ogura T. Intrapleural application of recombinant
interleukin-2 in patients with malignant pleurisy due to lung
cancer. A multi-institutional cooperative study. Biotherapy 1991;
3: 3459.
64. Zimmer PW, Hill M, Casey K, Harvey E, Low DE. Prospective
randomized trial of talc slurry vs bleomycin in pleurodesis for
symptomatic malignant pleural effusions. Chest 1997; 112:
4304.
65. Patz EF Jr, McAdams HP, Goodman PC, Blackwell S, Crawford J.
Ambulatory sclerotherapy for malignant pleural effusions.
Radiology 1996; 199: 1335.
66. van den Toorn LM, Schaap E, Surmont VF, et al. Management of
recurrent malignant pleural effusions with a chronic indwelling
pleural catheter. Lung Cancer 2005; 50: 1237.
67. Pollak JS, Burdge CM, Rosenblatt M, et al. Treatment of malignant
pleural effusions with tunneled long-term drainage catheters. J
Vasc Interv Radiol 2001; 12: 2018.
68. Pien GW, Gant MJ, Washam CL, Sterman DH. Use of an
implantable pleural catheter for trapped lung syndrome in patients
with malignant pleural effusion. Chest 2001; 119: 16416.
69. Putnam JB Jr, Walsh GL, Swisher SG, et al. Outpatient
management of malignant pleural effusion by a chronic indwelling
pleural catheter. Ann Thorac Surg 2000; 69: 36975.
70. Putnam JB Jr, Light RW, Rodriguez RM, et al. A randomized
comparison of indwelling pleural catheter and doxycycline
pleurodesis in the management of malignant pleural effusions.
Cancer 1999; 86: 19929.
71. Musani AI, Haas AR, Seijo L, Wilby M, Sterman DH. Outpatient
management of malignant pleural effusions with small-bore,
tunneled pleural catheters. Respiration 2004; 71: 55966.
72. Tremblay A, Michaud G. Single-center experience with 250
References 269
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120. Rhea JT, DeLuca SA, Greene RE. Determining the size of
pneumothorax in the upright patient. Radiology 1982; 144:
7336.
121. Conces DJ Jr, Tarver RD, Gray WC, Pearcy EA. Treatment of
pneumothoraces utilizing small caliber chest tubes. Chest 1988;
94: 557.
122. Casola G, vanSonnenberg E, Keightley A, et al. Pneumothorax:
radiologic treatment with small catheters. Radiology 1988; 166:
8991.
123. Reinhold C, Illescas FF, Atri M, Bret PM. Treatment of pleural
effusions and pneumothorax with catheters placed percutaneously
under imaging guidance. AJR Am J Roentgenol 1989; 152:
118991.
124. Peters J, Kubitschek KR. Clinical evaluation of a percutaneous
pneumothorax catheter. Chest 1984; 86: 71417.
125. Erasmus JJ, Goodman PC, Patz EF Jr. Management of malignant
pleural effusions and pneumothorax. Radiol Clin North Am 2000;
38: 37583.
126. Tarver RD, Conces DJ Jr. Chest intervention: drainage and biopsies.
In: Castaneda-Zuniga WR, Tadavarthy SM (eds). Interventional
radiology, 2nd ed. Baltimore: Williams & Wilkins; 1997: 135781.
127. Alfageme I, Moreno L, Huertas C, et al. Spontaneous
pneumothorax. Long-term results with tetracycline pleurodesis.
Chest 1994; 106: 34750.
128. Janzing HM, Derom A, Derom E, et al. Intrapleural quinacrine
instillation for recurrent pneumothorax or persistent air leak. Ann
Thorac Surg 1993; 55: 36871.
129. Milanez JR, Vargas FS, Filomeno LT, et al. Intrapleural talc for the
prevention of recurrent pneumothorax. Chest 1994; 106:
11625.
130. Perlmutt LM, Braun SD, Newman GE, et al. Transthoracic needle
aspiration: use of a small chest tube to treat pneumothorax. AJR
Am J Roentgenol 1987; 148: 84951.
131. Jay SJ. Diagnostic procedures for pleural disease. Clin Chest Med
1985; 6: 3348.
132. Diacon AH, Theron J, Schubert P, et al. Ultrasound-assisted
transthoracic biopsy: ne-needle aspiration or cutting-needle
biopsy? Eur Respir J 2007; 29: 35762.
133. Miller BH, Rosado-de-Christenson ML, Mason AC, et al. From the
archives of the AFIP. Malignant pleural mesothelioma: radiologic
pathologic correlation. Radiographics 1996; 16: 61344.
134. McCaughey WT, Al-Jabi M. Differentiation of serosal hyperplasia
and neoplasia in biopsies. Pathol Annu 1986; 21: 27193.
135. Chan JK, Loo KT, Yau BK, Lam SY. Nodular histiocytic/mesothelial
hyperplasia: a lesion potentially mistaken for a neoplasm in
transbronchial biopsy. Am J Surg Pathol 1997; 21: 65863.
136. Heilo A, Stenwig AE, Solheim OP. Malignant pleural mesothelioma:
US-guided histologic core-needle biopsy. Radiology 1999; 211:
6579.
137. Metintas M, Ozdemir N, Isiksoy S, et al. CT-guided pleural needle
biopsy in the diagnosis of malignant mesothelioma. J Comput
Assist Tomogr 1995; 19: 3704.
138. Boutin C, Rey F. Thoracoscopy in pleural malignant mesothelioma:
a prospective study of 188 consecutive patients. Part 1: Diagnosis.
Cancer 1993; 72: 38993.
139. Agarwal PP, Seely JM, Matzinger FR, et al. Pleural mesothelioma:
sensitivity and incidence of needle track seeding after imageguided biopsy versus surgical biopsy. Radiology 2006; 241:
58994.
140. West SD, Foord T, Davies RJ. Needle-track metastases and
prophylactic radiotherapy for mesothelioma. Respir Med 2006;
100: 103740.
141. Scott EM, Marshall TJ, Flower CD, Stewart S. Diffuse pleural
thickening: percutaneous CT-guided cutting needle biopsy.
Radiology 1995; 194: 86770.
142. Andriole JG, Haaga JR, Adams RB, Nunez C. Biopsy needle
characteristics assessed in the laboratory. Radiology 1983; 148:
65962.
143. Haaga JR, LiPuma JP, Bryan PJ, Balsara VJ, Cohen AM. Clinical
comparison of small-and large-caliber cutting needles for biopsy.
Radiology 1983; 146: 6657.
144. Matsumori Y, Yano S, Goto H, et al. ZD6474, an inhibitor of
vascular endothelial growth factor receptor tyrosine kinase,
inhibits growth of experimental lung metastasis and production of
malignant pleural effusions in a non-small cell lung cancer model.
Oncol Res 2006; 16: 1526.
21
Radiology: pleural ultrasound
COENRAAD FN KOEGELENBERG, CHRIS T BOLLIGER, ANDREAS DIACON
Introduction
An approach to thoracic ultrasonography
Diagnostic thoracic ultrasonography
Ultrasound-guided interventions
271
271
273
280
INTRODUCTION
Although the introduction of diagnostic sonography of the
abdomen dates back to the late 1940s, ultrasonography of
the thorax lagged behind by many decades. The inability of
ultrasound (US) to penetrate aerated tissue has diverted
chest physicians from recognizing its excellent ability to
visualize the chest wall, pleura and pathology of lung abutting the pleura. The major advantages of thoracic US
include its dynamic properties, low cost, lack of radiation,
mobility and short examination time.16 It is also well
suited for use in intensive care units, where suboptimal
conditions for radiography make the diagnosis of clinically
signicant thoracic abnormalities difcult.3 Furthermore,
US of the chest is increasingly being used to guide interventional procedures, such as thoracentesis, biopsies of the
chest wall, pleura or abutting lung and the placement of
intercostal drains. The indications for pleural and chest
wall US are summarized in Table 21.1. The main aim of
this chapter is to demystify ultrasonography for the chest
physician by reviewing the basic principles and techniques
from the perspective of the non-radiologist.
Conclusions
Acknowledgements
Key points
References
281
281
282
282
4
5
6
7
8
AN APPROACH TO THORACIC
ULTRASONOGRAPHY
Adapted with permission from: Tsai TH, Yang PC. Ultrasound in the
diagnosis and management of pleural disease. Curr Opin Pulm Med 2003;
9: 28290.
Technical principles
Ultrasounds are acoustic waves with a frequency above
human hearing. Most US scanners operate in the frequency range of 215 megahertz (MHz). A very basic
understanding of how the US scanner employs these ultra-
sound is focused in the transducer and is efciently transmitted into the thorax. Ultrasound waves are propagated
in liquid media (e.g. pleural effusions) or in tissues with a
high water content (e.g. muscle, liver, consolidated lung or
tumors), but are reected off interfaces between dissimilar
densities (e.g. gas or bone). If the US encounters gas (e.g.
normal aerated lungs or a pneumothorax) or solids (e.g.
ribs), the density difference is so great that most of the
acoustic energy is reected. This phenomenon is known as
acoustical impedance and explains why structures deeper
than the visceral pleura are invisible by means of ultrasonography in the non-diseased state.
The reected part of the sound waves is detected as an
echo. The time delay between emitted US and the received
echo is used to calculate the depth of the structure causing
the reection. Furthermore, the greater the difference
between acoustic impedances, the larger the echo will be.
The transducer captures sound waves returning to the
probe and converts these echoes into electrical pulses,
which are ultimately processed and transformed into a
digital image. The intensity and distribution of the pixels
appearing on the screen is determined by three characteristics of the echo, namely (1) its direction, (2) its intensity
and (3) the time elapsed from emission to capture. Images
may contain hyperechoic or white areas caused by highamplitude echoes and hypoechoic or dark areas from
low-amplitude echoes.
Patient positioning
The optimal patient position for scanning is a paramount
but under-appreciated aspect. Sonographic access to the
chest can be achieved via the abdomen, intercostal spaces
or the upper thoracic aperture (supraclavicular fossa). It is
important to review a patients chest radiograph and computed tomography (CT) scan prior to performing a chest
US examination. This will not only identify the area of
interest, but will also guide the positioning of the patient.
The posterior chest is best scanned with the patient in the
sitting position using a bedside table as an armrest (Figure
21.1a,b), whereas the lateral and anterior chest wall can be
examined with the patient in either the lateral decubitus or
even supine position (Figure 21.1c). Maximum visualization of the lung and pleura is achieved by examining along
the intercostal spaces. Raising the arm above the patients
head increases the intercostal space distance and facilitates
scanning in erect or recumbent positions. A patient can
fold the arms across the chest in order to displace the
scapulae when surveying the upper posterior thorax.
Superior sulcus pathology can be visualized apically with
the patient in the supine or sitting position.
Scanning
Once the patient is adequately positioned and the area of
interest is identied, liberal application of gel is the nal
step before scanning. It is advisable to hold the probe like
a pen for writing on paper, and not like chalk for writing
on a blackboard (Figure 21.1b). Experienced sonographers
keep their eyes on the screen while their hand moves the
probe across the area of interest and provides the posi-
(a)
(b)
(c)
(a)
(c)
(b)
Pleural effusions
SONOGRAPHIC DIAGNOSIS
The value of ultrasonography for detection and quantication of pleural effusions is uncontested. Ultrasound is particularly helpful in determining the nature of localized or
diffuse pleural opacities, and is more sensitive than decubitus expiratory lms in identifying minimal or loculated
effusions.8 Sonographically, a pleural effusion appears as
an anechoic, homogeneous space between parietal and visceral pleura (Figure 21.3). This space may change in shape
with respiration, and the atelectatic lung inside a large
effusion may appear as a tongue-like structure within the
effusion. In inammatory effusions, adhesions between
the two pleural surfaces may result in the absence of lung
motion above the effusion. If an abnormal elevation of a
hemidiaphragm is noted on the chest radiograph, subpulmonary effusion can be differentiated from a subphrenic
uid collection or diaphragm paralysis.9
DETERMINING THE NATURE OF A PLEURAL EFFUSION
To distinguish small effusions from anechoic pleural thickening can be challenging. Both may appear as anechoic on
US. Nearly 20 percent of echo-free pleural lesions will not
yield free uid, whereas a signicant percentage of
complex-appearing lesions will do so. Mobility is a good
sign for effusion. Marks et al.18 found that if a lesion
changed shape with respiratory excursion and if it contained movable strands or echo densities, the lesion was an
effusion. If a color Doppler is available, the uid color sign
is the most sensitive and specic ultrasonographic evidence
of a small effusion. The sign refers to the presence of a color
signal within the uid collection that is believed to arise
from transmitted motion during respiratory or cardiac
cycles. This sign has a sensitivity of 89.2 percent and specicity of 100 percent in detecting minimal uid collections.19
Pleural thickening
Pleural thickening is dened as focal lesions arising from
the visceral or parietal pleura that is greater than 3 mm in
width with or without an irregular margin (Figure 21.4). It
appears as broadening of the pleura and does not exhibit a
uid color sign or display movement relative to the chest
wall. Pleural thickening most often appears hypoechoic,
(a)
(b)
(c)
(d)
(e)
(f)
but increased echogenicity with focal shadowing is sometimes observed and is indicative of calcication.
disease (COPD) can mimic the sonographic sings of pneumothorax. This allows the exclusion, but not the conrmation of pneumothorax in such patients with US.23
Despite these limitations, ultrasonography is particularly
useful in intensive care units and in other situations where
radiographic equipment is unavailable. Herth et al.24 have
recently shown that a pneumothorax following transbronchial biopsy can be reliably excluded with US (sensitivity 100 percent; specicity 83 percent). This is likely to
reduce costs for chest radiographs, increase patient
comfort and offers an excellent opportunity to acquire and
practice pneumothorax detection.
Hydropneumothorax can also be identied with US by
means of the visualization of airuid boundary.25 The
sliding sign above the airuid level will be absent. A
mobile airuid level will generate a curtain sign with
respiration, because the air within the pleura obscures the
underlying effusion during inspiration.
Figure 21.3 (opposite) (a) Pleural effusion is presented as an echo-free space between the visceral and parietal pleura. Compressive
atelectasis of the lung may be seen in a large effusion. The effusion can be subclassied as anechoic (b), complex non-septated (c),
complex septated (d), or homogenously echogenic (e). Note the movable echogenic spots within the complex non-septated effusion, and
the oating strands and septa within the complex septated effusion (arrowheads). (f) Pleural effusion associated with pleural nodules or
nodular thickenings is characteristic of malignant effusion. PE, pleural effusion; D, diaphragm; RLL, right lower lobe; L, lung; T, pleural
tumor. Reproduced with permission from: Tsai TH, Yang PC. Ultrasound in the diagnosis and management of pleural disease. Curr Opin
Pulm Med 2003; 9: 28290.
(b)
(a)
Pleural tumors
Benign pleural tumors appear on US as well-dened
rounded masses of variable echogenicity on either the
parietal or visceral pleura. Both metastatic pleural tumors
and malignant mesothelioma appear as polypoid pleural
nodules or irregular sheetlike pleural thickening,26 often
with large pleural effusions (Figure 21.6).Tumors with low
echogenicity can exhibit posterior echo enhancement.
(a)
(b)
Figure 21.8 (a) An ultrasound (US) image showing a lung tumor with posterior echo enhancement. Note that both of the visceral and
parietal pleural lines are intact. (b) This US shows tumor extension beyond the pleura. The visceral pleural line is interrupted, and the
respiratory movement of the tumor is disturbed in real-time US. Invasion of the pleural cavity by the tumor is evident. L, lung; T, tumor; Pv,
visceral pleural; Pp, parietal pleura. Reproduced with permission from: Diacon AH, Theron J, Bolliger CT. Transthoracic ultrasound for the
pulmonologist. Curr Opin Pulm Med 2005; 11: 30712.
Diaphragmatic paralysis
The diaphragm is best visualized at the costophrenic angle
or through the liver or spleen. Sonographic examination of
a paralyzed diaphragm will yield paradoxical movement of
the diaphragm with respiration.30 This can be accentuated
with forced inspiration (sniff test). Long-term paralysis
causes muscle atrophy.30
nique for its simplicity. Following adequate patient positioning, the intended site of needle insertion is sonographically identied and marked, while the direction, the depth
of interest and the safety range for the procedure are memorized. The patient must not change position in order to
prevent a positional shift of the area of interest relative to
the skin mark. It is occasionally even necessary to ask the
patient to hold their breath for the duration of the aspiration. The practice of identifying a puncture site at a radiology department prior to transporting a patient elsewhere
for thoracentesis should be discouraged, particularly in the
case of small effusions, as both the uid collection and the
skin mark might shift considerably with minor changes in
body position.
Thoracentesis
ULTRASOUND-GUIDED INTERVENTIONS
Principles
Ultrasound is particularly well suited for assisting pleural
and chest wall interventions, including diagnostic thoracentesis, closed tube drainage, chest wall and pleural biopsies and biopsies of lung tumors abutting or invading the
pleura. The use of US for these procedures increases the
success rate and minimizes risk compared with procedures
carried out blindly.
With regard to needle biopsies, specic reusable probes
for real-time US guidance of needle biopsies are commercially available. Many prefer the so-called freehand tech-
Acknowledgements 281
ciated effusion decreases the risk of visceral pleural lacerations, which is particularly relevant in cases with minimal
pleural effusion.
Conventionally, closed pleural biopsies (e.g. with the
Abrams needle) could only safely be performed in the
presence of a sizeable pleural effusion or pneumothorax
determined clinically or on chest radiography. However,
US can demonstrate small uid collections and facilitate
the use of devices that were not primarily designed for
uid aspiration (e.g. Tru-cut needles). Numerous studies
have concluded that US-guided Tru-cut needle biopsies
have higher sensitivity and specicity in the diagnosis of
pleural malignancy and tuberculosis than unaided Abrams
needle biopsies.3841
CONCLUSION
The usefulness of US for chest physicians is rmly established. Basic thoracic ultrasonography is an elegant and
low-cost investigation that extends the physicians diagnostic and interventional potential at the bedside in
peripheral lung, pleural and chest wall disease. It has the
potential to replace CT-guided ne needle aspirations or
biopsies of all lesions involving the pleura and chest wall,
as well as lung masses or consolidations abutting the
pleura. Basic thoracic sonography is fairly simple and easy
to learn. Academic institutions should strive to have a
basic formal training program in ultrasonography in place
in order to ensure that all aspiring chest physicians are
familiar with chest ultrasonography.
ACKNOWLEDGEMENTS
We would like to thank Carol Lochner and Belinda Muller
for technical assistance with this manuscript. We are
indebted to the Holland-Stellenbosch Medical Foundation,
Veldhoven, The Netherlands for continued support.
KEY POINTS
REFERENCES
4.
5.
6.
7.
8.
9.
10.
11.
12.
13. Chen KY, Liaw YS, Wang HC, et al. Sonographic septation: a useful
prognostic indicator of acute thoracic empyema. J Ultrasound Med
2000; 19: 83743.
14. Tu CY, Hsu WH, Hsia TC, et al. Pleural effusions in febrile medical
ICU patients: chest ultrasound study. Chest 2004; 126: 127480.
15. Eibenberger KL, Dock WI, Ammann ME, et al. Quantication of
pleural effusions: sonography versus radiography. Radiology 1994;
191: 6814.
16. Lorenz J, Borner N, Nikolaus HP. Sonographic volumetry of pleural
effusions. Ultraschall Med 1988; 9: 21215.
17. Balik M, Plasil P, Waldauf P, et al. Ultrasound estimation of
volume of pleural uid in mechanically ventilated patients.
Intensive Care Med 2006; 32: 31821.
18. Marks WM, Filly RA, Callen PW. Real-time evaluation of pleural
lesions: new observations regarding the probability of obtaining
free uid. Radiology 1982; 142: 1634.
19. Wu RG, Yang PC, Kuo SH, Luh KT. Fluid color sign: a useful
indicator for discrimination between pleural thickening and
pleural effusion. J Ultrasound Med 1995; 14: 7679.
20. Chan SS. Emergency bedside ultrasound to detect pneumothorax.
Acad Emerg Med 2003; 10: 914.
21. Chan SS. The comet tail artifact in the diagnosis of pneumothorax.
J Ultrasound Med 2002; 21: 1060.
22. Simon BC, Paolinetti L. Two cases where bedside ultrasound was
able to distinguish pulmonary bleb from pneumothorax. J Emerg
Med 2005; 29: 2015.
23. Slater A, Goodwin M, Anderson KE, Gleeson FV. COPD can mimic
the appearance of pneumothorax on thoracic ultrasound. Chest
2006; 129: 54550.
24. Herth FJ, Eberhardt R, Ernst A, et al. Diagnosis of pneumothorax by
means of transthoracic ultrasound: a prospective trial. Eur Respir J
2004; 24: S491.
25. Targhetta R, Bourgeois JM, Chavagneux R, et al. Ultrasonographic
approach to diagnosing hydropneumothorax. Chest 1992; 101:
9314.
26. Gorg C, Restrepo I, Schwerk WB: Sonography of malignant pleural
effusion. Eur Radiol 1997; 7: 11958.
27. Sugama Y, Tamaki S, Kitamura S, et al. Ultrasonographic
evaluation of pleural and chest wall invasion of lung cancer. Chest
1988; 93: 2759.
28. Suzuki N, Saitoh T, Kitamura S: Tumor invasion of the chest wall in
lung cancer: diagnosis with US. Radiology 1993; 187: 3942.
29. Bruneton JN, Caramella E, Hery M et al. Axillary lymph node
metastases in breast cancer: preoperative detection with US.
Radiology 1986; 158: 3256.
30. Gottesman E, McCool MD. Ultrasound evaluation of the paralyzed
diaphragm. Am J Resp Crit Care Med 1997; 155: 15704.
31. Yang PC, Chang DB, Yu CJ, et al. Ultrasound guided percutaneous
cutting biopsy for the diagnosis of pulmonary consolidation of
unknown aetiology. Thorax 1992; 47: 45760.
32. Reissig A, Kroegel C. Transthoracic ultrasound of lung and pleura
in the diagnosis of pulmonary embolism: a novel non-invasive
bedside approach. Respiration 2003; 70: 44152.
33. Lichtenstein D, Meziere G. A lung ultrasound signs allowing
bedside distinction between pulmonary edema and COPD: the
comet-tail artifact. Intensive Care Med 1998; 24: 13314.
34. Diacon AH, Brutsche MH, Soler M. Accuracy of pleural puncture
sites: a prospective comparison of clinical examination with
ultrasound. Chest 2003; 123: 43641.
35. Yang PC, Kuo SH, Luh KT: Ultrasonography and ultrasound-guided
needle biopsy of chest diseases: indications, techniques,
diagnostic yields and complications. J Med Ultrasound 1993; 1:
5363.
36. Chen KY, Liaw YS, Wang HC, et al. Sonographic septation: a useful
prognostic indicator of acute thoracic empyema. J Ultrasound Med
2000; 19: 83743.
37. Tatersall DJ, Traill ZC, Gleeson FV. Chest drains: does size matter?
Clin Radiol 2000; 55: 41521.
References 283
38.
39.
40.
41.
42.
Chang DB, Yang PC, Luh KT, Kuo SH, Yu CJ. Ultrasound guided
pleural biopsy with Tru-cut needle. Chest 1991; 100: 132833.
Heilo A, Stenwig AE, Solheim OP. Malignant pleural mesothelioma:
US-guided histologic core needle biopsy. Radiology 1999; 211:
6579.
McLeod DT, Ternouth I, Nkanza N. Comparison of the Tru-cut
biopsy needle with the Abrams punch for pleural biopsy. Thorax
1989; 44: 7946.
Theron J, Diacon AH, Williams Z, Walzl G, Bolliger CT. Abrams
versus TruCut needle in tuberculous pleuritis: a pilot study. Eur
Respir J 2004; 24: 73s.
Diacon AH, Schuurmans MM, Theron J, et al. Safety and yield of
22
Pathology: histology
TIMOTHY C ALLEN, PHILIP T CAGLE
Introduction
Non-neoplastic lesions of the pleura
Neoplastic lesions of the pleura
Other rare primary malignant neoplasms of the pleura
285
285
286
289
INTRODUCTION
Since neoplastic and non-neoplastic diseases of the pleura
may produce very similar clinical, radiographic and gross
ndings, histopathology of pleural biopsies often has a
crucial role in patient care. Surgical samples of pleural
tissue may range from tiny needle biopsies to larger open
or thoracoscopic biopsies to decortication specimens to
extrapleural pneumonectomies.
Interpretation of pleural biopsies can be one of the
most challenging areas in surgical pathology because of
overlapping histopathological features of benign and
malignant diseases, as well as among different types of
malignancy. Sampling error, sample size and artifacts may
impact on the ability to arrive at a diagnosis. Immunohistochemical stains are often used for problematic pleural
biopsies and special panels of expert pleural pathologists,
for example, the United States and Canadian
Mesothelioma Reference Panel, have been set up for
biopsy referrals.
Future directions
Key points
References
290
290
290
Eosinophilic pleuritis
In eosinophilic pleuritis there is an increased number of
eosinophils, sometimes strikingly so, in the inammatory
inltrate which otherwise may show features of brinous
or brous pleuritis, mesothelial hyperplasia, etc. Since
eosinophilic pleuritis is often associated with some distinctive clinical situations, there may be accompanying
histopathological ndings in any underlying lung tissue
that may be sampled. A classic etiology of eosinophilic
pleuritis is spontaneous pneumothorax, which occurs generally in young adults. In these cases, the eosinophilic pleuritis may be associated with focal blebs, bullae or focal
honeycombing of the underlying lung tissue. Pneumothorax or hemothorax from a wide variety of causes can
potentially result in eosinophilic pleuritis and lymphangioleiomyomatosis may be seen in the underlying lung tissue
in women of childbearing age. Eosinophilic pleuritis may
also be associated with certain drug reactions and infections which may also produce characteristic ndings in the
underlying lung tissue.
Granulomatous pleuritis
Granulomatous pleuritis is characterized by the presence
of granulomatous inammation, which may consist of
well-formed granulomas or less circumscribed areas of
granulomatous inammation depending on the etiology.
Granulomatous pleuritis is often accompanied by features
of chronic pleuritis (i.e. chronic inammation and
brosis).
Infections, such as TB or fungal infections, that involve
the pleura classically produce well-formed granulomas
with or without central necrosis, but may occasionally
form less circumscribed areas of granulomatous inammation. It is important to remember that special stains for
organisms, for example the acid-fast stain for tuberculosis
or the Grocotts methenamine silver (GMS) stain for
fungus, are very helpful when positive, but a negative
special stain can occur even when infection is present.
Therefore, cultures are always recommended even when
special stains are negative.
Sarcoidosis is characterized by well-formed, compact
granulomas in a lymphangitic distribution that includes
the pleura. Signicant necrosis is not a usual feature of sarcoidosis granulomas, although small punctate areas of
necrosis may be present in some granulomas. Sarcoidosis
granulomas may be surrounded by chronic inammatory
inltrates or by brosis. Endogenous materials, for
example, Schaumann bodies or calcium oxalate crystals,
are often seen in the histiocytes of sarcoidosis, but are not
pathognomonic and may be seen in other types of granulomas. These should not be mistaken for foreign material.
Wegeners granulomatosis (see Chapter 32, Effusions
from connective tissue diseases) may involve the pleura
and causes a less circumscribed type of granulomatous
inammation rather than well-formed granulomas. The
classic histopathology picture is one of palisading histiocytes mixed with multinucleated giant cells, other inammatory cells and broblasts surrounding a central area of
necrosis. The necrosis begins as micro-abscesses with neutrophils and leukocytoclastic necrosis that coalesce and
enlarge into so-called geographic areas of basophilic
necrosis. While these features and those of vasculitis can be
seen in the pleura, Wegeners granulomatosis is usually
diagnosed on a biopsy of lung tissue.
Foreign body granulomatous reactions may occur in
the pleura. Most of these are the result of deliberate pleurodesis or iatrogenic instillation of foreign material into
the pleural cavity to cause its obliteration for the purpose
of treating recurrent pleural effusions.
Tubulopapillary, epithelial/mesothelial,
adenomatoid
Sarcomatous, rarely with heterologous
elements (bone, cartilage)
Mixed epithelial and sarcomatous
patterns
Predominance of connective tissue with
scant cellularity in much of the tumor,
usually sarcomatous, may be epithelial
Table 22.2 Characteristic results for selected immunostains for malignant mesothelioma versus other malignancies
Keratin
CK5/6
Vimentin
Calretinin
CEA, B72.3,
Leu M-1, BerEP4
TTF-1
EMA
HBME-1
Mesothelioma
Carcinoma
Sarcoma
Melanoma
1
1/2
1/2
1 (nuclear)
2
1
2/1
2/1
2 (rarely 1)
1/2
2 (occasionally 1)
2
1
2 (rarely 1)
2
2 (rarely 1)
2
1
2
2
2
1
1 (epithelial)
(thick, continuous),
(thin, discontinuous)
2
2
2
2
2 (epithelial)
2
CK5/6, cytokeratin 5/6; TTF-1, thyroid transcription factor 1; EMA, epithelial membrane antigen; HBME-1, antihuman mesothelial cell antibody.
liomas. Although these neoplasms are amenable to surgical excision and patients generally have a good to excellent
prognosis, they are most likely malignant neoplasms.7
Desmoplastic small round cell tumor is usually seen in
children, adolescents and young adults and is usually peritoneal but can arise or extend into the pleura.23
Other rare primary malignancies of the pleura include
the malignant variant of solitary brous tumor, synovial
sarcoma, osteosarcoma, chondrosarcoma, angiosarcoma
and malignant brous histiocytoma.7,14,24
FUTURE DIRECTIONS
The advent of experimental therapies for mesothelioma
provides greater incentive for earlier diagnosis of this
disease. Coincidentally, the diagnosis of mesothelioma at
earlier stages of disease is increasingly possible as a result of
the greater availability and popularity of techniques such
as thoracoscopic biopsy. Hence, in the near future, the
diagnosis of mesothelioma should entail improved patient
therapy and, therefore, accurate diagnosis will be even
more important than in the past. Better opportunities to
provide meaningful therapy for patients will enhance
interest in the development of antibodies and molecular
markers for the early and accurate diagnosis of mesothelioma on biopsy.
KEY POINTS
REFERENCES
References 291
21.
Churg A, Colby TV, Cagle PT, et al. The separation of benign and
malignant mesothelial proliferations. Am J Surg Pathol 2000; 24:
1183200.
22. Galateau-Sall F, Cagle PT. Non-malignant versus malignant
proliferations on pleural biopsy. In: Cagle PT (ed.). Diagnostic
pulmonary pathology. New York: Marcel Dekker, 2000; 55567.
23
Pathology: cytology
MARK R WICK
General clinicopathology considerations in the diagnosis
of pleural neoplasms
Cytopathological partitions in the diagnosis of pleural
neoplasms
293
296
GENERAL CLINICOPATHOLOGY
CONSIDERATIONS IN THE DIAGNOSIS OF
PLEURAL NEOPLASMS
Shortness of breath, chest pain and a u-like illness are
common presentations of patients with inammatory or
malignant pleural diseases.1,2 Thoracentesis is typically the
rst diagnostic procedure employed in evaluation of uid
in the pleural cavities. In benign conditions, the cytological presentation is usually that of moderate cellularity,
showing only scant mixed inammatory cells and benign
mesothelial elements, or, alternatively, a predominance of
specic leukocytes. The rst situation may be seen in association with cardiac, renal or hepatic insufciency; some
cases of viral pleuritis; and pneumoconioses affecting the
pleura (e.g. asbestos pleuritis).3 The second scenario
accompanies empyema or parapneumonic pleural effusions, in which cases the uid is neutrophil-rich, as well as
connective tissue diseases, tuberculosis, fungal pleuritis
and most viral infections.4,5 In the last four of those dis-
302
310
310
Figure 23.6 Dispersed small lymphoid cells in a lymphocyterich pleural effusion. The large cell in the eld is a mesothelial
cell. An image such as this may reect the presence of pleural
tuberculosis, collagen vascular disease or a lymphoproliferative
disorder. (See also Color Plate 23.)
cytoplasmic granules. Reactivity with argyrophilic histochemical techniques such as the SevierMunger, Grimelius
or ChurukianSchenk procedures is helpful in recognizing
that small-cell carcinomas have neuroendocrine features.
Once metastatic SCNCs are identied as such, there are
few other nuances of morphology or biochemistry that can
be used with certainty to predict their anatomic sources. In
particular, cellular peptide and amine products are broadly
shared among this group of neoplasms, regardless of their
topographic origins. Hence, anatomic patterns of metastasis and the relative frequency of SCNC in various organ
systems must be used as the principal data in determining
the likely source. The lung is by far the most common
origin for metastatic small-cell carcinomas in the pleura.
Small-cell mesotheliomas also exist, albeit rarely.46
These tumors are rather nondescript cytologically and histologically, and they most closely simulate the appearances
of small-cell carcinomas. Adjunctive pathologic studies are
mandatory.
Lymphohistiocytoid mesothelioma is another sarcomatoid variant, but it bears more resemblance to lymphoepithelioma-like carcinomas than to sarcomas.72 All forms
of sarcomatoid mesothelioma shed poorly into pleural
uid, and manifest scarce atypical spindle cells therein in
only a minority of cases.
Biphasic mesothelioma manifests a combination of the
epithelial and sarcomatoid patterns.
Histochemical studies still play an important role in
separating mesotheliomas from other neoplasms. The
most useful histochemical procedures in this setting are
the PAS stain with diastase digestion (D-PAS), the mucicarmine method and the colloidal iron procedure with
hyaluronidase digestion. The presence of neutral mucin in
the neoplastic cells on D-PAS or mucicarmine stains is a
diagnostic feature of adenocarcinoma, though up to 5
percent of mesotheliomas may show focal labeling for
mucicarmine or D-PAS.
tumors are useful in this context, and they are best used as
batteries. These include CA15.3, CA19-9, B72.3/CA72-4
and anti-carcinoembryonic antigen (CEA).7375 Another
polypeptide which is related to keratin-19 (CYFRA-21-1)
was found to have no value in this setting.76 Most studies
have shown that an elevated level of CEA (normal
5 ng/mL) is the most sensitive single indicator of pleural
malignancies, and is also relatively reliable as an individual
marker of metastatic carcinoma (as opposed to other neoplasms). B72.3/CA72-4 has a similar value.
In the opinion of the author, at least two of the aforementioned markers should be abnormal before a condent
biochemical diagnosis of a malignant effusion can be made.
None of the glycoproteins listed in this section is typically
elevated in malignant mesothelioma, and false positives
from benign pleural diseases can occur. Cytological examination is necessary in all cases with abnormal pleural uid
tumor marker levels, as well as situations in which the clinical suspicion for malignancy remains high.
CA-125 was characterized as a glycoproteinaceous membrane constituent of ovarian carcinoma cells. A closelysimilar or identical moiety was expressed by mesothelial
CA19-9 is a glycoprotein (sialylated lacto-n-fucopentose119) which is related to the Lea blood group antigen. It is
labeled by the monoclonal antibody known as 1116NS199 which was raised against a human colonic carcinoma cell
line. Carcinomas of the gastrointestinal tract, pancreas,
biliary tree, urinary bladder, ovaries and endometrium
manifest CA19-9 reactivity in the majority of cases,
whereas tumors of other anatomic locations are only sporadically positive. Hepatocellular carcinoma and renal cell
carcinoma are consistently negative for this marker.
PLACENTAL ALKALINE PHOSPHATASE
CD15 (ANTI-LEU-M1)
Figure 23.20 Nuclear positivity for thyroid transcription factor1 in metastatic pulmonary adenocarcinoma involving pleural
uid. (See also Color Plate 37.)
BG8
MoAb 44-3A6
Factor VIII
Surfactant apoprotein
Anti-Lewis antigen
Tn antigen
E-cadherin
TTF-1
MoAb SM3
Secretory component
(SC)
Pregnancy specic
protein
CA 199
OV632
NSE
CD57
Mab 45
HEA-125
Anti BRG
ICAM-1
VCAM
Parathyroid hormone
CD44H
IOB 3
P63
Mesothelioma
Result %
Adenocarcinoma
Result %
+
+
+
+
+
4
100
Rare
11
10
68
52
+
+
+
+
+
+
+
+
88
8
N.S.
62
76
62
77
100
100
062
60
+
+
+
+
+
+
+
+
0+6
8591
96
70
N.S.
100
87
84
91
+
+
+
N.S.
N.S.
+
+
+
N.S.
N.S.
+
+
+
3459
39
2063
N.S.
N.S.
N.S.
75
83
N.S.
N.S.
11
45
100
10b
Most sarcomas differ from metastatic sarcomatoid carcinomas and from sarcomatoid mesotheliomas in that they
are keratin negative. The principal exception is synovial
sarcoma,86 which is immunoreactive for epithelial
markers, including calretinin, and closely resembles
mesothelioma morphologically and immunophenotypically. However, synovial sarcoma was labeled by BER-Ep4
in 90 percent of cases, compared with 13 percent for
mesothelioma.87 Conversely, mesothelial tumors were
immunoreactive for Wilms tumor protein-1 (WT1) and
CD141 in the majority of cases, whereas synovial sarcoma
was typically negative. Ultimately, cytogenetic studies are
the most helpful in separating mesothelioma and synovial
sarcoma; the latter manifests a consistent t(X;18) chromosomal translocation that is not observed in mesothelial
lesions.88
Other immunohistochemical markers can be used to
determine the lineage of a sarcoma, once it has been
dened as such. These include: indicators of a generic
myogenous nature, such as desmin; striated muscle
differentiation (e.g. myoglobin, myogenin, myo-D1 and
fast myosin); proteins seen in smooth muscle cells that
include calponin and caldesmon; markers of peripheral
nerve sheath differentiation such as S100, CD56, CD57
and nerve growth factor receptor; proteins seen in
osteogenic sarcomas, including osteopontin and
osteonectin; and endothelial polypeptides such as CD31,
CD34, von Willebrand factor and receptor for Ulex
europaeus I lectin.
+
Desmoplastic small
round cell tumor
DES/MSA
DES/MSA
+
+
CK
CK
+ Neuroendocrinee
carcinoma
NSE/SYN/CGA
--
Malignant
lymphoma
or leukemia
LCA
LCA
--
+
+
EMA
EMA
--
--
Malignant
melanoma
S100/HMB-45/MART-1
Rhabdomyosarcoma
Peripheral
neuroectodermal
l
tumor (PNET)
)
--
--
CD57/SYN/MB2
DES/MSA/MYOD-1/MYOGN
--
Technically
inadequate
specimen
--
PNET
PNET
--
VIM
VIM
NSE/SYN/CD99
--
PNET
ET
PN
+
Malignant melanoma
S100/HMB-45/MART-1/Tyrosinase
-VIMENTIN
CD45
+
--
Malignant lymphoma
or leukemia
--
KERATIN/EMA
-+
BER-EP4/CD15/CEA/S100
Calretinin
Calretinin
+
+
Sarcoma
Carcinoma, NOS
Mesothelioma
Adenocarcinoma
-Technically
Technically
inferior specimen
S100 protein
-+
--
HMB-45/MART-1
Malignant melanoma
Vimentin
Vimentin
+
Calretinin and
CD141
PSA
TGB
+
Either or
both
B72.3/MOC-31
Both --
CALRET/CD141
Keratin mixture
---
VIM
--
RCC or NPC
ACC
Mesothelioma
NPC
HCC
--
--
EMA
EMA
Embryonal CA
---
PLAP
PLAP
Probable
sarcomatoid squamous
cell carcinoma
GCDFP
CEA-M
S100
PLAP
CA-125
CA19-9
CK20
ER
Thyroid carcinoma
Both
()
PSA/TGB
--
Mesothelioma
Prostatic carcinoma
PSA
TGB
Technically
inadequate
specimen
+
--
+
Leiomyosarcoma
Figure 23.26
--
--
Desmin/muscle-specific actin
--
+ Angiosarcoma
Embryonal CA
S100
ER
GCDFP
CEA
CA-125
SK20
--
EMA
--
PLAP
Keratin
--
S100
S100
--
Malignant
melanoma
Vimentin
--
Adrenocortical
carcinoma or sarcoma
----
S100/HMB-45/MART-1/TYR
--
Melanoma
PLAP
Seminoma
Seminoma
-VIMENTIN
CD45
---
Clear-cell Non-Hodgkins
lymphoma
Lymphoma
KERATIN
BER-EP4/CD15/CEA/S100
--
Clear-cell carcinoma
(EMA/CalRet) or
clear-cell mesothelioma
(EMA/CalRet)
or clear-cell HCC or
non-seminomatous germ
cell tumor (NSGCT)
(both EMA;
NSGCT also PLAP)
Clear-cell
carcinoma, NOS
Adrenocortical l
carcinoma or
sarcoma
-Technically
inferior specimen
KEY POINTS
REFERENCES
References 311
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
Saad RS, Lindner JL, Lin X, Liu YL, Silverman JE. The diagnostic
utility of D2-40 for malignant mesothelioma versus pulmonary
carcinoma with pleural involvement. Diagn Cytopathol 2006; 34:
8016.
Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a
new marker of lymphatic endothelium, reacts with Kaposis
sarcoma and a subset of angiosarcomas. Mod Pathol 2002;
15: 43440.
Lau SK, Weiss LM, Chu PG. D2-40 immunohistochemistry in the
differential diagnosis of seminoma and embryonal carcinoma: a
comparative immunohistochemical study with KIT (CD117) and
CD30. Mod Pathol 2007; 20: 3205.
Browning L, Parker A, Bailey D. D2-40 is a sensitive and specic
marker in differentiating primary adrenal cortical tumors from
both metastatic clear cell renal cell carcinoma and
pheochromocytoma. J Clin Pathol 2008; 61: 2936.
Wick MR, Moran CA, Mills SE, Suster S. Immunohistochemical
differential diagnosis of pleural effusions, with emphasis on
malignant mesothelioma. Curr Opin Pulm Med 2001; 7: 18792.
Gaertner E, Zeren EH, Fleming MV, Colby TV, Travis WD. Biphasic
synovial sarcomas arising in the pleural cavity: a clinicopathologic
study of ve cases. Am J Surg Pathol 1996; 20: 3645.
Miettinen M, Limon J, Niezabitowski A, Lasota J. Calretinin and
other mesothelioma markers in synovial sarcoma: analysis of
antigenic similarities and differences with malignant
mesothelioma. Am J Surg Pathol 2001; 25: 61017.
Argani P, Zakowski MF, Klimstra DS, Rosai J, Ladanyi M. Detection
of the SYT-SSX chimeric RNA of synovial sarcoma in parafnembedded tissue and its application in problematic cases. Mod
Pathol 1998; 11: 6571.
Cury PM, Butcher DN, Corrin D, Nicholson AG. The use of
histological and immunohistochemical markers to distinguish
pleural malignant mesothelioma and in-situ mesothelioma from
reactive mesothelial hyperplasia and reactive pleural brosis. J
Pathol 1999; 189: 2517.
Mayall FG, Jacobson G, Wilkins R. Mutations of p53 gene and
SV40 sequences in asbestos-associated and non-asbestosassociated mesotheliomas. J Clin Pathol 1999; 52: 2913.
Stoetzer OJ, Munker R, Darsow M, Wilmanns W. p53immunoreactive cells in benign and malignant effusions:
diagnostic value using a panel of monoclonal antibodies and
comparison with CEA staining. Oncol Rep 1999; 6: 4558.
Mangano WE, Cagle PT, Churg A, Vollmer RT, Roggli VL. The
diagnosis of desmoplastic malignant mesothelioma and its
distinction from brous pleurisy: a histologic and
immunohistochemical analysis of 31 cases including p53
immunostaining. Am J Clin Pathol 1998; 110: 1919.
Churg A, Colby TV, Cagle PT, et al. The separation of benign and
malignant mesothelial proliferations. Am J Surg Pathol 2000; 24:
11831200.
Ceyhan BB, Demiralp E, Celikel T. Analysis of pleural effusions
using ow cytometry. Respiration 1996; 63: 1724.
Joseph MG, Banerjee D, Harris P, Gibson S, McFadden RG.
Multiparameter ow cytometric DNA analysis of effusions: a
prospective study of 36 cases compared with routine cytology and
immunohistochemistry. Mod Pathol 1995; 8: 68693.
Pinto MM. DNA analysis of malignant effusions: comparison with
cytologic diagnosis and carcinoembryonic antigen content. Anal
Quant Cytol Histol 1992; 14: 2226.
Nance KV, Silverman JF. The utility of ancillary techniques in
effusion cytology. Diagn Cytopathol 1992; 8: 1859.
Esteban JM, Sheibani K. DNA ploidy analysis of pleural
mesotheliomas: its usefulness for their distinction from lung
adenocarcinomas. Mod Pathol 1992; 5: 62630.
El-Naggar AK, Ordonez NG, Garnsey L, Batsakis JG. Epithelioid
pleural mesotheliomas and pulmonary adenocarcinomas: a
comparative DNA ow-cytometric study. Hum Pathol 1991; 22:
9728.
References 313
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
24
Effusions from cardiac diseases
GARY T KINASEWITZ, KELLIE R JONES
Incidence/epidemiology
Pathogenesis
Clinical presentation
Radiology
Pleural uid characteristics
315
315
316
317
318
INCIDENCE/EPIDEMIOLOGY
Pleural effusions are a common manifestation of heart
disease. The incidence and characteristics of the effusion
will vary depending upon the nature of the underlying
cardiac disorder. When the underlying cardiac disorder is
severe enough to result in congestive heart failure, transudative pleural effusions will develop in a majority of
patients. Given the prevalence of heart disease in Western
society, it is not surprising that congestive heart failure is
the most common cause of transudative pleural effusions.1
Pericardial disease is less common, but both acute and
chronic pericardial disease can also give rise to pleural
effusions, even in the absence of heart failure. Depending
on the etiology of the pericardial disease, the pleural uid
may be either a transudate or an exudate.
The frequency with which pleural effusions are detected
varies with the population studied and the methods
employed. The routine chest radiograph will reveal effusions
in 58 to 73 percent of unselected patients admitted to the
hospital with congestive heart failure.2,3 Weiner-Kronish
and colleagues4 found pleural effusions by ultrasound examination in half of a group of patients admitted to a coronary
care unit with congestive heart failure. However, the incidence of pleural effusion in heart failure patients increases
when more sensitive techniques such as computed tomography (CT) or autopsy are employed. Kataoka5 prospectively
evaluated 60 patients with decompensated congestive heart
failure of varying etiologies admitted to a special Heart
Failure Unit in the hospital. He found 87 percent of the
patients had pleural effusions using CT examination. Less
than half of these effusions were visible on the routine
postero-anterior (PA) chest radiograph. Race and colleagues6 found pleural uid in over 90 percent of autopsied
Treatment
Future directions
Key points
References
319
320
320
320
PATHOGENESIS
The normal mechanisms responsible for the ltration of
pleural uid from the pleural capillaries and its reabsorption are reviewed in detail in Chapter 5, Physiology: uid
and solute exchange in normal physiological states. The
interstitium of the lung ordinarily plays no role in the
reabsorption of pleural uid under normal conditions.12
However, experimental studies have suggested that it may
be the major source of pleural uid in patients with congestive heart failure.
Allen and colleagues13 produced left atrial hypertension
and pulmonary edema in sheep by means of a left atrial
balloon catheter and found that the volume of pleural
CLINICAL PRESENTATION
The clinical presentation is generally typical of patients
with congestive heart failure. Increasing dyspnea, orthopnea and edema are the most common presenting symptoms. Patients with heart failure rarely complain of
pleuritic pain. Frequently, the effusions may be asymptomatic radiographic ndings in a patient with known congestive heart failure. Physical examination commonly
reveals evidence of biventricular failure with distended
Effusion present
( n = 19)
Effusion absent
( n = 18)
38.0 1.5
24.1 1.3
12.6 1.5
8
30.7 2.1*
17.2 1.5*
9.8 1.0
4
Values are mean SEM; *p < 0.05 effusion present versus effusion absent. Data from reference 4.
Radiology
317
RADIOLOGY
Most patients have bilateral effusions and cardiomegaly
apparent on the PA chest radiograph. Additional radiographic signs of heart failure including pulmonary vascular engorgement, increased septal markings and alveolar
edema may be present.2 Generally, the effusions are of
moderate size, 3001000 mL, and occupy less than half a
hemithorax.25 Minor differences in the size of the effusions
in each hemithorax are not uncommon. Several investigators have found that predominantly right-sided and predominantly left-sided effusions occurred with equal
frequency.26,27
Unless heart failure develops in the setting of an acute
myocardial infarction, the absence of cardiomegaly in a
patient with bilateral effusions should raise the suspicion
of some other disease. Rabin and Blackman28 found effusions due to heart failure in only 3 of 78 patients who presented with this clinical picture. Malignancy and serositis
accounted for over half the bilateral effusions in this study.
Unilateral effusions do occur in patients with heart failure
but they are less common (Table 24.2). Unilateral rightsided effusions have been observed in 16 percent of
patients while unilateral left-sided effusions were detected
Ref
no.
Method of
detection
Bilateral
effusions
Right
only
Left
only
3
26
27
43
25
6
Chest radiograph
Chest radiograph
Chest radiograph
Chest radiograph
Computed tomography
Autopsy
70
54
120
197
52
290
783
51
49
87
117
44
255
603
73
91
73
59
85
88
77
13
2
18
62
6
24
125
19
4
15
31
12
8
16
6
3
15
18
2
11
55
9
6
13
9
4
4
7
(a)
(a)
(b)
(b)
Figure 24.2 (a) Chest computed tomography scan of a patient
with congestive heart failure reveals increased septal markings
and bilateral effusions of equal size. (b) Mediastinal windows in
the same patient clearly demonstrate the bilateral effusions and
cardiomegaly.
Treatment 319
TREATMENT
The pleural membranes per se are intact in the patient with
congestive heart failure so that restoration of a normal
balance of Starling forces should permit the reabsorption
of the pleural uid. Diuretics, afterload reduction and digitalis are the mainstays of therapy. Howard and Dunn
demonstrated that aggressive diuretic therapy with continuous IV furosemide will reduce the length (and associated
cost) of hospital stay without any increase in morbidity.49
If treatment of the underlying heart failure is successful,
the effusion will resolve.
Since they often have the same etiology, the pleural effusions in patients with pericardial disease will respond to
treatment of the underlying process. Anti-inammatory
therapy for serositis and anti-tuberculous therapy for the
patient with tuberculosis will effectively treat both the
pleural effusion and the pericardial disease. However, if
there is clinical evidence of tamponade, immediate pericardial drainage is necessary and can be lifesaving. Malignant
pericardial disease usually signals far advanced disease and
often requires denitive local therapy for its control.
Pericardial sclerosis with doxycycline or bleomycin may
prevent the reaccumulation of uid in about three-quarters
of treated patients.5052 Alternatively, a pericardial window
can be created to allow the uid to drain into the pleural or
peritoneal cavities or the preperitoneal subcutaneous
space.5356 Pericardiectomy may be required for the patient
with symptomatic constrictive pericardial disease.11
When a patient with large pleural effusion remains dyspneic despite intensive medical therapy, therapeutic thoracentesis is indicated. Often the removal of 5001000 mL of
uid may produce immediate and dramatic symptomatic
relief, even before there is an increase in vital capacity or
the partial pressure of arterial O2 (PaO2). The benecial
effects of therapeutic thoracentesis include a reduction in
the resting volume of the chest wall which enables the
FUTURE DIRECTIONS
The pathogenesis of pleural uid accumulation in cardiac
disease is clear, but the explanation for its presence in atypical locations such as a pseudotumor, or the predominance
of left-sided effusions with pericardial disease, remains to
be elucidated. BNP is a promising marker indicating a
cardiac contribution to a pleural effusion. Cardiac disease
is so common in our society that physicians can expect to
encounter patients with an effusion caused by cardiac
failure and a concomitant second problem contributing to
the effusion. While additional testing such as cytological
examination may identify the second problem, one still
must rely on clinical intuition and the recognition of an
atypical presentation to prompt additional testing. A
marker for the complicated cardiac effusion is needed.
KEY POINTS
REFERENCES
= Key primary paper
= Major review article
= Paper that represents the rst formal publication of a
management guideline
References 321
17. Mellins RB, Levine OR, Fishman AP. Effect of systemic and
pulmonary venous hypertension on pleural and pericardial uid
accumulation. J Appl Physiol 1970; 29: 5649.
18. Pang LM, Mellins RB, Rodriguez-Martinez F. Effect of acute
lymphatic obstruction on uid accumulation in the chest in dogs.
J Appl Physiol 1975; 39: 9859.
19. Eid A, Keddissi JI, Kinasewitz GT. Hypoalbuminemia as a cause of
pleural effusions. Chest 1999; 115: 10669.
20. Szab G, Magyar Z. Effect of increased systemic venous pressure
on lymph pressure and ow. Am J Physiol 1967; 212: 146974.
21. Allen SJ, Drake RE, Laine GA, et al. Effect of thoracic duct drainage
on hydrostatic pulmonary edema and pleural effusion in sheep. J
Appl Physiol 1991; 71: 31416.
22. Wiener-Kronish JP, Goldstein R, Matthay RA, et al. Lack of
association of pleural effusion with chronic pulmonary arterial and
right atrial hypertension. Chest 1987; 92: 96770.
23. Maringhini A, Ciambra M, Patti R, et al. Ascites, pleural, and
pericardial effusions in acute pancreatitis: A prospective study of
incidence, natural history, and prognostic role. Dig Dis Sci 1996;
41: 84852.
24. Agner RC, Gallis HA. Pericarditis: Differential diagnostic
considerations. Arch Intern Med 1979; 139: 40712.
25. Kataoka H, Takada S. The role of thoracic ultrasonography for
evaluation of patients with decompensated chronic heart failure. J
Am Coll Cardiol 2000; 35: 163846.
26. Peterman TA, Brothers SK. Pleural effusions in congestive heart
failure and in pericardial disease. N Engl J Med 1983; 309: 313.
27. Woodring JH. Distribution of pleural effusion in congestive heart
failure: what is atypical? South Med J 2005; 98: 51823.
28. Rabin CB, Blackman NS. Bilateral pleural effusion: its signicance
in association with a heart of normal size. J Mt Sinai Hosp 1957;
24: 4563.
29. Van Gelderen WFC. Vanishing pleural uid collections in cardiac
failure simulating lung tumours. Australas Radiol 1994; 38:
936.
30. Weingardt JP, Guico RR, Nemcek AA Jr, et al. Ultrasound ndings
following failed clinically directed thoracenteses. J Clin Ultrasound
1994; 22: 41926.
31. Wu RG, Yuan A, Liaw YS, et al. Image comparison of real-time
gray-scale ultrasound and color doppler ultrasound for use in
diagnosis of minimal pleural effusion. Am J Respir Crit Care Med
1994; 150: 51014.
32. Matalon TA, Neiman HL, Mintzer RA. Noncardiac chest
sonography. Chest 1983; 83: 6758.
33. Horowitz MS, Schultz CS, Stinson EB. Sensitivity and specicity of
echocardiographic diagnosis of pericardial effusion. Circulation
1974; 50: 23947.
34. Singh S, Wann SL, Schuchard GH, et al. Right ventricular and right
atrial collapse in patients with cardiac tamponade a combined
echocardiographic and hemodynamic study. Circulation 1984; 70:
966.
35. Hall WJ, Mayewski RJ. Diagnostic thoracentesis and pleural biopsy
in pleural effusions. Ann Intern Med 1985; 103: 799802.
36. Sokolowski JW, Burgher LW, Jones FL Jr, et al. Guidelines for
thoracentesis and needle biopsy of the pleura. Am Rev Respir Dis
1989; 140: 2578.
37. Light RW, MacGregor IM, Luchsinger PC, et al. Pleural effusions:
The diagnostic separation of transudates and exudates. Ann Intern
Med 1972; 77: 50713.
38. Light RW, Erozan YS, Ball WC Jr. Cells in pleural uid. Arch Intern
Med 1973; 132: 85460.
39. Shinto RA, Light RW. Effects of diuresis on the characteristics of
pleural uid in patients with congestive heart failure. Am J Med
1990; 88: 2304.
40. Chakko SC, Caldwell SH, Sforza PP. Treatment of congestive heart
failure: Its effect on pleural uid chemistry. Chest 1989; 95:
798802.
41. Romero-Candeira S, Fernandez C, Martin C, et al. Inuence of
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
25
Effusions from malignancy
FRANCISCO RODRIGUEZ-PANADERO
Introduction
Pathogenesis
Clinical presentation
Radiographic appearance of malignant effusions
Diagnosis of malignant pleural effusions
Management of malignant pleural effusions
Management of pleural effusion in special conditions
323
323
323
325
325
327
329
331
334
334
335
335
INTRODUCTION
PATHOGENESIS
CLINICAL PRESENTATION
Most of the malignant effusions present with dyspnea on
exertion, which is progressive as the effusion is becoming
324
Dissemination
Breast
Superior v. cava
Mediastinal pleura
Pericardium
Ovary
Liquid drained
normally
Drainage blocked
by tumor
Mediastinal blockade
carcinoma of the ipsilateral mainstem bronchus resulting in atelectasis (see Figure 25.5). This can also occur
in cases of endobronchial metastasis from a distant
tumor;
a xed mediastinum caused by malignant tumor and/or
lymph nodes;
malignant mesothelioma (the radiodensity represents
predominantly tumor with a small to moderate effusion);
extensive tumor inltration of the ipsilateral lung radiographically mimicking a large effusion.
Ultrasound examination can be very useful in evaluating an effusion suspected of being malignant, both for
diagnostic12,13 or interventional purposes14 or to detect
complications, such as cardiac tamponade.15
(a)
(b)
Figure 25.4 (a) Lung cancer with massive pleural effusion and
contralateral mediastinal shift. Many therapeutic thoracenteses
were required, and large amounts of uid removed. (b) Same
patient, 11 months after talc poudrage.
326
100
80
Cytology
differential white cell count typically shows a predominance of either lymphocytes or other mononuclear cells.
The presence of neutrophils or eosinophils is much less
common but does not exclude a malignant effusion.
Adenosine deaminase (ADA) determination is routinely
recommended in countries with medium to high prevalence of tuberculosis. It can yield false positive results in
some cases of mesothelioma and lymphoma.
Almost all malignant effusions are exudates, but a few
can be transudates (approximately 1 percent in our thoracoscopy series). Malignant transudative effusions can
occur in lung cancer with obstruction of the mainstem
bronchus, but also in lymphoma and other malignancies.17
Blockade of lymphatic drainage may be invoked as one of
the possible pathogenetic mechanisms,18 but an underlying cardiac failure or other conditions that are usually
associated with transudative effusions should also be taken
into account.19
Approximately one-third of malignant effusions will
demonstrate a pleural uid pH of less than 7.30 at presentation (118 out of 359 with pH measured at the time of
diagnostic thoracoscopy in our series); this low pH correlates with glucose values of less than 60 mg/dL. The cause
of these low glucose, low pH malignant effusions appears
to be an increased tumor burden,20 resulting in decreased
glucose transfer into the pleural space and decreased efux
of acidic byproducts of glucose metabolism.21 For that
reason, malignant effusions with these properties have
been shown to have a higher diagnostic yield on cytology
and poorer response to pleurodesis (Figure 25.6), and they
are associated with a decreased overall survival.22,23 When
considering pleural pH as a predicting factor for survival,
one has to take into account that patients with mesothelioma tend to survive longer than those with metastatic
pleural carcinoma;24 they also have a tendency to show a
lower pH because of the marked pleural thickening caused
by mesothelioma.
Heffner and coworkers25 found in a metanalysis study
that although pH was by itself an independent predictor of
survival, it had insufcient predictive accuracy for select-
60
40
20
h
Un
Lu
kn
ow ng
n
or
ig
in
Ki
dn
ey
M
Co
es
ot lon
he
li
Ly om
a
m
ph
om
a
Ot
he
r
Sa
rc
Gl
om
ob
al a
se
rie
s
St
om
ac
t
ea
s
Ov
Br
ar
y
Origin of tumor
pH 7.30 (n 118)
pH 7.30 (n 241)
Cytology : 76%
Cytology : 57%
pH
7.60
7.10
P 0.0002
10
Lesion size
Small effusion
(1/3 of hemithorax)
Cytology
Primary known
Chemotherapy?
Cytology
Primary unknown
Observe
Pleurodesis if the effusion progresses
Figure 25.9
cytology.
328
Small effusion
(1/3 of hemithorax)
Cytology
Cytology
Thoracoscopy
Repeat thoracentesis
needle biopsy?
Observe if
negative
Talc poudrage?
Primary unknown
Repeat thoracentesis
needle biopsy?
Thoracoscopy
talc poudrage?
Thoracoscopy
Chemotherapy?
Pleurodesis
Figure 25.11
Cytology
Chemotherapy?
Talc poudrage
Unsuccessful
Cytology:
chemotherapy?
cytology
Contrast CT scan
Contrast CT scan
Bronchoscopy
Thoracoscopy
Transthoracic
needle biopsy
Transthoracic
needle biopsy
if bronchoscopy
negative
Bronchoscopy
if thoracoscopy
negative
Bronchoscopy
if TTNB
negative
Figure 25.12
Bronchoscopy
Transthoracic
needle biopsy
(TTNB)
Thoracoscopy
Thoracoscopy
if bronchoscopy
negative
Thoracotomy?
Bronchoscopy
if thoracoscopy
negative
Management of apparently large effusions with the mediastinum is not displaced or ipsilaterally shifted.
330
(b)
(a)
(c)
(d)
Figure 25.13 Malignant mesothelioma in a 75-year-old man with a past history of asbestos exposure. No pleural uid obtained. (a)
Chest radiograph at presentation (with chest pain). (b and c) Appearance on computed tomography scan. (d) Chest radiograph 17 months
later. Only palliative treatment for chest pain was applied.
Cytological diagnosis is rather difcult with mesothelioma because it is sometimes hard to establish a clear
distinction between mesothelioma and metastatic adenocarcinoma. Also, differentiating between reactive and
malignant mesothelial cells can be difcult. Cytology was
positive for malignancy in 56 percent in our cases of
mesothelioma, but the cytological diagnoses was correct
only in two-thirds of cases.
The aspect of the pleural uid can be chylous more frequently than in other malignancies because the thoracic
duct can be disrupted by lymphoma involvement:
among 51 cases of lymphoma in our thoracoscopy
series, we found a chyliform appearance in 15.6 percent
of the cases, while it was present in only 2 percent in our
series overall. A right-sided chylous pleural effusion in
lymphoma is mostly associated with involvement of the
thoracic duct at the lower part of the paravertebral zone
in the hemithorax (see also Chapter 29, Effusions from
lymphatic disruptions).
332
(a)
(b)
(c)
(a)
(b)
(c)
(d)
Figure 25.15 Metastatic cancer of the colon. Chemotherapy was given, but the effusion could not be controlled. (a) Chest radiograph
before thoracentesis. (b) Iatrogenic pneumothorax occurred after therapeutic thoracentesis. (c) Necrotic tumor nodules and diffuse
lymphangitis were observed on the visceral pleura at thoracoscopy. One of them (top of the gure, dark umbilicated lesion) was
spontaneously ruptured, with no biopsy performed. (d) Air leak and persistence of pneumothorax was observed after unsuccessful talc
pleurodesis.
334
Repeat pleurodesis
Repeat pleurodesis is especially appropriate in patients
that have a good performance status and with a high recurrence rate. According to our experience, a second talc
poudrage procedure, with increased dosage of talc, can be
helpful.
Repeated thoracentesis
In cases with very poor general condition, repeated thoracenteses may be the only choice available. However, this
option should be kept as a last choice since discomfort,
risks of infection and protein depletion can signicantly
adversely affect the already poor quality of life of those
patients.
Pleuroperitoneal shunt
A pleuroperitoneal shunt can be useful in patients that
have a trapped lung and that are in a generally good condition, provided that they have no signicant ascites.71
Parietal pleurectomy
Parietal pleurectomy by thoracotomy is very effective in
controlling the effusion, but it is associated with signicant
morbidity. Instead, thoracoscopic parietal pleural abrasion
or partial pleurectomy can be effectively performed
through video-assisted thoracoscopic surgery (VATS).
References 335
REFERENCES
= Key primary paper
= Major review article
= Paper that represents the rst formal publication of a
management guideline
1.
2.
3.
KEY POINTS
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
336
14. Macha HN, Reichle G, von Zwehl D, et al. The role of ultrasound
assisted thoracoscopy in the diagnosis of pleural disease. Clinical
experience in 687 cases. Eur J Cardiothorac Surg 1993; 7: 1922.
15. Kaplan LM, Epstein SK, Schwartz SL, Cao QL, Pandian NG. Clinical,
echocardiographic, and hemodynamic evidence of cardiac
tamponade caused by large pleural effusions. Am J Respir Crit
Care Med 1995; 151: 9048.
16. Antony VB, Loddenkemper R, Astoul P, et al. Management of
malignant pleural effusions. Eur Respir J 2001; 18: 40219.
17. Moltyaner Y, Miletin MS, Grossman RF. Transudative pleural
effusions. False reassurance against malignancy. Chest 2000; 118:
885.
18. Fernandez C, Martin C, Aranda I, Romero S. Malignant transient
pleural transudate: a sign of early lymphatic tumoral obstruction.
Respiration 2000; 67: 3336.
19. Assi Z, Caruso JL, Herndon J, Patz Jr EF. Cytologically proved
malignant pleural effusions. Distribution of transudates and
exudates. Chest 1998; 113: 13024.
20. Rodriguez-Panadero F, Lopez-Mejias J. Low glucose and pH levels
in malignant effusions; Diagnostic signicance and prognostic
value in respect to pleurodesis. Am Rev Respir Dis 1989; 139:
6637.
21. Good JT, Taryle DA, Sahn SA. The pathogenesis of low glucose,
low pH malignant effusions. Am Rev Respir Dis 1985; 131:
73741.
22. Sahn SA., Good JT Jr. Pleural uid pH in malignant effusions:
Diagnostic, Prognostic, and therapeutic implications. Ann Int Med
1988; 108: 3459.
23. Sanchez-Armengol A, Rodriguez-Panadero F. Survival and talc
pleurodesis in metastatic pleural carcinoma, revisited. Report on
125 cases. Chest 1993; 104: 14825.
24. Rodrguez-Panadero F, Del Rey Prez JJ. Survival of malignant
pleural mesotheliomas as compared to metastatic carcinomas. Eur
Respir Rev 1993; 3: 20810.
25. Heffner JE, Nietert PJ, Barbieri C. Pleural uid pH as a predictor of
survival for patients with malignant pleural effusions. Chest 2000;
117: 7986.
26. Antunes G, Neville E, Duffy J, Ali N. BTS guidelines for the
management of malignant pleural effusions. Thorax 2003; 58
(Suppl 2): ii2938.
27. Escudero Bueno C, Garca Clemente M, Cuesta Castro B, et al.
Cytologic and bacteriologic analysis of uid and pleural biopsy
specimens with Copes needle. Study of 414 patients. Arch Intern
Med 1990; 150: 11904.
28. Canto A, Rivas J, Saumench J, Morera R, Moya J. Points to consider
when choosing a biopsy method in cases of pleurisy of unknown
origin. Chest 1983; 84: 1769.
29. Maskell NA, Gleeson FV, Davies RJ. Standard pleural biopsy versus
CT-guided cutting-needle biopsy for diagnosis of malignant
disease in pleural effusions: a randomised controlled trial. Lancet
2003; 361: 132630.
30. Loddenkemper R. Thoracoscopy: State of the art. Eur Respir J
1998; 11: 21321.
31. Boutin C, Viallat JR, Cargnino P, Farisse P. Thoracoscopy in
malignant pleural effusions. Am Rev Respir Dis 1981; 124:
58892.
32. Loddenkemper R, Grosser H, Gabler A, et al. Prospective evaluation
of biopsy methods in the diagnosis of malignant pleural effusions:
intrapatient comparison between pleural uid cytology, blind
needle biopsy and thoracoscopy. Am Rev Respir Dis 1983; 127
(Suppl 4): 114.
33. Villena V, Lopez Encuentra A, De Pablo A, et al. Diagnstico
ambulatorio de los pacientes que precisan biopsia pleural. Estudio
de 100 casos consecutivos. [Ambulatory diagnosis of the patients
requiring a pleural biopsy. Study of 100 consecutive cases]. Arch
Bronconeumol 1997; 33: 3958.
34. Porcel JM, Vives M, Esquerda A, et al. Use of a panel of tumor
markers (carcinoembryonic antigen, cancer antigen 125,
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
References 337
65.
66.
67.
68.
69.
70.
71.
72.
73.
26
Effusions from infections: parapneumonic effusion
and empyema
NAJIB M RAHMAN, ROBERT JO DAVIES
The clinical importance of infection in the pleural space
Historical perspective
The epidemiology of pleural infection
The pathophysiology of pleural infection
Clinico-pathological stage correlations in pleural infection
Bacteriology
The diagnosis and clinical assessment of pleural infection
Differential diagnosis
Predictors of clinical outcome in pleural infection
341
342
342
343
345
345
348
349
350
Radiology
Antibiotics
Chest catheter drainage
Intrapleural brinolytics
Other brinolytics studies
Future directions
Key points
References
1.00
Probability of survival
Pleural infection remains an important disease with a signicant clinical impact on respiratory specialists, physicians in general internal medicine and thoracic surgeons.
Diagnosis is often challenging and a sophisticated multidisciplinary management strategy is required, including
physicians, surgeons, radiologists and microbiologists.
This disease is associated with a considerable morbidity
and mortality. Despite this background, there is great variation in the management of these patients118 with an
evidence-based optimal pattern of care still to be established. Recently published studies conrm previous ndings of an overall mortality for pleural infection of up to 20
percent1921 which rises further to about 35 percent in the
immunocompromised host. 22 This mortality appears to
be disease associated in that it occurs over the 6 months
after initial presentation20,21 and by implication is probably
amenable to reduction with improved care. Patients who
survive 6 months after their episode of pleural infection
have a survival similar to normal subjects over the next
4 years (Figure 26.1). The actual mortality risk from
empyema is substantially inuenced by the presence of comorbid disease. In our unit, over a 4-year period, all of the
patients who died from their pleural infection had comorbid disease.21 In addition to this mortality, up to 30
351
353
354
354
357
361
361
362
0.90
0.80
0.70
200
400
600
800
Survival (days)
HISTORICAL PERSPECTIVE
The rst recorded description of empyema is attributed
to the Egyptian physician Imhotep in around 3000BC,25
in which he described An abscess with prominent head
from the breast, perhaps suggestive of empyema complicated by chest wall invasion (empyema necessitans).
However, the rst reliable description of pleural
empyema and its treatment is attributed to Hippocrates
in about 500BC, who treated cases of pleural infection
with open thoracic drainage.26 This remained the primary
treatment for this disorder until the First World War,
though Hewitt and Bulau27,28 described methods for
closed pleural drainage using a chest tube and an underwater seal decades before (18761891). Napoleons
surgeon, Guillaume Dupuytren (17771835), after whom
digital contractures associated with liver disease are
named, succumbed to empyema after announcing that
we would rather die at the hands of God than of surgeons.29,30 The famous Italian tenor Enrico Caruso
(18731921) is likely to have died from empyema. One of
the most graphic historical accounts of pleural empyema
was written by the Oxford physician, Sir William Osler,
(after whom our Unit is named) who described his own,
ultimately terminal, illness in 1919, after refusing thoracic
surgery for his condition.31
The inuenza pandemic of 1919, during the First
World War, led to clusters of empyema cases among the
t young army recruits living in army camps. The treatment of choice was open surgical drainage resulting in a
mortality as high as 70 percent in some outbreaks,32,33
probably attributable to respiratory failure induced by
the large open pneumothorax produced by the thoracotomy.32 Since Streptococcus haemolyticus infection was
responsible for many of these cases, it is interesting to
consider that the streptokinase produced by this organism may have prevented brinous adhesions forming in
the pleural cavity, exacerbating the problem by facilitating complete lung collapse.34,35 The US Army Empyema
Commission was formed to address this problem and
this proved to be a landmark event in the care of this
disorder.34 The Commission noted that dogs with
empyema died more often if treated with early open
drainage rather than delayed intervention, and it advocated the closed tube drainage techniques described by
Hewitt and Bulau.27,28 Their summary recommendations
were:
1.
2.
3.
4.
The implementation of these changes reduced the mortality to 4.3 percent35 and they remain the core aims of physical and supportive therapy to this day.
The next major advance was the discovery of penicillin
that further decreased empyema mortality in the 1940s
and was also associated in a change in the microbiology of
the disease to produce the modern bacterial spectrum
described below.
Intrapleural brinolytic therapy was tried by Tillett and
Sherry36 in the 1940s but did not become standard practice
because of frequent antigenic side effects from this impure
product.
Surgical techniques improved beyond open drainage in
the late nineteenth century, when thoracoplasty was
described by Estlander (1897) and Schede (1890).37,38 This
eliminated the empyema cavity but required major surgery
and was disguring. Decortication of the pleura was rst
described by Fowler and Beck at the end of the nineteenth
century39,40 and most recently video-assisted thoracoscopic surgery (VATS) has been introduced to allow
pleural debridement without formal thoracotomy in some
patients.41
Frequency (%)
Parapneumonic effusion
Post-bacterial pneumonia
Hospital-acquired pneumonia
Primary empyema
Postoperative
Traumatic
Blunt trauma
Penetrating trauma
Iatrogenic
e.g. post chest tube insertion
Abdominal infection
e.g. subphrenic abscess
Miscellaneous
Esophageal perforation
Bacteremia
Rupture of lung abscess into pleural space
intravenous drug abuse (contaminated needles)
70
4
12
3
4
2
5
empyema is sufciently different from that of communityacquired disease that it should probably be considered a
different entity from both the epidemiological and therapeutic standpoints.
Other streptococci 7%
Strep pneumoniae 13%
Strep milleri
group 32%
Staphylococci 11%
Other 8%
Anaerobes 16%
Proteus 3%
Enterobacteriacea
7%
Strep milleri
group 5%
Other 5%
Haemophilus
influenza 3%
Pseudomonas 5%
Streptococci 5%
Enterococci 13%
Staphylococci 18%
Anaerobes 5%
Enterobacteriacea 16%
MRSA 28%
Figure 26.2
cohort.43,50
Bacteriology 345
CLINICO-PATHOLOGICAL STAGE
CORRELATIONS IN PLEURAL INFECTION
Several terms to describe the stages of evolution of pleural
infection are used when applied to the clinical situation.
While these terms are closely related to the pathological
stages as dened above, they are primarily used as a tool to
predict clinical course and guide clinical decision making,
and are hence different. Knowledge of the hierarchy of
clinical terms is important to avoid unnecessary investigations and prevent diagnoses from being missed. Each stage
is associated with a change in pleural uid characteristics,
which reect the pathological progression described above
(Table 26.3).
Empyema
Empyema correlates to the late brinopurulent stage, and
is dened as frank pus in the pleural space (i.e. macroscopic evidence of bacterial and inammatory cell death)
regardless of biochemical and microbiological parameters.
The presence of frank pus in the pleural space is treated
with immediate drainage.
BACTERIOLOGY
There is substantial variation in the reported microbiology
of pleural infection according to clinical context and series.
Appearance
Biochemical markers
Empyema
May be turbid
pH > 7.30
LDH may be elevated
Glucose > 60 mg/dL
or
Glucose pleural/serum ratio > 0.5
Neutrophils usually < 10 000/L
Negative
Negative
May be cloudy
pH < 7.20
LDH > 1000 IU/L
Glucose < 35 mg/dL
Pus
n/a
n/a
May be positive
May be positive
Frank Pus
empyema
Positive microbiology
confirmed pleural infection
Non-purulent and
negative microbiology
Pleural pH
7.20
complicated
parapneumonic
effusion
Intercostal drainage
Despite this variation, there emerges a consistent microbiological pattern which is distinct between communityand hospital-acquired empyema, and is furthermore
distinct from the microbiology of pneumonia.
Detailed microbiological data were recently reported50
from the largest randomized trial in pleural infection
(the MIST1 study20). This represents the largest single
cohort of well-dened microbiology in pleural infection.
In this study, a microbiological diagnosis was achieved
using standard methods in 58 percent (mirroring previous data), with a further 16 percent achieving diagnosis
using nucleic acid amplication techniques (bacterial
DNA polymerase chain reaction).50 The use of DNA
amplication reduced the number of cases remaining
microbiologically undiagnosed from 42 percent with
standard techniques to 26 percent.50 While blood cultures were positive in only 12 percent of cases, they were
often the only positive microbiological test in these
patients.50 The majority of culture positive cases (35
7.20
simple
parapneumonic
effusion
No drain required
Reassess if
not responding
percent of entire group, = 62 percent of microbiologypositive samples) were due to a single aerobic organism,
9 percent due to a single anaerobic organism and 13
percent due to polymicrobial infection. A distinct microbiological pattern was seen in community- and hospitalacquired disease.50
Combining all previous data over the past 10
years4,50,70116 (Table 26.4), a microbiological diagnosis was
reached in 1253 out of 2501 cases (50.1 percent) with
aerobic organisms the most frequent organisms identied
from infected pleural uid. These are most commonly
Gram-positive organisms from streptococcal species followed by Staphylococcus aureus. In the modern era, around
25 percent of culture positive cases are caused by
Streptococcus pneumoniae whereas it accounted for 60
percent of cases prior to the advent of antibiotics.50,117
However, many currently culture negative cases may be
due to this bacterium in patients who may have been
administered antibiotics prior to sampling.
Bacteriology 347
Number
948
680
169
346
36
117
248
197
40
11
20
228
52
64
37
15
18
42
206
51
51
50
21
31
2
22
7
96
1508
% of total
63
45
11.2
22.9
2.4
7.8
16
13.1
2.7
0.7
1
15
3.4
4.2
2.4
1
1.2
2.8
14
3.4
3.4
3.3
1.4
2.1
0.1
1.4
0.5
6
100
1.1
1.0
Cumulative survival
0.9
Community-acquired infection
0.8
0.7
Hospital-acquired infection
0.6
0.5
0.4
0.3
0.2
0.1
0.0
No. at risk
324
322
394
349
338
48
29
27
26
100
200
Time (days)
300
26
400
1.1
1.0
Cumulative survival
0.9
Streptococci
Anaerobic/mixed
Gram-negative
0.8
0.7
0.6
S. aureus
0.5
0.4
137
49
22
34
28
0.3
0.2
0.1
0.0
120
43
17
24
20
100
Mixed Aerobes
120
41
15
22
17
200
Time (days)
No. at risk
117
117
40
39
13
13
20
20
16
16
300
400
1.0
0.9
0.8
pH = 7.2
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
0.1 0.2
0.3 0.4
0.5 0.6
0.7 0.8
0.9 1.0
(a)
Doppler of
blood vessels
within lung
Small rim of
pleural uid
Liver
guide of need for intercostal drainage, they must be interpreted in the context of the clinical scenario, and resampling of pleural uid is advocated if clinical parameters
are not improving. Furthermore, a minority of patients
with an initial pleural uid pH of >7.2 will progress to
require thoracic surgery, reinforcing the need for clinical
evaluation above any single test. The occasional scenario
where the biology of the disease renders pH unhelpful
should also be remembered. In particular, Proteus
mirabilus infection tends to be associated with a high
pleural pH due to the urea splitting activity of this
bacterium, which generates an alkaline medium.75,76
Consolidated Lung
(b)
Figure 26.5 (a) Chest radiography of a 30-year-old man
admitted with infective symptoms and thought to have a pleural
effusion on chest X-ray, which prompted an attempt at bind
pleural aspiration (failed). (b) Subsequent ultrasound image
revealing heavily consolidated lung and a tiny amount of pleural
uid as the cause for the chest radiograph appearance. Normal
blood ow through consolidated lung is shown.
DIFFERENTIAL DIAGNOSIS
The most common problem with differential diagnosis is
the failure to make the correct positive diagnosis. The
potentially indolent presentation of pleural infection can
produce a patient with anorexia, weight loss, little fever,
raised blood inammatory markers and sometimes no respiratory symptoms. In this situation, respiratory disease
may not be considered in the differential diagnosis at all.
Alternatively, this presentation associated with a smooth
round subpleural chest radiograph opacity leads to an
incorrect diagnosis of bronchial malignancy. The best protection against these errors is to have a low threshold for
considering the diagnosis which is particularly important
as this is an eminently treatable disorder.
At the other end of the spectrum, not all patients with a
fever and an acidic/turbid/apparently purulent pleural
effusion have a pleural infection. Pleural involvement
occurs in up to 5 percent of patients with rheumatoid
arthritis with the majority of these patients being male.133
Patients often have markedly acidic pleural uid with a
low glucose level and present with pleuritis. The differentiation between this and a complicated parapneumonic
effusion is challenging. This differential diagnosis is generally easily established by the recognition of the coincident
joint disease and measurement of the serum rheumatoid
factor. However, the not-uncommon scenario of the
patient with rheumatoid arthritis who also has a pleural
infection must also be remembered. Interestingly, the
prevalence of pleural effusion in patients with rheumatoid
effusion seems to be declining and there is a clinical suspicion that this may relate to the use of modern disease modifying therapy such as methotrexate.
Pleural malignancy may also present with fever and an
acidic pleural effusion. Here, the systemic inammatory
response is probably related to tumor-induced cytokine
production. Such patients may have a particularly short
survival,134136 and low pleural uid pH has been related to
poor pleurodesis success and poorer prognosis.137140 It
can be impossible to resolve this differential diagnosis with
certainty at presentation, with the patient requiring treatment for presumed infection until the correct diagnosis is
established by later biopsies or clinical follow up. The
demonstration of predominantly neutrophils on the
pleural uid smear supports the diagnosis of pleural infection while the demonstration of mononuclear cells supports the diagnosis of malignancy.
In a patient with thick opaque pleural uid that is not
malodorous, then chylothorax and pseudochylous effusion enter the differential diagnosis. This differential can
usually be established by bench centrifugation of the
pleural uid (10 minutes at 3000 r.p.m.). This leaves a
clear supernatant in empyema as the cell debris is separated whereas chylous and pseudochylous effusions
remain milky.141 The diagnosis is then conrmed by the
measurement of pleural uid triglyceride and cholesterol
levels and by microscopy for cholesterol crystals.
Occasionally, pleural sepsis secondary to esophageal
rupture can be confused with primary empyema, especially
in the elderly where the rupture may not be associated with
a clear history of vomiting or chest pain. In these circumstances the diagnostic clues include: the presence of food
particles in the pleural uid, a raised pleural uid amylase
of salivary origin and possibly the presence of a hydropneumothorax on chest radiograph. Once suspected, imaging of
the esophagus (e.g. oral contrast enhanced computed
tomography (CT) scan Figure 26.7) is required and a
prompt thoracic surgical consultation is indicated.
Patients with pulmonary embolism can occasionally
present a diagnostic challenge as the patient may present
with fever, pleuritic pain and a pleural effusion. The
pleural uid biochemistry is not usually suggestive of
pleural infection, but is non-specic and CT pulmonary
angiography may sometimes be needed to evaluate this
possibility.142
Finally, if pancreatitis is suspected then a pleural uid
amylase can be ordered and this diagnosis rejected if the
level is normal.143
Oral contrast in
mediastinum
Empyema
Radiology
351
RADIOLOGY
Pleural effusions are often obvious on the chest radiograph
though infected effusions are often loculated and atypical
in appearance. The presence of fever, pulmonary inltrates
and uid should always alert the clinician to the possibility
of a parapneumonic collection (Figure 26.8). The lateral
chest radiograph may conrm pleural uid not suspected
on the postero-anterior image.24 Pleural uid loculation
often results in a D shaped subpleural opacity, which can
easily be misinterpreted as a lung mass by an inexperienced observer. In the ventilated patient who is often
imaged supine, free uid may layer out posteriorly and
then be represented as a hazy opacity of one hemithorax
with preserved vascular shadows.150
Thoracic ultrasound enables the exact localization of
any pleural uid collection and so facilitates image-guided
diagnostic aspiration if required.128,151 It can detect the
presence of as little as 5 mL of pleural uid and is also
highly effective in detecting loculations not seen on CT
images (Figure 26.9). However, the technique is limited by
the fact that it may not identify some separate uid loculations in inaccessible areas of the thorax.
In patients with complex pleural uid collections, contrast enhanced thoracic CT with contrast in the tissue
phase (about 90 seconds after injection) is the imaging
method of choice. It provides detailed information about
uid loculation (though it does not show septations within
loculations), pinpoints the position of existing chest tubes
and can identify any airway obstruction caused by tumour
or foreign body. In addition, CT with intravenous contrast
can usually differentiate between pleural empyema and
Table 26.5 Differentiating between a lung abscess and empyema on contrast enhanced thoracic computed tomography150,152,153
Lung abscess
Often round in shape
Vessels passing through or near
Indistinct boundary between lung parenchyma and collection
Thick and irregular wall, making contact with chest wall at
acute angle
(a)
Empyema
Lenticular in shape
No vessels closely associated
Compression of surrounding lung parenchyma
Smooth margins creating obtuse angles, following contours of
chest
(b)
Figure 26.11 Computed tomography scan (a) and magnetic resonance imaging (MRI) scan (b), T2 weighted images of septated pleural
effusion. The septations are clearly demonstrated on the MRI image. Image courtesy of Dr Fergus Gleeson, Oxford.
Antibiotics 353
ening (cold on PET scanning159,160), but is unable to reliably separate infection and malignancy in the context of
pleural effusion.
ANTIBIOTICS
All patients with parapneumonic effusions or empyema
should receive antibiotics from the time of diagnosis.
Where possible, the antibiotics prescribed should be
guided by bacterial culture results. However, these results
are usually not immediately available and approximately
40 percent of cases will be persistently culture-negative.4,50,70116 The patients clinical setting and the underlying cause of the empyema should therefore dictate the
initial choice of empirical antibiotic therapy, which will be
required for the duration of therapy in 40 percent of
cases.
Intravenous
Hospital-acquireda
Community-acquired
aOral
regimens are not recommended for hospital-acquired infection, but may be required for long-term treatment (see text).
MRSA, methicillin-resistant Staphylococcus aureus.
INTRAPLEURAL FIBRINOLYTICS
Background
The use of intrapleural brinolytic agents to chemically
disrupt the brinous pleural septations of empyema
(Figure 26.12) has been used to aid the drainage of infected
pleural uids for over 50 years. It was rst described in
1949 by Tillet and Sherry,36 who used partially puried
streptococcal brinolysin that contained both streptokinase and strepdornase (a DNAse) to drain infected postoperative haemothoraces. This was associated with
immunological side effects and the use of this agent failed
to become routine practice. Subsequently, the availability
of highly puried streptokinase and non-antigenic urokinase was, in part, responsible for renewed interest in this
therapy.
Streptokinase is a proteolytic enzyme derived from a
bacterial protein of group C beta-haemolytic streptococci.
It forms a complex with plasminogen that then converts
Interventions
Number of patients
Doses
Trial methodology
Results
Bouros et al.77
SK versus UK
50
25 SK versus 25 UK
Randomized
Double blind
Davies et al.85
SK versus saline
24
250 000 IU SK
100 000 IU UK
repeated daily if
required
250 000 IU SK daily
for 3 days
12 SK versus 12 saline
Bouros et al.78
UK versus saline
31
Tuncozgur et al.177
UK versus saline
15 UK versus 16 saline
49
Double blind
100 000 IU SK daily
for 3 days
100 000 IU UK for
5 days
24 UK versus 25 saline
Talib et al.111
SK versus saline
24
Diacon et al.86
SK versus saline
44
SK versus saline
430
Misthos et al.101
Intercostal drain
versus intercostal
drain + SK
127
70 intercostal drain
versus 57 intercostal
drain + SK
SK, streptokinase; UK, urokinase.
Randomized
Double blind
Randomized
Blinding unclear
Maskell et al.20
Randomized
Randomized
Non-blinded
Randomized
Placebo controlled
High rate of withdrawal
Wide inclusion criteria
Surgical referral based on radiology
250 000 IU SK bd for
Randomized
No difference in mortality, need for surgery or combined endpoint.
3 days
No difference in hospital stay, radiographic outcome or lung
function at 3 months. No difference between groups in subgroups
(purulent, short clinical history)
208 SK versus 222 saline Double blind
Surgical referral based on clinical opinion (not radiographic alone)
250 000 IU SK od for
Randomized
Higher treatment success in SK group (67% versus 87%, p < 0.05)
3 days (tube clamped
for 4 hours)
Non-controlled,
Shorter hospital stay and lower mortality in SK group (p < 0.001)
non-blinded
Proportion surviving
without surgery
1.00
0.75
Placebo
0.50
Streptokinase
No. at risk
Placebo
Streptokinase
Intrapleural DNAse
0.25
0.00
222
208
161
140
6
Months
150
129
12
145
125
120
101
Nutrition
Adequate nutrition was identied as a key aim of therapy,
and an important determinant of outcome in pleural
infection during the First World War. Unfortunately, it is
still sometimes overlooked, while complex modern therapies with adjunctive intrapleural agents and/or early minimally invasive surgery receive much attention. Empyema
patients characteristically suffer the protracted catabolic
consequences of chronic infection, including immunodeciency and slow recovery. In one series of 80 patients with
infected pleural uid, a low blood albumin level was the
most important determinant of a fatal outcome.202 It is
therefore essential to provide adequate nutritional support
from the time of diagnosis. This may require nasogastric
or occasionally intravenous feeding.
Bronchoscopy
A small number of empyema patients have a proximal
obstructing lesion as the cause of their empyema. In a UK
series of 119 cases, 40 percent underwent bronchoscopy
and bronchial disease was identied in only ve (<4
percent of the total sample).19 Bronchoscopy is therefore
not routinely appropriate in these patients.6 However,
failure of the empyema to resolve or clinical or radiographic features of bronchial obstruction should indicate
either thoracic computed tomography or bronchoscopy to
identify any bronchial pathology.
without surgical interventions and surgical options are associated with signicant morbidity. It is likely that patients
with late bropurulent or organizing empyema will require
a surgical procedure to establish complete drainage and adequate lung re-expansion, and a proportion of these patients
may require additional surgery.203
Management guidelines suggest that surgical referral
should be made after 7 days of failed medical therapy.6
There are currently a number of surgical options available
to achieve these goals and include;
1.
2.
3.
4.
VATS;
mini-thoracotomy;
open thoracotomy with decortications;
rib resection with open drainage.
Formal thoracotomy with decortication is a major procedure, and the techniques involved have changed little
over the past 50 years.204 This procedure involves removal
of all brous tissue and blood clot from the visceral pleura
and evacuation of all the pus and brous tissue from the
pleural cavity. This eliminates sepsis and allows the lung to
re-expand. The outcome from thoracotomy and decortication is excellent, with reported success rates of 95
percent118 in these highly selected patients, although its
morbidity is substantial. Thoracotomy in general is associated with signicant morbidity;99 one study reported that
over 80 percent will have post-thoracotomy pain at 3
months, decreasing only slightly to 61 percent at 1 year,
and between 3 and 5 percent of patients experience severe
pain.146 Around two-thirds of patients require treatment
for pain up to 6 months after thoracotomy.145 A longer
follow-up study reported 55 percent of patients experiencing chronic pain over 1 year after surgery, with 45 percent
experiencing pain at 2 years, 38 percent at 3 years and 30
percent over 4 years after surgery.144 While the reported
pain intensity was low, 23 percent of patients felt it interfered with their lives, and 9 percent required daily analgesia or intervention (anaesthetic block or referral to pain
clinic).144
The increasingly popular mini-thoracotomy is similar
to a formal thoracotomy and decortication but involves a
much smaller incision. This is possible as the operation is
assisted by the use of a camera that allows the surgeon to
work with open instruments through the small incision.
The introduction of VATS in the late 1980s offered a
less traumatic alternative to thoracotomy and its use in the
treatment of pleural infection has become widespread.66,205210 Its exact niche is still under evaluation, but
recent studies suggest that VATS is effective and is a less
invasive strategy than thoracotomy and decortication in
certain patient cohorts. Published retrospective series on
VATS management of empyema are generally favorable,
with reduced hospital inpatient time, postoperative complications and length of operating time.18,76,99,113,207214
Conversion rates to formal thoracotomy are highly variable in previous studies, ranging from 8 to 59
Interventions
Number of patients
Doses
Trial methodology
Results
SK versus VATS
20
Randomized
Assessor unblinded
High rate of medical
therapy failure
Randomized
9 SK versus 11 VATS
Bilgin et al.76
Sonnappa et al.108
Kurt et al.92
(Pediatric)
60 children
VATS versus drain + UK (30 drain + UK) versus
(24 VATS, 4 VATS +
mini-thoracotomy,
1 repeat VATS)
(Paediatric)
18 children
VATS versus intercostal 10 VATS versus 8
drain (brinolytic
intercostal drain
permissible after in
both groups)
n/a
35 VATS versus 35
intercostal drain
40 000u or 10 000 IU
UK bd for 3 days
(according to child age)
Assessor unblinded
Randomized
Assessor unblinded
Reteplase 0.02 IU/kg
up to 4 times/day
for up to 5 days
Randomized
Assessor unblinded
FUTURE DIRECTIONS
There is increasing interest in molecular techniques for the
diagnosis of pleural infection (e.g. bacterial DNA amplication), and further work is needed to assess this technique.
Although the current evidence suggests that
intrapleural brinolytic therapy is not associated with a
change in long-term outcome, there is interest in newer
brinolytic agents (for example, direct plasminogen activators) either alone or in conjunction with DNase. A
multi-centre randomized trial is currently under way in
the UK assessing these two agents.
The provision of VATs has transformed thoracic
surgery, but its exact role in empyema therapy has not
been the subject of a adequately powered randomized trial,
compared with more traditional methods of surgery or
medical management. There are early indications that
medical thoracoscopy may be useful as an early treatment,
but further evaluation is required.
KEY POINTS
REFERENCES
References 363
49. Yeh TJ, Hall DP, Ellison RG. Empyema thoracis: A review of 110
cases. Am Rev Respir Dis 1963; 88: 78590.
50. Maskell NA, Batt S, Hedley EL, et al. The bacteriology of pleural
infection by genetic and standard methods and its mortality
signicance. Am J Respir Crit Care Med 2006; 174: 81723.
51. Alfageme I, Munoz F, Pena N, Umbria S. Empyema of the thorax in
adults. Etiology, microbiologic ndings, and management. Chest
1993; 103: 83943.
52. Sahn SA, Taryle DA, Good JT Jr. Experimental empyema. Time
course and pathogenesis of pleural uid acidosis and low pleural
uid glucose. Am Rev Respir Dis 1979; 120: 35561.
53. Mavroudis C, Ganzel BL, Katzmark S, Polk HC Jr. Effect of
hemothorax on experimental empyema thoracis in the guinea pig.
J Thorac Cardiovasc Surg 1985; 89: 429.
54. Sasse SA, Jadus MR, Kukes GD. Pleural uid transforming growth
factor-beta1 correlates with pleural brosis in experimental
empyema. Am J Respir Crit Care Med 2003; 168: 7005.
55. Kunz CR, Jadus MR, Kukes GD, et al. Intrapleural injection of
transforming growth factor-beta antibody inhibits pleural brosis
in empyema. Chest 2004; 126: 163644.
56. Kroegel C, Antony VB. Immunobiology of pleural inammation:
potential implications for pathogenesis, diagnosis and therapy. Eur
Respir J 1997; 10: 241118.
57. Broaddus VC, Boylan AM, Hoeffel JM, et al. Neutralization of IL-8
inhibits neutrophil inux in a rabbit model of endotoxin-induced
pleurisy. J Immunol 1994; 152: 29607.
58. Broaddus VC, Hebert CA, Vitangcol RV, et al. Interleukin-8 is a
major neutrophil chemotactic factor in pleural liquid of patients
with empyema. Am Rev Respir Dis 1992; 146: 82530.
59. Idell S, Girard W, Koenig KB, McLarty J, Fair DS. Abnormalities of
pathways of brin turnover in the human pleural space. Am Rev
Respir Dis 1991; 144: 18794.
60. Aleman C, Alegre J, Monasterio J, et al. Association between
inammatory mediators and the brinolysis system in infectious
pleural effusions. Clin Sci (Lond) 2003; 105: 6017.
61. Sahn SA, Reller LB, Taryle DA, Antony VB, Good JT Jr. The
contribution of leukocytes and bacteria to the low pH of empyema
uid. Am Rev Respir Dis 1983; 128: 81115.
62. Light RW, MacGregor MI, Ball WC Jr, Luchsinger PC. Diagnostic
signicance of pleural uid pH and PCO2. Chest 1973; 64:
5916.
63. Miserocchi G. Physiology and pathophysiology of pleural uid
turnover. Eur Respir J 1997; 10: 21925.
64. Mutsaers SE, Kalomenidis I, Wilson NA, Lee YC. Growth factors in
pleural brosis. Curr Opin Pulm Med 2006; 12: 2518.
65. Hamm H, Light RW. Parapneumonic effusion and empyema. Eur
Respir J 1997; 10: 11506.
66. Landreneau RJ, Keenan RJ, Hazelrigg SR, Mack MJ, Naunheim KS.
Thoracoscopy for empyema and hemothorax. Chest 1996; 109:
1824.
67. Neff CC, vanSonnenberg E, Lawson DW, Patton AS. CT follow-up
of empyemas: pleural peels resolve after percutaneous catheter
drainage. Radiology 1990; 176: 1957.
68. Light RW. Pleural diseases, 3rd edn. Baltimore: Williams and
Wilkins, 1995.
69. Rahman NM, Batt S, Gleeson FV, et al. The relationship between
lung parenchymal CT appearances and pleural bacteriology in
pleural infection [abstract]. Am J Respir Crit Care Med 2006; 173:
A11.
70. Ahmed RA, Marrie TJ, Huang JQ. Thoracic empyema in patients
with community-acquired pneumonia. Am J Med 2006; 119:
87783.
71. Wait MA, Sharma S, Hohn J, Dal Nogare A. A randomized trial of
empyema therapy. Chest 1997; 111: 154851.
72. Alfaro C, Fergie J, Purcell K. Emergence of community-acquired
methicillin-resistant Staphylococcus aureus in complicated
parapneumonic effusions. Pediatr Infect Dis J 2005; 24: 2746.
73. Azoulay E, Fartoukh M, Galliot R, et al. Rapid diagnosis of
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
References 365
140.
141.
142.
143.
144.
145.
146.
147.
148.
149.
150.
151.
152.
153.
154.
155.
156.
157.
158.
159.
160.
161.
162.
163.
164.
165.
190.
191.
192.
193.
194.
195.
196.
197.
198.
199.
200.
201.
202.
203.
204.
205.
206.
207.
208.
209.
210.
27
Effusions from infections: tuberculosis
ESTEBAN PREZ-RODRIGUEZ, RICHARD W LIGHT
Introduction
Incidence and epidemiology
Etiology and pathogenesis
Symptoms and laboratory ndings
Radiology
Diagnosis
367
367
368
369
369
369
INTRODUCTION
Tuberculous pleurisy results from Mycobacterium tuberculosis infection of the pleura. It manifests as a pleural effusion with exudative characteristics and can be found either
isolated or in association with pulmonary tuberculosis
(TB).
Pleural TB is one of the most frequent extrapulmonary
manifestations of tuberculosis.1 In a summary of ve
studies carried out in Africa on human immunodeciency
virus (HIV)-positive patients, pleural tuberculosis represented approximately 60 percent of all cases of extrapulmonary TB.26 The incidence of coexisting pulmonary TB
is estimated to be between 34 and 50 percent.7
Since the introduction of anti-tuberculous agents and
measures for its control, the incidence of TB has decreased
signicantly in the developed world. With new infections
being controlled, pleural disease now is seen more as a
reactivation than a primary infection.
373
374
374
375
375
Diagnosis
369
RADIOLOGY
Approximately 30 percent of patients with pleural TB
present with ipsilateral radiological disease in the lung
parenchyma as assessed with the chest radiograph. This
percentage may be as high as 86 percent with chest computed tomography (CT).56
The pleural effusion is generally unilateral and small to
moderate in size. Massive effusions are observed in 1229
percent of cases, and tuberculosis is one of the three most
frequent causes of massive pleural exudates: malignancy
and empyema being the other two.57,58 Joseph et al.59
reported that massive effusions were more frequent in
HIV-positive patients. Less than 10 percent of tuberculous
effusions are bilateral and bilateral effusions are generally
in HIV-positive patients.
Identifying whether pleural TB is a primary infection or
a reinfection can be quite difcult.60 Some authors have
reported that patients with pleural tuberculosis were signicantly less likely to be genotypically clustered than
patients presenting with pulmonary tuberculosis.25
Normally, radiological criteria are used to differentiate
primary and reinfection tuberculosis. Primary TB manifests as lymphadenopathy or lower lobe inltrates. In cases
reported as pleural TB reactivation, the following characteristics are described: advanced age, tobacco habit,
alcohol abuse, signicant weight loss, presence of
Mycobacterium in sputum and pleural effusions of smaller
volume. However, 820 percent of patients with pulmonary TB have atypical radiological appearances,60 and
diagnosis often requires the use of immunological criteria.61
DIAGNOSIS
The clinical likelihood of the diagnosis of pleural TB varies
depending on the prevalence of TB and HIV co-infection.
In a signicant percentage of cases, pleural TB is found in
adults and elderly people. Elderly individuals tend to have
additional comorbidities, making the diagnosis more difcult. We have reported a diagnosis sensitivity of 58 percent
using age, clinical data and thorax X-ray.62
Pleural uid with TB pleuritis is usually an exudate
containing predominantly lymphocytes, with few
eosinophils (<10 percent), or mesothelial cells (<5
percent).63
A denitive diagnosis of tuberculous pleurisy requires
demonstration of M. tuberculosis in sputum or pleural
specimens or the presence of caseating granulomas in the
pleura. Sputum culture is positive in 3050 percent of
patients with pleural and pulmonary tuberculosis, but in
Seibert et al.1
Valdes et al.21
Moudgil et al.26
Chan et al.50
Antoniskis et al.66
Maartens et al.67
Kirsch et al.68
Valdes et al.69
NR, not reported.
No. of cases
Fluid culture
positive %
Biopsy histology
positive %
Biopsy culture
positive %
70
81
62
83
59
62
30
254
58
38
54
23
77
47
NR
37
84
5.76.5
60
51
58
84
80
80
(12/18) 67 (12/18)
8.56.8
NR
(2/5) 40 (2/5)
52
71
60
56
Diagnosis
371
Table 27.2 Utility of adenosine deaminase (ADA) in the diagnosis of tuberculous pleurisy
Authors
Maertens et al.67
Burgess et al.79,a
Valdes et al.80,a
Valdes et al.81,a
Baales J et al.82,b
Segura et al.83,b
Oca et al.84,b
Prez-Rodriguez et al.85,b
De Oliveira et al.86
Blake Berman87
Maritz et al.88
Total
aGalanti
No.
No. of cases of
tuberculous pleurisy
Sensitivity %
Specicity %
109
303
405
350
218
600
182
304
276
202
368
3317
82
143
91
76
82
170
46
48
54
82
107
981
45
50
47
47
70
71
45
40
40
4071
77
91
100
100
98
100
100
88
91
95
93
93.9%
83
81
95
91
96
92
97
97
96
96
81
91.3%
Table 27.3 Adenosine deaminase (ADA) and ADA1/ADApleural activity in the diagnosis of tuberculous pleuritis
Authors
Valds et al.80
Prez-Rodriguez et al.91
Total (TB)
ADA
S%
Sp %
Ef %
Total (TB)
350 (76)
103 (27)
100
89
93
92
91
101 (76)
103 (27)
ADA, adenosine deaminase; TB, no. with tuberculous pleuritis; S, sensitivity; Sp, specicity; Ef, efciency.
ADA1/ADApleural
S%
Sp %
100
100
97
99
Ef %
98
99
Treatment of patients with tuberculosis should generally be monitored by ofcial public health centers to
ensure: administration of correct therapy, which helps
prevent the emergence of resistant mycobacteria; coordination of contact tracing; monitoring of the pattern of
resistances to drugs in the community; adequate education
of patients; and identication of possible outbreaks.105
Therapy of pleural TB, as for pulmonary TB, is based on
the use of therapeutic regimens with combination of drugs
directed at reducing the population of mycobacteria
without creating resistance and at sterilizing the lesions
during the prolonged treatment phase. Duration of treatment, number of drugs, use of steroids, therapeutic
drainage and intrapleural urokinase are aspects of possible
controversy.
One of the most widely recommended therapeutic regimens is a 6-month treatment course. An initial phase with
isoniazid (510 mg/kg.day up to 300 mg/day), rifampin
(600 mg/day) and pyrazinamide (1.52 g/day) administered daily for 2 months is followed by isoniazid and
rifampin daily during the following 4 months.106 If the
patient lives in a region with more than 4 percent primary
resistance to isoniazid, comes from an area where high
Pleural effusion
Tuberculosis suspected
(symptoms, thoracic X-ray
and other analyses)
Tuberculosis suspected by
biochemical parameters
from pleural fluid
Tuberculosis clinically
suspected
ADA 35 IU
Lymph/neutrophil 0.75
age 35 years
Tuberculosis
Figure 27.1
Thoracenteses and
closed needle pleural
biopsy
Negative Mycobacterium
in pleural fluid or tissue
and no presence of
necrotizing granulomas
Mycobacterium
in pleural fluid or tissue
or
necrotizing granulomas
COMPLICATIONS
Residual pleural thickening, empyema and thoracic wall
infection are the most frequently described complications.
Others, such as non-Hodgkins lymphomas, sarcomas and
other malignancies can present themselves after chronic
inammatory processes119,120 but these complications are
very unusual.
Residual pleural thickening is the most frequent complication. Its incidence varies according to the time of evaluation and the degree of thickness. At the conclusion of
treatment, 4350 percent of patients have pleural thickening of more than 2 mm121,122 and 20 percent have more
References 375
KEY POINTS
Therapeutic drainage of the effusion can signicantly improve the symptoms. There is insufcient evidence to justify the routine use of
corticoids as adjuvant therapy.
Pleural thickening (>210 mm) complicates up
to 43 percent of cases. Neither pleural uid biochemistry nor type of treatment predicts the
development of pleural thickening. Empyema is
an unusual complication that requires pleural
drainage and prolonged anti-tuberculous treatment.
REFERENCES
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
References 377
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
121.
122.
123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.
28
Effusions from infections: atypical infections
LISETE R TEIXEIRA, FRANCISCO S VARGAS
Fungi
Bacteria
Parasites
379
382
383
FUNGI
Pleural disease associated with fungal infection represents
less than 1 percent of all pleural effusions.1
Candidiasis
Candida sp. is the most common pathogen in fungal
pleural empyema (Figure 28.1); the species known as albicans is found in more than 50 percent of cases.2 Empyema
has been reported as a complication of gastropleural
stula, spontaneous esophageal rupture and after chest or
abdominal surgeries.3 Since Candida sp. commonly colonize the skin, chest tube drainage or repeated thoracentesis after inadequate aseptic procedures predisposes to
fungal infection.2,3
Viruses
Key points
References
385
386
387
Aspergillosis
Tuberculosis, malignant diseases, granulocytopenia and
the use of corticosteroids, cytotoxic agents and multiple
antibiotics have been implicated in the development of
aspergillosis.5
The route of the pleural infection is through a bronchopleural or a pleurocutaneous communication. Aspergillus
can reach the structures adjacent to the pleura, resulting in
osseous involvement or the appearance of cutaneous
empyema necessitatis.6
The pleural effusion is an exudate or an empyema with
symptoms of fever, dyspnea, productive cough or
haemoptysis.1 When colonies of hyphae (Figure 28.2) are
seen in the pleural uid or in histological sections (pleural
biopsy), a presumptive diagnosis can be made, but it
should be conrmed by culture. Immunological tests serve
as important aids in the diagnosis, particularly in patients
with negative cultures. The detection of circulating antibodies or Aspergillus antigens is useful in establishing the
etiology.7 The appearance of pleural empyema with an
airuid level upon radiological study is indicative of a
bronchopleural stula requiring immediate treatment.6
Antifungal drugs and surgery (drainage and resection)
should be considered in the treatment of the pleural
Cryptococcosis
The genus Cryptococcus (Figure 28.3) which is found
throughout the world, contains many species, but only
Cryptococcus neoformans is considered a human
pathogen, and rarely produces pleural effusions.9 Some
predisposing condictions are: malignant lymphoma, dia-
betes mellitus, renal failure, treatment with immunosuppressive drugs and acquired immune deciency syndrome (AIDS).10
The organism is usually found in bird excreta that have
accumulated over long periods. At least four serotypes (A,
B, C and D) with epidemiological differences have been
identied. Serotypes A and D are the most common with
the highest prevalence of serotype A in Japan, South Asia,
Brazil, Australia and Southern California.7
The respiratory tract is thought to be the major portal
of entry for C. neoformans, but most cases of pulmonary
infection go unrecognized because they are mild or asymptomatic. The rare pleural involvement appears to occur
from extension of a subpleural pulmonary cryptoccocal
nodule into the pleural space.7,11
The effusion, usually unilateral, may vary in size and is
associated with underlying lung parenchymal lesions,
interstitial inltrates, masses, alveolar consolidation and
lymphadenopthy. The pleural uid is an exudate, frankly
bloody or serosanguinous. In approximately 50 percent of
cases, the lymphocytes are the predominant cells. Culture
of the uid is positive in about half of the patients; in the
remaining cases, the diagnosis is made by histological
study, culture of lung tissue or identication of cryptococcal antigen in the blood, pleural uid or cerebrospinal
uid.11
Serious underlying illness is frequently present.
Cryptococcal pleural effusion most commonly occurs in
patients with associated diseases such as AIDS, leukemia or
lymphoma. It is also observed in patients who have
received a transplant or who are being treated with corticosteroids and/or immunosuppressant drugs, which
depress the immune response.11 Patients with pleural cryptococcosis are candidates for therapy with amphotericin B
and/or uconazole.7,11
Coccidioidomycosis
Coccidioidomycosis is caused by the fungus Coccidioides
immitis, endemic in certain areas of the Americas.
However, the number of cases has been increasing due to
tourism and turnover of military personnel.12,13
Coccidioidomycosis is acquired by inhalation of
spores, the incubation period is usually 1016 days and
approximately 60 percent of infections are asymptomatic.1214
The symptoms are self-limited (u-like illness) with
recovery after 36 weeks. Hematogenous dissemination
tends to occur in patients with underlying diseases.12,14
Pleural effusion has been reported in 720 percent of
symptomatic cases. Effusions are usually left-sided and
rarely on the right or bilateral. Generally, they are small
and clear completely in a few days. In approximately 2
percent of cases the effusion is large, clearing in several
weeks or persisting for more than 1 year. In approximately
50 percent of patients, a pulmonary inltrate is observed;
Fungi
Histoplasmosis
The etiological agent Histoplasma capsulatum is a dimorphic fungus, whose growth is favored in warm humid soils
containing high concentrations of chicken, pigeon or bat
feces. It is an endemic mycosis in certain areas of America,
East Asia, Oceania, Africa and in the Middle-East. In
Europe, the sporadic cases reported in Italy, German,
France, Greece and Switzerland were imported from the
endemic areas.16
Histoplasmosis is acquired through inhalation of airborne spores and is almost never transmitted from person
to person. The granulomatous inammatory response to
H. capsulatum in immunocompetent hosts generally
resolves the infection over several weeks.17
The clinical pulmonary forms are: (1) acute; (2)
chronic and (3) progressive. Approximately 90 percent of
the acute pulmonary infections are asymptomatic. Most
clinically apparent acute pulmonary infections are mildto-moderate in severity, with non-specic symptoms.
Chronic pulmonary disease, which often mimics tuberculosis, occurs almost exclusively in patients with underlying severe chronic obstructive pulmonary disease.
Progressive disseminated pulmonary histoplasmosis
occurs commonly among infants and immunocompromised adults.16
381
Blastomycosis
Human blastomycosis, caused by Blastomyces dermatitidis,
occurs principally in the Ohio and Mississipi River valleys,
USA. Although the disease is commonly known as North
American blastomycosis, it has been reported from other
continents.7
The respiratory tract is the portal of entry in pulmonary
blastomycosis, clinically characterized by fever, chills,
cough and pleuritic chest pain. Although pleural thickening is common (88 percent), pleural effusion is rare (215
Sporotrichosis
Sporotrichosis is caused by the fungus Sporothrix schenckii,
which is found in decaying vegetation, sphagnum moss
and soil. The usual mode of infection is by cutaneous inoculation of the organism. Infection can be related to
zoonotic spread from infected cats or scratches from
digging animals.22
Extracutaneous manifestations are unusual. Pulmonary
sporotrichosis has rarely been reported; when present, it
simulates tuberculosis.22 Morissey and Caso23 described a
case of a pleural exudate with fungus stains positive for
S. schenkii. Examination of the pleura revealed noncaseating granulomas. Cultures of uid and pleural tissue
were negative for mycobacteria.
Treatment includes local measures (hyperthermia),
solution of potassium iodide, azoles, polyenes and allylamines.22
BACTERIA
Actinomyces or Nocardia
The clinical picture is similar to that observed in tuberculosis or fungal infections. The chest radiograph shows an
inltrative consolidation with multiple cavities associated
to pleural thickening or effusion. Nowadays destruction of
ribs or vertebrae is uncommon and sinus tracts of the chest
wall are rarely seen.24,25
The pleural uid is exudative with a predominance of
lymphocytes or an empyema with a predominance of
polymorphonuclear leukocytes. Sulfur granules in the
pleural uid are strongly suggestive of actinomycosis
(Figure 28.5). The granules are yellow-white on inspection
and appear as irregular masses of branched, Gram-positive
laments.1,25 The uid is an important source for isolation
of the organisms; it should be Gram-stained and cultured
anaerobically. Video-assisted thoracic surgery (VATS)
seems to be the most effective diagnostic method.24
The local management of the pleural effusion includes
tube thoracostomy if the uid is an empyema; decortication is sometimes necessary. The specic treatment consists of prolonged administration of high doses of
antibiotics.1,24
Nocardiosis
Nocardiosis is usually caused by Nocardia asteroides, a
Gram-positive aerobic bacteria. Other pathogenic human
species include Nocardia brasiliensis and Nocardia caviae.9
Nocardia species are not human commensals; their
presence in the upper respiratory tract should be considered as evidence of infection. They produce an acute, subacute or chronic pneumonia.9,26
The signs and symptoms of nocardiosis include
anorexia, weight loss, dyspnea, cough with purulent
sputum and occasionally hemoptysis. The presence of
pleuritic pain suggests pleural involvement. Patients with
pleural disease (2550 percent of cases) usually have
parenchymal inltrates and cavitation.9,27
Actinomycosis
Human actinomycosis is caused mainly by Actinomyces
israelii, a normal commensal of the oropharynx. The thoracic infection is caused by aspiration associated with periodontitis or following dental procedures. Alcohol abuse
may increase the risk because it increases the likelihood of
aspiration.24
Thoracic actinomycosis is more common among males,
mainly during the fth and sixth decades of life. The lung
lesion is suppurative with necrosis and abscess formation.
The prevalence of pleural effusion is between 50 and 80
percent.24,25
Parasites 383
Ehrlichiosis
There are two human ehrlichial diseases: a monocytic
disease caused by Ehrlichia chaffeensis and a granulocytic
disease caused by Anaplasma phagocytophilum. The disease
is not uncommon.The symptoms begin 7 days after a tick
bite and are characterized by high fever, headache, myalgias, nausea, vomiting and anorexia. Monoclonal antibodies have been used to detect the organism.31
Pulmonary inltrates and a pleural effusion develop in
approximately 50 percent of patients. The inltrates probably represent non-cardiogenic pulmonary edema with a
pathogenesis similar to the hantavirus syndrome. The
treatment of choice is tetracycline or doxycycline.1,31
Mycoplasma pneumoniae
The organism is a small bacterium derived from ancestral
anaerobic bacteria (clostridia). Bronchopneumonia
involving one or more lobes develops in 310 percent of
infected patients.32 Pleural effusion, generally small, occurs
in 520 percent of patients; empyema is a rare complication.1,33 The pathogenesis of pleural effusion is unclear, but
it is speculated that the presence of M. pneumoniae DNA
may elicit stronger immunological reaction causing lung
damage, with interleukin (IL)-8 and IL-18 playing a role in
the reaction.1,33 The diagnosis is established by increasing
specic antibody titers or by isolating M. pneumoniae from
the pleural uid. The detection of M. pneumoniae DNA in
throat swab specimens through the application of polymerase chain reaction (PCR) has been found to be a sensitive and specic diagnostic technique and the positive PCR
results using pleural uid samples have been found to be
strongly associated with the abnormalities observed on the
radiograms.34
Macrolides are the drugs of choice. No specic treatment is necessary for pleural effusion; however, a diagnostic thoracentesis should exclude a complicated
parapneumonic effusion.1,33
PARASITES
Amebiasis
Amebiasis, a parasitic disease caused by Entamoeba histolytica, is common in third-world countries. Humans
acquire the disease by ingesting the cyst. After the inges-
Echinococcosishydatidosis
Human echinococcosis is caused by three species of
Echinococcus: E. granulosus (producing cystic hydatic in 90
percent of cases), E. multilocularis and E. vogeli.7 When
feces containing the parasites eggs are ingested by
humans, larvae emerge in the duodenum, enter the blood
and lodge in the liver or in the lung. Echinococcus has a
worldwide distribution; however, it is seen more often in
most sheep- and cattle-raising areas.1
The organs most commonly affected are the liver and
the lungs. Pleural involvement is rare, it may be secondary
to hematogenous dissemination of the larvae, however, it
usually follows the rupture of a pulmonary or hepatic cyst
releasing its contents into the pleural cavity. Since the cyst
is not fertile after rupture in about 90 percent of cases,
pleural hydatidosis is rare, occurring in less than 10
percent of the episodes. When the cyst ruptures into the
pleural space, the patient becomes acutely ill, with chest
pain, dyspnea and occasionally goes into shock. In about
50 percent of patients, the rupture occurs simultaneously
into the pleural space and into the tracheobronchial tree.36
In geographic areas where echinococcosis occurs frequently, the diagnosis is usually apparent from the clinical
picture, radiological ndings and results of serological and
skin tests. In non-endemic areas, where physicians are
unfamiliar with echinococcosis, the diagnosis is suspected
only after the cytological examination of the pleural uid
with demonstration of echinococcal scoleces. Eosinophils
are frequently present in the pleural uid, unless it
becomes secondarily infected.1,37 The biochemical characteristics of the pleural uid have not been reported.
In patients with a rupture of a hydatid cyst, a thoracotomy to remove the parasite is recommended. Medical
treatment with benzimidazole compounds such as meben-
Paragonimiasis
Paragonimiasis is caused by numerous species of lung
ukes, (genus Paragonimus). The pulmonary form is the
most common presentation of Paragonimus westermani
and Paragonimus miyazakii. It is a food-borne parasitic
disease common in southeast Asia.38
Humans acquire paragonimiasis by eating undercooked crustaceans contaminated with metacercariae of
the worm. After ingestion, the metacercariae hatch in the
duodenum and the larval uke bore through the intestinal
wall, enter the peritoneal cavity and travel through the
diaphragm to reach the visceral pleura and lung. In the
lung, the adult remains for years producing eggs which are
expectorated or swallowed and excreted in the stools. Once
in water, the eggs turn into ciliated miracidia that infect
freshwater snails. Another larval form develops and is liberated as cercariae that penetrate craysh and crabs. Adult
lung ukes can live in the human host for as long as 20
years, highlighting the need for clinicians to be aware of
the disease in areas where the disease is not endemic.1
In pulmonary paragonimiasis, pleural disease occurs in
approximately 60 percent of patients. The pleural involvement is represented in 60 percent by pleural effusion (80
percent unilateral), in 30 percent by hydropneumothorax
(half are bilateral) and in 10 percent by pleural thickening.
Pleural paragonimiasis should be suspected in oriental
patients or in patients who have traveled to the Orient.1,39
The diagnosis is made by detecting eggs in sputum,
stool, bronchoscopic lavage or biopsy specimens, or by the
presence of a positive anti-Paragonimus antibody test. The
pleural uid is an eosinophilic exudate with low pH
(<7.10), low glucose (<10 mg/dL) and high LDH
(>1000 IU/L). The pleural uid white-cell count is usually
less than 2000/mm3 with marked eosinophilia. The blood
and sputum commonly show an elevated number of
eosinophils.1,39,40
It has been demonstrated that the levels of immunoglobulin (Ig)E and P. westermani-specic IgE and IgG
immunoglobulins are elevated and higher in the pleural
uid than in the serum, suggesting that these antibodies
are produced in the pleural space. Recently, it was demonstrated that interleukin (IL)-5 concentrations in pleural
effusions are higher in paragonimiasis than in transudates,
empyema, lung cancer or tuberculosis and that these levels
are correlated with the percentage of eosinophils in
peripheal blood and pleural uid.1,39,40
The drug of choice to treat is praziquantel or bithionol.
Pulmonary disease is rarely fatal. Thoracotomy with
decortication may be necessary when pleural surfaces are
abnormally thickened and penetration of the drugs into
the pleural space insufcient to eradicate the infection.1,39,40
Viruses 385
Trichomoniasis
Three species of Trichomonas sp. can parasitize humans:
T. vaginalis (cause of vaginitis), T. hominis (a non-pathogenic protozoan) and T. tenax (a rare cause of pulmonary
disease, including pleural effusion).7
In the few cases of pleural effusion caused by T. tenax,
the characteristics of the patients are similar: alcohol
abusers with poor oral hygiene. Despite its rarity, pleural
infection with Trichomonas should be considered in highrisk patients such as those with cancer, chronic lung
disease and immunosuppression.41
The Trichomonas species present in the lung or in the
pleural uid are generally part of a mixed microbial ora.
Antibiotic therapy should include metronidazole
(1.5 g/day) for 10 to 20 days.7,41
Loiasis
Human infection by the larial parasite Loa loa is characterized by migratory angioedema and subconjunctival
migration of adult parasites. Pulmonary involvement and
pleural effusion are rare. The uid is an eosinophilic
exudate with microlariae. Diethylcarbamazine is used in
the loiasis treatment.42
VIRUSES
Pleural effusions caused by viral infections tend to be small
and self-limiting. For these reasons, in the majority of
cases, the uid is not collected. Moreover, most hospitals
are not equipped to perform virus cultures. These facts
explain why the effusions are usually not recognized.
Adenovirus
A pleural effusion is observed in approximately 40 percent
of patients principally in infections with adenovirus types
3 and 7. The illness is endemic throughout the year and
occurs in all age groups although it is more common
among school-age children.43
The pleural uid is a paucicellular exudate with a predominance of mononuclear cells. In the acute phase, thoracocentesis may reveal an increased number of
polymorphonuclear leukocytes. The diagnosis is established by documenting increasing complement xation
titers or culturing viruses from the uid. At times, cytological evaluation can be diagnostic of viral infection.1,43
Hantavirus
Hantaviruses are members of the genus Hantavirus,
carried by infected rodents and transmitted to humans
Cytomegalovirus
Although Cytomegalovirus (CMV) and Pneumocystis
carinii are the most common opportunistic infections in
AIDS patients, the presence of a pleural effusion is uncommon. Moreover, CMV-infected cells are rarely identied
in the pleural uid (Figure 28.6). These inclusions have
been observed in the mesothelial cells, but they are not
specic.46
It is not well understood how the CMV infection produces a pleural effusion. It is likely that the infected cells
enter into the pleural space through small leaks caused by
recurrent pneumothorax, a frequent complication of P.
carinii pneumonia. It has been suggested that the obstruction of peripheral bronchioles leads to local air trapping
with overextension and rupture of the alveoli. This
sequence enables cells infected with virus to spread into
the pleural space, causing a pleural effusion.46,47
Dengue fever
Dengue fever is transmitted to human beings by mosquitoes. The chief characteristic is the increase of the capillary
permeability with leakage of plasma. Pleural effusion is
common (5095 percent) and generally is a bilateral small
exudate.1,52
Figure 28.6 Cytomegalovirus: photomicrograph (Papanicolaou
stained cytocentrifuge preparation, 400) showing an
intranuclear inclusion. (See also Color Plate 45.)
Herpes virus
Pulmonary infection with Herpes simplex virus manifests
as a pneumonitis, especially in the immunocompromised
host. The presence of pleural effusion is uncommon and
the isolation of the viruses from the pleural uid is rarely
achieved. The disease has been described predominantly in
men with advanced Human immunodeciency virus (HIV)
infection. The exudative and lymphocitic pleural effusion
shows a characteristic cytomorphological appearance,
resembling an immunoblastic not Burkitt or Burkitt-like
lymphoma and a clear immunophenotypic indetermination (non-B, non-T-cell).48
KEY POINTS
Hepatitis
Mononucleosis
Infectious mononucleosis occurs in older children and
adolescents. Pulmonary inltrates are well recognized but
pleural effusion is uncommon.50 Diagnosis is usually made
clinically in conjunction with a positive Monospot;
EpsteinBarr virus (EBV) serology can be used to conrm
the diagnosis.51
References 387
REFERENCES
24.
25.
26.
1. Light RW. Pleural diseases, 5th edn. Baltimore: Lippincott Williams
& Wilkins, 2007.
2. Chen KY, Ko SC, Hsueh PR, et al. Pulmonary fungal infection.
Emphasis on microbiological spectra, patient outcome, and
prognostic factors. Chest 2001; 120: 17784.
3. Schacherer D, Mayer S, Borisch I, et al. Esophagobronchial and
esophagomediastinal stula, pleural and pericardial effusion due
to severe pseudodiverticulosis of the esophagus. Z Gastroenterol
2006; 44: 4915.
4. Mora Duarte J, Betts R, Rotstein C, et al. Comparison of
caspofungin and amphotericin B for invasive candidiasis. N Engl J
Med 2002; 347: 202029.
5. Wex P, Utta E, Drozdz W. Surgical treatment of pulmonary and
pleuro-pulmonary Aspergillus disease. Thorac Cardiovasc Surg
1993; 41: 6470.
6. Soto-Hurtado EJ, Marn-Gmez E, Segura-Dominguez N, et al.
Pleural aspergillosis with bronchopleurocutaneous stula and
costal bone destruction: a case report. Lung 2005; 183: 41723.
7. Murray PR. Manual of clinical microbiology, 6th edn. Washington,
DC: ASM Press, 1995.
8. Regnard JF, Icard P, Nicolosi M, et al. Aspergilloma: A series of 89
surgical cases. Ann Thorac Surg 2000; 69: 898903.
9. George RB, Penn RL, Kinasewitz GT. Mycobacterial, fungal,
actinomycotic, and nocardial infections of the pleura. Clin Chest
Med 1985; 6: 6375.
10. Kawabata T, Matsuyama W, Higashimoto I, et al. Pleural
cryptococcosis with idiopathic CD4 positive T-lymphocytopenia.
Intern Med 2004; 43: 97781.
11. Young EJ, Hirsh DD, Fainstein V, et al. Pleural effusions due to
Cryptococcus neoformans: a review of the literature and report of
two cases with Cryptococcal antigen determinations. Am Rev
Respir Dis 1980; 121: 7437.
12. Batra P. Pulmonary coccidioidomycosis. J Thorac Imaging 1992; 7:
2938.
13. Osaki T, Morishita H, Maeda H, et al. Pulmonary
coccidioidomycosis that formed a fungus ball with 8-years
duration. Intern Med 2005; 44: 1414.
14. Chiller TM, Galgiani JN, Stevens DA. Coccidioidomycosis. Infect Dis
Clin North Am 2003; 17: 4157.
15. Mortara L, Bayer AS. Fever, cough, pleuritic chest pain and pleural
uid eosinophilia in a 30-year-old-man. Chest 1994; 105:
9189.
16. Kapotsis GE, Daniil Z, Malagan K, et al. A young male with chest
pain, cough and fever. Eur Respir J 2004; 24: 5069.
17. Fraser RS, Muller NL, Colman N, Pare PD. Histoplasmosis. In:
Diagnosis of diseases of the chest, 4th edn. Philadelphia:
W Saunders, 1999: 87690.
18. Kilburn CD, McKinsey S. Recurrent massive pleural effusion due to
pleural, pericardial and epicardial brosis in histoplasmosis. Chest
1991; 100: 171517.
19. Carter AB, Hunninghake GW. Massive pleural effusion in diffuse
granulomatous disease. Chest 1997; 112: 2848.
20. Alvarez GG, Burns BF, Desjardins M, et al. Blastomycosis in a
young African man presenting with a pleural effusion. Can Respir J
2006; 13: 4414.
21. Pellegrino A, De Capriles CH, Magaldi S, et al. Case report: Severe
juvenile type paracoccidioiidomycosis with hepatitis C. Am J Trop
Med 2003; 68: 3013.
22. Kauffman CA, Hajjeh R, Chapman R. Practice guidelines for the
management of patients with sporotrichosis. Clin Infect Dis 2000;
30: 6847.
23. Morissey R, Caso R. Pleural sporotrichosis. Chest 1983; 84: 507.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
29
Effusions from lymphatic disruptions
GUNNAR HILLERDAL
Denitions
Incidence and epidemiology
Clinical presentation
Some diseases with special aspects of chylothorax
Etiology and pathogenesis of pseudochylothorax
389
389
391
392
393
394
395
395
395
DEFINITIONS
Chylus or chyle is lymph coming mainly from the gastrointestinal tract. Except for medium-chained triglycerides, most types of fat will be resorbed into the
lymphatics of the intestines and delivered to the general
circulation via the thoracic duct. This explains the peculiar
composition of chylus with high levels of triglycerides,
cholesterol and chylomicrons. The content varies with
whether the person is fasting or has just enjoyed a meal
rich in calories, i.e. fat. Eating will considerably increase
the ow of chylus and its content of fat components.
Chylothorax is the occurrence of chylus in the pleural
space and results from leakage of the thoracic duct due to
damage of the wall, either by trauma or blockage of the
duct with subsequent rupture. The diagnosis is made by
analysis of the pleural uid.
Pseudochylothorax or cholesterol pleurisy is a pleural
uid with a very high content of cholesterol and occurs
when a uid has been present for a long time in the pleural
space surrounded by a brotic pleura with poor vascularization. There are no chylomicrons in the uid and usually
the level of triglycerides is also low. The cholesterol has
been formed in the encapsulated uid and has no connection with lymphatic vessels or chylus.
Both conditions have a common characteristic: the
pleural uid is usually thick, opalescent, whitish or the
colour of caf-au-lait or chocolate milk, due to the very
high fat content. Apart from that, and the high level of
cholesterol, the two conditions have nothing in common.
Etiology of chylothorax
Chylothorax is caused by leakage of chyle from the thoracic duct. This leakage is secondary to trauma, weakening
of the wall, or blockage of the duct (Table 29.1). The
thoracic duct is fairly weak and even an intense sudden
stretching of it can cause rupture, for example a forceful
cough or emesis. It has also been described after the strains
of childbirth both in mother and child, more usually in the
infant.19 It must be remembered that when a fairly trivial
damage such as a cough causes a chylothorax, some
underlying cause must always be suspected and appropriate investigations started. Similarly, when chylothorax
develops in a child, a malformation must be the rst suspicion.
usually an extremely rare complication of most of the different diseases listed in Table 29.1. For example, case
reports in the world literature of chylothorax as a complication of sarcoidosis, goiter or tuberculosis are easily
counted on one hand.
Congenital chylothorax is caused by malformation of
the thoracic duct more often than by the trauma of birth.20
One differential diagnosis could be parenteral nutrition
via a subclavian vein with penetration of the vessel and
leakage into the pleura of the parenteral uid. Analysis of
the pleural content and comparison with the intravenous
solution can give the diagnosis.21
CLINICAL PRESENTATION
The clinical presentation of chylothorax is as for any other
pleural effusion, the main symptom being dyspnea. The
chest X-ray shows the effusion, which should lead to a
diagnostic thoracentesis. The typical whitish uid should
alert the clinician to the possibility of the diagnosis.
Diagnosis of chylothorax
The diagnosis is by analysis of the fats within the pleural
uid. Triglyceride levels greater than 1.2 mmol/L are
highly suggestive of a chylous effusion. In equivocal cases
with lower triglycerides, a lipid electrophoresis can clarify
the diagnosis.33 Very low triglycerides virtually exclude the
diagnosis of chylothorax, but it should be remembered
that after prolonged fasting the levels can be quite low. In
these cases, one can measure the pleural levels of triglycerides after a meal containing a lipid composition, when
the levels should increase, thereby proving that the pleural
effusion is in fact a chylothorax.
Cholesterol values should also be measured simultaneously. High triglyceride levels can occur in pseudochylothorax,34 but in this disease the cholesterol level is
always very high (more than 200 mg/dL) and at
microscopy cholesterol crystals can be seen, which are
thought to be diagnostic.
Cells are also increased, usually more than 1000/mL.
There is a dominance of monocytes and, in particular, of
lymphocytes.
The gross appearance of the uid can be misleading,
and in any pleural effusion of undetermined cause, a
lipoprotein analysis can be helpful.34 Another differential
diagnosis of a turbid or milky uid is an empyema; centrifugation of the uid will in the case of an empyema
show a clear supernatant. The clinical picture is also different in most cases, the patient with empyema being obviously ill, with high fever, etc. The cell picture in empyemas
is also different with almost 100 percent granulocytes. In
rare cases, a chylothorax can become secondarily infected.
Investigations
Once the diagnosis of chylothorax has been established,
investigations as to the cause should be carried out. If there
is no history of trauma or surgery, or if the trauma seems
to be fairly trivial (such as a violent cough), a malignant
lymphoma should be excluded. A computed tomography
(CT) scan of the thorax and upper abdomen should be
performed to visualize any enlarged lymph nodes or other
signs of tumor, and to enable scrutiny of the lungs.
Lymphography can be made to show where the leakage or
blockage is situated.34 This can be of importance for the
clinical decisions of where to take biopsies.
If no cause has been found, thoracic surgery might be
necessary. Biopsies of any suspect area should be taken,
and before the operation it should also be decided whether
ligation of the ductus should be performed at the same
setting. Biopsy of the lung, especially any suspicious part
seen at CT, should be performed, since this is the best way
to diagnose a lymphangioleiomyomatosis. It should be
remembered, however, that even thoracic surgery might
not give a denitive diagnosis. A malignant lymphoma can
be very difcult to diagnose. In all unclear cases, treatment
of the chylothorax should be performed and the patient
then followed up.
Treatment
A large effusion causes respiratory distress, which can be
relieved by thoracentesis. However, the chylus usually
soon reaccumulates, and repeated thoracenteses can be
necessary. Apart from the diminished quality of life, the
patient will lose protein and other nutrients, so some alternative therapy will become necessary in these cases. A
number of different treatments have been tried (Table
29.2).
Treatment of the underlying disease is important and
will in some cases cause the chylothorax to disappear.
Examples are corticosteroids in sarcoidosis8 or treatment
of heart failure. In many instances, for example malignant
lymphomas, specic treatment will have a good effect on
the underlying disease,5 but the damage to the ductus can
remain and consequently so can the chylothorax; therefore, further measures will be necessary.
A low-fat diet, with medium-chain triglycerides, which
to the large extent are absorbed directly into the blood, will
cause the chyle to decrease in amount, but there will still be
vention, a minimally invasive procedure, is now recommended by many, especially if the patients nutritional
status is already poor.2
Chemical pleurodesis for pleural effusions has been
used with varying success for decades. Many different
drugs have been used, the choice of which depended less
on scientic investigations than on local customs. All of
these different drugs have also been used for chylothorax.
Examples are tetracycline, bleomycin43 and talc.44 Talc is
now the most popular substance and good results have
been reported. The general impression is that it is more
difcult to achieve a chemical pleurodesis in chylothorax
than in malignant pleurisy, probably due to the normal
pleura and perhaps a neutralizing effect of the chyle.
An alternative to pleurodesis where for some reasons this
is not feasible, is the pleuro-peritoneal shunt, which in principle is a one-way subcutaneous connection between the
pleura and the peritoneum with a pump that can be activated by light pressure. It requires daily pumping and thus
a cooperative patient. It has been used in some cases of chylothorax11,37 With time, the rupture in the duct often heals,
making it possible to remove the shunt, and it is therefore
recommended especially for infants and children.45
When conservative measurements and pleurodesis have
failed, ligation of the thoracic duct is an alternative. It is
successful in up to 90 percent of patients.46 However, as
mentioned, there can be large variations in the anatomy of
the duct and there can also be smaller tributaries which
can leak, and therefore sometimes a full thoracotomy is
necessary.47 If the patient has drunk full cream before the
operation, the leakage is often visible at surgery,48 but
whether this procedure is worthwhile is controversial. The
ductus is ligated shortly above the diaphragm, and where
the leakage occurs is thus unimportant if it occurs in the
main duct. The surgical procedure can also be performed
by thoracoscopy with good results.49,50 Due to the rich
network of collaterals there are never any problems with
lymph stasis afterwards.
Lymphangioleiomyomatosis
This disease of unknown etiology is rare and occurs only in
women and in their reproductive years. Cells which resemble smooth muscle cells proliferate in the lymphatic vessels
and in the lung, causing reticulonodular inltrates which
are slowly progressive and in the end result in pulmonary
insufciency.5052 Chylothorax occurs in a large proportion in 28 percent in one series50 but in only 13 percent
in another review.51 Pneumothorax and hemoptysis are
other symptoms. The prognosis is poor. Pleurodesis or
thoracic duct ligation can control the chylothorax, as can
octreotide in some reports, but the lung disease is progressive. Some benecial effects are probably seen with
oophorectomy and/or progesterone treatment.
(a)
(b)
Figure 29.2
References 395
Figure 29.3 Typical yellow nails on toes and edema of the foot
(and ankles). (See also Color Plate 47.)
FUTURE DIRECTIONS
Chylothorax is still a problem, but progress in its treatment has been made. The introduction of octreotide has
considerably improved outcome in many cases of chylothorax, but randomized studies are missing so far and
might be indicated in some diseases. In the yellow nail
syndrome, too little is still known about the pathogenesis;
it remains a fascinating but difcult to treat disease.
Hopefully, further studies will give us an effective treatment.
KEY POINTS
REFERENCES
19. Cammarata SK, Brush RE, Hyzy RC. Chylothorax after childbirth.
Chest 1991; 99: 153940.
20. van Straaten HLM, Gerards LJ, Krediet TG. Chylothorax in the
neonatal period. Eur J Pediatr 1993; 52: 25.
21. Wolthuis A, Lamdew RBM, Theunissen PHMH, Westerhuis LWJJM.
Chylothorax or leakage of total parenteral nutrition? Eur Respir J
1998; 12: 12335.
22. Restoy EG, Cueto FB, Arenas EE, Duch AA. Spontaneous bilateral
chylothorax: uniform features of a rare condition. Eur Respir J
1988; 1: 8723.
23. Flaherty S, Ellison R. Bilateral chylothorax following thymectomy:
resolution following unilateral drainage. Mil Med 1994; 159: 6278.
24. Janssen JP, Joosten HJM, Postmus PE. Thoracoscopic treatment of
postoperative chylothorax after coronary bypass surgery. Thorax
1994; 49: 1273.
25. Cheng WC, Chang CN, Lin TK. Chylothorax after endoscopic
sympathectomy; case report. Neurosurgery 1994; 35: 3302.
26. Riquet M, Darse-Derippe J, Saab M, et al. Chylome mdiastin aprs
mdiastinoscopie. A propos dune observation. Rev Mal Respir
1993; 10: 4736.
27. de Winter RJ, Bresser P, Remer JWP, Kromhout JG, Reekers J.
Idiopathic chylopericardium with bilateral reux of chyle. Am
Heart J 1994; 127: 9369.
28. Rose DM, Colvin SB, Danilowicz D, Isom OW. Cardiac tamponade
secondary to chylopericardium following cardiac surgery: case report
and review of the literature. Ann Thorac Surg 1982; 34: 3336.
29. Dunn RP. Primary chylopericardium: a review of the literature and
an illustrated case. Am Heart J 1975; 89: 36977.
30. Chyloptysis in adults. Presentation, recognition, and differential
diagnosis. Chest 2004; 125: 33640.
31. MacFarlane JR, Holman CW. Chylothorax. Am Rev Respir Dis 1972;
105: 28791.
32. Valentine VG, Raffn TA. The management of chylothorax. Chest
1992; 102: 58691.
33. Staats BA, Ellefson RD, Budahn LL, et al. The lipoprotein prole of
chylous and nonchylous pleural effusions. Mayo Clin Proc 1980;
55: 7004.
34. Hamm H, Pfalzer B, Fabel H. Lipoprotein analysis in a chyliform
pleural effusion: implications for pathogenesis and diagnosis.
Respiration 1991; 58: 294300.
35. Ngan H, Fok M, Wong J. The role of lymphography in chylothorax
following thoracic surgery. Br J Radiol 1988; 61: 10326.
36. Akaogi E, Mitsui K, Sohara Y, et al. Treatment of postoperative
chylothorax with intrapleural brin glue. Ann Thorac Surg 1989;
48: 11618.
37. Jensen GL, Mascioloi EA, Meyer LP, et al. Dietary modication of
chyle composition in chylothorax. Gastroenetrology 1989; 87: 7615.
38. Paes ML, Powell H. Chylothorax: an update. Br J Hosp Med 1994;
51: 48290.
39. Marts BC, Naunheim KS, Fiore AC, Pennington DG. Conservative
versus surgical management of chylothorax. Am J Surg 1992; 164:
5325.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
Lamberts SWJ, van der Lely AJ, de Herder WW, Hoand LJ.
Octreotide. New Engl J Med 1996; 334: 24654.
Kalomenidis I. Octerotide and chylothorax. Curr Opin Pulm Med
2006; 12: 2647.
Mares DC, Mather PN. Medical thoracoscopic talc pleurodesis for
chylothorax due to lymphoma. Chest 1998; 114: 7315.
Fogli L, Gorini P, Belcastro S. Conservative management of
traumatic chylothorax: a case report. Intensive Care Med 1993;
19; 1767.
Norum J, Aasebo U. Intrapleural bleomycin in the treatment of
chylothorax. J Chemother 1994; 6: 42730.
Graham DD, McGahren ED, Tribble CG, Daniel TM, Rodgers BM.
Use of video-assisted thoracic surgery in the treatment of
chylothorax. Ann Thorac Surg 1994; 57: 150712.
Murphy MC, Newman BM, Rodgers BM. Pleuroperitoneal shunts in
the management of persistent chylothorax. Ann Thorac Surg 1989;
48: 195200.
Noel AA, Gloviczki P, Bender CE, et al. Treatment of symptomatic
primary chylous disorders. J Vasc Surg 2001; 34: 78591.
Zoetmulder F, Rutgers E, Baas P. Thoracoscopic ligation of a
thoracic duct leakage. Chest 1994; 106: 12334.
Kent RB, Pinson TW. Thoracoscopic ligation of the thoracic duct.
Surg Endosc 1993; 7: 523.
Taylor JR, Ryu J, Colby TV, Rafn TA. Lymphangioleiomyomatosis:
clinical course in 32 patients. N Engl J Med 1990; 323: 125460.
Johnson S. Lymphangioleiomyomatosis. Eur Respir J 2006; 27:
105665.
Almoosa KF, McCormack FX, Sahn SA. Pleural disease in
lymphangioleiomyomatosis. Clin Chest Med 2006; 27: 35568.
Hillerdal G. Chyliform (cholesterol) pleural effusion. Chest 1985;
88: 4268.
Ferguson GC. Cholesterol pleural effusion in rheumatoid lung
disease. Thorax 1966; 21: 57782.
Debieuvre D, Gury JP, Ory P, Jobard JM. Association
pseudochylothorax et tuberculose pleurale. Rev Pneumol Clin
1994; 50: 1757.
Garcia-Pachon E, Fernandez LC, Lopez-Azorin F, Padilla-Navas I.
Pseudo-chylothorax in pleural effusion due to coronary artery
bypass surgery. Eur Respir J 1999; 13: 14878.
Hillerdal G. Pulmonary aspergillus infection invading the pleura.
Thorax 1981; 36: 74551.
Emerson PA. Yellow nails, lymphedema, and pleural effusions.
Thorax 1966; 21: 24753.
Iqbal M, Rossoff LJ, Marzouk KA, Steinberg HN. Yellow nail
syndrome. Resolution of yellow nails after successful treatment of
breast cancer. Chest 2000; 117: 151618.
Brofman JD, Hall JB, Scott W, Little AG. Yellow nails, lymphedema
and pleural effusion. Chest 1990; 97: 7435.
Makrilakis K, Pavlatos S, Giannikoupolos G, Toubanakis C,
Katsilambros N. Successful Octreotide treatment of chylous
pleural effusion and lymphedema in the Yellow Nail Syndrome.
Ann Int Med 2004; 141: 2467.
30
Effusions from vascular causes
JOS M PORCEL, RICHARD W LIGHT
Pleural effusions caused by pulmonary emboli
Pleural effusions caused by other pulmonary vascular
diseases
Hemothorax
397
403
Future directions
Key points
References
406
406
407
405
Pathogenesis
Although the precise pathogenesis of the pleural effusions
associated with pulmonary emboli is not known, the fact
that the associated pleural uid can either be an exudate or
(rarely) a transudate suggests that there may be two separate mechanisms.
The mechanism for the exudative pleural effusion is
probably related to increased permeability of the pulmonary capillaries to uid and protein. As a result of the
increased permeability, excess uid enters the interstitial
spaces of the lung and some of this interstitial uid traverses the visceral pleural. In the experimental situation,
more than 20 percent of interstitial uid exits the lung by
passing through the visceral pleura.7 Leckie and Tothill8
have shown that patients with exudative pleural effusion
secondary to pulmonary emboli have a large amount of
protein entering and leaving the pleural space.
The factor(s) responsible for the increased permeability
of the pulmonary capillaries is not denitely known; it is
probable that the increased permeability results from the
Clinical presentation
RISK FACTORS
There are many factors that predispose patients to pulmonary embolism. The most common are major surgery,
previous venous thromboembolism, trauma, immobility
(e.g. infection, acute rheumatism, falls without fractures,
prolonged air travel), malignancy and its treatment, estrogen therapy, hereditable and acquired thrombophilia (e.g.
activated protein C resistance, prothrombin G20210A
mutation, antiphospholipid antibody syndrome), pregnancy and the postpartum state, and hospitalization for
medical conditions including heart failure, stroke and
chronic lung disease. Less common risk factors are
advanced age, obesity, central venous catheters, acute
infections, or certain medical disorders such as myeloproliferative diseases, nephrotic syndrome, inammatory
bowel disease or paroxysmal nocturnal hemoglobinuria.14,15 Importantly, approximately 20 percent of
patients with pulmonary embolism have no predisposing
factors.16,17 Pulmonary embolism is thought to be a disease
of old people, yet 12 percent of 400 patients with pulmonary embolism in one series were under 40 years old.18
SYMPTOMS AND SIGNS
Patients with pulmonary emboli present with three different symptom complexes: (1) pleuritic chest pain or
hemoptysis (pulmonary infarction); (2) isolated dyspnea;
Investigations
CLINICAL PROBABILITY OF PULMONARY EMBOLISM
The best screening test for pulmonary embolus is measurement of the D-dimers in the peripheral blood. D-dimers
are degradation products that result from the breakdown
of cross-linked brin by plasmin. Fibrin is cross-linked by
factor XIII and is the primary component of thrombus
material. Increased levels of D-dimer are found in condi-
Wells criteria
Clinical signs and symptoms of deep venous thrombosis
Alternative diagnosis less likely than pulmonary embolism
Heart rate >100 beats/minute
Surgery or bedridden for 3 days in the previous 4 weeks
Previous deep venous thrombosis or pulmonary embolism
Hemoptysis
Active cancer (treatment within 6 months, or palliative)
Clinical probability
Low
Intermediate
High
Pulmonary embolism likely
Pulmonary embolism unlikely
Revised Geneva score
Heart rate
7594 beats/minute
95 beats/minute
Pain on lower-limb deep venous palpation and unilateral edema
Unilateral lower limb pain
Previous deep venous thrombosis or pulmonary embolism
Surgery or fracture of the lower limbs within 1 month
Active malignant condition (or considered cured <1 year)
Hemoptysis
Age >65 years
Clinical probability
Low
Intermediate
High
3
3
1.5
1.5
1.5
1
1
<2
26
>6
>4
4
3
5
4
3
3
2
2
2
1
<4
410
11
For the past several decades, the perfusion lung scan has
been the primary test by which the possibility of pul-
THORACIC ULTRASONOGRAPHY
SUMMARY
Complications
The two primary complications related to the pleural effusion in patients with pulmonary embolus are hemothorax
and pleural infection. If a pleural effusion enlarges in size
or if a contralateral pleural effusion develops after the initiation of anticoagulant therapy in a patient with a pleural
effusion caused by pulmonary embolism, the patient probably has one of these two complications or recurrent pulmonary emboli.
Patients who develop hemothorax as a complication of
therapy for pulmonary embolus usually develop an
increase in the size of their pleural effusion 47 days after
anticoagulant therapy is initiated.52,53 The coagulation
studies in patients who develop this complication are
usually within an acceptable therapeutic range. The pathogenesis of the hemothoraces in these instances is not clear.
Although they have been attributed to rupture of the pulmonary infarction,54 the evidence for this is somewhat
lacking. The treatment for spontaneous hemothorax complicating anticoagulant therapy is transfusion, as needed,
plus the immediate discontinuation of the anticoagulant
therapy and insertion of chest tubes.2 If brisk bleeding persists, a thoracotomy with resection of the infarcted lobe
may be necessary.54
No
Thoracentesis
Transudate
High
Consider alternative
diagnosis (e.g. heart failure)
Positive
D-dimer assay*
(rapid-ELISA or
advanced turbidimetric assay)
Normal CTA/CTV
Nondiagnostic findings
(subsegmental PE)
Low or moderate
PE probability
PE excluded
High PE
probability
Consider:
Digital subtraction angiography
Serial ultrasonography
Segmental or more
proximal PE
(and/or proximal DVT)
Negative
PE excluded
Figure 30.1 Suggested workup for patient with pleural effusion and suspected pulmonary embolus. PE, pulmonary embolism; CTA,
computed tomographic pulmonary angiography; CTV, computed tomographic venography; ELISA, enzyme-linked immunosorbent assay;
DVT, deep venous thrombosis.
*If measured by latex agglutination a normal D-dimer is only sufcient to exclude PE if the clinical probability of PE is low
If multidetector CTA is used, evaluation for deep venous thrombosis may not be necessary
Hemothorax 405
The seriousness of the syndrome is attested to by a mortality of approximately 5 percent.68 Treatment is supportive
and consists of antibiotics, oxygen, analgesics and transfusion or mechanical ventilation in the more severe cases.
HEMOTHORAX
Etiology
Hemothorax is the presence of a signicant amount of
blood in the pleural space. To establish the diagnosis of
hemothorax, the hematocrit on the pleural uid should be
at least 50 percent that of the peripheral blood. Blood
entering the pleural space coagulates rapidly. Presumably
as a result of physical agitation produced by movement of
the heart and the lungs, the clot may be debrinated.
Loculations occurs early in the course of hemothorax, as
with empyema.
Most hemothoraces result from penetrating or blunt
chest trauma. Approximately 40 percent of patients with
blunt chest trauma develop hemothorax, often in association with pneumothorax.2 An occasional hemothorax
results from iatrogenic manipulation, such as placement of
a subclavian venous catheter or following open-heart
surgery. On rare occasions, a hemothorax results from a
medical condition such as metastatic malignant pleural
disease, anticoagulant therapy, or thoracic endometriosis
(Table 30.2).
Spontaneous hemopneumothorax, dened as the accumulation of more than 400 mL of blood in the pleural
space in association with spontaneous pneumothorax, is a
rare condition occurring in young patients (less than 35
years) that may be life threatening.73 It complicates
approximately 3 percent of spontaneous pneumothoraces
and one-third of patients may experience hemodynamic
instability with hypovolemic shock.73 The bleeding into
the pleural space can result from a torn apical vascular
adhesion.
Diagnosis
In patients with penetrating or blunt chest trauma, the
diagnosis of hemothorax is usually established by the
demonstration of a pleural effusion with a chest radiograph or with ultrasound. In spontaneuous hemopneumothorax, the nding of pneumothorax with an ipsilateral
airuid level is characteristic. The use of chest CT scans
for the evaluation of patients with severe chest injury has
led to the identication of hemothoraces not seen on
supine chest radiographs (occult hemothoraces). For
example, Stafford et al.74 obtained chest radiographs and
chest CT scans in 410 patients with blunt or penetrating
chest trauma and reported that the chest radiograph
missed hemothoraces in 88 patients (21 percent), and
pneumothorax in 75 patients (18 percent).
When a diagnostic thoracentesis reveals pleural uid
that appears to be pure blood, a hematocrit should always
be obtained on the pleural uid. Frequently, even though
the pleural uid appears to be blood, the hematocrit on the
pleural uid is less than 5 percent. A hemothorax should
be considered to be present only when the pleural uid
hematocrit is equal to or greater than 50 percent of the
peripheral blood hematocrit.75
Treatment
The treatment of choice for patients with hemothorax is
the immediate insertion of a chest tube, which has the following advantages: (1) it allows more complete evacuation
of the blood from the pleural space; (2) it stops the bleeding if the bleeding is from pleural lacerations; (3) it allows
one to quantify easily the amount of continued bleeding;
(4) it may decrease the incidence of subsequent empyema
because blood is a good culture medium; (5) the blood
drained from the pleural space may be autotransfused; and
(6) the rapid evacuation of pleural blood decreases the
incidence of subsequent brothorax.2
Large-bore chest tubes (size 28 F to 32 F) should be
inserted in patients with hemothorax because the blood
frequently clots. Chest tubes should be removed as soon as
they stop draining or cease to function (e.g. <50 mL over
6 hours) because they can serve as conduits for pleural
infection. It is recommended that patients who are treated
with tube thoracostomy for traumatic hemothorax be
given antibiotics (e.g. cefazolin) empirically in order to
reduce the incidence of empyema and pneumonia.76 One
exception to prompt-chest tube insertion is suspicion of a
dissection or transection of the aorta, since intercostal
drainage in this situation can lead to rapid exsanguination.
Video-assisted thoracoscopic surgery (VATS) is feasible
and safe for stable patients with continued and uncontrollable bleeding, clotted hemothorax early after the injury or
complex empyema.77
In traumatic hemothorax, immediate thoracotomy is
indicated for massive bleeding (i.e. initial chest tube
output greater than 1500 mL), continued pleural hemor-
FUTURE DIRECTIONS
The combination of a highly sensitive D-dimer assay and
multidetector CTA will become the standard for diagnosing pulmonary embolism as the cause of a pleural effusion.
Additional studies in either animals or humans will be
carried out, which will delineate the exact pathogenesis of
the pleural effusion that occurs with pulmonary embolus.
Additional studies will also be carried out to characterize
the pleural uid that occurs with the acute chest syndrome
secondary to sickle cell anemia and with veno-occlusive
disease. The role of brinolytics in retained clotted hemothorax warrants further investigation.
KEY POINTS
References 407
REFERENCES
31
Effusions in immunocompromised hosts
BEKELE AFESSA, JOHN J MULLON
Introduction
Pleural diseases in patients with human immunodeciency
virus infection
Pleural diseases in transplant recipients
Pleural diseases in hematological malignancies
409
410
413
415
INTRODUCTION
The immune system is composed of two components:
non-specic and specic. The non-specic immune
system does not require prior exposure to infectious agents
or other antigens and consists of mucous membrane and
skin barriers, complements and leukocytes. The specic
immune system requires prior contact with infectious
agents or other antigens and consists of macrophages,
humoral immunity and cell-mediated immunity.
Immunocompromised hosts have primary or secondary
defects in their immune system (Tables 31.1 and 31.2).
Serious immune deciency is uncommon in solid tumors
unless treated with immunosuppressants. Neutropenic
416
416
417
417
417
Phagocytic
Neutropenia
Congenital
Cyclic
Chronic granulomatous disease
Leukocyte adhesion deciency
Hyperimmunoglobulin E syndrome
Myeloperoxidase deciency
ChediakHigashi syndrome
410
Malignancy
Hodgkins disease
Chronic lymphocytic leukemia
Multiple myeloma
Solid tumors
Others
Diabetes mellitus
Renal insufciency
Hepatic cirrhosis
Malnutrition
Alcoholism
Aging
Burn
GVHD, graft-versus-host disease; HIV, human immunodeciency virus; HSCT, hematopoietic stem cell transplant.
Infectious causes
Epidemiology
BACTERIAL
Table 31.3 Causes of pleural effusion in patients with human immunodeciency virus (HIV) infection
Causes
Non-infectious
Renal failure
Hypoalbuminemia
Kaposis sarcoma
Lymphoma
Bronchogenic carcinoma
Pancreatitis
Hepatic cirrhosis
Congestive heart failure
Pericarditis
Atelectasis
Acute respiratory distress syndrome
Pulmonary embolism
Trauma
Surgery
Number
Causes
Number
166
17
23
62
19
8
7
7
10
1
4
1
5
1
1
Infectious
Bacterial pneumonia
Empyema
Mycobacterium tuberculosis
Mycobacterium avium complex
Pneumocystis jiroveci
Cytomegalovirus
Aspergillus spp
Cryptococcus neoformans
Nocardia spp
Leishmanai donovani
Septic emboli
Unknown
403
185
7
165
4
25
1
2
7
3
2
2
54
Malignant causes
Ninety percent of the malignancies reported in acquired
immune deciency syndrome (AIDS) are either KS or nonHodgkins lymphoma (NHL).2 Most of the AIDS-dening
412
OTHER MALIGNANCIES
Miscellaneous causes
Renal failure, cardiac dysfunction, hypoalbuminemia,
pancreatitis, liver failure and other conditions listed in
Table 31.3 should be included in the differential diagnosis
of pleural effusions in AIDS.
IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME
414
Infectious causes
Viruses, bacteria, mycobacteria, fungi and protozoa cause
parapneumonic effusions and empyema in transplant
recipients. Parapneumonic effusions and empyemas
develop in 35 percent of lung transplant recipients and
they are more frequent in double than single lung transplant recipients.31,32 In a study of 68 living lobar lung
transplant recipients, empyema developed in two and both
requiring decortication.33 Approximately 30 percent of
liver transplant recipients may develop bacterial pneumonia, some with parapneumonic effusion, in the postoperative period.34
The diagnostic evaluation and treatment of transplant
recipients with parapneumonic effusion and empyema are
similar to those of other patients with these diseases.
BACTERIA
Malignant causes
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER
MYCOBACTERIA
OTHER HEMATOLOGICAL MALIGNANCIES
In endemic areas and in patients at high risk for M. tuberculosis infection, tuberculous pleural effusion should be
included in the differential diagnoses. The measurement of
ADA activity in pleural uid provides a good tool for the
diagnosis of tuberculous pleural effusion in transplant
recipients.38
FUNGI
NON-HEMATOLOGICAL MALIGNANCIES
Miscellaneous causes
LUNG TRANSPLANT RECIPIENTS
The pleural effusion that occurs in lung transplant recipients in the early postoperative period is bloody, exudative
and neutrophil predominant.31,53,54 In single lung transplant recipients, the effusion develops on the same side as
the graft.31 Pleural uid output as well as its cellularity,
lactate dehydrogenase, and total protein content decrease
rapidly over the rst week following lung transplant.53 Less
than 1 percent of cells in the pleural uid are of donor
origin by the eighth day of transplant.55 Late postoperative pleural effusions, usually exudative with lymphocyte predominance, occur in approximately 20 percent
of lung transplant recipients. In the absence of infection or
rejection, the effusions resolve without recurrence and no
pleural uid analysis is needed.
Pleural complications are more common in double
than in single lung transplantation. Stenosis or thrombosis
of pulmonary venous anastomosis may cause venous
outow impairment leading to unilateral edema and
pleural effusion.56 The pulmonary reimplantation
response, a form of non-cardiogenic pulmonary edema
that begins soon after lung transplant and resolves in days
to weeks, may be associated with pleural effusion.57
Reperfusion injury, rejection and infection may lead to
graft failure after lung transplant resulting in capillary leak
syndrome with pleural effusion.55 The pleural effusion in
acute lung rejection is exudative with lymphocyte predominance. Acute rejection occurs in most recipients and is
characterized by a dramatic response to steroid therapy.
Pleural complications, commonly air leak and loculated
pleural effusion, occur in approximately 35 percent of
living lobar lung recipients.33 Pleural effusions in lung
transplant recipients may result from subpleural hematoma, chylothorax and hemothorax.32 Persistent chylothorax and hemothorax may necessitate thoracic duct and
bronchial artery ligation.32
HEART TRANSPLANT RECIPIENTS
During the early post-transplant period, urinary obstruction due to a failed ureteroneocystotomy or ureteral injury
may lead to retroperitoneal urinoma with subsequent
urinothorax.63 Urinothorax can result from a perirenal
lymphocele during the later period after transplantation.55,64 Lymphocytic, exudative pleural effusion secondary to sarcoidosis, that resolved following corticosteroid
therapy, has been described in a kidney transplant recipient.65
HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
Pneumothorax
Pneumothorax develops in approximately 10 percent of
lung transplant recipients, the most common cause being
transbronchial lung biopsy.31,32 The pneumothoraces
usually resolve spontaneously or with tube thoracostomy.
Pneumothoraces have been reported in 7.0 percent of liver
transplant73 and 4.5 percent of heart transplant recipients.40 In HSCT recipients, pneumothorax may complicate
bronchoiolitis obliterans associated with chronic GVHD.74
416
Presentation
Rheumatoid disorders
Recurrent infection (pyogenic)
Pneumonia (Staphylococcus aureus, Pseudomonas, Candida, Aspergillus)
Pneumonia (encapsulated bacteria and viruses)
Opportunistic infections (viral, Pneumocystis, mycobacterial)
References 417
FUTURE DIRECTIONS
The global spread of HIV infection and the utilization of
immunosuppressant medications and transplant to treat
various diseases have led to an increased number of
immunocompromised hosts. Infectious and non-infectious pleural complications occur as the result of immunodeciency. Despite the heterogeneity of the conditions
causing immunodeciency, future prevention should
focus on minimizing the level of immunosuppression and
nding prophylactic measures to reduce the risk of pleural
complications. Currently, the diagnostic approach to
pleural effusion does not differ signicantly between the
immunocompromised host and immunocompetent
patients. Studies are needed to dene the best diagnostic
approach to pleural effusion in the various groups of
immunocompromised patients. Newer and better antibiotics and anti-neoplastic medications are likely to improve
the outcome of pleural complications in the immunocompromised host. However, research aimed at restoration of
immunocompetence should be given high priority.
KEY POINTS
REFERENCES
418
36. Thacker WL, Benson RF, Schifman RB, et al. Legionella tucsonensis
sp. nov. isolated from a renal transplant recipient. J Clin Microbiol
1989; 27: 18314.
37. Natrajan S, Hadeli O, Quan SF. Infected spontaneous chylothorax.
Diagn Microbiol Infect Dis 1998; 30: 312.
38. Chung JH, Kim YS, Kim SI, et al. The diagnostic value of the
adenosine deaminase activity in the pleural uid of renal
transplant patients with tuberculous pleural effusion. Yonsei Med
J 2004; 45: 6614.
39. Canver CC, Patel AK, Kosolcharoen P, et al. Fungal purulent
constrictive pericarditis in a heart transplant patient. Ann Thorac
Surg 1998; 65: 17924.
40. Lenner R, Padilla ML, Teirstein AS, et al. Pulmonary complications
in cardiac transplant recipients. Chest 2001; 120: 50813.
41. Collet G, Marty P, Le Fichoux Y, et al. Pleural effusion as the rst
manifestation of pulmonary toxoplasmosis in a bone marrow
transplant recipient. Acta Cytol 2004; 48: 11416.
42. Schulman LL, Reison DS, Austin JH, et al. Cytomegalovirus
pneumonitis after cardiac transplantation. Arch Intern Med 1991;
151: 111824.
43. Abe K, Suzuki K, Kamata N, et al. [High-resolution CT ndings in
cytomegalovirus pneumonitis after bone marrow transplantation].
Nippon Igaku Hoshasen Gakkai Zasshi 1998; 58: 711.
44. Harris NL, Ferry JA, Swerdlow SH. Posttransplant
lymphoproliferative disorders: summary of Society for
Hematopathology Workshop. Semin Diagn Pathol 1997; 14: 814.
45. Halkos ME, Miller JI, Mann KP, et al. Thoracic presentations of
posttransplant lymphoproliferative disorders. Chest 2004; 126:
201320.
46. Ohori NP, Whisnant RE, Nalesnik MA, et al. Primary pleural
effusion posttransplant lymphoproliferative disorder: Distinction
from secondary involvement and effusion lymphoma. Diagn
Cytopathol 2001; 25: 503.
47. Lamba M, Jabi M, Padmore R, et al. Isolated pleural PTLD after
cardiac transplantation. Cardiovasc Pathol 2002; 11: 34650.
48. Wolford JF, Krause JR. Posttransplant mediastinal Burkitt-like
lymphoma. Diagnosis by cytologic and ow cytometric analysis of
pleural uid. Acta Cytol 1990; 34: 2614.
49. Jones D, Ballestas ME, Kaye KM, et al. Primary-effusion lymphoma
and Kaposis sarcoma in a cardiac-transplant recipient. N Engl J
Med 1998; 339: 4449.
50. Park J, Park SY, Cho HI, et al. Isolated extramedullary relapse in
the pleural uid of a patient with acute myeloid leukemia
following allogeneic BMT. Bone Marrow Transplant 2002; 30:
579.
51. Germing U, Kobbe G, Sohngen D, et al. Early occurrence of an
adenocarcinoma after allogeneic bone marrow transplantation in
a patient with AML. Oncol Rep 1999; 6: 8557.
52. Motherby H, Ross B, Kube M, et al. Pleural carcinosis conrmed by
adjuvant cytological methods: a case report. Diagn Cytopathol
1998; 19: 3704.
53. Judson MA, Handy JR, Sahn SA. Pleural effusions following lung
transplantation. Time course, characteristics, and clinical
implications. Chest 1996; 109: 11904.
54. Shitrit D, Izbicki G, Fink G, et al. Late postoperative pleural
effusion following lung transplantation: characteristics and
clinical implications. Eur J Cardiothorac Surg 2003; 23: 4946.
55. Judson MA, Sahn SA, Hahn AB. Origin of pleural cells after lung
transplantation: from donor or recipient? Chest 1997; 112: 4269.
56. Liguori C, Schulman LL, Weslow RG, et al. Late pulmonary venous
complications after lung transplantation. J Am Soc Echocardiogr
1997; 10: 7637.
57. Khan SU, Salloum J, ODonovan PB, et al. Acute pulmonary edema
after lung transplantation: the pulmonary reimplantation
response. Chest 1999; 116: 18794.
58. Lee JT, Durzinsky DS, Wilson WR, et al. Pericardial tamponade and
massive pleural effusion complicating orthotopic heart
transplantation. J Cardiovasc Surg (Torino) 1999; 40: 3779.
References 419
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
32
Effusions from connective tissue diseases
DEMOSTHENES BOUROS, DIMITRIS A VASSILAKIS
Introduction
Systemic lupus erythematosus
Rheumatoid arthritis
Systemic sclerosis
Polymyositis/dermatomyositis
Sjgrens syndrome
Ankylosing spondylitis
Mixed connective tissue disease
421
421
423
424
425
425
425
425
Eosinophiliamyalgia syndrome
Angio-immunoblastic lymphadenopathy
ChurgStrauss syndrome
Wegeners granulomatosis
Miscellaneous diseases
Future directions
Key points
References
INTRODUCTION
Incidence
Deceased.
425
425
425
426
426
426
426
426
Clinical manifestations
Pleuritic pain occurs in most patients with lupus pleuritis.5
It is often distressing and may be prolonged,14 occasionally
necessitating pleurectomy.22 Although many patients
present with painless pleural effusions,23 frequent ndings
include fever, pleural rub and tachycardia.5 Lupus pleuri-
Radiographic imaging
On chest radiography, pleural effusions are generally
small, but occasionally massive.3036 They are bilateral in
approximately 50 percent, with no predilection for the
right or left side4 and may, in serial chest radiographs,
often change sides.14
Diagnosis
In patients with known SLE, the diagnosis is often obvious,
but in patients with pleuritis associated with non-specic
arthritis, the major differential diagnosis is rheumatoid
pleural disease (distinction between the two is covered in
the section on rheumatoid arthritis). SLE pleuritis should
be considered in any patient with an exudative pleural
effusion of unknown etiology.15 Measurement of lactic
acid has been proposed a rapid tool to distinguish between
bacterial pleural inammation and other causes of exudative effusions.37 However, a new pleural effusion in
patients with SLE remains a diagnostic challenge.38
Treatment
Pleural uid analysis
The pleural uid is usually exudative, yellow or serosanguineous.5,15 Hemothorax has also been reported.36,39
Neutrophils or monocytes predominate, but lymphocytes
are common in chronic effusions.3,5 Pleural uid
eosinophilia is generally considered to rule out underlying
SLE.40 The pleural uid pH is usually higher than 7.20, the
glucose concentrations are slightly decreased,5,41 but
usually higher than 60 mg/dL, and lactate dehydrogenase
(LDH) levels are less than the upper normal limits of
serum LDH.3
Reductions in pleural uid complement levels have
been observed,13,15,4244 possibly reecting complement
conversion by immune complexes.3,5,4244 Immune
complex deposition may engender pleural effusions by
increasing capillary permeability.45 Elevated CA-125 levels
have been reported in the pleural uid of a number of connective tissue diseases, including SLE.46,47
Prognosis
Small effusions do not require any treatment, usually
resolve spontaneously and have no known prognostic signicance.15 Conversely, pleuritic pain appears to be an
adverse prognostic marker,15,70,71 with a mean survival of
less than 4 years in affected cases.15
RHEUMATOID ARTHRITIS
Incidence
Pleural involvement in rheumatoid arthritis (RA) was rst
observed in the mid-nineteenth century.72 It has been
found at autopsy in half of the patients.4 On the other
hand, clinical evidence of pleural disease is found in less
than 5 percent of RA patients, while 20 percent experience
pleuritic pain at some stage.7375 Pleuritic pain seems to be
more prevalent in male patients.73,76 In one study with RA,
only 17 (3.3 percent) had pleural effusions, with higher
prevalence in males (7.9 percent) than females (1.6
percent).73 In another radiological/clinical study of 309 RA
patients, chest radiographic evidence of pre-existing
pleural disease was detected in 24 percent of males and 16
percent of females (compared with 16 and 8 percent of
control subjects).76
Differential diagnosis
Clinical manifestations
Fluid analysis
Radiographic imaging
Effusions are bilateral in 25 percent in chest radiographs,73
with no predilection for either side.80 Effusions are usually
small or moderate, but are occasionally massive,81,82 and
may be transient, chronic or recurrent.83 Up to one-third
of patients have simultaneous parenchymal lesions (interstitial lung disease or necrobiotic nodules).73,83
Diagnosis
The typical pleural effusion in RA is exudative with high
titers of rheumatoid factor, low pH, low glucose and high
LDH levels. The diagnostic likelihood is increased with
male gender, age >50, long-standing arthritis and the pres-
Fluid cytology
In a study of 24 patients with RA pleuritis,88 on the cytological examination of the pleural uid, a characteristic
triad of giant multinucleated macrophages, elongated
macrophages and a background of granular debris was
found. The above features have also been observed in other
studies,83,89 but in none of 10 000 non-rheumatoid effusions.88
Rheumatoid arthritis cells or RA cells (ragocytes
with characteristic inclusion bodies, representing phagocytic vacuoles or phagosomes, larger than lysosomes seen
in granular leukocytes) may be present,90 but they have no
diagnostic value88,91 since they may also be seen in tuberculous effusions and empyema.83
Glucose
In a pleural effusion with conrmed absence of bacteria
and acid-fast bacilli with a uid glucose concentration of
25 mg/100 mL or less, despite normal serum glucose concentrations, the diagnosis of RA is the most prominent.92
In 76 rheumatoid effusions, pleural glucose levels were less
than 20 mg/dL in 63 percent, and less than 50 mg/dL in 83
percent.80
The mechanism for low pleural glucose levels in RA is
unknown. Administering glucose increases serum but not
pleural glucose concentrations.75,92 However, glucose in
the pleura is not utilized rapidly; the addition of glucose to
pleural uid in vitro is not associated with signicant cellular glucose utilization.75 It has been suggested that the
rheumatoid inammatory process may inuence the activity of enzymes contributing to cellular membrane carbohydrate transport92 or produces substances interfering
with glucose entry into pleural uid.75
Cholesterol
High concentrations of total lipids and cholesterol have
been observed in some rheumatoid effusions.75,80,93 The
presence of cholesterol crystals in an occasional patient
may give rise to an opalescent sheen.80 Chronicity or high
cellularity are probably necessary for the development of a
high pleural uid lipid or cholesterol content.75,80
Infection
Although it has a highly variable prevalence, empyema is
not uncommon in RE. In one study, 16 percent of all adult
cases with empyema were RA patients. These patients were
half of the 10 patients observed during a 5-year period with
RA effusion.94 In another study, only one of 19 patients
with RA and a pleural effusion had an empyema.73 Among
67 patients with non-tuberculous empyema, three were
associated with RA in another study.95 Middle-aged males
seem to be particularly susceptible.95 Causative factors may
be corticosteroid therapy, a rheumatoid susceptibility to
infection, pre-existing chronic bronchopulmonary infection, pre-existing rheumatoid effusions, altered biochemical characteristics of pleural uid and the formation of
broncho-pleural stulas through necrotic rheumatoid
nodules.94
Biopsy
Most cases of needle biopsy of the pleura have shown nonspecic granulomatous or brotic changes.73,96 Only rarely
Treatment
Most effusions are asymptomatic and do not require specic treatment. Initial treatment with non-steroidal antiinammatory agents may sufce. Some patients respond
to corticosteroids,73,83,93,98 but others do not,4,99,100 and
effusions may recur despite continuing steroid therapy.
Repeated aspirations have been used to control effusions.
At times, persistent symptomatic effusions or pleural
thickening necessitate decortication.101103 In cases of
empyema, drainage and antibiotics are used.77,104
Intrapleural installation of corticosteroids has been
attempted with varying results.99,105 Decortication should
be considered in patients with symptomatic pleural thickening, although it can be technically difcult.103 The significance of pleural thickening can be estimated by serial
pleural pressure measurements during therapeutic thoracentesis; a rapid drop in pleural pressure denotes trapping
of the lung by thickened pleura.106
Long-term outcome
Rheumatoid effusions resolve within 4 weeks in 50 percent
and within 4 months in two-thirds of patients,73 but may
also persist for years in approximately 20 percent.4
SYSTEMIC SCLEROSIS
Pleural effusions have been observed with both
diffuse46,107,108 and limited109 scleroderma, but are uncommon. In a study evaluating the prevalence of serositis in
systemic sclerosis (SSc), none of 37 patients (including 19
with limited SSc) had a pleural effusion. In the same
study, reviewing medical records, pleural effusions were
identied in only four of 58 other SSc patients (7
percent),110 while pericardial effusions were present in 17
percent.
Since a percentage of SSc patients develop SLE overlap,
the above-mentioned low prevalence of pleural effusions
in these patients makes the association uncertain.111
In two cases, pleural effusions in SSc have been associated with elevated serum and pleural uid CA125
levels,46,107 which were seen to decrease with resolution of
the effusion in one case.46
POLYMYOSITIS/DERMATOMYOSITIS
Pleuritic pain is occasionally reported in these conditions,112114 but obvious clinical or radiographic evidence
of pleural disease is rare. In a clinicopathological analysis
of 65 autopsy cases, none of the patients with polymyositis
or dermatomyositis had pleural effusions clinically or at
autopsy.112 Two patients with massive pleural effusions
have been described, both presenting with marked pyrexia
and a good response to corticosteroid therapy.115 Although
cardiomyopathy and hypothyroidism might have contributed to pleural uid accumulation in one case, no confounding features were present in the second patient, a
34-year-old man with dermatomyositis and coexisting
interstitial lung disease.
SJGRENS SYNDROME
There are limited data regarding the epidemiology of
pleural disease in Sjgrens syndrome (SS). There were no
patients with pleural effusion in various series regarding
the prevalence of pleural effusion in patients with primary
SS.116119 In contrast, 5 of 343 secondary SS patients exhibited pleural involvement.120 Pleuritic pain was conned to
patients with secondary SS.119
In the few reports of pleural effusions associated with
primary SS, they were usually bilateral,116,121,122 but may be
unilateral.123 The uid is lymphocytic and exudative, with
normal glucose levels and pH and low adenosine deaminase levels.122124 Studies of serum and pleural uid in one
patient disclosed rheumatoid factor and anti-SS-A antibody, immune complexes and activation of complement,
all localized to the pleural uid.116 Analysis of pleural uid
T-cell receptor beta-chain variable (V beta) regions
revealed overexpression of V beta gene products, including
V beta 2 and V beta 13, previously shown to be overrepresented in salivary glands of SS patients.116
ANKYLOSING SPONDYLITIS
Infection of cavities within the apical brotic tissue in
patients with ankylosing spondylitis (AS) may lead to
underlying pleural thickening or even empyema. Only a
few cases of other forms of pleural disease in AS have been
reported,125127 since pleural involvement is rare.128 Pleural
disease has been identied in 2 of 53 patients (one tuberculous, one non-tuberculous effusion),129 2 of 255 patients
(idiopathic bilateral pleural calcication)130 and 1 of 200
patients (unexplained pleural thickening).131 In all the
above cases the nding may represent the pleural sequelae
of tuberculous or non-tuberculous infection, rather than a
direct complication of AS. Finally, in a radiographic study
of 2080 patients with AS, 10 patients were discovered with
non-apical pleural disease, which did not differ signicantly form the prevalence in controls. Three patients had
transient pleural exudates with normal pleural uid
glucose concentrations, and one had an empyema.132
EOSINOPHILIAMYALGIA SYNDROME
Pleural effusions do occur in patients with eosinophilia
myalgia syndrome (EMS). In one large series of 1531
patients, pleural effusions were found in 12 percent of the
178 who had chest radiographs.142 The prevalence was 33
percent in another study.143 Effusions are usually bilateral
and the uid is a sterile eosinophilic exudative.143,144
Pleural involvement is not necessarily clinically signicant
and has no documented therapeutic or prognostic implication.
ANGIO-IMMUNOBLASTIC
LYMPHADENOPATHY
Pleural effusions occur in angio-immunoblastic lymphadenopathy (AIL). Half of the patients in one study
were found to have a pleural effusion which was usually
associated with ascites and pedal edema.145 The characteristics of the pleural uid are not well described. In a
Japanese series, with a review of the Japanese literature,
pleural effusions were found in 50 percent, including all
ve index cases plus 8 of 21 patients previously reported in
the local literature.146
CHURGSTRAUSS SYNDROME
Pleural involvement in the ChurgStrauss syndrome
(CSS) was generally regarded as rare, based upon a single
KEY POINTS
WEGENERS GRANULOMATOSIS
In the reported studies on patients with Wegeners granulomatosis (WG), presenting mainly small groups of
patients, minor pleural involvement is not infrequent.
Effusions were present on thorax radiography in up to half
of the cases,152155 or less often on CT.156 There is even a
report of a patient with a pleural effusion which was the
presenting symptom of the disease.157 Pleural thickening
has occasionally been evident on chest radiography155 or
CT.158 Pleural aspiration has shown an exudative neutrophil predominant effusion with protein levels ranging
from 3.8 to 5.7 mg/dL.154
Pleural effusions in WG are seldom clinically important
and generally resolve spontaneously, or regress with the
introduction of corticosteroid and/or immunosuppressive
treatment.
MISCELLANEOUS DISEASES
Pleural effusions occasionally accompany other connective
tissue diseases, including polyarteritis nodosa,159 temporal
arteritis,160162 giant cell arteritis,163,164 Kawasaki disease,165
AdamantiadisBehets syndrome,166 human adjuvant
disease167 and adult-onset Stills disease.168170 The major
difculty in characterizing pleural involvement in these
disorders is the fact that these disorders are rare.
FUTURE DIRECTIONS
Multicenter studies are necessary in order to obtain a
better picture of the pleural involvement, which seems to
be a rare manifestation of diseases that are often uncommon themselves. These studies would aid diagnosis,
natural history and best treatment options for pleural
disease in connective tissue diseases.
Thoracoscopy, a procedure which is becoming widely
available, could be of signicant help in this investigation.
REFERENCES
References 427
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
55. Chao TY, Huang SH, Chu CC. Lupus erythematosus cells in pleural
effusions: diagnostic of systemic lupus erythematosus? Acta Cytol
1997; 41: 12313.
56. Hunder GG, Pierre RV. In vivo LE cell phenomenon. Arthritis Rheum
1970; 13: 5701.
57. Greis M, Atay Z. Zytomorphologische Begleitreaction bei malignen
Pleuraerguessen. Pneumonologie (suppl) 1990; 44: 2624.
58. Wang DY, Yang PC, Yu WL, et al. Comparison of different
diagnostic methods for lupus pleuritis and pericarditis: a
prospective three-year study. J Formos Med Assoc 2000; 99:
37580.
59. Khare V, Baethge B, Lang S, Wolf RE, Campbell GD Jr. Antinuclear
antibodies in pleural uid. Chest 1994; 106: 86671.
60. Win T, Groves AM, Phillips GD. Antinuclear antibody positive
pleural effusion in a patient with tuberculosis. Respirology 2003;
8: 3967.
61. Ferreiro JE, Reiter WM, Saldana MJ. Systemic lupus erythematosus
presenting as chronic serositis with no demonstrable antinuclear
antibodies. Am J Med 1984; 76: 11005.
62. Riska H, Fyhrquist F, Selander RK, Hellstrom PE. Systemic lupus
erythematosus and DNA antibodies in pleural effusions. Scand J
Rheumatol 1978; 7: 15960.
63. Porcel JM, Ordi-Ros J, Esquerda A, et al. Antinuclear antibody
testing in pleural uid for the diagnosis of lupus pleuritis. Lupus
2007; 16: 257.
64. Breuer GS, Deeb M, Fisher D, Nesher G. Therapeutic options for
refractory massive pleural effusion in systemic lupus
erythematosus: a case study and review of the literature. Semin
Arthritis Rheum 2005; 34: 7449.
65. Brasington RD, Furst DE. Pulmonary disease in systemic lupus
erythematosus. Clin Exp Rheumatol 1985; 3: 26976.
66. Ben Chetrit E, Putterman C, Naparstek Y. Lupus refractory pleural
effusion: transient response to intravenous immunoglobulins. J
Rheumatol 1991; 18: 16357.
67. Sherer Y, Langevitz P, Levy Y, Fabrizzi F, Shoenfeld Y. Treatment of
chronic bilateral pleural effusions with intravenous
immunoglobulin and cyclosporin. Lupus 1999; 8: 3247.
68. McKnight KM, Adair NE, Agudelo CA. Successful use of
tetracycline pleurodesis to treat massive pleural effusion
secondary to systemic lupus erythematosus. Arthritis Rheum 1991;
34: 14834.
69. Gilleece MH, Evans CC, Bucknall RC. Steroid resistant pleural
effusion in systemic lupus erythematosus treated with tetracycline
pleurodesis. Ann Rheum Dis 1988; 47: 10312.
70. Cook RJ, Gladman DD, Pericak D, Urowitz MB. Prediction of short
term mortality in systemic lupus erythematosus with time
dependent measures of disease activity. J Rheumatol 2000; 27:
18925.
71. Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in
systemic lupus erythematosus during a 5-year period. A
multicenter prospective study of 1,000 patients. European
Working Party on Systemic Lupus Erythematosus. Medicine
(Baltimore) 1999; 78: 16775.
72. Fuller HM. On rheumatism, rheumatic gout and sciatica: Their
pathology, symptoms and treatment. New York: S. S. & W. Wood,
1854.
73. Walker WC, Wright V. Pulmonary lesions and rheumatoid arthritis.
Medicine (Baltimore) 1968; 47: 50120.
74. Hyland RH, Gordon DA, Broder I, et al. A systematic controlled
study of pulmonary abnormalities in rheumatoid arthritis. J
Rheumatol 1983; 10: 395405.
75. Dodson WH, Hollingsworth JW. Pleural effusion in rheumatoid
arthritis. Impaired transport of glucose. N Engl J Med 1966; 275:
133742.
76. Jurik AG, Davidsen D, Graudal H. Prevalence of pulmonary
involvement in rheumatoid arthritis and its relationship to some
characteristics of the patients. A radiological and clinical study.
Scand J Rheumatol 1982; 11: 21724.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
References 429
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
149.
150.
151.
152.
153.
154.
155.
156.
157.
158.
159.
33
Effusions caused by drugs
IOANNIS KALOMENIDIS
Nitrofurantoin
Cardiovascular agents
Cytokines and immunomodulating agents
Ergot derivatives
Retinoids
Chemotherapeutic agents
Muscle relaxants
Vitamins
Anticoagulants
432
432
433
434
435
435
436
437
437
Mesalamine
Clozapine
Antidiabetic agents
Drug-induced lupus pleuritis
Other drugs
Direction of development
Key points
References
437
437
437
438
439
440
440
440
NITROFURANTOIN
Nitrofurantoin is an antibiotic used in the prophylaxis and
treatment of lower urinary tract infections. Since the mid1960s, when the nitrofurantoin-associated pleuropulmonary toxicity was rst recognized,3 over 2000 cases have
been reported.4 Respiratory reactions to nitrofurantoin
may be manifested in two distinct patterns characterized
by the length of treatment prior to the development of the
syndrome.5
The acute presentation (525 percent of the patients
taking the drug) occurs within the rst month of the onset
of the treatment. The symptoms that may appear even
within hours of the drug intake include dyspnea, nonproductive cough and fever. The chest radiograph usually
reveals alveolar and interstitial inltrates that are more
conuent at the lung bases. In one series of 335 patients,6
186 (56 percent) had inltrates, 65 (19 percent) had inltrates and effusion, 14 (3 percent) had only an effusion and
70 (21 percent) had a normal chest radiograph. Others
have reported that the frequency of the effusions may be as
high as 30 percent.4 The majority of the patients with the
acute syndrome have both peripheral eosinophilia
(>350/mm3) and lymphopenia (<1000/mm3).7 The only
reported pleural uid analysis showed 17 percent
eosinophils in the pleural uid.7
The chronic syndrome (5 percent of the patients taking
the drug) occurs when the patient has been taking nitrofurantoin for 2 months to 5 years. The presentation is
insidious, with the gradual onset of dyspnea and a nonproductive cough.5 Diffuse bibasilar inltrates are the
most common radiographic abnormality.6 Pleural effusion
occurs in fewer than 10 percent of patients and has never
been reported in the absence of pulmonary inltrates.5 The
pathogenesis of the acute syndrome may be related to a
hypersensitivity reaction and is not dose-related,8 while
the pathogenesis of the chronic syndrome is thought to
involve damage elicited by oxygen radicals.5,8
The diagnosis of nitrofurantoin pleuropulmonary reaction should be suspected in all patients with a pleural effusion who are taking nitrofurantoin. If the drug is
discontinued, the patient with the acute syndrome usually
improves clinically within 14 days, and the chest radiograph becomes normal within a week.6 Symptoms and
signs in patients with the chronic syndrome improve
much more slowly and pulmonary function may remain
permanently impaired.3,6
CARDIOVASCULAR AGENTS
Amiodarone
Amiodarone is a very effective antiarrhythmic drug, commonly prescribed for the prophylaxis and treatment of
supraventricular and ventricular dysrhythmias.
Pulmonary toxicity has been reported in up to 510
Beta-blockers
Practolol, a beta-blocker, was removed from the market in
1976 because it caused serious adverse effects including
skin, eye, ear, renal, peritoneal and pleuropulmonary disorders.1,8,14 Pleural effusions and pleuropulmonary brosis
have been reported. There is weak evidence that another
beta-blocker, oxyprenolol, may also cause pleural brosis.15 Pleural brosis associated with beta-blockers may be
progressive despite drug discontinuation and corticosteroid administration.
Minoxidil
Minoxidil, a potent vasodilator that is used in the treatment of severe arterial hypertension, has been associated
with the development of pericardial effusion that may
lead to tamponade.1 There is only one report of a patient
who developed exdutative bilateral pleural effusion and
pericardial effusion, 2 months after the initiation of the
drug.16 Both the pericardial and the pleural effusion
resolved upon the discontinuation of the drug. When
minoxidil was readministered, only the pericardial effu-
Imidapril
Yoshida and associates reported on a patient with hypertension treated with imidapril for 6 years who developed
low-grade fever and a left-sided pleural effusion17 with
pleural uid and peripheral eosinophilia (38 and 28
percent, respectively) that did no respond to antibiotics.
Fluid retention is a frequent adverse effect of rhIL-11 treatment and can manifest as peripheral and pulmonary
edema as well as pleural effusions.21 The frequency of
pleural effusions in one study of patients with breast
cancer patients was 42 percent.22 Although all of these
patients had distant metastases and thoracentesis was not
performed in any, the fact that all the pleural effusions
responded well to diuretic treatment suggests that the
most probable explanation of the effusions is uid overload.
Interferons
CYTOKINES AND IMMUNOMODULATING
AGENTS
Interleukin 2
Recombinant human interleukin 2 (rhIL-2), which has
been used in the treatment of melanoma or renal cell carcinoma, is associated with a variety of reversible adverse
effects, including fever, chills, lethargy, diarrhea, anemia,
thrombocytopenia, eosinophilia, confusion and diffuse
erythroderma.18 Respiratory abnormalities include
parenchymal inltrates and pleural effusion. Two
studies,18,19 including a total of 108 patients, indicated that
approximately half of those treated with rhIL-2 may
develop pleural effusion. Diffuse inltrates resembling
pulmonary edema (4180 percent) and focal inltrates (22
percent) may also be present. Pleural effusion may be
found in the absence of parenchymal abnormalities. The
characteristics of the uid were not reported. Patients
receiving bolus rather than constant intravenous therapy
were more likely to develop respiratory complications.18
Severe respiratory failure was reported in 35 percent of the
patients and some of them required intubation and
mechanical ventilation. As reported in one of these studies,
the pleural effusions tended to improve, but they persisted
for 4 weeks following therapy cessation in 17 percent of
patients.18 Pleural effusions resolved later than the
parenchymal inltrates.
The respiratory adverse effects of the rhIL-2 are probably a manifestation of the generalized capillary leak syndrome that may occur after the administration of this
cytokine. Berthianume et al.20 proposed that pulmonary
edema related to the rhIL-2 administration may be the
combined result of increased permeability and hydrostatic
pressure. Thus, it is possible that pleural uid originates
from the leaky capillaries in the lung.
Interleukin 11
Recombinant human interleukin 11 (rhIL-11) is used to
prevent severe thrombocytopenia and to reduce the need
for platelet transfusions following myelosuppressive
chemotherapy in patients with non-myeloid malignancies.
Interferons are used in the treatment of various malignancies and chronic hepatitis. Interferons can cause several
signicant adverse effects including depression, bone
marrow suppression, interstitial pneumonitis, retinopathy, hearing loss, vitiligo and autoimmune diseases, as well
as milder disorders including u-like symptoms,
headache, irritability and alopecia. Pleural effusion, possibly caused by recombinant human interferon-a, has been
reported in a patient with chronic hepatitis C.23 The
patient developed an asymptomatic, moderate, right-sided
exudative, lymphocytic pleural effusion 14 days after
beginning the treatment. Although a slight increase of
serum antinuclear antibody (ANA) titer was observed, the
patients symptoms and signs did not satisfy the criteria of
any autoimmune disorders, including systemic lupus erythematosus (SLE), a disease that may either be exacerbated
or induced by the drug. Tuberculus pleuritis, which is
encountered with increased frequency in patients on interferon treatment, was ruled out. The pleural effusion gradually resolved upon the discontinuation of the interferon.
Immunoglobulin
Bolanos-Meade et al.27 reported a patient with recurrent
pleural effusions attributed to the use of intravenous
immunoglobulin (IVIG) for the treatment of idiopathic
thrombocytopenic purpura. She was receiving a 2-day
course of the IVIG every four to six weeks. On the second
day of the seventh or the eighth course, bilateral exdutative
lymphocytic pleural effusions developed, but resolved
completely 2 weeks later. The effusions could not be attributed to infectious, malignant or autoimmune disease. The
same thing happened with the next course of the IVIG.
However, when a different preparation of IVIG was
administered, there was no recurrence of the pleural effusions. Thus, I would suggest that pleural effusion could
represent a reaction to a component of the rst preparation and not of the IVIG itself.
ERGOT DERIVATIVES
Ergot derivatives have been used in the treatment and prophylaxis of migraine and cluster headaches (methysergide,
ergotamine) and Parkinsons disease (bromocriptine,
dihydroergotamine, nicergoline, pergolide, dopergine,
lisuride, dihydroergocristine, dihydroergocryptine, cabergolide). The long-term administration of any of these
drugs can lead to a distinctive pattern of pleuropulmonary
abnormalities, consisting of pleural brosis with or
without effusion, occasionally associated with parenchymal brosis. First described by Graham et al.28 in 1966 in a
patient receiving methysergide, the potential of ergot
derivatives to produce these brosing abnormalities was
subsequently conrmed and thoroughly characterized.1,14,2939 A variety of other brosing disorders of the
retroperitoneum, mediastinum, pericardium and heart
valves, either singly or, rarely, in combination with pleural
disease has been also reported.14,35,37,39,40
The pathogenesis of the brosis which is induced by the
ergot derivatives remains unclear. It has been suggested that
brinogenesis may be related to the serotoninergic activity
of the drugs, as similar brosing disorders may be seen in
association with serotonin-secreting carcinoid tumors.37
Serotonin can cause either pleural vasoconstriction14 or
tinued the drug after the diagnosis was made had no clinical or radiographic evidence of progressive disease putting
into question the necessity of drug withdrawal. However,
Kok-Jensen et al.,29 who followed-up 12 patients with
pleural brosis caused by methysergide, reported that
those who continued to take methysergide for the longest
period after the onset had the worst disease after 6 months.
Therefore, given the possibility that the disease is doserelated and related to the length of the time the patient has
been on the drug, as well as the excellent outcome after the
drug withdrawal, I would agree with the recommendation
that patients who are taking ergot alkaloids on a long-term
basis should have a radiograph annually; if there is evidence of pleural or parenchymal disease, strong consideration should be given to stopping the ergot alkaloids and
using an alternative drug for the treatment of Parkinsons
disease.45
RETINOIDS
Isotretinoin
Isoretinoin, a retinoid compound, has been used in the
treatment of cystic acne and may be also useful as chemopreventive agent for various malignancies.8 There are two
case reports indicating that the drug can cause eosinophilic
pleural effusion 16 months after the initiation of treatment.46,47 Parenchymal disease or blood eosinophilia was
absent. The effusion resolved 13 months after drug discontinuation. Fever and cough were reported in one of
these patients, while the other experienced only dyspnea
on exertion. The manufacturer of isotretinoin has on le
three other cases of pleural effusion occurring in patients
who took isotretinoin for acne.47
CHEMOTHERAPEUTIC AGENTS
The most common respiratory adverse effect caused by
cytotoxic agents is interstitial pneumonitis that may
present with fever, cough and progressive dyspnea, evolve
into ARDS and be fatal.1,8 Interstitial lung brosis, pleural
effusion and pleural brosis may occur. Drug withdrawal
and corticosteroids usually lead to resolution of the symptoms, although the radiographic clearance may be only
partial. Pneumothorax has been rarely reported in patients
with lung metastases treated with combination chemotherapy regimens.14,51 The extent to which the drugs contribute in this complication is not dened. It is possible
that the administration of the chemotherapeutic agent
leads to the necrosis of a pleural metastases and a communication between the alveolus and the pleural space.
Methotrexate
The best known respiratory complication of methotrexate
treatment is life-threatening pneumonitis, which occurs in
patients who are taking long-term therapy for rheumatoid
arthritis or other autoimmune diseases.8,52 Lung histology
reveals non-specic inammatory ndings. Pleural disease
has not been reported in association with interstitial pneumonia. Two groups reported pleural disease associated
with methotrexate in patients with malignancies who
received high dose courses of methotrexate. Walden and
co-workers53 reported that 14 of 317 patients (4.5 percent)
with trophoblastic tumors who had been treated with
methotrexate developed pleuritic chest pain 25 days after
the injection. Pleural effusions were found in four. Pleural
disease was also reported in 18 of 210 patients (8.5
percent) who were treated for osteogenic sarcoma with
weekly courses of methotrexate.54 Most of the patients presented with severe pleuritic chest pain of sudden onset
after the third or fourth course of the treatment. Chest Xray revealed thickening of the interlobar pleura. There is
no report of pleural effusion. The pain resolved after 35
days but the pleural thickening persisted, sometimes even
for years.
Procarbazine
Procarbazine has been used in the treatment of Hodgkins
disease and lymphomas. Two case reports have described a
hypersensitivity-like reaction related to procarbazine
administration which is quite similar to the acute syndrome caused by the nitrofurantoin. This reaction
includes chills, cough, dyspnea, bilateral pulmonary inltrates with pleural effusions and blood eosinophilia.55,56
Pleural biopsy discloses eosinophilic inltration.
Rechallenge with procarbazine produced the same syndrome. When the drug was discontinued, the patients
symptoms and radiographic abnormalities resolved within
days.57,58
Bleomycin
Bleomycin is a cytotoxic antibiotic that is used in the treatment of a variety of malignancies. Adverse pleuropulmonary effects occur in up to 10 percent of the patients
treated with the drug and may be more common in older
patients and in those receiving higher cumulative doses.1
These include severe interstitial pneumonitis and brosis.
Pleural effusions have been demonstrated in a small
number of patients with acute pneumonitis.1,8 Tissue
damage associated with bleomycin appears to be induced
by oxidant radicals. For this reason, the risk of respiratory
complications increases when radiation or supplemental
oxygen are administered.2
Imatinib mesylate
Imatinib mesylate is a novel anti-neoplastic agent, most
frequently used in the treatment of chronic myeloid
leukemia and Philadelphia chromosome-positive acute
lymphoblastic leukemia. Pleural effusions associated with
the drug were initially reported in three pediatric patients
but the authors did not clearly prove that the effusions
should be attributed to the drug and not to the disease progression.59 Unilateral or bilateral pleural effusions with or
without associated pericardial effusions were subsequently
reported in four adults with hematological malignancies 2
days to 54 weeks after the drug was rst administered.60,61
Edema and gain of body weight has been described in one
patient.60 The pathogenesis of the effusions in these
patients is unknown though uid retention has been proposed as a possible mechanism. The pleural uid was characterized as an exudate although in one case its
characteristics were not described.60 Interestingly, while
the effusions resolved after the discontinuation of the drug
with or without corticosteroids, when treatment with imatinib was restarted they relapsed in only one of seven
patients.
MUSCLE RELAXANTS
Mitomycin
Mitomycin is another antibiotic derived agent, often used
in the treatment of adenocarcinomas. Mitomycin infrequently induces bilateral interstitial pneumonitis that can
be life threatening.1,8 Small pleural effusions or pleural
thickening frequently coexist.8,55
Dantrolene sodium
Docetaxel
Tizanidine
Cyclophosphamide
common etiologies were ruled out and the effusion disappeared over the rst month after the discontinuation of the
drug.
VITAMINS
A case of life-threatening eosinophilic pleural and pericardial effusion has been reported in a 76-year-old woman
taking vitamins B6 and H for alopecia.67 The patient presented with chest pain and dyspnea, attributed to cardiac
temponade and pleural effusion. Peripheral blood
eosinophilia was detected. The pleural effusion relapsed
despite pericardiotomy and serial thoracenteses.
Infectious, allergic, autoimmune and malignant diseases
were appropriately ruled out. Histological examination of
both the pleura and the pericardium revealed eosinophilic
inltrate. Symptoms and eosinophilia resolved 1 week
after the withdrawal of the vitamins and the patient was
symptom-free at a 2-year follow-up visit.
ANTICOAGULANTS
Eosinophilic pleural effusion has been reported in a
patient who presented with a dry cough and low-grade
fever, 9 months after the initiation of warfarin treatment.68
A right-sided exudative pleural effusion with 57 percent
eosinophils, as well as blood eosinophilia, was found. No
other etiologies for the syndrome were determined after
extensive evaluation. The blood eosinophilia declined after
the discontinuation of the drug. When warfarin was
administered again, a left-sided pleural effusion appeared
and the peripheral eosinophilia increased. Both the
peripheral eosinophilia and the pleural effusions gradually
resolved, after the nal withdrawal of the drug.
Hemothorax can rarely happen in patients receiving
anticoagulants or intrapleural brinolytics.14,69 Most commonly (9 of 12 reported cases), hemothorax occur in
patients being treated for pulmonary infarction. In all of
those cases, the anticoagulant used was heparin and the
complication occurred within the rst week of the
therapy.14 In another patient who was treated with
heparin, the bleeding source was pneumonia. The remaining two cases were taking warfarin and the hemothorax
occurred contralaterally to the pulmonary embolus.
Importantly, in the majority of the reported cases, the prothrombin time (PT) and partial thromboplastin time
(PTT) were within safe ranges.
MESALAMINE
Mesalamine, an anti-inammatory drug used in the treatment of inammatory bowel disease, has been associated
with the development of pulmonary inltrates with or
without pleural effusion.70 There is a case report of a 72-
CLOZAPINE
Clozapine, a commonly used antipsychotic agent, has been
associated with the development of pleural effusions.7377
The pleural effusions develop within 7 days to 2 months of
initial administration of the drug and are usually, but not
always,74 bilateral. Pericardial effusion73,77 and even constrictive pericarditis77 may accompany the pleural
effusions. Pleuritic chest pain, fever, headache, skin rash or
peripheral eosinophilia have also been observed in some of
these patients. In one patient, the pleural effusions were part
of a more generalized syndrome consisting of hepatitis,
hyperglycemia and glomerular injury.75 Pleural uid analysis, reported in only one case, revealed a neutrophil
predominant exudate.73 Symptoms and radiographic
abnormalities resolve within several days after the drug is
discontinued. When two of the above patients underwent
rechallenge, the symptoms and the effusions recurred.73,74
ANTIDIABETIC AGENTS
Gliclazide
A 52-year-old diabetic patient was reported, who developed a mild pneumonitis accompanied by an exudative
eosinophilic (pleural uid eosinophils were 80 percent)
ipsilateral pleural effusion, accompanied by peripheral
blood eosinophilia 2 weeks after beginning therapy with
gliclazide, an oral hypoglycemic agent. The peripheral
blood eosinophil count was 20 percent. The effusion and
the blood eosinophilia resolved over the rst month after
the withdrawal of gliclazide.78
Troglitazone
A 47-year old man presented with cough and dyspnea
1 week after the rst dose of troglitazone.79 Small bilateral
pleural effusions were evident 2 weeks later. The symp-
Procainamide
Approximately one-third of the patients taking the drug
will develop DIL pleuritis within the rst year of the
therapy, although the disorder can appear anytime
between the rst month and the twelfth year of beginning
treatment.8 Pleural involvement occurs in more than half,
while patchy parenchymal inltrates may be seen in 40
percent of patients.81
Hydralazine
Although half of the patients taking hydralazine have positive ANA, only 220 percent, most commonly women,
Isoniazid
Isoniazid (INH) may induce ANA in one-quarter of the
patients who take the drug, but INH-associated DIL is very
rare.8284 However, an increase in the size of a tuberculous
effusion or the development of a new pleural effusion 312
weeks after the initiation of anti-tuberculous treatment for
pulmonary or pleural tuberculosis could be due to a poorly
dened paradoxical response.8490 It is speculated that
this phenomenon represents an excessive response of the
cell-mediated immunity to an increased antigen load
resulting from the mycobacterial lysis. Gupta et al.85
reported that pleural uid was smear-positive in two, and
culture positive in four of the 29 of patients who developed
this paradoxical response.85 Pleural biopsy was negative
for mycobacteria or tuberculous histology in 15 of the 20
biopsies carried out. The majority of these patients (83
percent), as well as all of the patients reported by
others,8690 recovered without any modication in
chemotherapy.84 Hiroaka et al.84 reported two patients
who developed pleural effusion during anti-tuberculous
treatment for pulmonary tuberculosis.84 In both, the uid
was a lymphocytic exudate with normal glucose, high ANA
titer, low CH50 and low ADA, thus resembling lupus effusion. The rst patient had progressive rash and the INH
was replaced with pyrazinamide. The INH-containing
regimen was continued in the second patient. Pleural effusion disappeared in both. These two cases raise a question
about the relationship of what is thought to be a paradoxical response to anti-tuberculous treatment and INHinduced lupus pleuritis. Speaking practically, when should
the clinician continue or withdraw INH, in the face of
newly formed pleural effusion? The presence of pericarditis or generalized symptoms, such as rash and arthralgias,
as well as positive serum ANA, makes the DIL pleuritis
more likely. Furthermore, bilateral effusions are more
likely due to DIL, while all the 43 pleural effusions, previously reported as the result of paradoxical response were
unilateral.8490 High pleural uid ADA or the presence of
granuloma in the pleural biopsy suggest a tuberculous
origin. Pleural uid ANA titers are not particularly useful,
because 25 percent of the patients that take INH have elevated ANA8 and pleural uid ANA usually reects the
serum titers.45 However, a negative serum ANA virtually
rules out DIL. If DIL-associated symptoms are present, the
INH should be changed to another effective drug. If DIL
pleuritis is not clinically probable, the regimen should be
continued and if the effusion is symptomatic, a therapeutic aspiration should be performed. If the effusions tend to
OTHER DRUGS
Simvastatin
Simvastatin is an HMG-CoA reductase blocker used in the
treatment of hypercholesterolemia. There is one case
report of a patient who developed cough, progressive
dyspnea and fatigue 6 months after the initiation of the
therapy. Chest X-ray disclosed bilateral interstitial inltrates and a moderate sized right-sided pleural effusion.
Elevated liver function tests and serum IgE were detected.
BAL revealed eosinophilia of 34 percent. The pleural uid
was described as darkish brown but analysis was not performed. Thoracoscopic biopsies revealed interstitial lung
brosis and no pleural abnormalities. The discontinuation
of simvastatin and prednisone administration led to clinical improvement, normalization of the liver tests and fall
of the BAL eosinophil count.91 Roncato-Saberan et al.92
reported on a patient who presented with large bilateral
pleural effusions and weight loss while being on simvastatin treatment for 13 years. He had peripheral and pleural
uid eosinophilia. The pleural effusions resolved and the
patient regained weight within a month of the discontinuation of simvastatin with no relapse during a 2-year long
follow-up period. In addition to the above, simvastatin has
been reported to cause drug-induced lupus syndrome.93,94
L-Tryptophan
Acyclovir
Acyclovir is commonly used in the treatment of herpes
virus disease. There is only one report of pleuropulmonary
disease attributed to this drug.96 A 71-year-old man who
was being treated with acyclovir for ophthalmic herpes
zoster developed fever and bilateral pulmonary inltrates,
3 days after the initiation of the treatment. The next day he
presented with a left-sided pleural effusion and hemoptysis. A ventilation-perfusion lung scan was not indicative
of pulmonary embolism and microbiological examination
Metronidazole
There is one report97 of a 42-year-old atopic woman who
developed fever, skin rash and bilateral pneumonitis and
pleural effusions within a day of starting of oral metronidazole. The drug was discontinued and she recovered
completely over the next few days. Six months later, she
developed a similar syndrome, without pneumonitis, with
the rst dose of metronidazole. Drug withdrawal again led
to rapid improvement of the symptoms and complete
recovery.
Valproic acid
Valproic acid, an antiepileptic drug, may cause pleural
effusion. There is a report of a patient who developed
exudative pleural effusion 9 months after the rst administration of the drug.98 The pleural uid and the blood
eosinophil percentages were 62 and 26 percent, respectively. The uid gradually disappeared within several days
after the withdrawal of valproic and did not recur during a
6-month follow-up period. However, the fact that the
pleural uid appeared a week after the onset of ipsilateral
pneumonia makes it possible that it was really a postpneumonia pleural effusion. Subsequently, eosinophilic
pleural effusion and peripheral eosinophilia that resolved
after valproic withdrawal was reported in another patient.
More importantly, re-challenge with valproic acid produced recurrent symptoms.99 Another patient who was
taking valproic acid100 developed a febrile lymphocyte predominant exudative pleural effusion. Microbiology
studies, chest CT angiography and abdominal CT were
normal and thoracoscopic biopsy revealed non-specic
pleural inammation. The effusion disappeared when valproic acid was substituted by another anticonvulsant. The
authors did not state how long the patient had been in valproic acid treatment before the onset of pleuritis. More
recently, Savvas and associates101 attributed an episode of
bilateral febrile eosinophilic pleural effusions that developed 20 days after cardiac surgery to the valproic acid that
was administered because of seizures in the early postoperative period. However, other etiologies, including a posttraumatic pleural effusion and Dressler syndrome, were
not considered in this case. Interestingly, the disease persisted after the discontinuation of the valproic acid and
resolved only with systemic corticosteroids.
Dapsone
DIRECTION OF DEVELOPMENT
D-Penicillamine
Propylthiouracil
KEY POINTS
Itraconazole
A variety of widely used drugs, including antiinfectious, cardiovascular, cytotoxic, neuropsychiatric, anti-inammatory and immunomodulating agents, may cause pleural disease.
Drug-induced pleural disease should be considered in every patient with an undiagnosed pleural
effusion or unexplained pleural brosis.
Drug-induced pleural disease may be the sole
manifestation of a drug toxicity or may coexist
with pulmonary toxicity or even be part of generalized syndromes.
The discontinuation of the drug leads to resolution of the pleural disease in the vast majority of
the cases.
REFERENCES
Minocycline
Beck MJ. Drug-induced pleural disease. Clin Chest Med 1998; 19:
34150.
2. Huggins JT, Sahn SA. Drug-induced pleural disease. Clin Chest Med
2004; 25:14153.
3. Israel HL, Diamond P. Recurrent pulmonary inltration and pleural
effusion due to nitrofurantoin sensitivity. N Engl J Med 1962;
266:10246.
References 441
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
References 443
34
Effusions after surgery
ONER DIKENSOY, RICHARD W LIGHT
Introduction
Effusions after abdominal surgery
Effusions after cardiac surgery
Pleural effusion after lung transplantation
445
445
447
451
INTRODUCTION
Pleural effusion after surgery can be dened as occurrence
of a new pleural effusion following a recent surgical procedure. Although most of the pleural effusions occur within
rst couple of days following surgery, occurrence of late
pleural effusions following coronary artery bypass graft
(CABG) surgery has been reported.1,2
Most of the early studies concerning post-operative
pulmonary complications were carried out in a population
undergoing abdominal surgery and reported a very low
prevalence of pleural effusions after surgery.35 It is most
likely that the low sensitivity of the diagnostic modalities
utilized, and small sizes of the pleural effusions without
clinical symptoms, were the main reasons for the low frequency of post-operative pleural effusions in these studies.
The incidence of post-operative pleural effusions in more
recent studies has been as high as 100 percent depending
on the diagnostic modality used to detect the pleural effusion and the type of the surgical intervention.6
Although, any surgery can cause pleural effusion,
abdominal and thoracic interventions such as splenectomy, cholecystectomy and CABG surgery are the most
commonly reported surgical operations complicated by
pleural effusion in the early post-operative period.25 The
causes of pleural effusion after surgery are shown in
Table 34.1.
In this chapter, post-operative pleural effusions will be
discussed in detail by reviewing the related literature to
date.
451
452
452
452
Incidence
In early reports, the frequency of pleural effusions after
abdominal surgery was reported to be very low.
Wightman5 reviewed the pulmonary complications after
455 abdominal operations and found only one pleural
effusion. Forthman and Shepard3 reported no pleural effusions after 447 abdominal operations. Ti and Yong8 found
four pleural effusions after abdominal surgery in 346
patients. In none of these three series were routine postoperative chest roentgenograms obtained; however, Laszlo
et al.4 and Collins et al.11 obtained chest X-rays on the
second postoperative day after abdominal surgery in 44
and 132 patients, respectively, and neither study mentions
the occurrence of pleural effusion.
More recently, two studies prospectively assessed
patients undergoing abdominal surgery.7,9 In the rst
study by Light et al.,9 at a military hospital, all patients had
posteroanterior, left lateral and bilateral decubitus radiographs 4872 hours after surgery. Pleural effusions were
found in 97 (49 percent) patients after abdominal surgery.
The incidence of pleural effusions was higher after upper
abdominal surgery in patients with postoperative atelectasis, and in patients with free abdominal uid. Pleural
effusions appeared to be more common in older patients.
The mean age of patients with pleural effusion (33 years)
was higher than the mean age of patients without effusions
(27 years). They suggested that this was because older
patients were more likely to have atelectasis.
In the second study by Nielsen et al.,7 128 patients who
had undergone upper abdominal surgery were studied
prospectively for the incidence of post-operative pleural
effusions. Posterior and lateral chest radiographs were
obtained preoperatively and on the second and fourth day
after surgery. They found that 89 patients (69.5 percent)
developed a post-operative pleural effusion: 33 unilateral
and 56 bilateral. They concluded that patients with postoperative pleural effusions were older than those without
effusion (median ages, 58.7 versus 50.4 years respectively).
They found no correlation between the presence of postoperative pleural effusions and any of the following: type
of the operation, site of the abdominal incision, gender,
smoking habits or weight.
In the most recent study of pleural effusions after
diaphragm peritonectomy or resection for advanced mullerian cancer, the records of all patients with stage IIICIV
epithelial ovarian, fallopian tube or peritoneal cancer who
had diaphragm peritonectomy or resection as part of
optimal primary cytoreduction at their institution from
2000 to 2003 were reviewed.10 All patients had preoperative
and serial post-operative chest X-rays to detect and follow
pleural effusions. Of the 215 patients who had primary
cytoreduction during the study period, 59 (27 percent)
underwent diaphragm peritonectomy or resection. In
addition to standard cytoreduction, 31 (53 percent) of
these 59 patients had diaphragm surgery alone, while 28 (47
percent) had diaphragm surgery in combination with other
Etiology
A number of hypothesis have been suggested for the etiology of pleural effusions after abdominal surgery.7,9,12
Subphrenic abscess has been considered as the major cause
of these pleural effusions;12 however, the relation has been
severely questioned by the ndings of Light and George in
the above-mentioned study.9 The effusions likely to be
associated with subphrenic abscess usually become apparent 10 or more days post-operatively, and are typically
associated with signs and symptoms of systemic infection.13
In the studies by Light et al.9 and Nielsen et al.,7 similar
factors such as pancreatitis, pulmonary emboli and peritoneal uid were suggested to be occasional causes of
pleural effusions after abdominal surgery. However, these
two groups shared opposing views on the relative signicance of atelectasis, diaphragmatic irritation and site of the
incision with respect to the development of post-operative
pleural effusions.
In the study by Eisenhauer et al.,10 several hypotheses
on the etiology of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancer
were suggested: (1) the large portion of diaphragm left
uncovered by peritoneum after diaphragm peritonectomy
or resection; (2) unrecognized disruption of the diaphragmatic muscle or underlying pleura in the process of
diaphragm peritonectomy or resection may contribute to
small defects that later connect to the pleural space; (3)
large-volume ascites are seen in a larger proportion of their
patients undergoing diaphragm peritonectomy or resection than are commonly reported in patients undergoing
hepatectomy; or (4) the release of vascular endothelial
growth factor (VEGF) or inammatory mediators by
resection of tumor or direct surgery on the diaphragm. In
summary, one might suggest that multiple local or systemic factors play roles in the formation of pleural effusions after abdominal surgery. A subphrenic abscess
should be considered when a pleural effusion develops 10
or more days post-operatively and is associated with signs
and symptoms of systemic infection.
Clinical manifestations
Most of the effusions after abdominal surgery are found
incidentally due to the fact that they are small in size and
asymptomatic. In the study by Light et al.9 the effusions
0
1
2
3
4
5
Management
In most of the cases with pleural effusion following
abdominal surgery, the effusion is self-limited and does
not require any further intervention.7,9 If the patient is
febrile or has pleuritic chest pain and the size of the pleural
effusion is more than minimal, a diagnostic thoracentesis
should be performed. Chest tube drainage may be needed
in occasional cases with a complicated clinical course,
especially if the effusion is large and causes dyspnea or if
the pleural infection occurs. Subphrenic abscess, pulmonary embolus, pleural infection and pancreatitis should
always be considered in the differential diagnosis when
evaluating patients with pleural effusion after abdominal
surgery.14
No pleural uid
Blunting of costophrenic angle
More than blunting of costophrenic
angle but less than 25% of
hemithorax occupied by pleural uid
Pleural uid occupying 2550% of
hemithorax
Pleural uid occupying 5075% of
hemithorax
Pleural uid occupying more than
75% of hemithorax
INCIDENCE
Hurlbut et al.20 obtained chest radiographs 8 weeks postoperatively on 76 patients who had received IMA grafts,
and reported that ve (9.1 percent) of 55 patients who
underwent pleurotomy and three (14.5 percent) of 21
patients who had an IMA without pleurotomy had a
pleural effusion. In a recent retrospective study of 410
patients who had undergone CABG surgery, the incidence
of patients diagnosed with symptomatic newly developed
large pleural effusions from 30 days to 6 months postCABG was 3.1 percent.24
ETIOLOGY
Patients with PCIS present 1 week or more after myocardial injury. It has been reported that 65 percent of affected
patients presented within 3 months and 100 percent
within 12 months.44
Pericarditis almost always exists in patients with PCIS.
These patients present with chest pain and fever.1 On
physical examination a pericardial rub may be found.1 In
addition, leukocytosis, an elevated erythrocyte sedimentation rate and combinations of pulmonary inltrates and
pleural effusions may be found on radiological examination.1
Typically, small and left-sided pleural effusion is
present in almost 60 percent of patients, followed by bilateral, and rarely unilateral, right-sided effusions.40 The effu-
The majority of patients with PCIS respond well to the initiation of anti-inammatory agents such as aspirin or
indomethacin.1 Corticosteroids may be used in cases unresponsive to anti-inammatory drugs.45 Pleural effusion
due to PCIS rarely requires invasive interventions such as
therapeutic thoracentesis or any further procedure.
of these four effusions were exudative, suggesting that congestive heart failure was not the primary underlying cause.
However, it is likely that at least some of the effusions were
due to cardiac dysfunction. In their series, none of the
patients had any evidence for PCIS, such as pericarditis or
pneumonitis. Other possible explanations suggested for
these pleural effusions were interruption of the lymphatics
that normally drain the pleural space, leakage of uid from
the mediastinum, damage from topical hypothermia or a
hypersensitivity reaction to a drug.47
CLINICAL MANIFESTATIONS
Etiology
Pulmonary lymphatics play a major role in the clearance of
pleural uid within the lung (almost 80 percent), whereas
only 20 percent of the uid is cleared through the pleural
space.50 Because the lymphatics are transected during
surgery, the pleural space becomes the only route for uid
to exit from the lung. Two to four weeks are necessary for
the reestablishment of the lymphatic integrity. This timecourse corresponds with the observations of Judson et al.48
who noted decreasing amounts of pleural uid drainage by
the ninth post-operative day.
Management
Because these effusions are usually either self-limited or
easily treated systemically, it is seldom necessary to either
examine or drain small to moderate pleural uid collections in the rst 10 days after transplantation.48 When new
or persistent pleural effusions are observed beyond the
rst few weeks after transplantation, the following etiologies should be considered: empyema or parapneumonic
effusion, acute rejection, organizing pleural hematoma,
lymphoproliferative disorder and cardiac or renal failure.51
A diagnostic thoracentesis should be performed to help
identify the etiology of the effusion.
Etiology
There is limited data on the clinical manifestations and the
characteristics of the pleural effusion after lung transplantation. Judson et al.48 described the pleural uid character-
have been suggested: (1) trauma to the right hemidiaphragm and lymphatics,51 (2) blood component
therapy, (3) atelectasis, (4) low protein levels, (5) hepatic
hydrothorax,57 (6) heart failure and (7) renal insufciency.46,58
KEY POINTS
REFERENCES
3.
4.
Management
5.
These effusions are self-limited in most cases and thoracentesis is needed in less than 20 percent of the
patients.57,58,60 The usual course of these effusions is the
development over the rst several days to a week following
surgery with resolution within 36 weeks.52,53 The indications for thoracentesis are as follows: enlarging or persisting effusions or presence of evidence of pleural infection.46
In case of respiratory insufciency due to pleural effusion,
chest tube thoracostomy may be needed.58
6.
7.
8.
9.
10.
11.
12.
FUTURE DIRECTIONS
13.
14.
15.
16.
References 453
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
35
Hepatic hydrothorax
JOS CASTELLOTE, XAVIER XIOL QUINGLES
Denition
Etiology
Clinical presentation
Diagnosis
Treatment
455
455
456
456
457
DEFINITION
Hepatic hydrothorax is dened as the pleural effusion of
patients with hepatic cirrhosis and portal hypertension
without a primary cardiac, pulmonary or pleural
disease.13 Hepatic hydrothorax is an uncommon manifestation of portal hypertension and normally appears in
patients with ascites, as the source of the pleural uid is
ascites that crosses the diaphragm. However, the presence
of ascites is not necessary for the diagnosis as there have
been many reports of hepatic hydrothorax in which ascites
was not detectable even by ultrasonography.
Pleural uid of cirrhotic patients can become infected,
and spontaneous bacterial empyema (SBEM) is dened as
an infection of a pre-existing hydrothorax without a subjacent pneumonia.4,5 Generally, it is associated with spontaneous bacterial peritonitis (SBP), the infection of ascitic
uid, but as many as 40 percent of cases of SBEM are not
associated with SBP.
460
461
461
462
ETIOLOGY
Incidence
Hepatic hydrothorax accounts for 23 percent of all
pleural effusions.610 The incidence increases to 9.9 percent
when only massive pleural effusions are considered.10 In
patients with cirrhosis the incidence of hepatic hydrothorax is low but depends on the severity of the cirrhosis and
the presence of ascites. In a recent report of 862 Chinese
cirrhotic patients,11 132 (15 percent) had pleural effusion
although in most of them the effusion was only detectable
by ultrasonography, and thoracentesis could only be performed in 56 (6.5 percent). The four larger series of cirrhotic patients with ascites,1215 including a total of 1155
cases, show a very similar incidence of hepatic hydrotho-
It is now broadly accepted that hepatic hydrothorax is secondary to transfer of peritoneal uid directly via defects in
the diaphragm: this mechanism was suggested by the
observation of pneumothorax after injection of air into the
peritoneal cavity, and conrmed by higher radioactivity in
pleural uid than in lymph or plasma after injection of
albumin labeled with iodine-131 into ascitic uid. Many
other studies have proved that the injection of air, dyes or
radiolabeled material into the peritoneal cavity of patients
with hydrothorax is associated with the rapid movement
of these materials into the pleural space.1,22
Many otherwise normal people probably have tiny congenital holes in the diaphragm. In patients with ascites, the
CLINICAL PRESENTATION
Hepatic hydrothorax should be suspected when a cirrhotic
patient, especially with ascites, develops a pleural effusion.
It should also be suspected in patients with an isolated
right pleural effusion with transudative characteristics,
especially if it is massive. Hepatic hydrothorax can be
asymptomatic, or present with symptoms that can range
from dyspnea on exertion to overt respiratory failure,
depending on various factors such as the volume of the
effusion, the amount of ascites present, the speed of the
accumulation of pleural uid and the presence of associated pulmonary disease, which is not infrequent in alcoholic patients. Life-threatening dyspnea secondary to an
acute hepatic hydrothorax has been reported, probably
secondary to a sudden increase in intra-abdominal pressure, such as straining or coughing that caused rupture of
the pleuroperitoneal bleb.27
DIAGNOSIS
The diagnosis of hepatic hydrothorax is based on:
1. Presence of hepatic cirrhosis with portal hypertension;
2. Exclusion of a primary cardiac, pulmonary or pleural
disease;
3. Eventual conrmation of the passage of ascites to the
pleural space.
Treatment 457
TREATMENT
Hepatic hydrothorax is secondary to the passage of ascites
through a diaphragmatic defect, and ascites is secondary to
portal hypertension and salt retention by the kidney.
Treatment can be directed to improve salt retention
(diuretics), to reduce portal hypertension (transjugular
intrahepatic portosystemic shunt, TIPS), to close the
diaphragmatic defects (through VATS, with concomitant
talc pleurodesis) or to solve hepatic cirrhosis by liver transplantation. Therapeutic options and their relationship
with the pathophysiological cascade of hepatic hydrothorax are shown in Table 35.1.
The rst line of treatment is the same as for ascites:
sodium restriction and diuretic therapy, spironolactone,
Table 35.1 Therapeutic options depending on the physiopathological steps of hepatic hydrothorax
Therapeutic options
Liver cirrhosis
Portal hypertension
Splanchnic vasodilatation
Ascites
Diaphragmatic defects
Liver transplantation
TIPS
Vasoconstrictors:
Octreotide
Terlypressin
Diuretics
Peritoneo-venous shunts
Large volume paracentesis
Surgical closure
Diaphragm reinforcement
Videothoracoscopy
CPAP
Therapeutic thoracentesis
Pleurovenous shunts
Chemical pleurodesis
CPAP, continuous positive airway pressure; TIPS, transjuglar intrahepatic portosystemic shunt.
Treatment 459
Table 35.2 Results of transjugular intrahepatic portosystemic shunt (TIPS) in refractory hydrothorax
Authors
24
12
24
40
21
5
131
Aetiology
ChildPugh
Responsea
Complete
Partial
No
Mortality
40 days
60% alcohol
5C
54% alcohol
5 B, 19 C
0% alcohol
1 A, 5 B, 6 C
34% alcohol
30%B, 70%C
70% alcohol
24 B, 16 C
7 B, 14 C
2/5
(40%)
14/24
(58%)
5/12
(42%)
1/5
(20%)
5/24
(21%)
5/12
(42%)
0/5
(0%)
13/24
(54%)
4/12
(33%)
3 B, 2 C
1 A, 51 B, 79 C
39% B, 60% C
21/40
(53%)
12/19
(63%)
3/5
(60%)
57/105
(54%)
2/5
(40%)
5/24
(21%)
2/12
(16%)
11/40
(27%)
2/19
(11%)
1/5
(20%)
23/105
(22%)
8/40
(20%)
5/19
(11%)
1/5
(20%)
25/105
(24%)
6/40
(15%)
6/21
(29%)
1/5
(20%)
30/108
(28%)
response: lack of pleural effusion. Partial response: persistence of some pleural uid but no need for thoracentesis.
New or worsening encephalopathy during follow-up.
Survival
1 year
Encb
0%
37%
33%
56%
20%
64%
5%
60%
60%
Temperature >38
Dyspnea
Abdominal pain
Encephalopathy
Septic shock
Mortality
40
22
22
8
4
19
61
34
34
12
6
29
this method while this rate is only 33 percent when conventional microbiological techniques are used.5,11
During the infectious episode, pleural uid characteristics may change, although protein and glucose levels stay
stable, LDH increases and in some cases the pleural uid
can be dened as an exudate by Lights criteria due to LDH
increment.5 It has been suggested that the serumpleura
albumin gradient >12 g/L accurately differentiate between
hepatic hydrothorax or SBEM and other exudative pleural
effusions.37
In the four series reported including 65 cases,4,5,11,66 34
were culture negative and 31 (48 percent) were culture
positive, although etiological bacteria could be identied
in 39 cases (60 percent): Escherichia coli in 21 cases,
Streptococcus species in six, Klebsiella pneumoniae in ve,
Enterococcus species in four, Clostridium perfringens in one,
Pseudomonas stutzeri in one and Gemella morbillorum in
one. Due to the delay in culture results, pleural polymorphonuclear neutrophil (PMN) count is the cornerstone of
the diagnosis. Recently, the use of reagent strips to detect
leukocyte esterase in urine has been shown to be a very
sensitive and specic method for a rapid diagnosis of SBP
in cirrhotic patients with ascites69 and has also been validated in pleural uid to diagnose SBEM.70
Mortality in the four series was 29 percent (19 from 65).
Intravascular expansion with albumin improves survival
in cirrhotic patients with SBP,71 although this approach
has not been validated in patients with SBEM, it should
improve prognosis because an impairment of systemic circulation after SBEM should be expected.
Treatment with a third-generation cephalosporin, cefotaxime or ceftriaxone, should be initiated without waiting
for the pleural uid culture when pleural uid polymorphonuclear count is over 250 cells/mL. Aminoglycosides
are contraindicated in cirrhotic patients because of signicant side effects, especially renal insufciency. None of the
patients reported was treated with a chest tube, because
pleural uid did not meet the biochemical criteria for its
insertion. Since most patients were cured of the infection
without a chest tube and its insertion can be harmful in
patients with hepatic hydrothorax,44,45 a chest tube should
not be used for treating SBEM. Owing to frequent recidivism of the infection, prophylaxis with noroxacin is recommended to all survivors of an episode of SBEM.
Long-term survival of patients with SBEM is poor. In a retrospective series from our hospital, median survival of cirrhotic patients with SBEM was 13 months; thus, a SBEM
episode should be considered an indication for liver transplantation.5
FUTURE DIRECTIONS
The utility of albumin gradient in the diagnosis of hepatic
hydrothorax has not been studied and should be investigated before recommending its application.
KEY POINTS
REFERENCES
= Key primary paper
= Major review article
= Paper that represents the rst formal publication of a
management guideline
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23. Huang PM, Chang YL, Yang CY, Lee YC. The morphology of
diaphragmatic defects in hepatic hydrothorax. J Thorac Cardiovasc
Surg 2005; 130: 1415.
24. Rubinstein D, Mclnnes IE, Dudley FJ. Hepatic hydrothorax in the
absence of clinical ascites: diagnosis and management.
Gastroenterology 1985; 88: 18891
25. Mentes BB, Kayhan B, Gorgul A, Unal S. Hepatic hydrothorax in
the absence of ascites. Report of two cases and review of the
mechanism. Dig Dis Sci 1997; 42: 7818.
26. Kataki S, Yoshinaga YT, Takayama OHT, et al. Hepatic hydrothorax
in the absence of ascites. Liver 1998; 18: 21620.
27. Castellote J, Gornals J, Lpez C, Xiol X. Acute tension hydrothorax:
a life threatening complication of cirrhosis. J Clin Gastroenterol
2002; 34: 5889.
28. Castellote J, Xiol X, Corts-Beut R, et al. Complicaciones de la
toracentesis en pacientes cirrticos con derrame pleural. Rev Esp
Enferm Dig 2001; 93: 56670.
29. McVay PA, Toy PTC. Lack of increased bleeding after paracentesis
and thoracentesis in patients with mild coagulation abnormalities.
Transfusion 1991; 31: 16471.
30. Runyon BA. Paracentesis of ascitic uid. A safe procedure. Arch
Intern Med 1986; 146: 225961.
31. Mirouze D, Juttner HU, Reynolds TB. Left pleural effusion in
patients with chronic liver disease and ascites. Dig Dis Sci 1981;
26: 9848.
32. Light R. Pleural effusion. N Engl J Med 2002; 346: 19717.
33. Sahn S. The pleura. Am Rev Respir Dis 1988; 138: 184234
34. Sese E, Xiol X, Castellote J, Rodrguez-Farias E, Tremosa G. Low
complement levels and opsonic activity in hepatic hydrothorax. Its
relationship with spontaneous bacterial empyema. J Clin
Gastroenterol 2003; 36: 757.
35. Light RW. Diagnostic principles in pleural disease. Eur Respir J
1997; 10: 47681.
36. Romero S, Fernandez C, Martin C, et al. Inuence of diuretics on
the concentration of proteins and other components of pleural
transudates in patients with heart failure. Am J Med 2001; 110:
6816.
37. Tremosa G, Xiol X, Rodrguez E, et al. Valor del gradiente de
albmina en el diagnstico diferencial de los derrames pleurales
asociados a cirrosis heptica (abst). Gastreonterologia y
Hepatologia 2002; 25: 11314.
38. Zenda T, Miyamoto S, Murata S, Mabuchi H. Detection of
diaphragmatic defect as the cause of severe hepatic hydrothorax
with magnetic resonance. AJR Am J Roentgenol 1998; 93:
22889.
39. Arroyo V, Gines P, Gerbes AL, et al. Denition and diagnostic
criteria of refractory ascites and hepatorenal syndrome in
cirrhosis. Hepatology 1996; 23: 16473.
40. Chalasani N, Clark WS, Martin LG, et al. Determinants of mortality
in patients with advanced cirrhosis after transjugular intrahepatic
portosystemic shunting. Gastroenterology 2000; 118: 13844.
41. Runyon BA. Paracentesis of ascitic uid. A safe procedure. Arch
Intern Med 1996; 124: 81620.
42. McVay PA, Toy PTC. Lack of increased bleeding after paracentesis
and thoracentesis in patients with mild coagulation annormalities.
Transfusion 1991; 31: 16471.
43. Trachiotis GD, Vricella LA, Aaron BL, Hix WR. As originally
published in 1988: Reexpansion pulmonary edema. Updated 1997.
Ann Thorac Surg 1997; 4: 12067.
44. Runyon BA, Greenblatt M, Ming HC. Hepatic hydrothorax is a
relative contraindication to chest tube insertion. Am J
Gastroenterol 1986; 7: 5667.
45. Liu LU, Haddadin HA, Bodian CA, et al. Outcome analysis of
cirrhotic patients undergoing chest tube placement. Chest 2004;
126: 1428.
46. Dumortier J, Lepetre J, Scalone O, et al. Succesful treatment of
hepatic hydrothorax with octreotide. Eur J Gastroenterol Hepatol
2000; 12: 81720.
References 463
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
36
Effusions caused by gastrointestinal disease
CHARLIE STRANGE
Introduction
Pancreatic disease
Splenic diseases
Esophageal rupture
Gastric diseases
Diseases of the small and large intestines
Diaphragmatic rupture
465
465
466
467
468
468
468
INTRODUCTION
A variety of pleural effusions arise from diseases below the
diaphragm. Usually caused by diseases of the upper
abdomen, these effusions can provide diagnostic and
prognostic assistance to disease management. The pleural
space is anatomically only a few millimeters away from the
abdomen, separated by the muscular and tendenous portions of the diaphragms. Since small lymphatics cross the
diaphragm, any abdominal uid collection that contacts
the abdominal side of the diaphragm can cause pleural
uid to develop. In addition, any diaphragmatic disruption by surgery, catheters or trauma will allow uid to
reach the pleural space through the diaphragm.
Some effusions from abdominal diseases arise from
above the diaphragm. Because the muscular portion of
the diaphragm is richly vascularized, it may become
inamed. Therefore, abdominal events that affect the
inferior aspect of the diaphragm can cause sufcient vascular inammation on the thoracic side of the diaphragm
to exude pleural uid. These sympathetic pleural effusions may result if pleural uid production is high,
resorption through parietal pleural lymphatics is low or if
pain from the upper abdominal process produces pleuritic pain sufcient to cause atelectasis. Since small pleural
effusions have been associated with atelectasis, the differentiation between pulmonary and diaphragmatic source
of effusion in these patients remains unknown and clinically academic.
This chapter will focus on the gastrointestinal and
abdominal illnesses that have been shown to produce
pleural effusions. In an organ-by-organ approach, the
Gallbladder diseases
Hepatic and upper abdominal abscesses
Inammatory liver diseases
Generalized approach to therapy
Summary
Key points
References
468
468
469
469
470
470
470
PANCREATIC DISEASE
Pancreatitis is the most common gastrointestinal disease
that causes pleural effusions. In acute pancreatitis, inammatory pancreatic exudate enters the surrounding lymphatics that are part of the plexus of subperitoneal and
subdiaphagmatic lymphatics that communicate with the
pleural space through the diaphragm. Since pleural uid
amylase is higher than serum amylase in acute pancreatitis,
these lymphatics must be participating in transfer of pancreatic exudate to the pleural space.
Pancreatitis is now known to occur from more than 50
causes and diagnosis can be extremely difcult, particularly in patients with chronic disease in which amylase elevations can be small or non-existent. The inamed
pancreas varies in the intensity of inammation from mild
disease to frank necrosis with intraglandular hemorrhage.
Clinically signicant pleural effusions on chest radiography are seen in approximately 417 percent of cases of
acute pancreatitis. However, pleural effusions are much
more common if computed tomography (CT) is used,
being found in 50 percent of a recent series of 133 patients
within 72 hours of presentation.1 Pleural effusions often
are accompanied by peritoneal uid or pericarditis.2 These
effusions are often too small to sample and resolve when
obtained. Although serum amylase is elevated in this condition, it may be only mildly so, since the majority of
ductal drainage is released into the pleural space. Pleural
uid from pseudocysts or pancreatic stulae is always
exudative with a neutrophil-rich uid. Bloody effusions
can be associated with pleural uid eosinophilia.12
Fistulae between the pancreatic body and the pleural
space release large amounts of amylase-rich pancreatic
uid into the pleural space. The effusions are often large,
lling one-half of the hemithorax. Right-sided pancreatopleural effusions have been described with stulae that traverse the mediastinum where the esophagus penetrates the
diaphragm before entry into the pleural space through the
mediastinal pleura. Large bilateral effusions also have been
seen.13
It should be remembered that other conditions cause
pleural uid to have high amylase levels. Benign conditions include esophageal rupture, tuberculosis and cirrhosis.14 Rarely, pleural uid amylase may be elevated in
pneumonia.15 Malignant effusions metastatic from many
organs have been described that produce salivary amylase.
In the setting of amylase-rich peritoneal uid, the possibility of ovarian carcinoma or ectopic pregnancy should not
be forgotten.16
Successful therapy of pancreatic stulae with or without
pseudocyst has most readily been obtained by 24 weeks of
pancreatic rest, hyperalimentation and serial thoracentesis
that is successful approximately 50 percent of the time.17,18
No specic therapy is necessary for the pleural space.
Endoscopic management by stenting of the pancreatic duct
is possible in some cases.19 Successful treatment series using
nasopancreatic drains placed by ERCP have been reported.
This modality allows for serial imaging by stulograms
through the nasal side of the tube.20,21 Ligation of the
stula,22 radiation of the stula23 and subtotal pancreatectomy have been used in some case series.
Pancreatic abscess is a rare complication of acute pancreatitis that occurs in approximately 4 percent of cases.
Secondary infection of a pseudocyst can produce a similarly severe condition. Delays in abscess drainage may be
fatal. Pleural effusions occurred in 39 percent of a series of
63 patients with pancreatic abscess and contributed to signicant morbidity and mortality in these cases.24
SPLENIC DISEASES
Splenic infarctions, splenic hematomas and splenic
abscesses often produce pleural effusions. These effusions
are always left-sided and often accompanied by pleuritic
pain. The effusions are usually small, neutrophil-rich exudates that require no specic therapy. Yet, recognition of
the underlying diagnosis does make a difference. Rare presentations with tumors of the spleen, epidermoid cysts,25
splenic vein thrombosis26 and primary rupture of the
spleen with amyloidosis have been associated with pleural
effusions.
ESOPHAGEAL RUPTURE
Esophageal rupture is usually associated with trauma,
often from endoscopy or surgery. Spontaneous esophageal
rupture is a rare disease usually seen after protracted vomiting but may be seen as a complication of esophageal carcinoma, perforation of Barretts ulcer, intensive radiation
therapy, esophageal Crohns disease,34 herpetic esophagitis35 or tuberculous esophagitis.36 Delayed recognition of
this disease is common, accounting for signicant morbidity and mortality.
Iatrogenic rupture following dilation procedures for
esophageal stricture is the most common cause of
rupture.37 Other endoscopic procedures in which pleural
effusions have been described include the removal of
foreign bodies and sclerosis of esophageal varices.38 The
hallmark symptom of chest pain that is persistent for a few
hours after the procedure should be followed by a contrast
esophagram to establish the diagnosis, the discontinuation
of oral feeding and the administration of antibiotics.
Traumatic or post-surgical esophageal perforation
occurs from a variety of esophageal insults. Surgeries for
esophageal carcinoma are prone to leakage at the primary
anastamotic site; occasionally the esophagus is injured
during other thoracic operations.39 Rarely, blunt trauma
GASTRIC DISEASES
Abnormalities of the stomach rarely cause effusions. One
exception is gastric lymphoma that may present with a
lymphomatous effusion. The other gastric lesion that can
present with a pleural empyema is gastric carcinoma. Since
the stomach is immediately subjacent the left pleural
space, carcinoma of the greater curvature can create a
stula to the pleural space. When sampled, the pleural
uid is acidic, discolored and may contain bacteria. Cases
in which primary therapy has been initiated for empyema
without recognizing the primary cause of this lesion have
been described. Rarely, traumatic rupture of the stomach
has been shown to produce amylase-rich pleural effusions.57,58
DIAPHRAGMATIC RUPTURE
Rupture of the diaphragm usually occurs after trauma.
The diagnosis is not often missed since bowel loops on
radiography in the chest are prominent, particularly on
chest CT. However, the surgeon evaluating the condition
should recognize the potential for other disorders that
are similar, such as hernias of the foramen of
Bochdalek.61
GALLBLADDER DISEASES
Disease of the biliary tract is responsible for some pleural
effusions. The most common pleural effusion from the
gallbladder is a sympathetic effusion in the rst 24 hours
after cholecystectomy that has been found in one-third of
patients.62 Empyema of the gallbladder is often an indolent
infection that can lead to both local and distant uid collections. Fistulae that begin at the gallbladder bed can
directly communicate with the pleural space. These biliopleural stulae can be quite large with the most dramatic
presentations being gallstones in the pleural space63,64 or
communicating with the airways with expectoration of
gallstones.65
Biliopleural effusions also accompany transhepatic
biliary drainage for biliary tract obstruction. Since transhepatic catheters invariably cross the pleural space in the
costal recess, any catheter malfunction runs the risk of bile
entering the pleural space. The diagnosis at time of bile
leakage is established by pleural uid bilirubin concentrations higher than serum values. Animal models have suggested that bilirubin is rapidly absorbed from the pleural
space although a neutrophilic exudative inammatory
effusion persists.66
Pleural amylase
Comments
Biliopleural stula
PF = serum
Esophageal rupture
Elevated
Hepatitis
Mononuclear predominant
exudate
<1000
PF = serum
Pancreatitis
100050 000
>2 serum
Pancreatic stula
<10 000
Splenic infarction
<10 000
PF = serum
100050 000
occasionally pus
PF = serum
Abbreviations: CT, computed tomography; ERCP, endoscopic retrograde cholangiopancreatography; IU, international units; PF, pleural uid; PMN,
polymorphonuclear neutrophil; WBC, white blood cell count.
SUMMARY
The variety of causes of pleural effusions from gastrointestinal sources in the mediastinum and abdomen makes
recognition of these disorders very difcult.81 Once recognized, the therapy of each of these diseases usually requires
specialty consultation from gastroenterologists and thoracic or general surgeons. Therapy of pleural effusions of
gastrointestinal origin involves correcting the gastrointestinal problem. Although many disorders such as splenic
infarctions or hepatitis B may be self-limited, others
require specic therapy only recognized after establishing
the correct diagnosis.
KEY POINTS
REFERENCES
References 471
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
37
Effusions of obstetric or gynecological origin
RICHARD W LIGHT
Ovarian hyperstimulation syndrome
Fetal pleural effusions
Pleural effusions during pregnancy
Post-partum pleural effusion (immediate)
Post-partum pleural effusion (delayed)
473
475
476
477
477
Meigs syndrome
Endometriosis and pleural effusions
Catamenial hemothorax
Key points
References
478
479
480
480
481
and coworkers2 reviewed the medical charts and all available imaging studies of 771 women who had undergone
induction of superovulation with gonadotropins during
the period October 1990 to July 1992 at University
Hospital in Western Ontario and reported that the incidence of severe OHSS was 3 percent. In another report, the
medical records of all OHSS patients hospitalized between
January 1987 and December 1996 in 16 of the 19 tertiary
medical centers in Israel were reviewed.3 The authors were
able to nd a total of 2902 patients (3305 hospitalizations)
with OHSS of whom 196 (6.7 percent) had severe and 13
(0.4 percent) had critical OHSS. In this series, 27 of the 209
patients (12.9 percent) underwent thoracentesis,3 while
130 patients were dyspneic and received chest radiographs.
Thirty eight of the 130 patients (29 percent) had a pleural
effusion.
Clinical presentation
Women who develop OHSS initially complain of abdominal discomfort and distention, followed by nausea, vomiting and diarrhea. If the syndrome worsens, the patients
develop evidence of ascites and then hydrothorax and/or
shortness of breath. The respiratory symptoms develop
714 days after the injection of the hCG.13 In the most
severe stages, the patients develop increased blood viscosity due to hemoconcentration, coagulation abnormalities
and reduced renal function.2
When pleural effusions are present in patients with
OHSS, they most commonly are right-sided. In the series
of 38 patients reported by Abramov and coworkers, the
pleural effusion was right-sided in 20 (53 percent), leftsided in 7 (18 percent) and bilateral in 11 (29 percent).3
On rare occasions, a pleural effusion may be the sole manifestation of OHSS.14 The pleural effusion may be a signicant problem in patients with OHSS. In two different
patients, 8500 mL15 and 6800 mL,14 respectively, were
drained.
In patients with OHSS the pleural uid is an exudates.14
The mean pleural uid protein level from 14 patients was
4.2 3.6 gm/dL while the mean plasma protein in these
patients was only 4.4 gm/dL.16 The level of lactic acid dehydrogenase (LDH) is also in the exudative range.13
Investigations
The diagnosis is usually obvious in the patient with the
complete syndrome. If the pleural effusion is the sole manifestation, the diagnosis may be missed if a complete
history is not taken.
Clinical presentation
The two most common reasons for ultrasound examination when cases of fetal pleural effusion are detected are
polyhydramnios and preterm labor. The gestational age at
the time of diagnosis varies between 15 and 39 weeks with
a median gestational age of about 30 weeks.20 In a review
of the literature in 1998, 204 cases of isolated pleural effusion were found.31 The effusions were bilateral in 74
percent, unilateral right-sided in 11 percent and unilateral
left-sided in 14 percent.31
Complications
The placement of pleuroamniotic shunts is not without
complication. Catheter migration occurred 10 times in 80
fetuses in one review, but this did not contraindicate the
placement of a new shunt. Other complications include
obstruction of the shunt and migration of the catheter into
the maternal peritoneal cavity or the fetal thoracic cavity.38
Clinical presentation
Patients with this syndrome typically present with fever,
pleural effusions and pulmonary inltrates within a few
weeks of delivery.46 The patients also frequently present
with chest pain. Some of the patients also have evidence of
myocarditis and/or of thrombosis of various vessels.46 The
patients have either lupus anticoagulant or anticardiolipin
antibodies or both, but do not have antinuclear antibodies;
neither do they fulll the criteria for the diagnosis of systemic lupus erythematosus.46 All of the reported patients
reported had false-positive tests for syphilis.46,47 It should
be noted that the most well known complication of the
antiphospholipid syndrome is spontaneous abortion, most
commonly in the second trimester.
Investigations
Complications
The primary complications are myocarditis with congestive heart failure and venous thrombosis.
MEIGS SYNDROME
When this syndrome was originally described by Meigs in
1937, the syndrome consisted of the presence of ascites
and pleural effusions in patients with benign solid ovarian
tumors.48 Moreover, the syndrome required that when the
ovarian tumor was removed, the ascites and the pleural
effusion both had to resolve.48 Subsequent to the initial
description, it became apparent that a similar syndrome
could occur with benign cystic ovarian tumors, benign
tumors of the uterus (bromyomata), low-grade ovarian
malignant tumors without evidence of metastases49 and
endometriomas.50 Although Meigs still prefers to reserve
his name for only those cases in which the primary neoplasm is a benign solid ovarian tumor, I classify any patient
with a pelvic neoplasm associated with ascites and pleural
effusion in whom surgical removal of the tumor results in
permanent disappearance of the ascites and pleural effusion as having had Meigs syndrome.6
The anticardiolipin antibody can be measured by enzymelinked immunosorbent assay (ELISA). Currently, there is
no denitive assay for the lupus anticoagulant. Its presence
is suggested by any of several tests that show interference
with phospholipid function. A prolonged activated partial
thrombin time (aPTT) that does not become normal with
the addition of an equal volume of normal plasma is
strongly suggestive.47
Pregnant patients known to have antiphospholipid antibodies should be carefully monitored in the post-partum
Pleural effusions secondary to endometriosis are uncommon. In a review in 2000, only 13 cases were found and all
were in conjunction with massive ascites.64
Clinical presentation
Patients usually present with abdominal pain and distension, anorexia and nausea. The initial presumptive diagnosis is frequently malignancy because the patients usually
have signicant weight loss. Many patients also have clinical manifestations of endometriosis, such as progressive
dysmenorrhea, and cul-de-sac and uterosacral ligament
nodularity. Some patients have exacerbation of their
symptoms with their menstrual periods.
Investigations
Investigation
It is hoped that better treatment modalities will be developed for this condition, avoiding aggressive surgery.
KEY POINTS
CATAMENIAL HEMOTHORAX
Clinical presentation
Most patients who present with catamenial hemothorax
are nulliparous and the average age has been 32 years.65
References 481
REFERENCES
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
38
Benign brous tumor of the pleura
MARC DE PERROT
Introduction
Historical background
Clinical features
Radiological features
Histopathology
Management
Adjuvant therapy
483
483
484
484
485
485
486
INTRODUCTION
There are approximately 800 cases of solitary brous
tumors of the pleura (SFTP) reported in the literature.
Most of them are pedunculated mass and harbor benign
histological features.1 Although they may be relatively
large, these tumors are usually treated by simple excision
and do not recur if their resection is microscopically complete.2 Approximately 12 percent of SFTP, however, have
malignant behavior and eventually lead to death due to
local recurrence or metastastic disease.3 The malignant
form of SFTP still remains enigmatic. The behavior is
often unpredictable and does not always correlate with histological ndings.1 In addition, in some cases benign SFTP
may remain silent for several years before degenerating
into a malignant type.4
HISTORICAL BACKGROUND
The rst report of a primary localized pleural tumor is
attributed to Wagner in 1870.5 However, it was only in
1931 that Klemperer and Rabin6 published the rst accurate pathological description, and classied mesothelioma
as either localized or diffuse. Since tissue culture7 and
ultrastructural analysis8,9 demonstrated the presence of
epithelial-like cells in localized mesotheliomas, in 1942
Stout and Murray7 claimed that localized mesothelioma
had a mesothelial origin. However, other investigators
have shown that the mesothelial layer covering the tumor
was intact and they postulated that the epithelial cells seen
could have been trapped within growing brous mes-
Prognosis
Follow-up
Conclusions
Future directions of development
Key points
References
486
487
487
487
488
488
CLINICAL FEATURES
Solitary brous tumors of the pleura have been described
in all age groups from 5 to 87 years, but they peak in the
sixth and seventh decade of life with an even distribution
between men and women.1,3,18 The majority of benign
tumors are small and pedunculated, whereas most malignant SFTP are large and symptomatic.1,4,19,20 Symptoms
usually include cough, chest pain, and dyspnea (Table
38.2). More rarely, hemoptysis and obstructive pneumonitis are observed as a result of airway obstruction.1,4
%
60
18
15
12
2
2
1
1
DoegePotter syndrome.
HPO, hypertrophic pulmonary osteoarthropathy.
RADIOLOGICAL FEATURES
Benign and malignant SFTP usually appear as a welldened, homogeneous and rounded mass on the initial
chest radiograph.1,1921 Rarely, a pleural effusion is associated with malignant SFTP.1,20,21 While small tumors
arising from the parietal pleura classically form obtuse
angles with the chest wall, large or pedunculated SFTP may
form acute angles and be confused with intrapulmonary
masses.27,28 Pedunculated SFTP have occasionally been
reported to be moving on successive chest radiographs
because of their pedunculated attachment in the ssure of
the lung.29,30
Computed tomography (CT) scan usually demonstrates a well delineated, homogeneous and occasionally
lobulated mass of soft tissue attenuation.31 Although no
specic CT features have been described for the diagnosis
of SFTP, the tumors typically appear in contact with the
pleural surface and show displacement or invasion of the
surrounding structures.20 Heterogeneity may be observed
with benign and malignant variants of SFTP because of
myxoid degeneration, hemorrhage or necrosis (Figure
38.1). Tumors arising in an interlobar ssure may be more
difcult to differentiate from an intraparenchymal mass,
because the lesion appears to be surrounded by lung
parenchyma.32 Calcications may be observed in a few
tumors regardless of their benign or malignant histological
features.1,4,20
Magnetic resonance imaging (MRI) has limited use in
the assessment of pleural disease.33 However, the morphology and relationship of large SFTP to adjacent mediastinal
and major vascular structures may be better appreciated
with MRI than with CT.34 MRI is helpful in differentiating
the tumor from other structures and in conrming
intrathoracic localization when the tumor abuts the
Management 485
HISTOPATHOLOGY
Benign and malignant SFTP are widely distributed in the
chest. While most of the benign SFTP are small pedunculated tumors, the malignant variants are often larger than
10 cm and grow beneath the parietal pleura of the chest
wall, diaphragm or mediastinum.1,4,20,42
Macroscopically, benign and malignant tumors appear
as rm, smoothly lobulated masses. Most of them are
encapsulated by a thin, translucent membrane, containing
a reticulated vascular network. Firm adhesion without
signs of invasion may be present between visceral and parietal pleura at the surface of the tumor. The cut surface
appears gray-white to tan with a whorled pattern, and may
disclose areas of hemorrhage and necrosis.1,43
Hemorrhagic and necrotic areas may be present in benign
tumors, but they usually predominate in the malignant
form, most likely because of their larger size.1
Microscopically, SFTP are characterized by a proliferation of uniform elongated spindle cells intimately intertwining with various amounts of connective tissue. Zones
of hypercellularity may alternate with hypocellular or
brous areas within the same tumor. Typically, broblasts
and connective tissue are arranged in a so-called patternless pattern or storiform pattern, characterized by a haphazard distribution of spindle cells and collagen brils.44,45
Occasionally, an increased amount of blood vessels within
the tumor cause a hemangiopericytoma-like pattern.1,44
More rarely, other patterns such as herringbone and
neural palisading are also observed inside the tumor.1
Histological signs of malignancy include:
1. high mitotic counts dened as more than four mitoses
per 10 high-power eld (HPF);
2. mild to marked pleomorphism based on nuclear size,
irregularity and nuclear prominence;
3. bundles of high cellularity with crowding and overlapping of nuclei;
4. presence of necrotic and/or hemorrhagic zones;
5. stromal and/or vascular invasion.
MANAGEMENT
Complete en bloc surgical resection is the mainstay of
therapy for all benign and malignant SFTP. A distance of
12 cm from the tumor is usually recommended to have
adequate margins. While pedunculated tumors can be
safely resected with a wedge resection of the lung, large
sessile tumors can be difcult to resect because of extensive
adhesions and may occasionally require a lobectomy or a
pneumonectomy in order to achieve complete resection.5355 Frozen sections can be helpful to demonstrate
that the resection margins are free of tumors, but are not
routinely required.
Tumors adherent to the parietal pleura require an
extra-pleural dissection.22,53 However, concomitant chest
wall resection can be necessary if the tumor densely
adheres to or invades the chest wall.19 In 3 percent or less
of cases the tumor can be inverted and grow inside the
lung parenchyma (Figure 38.2).56,57 These tumors often
require a lobectomy or a sleeve lobectomy.43,53,58,59 In our
experience in Toronto, a sleeve lobectomy was required in
one case for a solitary brous tumor growing from the left
lower lobe bronchus inside the left main bronchus.
Interestingly, the tumor was growing without invading the
main bronchus and could be simply pulled back from the
main bronchus.52
Thoracoscopic approaches can be safely used to remove
small pedunculated tumors located on the visceral
pleura.53,60 Some authors have also recommended the
assistance of a video-camera to obtain a more precise view
of the resection margins in some large broad-based tumors
of the parietal pleura.53 Extreme caution should be used to
avoid contact between the tumor and the thoracoscopic
PROGNOSIS
ADJUVANT THERAPY
The role of adjuvant therapy in SFTP has not been systematically explored because of the limited number of
patients.61 However, evidence suggests that radiotherapy
and chemotherapy could be benecial in some patients.
Suter and colleagues19 have reported one patient who is
alive with no evidence of disease more than 20 years after
subtotal resection of the tumor followed by radiotherapy,
and Veronesi and colleagues62 have observed signicant
reduction of an inoperable recurrent SFTP with ifosfamide
and adriamycine. Although neoadjuvant therapy could be
helpful in large malignant tumors, its use is limited by the
difculty to obtain a precise preoperative diagnosis even
with an open biopsy.62 Currently, we would recommend
the administration of adjuvant therapy after resection of
malignant sessile tumors, in particular if they are recurrent.
Additional therapies such as brachytherapy and photodynamic therapy have been developed for malignant
mesothelioma and could be applied for other pleural
tumors. However, their use in SFTP has rarely been
reported and their utility remains unproven.61,63
Table 38.3 Summary of recent publications on solitary brous tumors of pleura (SFTP)a
Malignant
sessile
Malignant
pedunculated
Benign sessile
Benign
pedunculated
43
16 (37%)
27 (63%)
13 (30%)
15
13 (86%)
2 (14%)
1 (7%)
62
57 (92%)
5 (8%)
1 (2%)
65
64 (98%)
1 (2%)
1 (2%)
Includes all series reporting adequate follow-up for patients with a diagnosis of SFTP proven by histology and immunohistochemistry (adapted from
reference 52).
<2
8
14
63
>95
Malignancy is recognized by the presence of the following features: high cellularity with crowding and overlapping of nuclei, cellular pleomorphism; high
motitic count (>4/10 high-power eld), necrosis or stromal/vascular invasion.
FOLLOW-UP
CONCLUSIONS
KEY POINTS
Solitary brous tumor of the pleura is a mesenchymal tumor growing along the pleura or
within the lung parenchyma.
Solitary brous tumor of the pleura can be
benign or malignant.
Histological signs of malignancy include: high
cellularity with crowding and overlapping of
nuclei, cellular pleomorphism, high mitotic
count (>4/10 HPF), necrosis or stromal/vascular
invasion.
Complete en bloc surgical resection is the mainstay of therapy for all benign and malignant solitary brous tumors of the pleura.
Histological and morphological characteristics
are the principal indicators of outcome.
Benign pedunculated tumors are considered
benign with a risk of recurrence of less than 2
percent.
Benign sessile or intraparenchymal tumors have
an estimated risk of recurrence of 8 percent.
Malignant pedunculated tumors have an estimated risk of recurrence of 14 percent.
Malignant sessile tumors have the highest rate of
recurrence with an estimated risk of recurrence
of 63 percent.
REFERENCES
= Key primary paper
= Major review article
= Paper that represents the rst formal publication of a
management guideline
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
References 489
34. Ferretti GR, Chiles C, Cox JE, Choplin RH, Coulomb M. Localized
benign brous tumors of the pleura: MR appearance. J Comput
Assist Tomogr 1997; 21: 11520.
35. Norton SA, Clark SC, Sheehan AL, Ibrahim NBN, Jeyasingham K.
Solitary brous tumour of the diaphragm. J Cardiovasc Surg 1997;
38: 6856.
36. Arrive L, Hricak H, Tavares NJ, Miller TR. Malignant versus
nonmalignant retroperitoneal brosis: differentiation with MR
imaging. Radiology 1989; 172: 13943.
37. Falaschi F, Battolla L, Mascalchi M, et al. Usefullness of MR signal:
intensity in distinguishing benign from malignant pleural disease.
AJR Am J Roentgenol 1966; 166: 9638.
38. Verluis PJ, Lamers RJ. Localized pleural broma: radiological
features. Eur J Radiol 1994; 18: 1245.
39. Harris GN, Rozenstein A, Schiff MJ. Benign brous mesothelioma
of the pleura: MR imaging ndings. AJR Am J Roentgenol 1995;
165: 11434.
40. Alexander M, Yang S, Yung R, Brasic JR, Pannu H. Diagnosis of
benign solitary brous tumors by positron emission tomography.
South Med J 2004; 97: 12647.
41. Kramer H, Pieterman RM, Slebos DJ, et al. PET for the evaluation
of pleural thickening observed on CT. J Nucl Med 2004; 45: 9958.
42. Witkin GB, Rosai J. Solitary brous tumor of the mediastinum. A
report of 14 cases. Am J Surg Pathol 1989; 13: 54757.
43. Yokoi T, Tsuzuki T, Yatabe Y, et al. Solitary brous tumour:
signicance of p53 and CD34 immunoreactivity in its malignant
transformation. Histopathology 1998; 32: 42332.
44. Moran CA, Suster S, Koss MN. The spectrum of histologic growth
patterns in benign and malignant brous tumours of the pleura.
Semin Diagn Pathol 1992; 9: 16980.
45. Stout AP. Tumors of the pleura. Harlem Hosp Bull 1971; 5: 547.
46. Hanau CA, Miettinen M. Solitary brous tumor: histological and
immunohistochemical spectrum of benign and malignant variants
presenting at different sites. Hum Pathol 1995; 26: 4409.
47. Chilosi M, Facchetti F, Dei Tos AP, et al. bcl-2 expression in pleural
and extrapleural solitary brous tumours. J Pathol 1997; 181:
3627.
48. Suster S, Fisher C, Moran CA. Expression of bcl-2 oncoprotein in
benign and malignant spindle cell tumors of soft tissue, skin,
serosal surfaces, and gastrointestinal tract. Am J Surg Pathol
1998; 22: 86372.
49. Vallat-Decouvelaere AV, Dry SM, Fletcher CDM. Atypical and
malignant solitary brous tumors in extrathoracic locations.
Evidence of their comparability to intra-thoracic tumors. Am J
Surg Pathol 1998; 22: 150111.
50. Mentzel T, Bainbridge TC, Katenkamp D. Solitary brous tumour:
clinicopathological, immunohistochemical, and ultrastructural
analysis of 12 cases arising in soft tissues, nasal cavity and
nasopharynx, urinary bladder and prostate. Virchows Arch 1997;
430: 44553.
39
Undiagnosed pleural effusions
NICK A MASKELL
Introduction
Is the pleural effusion a transudate or exudate?
Revisiting the patients history
Excluding treatable disease
491
491
491
492
INTRODUCTION
Despite a full work up, approximately 15 percent of pleural
effusions elude a denite diagnosis.1 All respiratory physicians therefore face this problem in their clinical practice.
This chapter discusses an approach to this problem. The
principle aims are to exclude any treatable causes of the
effusion, avoid subjecting frail patients to unnecessary
interventions and at the same time manage patients
expectations.
497
497
497
497
Causes
Left ventricular failure
Mitral stenosis
Liver cirrhosis
Nephrotic syndrome
Hypoalbuminemia
Trapped lung (remote from
inammatory process)
Constrictive pericarditis
Urinothorax
Peritoneal dialysis
Superior vena cava obstruction
Pulmonary infarction
Connective tissue diseases
Fungal infections
Benign asbestos effusion
Yellow nail syndrome
Pancreatitis
sistent undiagnosed effusions because they are both lifethreatening and treatable. The effusions are usually unilateral and occupy less than one-third of the hemithorax.3 In
80 percent of cases they are exudates, 20 percent transudates and the pleural uid is often blood stained. The
pleural uid is often lymphocytic, but there are no characteristic features which enable pulmonary embolus to be
completely ruled out. Common presenting features
include pleuritic chest pain with associated shortness of
breath.5 If suspected, a D-dimer measurement is a useful
starting point, followed by a computer tomography pulmonary angiogram (CTPA) if the D-dimer test is positive.6
(Further discussion can be found in Chapter 30, Effusions
from vascular causes.)
The next step is to try and rule out any disease process
which is potentially amenable to treatment. Figure 39.1
shows a suggested algorithm for this process. Each of these
conditions will also be discussed in the text below.
Pulmonary embolus
Pulmonary embolism is the fourth leading cause of pleural
effusion.3,4 It always needs to be considered in cases of perRevisit history (particularly weight loss and
fever), repeat clinical examination, drug history
Is it an exudate or transudate
(use Lights criteria)
Exudate
Transudate
Meigs syndrome
Meigs syndrome was initially reported in 1937 in a small
group of women with ovarian bromas associated with
ascities and pleural effusions.8 A hallmark of this condition
is the resolution of both the pleural effusion and ascites
once the tumour has been surgically removed. It is postulated that uid probably moves into the pleural space
through small diaphragmatic defects and possibly through
diaphragmatic lymphatics moving from the peritoneal
cavity to the pleural cavity. In 70 percent of cases the effusion is right-sided, in 20 percent it is bilateral and is leftsided in the remaining 10 percent.911 The pleural uid is
usually an exudate and the diagnosis should be thought of
in female patients presenting with an effusion and ascites.
It is most common in women in their fth to seventh
Lymphoma
Often pleural effusions secondary to lymphoma are
accompanied with mediastinal lymphadenopathy.
However, this is not always the case and primary pleural
lymphoma is a recognized disease entity. The incidence of
lymphoma is currently increasing in the western world and
therefore a diagnosis of lymphoma should be entertained
in patients presenting with a lymphocytic effusion. Flow
cytometry and cytogenetics can be extremely helpful in
this setting but often pleural tissue or lymph node sampling will be required to obtain a denitive diagnosis.
(a)
(c)
(b)
negative than usual. These usually occur as part of a malignant process, but can occur after a parapneumonic illness
that has not been treated adequately or in a timely manner.
It therefore needs to be considered in difcult-to-diagnose
cases and not assumed to be denitely malignant in
origin.14,15 If the patient is t enough, decortication is the
treatment of choice, in symptomatic and non-malignant
cases. It also allows extensive sampling of the visceral
pleura to exclude underlying malignancy.
Tuberculous pleurisy
Figure 39.3 Computed tomography image of a man with nonHodgkins lymphoma with a paraspinal mass and unilateral pleural
effusion.
Figure 39.3 shows a CT image of a man with nonHodgkins lymphoma who presented with a unilateral
pleural effusion.
Trapped lung
Trapped lung occurs when a thick layer of brous tissues
encases part of the visceral pleura preventing the lung from
full expansion to the chest wall. This results in recurrent
pleural effusion as the intrapleural pressure will be more
(a)
(b)
Figure 39.5 Chest radiograph (a) and pseudochylous effusion
(b) in a man with rheumatoid arthritis. (For (b), see also Color
Plate 48.)
Pleural malignancy
Many undiagnosed effusions will eventually turn out to be
a malignant process. As cytology alone has a sensitivity of
only 60 percent and often the CT thorax does not reveal an
area of focal pleural thickening to undertake a percutaneous biopsy, the clinician will often nd himself in the
position where malignancy is suspected but the patient is
too frail for thoracoscopy. In these situations, watchful
waiting in the outpatient setting is often appropriate.
Thoracoscopy remains the diagnostic tool of choice for
undiagnosed effusions where malignancy is suspected.
Harris et al.26 described 182 consecutive patients who
underwent thoracoscopy over a 5-year period and showed
it to have a diagnostic sensitivity of 95 percent for malignancy. Malignancy was shown by thoracoscopy in
66 percent of patients who had previously had a nondiagnostic closed pleural biopsy and in 69 percent of
patients who had had two negative pleural cytological
specimens.26 A similar sensitivity for malignant disease was
described by Page et al.27 in 121 patients with undiagnosed
effusion. In addition, it has a very low complication rate.
In patients with a prior asbestos history, mesothelioma
should always be considered. In this setting the yield from
cytology alone can be as low as 25 percent and thoracoscopy improves this to 95 percent in some series.27 In
addition to obtaining a tissue diagnosis, several liters of
uid can be removed during the procedure and the opportunity is also provided for talc pleurodesis. Thoracoscopy
may therefore be therapeutic as well as diagnostic28 (see
also Chapters 47 and 48).
mild weight loss. The pleural uid aspirated may also not
reveal any clues as it might still be straw colored even it is
has been present for some time. The diagnostic problems
do not stop there as up to 40 percent of pleural uid cultures are negative. Sometimes the diagnosis is only made at
the time of video-assisted thoracoscopic surgery (VATS)
where biopsies show evidence of a chronic empyema
rather than the malignancy. The key message here is to
keep an open mind and always ask the question could this
be due to infection?
Cardiac failure
Cardiac failure is the most common cause of a transudative effusion (Chapter 24). Usually, this diagnosis is made
clinically and the chest X-ray reveals bilateral effusions.
However, they can occur unilaterally, and when they do
they are twice as common on the right side.29
Although these effusions are usually transudates, they
occasional present as exudates, particularly in patients
already on diuretics. The predominant cell count can be
lymphocytic and the uid often also contains mesothelial
cells. Plasma brain natriuretic peptide (BNP) level can be
very useful in diagnosing these less obvious cases.
Measuring pleural uid BNP level does not convey any
additional benet to the plasma level alone.30,31
Hepatic hydrothorax
Some patients present with a hepatic hydrothorax
without ascites and, therefore, needs to be thought about
in persistently undiagnosed pleural effusions. In one
series 27 of the 28 cases were right-sided. The explanation
of the pleural effusion in the absence of overt ascites is
that patients have defects in their diaphragm and the
uid ows into the pleural space because of negative
pleural pressure. Hepatic hydrothorax is secondary to the
passage of ascites through diaphragmatic defects and the
ascites is secondary to portal hypertension and salt retention. First-line treatment is sodium restriction and spirolactone.
Parapneumonic effusions
Nephrotic syndrome
References 497
Suspected problem
Cardiac failure
Pulmonary embolus
Chronic pancreatitis, esophageal rupture
Pleural lymphoma
Tubeculous pleuritis
Meigs syndrome or subphrenic collection, cirrohosis
Chylous/pseudochylous effusion
Hypothyroidism
Nephrotic syndrome
SUMMARY
After the standard initial workup for undiagnosed pleural
effusions, the cause is undetermined in around 15 percent
of cases. When faced with this problem it is sensible to rst
revisit the history (including drugs) and clinical examination. The next step is to re-evaluate whether it is a transudate or exudate by Lights criteria. This will help channel
further investigations.
All treatable causes of pleural effusions need to be considered and ruled out. These include pulmonary embolus
where a CTPA scan needs to be performed if suspected.
Serum BNP levels are another useful investigation
where congestive heart failure is thought possible. Special
tests to exclude TB and lymphoma may also be necessary.
Unfortunately, many of the remaining effusions will
eventually turn out to be due to malignancy. Often these
KEY POINTS
REFERENCES
7. Light RW, Rogers JT, Moyers JP, et al. Prevalance and clinical
course of pleural effusions at 30 days post coronary artery bypass
surgery. Am J Respir Crit Care Med 2002: 166: 15636.
8. Meigs JV, Cass JW. Fibroma of the ovary with ascities and
hydrothorax. Am J Obstet Gynecol 1937; 33: 24967.
9. Sahn SA. The pleura state of the art. Am Rev Respir Dis 1988;
138: 18423.
10. Majzlin G, Stevens FL. Meigs syndrome: case report and review of
literature. J Int Coll Surg 1964: 42: 62530.
11. Meigs JV. Fibroma of the ovary with ascities and hydrothorax
Meigs syndrome. Am J Obstet Gynecol 1954: 67: 96287.
12. Robinson BWS, Musk AW. Benign asbestos pleural effusion:
diagnosis and course. Thorax 1981; 36: 89690.
13. Joseph J, Strange C, Shan SA. Pleural effusions in hospitalised
patients with AIDS. Ann Intern Med 1983; 118: 856859.
14. Moore PJ, Thomas PA. The trapped lung with chronic pleural space,
a cause of recurring pleural effusion. Military Med 1967; 132:
9981002.
15. Farber JE, Lincoln NS. The unexpandable lung. I. Statement of the
problem. Am Rev Tuberc 1939: 40: 7049.
16. Berger HW, Mejia E. Tuberculous pleurisy. Chest 1973; 63: 8892.
17. Idell S. Evaluation of perplexing pleural effusions. Ann Intern Med
1994; 110: 5679.
18. Ocana IM, Martinez Vazquez JM, Seguna R, et al. Adenosine
deaminase in pleural uids. Chest 1983; 84: 513.
19. Idell S. Granulomatous disease of the pleura. Semin Respir Med
1994; 6: 319.
20. Good JT Jr, King TE, Antony VB, et al. Lupus pleuritis. Clinical
features and pleural uid characteristics with special reference to
pleural uid antinuclear antibodies. Chest 1983; 84: 71418.
40
Asbestos-related pleural diseases
A WILLIAM MUSK, NICHOLAS H DE KLERK
Introduction
Denitions
Epidemiology
Aetiology/pathogenesis
Pathology
Clinical features
499
500
500
501
502
502
INTRODUCTION
Asbestos is a term used for a number of brous silicates
with particular properties, which occur in deposits large
enough to be of commercial interest. Thus, the origin of
the term is geological as well as commercial. There are
other brous minerals, which have some similar biological
effects, particularly tremolite (a non-commercial amphibole), erionite (a brous silicate found in volcanic rock
and implicated in mesothelioma and pulmonary brosis in
Turkey) and wollastonite (a silicate used in ceramics) and
some forms of talc.1 Most (>90 percent) of the worlds
production of asbestos has been of chrysotile, which is of
the serpentine group of minerals. The remainder of production has been of crocidolite, amosite and anthophyllite,
which are amphiboles.2
Asbestos bers are generally strong, easily separable
(splitting longitudinally rather than transversely), long
and thin (aspect ratio >3:1), exible and heat and re
resistant. Whereas chrysotile bers tend to be feathery and
curved, the amphiboles are straight and thin, and more
durable. Crocidolite has very long thin bers, anthophyllite has the thickest bers and amosite bers are of intermediate dimensions. The amphiboles also differ in their
chemical composition and the properties of these same
minerals obtained from different places are also slightly
different.1
Variability in the biological activity of these four main
types of asbestos appears to be determined more by physical shape and durability than by chemical properties. The
entry of (brous) particles into the gas-exchanging regions
of the lungs from where they may gain access to the pleura
Investigations
Management
Complications
Future directions
Key points
References
502
503
504
504
504
504
DEFINITIONS
Circumscribed pleural plaques are discrete areas of hyaline
or calcied pleural brosis which are nearly always bilateral and localized on the parietal pleura of the chest wall,
diaphragm or mediastinum but may also occur in the
interlobular ssures when they simulate pulmonary neoplasms radiographically.5 Pleural plaques which occur on
the visceral pleura are associated with abnormality in the
underlying lung with interstitial brotic lines radiating out
and giving rise to the term hairy plaques.6
Diffuse pleural thickening is a condition of more extensive, active and progressive pleural brosis which involves
the visceral pleura (Figure 40.1). Calcication may also
occur in longstanding DPT. It is less specic for asbestos
exposure because other causes of exudative effusions (e.g.
empyema, hemothorax) may also cause it.6
Benign asbestos pleural effusion is a term applied to an
exudative pleural effusion occurring in a subject with
asbestos exposure (for which no alternative cause can be
identied).
Rolled atelectasis is a process that occurs within the
lung parenchyma adjacent to an area of diffuse pleural
EPIDEMIOLOGY
All varieties of asbestos may be responsible for the various
manifestations of benign pleural disease7 although
Hillerdal et al.8,9 have shown that subjects exposed to crocidolite or erionite are more likely to have diffuse pleural
thickening and benign asbestos pleural effusion (as well as
a greater risk of malignant mesothelioma) than those
exposed to Finnish anthophyllite in whom circumscribed
plaques are relatively more common.
Pleural plaques
Plaques are the most common manifestation of asbestos
exposure, especially in subjects with previous environmental or household exposure. They mainly occur posteriorly
and laterally following the contours of the eighth to tenth
ribs and rarely in the apices or costophrenic angles.10 The
distribution of pleural plaques in the general population is
related to the frequency of opportunities for asbestos exposure and age.11,12 Plain X-ray studies underestimate the
frequency of plaques by orders of magnitude: more sensitive radiographic techniques (such as computed
tomography [CT] scanning), surgical and post-mortem
studies show them to be much more frequent (Figure
40.2).13 Pleural plaques are more common in subjects with
higher asbestos ber counts in lung tissue (ie. they are doserelated).14 Also, plaques are more common in people living
in urban than in rural areas.15 Tobacco smoking does not
appear to inuence the occurrence of pleural plaques.
The natural history of circumscribed pleural plaques
following crocidolite exposure is that they appear to
Aetiology/pathogenesis 501
Rolled atelectasis
There is no consistent epidemiological data on the distribution and determinants of rolled atelectasis apart from
the clinical observation of its association with other manifestations of asbestos exposure, including asbestosis,
plaques and diffuse pleural thickening (Figure 40.3).
AETIOLOGY/PATHOGENESIS
With the exception of airborne exposure to one or other
of the varieties of asbestos, erionite, wollastonite or talc,
other factors do not appear to be important in the aetiology of benign asbestos-induced pleural disease: smoking
does not appear to be related to any of the diagnostic entities and Simian Virus 40 (SV40), which appears to have
been exonerated as a cause of malignant mesothelioma,22
has not been implicated (although not specically
sought).
PATHOLOGY
Circumscribed pleural plaques characteristically appear
macroscopically as shining white elevations with sharp
borders on the parietal pleura, most commonly on the mid
to lower zones of the costal pleura, the dome of the
diaphragm and the mediastinal (including the pericardial)
pleura. They are usually multiple, up to several centimeters
across and tend to lie parallel to the ribs. Microscopically
they consist of dense sparsely cellular (hyaline) brous
tissue covered with normal mesothelium. Asbestos bers
are rarely found within the plaques with light microscopy
but small bers may be seen occasionally with electron
microscopy. Calcication is seen microscopically quite
early but radiologically only late in the natural history of
CPP.26
CLINICAL FEATURES
Circumscribed pleural plaques are most commonly found
incidentally when plain chest X-rays or CT of the chest are
performed for some other reason (except if radiography is
being used to identify abnormality in subjects known to
have been exposed to asbestos). Although people with
plaques are frequently asymptomatic, there is an association of plaques with chest pain which is most likely to have
the characteristics of angina.27 Hence they may be found
when chest pain is being investigated. There is no guideline
to help determine if the pain is caused by the plaques so
that attribution to plaques is by careful exclusion of other
possible causes. Pleural plaques are associated with minor
changes in lung function (particularly vital capacity28)
when large groups of subjects with plaques are compared
with similar subjects without plaques.29 It is generally conceded that circumscribed plaques themselves are not
responsible for sufcient physiological abnormality to
cause exertional breathlessness. Thus other explanations
for breathlessness should be sought in dyspnoeic subjects
with plaques and it is not usually considered that the mere
presence of plaques entitles a person to workers compensation for disablement (with the proviso that they constitute an independent indicator of previous asbestos
exposure in an applicant with diffuse interstitial lung
disease, pleural effusion or lung cancer).30
Diffuse pleural thickening, in contrast to plaques, may
result in signicant reductions in lung volumes and cause
exertional dyspnoea especially when it is bilateral (see
further below). No association with chest pain has been
described so the presence of chest pain should raise the
issue of malignancy.
Benign asbestos pleural effusion usually presents with
exertional dyspnoea (or worsening dyspnoea if there is
associated disease) if it is of sufcient size. Pleuritic pain
may be a feature initially and this pain may persist or
recur. The presence of fever, sweating or other constitutional symptoms raises the index of suspicion that some
INVESTIGATIONS
Plain chest radiography
The standard plain postero-anterior chest radiograph is
still the most common means of identifying all the benign
asbestos-induced pleural diseases. It has often been performed for other indications and the benign disease found
incidentally, especially CPP. Lateral and oblique views
increase the likelihood of nding abnormality but are
rarely carried out because, if being specically sought, CPP
are much better demonstrated with CT of the chest: when
compared with autopsy or thoracotomy only about 15
percent of CPP are diagnosed by the radiologist.31 On
plain lm CPP are best seen tangentially and when calcied. If of sufcient thickness, non-calcied plaques may be
seen face-on on the plain lm as faint, sharply delineated
relatively homogeneous shadowing/inltrates. The
International Labour Organizations classication of
radiographs of pneumoconioses32 includes a systematic
means of recording the presence of benign asbestosinduced pleural diseases which is useful for epidemiological purposes but not of much value clinically. It does,
however, include a convenient denition of the extent of
thickening of the pleura constituting a plaque as opposed
to diffuse thickening which serves as a useful arbitrary
guide for descriptive purposes.
Circumscribed smooth non-calcied pleural shadowing bilaterally and mainly in the mid zones on the lateral
chest walls is likely to be due to subpleural fat as it is seen
more commonly in subjects with high body mass indices33
and does not of itself usually warrant further investigation,
although CT will demonstrate that the density of the shadowing is that of fat. Calcication within pleural plaques is
also much more readily and elegantly demonstrated by
CT. Healed rib fractures, metastases in the chest wall and
myeloma deposits need to be considered in the differential
diagnosis of CPP. Soft tissue shadowing from the serratus
anterior muscle and companion shadows (thin lines parallel to the upper ribs) also need to be recognized. Visceral
pleural plaques in the inter-lobar ssures need to be differentiated from pulmonary neoplasms.
Management 503
Computed tomography
Computed tomography of the chest provides a much more
elegant means of demonstrating the type, distribution and
extent of all the benign asbestos induced pleural diseases.
Technical recommendations for the performance of highresolution computed tomography (HRCT) scans to
provide highest quality images of the pleura are soft tissue
windows of approximately (height/width) 50/350
Hounseld Units.34
Ultrasound
Ultrasound is frequently and advisedly used to guide
pleural aspiration and intercostal catheter insertion in
patients with pleural thickening and effusion seen radiographically. It is not of diagnostic value per se.10
Pulmonary function
Circumscribed pleural plaques have a negligible effect on
lung function,28,39,40 although in population studies they
can be shown to have a small effect on lung volumes (total
lung capacity and vital capacity). They are not considered
to be disabling unless accompanied by other abnormality.
Diffuse pleural thickening in contrast to CPP may
markedly reduce lung volumes which in turn may result in
exertional breathlessness in the absence of asbestosis (i.e.
asbestos-induced diffuse interstitial lung disease).41 This
may result from inammatory involvement of the costal
surfaces of the diaphragms and lower costal pleura causing
a pleurodesis which limits the excursion of the diaphragm
and appears as loss of the costophrenic angle on the plain
chest X-ray as well as from reduced distensibility of the
pleura and the space-occupying effect of the thickened
pleura. Gas transfer measured by the single breath diffusing capacity for carbon monoxide (DLCO) is well preserved
(if there is no co-existing asbestosis) and the diffusion constant may be increased as a result of a disproportionately
reduced lung volume as measured by alveolar volume
(VA).42 The degree of breathlessness and limitation of
exercise capacity may be demonstrated by exercise testing
as in all the occupational lung disorders.43 DPT appears to
be associated with an increased ventilatory response to
exercise without oxygen desaturation (oxygen desaturation usually indicates interstitial disease) such that the
subjects maximum performance may be determined by
their ventilatory ability rather than by cardiovascular
limitation.
MANAGEMENT
Circumscribed pleural plaques
There are no specic management issues relating to CPP
beyond the recognition of their signicance as indicators
of asbestos or occasionally talc exposure in the past.45
Their presence therefore assists in attributing other abnormalities such as interstitial lung disease or pleural effusion
to past asbestos exposure, especially as some subjects seem
to not recall their exposure and some reporting radiolo-
COMPLICATIONS
FUTURE DIRECTIONS
The main specic management issue with DPT is its diagnostic differentiation from primary or secondary malignancy of the pleura, especially desmoplastic malignant
mesothelioma. It is important to be precise as management is determined by the cause of the pleural thickening. Mesothelioma is increasingly attracting treatment
with chemotherapy (despite an abysmal response rate)
and even surgery (despite the absence of any scientically
valid evidence that it improves quality of life or survival).
Also, secondary tumors (especially breast and prostate
cancers) in the pleura may require specic treatment
measures.
Decortication of the lung to improve lung volumes and
ventilatory capacity has not been a useful procedure.
Unlike pleural thickening in tuberculosis or other infective
causes of pleural thickening following empyema, a plane of
dissection/cleavage does not exist, making hemostasis
difcult and the response of lung volume unsatisfactory.
KEY POINTS
REFERENCES
References 505
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
41
Malignant mesothelioma
BRUCE WS ROBINSON
Introduction
Epidemiology
Pathogenesis
Clinical presentation
Diagnosis
507
507
508
508
509
INTRODUCTION
Mesothelioma is a malignant tumor of the serosal surfaces,
mostly of the pleura and peritoneum, almost always
caused by asbestos.1 Whilst there is a benign form of the
disease, that is rare and the term mesothelioma almost
always refers to the malignant form of the disease.
Mesothelioma was a rare disease but has become common
over the past few decades. It is now approximately as
common a cause of death as cancers of the liver, bone,
cervix, ovary and bladder in many countries.2 Its incidence
is expected to continue to increase for the next decade or
so (see below). Almost everyone who lives in the western
world, and increasing numbers in the developing world,
have asbestos bers in their lungs and many individuals
recall incidental asbestos exposure, e.g. plumbers, carpenters, insulation installers, home renovators, military personnel, school teachers plus students who handled
asbestos mats or blankets, and in many other situations.3
Indeed, the word mesothelioma is becoming well known
in the public arena due to the widespread publicity that
asbestos has received over the past 15 years and since the
death from mesothelioma of some famous individuals
such as actor Steve McQueen.
Media interest has produced awareness, even anxiety,
about mesothelioma. The complex medico-legal aspects of
the disease, plus this awareness, have led to a lot of interest
in mesothelioma.
EPIDEMIOLOGY
Whilst most common cancers do not have clearly dened
single carcinogens (even cigarette smoke has many poten-
Management
Palliation
Key points
References
511
512
512
512
tial carcinogens), the link between asbestos as a single carcinogen and mesothelioma is clearly established.3 There
are not many diseases with such a close link between the
occurrence in the community of the disease and exposure
to the carcinogen as dened as they are for mesothelioma.
In fact, mesothelioma is essentially a disease that would
still be rare but for the widespread use of asbestos. That
link was rst recognized by J.C. Wagner, a pathologist
working in South Africa.4
Mesothelioma is linked to exposure to asbestos but not
to cigarette smoking.3 Other generally recognized causes of
mesothelioma include endemic erionite exposure in
Turkey,5 ionizing radiation and chest injuries.6 There is a
potential role for Simian virus 40 (SV40) (discussed
below).
Males are more likely to get mesothelioma than females
through occupational exposure. The sporadic background
rate of mesothelioma is around one per million. This rises
to over 40 per million in some countries.2 As expected,
industrialized countries have higher rates than non-industrialized countries, relating to production and utilization
of asbestos7.
The post-war mesothelioma epidemic7 (Figure 41.1),
resulted from a rapid increase in asbestos use worldwide,
though the long incubation period between the onset of
the disease and time since rst exposure (usually over 30
years) means that the peak incidence of mesothelioma is
yet to be reached. Whereas cessation of exposure to
tobacco smoke reduces the risk of developing lung cancer
and approaches that of a never-smoker after 2530 years,
the risk of mesothelioma which is almost nil in the rst
1012 years following rst exposure, progressively
increases with increasing time.8
900
800
700
600
500
400
300
200
100
0
8185
8690
9195
96 00
PATHOGENESIS
There are several ways in which a mineral ber such as
asbestos induces cancer:
1. Pleural irritation ber shape and length-to-width ratio
are the main attributes that determine penetration and
capacity to irritate the pleural space.9 Long and thin
bers penetrate the lung and scratch the mesothelial
surface, inducing multiple cycles of damage, repair and
local inammation, leading either to scarring
(plaques) or cancer (mesothelioma).
2. Mitosis interference asbestos bers can interfere with
the mitotic spindle by piercing the mitotic spindle
causing disruption to mitosis. This can lead to aneuploidy and the other forms of chromosome damage
seen in mesothelioma.10
3. Toxic oxygen radicals asbestos-induced DNA damage
is partly mediated by iron-related reactive oxygen
species (ROS) this can also lead to strand breakage.11
4. Kinase-mediated signaling asbestos induces the phosphorylation of the mitogen-activated protein (MAP)
kinases and extracellular signal-regulated kinases
(ERK) 1 and 2 and this is associated with expression of
early response proto-oncogenes (fos/jun or activator
protein 1 family members).12 Many growth factors
drive mesothelioma proliferation but the only factors
whose blockade has been shown to slow mesothelioma
growth are transforming growth factor beta (TGF-b)
and platelet-derived growth factor (PDGF) A chain.13
CLINICAL PRESENTATION
Pleural effusion, usually with breathlessness and often with
chest wall pain, is the most common presentation in
mesothelioma patients.18 Unexplained pleural effusion
with chest wall pain should evoke a detailed clinical history
of possible asbestos exposure. Weight loss and fatigue
usually occur later in the course of disease and are associated with a poor prognosis.18 Mesothelioma can occasionally be discovered on chest X-ray as asymptomatic pleural
effusions or pleural masses. Peritoneal mesothelioma presents with abdominal distension, abdominal pain and
sometimes bowel obstruction.19 Mesotheliomas do occur
in the pericardium or tunica vaginalis, though rarely, and
present with features of pericardial effusion/tamponade or
blood-stained hydrocoele.20,21
A xed hemithorax clinically, i.e. unilateral lack of
expansion, is usually a late sign. Clubbing is rare.
Peritoneal mesothelioma manifests as ascites, tenderness and, later in their course, palpable masses.19
Subcutaneous masses are almost always associated with
surgery or the insertion of intercostal drainage tubes.18
Local invasion of superior vena cava (presenting as
obstruction), the spinal cord (resulting in back pain and
paralysis), the pericardium (resulting in pericardial effusions and tamponade), the contralateral lung (presenting
as contralateral pleural effusion) or sympathetics (presenting as Horners Syndrome) do occur, but rarely at presentation.18
Diagnosis
509
tinguish mesothelioma from adenocarcinoma and is occasionally necessary to distinguish desmoplastic/sarcomatoid mesothelioma from brous pleuritis.
DIAGNOSIS
Pathology
Differentiation of mesothelioma from adenocarcinoma in
tissues and from reactive mesothelial cells in effusion
samples are the major issues for pathologists.24
CYTOPATHOLOGY
The quality of current immunohistochemical and ultrastructural methods of cytological assessment make cytological diagnosis alone quite accurate in experienced hands
with the appropriate antibodies.25 Closed needle biopsy
using Abrams needle often produces inconclusive results.
Ultrastructural examination is helpful. Fine needle
aspiration cytology is useful for sampling pulmonary,
chest wall or lymph node masses, when there is no effusion
present in particular. Core biopsy samples are used for
large pleural-based lesions, especially in the absence of an
effusion.26
The immunocytochemical stains used to distinguish
mesothelioma from adenocarcinoma and other diseases
are listed below but, importantly, calretinin identies cells
as being of mesothelial origin and epithelial membrane
antigen (EMA) staining in cytological samples in a thick
membrane distribution using the correct antibody is
highly suggestive of mesothelioma.27
Imaging
HISTOPATHOLOGY
1.50
1.00
0.75
0.50
0.25
Asbestosis
IPF
Sarcoidosis
SLE
RA Lung
Other ILD
TB
Other
Lung cancer
Breast cancer
Other cancer
Pleural
effusions
Gross
thickening
Infection
Inflammatory
Transudates
Malignancy
Healthy
controls
Plaques
Non-exposed
Asb-exposed
0.00
Mesothelioma
1.25
Other
cancers
Inflammatory
diseases
Other lung diseases
Management 511
MANAGEMENT
More effective chemotherapies and new approaches to
surgery have occurred in recent years.
Radiotherapy
Radiotherapy results have been disappointing except for
local post-surgical radiotherapy to prevent seeding of
tumor cells.56 The diffuse nature of the tumor makes it difcult to undertake radical radiotherapy without causing
pneumonitis. Intensity modulated radiotherapy (IMRT) is
being used in some centers with benet.57 Local radiotherapy, e.g. radioactive colloids and other forms of
brachytherapy, have been disappointing.
Immunotherapy
Mesothelioma appears to be sensitive to destruction by
immunotherapies though none have entered routine clinical use.58 Anti-mesothelioma immune responses can be
detected in many patients.59 Recombinant interferon alpha
given systemically produced response rates of around
1015 percent, and although that approach is complicated
by lethargy, weight loss and fevers, some patients exhibit
long-lasting responses.60
Surgery
Diagnostic surgery includes video thoracoscopy, open
pleural biopsy and/or mediastinoscopy or laparoscopy to
establish a diagnosis of mesothelioma.51 Palliative surgery
includes partial pleurectomy with pleurodesis, thoracoscopy with pleurodesis and pleuroperitoneal shunting.52
Potentially curative surgery, which is only used in a
limited number of centres, involves extrapleural pneumonectomy usually followed by some form of adjuvant
therapy. The difculty of the surgery and peri-operative
mortality rate combined to make the role of radical
surgery controversial.5356
Chemotherapy
Cures are rare with chemotherapy regimes but recently
several regimes have been shown to be of value for pallia-
Gene therapy
Gene therapy using either suicide gene therapy or
immunogene therapy have been used clinically in
mesothelioma. These pioneering approaches are reviewed
elsewhere (see Chapter 49, Gene therapy in pleural
disease).
Other therapies
Photodynamic therapy, involving the generation of toxic
oxygen radicals in mesothelioma cavities, is laborious and
time-consuming and is an effective form of cytoreduction.61 Clinical trials using other novel agents (e.g. the antiangiogenic agents SU5416, bevacizumab, thalidomide and
PTK/ZK 787) have been or currently are being tried.62,63
PALLIATION
Recurrent pleural effusions are best controlled by pleurodesis, e.g. talc instillation or occasionally surgery.
Invasion of the chest wall can cause localized somatic pain,
intercostal nerve invasion or vertebral invasion can cause
neuropathic pain and lung invasion can cause diffuse visceral pain.67 There is no limit of dose for opioids to control
this pain, e.g. use liquid morphine plus sustained release
morphine in doses that do not cause unnecessary side
effects. Somatic pain responds to non-steroidal antiinammatory drugs and neuropathic pain requires an
anti-convulsant such as carbamazepine or sodium valproate.68 Some patients require procedural pain relief, e.g.
intrathecal analgesia or nerve block.67 Weight loss and
anorexia respond to dietary advice and to drug therapy,
e.g. dexamethasone. Dyspnea due to pleural effusion, or
more commonly tumor spread, is also common.
Psychosocial care is also important in palliation given
the fear, anger and suffering associated with this disease.
KEY POINTS
REFERENCES
3. Greenberg AK, Lee TC, Rom WN. The North American experience
with malignant mesothelioma. In: Robinson BWS, Chahinian AP
(eds). Mesothelioma. London: Martin Dunitz, 2002; 127.
4. Wagner JC, Sleggs CA, Marchand P. Diffuse pleural mesothelioma.
Br J Ind Med 1960; 17: 26071.
5. Baris YL, Simonato L, Artvinli M, et al. Epidemiological and
environmental evidence of the health effects of exposure to
erionite bers. Int J Cancer 1987; 39: 1017.
6. Comin CE, de Klerk NH, Henderson DW. Malignant mesothelioma.
Ultrastruct Pathol 1997; 21: 31520
7. de Klerk NH, Musk AW. Epidemiology of mesothelioma. In:
Robinson BWS, Chahinian AP (eds). Mesothelioma. London: Martin
Dunitz, 2002: 33950.
8. de Klerk NH, Musk AW, Williams VM, et al. Comparison of
measures of exposure to asbestos in former crocidolite workers
from Wittenoom Gorge, W. Australia. Am J Ind Med 1996; 30:
57987.
9. Sebastien P, Janson X, Gaudichet A, Hirsch A, Bignon J. Asbestos
retention in human respiratory tissues: comparative measurements
in lung parenchyma and in parietal pleura. IARC Sci Publ 1980; 30:
23746.
10. Ault, JG, Cole RW, Jensen CG, et al. Behavior of crocidolite
asbestos during mitosis in living vertebrate lung epithelial cells.
Cancer Res 1995; 55: 7928.
11. Shatos, MA, Doherty JM, Marsh JP, Mossman BT. Prevention of
asbestos-induced cell death in rat lung broblasts and alveolar
macrophages by scavengers of active oxygen species. Environ Res
1987; 44: 10316.
12. Zanella CL, Posada J, Tritton TR, Mossman, BT. Asbestos causes
stimulation of the extracellular signal-regulated kinase 1
mitogen-activated protein kinase cascade after phosphorylation of
the epidermal growth factor receptor. Cancer Res 1996; 56:
53348.
13. Marzo AL, Fitzpatrick DR, Robinson BWS, Scott B. Antisense
oligonucleotides specic for transforming growth factor beta 2
inhibit the growth of malignant mesothelioma both in vitro and in
vivo. Cancer Res 1997; 57: 32007.
14. Gazdar AF, Carbone M. Molecular pathogenesis of mesothelioma
and its relationship to Simian Virus 40. Clin Lung Cancer 2003; 5:
17781.
15. Shivapurkar N, Wiethege T, Wistuba II, et al. Presence of simian
virus 40 sequences in malignant mesotheliomas and mesothelial
cell proliferations. J Cell Biochem 1999; 76: 1818.
16. Murthy SS, Testa JR. Asbestos, chromosomal deletions, and tumor
suppressor gene alterations in human malignant mesothelioma. J
Cell Physiol 1999; 180: 1507.
17. Pylkkanen L, Sainio M, Ollikainen T, et al. Concurrent LOH at
multiple loci in human malignant mesothelioma with
preferential loss of NF2 gene region. Oncol Rep 2002; 9:
9559.
18. Scott B, Mukherjee S, Lake R, Robinson BWS. Malignant
mesothelioma. In: Hanson H (ed.). Textbook of lung cancer.
London: Martin Dunitz, 2000; 27393.
19. Berry G, de Klerk NH, Reid A, et al. Malignant pleural and
peritoneal mesotheliomas in former miners and millers of
crocidolite at Wittenoom, Western Australia. Occup Environ Med
2004; 61: 14.
20. Hirano H, Maeda T, Tsuji M, et al. Malignant mesothelioma of the
pericardium: case reports and immunohistochemical studies
including Ki-67 expression. Pathol Int 2002; 52: 66976.
21. Abe K, Kato N, Miki K, et al. Malignant mesothelioma of testicular
tunica vaginalis. Int J Urol 2002; 9: 6023.
22. Lumb PD, Suvarna SK. Metastasis in pleural mesothelioma.
Immunohistochemical markers for disseminated disease.
Histopathology 2004; 44: 34552.
23. Musk AW. More cases of miliary mesothelioma. Chest 1995; 108:
587.
24. Segal A, Whitaker D, Henderson D, Shilkin K. Pathology of
References 513
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
42
Spontaneous pneumothorax
ANDREW C MILLER
Historical background
Denitions
Epidemiology
Pathogenesis
Clinical features
515
515
515
517
519
HISTORICAL BACKGROUND
In 1903 Emerson1 published a compilation of all previous
literature on pneumothorax, including the rst examples
of its naming (Itard 1803), use of needle aspiration (B. Bell
1804), full clinical description (Laennec 1819), a primary
case with blebs (McDowell 1856), the coin sign
(Trouseau 1857), underlying physics (J. Bell 1857), pleural
reabsorption of air (Skoda 1857), fatal tension (Medsel
1859), treatment by indwelling catheter (Orlebar 1882),
and the value of oxygen therapy (Rodet and Nicholas
1895). Both before and since then, cavitatory tuberculosis
was thought to be the main cause, as in 78 percent of cases
in Vienna in 1880.2 This perspective changed following
publication of a landmark doctoral thesis by Kjrgaard in
1932.3 Until then only 200 cases of primary pneumothorax, mainly as single case reports, had been identied.
Kjrgaard considered pneumothorax simplex to be
comparatively rare, but recognized that many minor
cases were being overlooked; hence all but 18 percent of
his 51 cases had complete lung collapse, the reverse of subsequent experience.
Chest radiography
Medical management
Operative management
Key points
References
520
521
524
526
526
EPIDEMIOLOGY
DEFINITIONS
Incidence
Denition
Example
Normal lungs
Generalized: chronic disease
Bullous
Fibrotic
Miscellaneous
Other
Cavitatory
Malignant
Miscellaneous
Presentation
Chest radiograph
Resolution on medical
management
Prevention of recurrence
Primary
Secondary
Usually >45 years
Occasional
Often severe
Usually small or moderate
Occasional
Changes of underlying disease
Observation alone
Simple aspiration
Medical pleurodesis
Operative approach
Not appropriate
Thoracoscopy
Age
Chest pain
Dyspnoea
Degree of collapse
Pleural reaction
Other ndings
Gender
The above male:female ratio of 2.5:1, similar to that in
large series from tertiary centers,9 is likely to be more
Pathogenesis 517
Age
Primary pneumothorax is mainly a disease of young adults
with a unimodal age distribution for the rst episode
peaking in the early twenties;10,2125 therefore, it is not
unusual for patients to present in early adolescence.2629 As
expected, most cases of secondary pneumothorax due to
emphysema and pulmonary brosis occur in the second half
of life whereas Langerhans-cell histiocytosis,30 lymphangioleiomyomatosis, cystic brosis and acquired immune
deciency syndrome (AIDS) usually affect young adults.
Body shape
It has long been recognized that pneumothorax and its
recurrence are particularly common in young men with an
ectomorphic build.24,25,31,32 Such individuals are already
taller than controls at age 6 years with a particularly rapid
increase at puberty;33 this may accentuate the known pressure differential between the lung apex and base which
accounts for the upper lobe alveoli being larger.34 This is
cited as the reason for such pathological changes being
particularly common at the apices. A contributing factor
might be abnormal connective tissue, since there seems to
be an association between primary pneumothorax and
both mitral valve prolapse35,36 and EhlersDanlos syndrome.37
Familial
There have been occasional reports on families with
several members having pneumothorax, with a probable
autosomal dominant inheritance;3845 in one large cohort 3
percent had affected close relatives.41 In some this seems to
be due to mutations in the folliculin gene, as in the autosomal dominant BirtHoggDube syndrome which causes
pneumothorax due to thin-walled subpleural cysts.45,46
Smoking
As well as being an important factor in secondary pneumothorax due to emphysema, it has long been known that
current smoking is usual in those with primary pneumothorax. The strength of the association is directly related to
the amount smoked,5,11,24,38,47 with heavy smokers having a
12 percent lifetime risk of developing pneumothorax compared with 0.1 percent for never smokers.5 However, in
two large cohorts of mainly young patients a third were
non-smokers.25,26
Exercise
Despite what patients assume, there is no theoretical
reason to suppose that lung collapse would occur
Environmental factors
Although various claims have been made that the incidence of pneumothorax is related to seasons of the year,
changes in barometric pressure, thunderstorms, humidity
and phases of the moon,5457 the suggested mechanisms
seem unconvincing and evidence is very weak.25,27,5860
Equally surprising is a suggested association with proximity to loud music.61
Geographical variations
In parts of the world where pulmonary tuberculosis
remains common, there continue to be reports6266 of
patients with pneumothorax secondary to advanced cavitatory disease, often with associated pleural uid (see
section Persistent air leak). An occasional cause in
Mediterranean countries is pulmonary hydatid disease.67
PATHOGENESIS
Studies on articially inated animal68 and human69 lungs
demonstrate that the visceral pleura is very resistant to
rupture, as Kjrgaard recognized.3 In fatal cases of barotrauma due to diving, those with pneumothorax all had
pleural adhesions and lung bullae.70 Cases have been
described after the rapid and high intrathoracic pressure
changes in weightlifting,71 obstetric delivery,16,72,73
cannabis use74 and even vomiting75 and lung function
testing.76 Most of these are secondary to pneumomediastinum which is uncommon at presentation in spontaneous pneumothorax. Pneumothorax is a recognized
hazard of the rapid G-force changes in military aviation51,58,77,78 and of bungee-jumping,79 but it is likely that
most of these patients have the same underlying pathology
found in other cases of primary pneumothorax.51
Primary pneumothorax
Although only occasionally visible on standard chest radiographs,50,80 the great majority of patients have subpleural
blebs, bullae and/or localized emphysematous changes
on computed tomography (CT),8184 inspection at
surgery,22,38,50,80,8589 pathology of resection specimens,38,9095 and at autopsy.70 Despite recent alternative
views,9698 there is no reason to modify the generally
accepted concept that the ruptured bled is the etiological
factor;50 indeed, in some cases the site of air leak can be
Airways disease
Pneumothorax is a well-recognized, potentially lethal and
often hard to treat complication of emphysema. However,
chronic obstructive pulmonary disease is common and the
risk of this complication is very low, occurring in only 1 in
400 of Mayo Clinic patients.111 Clinical experience suggests
that incidence increases with severity of emphysema, particularly in those with sizeable bullae (Figure 42.1). In
cystic brosis extensive subpleural pathology is common;91
otherwise pneumothorax is rare in airway diseases such as
bronchiectasis. Likewise, it occurs in less than 1 percent of
patients with bronchial carcinoma112 (which is only occasionally subpleural, and where associated emphysema
might instead explain pneumothorax113). So, does asthma
(which does not affect the lung parenchyma) really predispose to pneumothorax, as is widely assumed and
taught?12,23 Asthma is very common and some patients will
happen to have subpleural blebs that might rupture during
an acute attack;114 in most cases where the two conditions
coexist the asthma is mild and pneumothorax occurs
outside an exacerbation.12,115 Chest radiography reveals
pneumothorax in under 2 percent of adults with acute
asthma,116,117 although in up to 8 percent of those that subsequently need assisted ventilation.118
Interstitial disease
Pneumothorax secondary to interstitial lung disease
(Table 42.1) is common, often complicated by persistent
air leak and has a high risk of recurrence. An instructive
example is sarcoidosis in one series from a specialist unit
this was the cause of pneumothorax in 26 of 505 patients127
where pneumothorax can occur both in the active form
if granulomata involve the pleura128 (the same explanation
as for the occasional pleural effusion in this disease) and in
the chronic form if brosis leads to the development of
subpleural bullae or cavities (Figure 42.2).129,130
Pain
active or previous infection with Pneumocystis or tuberculosis, and radiographic evidence of bullae and cysts; CT
scans show that the latter are very common,138 probably
resulting from recurrent lung infection.
Catamenial pneumothorax
The authors of the rst case report139 suggested that this
was due to transperitoneal migration of endometrial tissue
from the pelvis through small defects that are known to be
common in the right (rarely the left140) diaphragm, a view
largely conrmed since.141144 One case with lifethreatening hemopneumothorax has been reported.145
Dyspnea
CLINICAL FEATURES
Occasionally, spontaneous pneumothorax, even bilateral,
may be detected in an asymptomatic patient;108,109,146 in a
survey of 994 Air Force personnel 7 percent were only
detected on routine chest radiography.58 However, most
patients present because of chest pain and/or dyspnea.
Pain is almost always the main presenting symptom in
primary pneumothorax;22,2528,115 in secondary cases,
which includes most elderly patients with pneumothorax,
the dominant symptom is dyspnea.111,118,147,148 In primary
cases symptoms usually come on suddenly and subside
Other
Of the classical clinical signs, the most common are
reduced ipsilateral chest expansion21 and breath sounds,25
hyper-resonance being found mainly in moderate or complete collapse. Chest examination is unhelpful in some
primary and most secondary118 cases. An occasional auscultatory nding with shallow left-sided collapse is a clicking, crunching or crackling sound at the cardiac apex in
time with the pulse,160,161 distinct from those described in
mediastinal emphysema.162 Some with noisy pneumothorax are themselves aware of these sounds.160 Although
not widely known, commonly patients with resolving
pneumothorax (whether right- or left-sided) describe or
admit to bubbling sounds in that lung, particularly on
lying down and varying with posture, disappearing when
the lung fully re-inates. Some even have electrocardiographic changes leading to a mistaken diagnosis of pericarditis, myocardial infarction or pulmonary embolism.
Although subcutaneous emphysema and pneumomediastinum may occur in traumatic pneumothorax and
with barotrauma, they are rare in spontaneous pneumothorax at presentation although they commonly complicate drainage procedures;13 in experimental or articial
pneumothorax air cannot be forced into the mediastinum.
Where they are associated, the pneumothorax is small and
complicates the pneumomediastinum rather than the
other way round.69,162,163 The pathogenesis of mediastinal
emphysema differs in that rupture occurs in alveoli contiguous with connective tissue in the pulmonary vasculature and then spreads towards the mediastinum,69 which
requires much less pressure to rupture than visceral
pleura. Spontaneous pneumomediastinum is a benign
condition which can nearly always be diagnosed on clinical grounds and good-quality chest radiography; management is conservative164 and a good clinician will not
request CT scanning165 or tests to exclude esophageal perforation.
CHEST RADIOGRAPHY
Size of pneumothorax
Although attempts have been made to calculate the percentage of lung collapse from standard radiographs,173177
only the simplest (the Light index176) correlates well with
the volume of air that can be aspirated.178 The latter is predicted best by CT, probably because the lung collapses
asymmetrically; in any case the authors179 also concluded
perhaps more emphasis should be placed on the clinical
status of the patient when making a decision of treatment
strategy. This latter premise is reected in the 1993 British
Thoracic Society (BTS) guidelines, which instead used
three dened categories (small, moderate and large).
However, in line with others, 157,180 the BTS now prefers
two groupings only, using a plain lm rim of air of 2 cm
(equivalent to 50 percent collapse) as cut-off.166 Some
studies refer to patients with complete or total pneumothorax even though semantically these terms should be
reserved for those with an airless lung. In any case, initial
management depends not only upon the size of pneumothorax but also its cause and degree of associated
breathlessness.
Technical considerations
Since expiratory lms exaggerate the radiographic changes
of pneumothorax, standard practice was to request paired
lms in suspected cases, a practice that is now discouraged,166 and in reality only inspiratory lms are routinely
requested for patients presenting with chest pain or
dyspnea. Apparent justication for inspiratory-only lms
comes from two studies in which the only errors were in
two (out of 138) patients with minimal collapse,167,168 but
these lms were reported by experienced radiologists,
whereas in most emergency rooms decisions are based on
those viewed by junior doctors. The latter are less accurate
in recognizing pneumothorax than their seniors,169 and
Tension
The BTS also redened tension as any pneumothorax
with cardio-respiratory collapse, because of the widespread misunderstanding that the presence of mediastinal
shift plus depression and attening of the diaphragm on
radiography represents a medical emergency. Such
changes have been recorded in 19 percent of all cases of
pneumothorax;181 they are very common in large pneumothorax,38,53,157 and many such patients are not unduly
distressed (Figure 42.3).181,182 In contrast with true tension
(discussed in Chapter 43, Non-spontaneous pneumotho-
(a)
(b)
Figure 42.3 This is not a tension pneumothorax. A 51-year-old man referred with a week of mild dyspnea. Radiograph (a) showed a
large left pneumothorax with displacement of heart and hemidiaphragm, fully resolving after simple aspiration in clinic (b). He was not
admitted and has had no recurrence.
rax), uoroscopic screening shows that these shifts disappear during deep inspiration.183
Cardiovascular collapse is rare in primary pneumothorax;180,184 yet even recently it has been stated that
patients with radiographic tension are at risk of sudden
deterioration and possibly cardiac arrest potentially lifethreatening situation. However, only one of the four
patients described was unstable,185 and this was due to
hemopneumothorax, as in one of two previously reported
who were severely ill.21 Kjrgaard did describe eight such
patients, but these were collected from a large area over 20
years and only three were sufciently ill to require urgent
drainage.3 There seems no reason to dissent from the view
of Nissen180 that untreated pneumothorax in otherwise
healthy people is very seldom fatal. Conversely, a patient
with secondary pneumothorax who rapidly deteriorates
even when radiological collapse is small should be decompressed by immediate cannulation.
MEDICAL MANAGEMENT
Only one national guideline has been introduced, by the
BTS in 1993, which 10 years later was updated, modied
and expanded.6,166 The BTS approach is now included in
all UK textbooks of general, respiratory and emergency
medicine, and has been introduced elsewhere.7,186
Otherwise, there is widespread variation in practice
with little agreement on fundamental issues such as the
Historical
In the early part of the last century most cases, even with
major lung collapse, were treated with bed rest because it
was assumed that they had underlying tuberculosis. As
spontaneous pneumothorax was increasingly recognized,
some physicians familiar with inducing articial pneumothorax in tuberculosis (often in outpatients who continued at work) used the same apparatus for aspirating
pneumothorax,49,192 which others avoided because of fear
that the metal needles available might puncture the
lung.3,86,115,193 Increasing thoracic surgical experience with
rubber tube drains (originally used mainly in postoperative cases) led to their adoption by other specialists
for pneumothorax, and references to metal needles were
withdrawn in later editions of medical textbooks.192,194 The
Observation
It is widely accepted that a primary pneumothorax of less
than 15 percent does not require intervention, but the BTS
documents agree with earlier clinical practice that observation is appropriate in greater degrees of collapse provided
that the patient is only mildly breathless. In the UK this
can be carried out as an outpatient procedure because
much of the population live relatively near their district
general hospital. The great majority of patients with minor
lung collapse have a closed pneumothorax. It has been
known since the nineteenth century that intrapleural air is
rapidly reabsorbed; early animal experiments showed this
to be accelerated by breathing an oxygen-rich
mixture.205,206 This has been conrmed by more sophisticated recent research in rabbits207,208 as well as in human
studies.209,210 An early study calculated that air reabsorbs at
a rate of approximately 1.25 percent of the lung volume
per day,211 but a more accurate gure is 2.2 percent (95
percent condence interval 1.43.0 percent).212 The suggestion that patients with primary pneumothorax may not
need hospitalization has been criticized as being potentially dangerous,213 but this has been widely practiced for
Drainage
If the pneumothorax is closed then any method of draining the air will be successful. Although it has long been
assumed, and taught, that the presence of a large-bore
intercostal drain for a few days promotes pleural adherence, thus allegedly reducing the risk of recurrence,86 a
randomized controlled trial showed that in this respect it
was no better than simple aspiration.204 This British study
has since been conrmed by two larger trials from
Belgium216 and Kuwait,217 as well as in a French comparison of indwelling catheter with large-bore drains.218
but then after a few minutes further air can again be aspirated there is a small air leak;232 and (3) if after coughing,
no more air can be aspirated after several minutes, it is a
closed pneumothorax and after conrmatory chest radiograph the patient can be discharged or the cannula can be
secured in place for a few hours.233 The accepted approach
if aspiration is unsuccessful is insertion of an indwelling
catheter; whether this is always necessary is discussed later
(see section Persistent air leak). Unlike catheters, plastic
cannulae (which are very cheap, readily available and
extremely easy for inexperienced doctors to use) are easily
dislodged from the pleural cavity if left in situ for the effect
of aspiration to be assessed. Also, the cannula must be at
least 5 cm long to be sure of penetrating the pleura234 and
is perhaps preferably inserted using an axillary rather than
an anterior approach.235
There is less information on simple aspiration in secondary pneumothorax, where it is successful in 47 percent
(32/68 4 studies219); the latest of these was the largest, in
which an indwelling drain was only required in 19 of 35.236
As well as being effective in many, in those who fail the size
of the air leak can be inferred, as above. Although standard
practice has been to use a large-bore drain (at least 16 FG),
usually an indwelling catheter is effective,222 although less
advisable in those who clearly have a large air leak and who
are likely to require prolonged drainage. BTS guidelines no
longer advocate large-bore bore tube drains, and catheter
drainage instead is recommended.166
Simple aspiration
Indwelling catheter
Advantages
Disadvantages
Needs to be removed
Ineffective if air leak
Some experience required
Catheter tip may shear
May become kinked/blocked
Operator must be experienced
Restricts mobility
Often painful
Major complications possible
this is that deferring such a decision by clamping is unnecessary, a practice which most British pulmonologists abandoned following advice from thoracic surgeons and the
1993 BTS guidelines. If air leakage has ceased, clamping
confers no advantage, but if not a dangerous situation may
develop unrecognized. Such a consensus has not been
reached elsewhere.190 It makes no difference whether the
drain is removed in expiration or inspiration.255
In the absence of a persistent air leak, failure of the lung
to re-expand is nearly always due to the drain having
becoming blocked, displaced (Figure 42.6), disconnected
or clamped; occasionally it results from lung brosis or
bronchial obstruction.256
OPERATIVE MANAGEMENT
Urgent surgical intervention is required in those with
spontaneous hemo-pneumothorax who are hemodynamically compromised, although milder cases can be managed
conservatively.153,257 Non-urgent cases may be treated
either by medical thoracoscopists (Chapter 47) or thoracic
surgeons (Chapter 48), who strongly disagree about which
procedure is best. Different practices both between and
within countries are largely governed by who admits the
patient: (1) thoracic surgeon, or (2) non-interventional
pulmonologists with established surgical links, or (3) pulmonologist experienced at medical thoracoscopy.
Whichever is preferred, patients can be reassured that this
will have no long-term effect on lung function or physical
tness.258,259 However, there is a signicant incidence of
chronic troublesome post-operative pain and paraesthesia,103,260,261 sometimes not mentioned in ongoing debates
about indications for, timing of and technique of operative
intervention.
At presentation
In a 1992 survey two-thirds of Dutch specialists in large
institutions perform thoracoscopy for the rst episode,187
and others have suggested that all such patients should be
referred for surgical repair;262265 a variation on this
approach is described by a Russian team who perform thoracoscopy in all patients before deciding who should
proceed to surgery.266 The great majority of experts190 consider this inappropriate both because it is occasionally
harmful but mainly because most patients respond to
conservative treatment and never have recurrence.
Nevertheless there is an intermediate, and increasingly
popular, surgical approach: early video-assisted thoracoscopic surgery (VATS) in the minority who fail initial aspiration. The arguments for such an interventional
approach, designed to reduce hospital stay, seem less compelling in the light of the following discussion.
Prevention of recurrence
Where the initial episode resolves with conservative management, most specialists wait until a second episode
before advising operative intervention; even then only half
the patients will have a further recurrence, and if each
occasion was managed without hospitalization, many
prefer further conservative management.
The likelihood of further episodes is independent of
whether management is conservative or by drainage
without pleurodesis, and is not affected by the drainage
method used.7,12,49,164,216218,279 Several studies280 give a
wide spread of recurrence rates (1652 percent, mean 30
percent). In the most methodologically sound report,281
the 1-, 5- and 10-year recurrence rates for primary pneumothorax were 15, 23 and 29 percent, respectively.
Recurrence appeared more common in secondary pneumothorax, but numbers in this group were low, and other
publications disagree.9,282 The Dutch nding that recurrence rate decreases with time conrmed those of a much
larger series,58 most further episodes occurring within the
rst year. Ectomorphic build and continued smoking are
independent risk factors for recurrence,281,283 although
such information leads to smoking cessation in few.38,83,98
Although CT scanning may predict which patients are
KEY POINTS
REFERENCES
= Key primary paper
= Major review article
= Paper that represents the rst formal publication of a
management guideline
1.
2.
3.
4.
5.
6.
7.
8.
9.
References 527
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36. Bitar ZI, Ahmed S, Amin AE, Jamal K, Ridha M. Prevalence of mitral
valve prolapse in primary spontaneous pneumothorax. Prim Care
Respir J 2006; 15: 3425.
37. Lopes C, Manique A, Sotto-Mayor R, et al. Ehlers-Danlos syndrome
a rare cause of spontaneous pneumothorax [Portuguese]. Rev
Port Pneumol 2006; 12: 47180.
38. Hallgrimsson JG. Spontaneous pneumothorax in Iceland with
special reference to idiopathic type: a clinical and epidemiological
investigation. Scand J Thorac Cardiovasc Surg 1978; Suppl 21:
185.
39. Lenler-Petersen P, Grunnet N, Jespersen TW, Jaeger P. Familial
spontaneous pneumothorax. Eur Respir J 1990; 3: 3425.
40. Nickoladze GD. Surgical management of familial spontaneous
pneumothorax. Respir Med 1990; 84: 1079.
41. Abolnik IZ, Lossos IS, Zlotogora J, Brauer R. On the inheritance of
primary spontaneous pneumothorax. Am J Med Genet 1991; 40:
1558.
42. Yellin A, Shiner RJ, Lieberman Y. Familial multiple bilateral
pneumothorax associated with Marfan syndrome. Chest 1991;
100: 5778.
43. Cheng YJ, Chou SH, Kao EL. Familial spontaneous pneumothorax:
report of seven cases in two families [Chinese]. Kao J Med Sci
1992; 8: 3904.
44. Morrison PJ, Lowry RC, Nevin NC. Familial primary spontaneous
pneumothorax consistent with true autosomal dominant
inheritance. Thorax 1998; 53: 1512.
45. Chiu HT, Garcia CK. Familial spontaneous pneumothorax. Curr
Opin Pulm Med 2006; 12: 26872.
46. Toro JR, Pautler SE, Stewart L, et al. Lung cysts, spontaneous
pneumothrorax and genetic associations in 89 families with
BirtHoggDube syndrome. Am J Respir Crit Care Med 2007; 22:
22.
47. Elfeldt RJ, Schroder D, Schroeder P, Schaube H, Nissen R. Relation
between smoking and idiopathic spontaneous pneumothorax: a
casecontrol study. Theor Surg 1993; 8: 1315.
48. Lindskog GE, Halasz NA. Spontaneous pneumothorax. Arch Surg
1957; 75: 6938.
49. Lenox-Smith I. Spontaneous pneumothorax: a study of 94 cases.
Br J Dis Chest 1962; 56: 110.
50. Klassen KP, Meckstroth CV. Treatment of spontaneous
pneumothorax: prompt expansion with controlled thoracotomy
tube suction. J Am Med Assoc 1962; 182: 1115.
51. Voge VM, Anthracite R. Spontaneous pneumothorax in the USAF
aircrew population: a retrospective study. Aviat Space Environ
Med 1986; 57: 93949.
52. Bense L, Wiman LG, Hedenstierna G. Onset of symptoms in
spontaneous pneumothorax: correlations to physical activity. Eur J
Respir Dis 1987; 71: 1816.
53. Marquette CH, Marx A, Leroy S, et al. Simplied stepwise
management of primary spontaneous pneumothorax: a pilot study.
Eur Respir J 2006; 27: 4706.
54. Bense L. Spontaneous pneumothorax related to falls in
atmospheric pressure. Eur J Respir Dis 1984; 65: 5446.
55. Ozenne G, Poignie P, Lemercier JP, Nouvet G, Grancher G.
Meteorological conditions and spontaneous pneumothorax: a
retrospective study of 165 cases in the Rouen region. Rev Pneumol
Clin 1984; 40: 2733.
56. Smit HJM, Deville WL, Schramel FMNH, et al. Atmospheric
pressure changes and outdoor temperature changes in relation to
spontaneous pneumothorax. Chest 1999; 116: 67681.
57. Sok M, Mikulecky M, Erzen J. Onset of spontaneous pneumothorax
and the synodic lunar cycle. Med Hypotheses 2001; 57: 63841.
58. Cran IR, Rumball CA. Survey of spontaneous pneumothorax in the
Royal Air Force. Thorax 1967; 22: 4625.
59. Morales Suarez-Varela M, Martinez-Selva MI, Llopis-Gonzalez A,
Martinez-Jimeno JL, Plaza-Valia P. Spontaneous pneumothorax
related with climatic characteristics in the Valencia area. Eur J
Epidem 2000; 16: 1938.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
103.
104.
References 529
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
126.
127.
128.
154. Askin FB, McCann BG. Reactive eosinophilic pleuritis. Arch Pathol
Lab Med 1977; 101: 18791.
155. De Smedt A, Vanderlinden E, Demanet C, et al. Characterisation of
pleural inammation occurring after primary spontaneous
pneumothorax. Eur Respir J 2004; 23: 896900.
156. Noppen M. Normal volume and cellular contents of pleural uid.
Paediatr Respir Rev 2004; 5: (Suppl A):S2013.
157. Vincent M, Celard P, Pinet F, et al. Radiology of spontaneous
pneumothorax in young patients: a study of 200 cases [French].
Sem Hop 1984; 60: 75965.
158. Aitchison F, Bleetman A, Munro P, McCarter D, Reid AW. Detection
of pneumothorax by accident and emergency ofcers and
radiologists on single chest lms. Arch Emerg Med 1993; 10:
3436.
159. Bulynin VI, Redkin AN, Solod NV. Prehospital diagnostic errors and
therapeutic policy in spontaneous pneumothorax [Russian]. Klin
Med 1997; 75: 413.
160. Scadding JG, Wood P. Systolic clicks due to left-sided
pneumothorax. Lancet 1939; ii: 120811.
161. Semple T, Lancaster WM. Noisy pneumothorax: observations based
on 24 cases. Br Med J 1961; 2: 13426.
162. Hamman L. Spontaneous mediastinal emphysema. Bull John
Hopkins Hosp 1939; 64: 121.
163. Aisner M, Franco J. Mediastinal emphysema. New Engl J Med
1949; 241: 81825.
164. Freixinet J, Garcia F, Rodriguez PM, et al. Spontaneous
pneumomediastinum: long-term follow-up. Respir Med 2005; 99:
11603.
165. Koullias GJ, Korkolis DP, Wang XJ, Hammond GL. Current
assessment and management of spontaneous
pneumomediastinum: experience in 24 adult patients. Eur J
Cardiothorac Surg 2004; 25: 8525.
166. Henry M, Arnold T, Harvey J. BTS guidelines for the management
of spontaneous pneumothorax. Thorax 2003; 58 (Suppl 2):
39S52S.
167. Bradley M, Williams C, Walshaw MJ. The value of routine
expiratory lms in the diagnosis of pneumothorax. Arch Emerg
Med 1991; 8: 11516.
168. Schramel FM, Wagenaar M, Sutedja TG, Golding RP, Postmus PE.
Diagnosis of pneumothorax not improved by additional roentgen
pictures of the thorax in the expiration phase [Dutch]. Ned
Tijdschr Geneeskd 1995; 139: 1313.
169. Eisen LA, Berger JS, Hegde A, Schneider RF. Competency in chest
radiography: a comparison of medical students, residents, and
fellows. J Gen Intern Med 2006; 21: 4605.
170. Waitches GM, Stern EJ, Dubinsky TJ. Usefulness of the double-wall
sign in detecting pneumothorax in patients with giant bullous
emphysema. Am J Roentgenol 2000; 174: 17658.
171. Bourgouin P, Cousineau G, Lemire P, Hebert G. Computed
tomography used to exclude pneumothorax in bullous lung
disease. J Can Assoc Radiol 1985; 36: 3412.
172. Glazer HS, Anderson DJ, Wilson BS, Molina PL, Sagel SS.
Pneumothorax: appearance on lateral chest radiographs.
Radiology 1989; 173: 70711.
173. Axel L. A simple way to estimate the size of a pneumothorax.
Invest Radiol 1981; 16: 1656.
174. Rhea J, de Luca S, Greene R. Determining the size of
pneumothorax in the upright patient. Radiology 1985; 144:
7336.
175. Collins CD, Lopez A, Mathie A, et al. Quantication of
pneumothorax size on chest radiographs using interpleural
distances: regression analysis based on volume measurements
from helical CT. Am J Roentgenol 1995; 165: 112730.
176. Light RW. Pneumothorax. In: Light RW (ed). Pleural diseases, 3rd
edn. Baltimore: Williams & Wilkins, 1995: 24277.
177. Choi BG, Park SH, Yun EH, Chae KO, Shinn KS. Pneumothorax size:
correlation of supine anteroposterior with erect posteroanterior
chest radiographs. Radiology 1998; 209: 5679.
References 531
43
Non-spontaneous pneumothorax
MICHAEL H BAUMANN
Introduction
Non-iatrogenic traumatic pneumothorax
Iatrogenic pneumothorax
Tension pneumothorax
533
533
537
540
Future directions
Key points
References
541
542
542
INTRODUCTION
Classication
Pneumothorax references continue to subdivide pneumothorax into spontaneous and traumatic.13 The preceding
chapter (Chapter 42) dealt with spontaneous pneumothoraces. Spontaneous pneumothoraces occur without
preceding trauma or obvious underlying precipitating
cause and are classied as primary (no clear underlying
lung disease) and secondary (an underlying causal lung
disease present). This chapter will focus upon traumatic
and tension pneumothoraces. Traumatic pneumothoraces
occur as a result of direct or indirect trauma and can be
subdivided into non-iatrogenic and iatrogenic. Noniatrogenic pneumothoraces occur as a result of direct or
indirect trauma, generally to the chest, unrelated to any
medical procedure. Traumatic pneumothoraces resulting
from medical interventions are termed iatrogenic pneumothoraces. Tension pneumothorax may occur with any
of the aforementioned categories of pneumothorax.
Traumatic pneumothoraces may be classied by mechanism of injury into penetrating and non-penetrating
(blunt).2 The object penetrating the chest disrupts the visceral pleural surface prompting pleural air entry or allows
air entry through the breached chest wall. The etiology of
pneumothorax arising from blunt chest trauma is less
immediately apparent in the absence of a rib fracture lacerating the visceral pleura. Blunt chest trauma may
prompt abrupt alveolar pressure elevations causing alveolar rupture. Air may then dissect into the lung interstitium
and then to the visceral pleural or the mediastinal pleural
surface. Rupture of either the visceral or mediastinal
pleura may then cause a pneumothorax.
NON-IATROGENIC TRAUMATIC
PNEUMOTHORAX
Incidence and epidemiology
Trauma related deaths exceed 50 000 per year in the
USA. Chest trauma is causal in 25 percent of these deaths
and plays a signicant role in an additional 50 percent.
Pneumothorax ranks second to rib fractures as the most
common manifestation of chest injury and may be noted
in 4050 percent of patients with chest trauma.46
Traumatic pneumothorax may also present after blunt
trauma to the abdomen.4,6 At least 20 percent of traumatic pneumothoraces have an accompanying hemothorax.7
Clinical presentation
Up to 6 percent of traumatic pneumothoraces present with
tension.8 Alternatively, a substantial number of traumatic
pneumothoraces may be occult, not seen on an initial chest
radiograph but found by additional imaging. The proportion of trauma-related pneumothoraces that are occult
compared with those seen on chest radiography ranges
from 29 to 72 percent,9,10 emphasizing the need for a high
index of suspicion and incorporating early routine computed tomography (CT) in all chest and multi-trauma
patients.7 Subcutaneous emphysema, pulmonary contusion, and rib fracture(s) are independent predictors of
an occult pneumothorax (Table 43.1).10 CT imaging
detects other abnormalities in addition to pneumothorax,
including lung contusion, diaphragmatic rupture and
hemothorax leading to an alteration in patient care in up to
41 percent of cases.7 Pneumothorax detection is critical
given concerns for progression, particularly if the patient is
Sensitivity (%)
Specicity (%)
PPV (%)
NPV (%)
Odds ratio
p -value
16
45
59
98
81
73
57
32
30
86
88
90
5.47
3.25
2.65
0.005
0.001
0.005
mechanically ventilated or anesthesia becomes necessary.5,6,9,10 Consideration and evaluation for disruption of
major airways should be considered in the traumatic pneumothorax patient, often with a persistent air leak, where
their condition deteriorates out of proportion to the ndings on the chest radiograph or physical examination.11,12
CXR
1.5 cm size
1.5 cm size
Minuscule/anterior
Chest tube
Anterolateral
Chest tube
Clinically stable
Clinically unstable
Clinically stable
Clinically unstable
Observe in
hospital
Chest tube
Observe in
hospital
Chest tube
Follow-up issues
The most common ndings upon prospective outpatient
follow-up of 530 traumatic pneumothorax patients in
descending order of frequency are chest pain (n = 70,
13.2 percent), residual air (n = 56, 10.6 percent), pyrexia (
38C, n = 54, 10.2 percent), and atelectasis (n = 25, 4.7
percent). All other ndings were 2.5 percent. Notably, on
discharge, 119 patients receiving chest tubes had minor
residual air not requiring drainage after chest tube
removal. Ten of the 56 patients seen during outpatient
follow-up demonstrated air requiring drainage, with two
requiring thoracostomy.8 In contrast, a retrospective
review builds the case for not obtaining follow-up chest
radiographs in selected patients during outpatient
reassessment. One-hundred and fty-ve hospitalized
trauma patients requiring chest tube placement for traumatic pneumothorax (n = 79, 51 percent), hemothorax
(n = 28, 18 percent) or hemopneumothorax (n = 34, 22
percent) were reviewed. Of the 61 patients seen in outpatient follow-up with an accompanying chest radiograph,
92 percent (n = 56) were found to have no pneumothorax,
5 percent (n = 3) a small pneumothorax and 3 percent
(n = 2) a resolving pneumothorax.20 The authors conclude
that a chest radiograph is not necessary in the asymptomatic trauma patient during follow-up if the pre-discharge
chest radiograph is negative for pneumothorax or hemothorax.20 However, patients with minor blunt chest
trauma treated as outpatients (two or less rib fractures,
<65 years of age, no lung or other system injury) require
close follow-up. Of 709 such patients, 14 (1.8 percent)
developed a delayed pneumothorax within 48 hours and
52 (7.3 percent) developed a delayed hemothorax within
2 weeks. No surgical management for the delayed pneumothoraces was required; however, 42 (81 percent) of the
delayed hemothoraces required chest tube placement.21
Air travel
What advice should be given to a patient requesting to
pursue air travel after a traumatic pneumothorax?
Cheatham and Safcsaks published prospective evaluation
of 12 consecutive patients with recent traumatic pneumothorax notes that air travel appears safe 14 days following
radiographic resolution of their pneumothorax.22 Of 10
patients waiting at least 14 days after radiographic resolution before commercial air travel, all were asymptomatic
in ight. One of two patients who ew earlier than 14 days
developed respiratory distress suggestive of pneumothorax
recurrence.22 These ndings support the earlier recommendations by the Aerospace Medical Association Air
Transport Medicine Committee suggesting that air travel
should be safe 23 weeks after successful drainage of
unspecied types of pneumothoraces.23 Commercial airlines have adopted a 6-week no y rule between pneumothorax occurrence and air travel.24 The British Thoracic
IATROGENIC PNEUMOTHORAX
Incidence and epidemiology
Iatrogenic pneumothoraces (IP) occur commonly and
their incidence is likely on the rise due to the ever-growing
adoption of and evolution in invasive diagnostic and supportive modalities. Steier and colleagues25,26 noted such an
increase in IP in the early 1970s and attributed it to the use
of volume-controlled ventilation and subclavian vein
catheterization. With rising use of invasive diagnostic and
therapeutic interventions involving the neck, thorax and
abdomen, IP incidence continues to climb with ever
increasing possible etiologies.27 Such diversity in etiology
places a signicant responsibility on the physician to be
suspicious for pneumothorax in any patient recently subjected to a diagnostic or therapeutic procedure involving
the mouth, neck, chest or abdomen.
Reported IP incidence and proportion in relation to
traumatic and spontaneous pneumothoraces varies
widely. Weissber and Refaely28 reported only 6 percent of
hospitalized patients with pneumothorax as iatrogenic in
origin with 60 percent being spontaneous, and 34 percent
being traumatic, at a metropolitan medical center. In contrast, IP (106 of 204 pneumothoraces, 52 percent)
exceeded spontaneous (98 of 204 pneumothoraces, 48
percent) at the Long Beach Veterans Administration
Hospital.29 The experience of the physicians performing
various procedures also affects the IP, as noted in central
vein catheterization.30 The variable incidence is also likely
due to reporting institution type (academic or nonacademic institution, trauma or non-trauma center), institutional utilization of various invasive procedures and inor out-patient management.
Despite the variability in reports, the six most common
causes in 535 patients suffering an IP in the Veterans
Administration patient population in the early 1990s were
transthoracic needle lung biopsy (24 percent), subclavian
vein catheterization (22 percent), thoracentesis (20
percent), transbronchial biopsy (10 percent), pleural
biopsy (8 percent) and positive-pressure ventilation (7
percent).31 Reported occurrence rates vary from 10 to 50
percent for transthoracic needle lung biopsy, <1 to >13
percent for central line placement and 520 percent for
thoracentesis and pleural biopsy. Mechanical ventilation
and transbronchial lung biopsy are other frequently
reported causes2 with reported occurrence rates of 140
percent and <1 to 3 percent, respectively.32 IP may be asso-
Table 43.2 Potential risk factors associated with the development of a pneumothorax after transthoracic needle biopsy
Author
Cox et al.41
Laurent et al.42
Saji et al.43
Yamagami et al.44
Topal and Ediz45
Yeow et al.46
Choi et al.40
Study type
n (biopsies
or patients)
Iatrogenic
pneumothorax
( n , %)
Lesion
depth
Small
lesion
size
Emphysema
Number
of needle
passes
Needle
size
Unclear
Prospective
Retrospective
Prospective
Unclear
Unclear
Prospective
356
307
289
134
453
660
458
144 (40%)
61 (20%)
77 (27%)
46 (34%)
85 (19%)
155 (23%)
85 (19%)
+
+
+
+
+
+
NA
+
+
NA
+
+
+
NA
+
+
NA
NA
NA
NA
NA
NA
NA
+, Statistically signicant positive correlation with iatrogenic pneumothorax occurrence; -, no statistically signicant correlation with iatrogenic
pneumothorax occurrence; NA, not assessed.
Table 43.3 Statistically signicant risk factors (multivariate analysis) associated with the occurrence of an iatrogenic pneumothorax in
the intensive care unit setting57
Risk
Weight <80 kg
History of AIDS
Diagnosis of ARDS on admission
Diagnosis of cardiogenic edema on admission
Central vein or PA catheter insertion, rst 24 hours
Inotrope, rst 24 hours
Hazard ratio
95% CI, p
2.4
2.8
5.3
2.0
1.7
2.1
1.34.2, 0.004
1.26.4, 0.02
2.611, <0.001
1.13.6, 0.03
1.02.7, 0.04
1.33.4, 0.002
CI, condence interval; AIDS, acquired immunodeciency syndrome; ARDS, acute respiratory distress syndrome; PA, pulmonary artery.
Clinically stable
COPD**
Symptomatic or
COPD
Observe
TENSION PNEUMOTHORAX
Incidence, epidemiology and pathophysiology
Both spontaneous and traumatic (non-iatrogenic and
iatrogenic) pneumothoraces may present with or develop
into tension pneumothorax. Tension pneumothorax is
present when the intrapleural pressure exceeds atmospheric pressure throughout expiration and frequently
during inspiration.2 Many patients suffering a tension
pneumothorax have positive pressure applied to their
airways during mechanical ventilation71 or during resuscitation.72 Seventy-one of 74 patients developing pneumothorax during mechanical ventilation had a tension
component in Steier and colleagues review.26 Presentation
is particularly abrupt in patients receiving mechanical ventilation and may carry a particularly high mortality rate.26
Intra- and post-cardiopulmonary resuscitation (CPR)
patients should receive special scrutiny for the possibility
of tension of pneumothorax, particularly if positive-pressure ventilation is administered. Unsuspected or untreated
tension pneumothoraces were found in 12 of 3500 autopsies. Ten of these 12 patients were receiving some form of
endotracheal positive pressure. Eight of these 10 patients
were mechanically ventilated; two were receiving intermittent positive pressure. Seven of these 10 patients had also
received CPR.72 Successful diagnosis and treatment of
intra- and post-resuscitation tension pneumothorax could
mean the difference between successful and unsuccessful
CPR. Tension may also develop in spontaneously breathing patients but inherent is the presumed presence of a
one-way valve process permitting air to enter the pleural
space during inspiration but not exit during expiration.
Treatment
Urgent treatment of tension pneumothorax is key. As
noted, mortality may be considerably increased awaiting
chest radiographic conrmation. Treatment provides conrmation of the diagnosis. Prompt drainage by placement
of an intravenous needle (1416 F) in the pleural space will
usually elicit an audible rush of air due to air rushing out
of the pressurized pleural space. Alternatively, the needle
may be tted with a partially water (sterile) lled syringe
and introduced into the pleural space until air is aspirated.
Marked bubbling after the syringe plunger is removed
conrms pleural air under pressure. Needle placement
through the second anterior intercostal space has been
advocated,2 however, placement of the needle through the
lateral fth intercostals space may be safer.84 Prompt subsequent placement of a chest tube is required regardless of
whether an audible air rush or water syringe bubbling is
noted, given the potential for having induced a pneumothorax in an already compromised patient by placing a
needle into the chest. Placement of a larger-bore chest tube
in the setting of a tension pneumothorax in a mechanically
ventilated patient is preferred.
FUTURE DIRECTIONS
Additional prospective studies of all aspects of the management of both spontaneous and non-pneumothorax are
Tension pneumothorax
KEY POINTS
Non-iatrogenic traumatic pneumothorax
The most common causes of iatrogenic pneumothorax are transthoracic needle lung biopsy, subclavian vein catheterization, thoracentesis,
transbronchial lung biopsy, pleural biopsy and
mechanical ventilation
Iatrogenic pneumothorax should be considered
in any patient with deteriorating cardiopulmonary status after a procedure, even several
days after the procedure.
Smaller targeted lung lesions and greater lesion
depth during transthoracic lung biopsy pose
increased risks for an iatrogenic pneumothorax.
Tension pneumothorax may occur with spontaneous and traumatic pneumothoraces. However,
mechanically ventilated patients more commonly have tension pneumothorax.
Tension pneumothorax is an emergent problem
preferably diagnosed clinically and treated
promptly by placement of a drainage catheter.
Waiting for a conrmatory chest radiograph
increases mortality.
REFERENCES
= Key primary paper
= Major review article
= Paper that represents the rst formal publication of a
management guideline
1.
2.
Iatrogenic pneumothorax
Mortality risk is 2.6 times greater in patients sustaining an iatrogenic pneumothorax in the ICU
setting versus those without an iatrogenic pneumothorax. Associated risk factors for developing
an iatrogenic pneumothorax in the ICU include
a history of AIDS, diagnosis of ARDS or cardiogenic pulmonary edema on admission, and
placement of a central venous catheter or use of
an inotropic agent within the rst 24 hours of
admission.
Simple observation or the placement of a smallbore chest tube may be used to treat iatrogenic
pneumothorax. Use of a chest tube for iatrogenic
pneumothorax treatment is preferred for larger
pneumothoraces, symptomatic patients, in
patients with underlying COPD and in mechanically ventilated patients.
3.
4.
5.
6.
7.
References 543
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
Poulose BK, Ray WA, Arbogast PG, et al. Resident work hour limits
and patient safety. Ann Surg 2005; 241: 84756.
Rosen AK, Zhao S, Rivard P, et al. Tracking rates of patient safety
indictors over time. Lessons from the Veterans Administration.
Med Care 2006; 44: 85061.
Thomas C, Butler C. Delayed pneumothorax and hydrothorax with
central venous migration. Anaesthesia 1999; 54: 98790.
Laronga C, Meric F, Truong MT, et al. A treatment algorithm for
pneumothoraces complicating central venous catheter insertion.
Am J Surg 2000; 180: 5237.
Plaus WJ. Delayed pneumothorax after subclavian vein
catheterization. J Parenter Enter Nutr 1990; 14: 41415.
Byrd RP, Fields-Ossorio C, Roy TM. Delayed chest radiographs
and the diagnosis of pneumothorax following CT-guided ne
needle aspiration of pulmonary lesions. Respir Med 1999; 93:
37981.
Choi C-M, Um S-W, Yoo C-G, et al. Incidence and risk factors of
delayed pneumothorax after transthoracic needle biopsy of the
lung. Chest 2004; 126: 161621.
Cox JE, Chiles C, McManus CM, et al. Transthoracic needle
aspiration biopsy: variables that affect risk of pneumothorax.
Radiology 1999; 212: 1658.
Laurent F, Michel P, Latrabe V, et al. Pneumothoraces and chest
tube placement after CT-guided transthoracic lung biopsy using
coaxial technique: incidence and risk factors. AJR Am J
Roentgenol 1999; 172: 104953.
Saji H, Nakamura H, Tsuchida T, et al. The incidence and the risk of
pneumothorax and chest tube placement after percutaneous CTguided lung biopsy. The angle of the needle trajectory is a novel
predictor. Chest 2002; 121: 15216.
Yamagami T, Nakamura T, Iida S, et al. Management of
pneumothorax after percutaneous CT-guided lung biopsy. Chest
2002; 121: 115964.
Topal U, Ediz B. Transthoracic needle biopsy: factors affecting risk
of pneumothorax. Eur J Radiol 2003; 48: 2637.
Yeow K-M, Su I-H, Pan K-T, et al. Risk factors of pneumothorax
and bleeding. Multivariant analysis of 660 CT-guided coaxial
cutting needle lung biopsies. Chest 2004; 126: 74854.
Bungay H, Berger J, Traill Z, et al. Pneumothorax post CT-guided
lung biopsy: a comparison between detection on chest
radiographs and CT. Br J Radiol 1999; 72: 11603.
Tanisaro K. Patient positioning after ne needle lung biopsy-effect
on pneumothorax rate. Acta Radiologica 2003; 44: 525.
Masterson AV, Haslam P, Logan PM, et al. Patient positioning after
lung biopsy: inuence on the incidence of pneumothorax. Can
Assoc Radiol J 2003; 54: 314.
Berger R, Smith D. Efcacy of the lateral decubitus position in
preventing pneumothorax after needle biopsy of the lung. South
Med J 1988; 81: 11403.
Fish G, Stanley J, Miller KS, et al. Postbiopsy pneumothorax:
estimating the risk by chest radiography and pulmonary function
tests. AJR Am J Roentgenol 1988; 150: 714.
Miller K, Fish G, Stanley J, et al. Prediction of pneumothorax rate
in percutaneous needle aspiration of the lung. Chest 1988; 93:
7425.
Anderson CLV, Crespo JC, Lie Th. Risk of pneumothorax not
increased by obstructive lung disease in percutaneous needle
biopsy. Chest 1994; 105: 17058.
Poe RH, Kallay MC, Wicks CM, et al. Predicting risk of
pneumothorax in needle biopsy of the lung. Chest 1984; 85:
2325.
Amato M, Barbas C, Medeiros D, et al. Effect of protectiveventilation strategy on mortality in the acute respiratory distress
syndrome. N Engl J Med 1998; 338: 34754.
Network ARDS. Ventilation with lower tidal volumes as
compared with traditional tidal volumes for acute lung injury and
the acute respiratory distress syndrome. N Engl J Med 2000; 342:
13018.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.
77.
78.
79.
80.
81.
82.
83.
84.
44
Pediatric pleural diseases
ELIZABETH A PERKETT, PAUL E MOORE
Introduction
Fetal pleural effusion
Diagnosis of pleural effusions in infants and children
Chylothorax
Pediatric effusions
545
545
546
546
547
INTRODUCTION
The overall anatomy and physiology of the pleural space in
children is the same as in adults.1 Many of the past reports
of pediatric pleural effusions have been retrospective and
include small numbers of patients and data from adult
studies were extrapolated to pediatrics. However, several
recent studies highlight the differences in pediatric and
adult patients with pleural disease.2 Not only is the differential diagnosis of pediatric pleural effusions different
from that for adults, but pediatric co-morbid conditions
are different which likely inuences outcomes. For
example, a prospective study of brinolytic therapy for
parapneumonic effusions in adults concluded no benet3
while a study of pediatric patients suggested advantages to
brinolytic therapy.4 In 2005, The British Thoracic Society
(BTS) published the rst pediatric specic guidelines for
the management of pleural infection children.5 While this
is a very useful document and provides an extensive review
of the literature, the authors highlight the need for additional pediatric data.
Future therapies
Summary
Key points
References
549
549
549
549
atrics, thoracentesis is frequently performed and is denitely needed for diagnostic studies of acute infectious
effusion, malignancies and chylothorax. Pediatric parapneumonic effusions are sometimes detected when the
patient is in the recovery phase of an infection and the
effusion is not causing any symptoms. In such patients,
diagnostic thoracentesis is often not necessary, but close
follow-up is indicated to determine that there has been
resolution of the effusion.
CHYLOTHORAX
The exact incidence of neonatal effusions is not known. A
retrospective review of neonates admitted to six referral
centers found that 32 percent were congenital and 68
percent acquired.16 The most common form of pleural
effusion in the newborn is a chylothorax which occurs
most frequently on the right side.17 With congenital idiopathic chylothorax, symptoms may be present at birth or
develop in the rst week of life. Secondary chylothorax
may present at birth or later, depending on the underlying
cause. The diagnosis of chylothorax is made by thoracentesis and examination of the uid, keeping in mind that if
enteral feedings have not been initiated, the uid will be
clear and yellow, not milky. Cellular analysis will reveal a
predominance of lymphocytes (90 percent) which are predominantly T lymphocytes. The etiology may be idiopathic or secondary to trauma to the thoracic duct during
thoracic surgery or repair of congenital heart diseases.17
Blunt trauma, including non-accidental trauma, has been
associated with chylothorax.18 Secondary chylothorax can
occur secondary to increased venous pressure associated
with congenital heart disease or thrombosis (e.g. from
central lines). Treatment of the underlying condition is
important in the management of patients with chylothorax but, if the effusion is large, drainage will be needed to
relieve respiratory distress. Although simple chest tube
drainage may relieve the respiratory distress, loss of large
volumes of uid, including proteins and lymphocytes, may
result in the risk of infection from immunosuppresssion
and metabolic disturbances, and replacement of proteins
may be indicated. Initial conservative management is
aimed at decreasing lymph ow by restricting dietary fats
to medium chain triglycerides or total parental nutrition
(TPN). There are several case reports of successful therapy
with octreotide, a synthetic analogue of somatostatin,
which is thought to reduce lymph ow.19 Patients with
direct trauma to the thoracic duct frequently have spontaneous resolution with conservative management. In one
series, patients with elevated venous pressure had longer
duration and higher volume of drainage. Overall, 80
percent of the patients responded to conservative management.17 There are various criteria for failure of conservative management, but most suggest 23 weeks before
considering surgical intervention. VATS allows a less
Pulmonary lymphangiectasis
Pulmonary lymphangiectasis is associated with abnormal
pulmonary lymphatics in the pleura and interstitium of
the lung.20 The overall incidence is unknown and scattered
cases continue to be reported, but pulmonary lymphangiectasis is very rare. Esther and Barker21 proposed categorizing pulmonary lymphangiectasis as primary or
secondary (which is related to pulmonary venous or lymphatic obstruction). Diagnosis may be suspected by the
presence of increased interstitial markings that are apparent on chest radiograph secondary to the dilated lymphatics throughout the pleural and connective tissue. Open
lung biopsy is usually required for denitive diagnosis.
Patients with pulmonary lymphangiectasis who present
with respiratory distress in the newborn period had previously been thought to have a very poor prognosis, but with
aggressive supportive care pleural effusions seem to
subside, and infants are surviving beyond the neonatal
period.
PEDIATRIC EFFUSIONS
Pleural effusions are uncommon ndings on pediatric
radiographs. Beyond the newborn period, a newly detected
pleural effusion is most likely secondary to infection a
parapneumonic effusion. The true incidence of pleural
effusions in the pediatric population is not known because
most studies are retrospective and based on hospitalized
children. Alkrinawi and Chernick22,23 reviewed charts of
127 pediatric patients (<18 years of age) admitted with
pleural effusions from 1987 to 1995. Fifty percent of the
patients had pneumonia with a parapneumonic effusion.
Other etiologies included congenital heart disease (17
percent mostly post-operative, 2 percent congestive
heart failure), malignancy (10 percent), renal (9 percent)
and trauma (7 percent). As in other studies, pleural uid
was more than twice as likely to occur in boys.
Malignancies
Although a small percentage of pediatric pleural effusions
are associated with malignancies, it is a very important category. Malignancy must be considered in a child who presents with an effusion, without symptoms or history
suggesting infection or trauma. Lymphomas are common
childhood cancers and frequently present with a mediastinal mass and pleural effusion.27,28 One report found 71
percent of patients with lymphoblastic lymphoma had a
pleural effusion at presentation while only 11 percent of
patients with Hodgkins disease presented with effusions.27
A large effusion may result in respiratory compromise,
necessitating drainage, but pleural uid analysis can also
provide a denitive diagnosis in most cases.29 Pleural effusions have been seen with other intrathoracic malignancies
including leukemia, neuroblastoma, Wilms tumor, sarcomas and mesothelioma (extremely rare in pediatrics).30,31
Pleurodesis is used in adult oncology patients but there
is little information about its usefulness in pediatric
patients. In a report of seven end-stage pediatric oncology
patients with intractable pleural effusions, pleurodesis
with doxycycline provided signicant relief of respiratory
symptoms.32
Infections
Tuberculous pleural effusions occur in children, but less
frequently than in adults. A review of 175 children <18
years of age with primary pulmonary tuberculosis (TB)
revealed that 22 percent had an effusion identied on the
chest radiograph.33 The average age of the children with
effusions was signicantly greater 13.5 years versus 7.0
years than the age of patients with parenchymal TB. The
effusion was unilateral and was the only radiographic
nding in 41 percent. TB should be considered in cases of
pleural effusions where other etiologies are not clearly
identied. TB workup would include a thorough history
for contacts and skin testing. In older children workup
would be similar to adults, including assessment of
sputum and pleural uid. In young children, induced
sputum or gastric aspirate may be needed.
In pediatric patients infections with Mycoplasma pneumoniae and viruses are very common. Pleural effusions
References 549
There is little information about the long term consequences of empyema in children. A small studied looked at
the results of spirometry and exercise testing in children
following recovery from empyema.47 No differences were
found in children who had chest tube drainage and those
who only received antibiotics. Another report measured
lung function 324 months after discharge and found no
evidence of restrictive lung disease in children with antibiotics and simple chest tube drainage.45 Yet another study
found a restrictive defect in patients at 3 months after
treatment for empyema but most had normalized in
1 year.48
1.
2.
3.
4.
5.
6.
FUTURE THERAPIES
7.
Improved diagnostic testing is needed to better characterize pediatric pleural effusions. A better characterization of
patients, and the nature of their effusions, will result in
improved understanding of the natural history of the effusions and optimal management.
8.
9.
SUMMARY
The incidence of pleural disease and effusions is uncommon in children when compared with that in adults and,
in general, pediatric outcomes are better than that in
adults which may reect less severe co-morbidities. The
underlying etiologies in the fetus and young children are
frequently related to other congenital conditions. In the
neonate, chylothorax is the most common pleural effusion. As children progress from infancy to childhood,
parapneumonic effusions become more frequent.
Pediatric-specic diagnostic and therapeutic approaches
need to be developed.
10.
11.
12.
13.
14.
15.
KEY POINTS
16.
17.
18.
19.
20.
21.
22.
23.
REFERENCES
= Key primary paper
= Major review article
= Paper that represents the rst formal publication of a
management guideline
24.
25.
Montgomery MSD. Air and liquid in the pleural space. In: Chernick
VBT, Wilmott RW, Bush A (eds). Kendigs disorders of the
respiratory tract in children, 7th edn. Phildelphia: Saunders, 2006:
36887.
Bush A. Update in pediatric lung disease 2006. Am J Respir Crit
Care Med 2007; 175: 53240.
Maskell NA, Davies CW, Nunn AJ, et al. U.K. Controlled trial of
intrapleural streptokinase for pleural infection. N Engl J Med; 352:
86574.
Thomson AH, Hull J, Kumar MR, Wallis C, Balfour Lynn IM.
Randomised trial of intrapleural urokinase in the treatment of
childhood empyema. Thorax 2002; 57: 3437.
Balfour-Lynn IM, Abrahamson E, Cohen G, et al. BTS guidelines for
the management of pleural infection in children. Thorax; 60 (Suppl
1): i121.
Longaker MT, Laberge JM, Dansereau J, et al. Primary fetal
hydrothorax: natural history and management. J Pediatr Surg
1989; 24: 5736.
Bianchi D. Hydrothorax. In: Bianchi DW, Crombleholm TM, DAlton
ME (eds). Fetology: Diagnosis and management of the fetal
patient. New York: McGraw-Hill, 2000; 31321.
Waller K, Chaithongwongwatthana S, Yamasmit W, Donnenfeld
AE. Chromosomal abnormalities among 246 fetuses with pleural
effusions detected on prenatal ultrasound examination: factors
associated with an increased risk of aneuploidy. Genet Med 2005;
7: 41721.
Bellini C, Boccardo F, Campisi C, Bonioli E. Congenital pulmonary
lymphangiectasia. Orphanet J Rare Dis 2006; 1: 43.
Jacquemont S, Barbarot S, Boceno M, Stalder JF, David A. Familial
congenital pulmonary lymphangectasia, non-immune hydrops
fetalis, facial and lower limb lymphedema: conrmation of
Njolstads report. Am J Med Genet 2000; 93: 2648.
Klam S, Bigras JL, Hudon L. Predicting outcome in primary fetal
hydrothorax. Fetal Diagn Ther 2005; 20: 36670.
Smith RP, Illanes S, Denbow ML, Soothill PW. Outcome of fetal
pleural effusions treated by thoracoamniotic shunting. Ultrasound
Obstet Gynecol 2005; 26: 636.
Kalfa N, Allal H, Lopez M, et al. Thoracoscopy in pediatric pleural
empyema: a prospective study of prognostic factors. J Pediatr Surg
2006; 41: 17327.
Kearney SE, Davies CWH, Davies RJO, Gleeson FV. Computed
tomography and ultrasound in parapneumonic effusions and
empyema. Clin Radiol 2000; 55: 5427.
Heller RM, Hernanz-Schulman M. Applications of new imaging
modalities to the evaluation of common pediatric conditions. J
Pediatr 1999; 135: 6329.
Rocha G, Fernandes P, Rocha P, et al. Pleural effusions in the
neonate. Acta Paediatr 2006; 95: 7918.
Beghetti M, La Scala G, Belli D, et al. Etiology and management of
pediatric chylothorax. J Pediatr 2000; 136: 6538.
Geismar SL, Tilelli JA, Campbell JB, Chiaro JJ. Chylothorax as a
manifestation of child abuse. Pediatr Emerg Care 1997; 13: 3869.
Siu SL, Lam DS. Spontaneous neonatal chylothorax treated with
octreotide. J Paediatr Child Health 2006; 42: 657.
Noonan JA, Walters LR, Reeves JT. Congenital pulmonary
lymphangiectasis. Am J Dis Child 1970; 120: 31419.
Esther CR Jr, Barker PM. Pulmonary lymphangiectasia: diagnosis
and clinical course. Pediatr Pulmonol 2004; 38: 30813.
Alkrinawi S, Chernick V. Pleural uid in hospitalized pediatric
patients. Clin Pediatr (Phil) 1996; 35: 59.
Alkrinawi S, Chernick V. Pleural infection in children. Semin Respir
Infect 1996; 11: 14854.
Kiziltepe U, Eyileten ZB, Uysalel A, Akalin H. Prolonged pleural
effusion following Fontan operation: effective pleurodesis with
talc slurry. Int J Cardiol 2002; 85: 2979.
Cava JR, Bevandic SM, Steltzer MM, Tweddell JS. A medical
strategy to reduce persistent chest tube drainage after the fontan
operation. Am J Cardiol 2005; 96: 1303.
26. Chan SY, Lau W, Wong WH, et al. Chylothorax in children after
congenital heart surgery. Ann Thorac Surg 2006; 82: 16506.
27. Chaignaud BE, Bonsack TA, Kozakewich HP, Shamberger RC.
Pleural effusions in lymphoblastic lymphoma: a diagnostic
alternative. J Pediatr Surg 1998; 33: 13557.
28. Pietsch JB, Whitlock JA, Ford C, Kinney MC. Management of
pleural effusions in children with malignant lymphoma. J Pediatr
Surg 1999; 34: 6358.
29. Wong JW, Pitlik D, Abdul-Karim FW. Cytology of pleural,
peritoneal and pericardial uids in children. A 40-year summary.
Acta Cytol 1997; 41: 46773.
30. Easa D, Balaraman V, Ash K, Thompson B, Boychuk R. Congenital
chylothorax and mediastinal neuroblastoma. J Pediatr Surg 1991;
26: 968.
31. Goyal M, Swanson KF, Konez O, Patel D, Vyas PK. Malignant
pleural mesothelioma in a 13-year-old girl. Pediatr Radiol 2000;
30: 7768.
32. Hoffer FA, Hancock ML, Hinds PS, et al. Pleurodesis for effusions in
pediatric oncology patients at end of life. Pediatr Radiol 2007; 37:
26973.
33. Merino JM, Carpintero I, Alvarez T, et al. Tuberculous pleural
effusion in children. Chest 1999; 115: 2630.
34. Ward MA. Lower respiratory tract infections in adolescents.
Adolesc Med 2000; 11: 25162.
35. Jaffe A, Balfour-Lynn IM. Management of empyema in children.
Pediatr Pulmonol 2005; 40: 14856.
36. Schultz KD, Fan LL, Pinsky J, et al. The changing face of pleural
empyemas in children: epidemiology and management. Pediatrics
2004; 113: 173540.
37. Hardie WD, Roberts NE, Reising SF, Christie CD. Complicated
parapneumonic effusions in children caused by penicillinnonsusceptible Streptococcus pneumoniae. Pediatrics 1998; 101:
38892.
38. Tan TQ, Mason EO Jr, Barson WJ, et al. Clinical characteristics and
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
45
Drainage techniques
HENRI COLT
Introduction
Thoracentesis
Closed needle pleural biopsy
Chest tubes
551
551
557
559
INTRODUCTION
Health care providers today must do their best to choose
the most appropriate diagnostic or therapeutic drainage
procedure among those available for a particular patient.
This is not always a simple task, demanding thought,
expertise and experience. Indications should be individualized. Ideally, operators should be aware of or experienced in several methods of drainage so that choices are
based upon what is best for the patient and not on what is
simply available within a single physicians personal procedural arsenal. In the next paragraphs a step-by-step
approach to several drainage techniques used to diagnose
and treat patients with pleural diseases is described.
THORACENTESIS
Denition, indications and contraindications
Thoracentesis is dened as a drainage technique during
which a needle is inserted into the pleural cavity in order
to remove uid. The major indication for a diagnostic thoracentesis is when a patient has a rst episode pleural effusion unless uid overload is the obvious cause. Such a
procedure is safely performed at the bedside, in a special
procedure unit or operating theater, in the intensive care
unit or in a radiology suite using a variety of instruments.
The major contraindication is found in patients with
bleeding disorders. Although caution is obviously necessary in patients receiving anticoagulants or thrombolytic
agents,1 using small needles, thoracentesis is safe even in
these individuals. Several studies have demonstrated no
increased risk of bleeding despite presence of a low platelet
count (25 000 per mm3 or less). As in procedures such as
563
565
565
565
Thoracentesis 553
Thoracentesis instrumentation
Several needles and thoracentesis kits are commercially
available. Examples include the Pharmaseal needlecatheter kit, distributed by Allegiance Healthcare Corp
(McGaw Park, IL, USA), the ArgyleTurkel needle previously distributed by Sherwood, Davis and Geck, and the
ArrowClark thoracentesis kits distributed by Arrow
(Reading, PA, USA). Other needles include the Wang thoracentesis needle, and the Garg thoracentesis needle, each
distributed by Bard Interventional Products, Melrose
Laboratories (Melrose, NJ, USA). There is also a reusable
stainless steel needle available called the Boutin pleural
needle, manufactured and distributed by the Richard Wolf
Medical Instrumentation Corporation (Vernon Hills, IL,
USA) (Figures 45.245.4).
General techniques
After having carefully explained the procedure to the
patient and obtaining informed consent, the procedure
can be started. Atropine 1.0 mg need not be administered,
but should be available for potential subcutaneous or
intramuscular injection, should patients become hypotensive and sweaty or develop other signs suggestive of a vasovagal reaction. Most patients do not require anti-anxiety
medication, although those who request it might receive a
small amount (most often less than 2 mg) of intravenous
midazolam. With the patient seated, the physical examination identies the site for thoracentesis. The site is cleaned
thoroughly with antiseptic solution, which may include
Betadine swab, gel or liquid solution. The area covered
should be up to 5 cm around the selected site. I keep my
sterile eld extremely small there is no need to prep the
patients entire back!
It is essential to anesthetize the skin and intercostal
space with satisfactory amounts of anesthetic solution.
Often, 5 mg of lidocaine is included in thoracentesis kits.
Thoracentesis should and can almost always be a painless
procedure. It is often taught to anesthetize the skin, the
periosteum of the rib, as well as the parietal pleural. I nd
that anesthetizing the periosteum is painful and usually
unnecessary. Once the site (intercostal space) has been
selected, it can be maintained using two ngers of one
hand placed onto the patients posterior chest. Holding the
syringe in the other hand, a small wheal is raised using 1
percent lidocaine and a short 25 gauge needle. Additional
Lung
Fluid
Diaphragm
(a)
(a)
Lung
Fluid
Diaphragm
(b)
(b)
Lung
Fluid
Diaphragm
(c)
(c)
Figure 45.5 Diagnostic thoracentesis. (a) The skin is injected
using a 25-gauge needle with a local anesthetic agent. (b) The
periosteum is injected with the local anesthetic. (c) The pleural
space is entered, and pleural uid is obtained. (From Light RW,
Pleural diseases, 3rd edn. Lippincott, Williams and Wilkins, 1995,
Figure 23.2, with permission.)
Thoracentesis 555
scan), multiloculated or in patients with poor lung function or signicant bullous disease.
Figure 45.8
(a)
(a)
The Abrams biopsy needle is a three-part needle consisting of a 4 mm diameter outer cannula with a beveled notch
proximal to its tip, a hollow inner cannula and an inner
stylet. The outer cannulas tip is blunt and usually will not
damage the lung. The stylet is inserted into the inner
cannula, which is then inserted through the outer cannula
and locked into place by twisting it clockwise. The entire
assembly is inserted through a small stab incision through
the intercostal tissues and into the pleural space. As the
stylet is removed, a 20 mL syringe can be attached in its
place to the outer cannula. The hexagonal proximal tip of
the inner cannula is then twisted counter-clockwise so that
the beveled notch is pointing downwards. The entire
ensemble is then withdrawn. Constant pressure should be
maintained while tilting the distal tip of the needle up to
45 downward. When resistance is felt, parietal pleura has
hopefully been caught inside the notch. The hexagonal
proximal tip is then rotated clockwise. This closes the
beveled opening. Thus, the cutting action of the rotating
inner cannula samples the pleura. Once the specimen is
obtained, the entire ensemble is removed from the chest.
Obviously, more samples increase yield for representative
tissue. (Figures 45.10 and 45.11).
(b)
(b)
(c)
(c)
(d)
(d)
(e)
(e)
Closed needle pleural biopsy should be a painless procedure. Abundant local anesthesia to the skin, intercostal
tissues and parietal pleura is mandatory. Procedurerelated complications include pneumothorax, both from
introduction of a small amount of air during the procedure (which might be expected in up to 15 percent of
cases), or by causing laceration of lung parenchyma. A
chest radiograph is almost always warranted after closed
needle pleural biopsy.
Other procedure-related complications include subcutaneous emphysema, pneumomediastinum, vasovagal
reactions and hemothorax.35,36 On rare occasions, a closed
Figure 45.10
(a)
(a)
(b)
(b)
(c)
(c)
(d)
(d)
Insertion techniques
pleural biopsy needle samples the liver, spleen or kidney.
One should therefore be particularly careful to never
perform closed needle pleural biopsy too low.
A comment is warranted pertaining to the apparent
decline in the number of closed-needle pleural biopsies
being performed in Europe, Asia and the USA.
Thoracoscopy and ex-rigid pleuroscopy37,38 are excellent
alternatives to blind sampling, and provide the added
benet of removing all pleural uid, evaluating the visceral
and parietal pleural surfaces, breaking down adhesions to
enhance lung expansion, and obtain forceps biopsies. In
addition, increasingly, measurements of adenosine deaminase assist in making a diagnosis of tuberculous pleurisy,
and increased use of computed tomography helps with differential diagnosis of malignant and nonmalignant effusions. Only time will tell whether closed needle biopsy
becomes an antiquated technique.39
CHEST TUBES
Denition, indications and contraindications
Chest tube drainage consists of a percutaneous insertion of
a small- or large-bore tube, usually made of silicone or
polyurethane, into the pleural cavity.40 This procedure is
warranted in certain patients with pleural and pulmonary
(a)
(a)
(b)
(b)
(d)
(d)
(e)
(e)
(c)
(c)
Figure 45.12 Catheter over guidewire (Seldinger technique) of a small-bore chest tube insertion. (a) The pleural space is accessed. (b)
The guidewire is threaded through the needle. (c) The dilator is threaded over the guidewire, then removed. (d) The chest tube is threaded
over the guidewire. (e) The guidewire is removed, leaving the chest tube in position. The chest tube will be secured using a simple stitch
tied down onto the chest tube using a surgeons knot. (From Colt HG, Manual of pleural procedures, Lippincott, Williams and Wilkins, 1999,
Figure 12.5, with permission.)
(a)
(a)
(b)
(b)
(c)
(c)
(d)
(d)
(e)
(e)
Figure 45.15
Figure 45.18 Denver indwelling pleuroperitoneal, or pleuralexternal shunt (Denver Biomedical, Boulder CO, USA).
To suction
Air
20 cm
H2O
20 cm
Suction control
bottle
18 cm
H2O
Water-seal
bottle
H2O
Collection
bottle
To patient
20
25
15
20
1600
2300
1400
700
600
500
2100
1200
400
300
1900
1000
200
150
1700
800
100
50
10
15
10
5
0
(S)
2500
(W)
(C)
Figure 45.21 Patient holding commercially available negativepressure pleural drainage apparatus.
References 565
Figure 45.22
KEY POINTS
FUTURE DIRECTIONS
As new technologies become available, drainage procedures should become even more safe, and comfortable for
patients. Novel devices might improve the efciency of
drainage techniques and pleurodesis, allowing operators to
expand indications and improve curative or palliative care
to patients with trapped lung, persistent pneumothorax or
chylothorax, for example. Increased availability of Flexrigid pleuroscopy, performed as readily as exible bronchoscopy, might enhance the way chest physicians work
REFERENCES
References 567
53. Grodzin CJ, Balk RA. Indwelling small pleural catheter needle
thoracentesis in the management of large pleural effusion. Chest
1997; 111: 9818.
54. Bell RL, Ovadia P, Abdullah F, Spector S, Rabinovici R. Chest tube
removal: end-inspiration or end-expiration? J Trauma, 2001; 50:
6747.
55. Bailey RC. Complications of tube thoracostomy in trauma. J Accid
Emerg Med 2000; 17: 11114.
56. Baldt MM, Bankier A, Germann PS, et al. Complications after
emergency tube thoracostomy: assessment with CT. Radiology
1995; 195: 53943.
57. Chan L, Reilly KM, Henderson C, Kahn F, Salluzzo RF. Complication
rates of tube thoracostomy. Am J Emerg Med 1997; 15: 36870.
58. Desai AV, Phipps PR, Barnes DJ. Shock and ipsilateral pulmonary
oedema after tube thoracostomy for spontaneous pneumothorax. J
Accid Emerg Med, 1999; 16: 4545.
59. Foresti V, Villa A, Casati O, Parisio E, De Filippi G. Abdominal
placement of tube thoracostomy due to lack of recognition of
paralysis of hemidiaphragm. Chest 1992; 102: 2923.
60. Etoch SW, Bar-Natan MF, Miller FB, Richardson JD. Tube
thoracostomy. Factors related to complications. Arch Surg 1995;
130: 5215; discussion 5256.
61. Shapira OM, Aldea GS, Kupferschmid J, Shemin RJ. Delayed
perforation of the esophagus by a closed thoracostomy tube.
Chest 1993; 104: 18978.
62. Zieren J, Enzweiler C, Mller JM. Tube thoracostomy complicates
unrecognized diaphragmatic rupture. Thoracic Cardiovasc Surg
1999; 47: 199202.
46
Pleurodesis
HELEN E DAVIES, YC GARY LEE
Indications for pleurodesis
How pleurodesis works
What is a successful pleurodesis?
Practical aspects of pleurodesis
Technical aspects of pleurodesis
Timing of pleurodesis
Patient selection
Transplant considerations
569
570
570
571
571
574
575
575
575
576
577
577
578
579
579
Pneumothorax
The main indications for pleurodesis are recurrent, symptomatic malignant pleural effusion or pneumothorax. In
selected cases pleurodesis is performed for benign, recurrent pleural effusion.
In the future there is likely to be a rise in the number of
potential candidates for pleurodesis reecting the
increased incidence of malignant effusion in an ageing
population and cases of secondary pneumothorax related
to underlying chronic obstructive pulmonary disease.
570
Pleurodesis
Other
Benign, recurrent, symptomatic pleural effusions may also
be treated with pleurodesis should conservative management fail (see below).
Table 46.1 Success rates and relative efcacy of commonly used pleurodesis agents22,38,51,56,57,60,61,70,129
Pleurodesing agent
Talc poudrage
Talc slurry
Doxycycline
Tetracycline
Bleomycin
Quinacrine
Iodopovidone
Corynebacterium parvum
Silver nitrate
CR, complete response.
Dose
6897
7294
6188
4767
4270
6491
6492
3276
7590
2.510 g
2.510 g
500 mg (1 to 3 instillations required)
500 mg20 mg/kg (1 dose or multiple: no difference)
15240 units
500 mg (1 or 2 treatments required)
100 mL of 2%
3.514 mg
20 mL of 0.5%
572
Pleurodesis
Table 46.2 Prospective randomized trials comparing talc with other agents
Authors
Number of
patients
Outcome measure
36
35
Ong et al.49
50
Haddad et al.44
71
Results
Quinacrine, an anti-malarial agent, has been used routinely in Scandinavia for decades.59 Ukale et al.59 reported
pleurodesis success rates of 89 percent with quinacrine
574
Pleurodesis
Randomized trials are required to determine optimal combinations and compare with current practice.
TIMING OF PLEURODESIS
Malignant pleural effusion
No consensus exists regarding the timing of pleurodesis.
Some pulmonologists advise pleurodesis as soon as a
malignant pleural effusion is diagnosed whereas others
delay until symptomatic recurrence. The reported success
rate of pleurodesis between these groups is similar;33
however more advanced pleural malignancy reduces the
likelihood of success.73 Delay also increases the risk of
eventual development of a trapped lung which will preclude pleurodesis.
Timing of pleurodesis in chemotherapy-sensitive
tumor is controversial. In ISPP, two-thirds favored waiting
to see if chemotherapy is effective in controlling effusion
accumulation, but one-third would pleurodese.
Oncologists often favor the former option.74 No data exist
on how often these chemotherapy-sensitive tumors recur,
and no denitive strategy is known. Risks of not pleurodesing include a potential site of infection during neutropenic sepsis and third spacing of chemotherapeutic
drugs with resultant toxicity.75 The Food and Drug
Administration (FDA) body recommends that pleural
effusions secondary to malignant pleural mesothelioma be
drained prior to chemotherapy with Pemetrexed.
After the chest tube insertion, instillation of the pleurodesis agent is traditionally delayed until the daily pleural
uid drainage rate is <150 mL. This practice is supported
by the majority of pulmonologists,33 but increases the
period of drainage, prolongs hospital stay and has not been
shown to be more effective. The amount of uid drained,
when the X-ray shows no residual uid, likely represents
the amount of uid formation and may not be further
reduced by prolonged drainage. There is an equal chance
of success if pleurodesis is performed when radiographic
lung re-expansion is achieved and this practice is recommended.76
Pneumothorax
Debate surrounding the optimal timing and type of pleurodesis in patients with primary spontaneous pneumothorax continues. Historical series suggest that surgical
intervention with pleurectomy or mechanical abrasion is
superior, however, little evidence-based justication exists
for this approach over chemical pleurodesis in primary
pneumothoraces.
Discussion and referral for surgical intervention is generally recommended at day ve to seven in patients with a
persistent air leak despite tube drainage, although this cutoff time is arbitrary.11,77,78 VATS allows identication and
Hepatic hydrothorax
Often, hepatic hydrothoraces form, in part, by the transdiaphragmatic migration of ascitic uid. Caution should
be exercised against routine chest drain placement in such
patients as massive uid loss may occur associated with
secondary loss of electrolytes and protein. If medical treatment fails and repeated therapeutic thoracenteses for
symptomatic relief are required, pleurodesis may be
attempted. The concomitant application of continuous
positive airway pressure ventilation to decrease the peritoneopleural pressure gradient (and reduce passage of ascitic
uid into the pleural cavity via diaphragmatic stomata)
showed promising initial results but these have not been
validated in larger studies.82 Video-assisted thoracoscopy
with closure of demonstrable diaphragmatic defects and
simultaneous talc pleurodesis offers a potential therapeutic strategy although identication of patients with such
defects is not yet possible.83,84
Chylothorax
After conservative measures have failed, and/or ligation of
the thoracic duct is not suitable, pleurodesis should be
PATIENT SELECTION
TRANSPLANT CONSIDERATIONS
Performance status reects the predicted survival of
patients with malignant pleural effusion and should be
assessed in all patients prior to pleurodesis.8890 If the
expected survival is short (arbitrary suggestion, less than
3 months), less invasive procedures are appropriate (e.g.
therapeutic thoracentesis). Patients with a good performance status are more likely to derive benet from pleurodesis.89,90
Pleurodesis is only recommended in malignant pleural
effusion if symptomatic improvement from thoracentesis
is exhibited.91,92 Dyspnea is often multi-factorial and up to
50 percent of patients do not have demonstrable symptomatic relief following uid evacuation.93 In this group,
alternative causes for dyspnea should be addressed, e.g.
obstructive airways disease, lymphangitis, pulmonary
embolism or trapped lung. The presence of trapped
lung, when lung expansion is restricted either by visceral
pleura tumor encasement or by endobronchial obstruction, prohibits effective pleurodesis as the pleural surfaces
do not oppose. Pleurodesis may also precipitate brosis of
the visceral pleura exacerbating restriction of the underlying lung.
In patients with metastatic malignant disease involving
serosal surfaces, pleural, pericardial and ascitic uid collections may concomitantly occur. Clinical management of
such patients is often difcult. Statistically, patients with
extensive disease have a very short prognosis (e.g. weeks)
particularly if other treatment modalities (e.g. chemotherapy) are not a viable option. Repeated therapeutic aspiration may be more appropriate. Insertion of an ambulatory
indwelling pleural catheter may also provide relief in such
cases. Ascitic uid should be drained prior to attempted
pleurodesis to reduce the transdiaphragmatic migration of
uid, which may reduce likelihood of success.
The identication of clinical or biochemical parameters
to guide selection of patients for pleurodesis has been the
focus of much previous research. Several measures have
been suggested including patients performance status, size
of effusion on chest X-ray and pleural uid LDH (>2
upper normal limit for serum), glucose (<60 mg/dL) or
pH (<7.20).90,94,95 Low pleural uid glucose (and pH)
appears to arise secondary to tumor inltration, which
decreases glucose transport into the pleural space, as well
as via increased glucose utilization by cancer cells and
reduced efux of acidic byproducts from the pleural
Patient rotation
Whether rotation of the patient following administration
of the pleurodesing agent aids its distribution and
576
Pleurodesis
Clamping time
Whether prolonged contact of a pleurodesing agent with
the pleural surface is required to induce inammation and
successful pleural union has not been assessed, and no
studies address the optimal chest tube clamping time.
Signicant variations in practice occur and most pulmonologists clamp the tube for 14 hours.33
Suction
In order to achieve opposition of the pleural membranes,
suction is applied in some centers following release of tube
clamping. No universal guideline exists but some advocate
suction until tube drainage is less than 100 mL daily. If
used, careful graded suction should be initiated to prevent
re-expansion pulmonary edema.
Effect of heparin
Chest tube removal
The optimal duration for drainage following pleurodesis is
unknown, though most chest drains can be taken out at 48
hours. Some pulmonologists use daily uid drainage to
guide removal whereas others remove the drain at a specic time after pleurodesis regardless of uid volume.33 A
recent study (n = 41) showed no difference in pleurodesis
success rates in patients randomized to drain removal at 24
hours compared with those whose drain was removed at
72 hours. However, length of hospital stay was signicantly reduced in the former group (4 days versus 8 days;
p < 0.01).111
SIDE EFFECTS/COMPLICATIONS OF
PLEURODESIS
Best analgesia
Pleurodesis can be painful, presumably from the intense
pleural inammation provoked. Instillation of intrapleural
analgesia is recommended before administration of the
pleurodesing agent99 but evidence supporting this practice
is scant and questions remain on whether the effectiveness
of the anesthetic is maintained following dilution when the
pleurodesing agent is subsequently introduced. Only one
small non-randomized (n = 20) study has compared
250 mg versus 200 mg of intrapleural lidocaine and the
result was difcult to interpret.112 Further randomized,
blinded trials are needed.
Repeat pleurodesis
Repeated talc pleurodesis may be appropriate in patients
with good performance status, although anecdotally it is
associated with lower success rates. One comparison study
between 500 mg quinacrine (n = 54) and 5 g talc slurry
(n = 56) reported the need for repeat administration in 31
versus 7 percent of patients respectively following initial
treatment. Repeat talc instillation was successful in 50
percent of patients (2/4), increasing the overall success rate
by only 3.6 percent.51
A different agent may be used but quality evidence to
support this practice is lacking.
Pleuroperitoneal shunt
Insertion of a pleuroperitoneal shunt may be considered if
pleurodesis fails. Shunt occlusion (approximately 10
percent), pain, and infection are potential complications.
Parietal pleurectomy
Parietal pleurectomy aims to create uniform adhesions
between the visceral pleura and chest wall. For recurrent
spontaneous pneumothorax, failure rates of <0.5 percent
are quoted (although this rate is not for patients who have
already failed pleurodesis).31,77 Parietal pleurectomy is
effective in patients with refractory malignant pleural effusions, however, case selection is important as it is not suitable for patients with a trapped lung and should be
reserved for patients with exceptionally good performance
status and prognosis.
ALTERNATIVES WHAT TO DO IF
PLEURODESIS FAILS
Repeated thoracentesis
578
Pleurodesis
Non-invasive palliation
Opiates to alleviate the sensation of dyspnea, and supplementary oxygen therapy may be appropriate in terminally
ill patients with symptomatic effusions. Other possible
contributory factors for the dyspnea should be addressed.
FUTURE DIRECTIONS
The incidence of pleural disease is rising as a result of an
ageing population at risk of developing diseases associated
with pleural effusion (e.g. malignancy) and pneumothorax
(e.g. chronic respiratory disease).
Little data exist on the best selection of patients who
will have successful pleurodesis. Recommendations given
by professional societies are often based on expert opinions. More research is required on the role of pleurodesis
to substantiate advice given to fellow physicians and in
particular to address the following:
(a)
(b)
Figure 46.2 (a) Equipment for insertion of ambulatory
indwelling pleural catheter. The distal end of the catheter (arrow)
is inserted into the pleural cavity using a standard Seldinger
technique. It is then tunneled subcutaneously, the proximal end
remaining visible (image (b)). A Dacron cuff ( ) secures the
catheter in position at the midpoint of the subcutaneous tract.
The catheter has a one-way valve (A) into which the drainage
tubing, attached to a collecting bottle, is placed for drainage as
required. (b) Indwelling pleural catheter in situ.
Heimlich valve
The one-way Heimlich valve enables patients with recurrent persistent pneumothorax to be treated as outpatients.
1. Determine the target outcome. In patients with recurrent malignant pleural effusion most previous studies
have chosen the development or amount of pleural
uid reaccumulation as the primary outcome. For the
patient with a malignant pleural effusion and an
average life span of 6 months, the prime aim should be
to improve quality of life by reducing morbidity.
Measurements of quality of life may therefore be more
appropriate as endpoints in future studies of management of malignant pleural effusions. A randomized trial
recently started in the UK comparing conventional
inpatient talc pleurodesis against ambulatory
indwelling pleural catheter drainage (without chemical
pleurodesis) as rst-line management of malignant
effusions, using quality of life and symptoms of breathlessness as endpoints, is an important rst step towards
symptom-based outpatient management.
2. Identify and characterize those patients who are likely
to benet from pleurodesis. Dependable predictors for
pleurodesis failure would allow identication of
patients who are unlikely to benet from pleurodesis
and hence reduce unnecessary exposure of this cohort
to potentially serious side effects of sclerosing agents.
Initial determination of pleural uid pH may give a clue
towards the chance of pleurodesis success but more
accurate and repeatable markers would be invaluable.
3. Assessment of novel agents as clinical pleurodesis
agents is required. Recent manipulation of cytokines,
such as TGF-b, to generate effective pleurodesis in
animals is exciting but further research to determine
applicability in humans is crucial. Randomized trials to
assess optimal application of current pleurodesis agents
and re-evaluate ones previously discounted, e.g. silver
nitrate, would be valuable, as well as evaluating combination therapies for a potential synergistic effect.
References 579
KEY POINTS
REFERENCES
1. Marel M, Zrustova M, Stasny B, Light RW. The incidence of pleural
effusion in a well-dened region. Epidemiologic study in central
Bohemia. Chest 1993; 104: 14869.
2. Lee YCG, De Clerk NH, Henderson DW, Musk AW. Malignant
mesothelioma. In Hendrick DJ, Burge PS, Beckett WS, Churg A
(eds). Occupational disorders of the lung. Recognition,
management and prevention. London: WB Saunders & Co., 2002:
35979.
3. Lee YCG, Dean A, Thompson RI, Robinson BWS. Clinical and
palliative care aspects of malignant mesothelioma. In Robinson
BWS, Chahinian P (eds). Mesothelioma. London: Martin Dunitz,
2002: 11126.
4. Sahn SA. Malignancy metastatic to the pleura. Clin Chest Med
1998; 19: 35161.
580
Pleurodesis
29. Mutsaers SE, Kalomenidis I, Wilson NA, Lee YC. Growth factors in
pleural brosis. Curr Opin Pulm Med 2006; 12: 2518.
30. Weeden D, Smith GH. Surgical experience in the management of
spontaneous pneumothorax, 197282. Thorax 1983; 38: 73743.
31. Thomas P, Le Mee F, Le Hors H, et al. [Results of surgical treatment
of persistent or recurrent pneumothorax]. Ann Chir 1993; 47:
13640.
32. Bethune N. Pleural poudrage: a new technique for the deliberate
production of pleural adhesions as a preliminary to lobectomy. J
Thorac Surg 1935; 4: 25161.
33. Lee YC, Baumann MH, Maskell NA, et al. Pleurodesis practice for
malignant pleural effusions in ve English-speaking countries:
survey of pulmonologists. Chest 2003; 124: 222938.
34. Tan C, Sedrakyan A, Browne J, Swift S, Treasure T. The evidence on
the effectiveness of management for malignant pleural effusion: a
systematic review. Eur J Cardiothorac Surg 2006; 29: 82938.
35. Antony VB, Loddenkemper R, Astoul P, et al. Management of
malignant pleural effusions. Eur Respir J 2001; 18: 40219.
36. Kennedy L, Sahn SA. Talc pleurodesis for the treatment of
pneumothorax and pleural effusion. Chest 1994; 106: 121522.
37. Yim AP, Chan AT, Lee TW, Wan IY, Ho JK. Thoracoscopic talc
insufation versus talc slurry for symptomatic malignant pleural
effusion. Ann Thorac Surg 1996; 62: 16558.
38. Dresler CM, Olak J, Herndon JE, et al. Phase III intergroup study of
talc poudrage vs talc slurry sclerosis for malignant pleural
effusion. Chest 2005; 127: 90915.
39. Webb WR, Ozmen V, Moulder PV, Shabahang B, Breaux J. Iodized
talc pleurodesis for the treatment of pleural effusions. J Thorac
Cardiovasc Surg 1992; 103: 8815.
40. Adler RH, Sayek I. Treatment of malignant pleural effusion: a
method using tube thoracostomy and talc. Ann Thorac Surg 1976;
22: 815.
41. Diacon AH, Wyser C, Bolliger CT, et al. Prospective randomized
comparison of thoracoscopic talc poudrage under local anesthesia
versus bleomycin instillation for pleurodesis in malignant pleural
effusions. Am J Respir Crit Care Med 2000; 162: 14459.
42. Fentiman IS, Rubens RD, Hayward JL. Control of pleural effusions
in patients with breast cancer. A randomized trial. Cancer 1983;
52: 7379.
43. Fentiman IS, Rubens RD, Hayward JL. A comparison of
intracavitary talc and tetracycline for the control of pleural
effusions secondary to breast cancer. Eur J Cancer Clin Oncol
1986; 22: 107981.
44. Haddad FJ, Younes RN, Gross JL, Deheinzelin D. Pleurodesis in
patients with malignant pleural effusions: talc slurry or
bleomycin? Results of a prospective randomized trial. World J Surg
2004; 28: 74953.
45. Hamed H, Fentiman IS, Chaudary MA, Rubens RD. Comparison of
intracavitary bleomycin and talc for control of pleural effusions
secondary to carcinoma of the breast. Br J Surg 1989; 76:
12667.
46. Hartman DL, Gaither JM, Kesler KA, et al. Comparison of
insufated talc under thoracoscopic guidance with standard
tetracycline and bleomycin pleurodesis for control of malignant
pleural effusions. J Thorac Cardiovasc Surg 1993; 105: 7437.
47. Lynch T, Kalish L, Mentzer SJ, et al. Optimal therapy of malignant
pleural effusions: report of a randomised trial of bleomycin,
tetracycline, and talc and a meta-analysis. Int J Oncol 1996; 8:
18390.
48. Noppen M, Degreve J, Mignolet M, Vincken W. A prospective,
randomised study comparing the efcacy of talc slurry and
bleomycin in the treatment of malignant pleural effusions. Acta
Clin Belg 1997; 52: 25862.
49. Ong KC, Indumathi V, Raghuram J, Ong YY. A comparative study of
pleurodesis using talc slurry and bleomycin in the management of
malignant pleural effusions. Respirology 2000; 5: 99103.
50. Zimmer PW, Hill M, Casey K, Harvey E, Low DE. Prospective
randomized trial of talc slurry vs bleomycin in pleurodesis for
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
References 581
97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
582
Pleurodesis
118. Campos JR, Werebe EC, Vargas FS, Jatene FB, Light RW.
Respiratory failure due to insufated talc. Lancet 1997; 349:
2512.
119. Marel M, Skacel Z, Bednar M, Julak J, Light RW. Corynebacterium
parvum, bleomycin and talc in the treatment of malignant pleural
effusions. J BUON 1998; 1: 16570.
120. Migueres J, Jover A. [Indications for intrapleural talc under
pleuroscopic control in malignant recurrent pleural effusions.
Based on 26 cases (authors transl)]. Poumon Coeur 1981; 37:
2957.
121. Nandi P. Recurrent spontaneous pneumothorax; an effective
method of talc poudrage. Chest 1980; 77: 4935.
122. Rehse DH, Aye RW, Florence MG. Respiratory failure following talc
pleurodesis. Am J Surg 1999; 177: 43740.
123. Rinaldo JE, Owens GR, Rogers RM. Adult respiratory distress
syndrome following intrapleural instillation of talc. J Thorac
Cardiovasc Surg 1983; 85: 5236.
124. Todd TR, Delarue NC, Ilves R, Pearson FG, Cooper JD. Talc poudrage
of malignant pleural effusion. Chest 1980; 78: 5423.
125. Ferrer J, Villarino MA, Tura JM, Traveria A, Light RW. Talc
preparations used for pleurodesis vary markedly from one
preparation to another. Chest 2001; 119: 19015.
126. Janssen JP, Collier G, Astoul P, et al. Safety of pleurodesis with talc
poudrage in malignant pleural effusion: a prospective cohort
study. Lancet 2007; 369: 15359.
127. Lange P, Mortensen J, Groth S. Lung function 2235 years after
treatment of idiopathic spontaneous pneumothorax with talc
poudrage or simple drainage. Thorax 1988; 43: 55961.
128. Gyorik S, Erni S, Studler U, et al. Long term follow up of
thoracoscopic talc pleurodesis for primary spontaneous
pneumothorax. Eur Respir J 2006.
129. Vargas FS, Teixeira LR, Vaz MA, et al. Silver nitrate is superior to
talc slurry in producing pleurodesis in rabbits. Chest 2000; 118:
80813.
130. Sorensen PG, Svendsen TL, Enk B. Treatment of malignant pleural
effusion with drainage, with and without instillation of talc. Eur J
Respir Dis 1984; 65: 1315.
47
Medical thoracoscopy
ROBERT LODDENKEMPER
Introduction
Historical background
Techniques
Contraindications and prevention of complications
Indications
Pleural effusions
Malignant pleural effusions
Talc poudrage
583
583
584
587
587
588
588
590
INTRODUCTION
Thoracoscopy was rst used almost 100 years ago, primarily as a diagnostic procedure,1 but soon also as a therapeutic technique for lysis of pleural adhesions by means of
thoracocautery (Jacobaeus operation) to facilitate pneumothorax treatment of tuberculosis.2 Later, the addition of
the term medical was necessary3 in order to distinguish
this procedure from surgical thoracoscopy which is much
more invasive, using general anesthesia, a double-lumen
endotracheal tube and multiple points of entry.4 Surgical
thoracoscopy is better described as video-assisted thoracic
surgery (VATS), whereas medical thoracoscopy can be
performed under local anesthesia or conscious sedation, in
an endoscopy suite, using non-disposable rigid or semirigid instruments. It is therefore considerably less invasive
and less expensive.5
Medical thoracoscopy is today primarily a diagnostic
method, but it can also be applied for therapeutic purposes. Pleural effusions are by far the leading indication for
medical thoracoscopy, both for diagnosis mainly in exudates of unknown etiology and for staging in diffuse malignant mesothelioma or lung cancer and for treatment by
talc pleurodesis in malignant or other recurrent effusions,
or in cases of empyema. An excellent indication for
medical thoracoscopy is pneumothorax, for staging as well
as for local treatment. For those familiar with the technique, other mainly diagnostic indications are biopsies
from the diaphragm, the lung, the mediastinum and the
pericardium. In addition, medical thoracoscopy is a
590
592
592
593
594
594
594
594
HISTORICAL BACKGROUND
Hans-Christian Jacobaeus, an internist working in
Stockholm/Sweden, in 1910 introduced thoracoscopy at the
same time as laparoscopy in a paper entitled Concerning the
possibility of using cystoscopy in the examination of serous
cavities.1 However, it has to be mentioned that Francis
TECHNIQUES
Medical thoracoscopy is an invasive technique, which
should be used only when other simple methods fail. As
Techniques 585
(a)
(b)
(c)
(d)
Figure 47.2
coscopy, a chest tube is introduced through which immediate suction is started carefully.
The one-entry technique is easy to perform under local
anesthesia20,23,24,35 but some premedication (midazolam/
hydrocodon or others) should be routinely administered.
Thoracoscopy is usually carried out in the lateral decubitus
position, with the hemithorax to be studied facing
upwards. Fluoroscopy allows evaluation of adhesions
between the lung and chest wall, which might complicate
introduction of the thoracoscope. It should be recalled
that the diaphragm is positioned much higher than when
the patient is upright. The site of induction of the thoracoscope depends on the location of radiographically detected
abnormalities, while avoiding potentially hazardous areas
such as that of the internal mammary artery, the axillary
region with the lateral thoracic artery and the infraclavicular region with the subclavian artery. The region of the
diaphragm is unsuitable, not only because adhesions are
frequent, but also because the liver or spleen may be accidentally injured. Insertion of the cannula in the lateral thoracic region between the mid- and anterior axillary lines in
the sixth or seventh intercostal space is preferred.
After introducing the trocar, the pleural effusion if
present should be removed as completely as possible.
This can be done without risk because, by using a suction
tube which does not completely occlude the cannula, air
rapidly enters the pleural space to provide pressure equilibration. After removing the effusion, the thoracoscope is
introduced and the entire cavity inspected (Figures 47.4
and 47.5). In case of a pleural effusion, biopsies are taken
from several suspicious areas, including the anterior and
posterior chest wall and the diaphragm (Figure 47.6).
Biopsies from the lung are not taken routinely, but only
when the parietal pleura appears normal but the lung
surface shows abnormal lesions, to avoid creation of a
stula. Biopsies are taken for histologic evaluation and, if
suspicious, for tuberculosis culture.
Following thoracoscopy, a chest tube should be introduced and connected to a suction system. Suction should
be applied carefully, especially in cases of trapped lung,
long-standing effusion or pneumothorax, in order to
avoid re-expansion pulmonary edema, or creation of a
stula.
If indicated, talc poudrage is performed by uniform distribution of talc to all pleural surfaces under direct visual
control (Figures 47.7 and 47.8). Additional pain medication should be given as necessary.41
The two-entry technique is usually performed under
general or neuroleptic anesthesia, if biopsies are taken
through the second point of entry. Details are given in the
Figure 47.4 Thoracoscopic view into the left pleural cavity with
normal upper and lower lobes of the lung. The chest wall pleura is
covered by a whitish layer of small tumor nodules (diffuse
malignant pleural mesothelioma). (See also Color Plate 49.)
Indications 587
INDICATIONS
Medical thoracoscopy is primarily a diagnostic procedure.3,5 The indications for its use include evaluation of
exudative effusions of unknown cause, staging of malignant mesothelioma or lung cancer, and treatment of
malignant or other recurrent effusions with talc pleurodesis. The procedure is not only the gold standard in the
diagnosis of pleural effusions, but it is also a remarkable
tool for research as a gold standard in the study of pleural
effusions. It can also be useful in the management of early
empyema and of pneumothorax. If placement of a chest
tube is indicated anyhow, and if the facilities are available,
medical thoracoscopy should be performed at the time of
chest-tube insertion by the trocar technique. For those
familiar with the technique, other, mainly diagnostic indications are biopsies from the diaphragm, the lung, the
mediastinum and the pericardium, but today there is a
denite trend towards its use almost exclusively in pleural
effusions and pneumothorax.
The changed indications for medical thoracoscopy are
reected by the development at our own institution,
Lungenklinik Heckeshorn in Berlin/Germany.15 Pleural
effusions are by far the most frequent application of
medical thoracoscopy (over 90 percent). A decline in the
other indications is explained by several factors. Medical
thoracoscopy for diagnostic purposes in localized lung and
chest wall lesions has been almost abandoned since
imaging techniques such as computed tomography (CT)
or magnetic resonance imaging (MRI) very often deliver
the diagnosis or allow differentiation between malignant
and benign disease. Furthermore, VATS or surgical thoracoscopy has the advantage that the lesion can be removed
simultaneously. Our indications for lung biopsies in
diffuse lung disease have decreased, too. This is due to the
improved diagnostic results of bronchoscopy using transbronchial lung biopsies and bronchoalveolar lavage, as
well as to the development of high-resolution CT (HRCT),
which has considerably improved the diagnostic evaluation of diffuse lung diseases. At our institution, for many
years, the department of thoracic surgery has been responsible for almost all patients with spontaneous pneumothorax. However, the thoracic surgeons today routinely
apply medical thoracoscopy at the time of chest-tube
insertion through the cannula, under local anesthesia, in
their cases with spontaneous pneumothorax.47 They also
PLEURAL EFFUSIONS
Conservative estimates suggest that approximately 25
percent of the cases seen in a general pulmonologists practice demonstrate pleural effusions.49,50 In approximately
25 percent of these cases, a specic diagnosis cannot be
made, even after thoracentesis and closed pleural biopsy.51
In a series by Boutin et al.32 of 1000 consecutive patients
with pleural effusion, 215 cases remained undiagnosed
even after repeated pleural uid analysis and performance
of pleural biopsies. This is in agreement with the results of
several other authors, who report that without thoracoscopy, at least 2025 percent of pleural effusions remain
undiagnosed, although this certainly depends strongly on
patient populations.
Several studies have tried to determine the diagnostic
accuracy of medical thoracoscopy in the setting of undiagnosed pleural effusion, but the results vary widely, with a
range of 69 to 90 percent. Closer evaluation of the study
designs reveals that the duration of follow-up was occasionally short and frequently not mentioned at all. One
well-designed study reported by Menzies52 with follow-up
periods between 1 and 2 years found a sensitivity of 91
percent, specicity of 100 percent, accuracy of 96 percent,
and negative predictive value of 93 percent. Boutin et al.32
reported a false-negative rate of 15 percent within 1 year of
follow-up, while Enk and Viskum53 reported a diagnostic
accuracy of 69 percent with a 5-year follow-up period. A
retrospective study of 709 patients with pleural effusion
showed that 29 percent remained inconclusive after thoracoscopy.54 After long-term follow-up, a malignancy was
found in 4.3 percent and a true benign disease in 24.7
Sensitivity (%)
62
44
74
95
96
97
scopies in 45 patients with lung cancer and pleural effusion. In 37, they found pleural invasion; three patients had
mediastinal disease, the remaining ve had no evident
metastatic disease, and, therefore, no contraindication for
tumor resection. Canto et al.63 found no thoracoscopic
evidence of pleural involvement in 8 of 44 patients, six
proceeded to resection with no pleural involvement
found.63
In diffuse malignant mesothelioma, medical thoracoscopy can provide an earlier diagnosis and better histologic classication than closed pleural biopsy because of
larger and more representative biopsies, and more accurate staging.64,65 This may have important therapeutic
implications, since much better responses to local
immunotherapy or local chemotherapy have been
observed in the early stages (I and II).6668 The technique is
also helpful in the diagnosis of benign asbestos-related
pleural effusion (BAPE) by excluding mesothelioma or
malignancies. Fibrohyaline or calcied, thick and pearly
white pleural plaques may be found, indicating possible
asbestos exposure.68 Thoracoscopic pulmonary biopsies
and even biopsies from special lesions on the parietal
pleura may demonstrate high concentrations of asbestos
bers and thereby provide further support for a diagnosis
of asbestos-induced disease.69
A further advantage of medical thoracoscopy in
metastatic pleural disease is that biopsies of the visceral
and diaphragmatic pleura are possible under direct observation. In addition, because of the larger size of thoracoscopic biopsies, these may provide easier identication of
primary tumor, including hormone receptor determination in breast cancer,70,71 and improved morphological
classication in lymphomas.72 In addition, the extent of
intrapleural tumor spread can be semiquantied using a
scoring system which has been shown to correlate quite
closely with survival,73 and with the success of talc pleurodesis.74
The main advantage in using thoracoscopy to diagnose
malignancy is that talc poudrage can be performed during
medical thoracoscopy (Figures 47.7 and 47.8), which is
probably the best conservative option today for pleurodesis, with success rates of more than 80 percent.28,75 These
high success rates may be due to the more even distribution of talc powder to all parts of the pleura. It has also
proven very efcient in the treatment of lymphomatous
Table 47.2 Sensitivity (%) of medical thoracoscopy and pleural uid cytology in different malignant etiologies. Prospective simultaneous
comparison at Lungenklinik Heckeshorn, Berlin, Germany
Method
Bronchial
carcinoma
( n = 67)
Extrathoracic
primaries
( n = 154)
Diffuse malignant
mesothelioma
( n = 66)
All
(n = 287)
67
96
62
95.5
58
92
62
95
TALC POUDRAGE
Talc poudrage is the most widely reported method of talc
instillation into the pleural space.19 It can be easily performed at medical thoracoscopy (Figure 47.3) under local
anesthesia with some additional pain medication, if necessary.
As a prerequisite for successful pleurodesis, all pleural
uid must be removed before spraying talc. Removal can
be easily accomplished during thoracoscopy, as air is
entering the pleural cavity, thus creating the desired equilibrium in pressures. Complete collapse of the lung is
desirable, because it permits wide and uniform distribution of the talc.28,75
The optimal dose of talc for poudrage is not known, but
usually about 46 g (812 mL) are recommended for
malignant effusions.39,77 Thoracoscopic inspection of the
pleural cavity should be done during talc insufation to
ensure that talc is uniformly distributed over pleural surfaces (Figures 47.7 and 47.8).
After talc poudrage, an 811 mm (2430 French) chest
tube should always be inserted. Suction should be applied
carefully and progressively to avoid creation of air leaks
which can be caused by necrotic tissue in the visceral
pleura. The chest tube can be removed when the daily
amount of uid production is lower than 100 mL.
Pleurodesis success rates with talc poudrage are usually
above 80 percent, but there are only few prospective
studies comparing talc with other pleurodesis agents.7883
The advantage of talc poudrage compared with slurry is
probably the more even distribution over the whole
pleural surface, which can be achieved under visual
control.75 In our own experience, we observe fewer loculations than with talc slurry. In a large randomized trial of
talc poudrage versus talc slurry with 501 patients, an
advantage of poudrage was seen only in those patients
(whether they lived 30 days or not) who had more than 90
percent lung re-expansion (78 versus 71 percent efcacy of
sclerosis with prevention of recurrence, p = 0.045).84 If the
two most common etiologies (breast and lung cancer) for
malignant pleural effusion were examined, there was also a
statistical difference favoring poudrage (p = 0.022) in
patients living 30 days with more than 90 percent reexpansion. The authors concluded that prevention of
recurrence of malignant pleural effusions from breast or
lung cancers can be achieved with a success rate of 82
percent with poudrage versus 67 percent with slurry.
Talc is inexpensive and highly effective. Its most
common short-term adverse effects include fever, due to
systemic inammatory reaction, 85 and pain. Cardiovascular complications such as arrhythmias, cardiac arrest,
chest pain, myocardial infarction or hypotension have
been noted; whether these complications result from the
procedures or are related to talc per se has not been determined.19 Acute respiratory distress syndrome (ARDS),
acute pneumonitis and respiratory failure have also been
reported to occur after both talc poudrage and
slurry.84,86,87 The development of respiratory failure most
likely is related to dose and, in particular, particle size.8890
It is remarkable that several large series from Europe and
from Israel did not observe ARDS after thoracoscopic talc
insufations.28,75,9193 This was also found in a large multicenter, open-label, prospective cohort study of 558
patients with malignant pleural effusions who underwent
medical thoracoscopy and talc poudrage with 4 g of calibrated French graded large-particle talc. No patient developed acute respiratory distress syndrome, proving that the
use of large-particle talc for pleurodesis is safe.77,94
In vitro studies suggest that talc induces apoptosis in
human malignant mesothelioma cells and might therefore
have an anti-tumorous effect.95 One explanation may be
that talc mediates angiostasis in malignant pleural effusion
via endostatin induction.96
Table 47.3 Sensitivity (%) of non-surgical biopsy methods in tuberculous pleural effusions (histological
and bacteriological results). Prospective simultaneous comparison (n = 100)
Method
Effusion (E)
Closed needle (N)
E+N
Medical thoracoscopy (MT)
MT + N
MT + E
Histology
positive
Culture
positive
Histology and/
or culture
38
38
94
95
94
28
25
39
76
76
78
28
51
61
99
99
100
Figure 47.10 Tuberculous pleural effusion with typical sagolike nodules on the inamed pleura. (See also Color Plate 54.)
EMPYEMA
Medical thoracoscopy can also be used in the management
of early empyema.48,106108 In cases with multiple loculations, it is possible to open these spaces to remove the brinopurulent membranes (Figure 47.11) by forceps and to
create one single cavity, which can be drained and irrigated
much more successfully. This was demonstrated in a retrospective study of 127 patients of whom 94 percent were
treated successfully for multiloculated empyema. Only 6
percent of the patients required a surgical approach.108
This treatment should be carried out early in the course of
parapneumonic effusion/empyema, before the adhesions
SPONTANEOUS PNEUMOTHORAX
In spontaneous pneumothorax, medical thoracoscopy can
be applied easily for diagnostic and therapeutic purposes,
if the skills and facilities for this technique are available.20,28,39,111,112 In particular, if a chest tube is introduced
by the trocar technique, it is easy to use an optique for
visual inspection of the lung and pleural cavity, before
insertion of the chest tube through this cannula. On
inspection during medical thoracoscopy, the underlying
lesions can be directly assessed (Figure 47.12) according to
the classication of Vanderschueren: stage I with an endoscopically normal lung; stage II with pleuropulmonary
KEY POINTS
OTHER INDICATIONS
The efcacy of forceps lung biopsy has been demonstrated
in diffuse lung diseases,20,21 whereas the results in localized
lung diseases in chest wall lesions have been less positive.5,20,124 Here, VATS is currently the preferred approach
for these indications. However, medical thoracoscopy still
maintains its efcacy for visceral pleura and peripheral
lung biopsy, in particular in the presence of pleural effusion and lung disorders.5,124
A further therapeutic indication is thoracoscopic sympathectomy, which is minimally invasive and an accepted
intervention for patients with a variety of autonomous
nervous system disturbances. Essential hyperhidrosis
patients and well-selected patients with other disorders
can be helped with this procedure, which can also be performed by interventional pulmonologists.124,125
FUTURE DIRECTIONS
The most important role of medical thoracoscopy in the
future will be mainly in diagnosing unexplained pleural
effusions after non-diagnostic pleural uid work-up. An
exact early diagnosis for the pleural effusions will become
even more important as more progress is made in the
treatment of different entities (targeted cancer treatment,
gene therapy, etc.).
Further indications for medical thoracoscopy as an
important part of interventional pulmonology will be the
application of talc poudrage for malignant or recurrent
pleural effusion, and for the management of empyema in
spontaneous pneumothorax.
Since thoracoscopy in many countries is performed by
thoracic surgeons, usually as the much more invasive
surgical procedure (VATS), training in medical thoracoscopy/pleuroscopy should become an intrinsic component of pulmonary training programmes. The
development of semi-exible pleuroscopes may facilitate
the introduction of medical thoracoscopy into routine
respiratory practice, at least in tertiary pulmonary
centers.
REFERENCES
= Key primary paper
= Major review article
= Paper that represents the rst formal publication of a
management guideline
1.
References 595
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.
95.
96.
97.
98.
References 597
113.
114.
115.
116.
117.
118.
119.
120.
121.
122.
123.
124.
125.
48
Surgery for pleural diseases
DAVID A WALLER, ANTONIO E MARTIN-UCAR
Introduction
Spontaneous pneumothorax
Pleural empyema
Malignant pleural effusion
Miscellaneous
599
599
603
605
606
INTRODUCTION
Advances in surgery of the pleural cavity have been facilitated by the application of video-assisted thoracic surgery
(VATS). This minimally invasive technique has not only
prompted revision of standard selection criteria for
surgery but has also extended the indications for surgery.
VATS has also enabled pulmonologists to undertake
simple invasive pleural procedures. Nevertheless, whilst
basic diagnostic procedures are widely applicable, therapeutic VATS requires specialized training if basic surgical
principles are to be adhered to. Thus, some VATS procedures are only performed by specialist surgeons and this
specialization extends to some open pleural surgery which
is carried out in only a limited number of centers. This
chapter will address the whole spectrum of pleural surgery
from procedures within the remit of general surgeons to
those practiced in only a handful of centers worldwide.
SPONTANEOUS PNEUMOTHORAX
Indications for surgical intervention
PRIMARY SPONTANEOUS PNEUMOTHORAX
Complications of surgery
Future surgical directions
Key points
References
607
608
608
609
Secondary spontaneous pneumothorax (SSP) is an indication of an air leak from underlying pulmonary pathology
(usually emphysema) which should be treated assuming
the patient is t for operation. In the previously mentioned
ACCP consensus statement, 81 percent of the panel recommended an intervention to prevent recurrence after the
rst episode because of the potentially serious complications of a secondary pneumothorax.1 Selection criteria for
surgery in this group of typically elderly patients with
emphysema include: absence of hypercapnia (partial pressure of CO2 [PCO2] < 7 KPa); maintained exercise tolerance (walk test > 150 m) and absence of signicant
cardiovascular co-morbidity. Pulmonary function tests
performed during the episode of SSP are likely to be inaccurate and do not contribute to patient selection for
surgery. For patients with persistent air leaks, continued
observation for no more than 5 days is recommended.
Surgical method
Prevention of persistent air leak or future recurrence
requires initial identication of the source of the air leak,
i.e. macroscopic blebs or bullae. Complete intrathoracic
inspection requires division of all pleural adhesions since
these often conceal the culprit lesion. The area of air leak is
then controlled by any one of stapling, suturing or ligation.
Obliteration of pleural space is then required to prevent
recurrence in the likelihood of a new source of air leak or
if a current air leak has not been identied. These procedures are either performed by VATS or by open thoracotomy. VATS is enabled by the insertion of a 510 mm
video thoracoscope via a 23 cm incision in the lateral axillary line in the sixth intercostal space. Bleb excision and
parietal pleurectomy or abrasion are then accomplished
via two more similar incisions placed anteriorly and posteriorly in the fourth intercostal space. Instruments may be
introduced via rigid or exible tube cannulae or ports.
Bleb excision or bullectomy is generally carried out with an
endoscopic linear cutter which leaves up to three parallel
rows of staples on the lung surface (Figure 48.1). When
excising the emphysematous bulla the staple lines may be
reinforced with material such as bovine pericardium to
reduce post-operative air leak.
Parietal pleurectomy is performed by insertion of a long
Roberts artery forceps into the extrapleural plane via the
anterior incision under video control. The forceps are
advanced towards the apex stripping off the pleural sheet
with a sweeping motion. This process is then repeated
from the posterior incision. Once the pleural sheet has
been raised, its edge is grasped by the forceps and the sheet
withdrawn from the chest using a twisting motion to wrap
the sheet around the forceps whilst applying gentle traction (Figure 48.2). A single 24 or 28 F drain is left in situ
via one port and usually connected to underwater seal
the reduced release of inammatory and vasoactive mediators after VATS. This may explain why VATS is better tolerated.21
In one of the few prospective randomized comparisons
of the use of VATS versus open surgery (limited posterolateral thoracotomy) for spontaneous pneumothorax we
found that stapled bullectomy and apical parietal pleurectomy could be performed equally reliably for PSP.9
Operating time was no longer for VATS but the postoperative analgesic requirement and hospital stay were
reduced. VATS resulted in less early post-operative respiratory dysfunction with a drop in FEV1 (forced expiratory
volume in 1 second) of 29 percent and in FVC (forced vital
capacity) of 19 percent compared with falls of 43 and 39
percent, respectively, after lateral thoracotomy.
There has been no similar prospective randomized
comparison of VATS and limited axillary thoracotomy
(LAT). Whilst Dumont et al.22 showed shorter stay, less
pain and similar recurrence than LAT in a retrospective
review of only 79 patients, Miller et al.23 found no benets
from VATS. Similar ndings have been described by other
authors24,25 who showed perioperative benets from VATS
but higher recurrence related to resection of fewer bullae
than limited axillary thoracotomy. These ndings may be
explained by unfamiliarity with the newer technique of
VATS. Indeed, the early comparisons of VATS with traditional methods may not have appreciated the technical difculties in learning a new technique. It has been shown
that VATS results improve with surgical experience with
fewer complications26 and a decrease in operating time
and hospital stay;10 in the largest reported series of VATS,
the fact that the recurrence rates are slightly higher than
the accepted rates for open surgery (Table 48.1) may be
explained by this. In a systematic review of four trials of
VATS versus thoracotomy in over 200 patients, Sedryakan
et al.27 found that VATS resulted in a reduced need for
analgesia and length of stay.
Medical thoracoscopy
The use of video-assisted thoracoscopy in a spontaneously
ventilating patient without double-lumen intubation has
become to be known as medical thoracoscopy. There are
several proponents of this technique in the treatment of
spontaneous pneumothorax with simple talc insufation
being the usual method employed. Indeed, there are proponents of its use in rst-time PSP in preference to tube
drainage alone.28 Whilst early recurrence is reported to be
low, recurrence is higher than open surgery when macroscopic bullae are present.29 This results from a failure to
treat the source of the air leak attributable to the absence
of single-lung ventilation which precludes complete
intrathoracic inspection. In the event of recurrence after
initial medical thoracoscopic talc insufations, subsequent
VATS is precluded by patchy adhesions, thoracotomy is
required and the benets of VATS are lost. We do not
Liu et al.102
Cardillo et al.18
Hurtgen et al.103
Ohno et al.104
Yim105
Waller10
Bertrand et al.106
Freixinet et al.107
Naunheim et al.13
Chan et al.108
Hatz et al.109
Study
Number
Deaths
Conversion
to
thoractomy
Persistent
air leak
Drain
time
(days)
Hospital
stay
(days)
Median
follow-up
Recurrence
Multicenter
Retrospective
Multicenter
Retrospective
Retrospective
Prospective
Retrospective
Multicenter
Multicenter
Retrospective
Retrospective
757
432
1365
424
224
180
163
132
121
109
109
0
0
2
0
0
2
0
0
0
0
0
10 (2.3%)
0
0
2
0
3
0
31 (4%)
6 (1.3%)
39 (2.9%)
26 (6.1%)
10 (4.4%)
6 (3.6%)
8 (6%)
10 (8%)
3 (3.1%)
5.4
4.4
4.5
6.1
3
4
4.4
5.6
4.3
30 months
38 months
31 months
20 months
24 months
24 months
13 years
13 months
44 months
53 months
16 (2.1%)
19 (4.4%)
88 (6.5%)
40 (9.4%)
4 (1.8%)
12 (6.6%)
3 (1.8%)
8 (6%)
5 (4.1%)
5 (5.7%)
5 (4.6%)
Special considerations
CYSTIC FIBROSIS
CATAMENIAL PNEUMOTHORAX
PLEURAL EMPYEMA
Indications for surgical intervention
PARAPNEUMONIC EFFUSIONS
Surgical method
PRINCIPLES OF SURGERY
Surgical results
VATS VERSUS FIBRINOLYSIS
SURGICAL APPROACH
Pleural debridement by VATS has been shown to effectively treat brinopurulent empyema (Table 48.2). Some
authors advocate VATS debridement as an initial, interim
measure to limit the risk of toxic episodes and stabilize the
patient prior to an elective thoracotomy and decortications.42 When directly compared with thoracotomy in the
management of brinopurulent PPE, VATS has been
found to have comparable clinical effectiveness but advantages in terms of faster post-operative recovery.41
Percutaneous brinolysis is not effective once an
empyema has become chronic and the inammation
organized and its use adds nothing to prevent the need for
surgery despite apparently increasing the volume of
drainage.50 In the organizing phase of empyema (category
4), when the underlying lung has become entrapped, treatment is directed not only at pleural debridement but at
removal of the thickened visceral pleural cortex by decortication. It has been thought that this procedure could only
diate conversion rate of up to 28 percent due to the presence of an organized cortex.4143 There was also a late
requirement for open surgery in 510 percent due to
recurrent sepsis or failure to achieve full lung re-expansion.
Whether VATS mechanical debridement is preferable
to intrapleural brinolysis and percutaneous catheter
drainage is a topic of debate. A small but prospective, randomized trial found VATS to have a higher primary treatment success and shorter hospital stay with consequent
cost savings in adults.44 Certainly the use of brinolysis
should be carefully monitored as delay in referral for surgical intervention reduces the likelihood of successful
VATS due to the formation of brous pleural adhesions
Table 48.2 Results of video-assisted thoracoscopic surgery (VATS) for pleural empyema
Author
Landreneau et al.51
Solaini et al.110
Lackner et al.111
Cassina et al.112
Waller et al.53
Lawrence et al.42
Striffeler et al.43
Angelillo Mackinley
et al.41
Cunniffe et al.113
Ridley and
Braimbridge39
Wait et al.44
aLate
Early/
latea
Number
Conversion to
thoracotomy
Mixed
Early
Early
Mixed
Mixed
Early
Early
Early
76
40
17
45
36
31
67
31
8 (17%)
1 (2.5%)
4 (23%)
8 (18%)
15 (41%)
3 (10%)
19 (28%)
3 (10%)
Early
Mixed
10
18
0
0
Early
11
Reoperation
Drain
time
(days)
Hospital
stay
(days)
Mortality
Complications
0
0
10 (32%)
3 (4%)
0
3.3
4.8
7
7
4.3
4.1
4.2
7.4
11
10.7
6.8
11.5
6.7
5 (6.6%)
0%
0%
1 (3%)
3 (4%)
1 (3%)
2 (3%)
5 (11%)
5 (16%)
5 (16%)
0
10 (55%)
4.5
10.7
11
0%
2 (11%)
0%
5 (6%)
0%
5.8
8.7
TUBERCULOUS EMPYEMA
The original description of thoracoscopy was for adhesiolysis for tuberculosis (TB).57 VATS has been shown to be
useful in the diagnosis of TB effusion and in the debride-
PLEURODESIS
nodal size,70 therefore cervical mediastinoscopy is mandatory. Future preoperative selection may include biological
markers of angiogenesis, i.e tumor microvessel counts or
matrix metalloproteinase expression.71
The operation of extrapleural pneumonectomy (EPP)
involves the en-bloc excision of the entire pleural surface
with underlying lung and adjacent pericardium and
hemidiaphragm. Mediastinal lymph node clearance is also
advocated. The pericardium and diaphragm are replaced
with prosthetic patches.The operation is usually performed via a lateral thoracotomy but we have found postoperative benets from a median sternotomy approach.72
The initial reported operative mortality of 25 percent
for extrapleural pneumonectomy73 was initially thought to
be preclusive but recent series reecting improvements in
perioperative care report operative mortality of as low as
3.8 percent.68 Unfortunately, despite wider application,
radical treatment has had little impact on overall survival
from mesothelioma. The best 5-year survival gures are
reported for those with the prognostic factors above and
these represent a minority of those referred for surgery.
With multi-modality treatment including radical surgery,
radical hemithorax irradiation and chemotherapy median
survival ranges from 33 to 51 months.68,74 Despite these
aggressive attempts at local disease control, including
intracavitary chemotherapy,75 survival from mesothelioma
surgery is thwarted by distant disease progression,76,77
commonly in the peritoneal cavity or the contralateral
pleural cavity. Several authors therefore advocate radical
pleurectomy/decortication, with preservation of the lung,
in preference to EPP78,79 as it is associated with lower operative mortality and potentially better functional status. We
utilize this form of radical debulking in those with positive
mediastinoscopy whose survival is limited.80
MISCELLANEOUS
Clotted hemothorax
A retained hemothorax may be expected in around 2
percent of patients with thoracic injuries.81 CT is needed to
predict the need for evacuation of the clotted blood as
chest radiography alone is insensitive. VATS is effective in
Cytology/closed biopsy
VATS
Lung expands
VAT pleurectomy
Talc pleurodesis
Trapped lung
Sterile space
Shunt
Decortication
Infected space
Drain
Decortication
Early VATS intervention has been shown to be a more efcient and economical strategy than intercostal tube
drainage. A prospective randomized trial82 found a reduction in hospital stay of around 3 days and a 40 percent
saving in the cost of the hospital episode.
Chylothorax
SURGICAL INDICATIONS
Ligation of thoracic duct has been described in posttraumatic or post-surgical cases of chylous stula.
However, even ligation of a successfully identied duct
may not fully control the leak due to the presence of
lymphatic collaterals. In cases of intractable chylous
stula, identication of the stula site or dissection of
the thoracic duct may be avoided by supradiaphragmatic
ligation of the lower end of the duct just above the cisterna chili.84 To aid intraoperative identication of the
site of chylous leak, the patient should ingest 50 mL of
full-fat cream immediately prior to surgery. This will lead
to the leakage of pure white chyle which is more easily
seen. VATS has been successfully used to achieve ligation, suturing or clipping of the thoracic duct85 (Figure
48.8). VATS talc pleurodesis may also be useful, particularly in cases where there is a diffuse chylous leak due to
increased lymphatic pressure and may be superior to
chemoradiation in lymphoma.86
COMPLICATIONS OF SURGERY
Pleurectomy
Post-operative hemothorax occurs in less than 4 percent of
patients after parietal pleurectomy.91 Patients are at more
risk from total rather than apical pleurectomy.92 Chronic
intercostal neuralgia has been reported after VATS;93 in a
small series of 60 patients (76 percent follow-up) 19 complained of chronic pain, in 12 of these mild pain only was
reported related to trocar sites. Pain was greatest after
pleurectomy. Horners syndrome has been reported anecdotally after pleurectomy, possibly due to excessive traction on the apical pleural sheet.
Cirrhotic hydrothorax
Pleural biopsy
The most likely mechanism for this condition, which
develops in approximately 5 percent of patients with cirrhosis, is the passive collection of pleural uid due to the
movement of ascites along a pressure gradient through
small diaphragmatic fenestrations.87 Repeated thoracocentesis or tube drainage are contraindicated due to the resultant hypovolemia, protein loss and infection. Therapy
Talc pleurodesis
The fear of mesothelioma development as a long-term
sequelae of talc poudrage is unfounded in the era of
asbestos-free talc.95 Long-term restrictive respiratory
impairment is also not a major concern.96 A potentially
more serious risk from talc pleurodesis in the surgical
setting is the development of acute respiratory distress
after insufations.97 However, recent large series19 have
not seen this complication, particularly where largeparticle talc is used.98
Pleural empyema
Decortication
Tumor decortication must ensure full lung re-expansion
as these patients are particularly at risk from infection of
any residual space with the formation of an empyema. In
our own series we have found this complication in 4
percent of patients.66 Other specic complications include
an iatrogenic parenchymal lung injury with resultant persistent air leak, post-operative hemothorax and iatrogenic
injuries to the azygos vein, thoracic duct or esophagus (the
intraoperative placement of an esophageal bougie aids
identication of the organ and reduces the risk of inadvertent injury).
Extrapleural pneumonectomy
Major morbidity is experienced by over 40 percent of
patients undergoing this extensive operation,99 most commonly supraventricular cardiac arrythmias. Specic technical complications include detachment of prosthetic
patches, bronchopleural stulae, esophageal rupture and
post-operative hemorrhage. We have also observed rapid
lling of the pneumonectomy space with serous uid
leading to mediastinal shift and hemodynamic compromise.100 There is debate whether the use of induction
chemotherapy increases the risk of post-operative complications.100,101
Hemothorax
The earlier use of VATS in the assessment of major thoracic trauma may prevent unnecessary thoracotomy from
compounding the risks of the injury itself.
KEY POINTS
Spontaneous pneumothorax
References 609
REFERENCES
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
44.
45.
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
References 611
85. Graham DD, McGahren ED, Tribble CG, Daniel TM, Rodgers BM.
Use of video-assisted thoracic surgery in the treatment of
chylothorax. Ann Thorac Surg 1994; 57: 150711.
86. Mares DC, Mathur PN. Medical thoracoscopic talc pleurodesis for
chylothorax due to lymphoma: a case series. Chest 1998; 114:
7315.
87. Strauss RM, Boyer TD. Hepatic hydrothorax. Semin Liver Dis 1997;
17: 22732.
88. Scholz DG, Nagorney DM, Lindor KD. Poor outcome from
peritoneovenous shunts for refractory ascites. Am J Gastroenterol
1989; 84: 5403.
89. Milanez de Campos JR, Filho LO, de Campos Werebe E, Sette H Jr,
Fernandez A, Filomeno LT, Jatene FB. Thoracoscopy and talc
poudrage in the management of hepatic hydrothorax. Chest 2000;
118: 1317.
90. Lazaridis KN, Frank JW, Krowka MJ, Kamath PS. Hepatic
hydrothorax: pathogenesis, diagnosis, management. Am J Med
1999; 107: 2627.
91. Thomas P, Le Mee F, Le Hors H, et al. Results of surgical treatment
of persistent or recurrent pneumothorax. Ann Chir 1993; 47:
13640.
92. Weeden D, Smith GH. Surgical experience in the management of
spontaneous pneumothorax, 197282. Thorax 1983; 38: 73743.
93. Passlick B, Born C, Sienel W, Thetter O. Incidence of chronic pain
after minimal-invasive surgery for spontaneous pneumothorax.
Eur J Cardiothorac Surg 2001; 19: 3558; discussion 89.
94. Boutin C, Rey F, Vaillat J-R. Prevention of malignant seeding after
invasive diagnostic procedures in patients with pleural
mesothelioma. Chest 1995; 108: 7548.
95. Chappel A, Johnson A, Charles J, et al. A survey of the long-term
effects of talc and kaolin pleurodesis. Research Committee of the
British Thoracic Association and the Medical Research Council
Pneumoconiosis Unit. Br J Dis Chest 1979; 73: 2858.
96. Lange P, Mortensen J, Groth S. Lung function 2235 years after
treatment of idiopathic spontaneous pneumothorax with talc
poudrage or simple drainage. Thorax 1988; 43: 55961.
97. Brant A, Eaton T. Serious complications with talc slurry
pleurodesis. Respirology 2001; 6: 1815.
98. Janssen JP, Collier G, Astoul P, et al. Safety of pleurodesis with talc
poudrage in malignant pleural effusion: a prospective cohort
study. Lancet 2007; 369: 15359.
99. Sugarbaker DJ, Jaklitsch MT, Bueno R, et al. Prevention, early
detection and management of complications after 328
consecutive extrapleural pneumonectomies. J Thorac Cardiovasc
Surg 2004; 128: 13846.
100. Stewart DJ, Martin-Ucar AE, Edwards JG, West K, Waller DA.
Extrapleural pneumonectomy for malignant pleural mesothelioma;
the risks of induction chemotherapy, right-sided procedures and
prolonged operations. Eur J Cardiothorac Surg 2005; 27: 3738.
101. Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant
chemotherapy followed by extrapleural pneumonectomy in
malignant pleural mesothelioma. J Clin Oncol 2004; 22: 34517.
102. Liu HP, Yim AP, Izzat MB, et al. Thoracoscopic surgery for
spontaneous pneumothorax. World J Surg 1999; 23: 11336.
103. Hrtgen M, Linder A, Friedel G, et al. Video-assisted thoracoscopic
pleurodesis. A survey conducted by the German Society for
Thoracic Surgery. Thorac Cardiovasc Surg 1996; 44: 199203.
104. Ohno K, Miyoshi S, Minami M, et al. Ipsilateral recurrence
frequency after video-assisted thoracoscopic surgery for primary
spontaneous pneumothorax. Jpn J Thorac Cardiovasc Surg 2000;
48: 75760.
105. Yim APC. Video-assisted thoracoscopic management of primary
spontaneous pneumothorax. Ann Acad Med Singapore 1996; 25:
66872.
106. Bertrand PC, Regnard JF, Spaggiari L, et al. Immediate and longterm results after surgical treatment of primary spontaneous
pneumothorax by VATS. Ann Thorac Surg 1996; 61: 16415.
107. Freixinet J, Canalis E, Rivas JJ, et al. Surgical treatment of primary
spontaneous pneumothorax with video-assisted thoracic surgery.
Eur Respir J 1997; 10: 40911.
108. Chan P, Clarke P, Daniel FJ, et al. Efcacy study of video-assisted
thoracoscopic surgery pleurodesis for spontaneous pneumothorax.
Ann Thorac Surg 2000; 70: 2537.
109. Hatz RA, Kaps MF, Meimarakis G, et al. Long-term results after
video-assisted thoracoscopic surgery for rst-time and recurrent
spontaneous pneumothorax. Ann Thorac Surg 2000; 70: 2537.
110. Solaini L, Prusciano F, Bagioni P. Video-assisted thoracic surgery
in the treatment of pleural empyema. Surg Endosc 2007;
21: 2804.
111. Lackner RP, Hughes R, Anderson LA, et al. Video-assisted
evacuation of empyema is the preferred procedure for
management of pleural space infections. Am J Surg 2000; 179:
2730.
112. Cassina PC, Hauser M, Hillejan L, et al. Video-assisted
thoracoscopy in the treatment of pleural empyema: stage-based
management and outcome. J Thorac Cardiovasc Surg 1999; 117:
2348.
113. Cunniffe MG, Maguire D, McAnena OJ, et al. Video-assisted
thoracoscopic surgery in the management of loculated empyema.
Surg Endosc 2000; 14: 1758.
49
Gene therapy in pleural diseases
STEVEN M ALBELDA, DANIEL H STERMAN
Introduction
Vectors used in pleural gene therapy
Pleural gene therapy for the treatment of systemic diseases
Gene therapy for the treatment of pleural diseases
613
613
613
614
INTRODUCTION
Gene therapy (the treatment of disease based upon the
transfer of genetic material) involving the pleural space
offers a number of potential unique advantages.1 The
pleural space has a large surface area lined by a thin layer
of mesothelial cells, the ideal conguration for efcent
gene transfer. Liquids or cell suspensions injected into the
pleural space can disseminate rapidly and uniformly,
potentially allowing a very large number of cells to be
transduced. The patterns of uid drainage from the pleural
space through vascular and lymphatic channels ensure
rapid systemic uptake. Access to the pleural space is relatively easy and safe through a needle-catheter system or a
small indwelling tunneled catheter. Fusion of the pleural
space is quite benign, and in some instances (i.e. where
pleural effusions cause symptoms) may be desirable.
Gene transfer to the pleural space could be used in at
least two possible scenarios. First, the cells of the pleural
space could be used as factories to produce gene products
that would be secreted and then transferred into the systemic circulation. Second, gene therapy could be used in
the treatment of pleural diseases, in particular pleural
malignancies, including primary tumors (malignant
mesotheliomas) and secondary, metastatic tumors.
Conclusions
Key Points
References
617
617
618
geted, in vivo gene transfer efciency, duration of expression and induction of inammation.
The most widely used vector system in pleural gene
therapy has been recombinant, replication-incompetent
adenovirus. This vector system offers a high-efciency
transduction of target cells (including non-dividing cells)
and high expression levels of the delivered transgene.
However, gene expression is transient and accompanied by
prominent local and systemic inammatory responses.
Mesothelial and mesothelioma cells in culture are quite
easily transduced by adenoviral vectors. Adenoviral
vectors have been injected into the pleural and peritoneal
spaces in animal models where uniform and high-level
gene transduction occurs.36
Adeno-associated virus (AAV) is a defective parvovirus
with a single-strand DNA genome and a naked protein
coat that persists in an episomal state that allows for stable,
long-term gene expression, while potentially circumventing the safety concerns surrounding an integration event.
Most of the initial studies of AAV were performed with
serotype 2 (AAV2). However, many additional serotypes
of AAV viruses have recently been identied.7 These alternative serotypes use different entry mechanisms so that
they have varying tissue tropisms.
The rst requirement for successful gene therapy is efcient gene delivery. A variety of viral and non-viral gene
transfer vectors have been developed.2 As summarized in
Table 49.1, each of these vectors has certain advantages
with regard to DNA carrying capacity, types of cells tar-
Cell range
In vivo gene
delivery
efciency
Duration of
expression
Co-transfer
viral gene
elements
Inammatory
response
Retrovirus
<8 kb
Low
Stable integration
Yes
Low
Adenovirus
Adeno-associated
virus
78 kb
<5 kb
Moderate
Moderate
Transient
Long term
Yes
Minimal
High
Low
Lentivirus
<8 kb
Low
Stable integration
Yes
Low
Liposome
Autologous
transduced cell
Herpes virus
Vaccinia virus
>10 kb
unlimited
Replicating
cells only
Most cells
Primarily muscle,
liver, and brain
depends on serotype
Many nondividing cells
Most cells
Fibroblast, myoblast,
mesothelial
Most cells
Most cells
Low
Moderate
Transient
Months
No
No
Moderate
Low
Moderate
Moderate
Transient
Transient
Yes
Yes
High
High
Vector
>10 kb
>10 kb
ent systemic expression of transgenes.1,10,11 De et al.10 compared the efciency of an AAV5-based vector expressing
a1-antitrypsin (a1AT) with that of an AAV2 vector
expressing the same transgene by intrapleural and intramuscular routes in mice and found that the AAV5 vector
achieved lung (bronchoalveolar lavage) and serum levels
that were 10-fold greater than the AA2 vector. At 40 weeks
post-instillation, a1AT levels were a remarkable
900 mg/mL 1.6-fold higher than the accepted therapeutic
serum level of 570 mg/mL. In a follow-up study,11 the same
group performed a comprehensive screen of 25 AAV
serotype vectors and showed the highest efciencies were
seen with AAV5, AAV8, AAV9 and AAV rhesus monkey10 vectors. Application of this approach in non-human
primate models is ongoing, but has not yet been published.
Issues of importance would be how long the transfected
mesothelial cells would remain alive and secretory, as well
as development of potential immune responses against the
transgene or AAV proteins. These studies raise the exciting
possibility of using AAV gene delivery to the pleural space
for genetic pulmonary diseases such as a1AT or other systemic diseases, such as hemophilia, lysosomal storage disorders or diabetes.1
Preclinical studies
It is currently difcult to envision a large number of clinical scenarios where pleural gene therapy would be both
useful and cost-effective. The two large classes of non-
Examples
Herpes simplex thymidine kinase gene plus ganciclovir
Cytosine deaminase gene plus 5-urocytosine
p53, p16, p14ARF, Bak, Anti-sense SV40-T antigen
Soluble form of the VEGF receptor (Flt-1), anti-angiogenic pigment
epithelium-derived factor
Interleukin-2, interleukin-12, Type 1 and Type 2 interferons, GM-CSF
Liposome/DNA complexes, mycobacterial heat shock protein gene
(HSP-65), anti-CD40
SV40 T-antigen
Herpes virus, Vaccinia virus, Adenovirus
GM-CSF, granulocyte macrophage colony-stimulating factor; SV40, Simian virus 40; VEGF, vascular endothelial growth factor.
INDUCTION OF APOPTOSIS
Delivery of the wild-type p53 gene has been the most frequent method of experimental gene therapy of solid
tumors, since mutations in the p53 tumor suppressor gene
account for the majority of genetic abnormalities in solid
tumors. Even though most MMs contain wild-type p53,
over-expression of p53 using an adenoviral vector has
inhibited cell growth.13 Other molecular approaches used
in mesotheliomas have been re-expression of p16INK4a,14 or
the p14ARF protein complex.15 An alternate method of
inhibiting MM cells is the introduction of downstream
promoters of apoptosis such as the pro-apoptotic Bcl-2
family member Bak.16 The potential role for SV40 as a
causative factor in MM oncogenesis and proliferation is
the rationale for experiments by Schrump and colleagues
showing that anti-sense oligonucleotides designed to abrogate Simian virus 40 (SV40) Tag expression induce apoptosis and enhance sensitivity to chemotherapeutic agents
in SV40-positive MM cells in vitro.17
Given that in vivo gene transfer is quite inefcient, a
major limitation of all of these approaches is that inducing
cell death in only the transduced cells (without bystander
effects), will have only limited therapeutic efcacy.
An attractive approach in cancer gene therapeutics is suicide gene therapy where a neoplasm is transduced with a
cDNA encoding for an enzyme rendering tumor cells sensitive to a benign agent by converting the prodrug to a
toxic metabolite. Enzymes used most commonly are the
herpes simplex virus-1 thymidine kinase (HSVtk) gene
which makes cells sensitive to the nucleoside analog ganciclovir (GCV) or the yeast enzyme cytosine deaminase
which converts 5-uorocytosine to the toxic 5-uorouracil.
Therapeutic efcacy in the former is enhanced by a
bystander effect that involves passage of toxic GCV
metabolites from transduced to non-transduced cells via
gap junctions or apoptotic vesicles and induction of antitumor immune responses capable of killing tumor cells not
expressing the transgene.
The transfer of HSVtk DNA to target pleural or peritoneal tumor cells has been accomplished using a variety
of delivery systems including carrier cells,20,21 liposomes,22,23 plasmid DNApolyethylenimine complexes22
and AAV2 vectors.24 The most effective vector, however,
has been adenovirus. Initial experiments demonstrated
that replication-decient adenoviral HSVtk vectors
(Ad.HSVtk) efciently transduced mesothelioma cells
both in tissue culture and in animal models and facilitated
HSVtk-mediated killing of human MM cells in the presence of low concentrations of GCV.25 Subsequently,
Ad.HSVtk/GCV gene therapy was used successfully to treat
established intraperitoneal human MM tumors and lung
cancers in immunodecient mice26 and in rat models of
pleural MM.5,27
ANTI-ANGIOGENESIS
IMMUNO-GENE THERAPY
(a)
Clinical trials
(b)
CONCLUSIONS
Pleural gene therapy could potentially be used to treat systemic diseases by providing a large and easily accessible
cellular target for gene transduction and protein secretion
or for the treatment of a number of pleural diseases.
Studies using novel AAV serotypes are especially promising in this regard. The other area where pleural gene
therapy is likely to become useful is in the treatment of
pleural diseases, especially pleural malignancies. A number
of clinical trials in cancer patients have been completed
that show the safety and feasibility of this approach.
Gene therapy has not yet been proven as a useful therapeutic tool for the treatment of pleural diseases. However,
the eld is less than 15 years old and great initial progress
has been made. The authors have no doubt that gene
therapy will be an important treatment strategy in the near
future.
KEY POINTS
REFERENCES
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13. Giuliano M, Catalano A, Strizzi L, et al. Adenovirus-mediated wildtype p53 overexpression reverts tumourigenicity of human
mesothelioma cells. Int J Mol Med 2000; 5: 5916.
14. Frizelle SP, Rubins JB, Zhou JX, Curiel DT, Kratzke RA. Gene therapy
of established mesothelioma xenografts with recombinant
p16INK4a adenovirus. Cancer Gene Ther 2000; 7: 14215.
15. Yang CT, You L, Uematsu K, et al. p14(ARF) modulates the cytolytic
effect of ONYX-015 in mesothelioma cells with wild-type p53.
Cancer Res 2001; 61: 595963.
16. Pataer A, Smythe WR, Yu R, et al. Adenovirus-mediated Bak gene
transfer induces apoptosis in mesothelioma cell lines. J Thorac
Cardiovasc Surg 2001; 121: 617.
17. Waheed I, Guo ZS, Chen GA, et al. Antisense to SV40 early gene
region induces growth arrest and apoptosis in T-antigen-positive
human pleural mesothelioma cells. Cancer Res 1999; 59:
606873.
18. Mae M, Crystal RG. Gene transfer to the pleural mesothelium as a
strategy to deliver proteins to the lung parenchyma. Hum Gene
Ther 2002; 13: 147182.
19. Merritt RE, Yamada RE, Wasif N, Crystal RG, Korst RJ. Effect of
inhibition of multiple steps of angiogenesis in syngeneic murine
pleural mesothelioma. Ann Thorac Surg 2004; 78: 104251.
20. Schwarzenberger P, Harrison L, Weinacker A, et al. The treatment
of malignant mesothelioma with a gene modied cancer cell line:
a phase I study. Hum Gene Ther 1998; 9: 26419.
21. Schwarzenberger P, Harrison L, Weinacker A, et al. Gene therapy
for malignant mesothelioma: a novel approach for an incurable
cancer with increased incidence in Louisiana. J La State Med Soc
1998; 150: 16874.
22. Aoki K, Yoshida T, Matsumoto N, et al. Gene therapy for peritoneal
dissemination of pancreatic cancer by liposome-mediated transfer
of herpes simplex virus thymidine kinase gene. Hum Gene Ther
1997; 8: 110513.
23. Nagamachi Y, Tani M, Shimizu K, Yoshida T, Yokota J. Suicidal
gene therapy for pleural metastasis of lung cancer by liposomemediated transfer of herpes simplex virus thymidine kinase gene.
Cancer Gene Ther 1999; 6: 54653.
24. Berlinghoff S, Veldwijk MR, Laufs S, et al. Susceptibility of
mesothelioma cell lines to adeno-associated virus 2 vector-based
suicide gene therapy. Lung Cancer 2004; 46: 17986.
25. Smythe WR, Hwang HC, Elshami AA, et al. Treatment of
experimental human mesothelioma using adenovirus transfer of
the herpes simplex thymidine kinase gene. Ann Surg 1995; 222:
7886.
26. Hwang HC, Smythe WR, Elshami AA, et al. Gene therapy using
adenovirus carrying the herpes simplex-thymidine kinase gene to
treat in vivo models of human malignant mesothelioma and lung
cancer. Am J Respir Cell Mol Biol 1995; 13: 716.
27. Elshami AA, Kucharczuk JC, Zhang HB, et al. Treatment of pleural
mesothelioma in an immunocompetent rat model utilizing
adenoviral transfer of the herpes simplex virus thymidine kinase
gene. Hum Gene Ther 1996; 7: 1418.
28. Lanuti M, Rudginsky S, Force SD, et al. Cationic lipid: bacterial
DNA complexes elicit adaptive cellular immunity in murine
intraperitoneal tumor models. Cancer Res 2000; 60: 295563.
29. Rudginsky S, Siders W, Ingram L, et al. Antitumor activity of
cationic lipid complexed with immunostimulatory DNA. Mol Ther
2001; 4: 34755.
30. Leong CC, Marley JV, Loh S, Robinson BW, Garlepp MJ. The
induction of immune responses to murine malignant
mesothelioma by IL-2 gene transfer. Immunol Cell Biol 1997; 75:
3569.
31. Caminschi I, Venetsanakos E, Leong CC, et al. Cytokine gene
therapy of mesothelioma. Immune and antitumor effects of
transfected interleukin-12. Am J Respir Cell Mol Biol 1999; 21:
34756.
32. Mukherjee S, Nelson D, Loh S, et al. The immune anti-tumor
effects of GM-CSF and B7-1 gene transfection are enhanced
References 619
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45. Harrison LH Jr, Schwarzenberger PO, Byrne PS, et al. Genemodied PA1-STK cells home to tumor sites in patients with
malignant pleural mesothelioma. Ann Thorac Surg 2000; 70:
40711.
46. Sterman DH, Treat J, Litzky LA, et al. Adenovirus-mediated herpes
simplex virus thymidine kinase/ganciclovir gene therapy in
patients with localized malignancy: results of a phase I clinical
trial in malignant mesothelioma. Hum Gene Ther 1998; 9:
108392.
47. Molnar-Kimber KL, Sterman DH, Chang M, et al. Impact of
preexisting and induced humoral and cellular immune responses in
an adenovirus-based gene therapy phase I clinical trial for
localized mesothelioma. Hum Gene Ther 1998; 9: 212133.
48. Sterman DH, Molnar-Kimber K, Iyengar T, et al. A pilot study of
systemic corticosteroid administration in conjunction with
intrapleural adenoviral vector administration in patients with
malignant pleural mesothelioma. Cancer Gene Ther 2000; 7:
15118.
49. Sterman DH, Recio A, Vachani A, et al. Long-term follow-up of
patients with malignant pleural mesothelioma receiving high-dose
adenovirus herpes simplex thymidine kinase/ganciclovir suicide
gene therapy. Clin Cancer Res 2005; 11: 744453.
50. Zarogoulidis K, Kontakiotis T, Papagiannis A, Xafenias A, Kortsaris
A. Management of resistant lung cancer malignant pleural
effusion by intrapleural gene therapy. J Clin Oncol 2004; 22: 3168.
51. Shen Y, Nemunaitis J. Fighting cancer with vaccinia virus:
teaching new tricks to an old dog. Mol Ther 2005; 11: 18095.
52. Pitako J, Squiban P, Acres B, Digel W. A randomized phase II single
center study of gene transfer-based non-specic immunotherapy
of malignant mesothelioma (MM) by intratumoral injections of an
interleukin-2 producing vero cells. Proc Am Soc Clin Oncol 2003;
22(abstr 920).
53. Sterman DH, Gillespie CT, Carroll RG, et al. Interferon beta
adenoviral gene therapy in a patient with ovarian cancer. Nat Clin
Pract Oncol 2006; 3: 6339.
54. Sterman DH, Recio A, Carroll RG, et al. A Phase I clinical trial of
single-dose intrapleural interferon-beta gene transfer for
malignant mesothelioma and metastatic pleural effusion: high
rate of antitumor immune responses. Clin Cancer Res 2007; 13(15
Pt1): 445666.
55. Kruklitis RJ, Singhal S, DeLong P, et al. Immunogene therapy with
interferon-b before surgical debulking delays recurrence and
improves survival in a murine model of malignant mesothelioma. J
Thorac Cardiovasc Surg 2004; 127: 12330.
50
Future directions
YC GARY LEE, RICHARD W LIGHT
Introduction
Pleural disease is common and important
Recent advances and controversies
Current state of affairs
To bring forward the eld of pleural disease
621
621
622
623
623
INTRODUCTION
Congratulations on arriving at the nal chapter of this
book!
The eld of pleural disease includes a diverse range of
clinical presentations that are both common and important. The signicance and diversity of pleural diseases have
been well covered in the clinical chapters of this text. In
addition, it is an exciting eld never short of new developments and controversies. For a long time pleural disease
has failed to attract the same level of attention and interests as other medical elds of similar importance. The level
of pleural research and the acquisition of new knowledge
often lag behind other common clinical conditions. There
is also a common misconception that pleural disease,
when compared with other respiratory conditions, is less
exciting or of less signicance and as such many consider
pleural disease research outside the mainstream.1
This chapter discusses why pleural disease is relatively
neglected and the possible measures that can promote
pleural disease research and improve the clinical standard
of management of pleural diseases. We highlight the recent
advances in pleural disease management since the publication of the rst edition of this text. We also provide our
predictions on how pleural disease will evolve over the
next couple of decades.
623
626
626
Our predictions for the evolution of pleural disease during the rst part of the twenty-rst century 623
Lack of commercial interest and drug company sponsorship is a signicant disadvantage in pleural research,
when compared with more marketable conditions such
as asthma or pneumonia. Many physicians also view
pleural disease (especially malignant effusions) as a terminal event not worthy of efforts to improve its practice. The
lack of funding and interest result in a lack of good
research, making it difcult to attract funding and recruit
talented young investigators. The net result is a vicious
cycle in which pleural disease research continues to be
ignored.
The pleural disease research community lacks a central
organization to liase and put together investigators of
similar interests. This partly explains the relative lack of
large multi-center collaboration efforts. There exist no
pleural disease interest groups within the major thoracic
societies (e.g. the American Thoracic Society, European
Respiratory Society or Thoracic Society of Australia and
New Zealand), as there are for airways diseases, pulmonary
vascular disease or lung brosis. There are no large patient
support groups, such as those for asthma or lymphangioleiomyomatosis. No specialized forum exists for
researchers in pleural disease to exchange ideas. Unlike for
asthma or lung cancer, there are no scientic publications
with a focus on pleural disease research. The International
Pleural Newsletter, a free publication available at
www.musc.edu/pleuralnews, is an attempt to provide
useful knowledge on pleural diseases to the wider medical
community, with the hope of promoting interests and
research in pleural disease.
Overall predictions
The incidence of pleural diseases will continue to rise. This
is because the general population will live longer and the
elderly population is more likely to develop diseases associated with pleural effusions such as congestive heart
failure, malignancy and pneumonia. As medical practice
evolves, there are more interventions that lead to pleural
disease (e.g. transthoracic needle aspiration and radiofrequency ablation causing pneumothorax; CABG surgery
and fertility induction producing pleural effusions).
Historically, high-prole pleural researchers are predominantly based in the USA, from where a large proportion of high-impact clinical studies and cutting edge basic
research on pleural diseases were published. With rising
interests in pleural disease worldwide and globalization of
technology, YCGL predicts that pleural research will be
more evenly distributed around the world. European and
Australian centers have already taken a lead in pleural
infection and asbestos-related pleural diseases. It would be
encouraging to see the number of centers with pleural
interests continue to grow around the world.
4.
5.
6.
7.
Our predictions for the evolution of pleural disease during the rst part of the twenty-rst century 625
3.
4.
5.
6.
KEY POINTS
Pleural diseases are common, but clinical interests and research in pleural diseases often fall
below that of other respiratory illnesses
The past few years have seen a signicant increase
in multi-center clinical studies that affect patient
management. Large particle size talc preparations have been shown to be safer than small particle size ones. The effectiveness of talc, given as
slurry or poudrage, does not differ signicantly.
Intrapleural streptokinase was not associated
with signicant clinical benets in a large randomized trial. New anti-folate drugs can improve
survival of mesothelioma patients.
Pleural disease is never short of controversies: the
best route of administration of talc (slurry versus
poudrage), use of brinolytics in empyema, role
of SV40 in development of mesothelioma and
benets of prophylactic radiotherapy in
mesothelioma all remain controversial.
Advances in pleural research and clinical disease
management depend on raising the prole of
pleural disease as a sub-specialty. Research collaborations among international centers and
between clinical researchers and laboratory scientists are crucial.
REFERENCES
1. Lee YCG. Pleural disease: A forgotten frontier in respiratory
research. Respirology 2006; 11: 45.
2. Maskell NA, Davies CW, Nunn AJ, et al. UK Controlled trial of
intrapleural streptokinase for pleural infection. N Engl J Med
2005; 352: 86574.
3. Diacon AH, Theron J, Schuurmans MM, Van de Wal BW, Bolliger
CT. Intrapleural streptokinase for empyema and complicated
parapneumonic effusions. Am J Respir Crit Care Med 2004; 170:
4953.
4. Dresler CM, Olak J, Herndon 2nd JE, et al. Phase III intergroup
study of talc poudrage vs talc slurry sclerosis for malignant pleural
effusion. Chest 2005; 127: 90915.
5. Maskell NA, Lee YCG, Gleeson FV, et al. Prospective randomized
trials comparing the inuence of talc of different particle sizes
and tetracycline on lung and systemic inammation after
pleurodesis. Am J Respir Crit Care Med 2004; 170: 37782.
6. Janssen JP, Collier G, Astoul P, et al. Safety of pleurodesis with talc
poudrage in malignant pleural effusion: a prospective cohort
study. Lancet 2007; 369: 15359.
7. Vogelzang NJ, Rusthoven J, Symanowski J, et al. Phase III study of
pemetrexed in combination with cisplatin versus cisplatin alone in
patients with malignant pleural mesothelioma. J Clin Oncol 2003;
21: 263644.
8. van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase
III study of cisplatin with or without raltitrexed in patients with
malignant pleural mesothelioma: an intergroup study of the
European Organisation for Research and Treatment of Cancer Lung
Cancer Group and the National Cancer Institute of Canada. J Clin
Oncol 2005; 23: 68819.
References 627
Index
angiogenesis 86
talc pleurodesis 118, 118
angiotensin-coverting enzyme (ACE)
inhibitors 81
animal models 16979
access to pleural space 170, 185
anatomical characteristic differences
170
choice of 1701
experimental end-points 1701
genetically engineered 170
ideal 169
imaging techniques 171
intrapleural drug pharmacokinetics
179
intrapleural injection 170
laws/regulations 169
need for 169
species choice 170
talc, extrapleural deposition 119,
119
see also individual diseases
ankylosing spondylitis (AS) 425
anti-anxiety medication, thoracentesis
553
anti-CD40 antibody therapy, malignant
mesothelioma 195
anti-IL-6 antibodies 192
anti-IL-8 antibodies 86
anti-leu-M1 304
anti-mycobacterial antibodies 372
anti-P32, tuberculosis pleuritis 372
anti-TGF-b antibodies 72
antibiotics
children 548
empyema 3534
intrapleural administration 1634
membrane penetration 157
parapneumonic effusions 3534
plasma protein binding 156
pleural infection 61, 353, 3534
toxicity 164
see also individual drugs
anticardiolipin antibody 478
anticoagulants 108, 402, 437
antidiabetic drugs 4378
antifungal agents 380, 381
antimicrobial agents 1605
ascitic fluid pharmacokinetics 1602
630 Index
blastomycosis 3812
blebs
excision 600, 600
hepatic hydrothorax 456
spontaneous pneumothorax 51718,
593
bleeding disorders 551
bleomycin 436, 573
blood gases
pleural effusion 523
pneumothorax 567
blood (serum) peptidome 136
blunt dissection technique, chest tube
insertion 5601, 561
body-cavity-based lymphoma 412, 414
body shape, spontaneous pneumothorax
517
Boerhaaves syndrome 59
Boutin pleural puncture needle, reusable
555, 555
bovine serum albumin (BSA) 174
brain natriuretic peptide (BNP), cardiac
failure 496
breast carcinomas, metastatic 294, 294,
295
breath sounds, spontaneous
pneumothorax 520
British Thoracic Society (BTS)
post-traumatic pneumothorax air
travel guidelines 5367
spontaneous pneumothorax size
guidelines 520
bromocriptine 4345
bronchial arteries 17, 18
bronchial/bronchiogenic carcinoma
HIV patients 412
obstructive 325, 325, 329
spontaneous pneumothorax 518
transplant recipients 414
bronchopleural fistula 254, 255, 587
bronchoscopy
malignant pleural effusions 329
pleural infection 358
BuddChiari syndrome 415
bullae 593, 593
pneumothorax vs. 253, 253
bullectomy, spontaneous pneumothorax
600
Burkitt-like lymphoma 414
bystander effect 615
c-met 32, 745
C19-9, tumor marker 304
CA-125, tumor marker 3034
cabergoline 434
cadherin 65
calretinin, malignant mesothelioma
288, 288, 305, 509
candidiasis 379, 379, 414
candlewax lesions 113
canine models, chylothorax 178
capillary leak syndrome 474
capillary pores, drug movement 157
Index 631
632 Index
definition 389
diagnosis 391, 4956
differential diagnosis 390, 391
empyema vs. 350, 391
etiology 38990, 390
fetal pleural effusions 475
future directions 395
incidence 389
investigations 391
lung transplant recipients 415
lymphoscintigraphy 244
pathogenesis 3901
pleural fluid 210, 496
radiology 2434, 391
surgical indications 607
surgical methods 607, 607
treatment 3912, 392
triglycerides 221
chylus (chyle) 389, 391
ciprofloxacin 162, 1623
circumscribed pleural plaques (CPP)
clinical features 502
definition 500
epidemiology 5001
etiology/pathogenesis 501
management 5034
pathology 502
pulmonary function tests 503
radiology 500, 502, 503
cirrhosis, hepatic hydrothorax 455
cirrhotic hydrothorax 607
cisplatin
intrapleural pharmacokinetics 1667
malignant mesothelioma 131, 192
cisterna chyli 390
clear-cell papillary thyroid carcinoma
(CCPTC) 300
clear-cell thyroid carcinomas 300
diagnostic algorithm 309
clear-cell tumors, cytology 299, 299300
consistent architectural pattern
lacking 300
nested architecture 299300
clearance (Cl), drugs 155
clindamycin 353
clinical proteomics 135
future perspectives 147
limitations 1467
low-abundance protein amplification
problems 146
sample biological variability 146
closed needle pleural biopsy 5579
Abrams needle 558, 558, 559
alternatives to 559
area selection 557
complications 5589
contraindications 557
cope needle 557, 558
definition 557
indications 557
malignant pleural effusions 326
patient positioning 557
techniques 557
Index 633
634 Index
drugs
intrapleural administration 15960
membrane penetration 1557
disease pleura 159
drug molecular size/weight 157
ionization and 157
normal pleural cavity 1579
see also pharmacokinetics
duplex ultrasonography, leg veins 4012
dyspnea
drug-induced effusions 431
ergot derivatives 434
malignant pleural effusions 3234
pleural effusion 202
post-CABG pleural effusions 448
pulmonary embolism 398
rheumatoid arthritis 423
spontaneous pneumothorax 519
echinococcosis-hydatidosis 384
echocardiography, pulmonary embolism
402
ectomorphic build, spontaneous
pneumothorax 517
effusions see pleural effusions
ehrlichiosis 383
Ej-ras gene 191
electrocardiography, pulmonary
embolism 398
electronic transducer systems, pleural
manometry 229
electrospray ionization (ESI) 1445, 145
elimination, drug 1545
diseased pleura 159
first-order 154, 154
intrapleural drug administration 159
antibiotics 1634
antineoplastic agents 1667
one-compartment model 153
zero-order 154
elimination rate constant 1545
Emerson pump 564
emphysema
iatrogenic pneumothorax 538
spontaneous pneumothorax 518,
518, 520
empyema 34166
adenosine deaminase levels 222
animal models 175, 343
antibiotics 3534
chest radiography 2401, 351, 351
children
long-term consequences 549
management 548
chylothorax vs. 350, 391
classification 344
CT 241, 241, 3512, 352, 352
decortication complication 608
drainage failure 344
drug penetration, animal data 164,
164
esophageal rupture 467
fibrinolytic therapy 106
overexpression 76
epirubicin, interleukin 2 and 83
epithelial membrane antigen (EMA)
303, 509
EpsteinBarr virus (EBV) 386, 412, 469
ergot derivatives 4345
ergotamine 434
erionite 114, 131, 499
erlotinib 76
esophageal carcinoma with fistulae 468
esophageal rupture 4678
animal models 178
chest radiography 467
diagnosis 467
empyema 467
history 202
iatrogenic 467
mediastinitis 467
pleural effusion 178, 469
pleural fluid amylase 221
pleural fluid characteristics 467
pleural fluid glucose 220, 220
secondary pleural sepsis 350, 350
spontaneous 467
surgery 468
traumatic/post-surgical 467
esophagram, esophageal rupture 467
estrogen receptor protein (ERP) 305
ethambutol 374
European Respiratory Society/American
Thoracic Society (ERS/ATS)
Consensus Statement on
Management of Malignant Pleural
Effusions 3256, 331
Ewing family of tumors 2967
Ewings sarcoma (ES) 296
exercise, pneumothorax induction 517
exercise tolerance
pleural effusion effects 54, 54
pneumothorax effects 57
experimental models 16986
malignant mesothelioma see
malignant mesothelioma (MM)
expiration, fluid/particle removal during
21
expiratory chest radiography,
pneumothorax 252
extended thoracoscopy 584
extraction ratio 155
ExtraPancreatic Inflammation on CT
score (EPIC scoring system) 466
extrapleural pneumonectomy (EPP)
606, 608
exudative pleural effusion
benign vs. malignant 137
causes 211, 491
definition 212
differential diagnoses 136
drug penetration 159
nucleated cells 215
pleural fluid pH 218
pulmonary embolism 3978
transudative vs. 238, 491, 491
Index 635
636 Index
incidence 537
management 539, 53940, 625
observation 539
persistent air leak 540
risk factors 538, 5389
surgical management 540
symptoms 537
thoracentesis-induced 556
transthoracic needle biopsy 5378,
538
treatment 53940
ICU hemodynamic transducers 229
IFN-g/IFN-g receptor (IFN-gR) complex
polymorphism 88
imatinib mesylate
platelet-derived growth factor
inhibition 78
pleural effusion induction 436
imidapril 433
immune deficiencies
primary 409, 416
complications 416, 416
secondary 410
immune reconstitution inflammatory
syndrome (IRIS) 413
immuno-gene therapy 61516
immunocompromised host, effusions
40919
future directions 417
immunoglobulin(s) 61, 434
immunoglobulin E (IgE),
paragonimiasis 384
immunoglobulin G (IgG),
paragonimiasis 384
immunohistochemistry, solitary fibrous
tumor of the pleura 485
immunological studies, pleural fluid
analysis 2212
immunology 71100
immunomodulating agents 4334
immunosuppressants, systemic lupus
erythematosus 422
immunotherapy, malignant
mesothelioma 511
experimental models 1945
immunotoxins 192
indwelling pleural catheters
ambulatory
insertion equipment 578
pleurodesis alternative 577, 578
spontaneous pneumothorax 600
malignant pleural effusions 334
future directions 625
long-term 2613, 262
pleural infection 361
spontaneous pneumothorax drainage
5223, 523
infection see pleural infection
infectious mononucleosis 386
inflammation see pleural inflammation
influenza hemagglutinin (HA) 193
influenza pandemic (1919) 342
inhibitors of apoptosis (IAPs) 32
Index 637
innate immunity 59
inspiration, fluid/particle removal
during 21
insulin-like growth factor (IGF) 789
mesothelioma 789
insulin-like growth factor binding
protein 2 (IGFBP-2) 79
insulin-like growth factor-I (IGF-I) 78
malignant effusion marker 79
malignant mesothelioma growth
regulation 32
mesothelial cell proliferation 31, 31
PAI-1 expression 104
insulin-like growth factor-II (IGF-II) 78
solitary fibrous tumor of the pleura
79, 484
insulin-like growth factor receptor
(IGFR) 78
mesothelioma 789
insulin-like growth factor receptor type I
(IGF-RI) 78
insulin-like growth factor receptor type
II (IGF-RII) 78
insulin, PAI-1 expression 104
insulin receptor (IR), solitary fibrous
tumors 79
insulin receptor substrate (IRS)-1 79
insulin receptor substrate (IRS)-2 79
integrins
asbestos fiber uptake 33
defense mechanism 61
expression 63
intensity modulated radiotherapy
(IMRT) 511
intensive care unit (ICU), iatrogenic
pneumothorax 5389, 539
intercellular adhesion molecules
(ICAMs) 63
intercostal bundle, thoracentesis 552
interferon(s) (IFNs) 879, 433
mesothelioma 889
pleural inflammation 88
receptors 88
tuberculous pleuritis 88
type I 878
gene therapy 616
type II 88
VEGF suppression 81
interferon alpha (IFN-a) 88
anti-inflammatory properties 88
intracavitary administration,
malignant effusions 89
mesothelioma growth inhibition 88
interferon beta (IFN-b) 88
gene therapy 616, 617
intracavitary administration,
malignant effusions 89
mesothelioma 889
interferon gamma (IFN-g) 88
acquired immunity 63
gene therapy 616
mesothelioma
gene transfer 889
growth inhibition 88
intrapleural administration 89
tuberculous pleuritis 88, 372
interleukin-1 (IL-1) 812
human pleural effusions 82
inflammation 81
interleukin-8 release 856
mesothelial cell proliferation 81
pleural fibrosis 82
interleukin-1 (IL-1) receptor antagonist
86
interleukin-2 (IL-2) 823
drug-induced effusions 433
epirubicin and 83
gene therapy 616, 617
mesothelioma therapy 83
pleural effusion 823
therapeutic application, pleural
malignancy 83
tuberculosis pleuritis 3723
interleukin-5 (IL-5) 384
interleukin-6 (IL-6) 835
inflammation 84
mesothelial cell proliferation 31, 31
mesothelioma 85, 194
ovarian hyperstimulation syndrome
474
overexpression 84
pleural effusions 845
pleural tuberculosis 84, 3723
thrombocytosis 85
interleukin-6 (IL-6) antibodies,
malignant mesothelioma 194
interleukin-6 (IL-6) receptors 84
interleukin-8 (IL-8) 856
angiogenesis 86
asbestos-induced pleural
inflammation 115
chemotaxis 86
empyema 86
inhibition 86
mesothelial cell immune response 62
neutrophil counts 215
pleurodesis 86
release 856
talc pleurodesis 117
tuberculous pleurisy 368
tumor growth 86
interleukin-10 (IL-10) 867
pleural effusions 867
tuberculous effusions 87
tumor cells 87
interleukin 11 (IL-11) 433
interleukin-12 (IL-12) 87
anti-tumor effects 87
gene therapy candidate 87
malignant mesothelioma 194
pleural malignancy 87
tuberculous pleuritis 87, 3723
interlobar fissures 15
intermediate filament proteins 3023
internal mammary artery (IMA) graft
447, 448
638 Index
Index 639
palliation 512
pathogenesis 12534, 508
pathology 509
perimental models 1934
peritoneal 508
PET 509, 510
PET-CT 252, 252
platelet-derived growth factor 78
pleural effusion 330, 508
management 32930
pleural irritation 508
prognosis 511
prophylactic radiotherapy 587
recent advances/controversies 622
recurrent cytogenic abnormalities 126
Simian virus 40 75, 1889, 508
somatic genetic changes 334
staging 511
surgery 511, 606
symptoms 125
transplant recipients 414
tumor markers 305
tumor suppressor genes 34, 128, 128,
12830, 191
ultrasound 278
malignant pleural effusions 32337
adenosine deaminase 326
ambulatory drainage and
sclerotherapy 261
animal models 172, 173
biopsy 3267
causes 1367
clinical presentation 3234
clinical study prospects 3345
cytology 326, 326
diagnosis 3257
flow cytometry 327
incidence 323
long-term indwelling pleural silicone
catheters 2613, 262
management/treatment 327, 3279,
328
future directions 625
ipsilateral lung cancer and 329
mediastinal position in 327, 328
palliative therapy 83, 260
pathogenesis 323, 324
PET-CT 243
pleural fluid amylase 221
pleural fluid analysis 3256
pleural fluid formation prevention
335
pleural fluid glucose 218, 21920,
326, 326
pleural fluid pH 218, 219, 326, 326,
327
quality of life 625
radiology 2423, 243, 261, 275, 325,
325
surgery 6056, 606, 608
transudative 326
tube thoracostomy 2603
tumor markers 327
640 Index
methylthioadenosine phosphorylase
(MTAP) deficiency 1312
methylthioadenosine phosphorylase
gene (MTAP) 129
methysergide 434, 435
metronidazole 353, 439
mica 113
microbial virulence factors 60
microvilli 16, 1617, 27, 28
malignant mesothelioma 29, 29
Miles vascular permeability assay 179
Milrose thoracentesis needle 556
mineral dusts
mesothelial damage mechanisms
11416
pleural reactions 11323
see also individual dusts
mini-thoracoscopy 584
mini-thoracotomy 358
minocycline 440, 572
minoxidil 4323
MIST1 study 3467, 355, 357, 357, 604
MIST2 622
mitogen-activated protein (MAP)
kinases 115
mitomycin, adverse effects 436
mitomycin C 192
mitosis interference, malignant
mesothelioma 508
mixed connective tissue disease
(MCTD) 425
mixed dust fibrosis 113
MOC-31, tumor marker 303
model of end-stage liver disease
(MELD), TIPS survival 460
modified Lights criteria 491
molecular mimicry 60
monoclonal antibodies
parapneumonic effusions 625
tuberculosis pleuritis 372
as tumor markers 302, 304
monocyte chemotactic protein-1 (MCP1) 62, 115, 117, 368
monocytes 63
mononuclear cells 64
mononuclear leukocyte adhesion 76
MRI see magnetic resonance imaging
(MRI)
mucins, membrane-bound 61
mucociliary escalator 114
Muerto Canyon virus 385
Multi-center International Sepsis Trial
(MIST) 6223
multi-compartment model,
pharmacokinetics 153, 159
multidimensional protein identification
technology (MudPIT) 1456
multiple myeloma 416
murine models
benign asbestos-induced pleural
diseases 177
genetic 170
malignant mesothelioma 189, 190, 195
Index 641
642 Index
Index 643
pleural infection
anaerobic 347, 347
animal models 175
antibiotics 3534
atypical 37988
bacterial see bacterial infection
bacteriology 343, 3458, 347
causes 3423, 343
clinical assessment 3489
clinical outcome predictors 3501
clinico-pathological stage correlations
345, 345
community-acquired disease 347,
353
comorbid disease 341
diagnosis 3489
diagnostic algorithm 346
differential diagnosis 34950
epidemiology 3423
exudative phase 343
fibropurulent phase 3434
fungal see fungal infection
future directions 361
granuloma formation 286
historical perspective 342
hospital-acquired 3423
antibiotics 353, 3534
bacteriology 343, 347
incidence 342
inflammation 5970
loculation 344
malignancy vs. 350
mixed infection 347
mortality 341, 341, 347, 348
natural healing/organizing stage 344
parasitic 3836
pathophysiology 3434
pediatric pleural effusions 5479
pleural fluid analysis 3489, 349
pleural scarring 344
pulmonary embolism 402
radiology 3513
rheumatoid arthritis 424
surgery 3589, 360
treatment, non-surgical patients
35961
viral 3856, 548
see also specific infections
pleural inflammation 5970
animal models 1724
histologic assessment 1723
asbestos-induced 115
drug penetration 159
epidermal growth factor 76
induction techniques 1734, 174
infection 5970
inhibition 667
initiation 645
interferons 88
mesothelial cell proliferation 23
perpetuation 656
repair 66
resolution 66
644 Index
Index 645
radiology 2524
recurrence rates 525
secondary 515, 516, 520
pleurodesis 569
surgical indications 599
smoking 517, 518
spontaneous hemopneumothorax 405
surgery 5246, 599602
bleb resection 601
flying, postoperative 526
future directions 608
indications 599
methods 600
occupational considerations 526
persistent air leak 525
at presentation 525
procedure choice 601
recreational considerations 526
recurrence prevention 5256
thoracentesis-induced 556
transplant recipients 415
tube thoracostomy 2656
ultrasound 254, 277, 277
Vanderschueren classification 593
podoplanin 305
polyhydramnios 475
polymerase chain reaction (PCR)
DNA microarray, malignant
mesothelioma 511
Mycoplasma pneumoniae 383
tuberculosis pleuritis 370
polymorphonuclear neutrophil (PMN)
count, spontaneous bacterial
empyema 461
polymyositis 425
pores, drug penetration 159
positive-pressure ventilation, traumatic
pneumothorax 534
positron emission tomography (PET)
asbestos-related pleural diseases 503
diffuse malignant pleural thickening
250
malignant mesothelioma 509, 510
pleural infection 3523
solitary fibrous tumor of the pleura
485
positron emission tomography
combined with computed
tomography (PET-CT) 234
malignant mesothelioma 251, 252
malignant pleural effusions 243
post-CABG pleural effusions 44751,
492
clinical manifestations 4489
early 447
etiology 448
grading 447
incidence 4478
late 4478
management 449, 626
off-pump (OP-CABG) surgery 448
pleural fluid characteristics 449
vascular endothelial growth factor 80
radiology 2434
Pseudomonas aeruginosa 60
pulmonary abscess see lung abscess
pulmonary arteriograms, pulmonary
embolism 401
pulmonary circulation, aging 1718
pulmonary edema
cardiac disease 316
ultrasound 280
pulmonary embolism 350
arterial blood gases 398
chest radiography 398
clinical presentation 398
clinical probability 399, 400
CT 399
deep vein thrombosis 4012
diagnosis 205, 403
electrocardiography 398
hemothorax 402
investigations 399402
management 402
ovarian hyperstimulation syndrome
475
pleural effusions 397402
complications 402
diagnosis 492
epidemiology 397
exudative 3978
fluid loculations 399
incidence 397
pathogenesis 3978
pregnancy-related 477
transudative 398
unilateral 398
pleural fluid findings 399, 492
pleural infection 402
pulmonary infarction 399
signs/symptoms 398
treatment 402
ultrasound 27980, 402
pulmonary function
asbestos-related pleural diseases 503
pleural effusion effects 51, 512
animal models 179
pneumothorax effects 56, 56
animal models 179
post-therapeutic thoracentesis 51, 51
pulmonary infarction 27980
pulmonary ligaments 14
pulmonary lymphangiectasis 547
pulmonary reimplantation response
415
pulmonary veno-occlusive disease 405
pulse rate, pleural disease 3
purified protein derivative (PPD),
tuberculosis 205
pus
empyema 348
pleural fluid analysis 210, 215
Puumala hantavirus 385
pyogenic liver abscess 469
pyothorax-associated lymphoma 416
pyrazinamide 3734
646 Index
Q fever 383
Q (quadrupole) mass filter 145
quinacrine 573
quinolones 158
rabbits
mesothelial cell harvesting 186
pleural fluid studies 39
tuberculous pleurisy/pleuritis models
176
radiology
air 2524
diagnostic 23358
techniques 2334
diffuse pleural disease 24752
focal pleural disease 2447
future directions 255
hemothorax 244
interventional see interventional
radiology
malignant mesothelioma 2501
normal anatomy 2346
pleural effusion 203
pleural fluid 23640
pleural infection 3513
tuberculous effusions 369
see also individual techniques
radiotherapy
malignant mesothelioma 511, 587
solitary fibrous tumor of the pleura
486
Ral guanine nucleotide dissociation
stimulator (RalGDS) 130
rapamycin 131
Ras signaling pathway 745
Raynolds phenomenon 495
re-expansion pulmonary edema 230,
332, 458, 524
reactive nitrogen species (RNS) 33, 62
reactive oxygen species (ROS)
asbestos-related mesothelial damage
33, 115, 1256
malignant mesothelioma 508
mesothelial cell immune response 62
receptor for hyaluronic acid mediated
motility (RHAMM) 656
recombinant human growth hormone
(rhGH) 79
recombinant human interleukin 2 (rhIL2) 83, 1945, 433
recombinant human interleukin 11
(rhIL-11) 433
recombinant interferon alpha 194, 433,
511
referred pain, diaphragm 18
refractory ceramic fibers (RCF) 116,
18990
refractory hydrothorax (RH) 4589
refractory hypoglycemia (DoegePotter
syndrome) 484
Registro Informatizado de la
Enfermedad TromboEmblica
(RIETE) registry 398
Index 647
SU5416 80
subcostal muscles 236
subphrenic abscess 446, 468, 494
subpulmonary effusion, radiology
2378, 275
suction
occult traumatic pneumothorax 534
pleurodesis 576
spontaneous pneumothorax 524
suicide gene therapy 615
superantigens 60
superficial lymphatic plexus 19
superior vena cava syndrome 403
surface-enhanced laser
desorption/ionization-time of fight
(SELDI-TOF) 144, 144
surface-enhanced laser
desorptionionization (SELDI)
142, 144, 146
surgery 599611
complications 6078
future directions 608
see also individual techniques
synovial sarcoma 2967, 306
systemic lupus erythematosus (SLE)
pleural effusions 4212, 495
pleural fluid analysis 2212, 222,
422
rheumatoid arthritis vs. 423
systemic sclerosis 424
T cells 64
gd type 63
pleural fluid analysis 217
Tag 188
talc
contaminants 577
extra-pleural deposition 577
extrapleural deposition 119, 11920
inflammation 66, 11719
fibrinous 11718
pleural 117, 118
particle characteristics 11617, 577
particle-mesothelium interaction 33,
117
safety 5767
talc pleurodesis 11620, 5712
adverse effects 590
angiogenesis 118, 118
chylothorax 392
complications 608
malignant pleural effusions 3312
medical thoracoscopy 586, 586
other agents vs. 572, 572
pleural symphysis 11718
reactions 11620
recent advances/controversies 622
repeat 577
spontaneous pneumothorax 601
success rates 571, 5712
systemic reactions 11819
transforming growth factor beta vs.
73
648 Index
thoracentesis contd
thoracic aortic dissection 404
tuberculosis 369, 374
ultrasound-guided 280
thoracic aortic dissection 4034
thoracic duct 3901
chylothorax 389, 3901, 607
ligation 392, 607
traumatic rupture 390
valves 391
variations 390
thoracocautery (Jacobaeus operation) 6,
583, 584
thoracoplasty 8, 342
thoracoscopic sympathectomy 594
thoracoscopy, medical 58397
benign asbestos-related pleural
effusion 589
biopsy 585
cardiorespiratory function
monitoring 587
chest tube introduction 586
complication prevention 587
contraindications 587
empyema 592, 5923
fibrinolysins vs. 107
fluoroscopy in 585
future directions/predictions 594, 626
historical perspectives 67, 7, 5834
indications 583, 5878
instrumentation 584, 585
malignant mesothelioma 589
malignant pleural effusions 327,
58890
sensitivity 5889, 589
staging 586, 589
metastatic pleural disease 589
mortality rates 587
parapneumonic effusions 5923
pleural effusion 587, 588
pleural fibrosis 107
pleural infection 359
pleural malignancy 496
pleural space requirements 584
pleurodesis and 585, 585
solitary fibrous tumor of the pleura
4856
spontaneous pneumothorax 525,
587, 5934, 6012
talc poudrage and 5934
surgical vs. 583
talc pleurodesis in 586, 586
malignant pleural effusions 586,
589
techniques 5847
endoscopy 585
single-entry 584, 5856, 586
two-entry 5845, 5867
training 583
tuberculous pleural effusions 5902
Abrams needle biopsy vs. 591
fibrous adhesions 590, 591
other techniques vs. 590, 591
Index 649
hemothorax 406
malignant pleural effusions 2603
drainage system 261
palliative procedure 260
patient preparation 261
post-procedure chest radiography
261
sclerosant instillation 261
skin incision 261
streptokinase instillation 261
technique 2613
parapneumonic effusions 2635
catheter size 264, 264
CT-guided catheter insertion 263
intrapleural fibrinolytics 2635
technique 2635
pleurodesis 571
pneumothorax 265, 2656
catheter insertion 266
imaging-assisted guidance 2656
post-procedural chest radiography
266
technique 2656
tuberculin skin test, HIV patients 411
tuberculosis
diagnosis 205
empyema 361
HIV patients 411
interleukin-6 84
pseudochylothorax 394
tuberculostearic acid 372
tuberculous effusions
animal models 368
children 547
diagnosis 205, 215
HIV patients 3678, 411
interleukin-10 87
massive 369
pleural fluid analysis 220, 222
radiology 369
tuberculous empyema 242, 374, 605
tuberculous pleurisy/pleuritis 36778
ADA 3701, 371, 372
animal models 1756
human disease correlation 176
complications 374, 375
diagnosis 36973, 370, 372, 494
algorithm 373
epidemiology 3678
etiology 3689
future directions of development
3745
granuloma 370
incidence 3678
interferons 88
laboratory findings 369
management 3734
pathogenesis 3689
physical examination 369
reactivation 368
symptoms 369
thoracic wall involvement 374
treatment 3734
tumor-associated glycoprotein
(TAG)-72/CA72-4 303
tumor cells
pleural inflammatory response
inhibition 66
seeding, pleural biopsy complication
607
tumor cytotoxic factor see hepatocyte
growth factor (HGF)
tumor infiltrating lymphocytes (TIL)
193
tumor infiltrating macrophages (TIM)
193
tumor markers
malignant pleural effusions 327
see also individual markers
tumor necrosis factor-a (TNF-a) 812
asbestos exposure 126
functions 81
inflammation 81
interleukins and 84, 856
mesothelioma 82
pleural effusions 82
pleural fibrosis 82
pleural infection 3434
pleural malignancy 82
SN38-mediated apoptosis 82
therapeutic inhibition 82
tumor necrosis factor-a-converting
enzyme (TACE) 82
tumor suppressor genes (TSGs),
malignant mesothelioma 34, 127
two chain uPA see urokinase-type
plasminogen activators (uPA)
two-compartment model,
pharmacokinetics 153, 1534, 154,
159
two-dimensional gel electrophoresis
13840, 139, 142
tyrphostin AG-1478 76
ultrasound 233, 27183
acoustical impedance 272
advantages 271
approach to 2713
asbestos-related pleural diseases 503
cardiac disease 315, 318
chest wall pathology 279
comet tail artifact 234, 274, 275
absence, pneumothorax 254, 277,
277
curtain-sign 275, 277
diagnostic 27380
diaphragm 234
diaphragmatic paralysis 279
echoes 272
empyema 238, 241
flap/swirl sign 238
freeze function 272
gain 272
hydropneumothorax 277
hyperechoic structures 272
hypoechoic structures 272
indications 271
localized fibrous tumors 246
lung abscess 279, 280
lung parenchyma 275
lung sliding sign 234, 273, 274
lung tumors 278, 278, 279
malignant mesothelioma 278
malignant pleural effusions 242, 242,
275, 325
normal anatomy 234, 2735, 274
parapneumonic effusions 241
patient positioning 272, 273
plerosis efficacy assessment 239
pleural effusion 2389, 275
children 546
diagnosis 275, 276
exudative 275
fibrin strands 238, 239
mobility 275
nature determination 275
pleural thickening vs. 239, 275
tongue-like structure 275
transudates 275
treatment decision making 2389
volume estimation 239, 275
pleural fluid 2389
pleural infection 351, 351
pleural nodules 238, 238
pleural stripe 234, 235
pleural thickening 2757, 277
diffuse benign, non-asbestos related
248
pleural effusion vs. 275
pleural tumors 278, 278
pneumonia 279
pneumothorax 254, 277, 277
pulmonary edema 280
pulmonary embolism 27980, 402
pulmonary infarction 27980
pulmonary pathology, diverse
27980
reverberation artifacts 234, 274, 275
rib fracture 279
scanner 271
scanning 2723, 273
septated pleural effusions 275
subpulmonary effusion 275
technical principles 2712
transducer 271, 272
transudative vs. exudative effusion
238
unit 272
venous thrombosis 280
ultrasound-guided interventions 2801
aspirations 281
biopsy 266, 281
closed pleural biopsy, pleural effusion
2801
closed tube drainage 280
cutting needle biopsies 281
freehand technique 280
lung abscess biopsy 281
needle biopsies 281
650 Index